,generic_name,reasoning,less_determination,binary_determination,descriptive_determination,initial_prompts,no_less_most_prompts,yes_no_prompts,descriptive_prompts,set_id,urls
0,68GA-DOTATATE,"1. The drug label does not mention any specific cardiotoxicity risks associated with NETSPOT itself.

2. The drug label does not indicate any cardiotoxicity reactions directly caused by NETSPOT.

Overall, based on the information provided in the drug label, NETSPOT does not appear to be associated with cardiotoxicity risks or reactions.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",b2b3be70-17d8-4093-896c-f1c54a2cf242,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=b2b3be70-17d8-4093-896c-f1c54a2cf242&type=display
1,ABACAVIR,"1. The drug label warns about the risk of myocardial infarction associated with the use of abacavir. Several studies have reported an association between abacavir and the risk of myocardial infarction, although there is inconsistency in the data, and no established biological mechanism explains this potential risk.

2. The drug label advises considering the underlying risk of coronary heart disease when prescribing antiretroviral therapies, including abacavir. It recommends taking action to minimize modifiable risk factors such as hypertension, hyperlipidemia, diabetes mellitus, and smoking to reduce the risk of cardiotoxicity.

3. The drug label does not directly attribute the risk of myocardial infarction to abacavir but suggests that healthcare providers should be cautious and consider the potential risk of cardiotoxicity when prescribing the medication.",Less,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",5409c8ed-17c3-454f-bb88-d597ba8f84ec,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=5409c8ed-17c3-454f-bb88-d597ba8f84ec&type=display
2,ABALOPARATIDE,"1. The drug TYMLOS (abaloparatide) is associated with an increase in heart rate, with a mean peak increase of 15 beats per minute (bpm) and 20 bpm at the first time point after dosing with 80 mcg and 240 mcg, respectively. However, there were no clinically meaningful effects of abaloparatide on QTcI (individually corrected QT intervals) or cardiac electrophysiology. (The drug itself was associated with an increase in heart rate but did not cause clinically meaningful effects on QTcI or cardiac electrophysiology.)

2. In a clinical study, an accidental overdose of TYMLOS was reported in a patient who received 400 mcg in one day (5 times the recommended clinical dose). The patient experienced asthenia, headache, nausea, and vertigo. The effects of overdose may include hypercalcemia, nausea, vomiting, dizziness, tachycardia, orthostatic hypotension, and headache. (The drug TYMLOS was associated with potential cardiotoxicity reactions in cases of overdose.)

3. A 4-way cross-over thorough QT/QTc study conducted in healthy subjects who received single doses of abaloparatide showed an increase in heart rate, with a mean peak increase of 15 beats per minute (bpm) and 20 bpm at the first time point after dosing with 80 mcg and 240 mcg, respectively. There were no clinically meaningful effects of abaloparatide on QTcI or cardiac electrophysiology. (The drug itself was associated with an increase in heart rate but did not cause clinically meaningful effects on QTcI or cardiac electrophysiology.)",Less,Yes,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",712143d9-e21e-4013-bb3b-3426a21060a8,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=712143d9-e21e-4013-bb3b-3426a21060a8&type=display
3,ABEMACICLIB,"1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with VERZENIO (abemaciclib) itself.

2. The adverse reactions discussed in the label primarily focus on gastrointestinal issues, hematologic abnormalities, lung-related concerns, hepatotoxicity, venous thromboembolism, and embryo-fetal toxicity. No direct mention of cardiotoxicity risks or reactions related to VERZENIO is provided in the drug label.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",be4bc0de-0fdc-4d46-8d25-be43c79e6a06,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=be4bc0de-0fdc-4d46-8d25-be43c79e6a06&type=display
4,ABIRATERONE ACETATE,"1. YONSA may cause hypertension, hypokalemia, and fluid retention due to increased mineralocorticoid levels, potentially leading to cardiovascular adverse reactions. Monitor patients for these effects monthly. The drug itself is associated with the risk of mineralocorticoid excess, which can lead to cardiovascular issues.

2. Adrenal insufficiency occurred in patients taking abiraterone acetate, particularly when corticosteroids were interrupted or reduced, potentially masking symptoms. Monitor for signs of adrenocortical insufficiency and adjust corticosteroid dosage as needed. The drug itself is associated with the risk of adrenal insufficiency, which can have cardiovascular implications.

3. Hepatotoxicity, including severe liver toxicity, has been reported with abiraterone acetate, leading to fatalities. Monitor liver function tests regularly and interrupt or discontinue treatment as necessary. The drug itself is associated with the risk of severe hepatotoxicity, which can have cardiovascular consequences.

4. In combination with radium Ra 223 dichloride, abiraterone acetate has been linked to increased fractures and mortality, leading to recommendations against this combination. The drug itself is associated with the risk of increased fractures and mortality when used in combination with radium Ra 223 dichloride, which can impact cardiovascular health.

5. Cardiac failure occurred more frequently in patients treated with abiraterone acetate compared to placebo, with grade 3-4 cardiac failure leading to treatment discontinuations and deaths. The drug itself is associated with the risk of cardiac failure, which can be a serious cardiovascular adverse reaction.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",b8967e10-f768-47ce-ac9e-2324c8390132,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=b8967e10-f768-47ce-ac9e-2324c8390132&type=display
5,ACALABRUTINIB,"1. The drug label mentions that Grade 3 atrial fibrillation or flutter occurred in 1.1% of patients treated with CALQUENCE, with all grades of atrial fibrillation or flutter reported in 4.1% of all patients. The label advises monitoring for symptoms of arrhythmia and managing them appropriately. (The drug itself was associated with the risk of atrial fibrillation or flutter.)

2. Additionally, the label states that serious and fatal hemorrhagic events have occurred in patients with hematologic malignancies treated with CALQUENCE. Major hemorrhage occurred in 3.0% of patients, with fatal hemorrhage in 0.1% of patients. The label recommends considering the risks and benefits of antithrombotic agents when co-administered with CALQUENCE and monitoring patients for signs of bleeding. (The drug itself was associated with the risk of hemorrhagic events.)

3. The label also mentions that CALQUENCE may cause fetal harm and dystocia when administered to pregnant women based on animal studies. It advises pregnant women of the potential risk to a fetus. (The drug itself was associated with the risk of fetal harm and dystocia in pregnant women based on animal studies.)

Overall, CALQUENCE is associated with cardiotoxicity risks such as atrial fibrillation, flutter, and hemorrhagic events, as well as potential risks to fetal development in pregnant women based on animal studies.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",b1409184-3267-4d8c-8f17-4e01f69828b1,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=b1409184-3267-4d8c-8f17-4e01f69828b1&type=display
6,ACAMPROSATE CALCIUM,"1. The drug label does not mention any cardiotoxicity risks or cardiotoxicity reactions associated with the use of Campral (acamprosate calcium). 

Therefore, based on the information provided in the drug label, there are no indications that Campral is associated with cardiotoxicity risks or reactions.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",fe6f754f-62b4-4c86-805d-221332409516,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fe6f754f-62b4-4c86-805d-221332409516&type=display
7,ACARBOSE,"1. The drug label does not mention any direct association or causation of cardiotoxicity risks with the drug itself.
2. The drug label does not mention any direct association or causation of cardiotoxicity reactions with the drug itself.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",c85bc02a-bf18-4690-84b8-2c256bce5f9f,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=c85bc02a-bf18-4690-84b8-2c256bce5f9f&type=display
8,ACEBUTOLOL HYDROCHLORIDE,"1. **Warnings - Cardiac Failure**: The drug itself is associated with the risk of exacerbating cardiac failure due to its inhibition of sympathetic stimulation, which may be essential for supporting circulation in individuals with diminished myocardial contractility. The label advises caution in patients with a history of heart failure controlled with digitalis and/or diuretics when using this drug.

2. **Warnings - In Patients Without a History of Cardiac Failure**: The drug itself is associated with the risk of potentially leading to cardiac failure in patients with aortic or mitral valve disease or compromised left ventricular function due to continued depression of the myocardium with beta-blocking agents over time.

3. **Warnings - Exacerbation of Ischemic Heart Disease Following Abrupt Withdrawal**: The drug itself is associated with the risk of exacerbating angina pectoris and myocardial infarction following abrupt cessation of therapy, particularly in patients with coronary artery disease. The label advises against interrupting therapy without medical advice and recommends gradual withdrawal over about two weeks.

4. **Warnings - Peripheral Vascular Disease**: The drug itself is associated with the risk of reducing cardiac output and potentially worsening arterial insufficiency symptoms in patients with peripheral or mesenteric vascular disease. Caution is advised in such patients to monitor for progression of arterial obstruction.

5. **Warnings - Bronchospastic Disease**: The drug itself is associated with the risk of potentially aggravating bronchospastic disease due to its beta-blocking effects. While low doses may be cautiously used in patients with bronchospastic disease, the label recommends close monitoring and availability of bronchodilators.

6. **Warnings - Anesthesia and Major Surgery**: The drug itself is associated with the risk of impairing the heart's ability to respond to adrenergically mediated reflex stimuli during anesthesia, potentially leading to excessive myocardial depression. Caution is advised when using anesthetic agents that depress the myocardium, and careful monitoring is recommended.

7. **Warnings - Diabetes and Hypoglycemia**: The drug itself is associated with the risk of potentiating insulin-induced hypoglycemia and masking some of its manifestations, such as tachycardia, in diabetic patients. Patients are advised to be aware of the possibility of masked hypoglycemia.

8. **Warnings - Thyrotoxicosis**: The drug itself is associated with the risk of masking clinical signs of hyperthyroidism, such as tachycardia. Abrupt withdrawal of beta-blockade may precipitate a thyroid storm, necessitating close monitoring in patients suspected of developing thyrotoxicosis when withdrawing the drug.",Less,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",7eee95bf-0452-4d6e-9712-33403768695a,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7eee95bf-0452-4d6e-9712-33403768695a&type=display
9,ACETAMINOPHEN,"1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with the use of Acetaminophen Injection itself. 

2. However, it is important to note that acetaminophen has been associated with cases of acute liver failure, which can have indirect effects on the cardiovascular system due to the liver's role in metabolism and detoxification. 

3. Additionally, caution should be exercised when administering acetaminophen in patients with conditions such as severe hepatic impairment, active hepatic disease, alcoholism, chronic malnutrition, severe hypovolemia, or severe renal impairment, as these conditions may indirectly impact cardiovascular function. 

4. No direct cardiotoxicity risks or reactions related to the use of Acetaminophen Injection were explicitly mentioned in the drug label.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",88c29438-3648-4b09-bd43-70ad7a35bcb5,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=88c29438-3648-4b09-bd43-70ad7a35bcb5&type=display
10,ACETAZOLAMIDE,"1. The drug label mentions that acetazolamide therapy is contraindicated in situations where sodium and/or potassium blood serum levels are depressed, in cases of marked kidney and liver disease or dysfunction, in suprarenal gland failure, and in hyperchloremic acidosis, indicating that the drug itself is associated with cardiotoxicity risks.

2. Long-term administration of acetazolamide is contraindicated in patients with chronic noncongestive angle-closure glaucoma since it may permit organic closure of the angle to occur while the worsening glaucoma is masked by lowered intraocular pressure, suggesting that the drug itself can lead to cardiotoxicity reactions.

3. The drug label also warns about the potential for metabolic acidosis, electrolyte imbalance (including hypokalemia and hyponatremia), and loss of appetite as adverse reactions to acetazolamide, indicating that the drug itself can cause cardiotoxicity reactions.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",923031ec-8142-4570-b3a6-210441d97105,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=923031ec-8142-4570-b3a6-210441d97105&type=display
11,ACETOHYDROXAMIC ACID,"1. The drug label mentions that superficial phlebitis involving the lower extremities occurred in several patients during early clinical trials, with one patient developing deep vein thrombosis. It is unclear whether the phlebitis was related to or exacerbated by treatment with the drug. No patient in the later controlled clinical trial developed phlebitis. Embolic phenomena were reported in three patients taking the drug in the Phase II trial, and these resolved following discontinuation of the drug and appropriate medical therapy. (The drug was associated with potential cardiotoxicity risks and reactions, including phlebitis and embolic phenomena.)

2. Palpitations have been reported in patients taking the drug. (The drug was associated with potential cardiotoxicity risks and reactions, including palpitations.)

3. Radiographic evidence of small pulmonary emboli was seen in three patients with phlebitis in their lower legs. (The drug was associated with potential cardiotoxicity risks and reactions, including pulmonary emboli.)

4. The drug label also mentions that the most serious side effects seem to occur in patients with poor kidney function and/or in patients with a previous history of these conditions. (The drug was associated with potential cardiotoxicity risks and reactions in patients with poor kidney function or a history of such conditions.)

5. The drug label advises that unusual symptoms should be reported to the physician, as mild symptoms usually do not warrant discontinuation of treatment, while severe symptoms may necessitate temporary cessation of treatment and/or alteration of dosage. (The drug was associated with potential cardiotoxicity risks and reactions that may require medical attention and possible treatment adjustments.)",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",6660b616-a82d-9109-19ce-2bdf9747acea,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=6660b616-a82d-9109-19ce-2bdf9747acea&type=display
12,ACETYLCHOLINE CHLORIDE,"1. The drug label mentions that adverse reactions have been reported rarely, indicating systemic absorption, with potential cardiotoxic effects such as bradycardia, hypotension, flushing, breathing difficulties, and sweating. The drug itself is associated with the risk of systemic absorption leading to these cardiotoxic reactions.

2. In cases of overdosage, the label recommends the use of atropine sulfate or epinephrine to counteract possible cardiotoxic effects like severe cardiovascular responses. The drug itself can lead to potential cardiotoxicity in cases of overdosage.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",e701ef07-9499-4b56-931f-f4eb3eedbe24,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=e701ef07-9499-4b56-931f-f4eb3eedbe24&type=display
13,ACETYLCYSTEINE,"1. The drug label mentions that serious acute hypersensitivity reactions, including rash, hypotension, wheezing, and shortness of breath, have been observed in patients receiving intravenous acetylcysteine for acetaminophen overdose. The label states that these reactions occurred soon after the initiation of the infusion, indicating that the drug itself may be associated with cardiotoxicity risks.

2. The label also notes that one patient with asthma developed bronchospasm and died after intravenous administration of acetylcysteine. It suggests that ACETADOTE should be used with caution in patients with asthma or a history of bronchospasm, indicating a potential association between the drug and cardiotoxicity reactions.

3. Additionally, the label mentions that acute flushing and erythema of the skin may occur in patients receiving acetylcysteine intravenously. It states that these reactions usually occur 30 to 60 minutes after initiating the infusion and may resolve spontaneously, but if the reaction involves more than flushing and erythema, it should be treated as a hypersensitivity reaction. This suggests that the drug itself may be associated with cardiotoxicity risks.

4. The label further discusses the incidence of drug-related adverse reactions during a loading dose/infusion rate study, where hypersensitivity reactions were compared between a 15-minute and 60-minute intravenous infusion of acetylcysteine. The study showed that 17% of patients developed acute hypersensitivity reactions, indicating a potential association between the drug and cardiotoxicity reactions.

5. In a safety study conducted in Canada, the label reports that the incidence of hypersensitivity reactions in adult patients receiving intravenous acetylcysteine was 8%, with reactions such as urticaria/facial flushing, pruritus, respiratory symptoms, edema, hypotension, and anaphylaxis. This data suggests a potential association between the drug and cardiotoxicity risks.

6. The label also mentions the distribution of reported hypersensitivity reactions in pediatric patients receiving intravenous acetylcysteine, with an overall incidence of 10%. This includes reactions such as urticaria/facial flushing, pruritus, respiratory symptoms, edema, anaphylaxis, and hypotension, indicating a potential association between the drug and cardiotoxicity reactions in pediatric populations.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",472f158a-5ab9-4308-8e49-1116e6ea3d39,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=472f158a-5ab9-4308-8e49-1116e6ea3d39&type=display
14,ACETYLSALICYLIC ACID,"1. The drug DURLAZA is indicated to reduce the risk of death and myocardial infarction in patients with chronic coronary artery disease, such as those with a history of MI or unstable angina pectoris, suggesting a potential benefit in reducing cardiotoxic events. (Drug associated with reducing cardiotoxicity risk)

2. DURLAZA is contraindicated in patients with a hypersensitivity to nonsteroidal anti-inflammatory drugs (NSAIDs) and in patients with the syndrome of asthma, rhinitis, and nasal polyps, which may cause severe urticaria, angioedema, or bronchospasm, potentially leading to cardiotoxic reactions. (Drug associated with potential cardiotoxic reactions)

3. DURLAZA may cause gastric ulceration and bleeding, particularly in patients with active peptic ulcer disease, which can lead to complications such as anemia and hemodynamic instability, potentially impacting cardiac function. (Drug associated with potential cardiotoxic reactions)

4. DURLAZA can cause fetal harm when administered to a pregnant woman, potentially affecting the development of the fetus, including cardiovascular structures, leading to cardiotoxic effects in the unborn child. (Drug associated with potential cardiotoxic reactions)",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",4c2a1403-3862-1efd-0a91-444989222b37,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=4c2a1403-3862-1efd-0a91-444989222b37&type=display
15,ACITRETIN,"1. The drug label mentions that acitretin is contraindicated in patients with chronic abnormally elevated blood lipid values, indicating a potential risk of cardiotoxicity associated with the drug itself.

2. The label also states that there is a warning about possible cardiovascular effects associated with the use of acitretin, suggesting that the drug may be linked to cardiotoxicity reactions.

3. Additionally, the label mentions that there have been reports of hepatitis-related deaths worldwide in subjects who received etretinate (the active metabolite of acitretin) for a short period before presenting with hepatic symptoms or signs, indicating a potential risk of cardiotoxicity associated with the drug.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",a5be620f-d721-40c1-a062-d21c70bfcbed,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a5be620f-d721-40c1-a062-d21c70bfcbed&type=display
16,ACYCLOVIR,1. The drug label for ZOVIRAX Cream does not mention any cardiotoxicity risks or cardiotoxicity reactions associated with the use of the drug.,No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",125dbe4e-94ba-45bd-a714-f9c4b8e8b5c2,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=125dbe4e-94ba-45bd-a714-f9c4b8e8b5c2&type=display
17,ADEFOVIR DIPIVOXIL,"1. The drug label for HEPSERA does not mention any specific cardiotoxicity risks or reactions associated with the drug itself. 

2. The label primarily focuses on warnings and precautions related to severe acute exacerbations of hepatitis, nephrotoxicity, HIV resistance, lactic acidosis, and severe hepatomegaly with steatosis. 

3. While the label does not directly mention cardiotoxicity risks or reactions, it is important to note that patients with underlying renal dysfunction or taking concomitant nephrotoxic agents may be at higher risk for adverse renal effects, which could indirectly impact cardiovascular health. 

4. Overall, the drug label does not highlight any direct cardiotoxicity risks or reactions specifically attributed to HEPSERA.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",80595d45-2224-47d1-bd5c-4b11a824e5bd,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=80595d45-2224-47d1-bd5c-4b11a824e5bd&type=display
18,ADENOSINE,"1. The drug label mentions that adenosine injection, USP may produce a short-lasting first-, second-, or third-degree heart block, which is a cardiotoxicity risk associated with the drug's mechanism of action in decreasing conduction through the A-V node (caused by the drug).
   
2. The label also warns that patients who develop high-level block on one dose of adenosine injection, USP should not be given additional doses, as this effect is generally self-limiting but requires appropriate therapy (associated with the drug).

3. Additionally, the label states that transient or prolonged episodes of asystole have been reported with fatal outcomes in some cases, and ventricular fibrillation has been rarely reported following adenosine injection, USP administration, particularly when used concomitantly with digoxin and verapamil (associated with the drug).

4. The label further mentions that at the time of conversion to normal sinus rhythm, various new rhythms may appear on the electrocardiogram, such as premature ventricular contractions, atrial premature contractions, atrial fibrillation, sinus bradycardia, sinus tachycardia, skipped beats, and varying degrees of A-V nodal block, with these findings observed in 55% of patients (associated with the drug).

5. Moreover, the label cautions that adenosine injection, USP may cause bronchoconstriction in patients with obstructive lung disease, such as asthma, and should be used with caution in such patients, as respiratory compromise has occurred during adenosine infusion in patients with obstructive pulmonary disease (associated with the drug).

6. The label also reports post-marketing adverse events related to cardiovascular effects, including prolonged asystole, ventricular tachycardia, ventricular fibrillation, transient increase in blood pressure, bradycardia, atrial fibrillation, and Torsades de Pointes, which have been reported with adenosine injection, USP (associated with the drug).",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",1809fc7e-f5d8-18d8-e063-6394a90a7713,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=1809fc7e-f5d8-18d8-e063-6394a90a7713&type=display
19,AFATINIB,"1. In the clinical trials experience section, it is mentioned that ventricular dysfunction was observed in 2.2% of patients treated with GILOTRIF, which is defined as diastolic dysfunction, left ventricular dysfunction, or ventricular dilation, all below Grade 3 severity. This suggests that GILOTRIF may be associated with ventricular dysfunction.

2. The same section reports that fatal adverse reactions in GILOTRIF-treated patients included pulmonary toxicity/ILD-like adverse reactions, sepsis, and pneumonia. This indicates that GILOTRIF may be associated with pulmonary toxicity and pneumonia, which can have cardiotoxic effects.

3. Additionally, in the previously treated, metastatic squamous NSCLC trial, serious adverse reactions occurred in 44% of patients treated with GILOTRIF, with the most frequent serious adverse reactions being pneumonia, diarrhea, dehydration, and dyspnea. This suggests that GILOTRIF may be associated with serious cardiotoxic effects such as pneumonia and dehydration.

4. Furthermore, the clinical trials excluded patients with abnormal left ventricular ejection fraction (LVEF) below the institutional lower limit of normal. This exclusion criterion implies that GILOTRIF may have potential cardiotoxic effects on LVEF.

Overall, the drug label indicates that GILOTRIF may be associated with cardiotoxicity risks and reactions, including ventricular dysfunction, pulmonary toxicity, pneumonia, and potential effects on LVEF.",Less,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",fd638e5e-8032-e7ca-0179-95e96ab5d387,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fd638e5e-8032-e7ca-0179-95e96ab5d387&type=display
20,ALBENDAZOLE,1. The drug label for Albendazole tablets does not mention any cardiotoxicity risks or cardiotoxicity reactions associated with the use of the drug.,No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",06b5eefc-0b95-4862-b9b6-770063f2adf0,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=06b5eefc-0b95-4862-b9b6-770063f2adf0&type=display
21,ALBUTEROL,"1. The drug label mentions that albuterol tablets, like all other beta-adrenergic agonists, can produce a clinically significant cardiovascular effect in some patients as measured by pulse rate, blood pressure, and/or symptoms. This indicates that the drug itself is associated with the risk of cardiotoxicity.

2. It further states that beta-agonists have been reported to produce electrocardiogram (ECG) changes, such as flattening of the T wave, prolongation of the QTc interval, and ST segment depression. The clinical significance of these findings is unknown. This suggests that the drug may cause ECG changes associated with cardiotoxicity, but the impact of these changes is uncertain.

3. The label also warns about the potential for deterioration of asthma, indicating that if the patient needs more doses of albuterol tablets than usual, it may be a marker of destabilization of asthma. This requires reevaluation of the patient and the treatment regimen, with special consideration for the possible need for anti-inflammatory treatment. This does not directly relate to cardiotoxicity but highlights the importance of monitoring and managing asthma to prevent exacerbations that could lead to cardiovascular complications.

4. Additionally, the label mentions that albuterol tablets, like other beta-adrenergic agonists, can produce a significant cardiovascular effect in some patients, as measured by pulse rate, blood pressure, symptoms, and/or electrocardiographic changes. This indicates that the drug itself can lead to cardiovascular effects in patients.

5. The label also discusses the potential for adverse reactions such as hypertension, angina, and other cardiovascular symptoms, which can be caused by albuterol tablets. This suggests that the drug may contribute to cardiotoxicity reactions in some individuals.",Less,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",601a18ed-d66e-498f-a804-f1a3330827d4,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=601a18ed-d66e-498f-a804-f1a3330827d4&type=display
22,ALCOHOL,"1. **Warnings and Precautions:**
   - **Cardiotoxicity Risk:** The drug ABLYSINOL (dehydrated alcohol) injection is associated with transient heart block at the time of injection, which is common. A temporary pacing wire is routinely inserted to mitigate this risk.
   - **Cardiotoxicity Reaction:** Approximately 10% of complete heart block events following the injection of ABLYSINOL become permanent and may require placement of a permanent pacemaker. This indicates a direct association between the drug and the risk of persistent heart block.

2. **Warnings and Precautions:**
   - **Cardiotoxicity Risk:** Patients should be monitored for heart failure, chest pain, and arrhythmias several days after the procedure involving ABLYSINOL injection. This suggests a potential cardiotoxicity risk associated with the drug.
   - **Cardiotoxicity Reaction:** Adverse reactions reported include arrhythmias, such as ventricular tachycardia and/or ventricular fibrillation, indicating a direct link between the drug and cardiotoxicity reactions.

3. **Warnings and Precautions:**
   - **Cardiotoxicity Risk:** Ventricular tachycardia and ventricular fibrillation requiring electrocardioversion occurred at a frequency of approximately 1% following the administration of ABLYSINOL. This highlights a potential cardiotoxicity risk associated with the drug.
   - **Cardiotoxicity Reaction:** Continuous electrocardiographic monitoring for 48 hours post-procedure is recommended to monitor for potential ventricular arrhythmias, indicating a direct association between the drug and cardiotoxicity reactions.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",314b1dab-8f4f-49ae-a105-f974842818b8,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=314b1dab-8f4f-49ae-a105-f974842818b8&type=display
23,ALECTINIB HYDROCHLORIDE,"1. The drug label for ALECENSA (alectinib) includes warnings and precautions regarding bradycardia, a condition where the heart rate is slower than normal. The label states that symptomatic bradycardia occurred in patients treated with ALECENSA, with 11% of patients experiencing this adverse reaction. The drug itself was associated with the risk of symptomatic bradycardia.

2. The label advises monitoring heart rate and blood pressure regularly for patients taking ALECENSA. It recommends withholding the drug if symptomatic bradycardia occurs until recovery to asymptomatic bradycardia or to a heart rate of 60 bpm or above. The drug itself was associated with the risk of symptomatic bradycardia and provided guidance on managing this adverse reaction.

3. In cases of life-threatening bradycardia, the label recommends permanently discontinuing ALECENSA if no contributing concomitant medication is identified. If a contributing concomitant medication is identified and adjusted, the drug may be resumed at a reduced dose upon recovery to asymptomatic bradycardia or to a heart rate of 60 bpm or above. The drug itself was associated with the risk of life-threatening bradycardia and provided instructions for managing this severe adverse reaction.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",42c49deb-713b-427a-9670-08af08adcffb,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=42c49deb-713b-427a-9670-08af08adcffb&type=display
24,ALENDRONATE SODIUM,"1. **Contraindications**: FOSAMAX is contraindicated in patients with abnormalities of the esophagus that delay esophageal emptying, inability to stand or sit upright for at least 30 minutes, and hypocalcemia, but there is no direct mention of cardiotoxicity risks associated with the drug itself.

2. **Warnings and Precautions - Upper Gastrointestinal Adverse Reactions**: FOSAMAX may cause local irritation of the upper gastrointestinal mucosa, potentially leading to esophageal adverse experiences. Patients are advised to follow dosing instructions to minimize the risk of esophageal reactions. The drug itself is associated with the risk of esophageal adverse reactions, not cardiotoxicity.

3. **Warnings and Precautions - Mineral Metabolism**: Hypocalcemia must be corrected before initiating therapy with FOSAMAX. The drug may cause small, asymptomatic decreases in serum calcium and phosphate levels, especially in patients with certain conditions. While this section discusses mineral metabolism, it does not directly link FOSAMAX to cardiotoxicity risks.

4. **Warnings and Precautions - Musculoskeletal Pain**: Severe and occasionally incapacitating bone, joint, and muscle pain have been reported in patients taking bisphosphonates, including FOSAMAX. However, this section does not mention any direct association between FOSAMAX and cardiotoxicity risks.

5. **Warnings and Precautions - Osteonecrosis of the Jaw**: Osteonecrosis of the jaw (ONJ) has been reported in patients taking bisphosphonates, including FOSAMAX. While this is a serious adverse reaction, it is specific to the jaw and not directly related to cardiotoxicity risks.

6. **Warnings and Precautions - Atypical Subtrochanteric and Diaphyseal Femoral Fractures**: Atypical femur fractures have been reported in bisphosphonate-treated patients, including those taking FOSAMAX. This section highlights a specific type of fracture but does not mention cardiotoxicity risks associated with the drug.

In summary, while FOSAMAX is associated with various adverse reactions and risks, including esophageal adverse reactions, musculoskeletal pain, and jaw-related issues, there is no direct mention of cardiotoxicity risks or cardiotoxic reactions in the drug label.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",14e931fd-2c5f-4d90-b7db-5980706f4a56,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56&type=display
25,ALFENTANIL HYDROCHLORIDE,"1. The drug label mentions that alfentanil hydrochloride injection may cause bradycardia, which is a slow heart rate. This indicates that the drug itself is associated with the risk of bradycardia.

2. Additionally, the label states that severe bradycardia and asystole (absence of heart contractions) have been successfully treated with atropine and conventional resuscitative methods. This suggests that the drug can lead to severe bradycardia and asystole, indicating a cardiotoxicity risk associated with alfentanil hydrochloride injection.

3. The label also highlights the importance of monitoring patients closely while receiving the drug and having atropine and other resuscitative equipment present. This emphasizes the need for vigilance regarding potential cardiotoxic reactions during the administration of alfentanil hydrochloride injection.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",098af6c6-7400-4b2b-bae6-03d5913ad712,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=098af6c6-7400-4b2b-bae6-03d5913ad712&type=display
26,ALFUZOSIN HYDROCHLORIDE,"1. Alfuzosin, the active ingredient in UROXATRAL, was evaluated for its effect on QT interval in a study with healthy male subjects. The study showed that the 40 mg dose of alfuzosin had a greater effect on QT interval compared to the 10 mg dose, but there was no signal of Torsade de Pointes in post-marketing experience outside the United States.

2. A separate study evaluated the co-administration of alfuzosin with a drug of similar QT effect size. The study showed that the co-administration increased the QT effect, but the increase was not more than additive. The clinical impact of these QT changes is unknown.

3. UROXATRAL has been associated with cardiac disorders such as tachycardia, chest pain, angina pectoris in patients with pre-existing coronary artery disease, and atrial fibrillation in post-marketing experience. These reactions were reported voluntarily, and the frequency of occurrence is uncertain.

4. UROXATRAL has been associated with a mean placebo-subtracted QTcF increase of 1.9 msec when administered alone. Co-administration with a drug of similar QT effect size showed an increased QT effect, but the increase was not more than additive. The clinical significance of these QT changes is not fully understood.",Less,Yes,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",1c5502c7-7731-4d3e-b4fe-7fd44dd5908b,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=1c5502c7-7731-4d3e-b4fe-7fd44dd5908b&type=display
27,ALLOPURINOL,"1. The drug label for ALOPRIM does not mention any specific cardiotoxicity risks or reactions associated with the drug itself. 

2. The label primarily focuses on indications, dosage, administration, contraindications, warnings, precautions, adverse reactions, drug interactions, and use in specific populations, but does not highlight any cardiotoxicity risks related to ALOPRIM.

3. While the label provides detailed information on skin rash, hypersensitivity, renal function impairment, hepatotoxicity, myelosuppression, and drowsiness as potential adverse reactions, there is no mention of cardiotoxicity risks or reactions attributed to ALOPRIM. 

4. The drug label emphasizes the importance of monitoring renal function, liver enzymes, and blood counts, but does not discuss any cardiotoxic effects or risks associated with ALOPRIM use.

5. Overall, the drug label for ALOPRIM does not indicate any direct association between the drug and cardiotoxicity risks or reactions. It primarily focuses on other potential adverse effects and precautions related to the use of ALOPRIM in patients with specific medical conditions.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",10cc918f-aa44-415b-932d-2404695ac449,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=10cc918f-aa44-415b-932d-2404695ac449&type=display
28,ALMOTRIPTAN,"1. Almotriptan tablets are associated with serious adverse cardiac events, including acute myocardial infarction and life-threatening disturbances of cardiac rhythm. The incidence of these events is extremely low, and the drug can cause coronary vasospasm, which may lead to cardiac events. Patients with risk factors for coronary artery disease (CAD) should undergo a cardiovascular evaluation before using almotriptan tablets. The drug should not be given to patients with documented ischemic or vasospastic coronary artery disease.

2. Sensations of pain, tightness, pressure, and heaviness in the chest, throat, neck, and jaw have been reported after treatment with almotriptan tablets. Patients experiencing signs or symptoms suggestive of angina should be evaluated for CAD before receiving additional doses of the medication. Patients with CAD or Prinzmetal's variant angina should not receive almotriptan tablets.

3. Cerebrovascular events, including cerebral hemorrhage, subarachnoid hemorrhage, stroke, and fatalities, have been reported in patients treated with other triptans. Care should be taken to exclude other potentially serious neurological conditions before treating headaches with almotriptan tablets. Patients with migraine may be at increased risk of certain cerebrovascular events.

4. Almotriptan tablets may cause vasospastic reactions other than coronary artery vasospasm, such as peripheral and gastrointestinal vascular ischemia. Reports of transient and permanent blindness and significant partial vision loss have been associated with triptan use. Patients experiencing symptoms suggestive of decreased arterial flow should undergo further evaluation.

5. The development of serotonin syndrome, a potentially life-threatening condition, may occur with triptans like almotriptan tablets, especially when used in combination with selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs). Patients should be carefully monitored for symptoms of serotonin syndrome if concomitant treatment is necessary.

6. Overuse of acute migraine drugs, including almotriptan tablets, may lead to medication overuse headache. Detoxification of patients and treatment of withdrawal symptoms may be necessary. Patients should be advised on the risks of overusing migraine medications.

7. Almotriptan tablets have been associated with significant elevations in systemic blood pressure on rare occasions, both in patients with and without a history of hypertension. The drug is contraindicated in patients with uncontrolled hypertension. Small increases in blood pressure have been observed in clinical studies, and patients should be monitored for blood pressure changes during treatment.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",6fa380c4-c885-4743-85bf-88819ae68645,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=6fa380c4-c885-4743-85bf-88819ae68645&type=display
29,ALOSETRON HYDROCHLORIDE,"1. The drug label for LOTRONEX does not mention any direct association or causation of cardiotoxicity risks with the drug itself.

2. The label primarily focuses on serious gastrointestinal adverse reactions, including ischemic colitis and complications of constipation, which have been reported with the use of LOTRONEX. These events have resulted in hospitalization, blood transfusion, surgery, and death, but no direct mention of cardiotoxicity risks is made.

3. The adverse reactions section of the label does not list any cardiotoxicity reactions associated with LOTRONEX. Adverse reactions reported in clinical trials and postmarketing experience mainly focus on gastrointestinal issues like constipation, abdominal discomfort, and pain, rather than cardiotoxicity concerns.

Overall, based on the information provided in the drug label, LOTRONEX is not directly linked to cardiotoxicity risks or cardiotoxic reactions. The focus of the label is primarily on serious gastrointestinal adverse reactions and related complications.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",35cbb9d5-639b-207a-e054-00144ff88e88,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=35cbb9d5-639b-207a-e054-00144ff88e88&type=display
30,ALPELISIB,"1. VIJOICE is not approved for use in the oncology setting, where severe hypersensitivity reactions, including anaphylaxis, anaphylactic shock, and angioedema, have occurred in adult patients treated with alpelisib, the active ingredient in VIJOICE. Permanently discontinue VIJOICE in the event of severe hypersensitivity.

2. Severe cutaneous adverse reactions (SCARs), such as Stevens-Johnson syndrome (SJS), erythema multiforme (EM), toxic epidermal necrolysis (TEN), and drug reaction with eosinophilia and systemic symptoms (DRESS), have occurred in adult patients treated with alpelisib in the oncology setting and may occur in patients treated with VIJOICE. If signs or symptoms of SCARs occur, interrupt VIJOICE until the etiology of the reaction has been determined. Consultation with a dermatologist is recommended.

3. Severe hyperglycemia, associated with hyperglycemic hyperosmolar non-ketotic syndrome (HHNKS) or fatal cases of ketoacidosis, has occurred in adult patients treated with alpelisib in the oncology setting and may occur in patients treated with VIJOICE. Before initiating treatment with VIJOICE, test fasting plasma glucose (FPG), HbA1c, and optimize blood glucose. Monitor fasting glucose levels regularly and initiate or optimize anti-hyperglycemic medications as clinically indicated. Interrupt, reduce dose, or discontinue VIJOICE if severe hyperglycemia occurs.

4. Severe pneumonitis, including acute interstitial pneumonitis and interstitial lung disease, has occurred in adult patients treated with alpelisib in the oncology setting and may occur in patients treated with VIJOICE. In patients with new or worsening respiratory symptoms, interrupt VIJOICE immediately and evaluate for pneumonitis. Permanently discontinue VIJOICE in all patients with confirmed pneumonitis.

5. Severe diarrhea, leading to dehydration and in some cases acute kidney injury, as well as colitis, have occurred in adult patients treated with alpelisib in the oncology setting and may occur in patients treated with VIJOICE. Monitor for diarrhea and colitis symptoms, interrupt, reduce dose, or permanently discontinue VIJOICE based on the severity of these adverse reactions. Additional treatment may be necessary for patients with colitis.",Most,No,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",638069a4-aee0-46c9-9e21-54ad449c163c,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=638069a4-aee0-46c9-9e21-54ad449c163c&type=display
31,ALPRAZOLAM,"1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with XANAX XR itself. 

2. The adverse reactions section of the label includes infrequent reports of palpitations and sinus tachycardia, which are categorized under cardiac disorders. These reactions were observed in patients with panic disorder treated with XANAX XR during premarketing evaluation. However, it does not state that XANAX XR caused these cardiotoxicity risks.

3. The label also lists hypotension as an infrequent vascular disorder reported during premarketing evaluation of XANAX XR. Again, it does not directly attribute these vascular disorders to XANAX XR as a cause of cardiotoxicity risks.

Overall, while the drug label mentions some cardiac and vascular-related adverse reactions observed in patients taking XANAX XR, it does not explicitly state that XANAX XR is associated with cardiotoxicity risks or reactions.",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",aa58fff3-c297-49be-838b-599c32ad9835,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=aa58fff3-c297-49be-838b-599c32ad9835&type=display
32,ALPROSTADIL,"1. **Cardiotoxicity Risk**: The drug CAVERJECT is associated with potential cardiovascular risks related to underlying medical conditions. It is advised that treatments for erectile dysfunction, including CAVERJECT, should generally not be used in men for whom sexual activity is inadvisable due to their underlying cardiovascular status. The evaluation of erectile dysfunction should include identifying potential underlying causes and appropriate treatment following a complete medical assessment. (The drug itself is not causing cardiotoxicity but is associated with potential risks in patients with preexisting cardiovascular conditions.)

2. **Cardiotoxicity Reactions**: In clinical studies, systemic adverse reactions reported with CAVERJECT included dizziness in 1% of subjects. Other systemic reactions reported in <1% of patients included testicular pain, scrotal edema, hematuria, pelvic pain, hypotension, vasodilation, vasovagal reaction, diaphoresis, rash, and non-application site pruritus. Additionally, three patients (0.2%) discontinued treatment due to symptomatic hypotension. (The drug itself is associated with systemic adverse reactions, including hypotension, which is a cardiotoxicity reaction.)",Less,Yes,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",a295fc1e-d82c-4f44-bc2d-a552bf594c98,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a295fc1e-d82c-4f44-bc2d-a552bf594c98&type=display
33,ALVIMOPAN,"1. The drug label warns of a potential risk of myocardial infarction with long-term use of ENTEREG, as seen in a clinical trial where an increased incidence of myocardial infarction was observed in patients taking alvimopan for chronic non-cancer pain. The causal relationship with long-term use has not been established, indicating that the drug itself was associated with the cardiotoxicity risk.

2. The label specifies that ENTEREG is available only through a restricted program for short-term use due to the potential risk of myocardial infarction with long-term use, emphasizing that the drug itself was linked to the cardiotoxicity risk.

3. Patients recently exposed to opioids may be more sensitive to the effects of ENTEREG, potentially leading to gastrointestinal adverse reactions, but this is not directly related to cardiotoxicity risks associated with the drug.

4. The label mentions that patients with severe hepatic impairment are at an increased risk of serious adverse reactions due to higher plasma concentrations of alvimopan, and the use of ENTEREG is not recommended in this population. This indicates that the drug itself can lead to serious adverse reactions, including potential cardiotoxicity risks, in patients with severe hepatic impairment.

5. No studies have been conducted in patients with end-stage renal disease, complete gastrointestinal obstruction, or those with pancreatic or gastric anastomoses, and the use of ENTEREG is not recommended in these populations. While these conditions are not directly related to cardiotoxicity risks, they highlight the importance of caution in specific patient populations due to potential adverse reactions associated with the drug.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",77a67dc6-35d3-48ff-9d18-292d4d442f70,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=77a67dc6-35d3-48ff-9d18-292d4d442f70&type=display
34,AMANTADINE,"1. The drug label does not mention any specific cardiotoxicity risks associated with GOCOVRI itself.

2. In the section on overdosage, it is noted that deaths have been reported from overdose with amantadine, the active ingredient in GOCOVRI. Acute toxicity may be attributable to the anticholinergic effects of amantadine, and drug overdose has resulted in cardiac, respiratory, renal, or central nervous system toxicity. Pulmonary edema, respiratory distress, renal dysfunction, and central nervous system effects like agitation, lethargy, and coma have been reported with amantadine overdose. Hyperthermia and arrhythmias have also occurred with amantadine overdose.

3. The drug label does not mention any specific cardiotoxicity reactions associated with GOCOVRI itself.",Less,No,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",82ff865f-78f3-4c94-b6a9-727a54944b28,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=82ff865f-78f3-4c94-b6a9-727a54944b28&type=display
35,AMANTADINE HYDROCHLORIDE,"1. The drug label mentions that deaths have been reported from overdose with amantadine hydrochloride, with acute toxicity potentially attributable to the anticholinergic effects of the drug. This suggests that amantadine hydrochloride itself may be associated with cardiotoxicity risk.

2. The label also warns about cardiac dysfunction, including arrhythmia, tachycardia, and hypertension, as potential reactions to amantadine hydrochloride overdose. This indicates that the drug itself may cause cardiotoxicity reactions.

3. Additionally, the label mentions that drug overdose with amantadine hydrochloride has resulted in cardiac dysfunction, respiratory distress, renal dysfunction, and central nervous system effects, including arrhythmia, tachycardia, and hypertension. These adverse reactions suggest that amantadine hydrochloride can lead to cardiotoxicity risks and reactions.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",97d6bd4a-31ca-4b33-8353-a536835ef1e1,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=97d6bd4a-31ca-4b33-8353-a536835ef1e1&type=display
36,AMBRISENTAN,"1. The drug label warns about fluid retention as a known class effect of endothelin receptor antagonists, including Letairis. It states that there was an increased incidence of peripheral edema in patients treated with Letairis compared to placebo, indicating a potential cardiotoxicity risk associated with Letairis.

2. The label mentions that there have been postmarketing reports of fluid retention in patients with pulmonary hypertension, occurring within weeks after starting Letairis. Patients required intervention with a diuretic, fluid management, or hospitalization for decompensating heart failure, suggesting a potential cardiotoxicity reaction associated with Letairis.

3. It also highlights that if clinically significant fluid retention develops, further evaluation should be undertaken to determine the cause, such as Letairis or underlying heart failure, and the possible need for specific treatment or discontinuation of Letairis therapy. This indicates a potential cardiotoxicity risk associated with Letairis.

4. The label warns that peripheral edema/fluid retention is more common with Letairis plus tadalafil than with Letairis or tadalafil alone, suggesting a potential increased cardiotoxicity risk when Letairis is used in combination with tadalafil.

5. Additionally, the label mentions that if patients develop acute pulmonary edema during initiation of therapy with Letairis, the possibility of pulmonary veno-occlusive disease (PVOD) should be considered, and if confirmed, Letairis should be discontinued. This indicates a potential cardiotoxicity reaction associated with Letairis, specifically related to the risk of pulmonary edema in the context of PVOD.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",725d4e73-6c83-477a-adc6-0ae4a133a844,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=725d4e73-6c83-477a-adc6-0ae4a133a844&type=display
37,AMIFAMPRIDINE PHOSPHATE,"1. The drug FIRDAPSE (amifampridine) is a potassium channel blocker indicated for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults and pediatric patients 6 years of age and older. (No mention of cardiotoxicity risk associated with the drug itself)
   
2. FIRDAPSE can cause seizures, and seizures have been observed in patients without a history of seizures taking FIRDAPSE at the recommended doses, at various times after initiation of treatment, at an incidence of approximately 2%. Many of the patients were taking medications or had comorbid medical conditions that may have lowered the seizure threshold. (No mention of cardiotoxicity risk associated with the drug itself)

3. In a case report, a patient who inadvertently received a total daily amifampridine dose of 360 mg/day (more than 4 times the maximum recommended total daily dose) experienced general weakness, paresthesia, nausea, vomiting, palpitations, convulsions, and paroxysmal supraventricular tachycardia, ultimately leading to cardiac arrest. The patient recovered following withdrawal of amifampridine. (The drug FIRDAPSE was associated with cardiotoxicity reactions in this case)

4. FIRDAPSE was studied for its effect on QTc interval prolongation in healthy individuals, and at an exposure 2-fold the expected maximum therapeutic exposure of amifampridine, FIRDAPSE did not prolong QTc to any clinically relevant extent. (No mention of cardiotoxicity risk associated with the drug itself)

In summary, while FIRDAPSE has been associated with seizures and a case report of cardiotoxicity reactions, the drug itself was not directly linked to cardiotoxicity risks in the provided drug label information.",Less,Yes,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",f015fe60-3128-4a43-8c31-19fc6b5def3f,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=f015fe60-3128-4a43-8c31-19fc6b5def3f&type=display
38,AMIFOSTINE,"1. **Warnings and Precautions - Hypotension and Cardiovascular Events:** The drug ETHYOL is associated with hypotension and cardiovascular events. Patients who are hypotensive or dehydrated should not receive ETHYOL. Monitoring blood pressure during infusion is recommended, and interruption and restart of infusion may be necessary if a decrease in systolic blood pressure is observed. The drug should not be administered to hypotensive patients who are taking antihypertensive therapy that cannot be stopped for 24 hours prior to ETHYOL administration.

2. **Warnings and Precautions - Severe Cutaneous Reactions:** Severe cutaneous reactions, including fatal cases, have been reported in patients treated with ETHYOL. These reactions may include erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, and other severe skin reactions. Monitoring patients for severe cutaneous reactions is advised, and discontinuation of ETHYOL is recommended for certain types of reactions.

3. **Warnings and Precautions - Hypersensitivity:** Hypersensitivity reactions, including anaphylaxis, have been reported with ETHYOL administration. These reactions may include pyrexia, chills, dyspnea, chest discomfort, and skin reactions. Immediate discontinuation of ETHYOL is advised in cases of severe allergic reactions.

4. **Warnings and Precautions - Nausea and Vomiting:** Nausea and vomiting are common adverse reactions following ETHYOL infusion. Severe nausea and vomiting may occur, particularly in patients receiving chemotherapy. Antiemetic medication should be administered prior to and in conjunction with ETHYOL to manage these symptoms.

5. **Warnings and Precautions - Hypocalcemia:** ETHYOL use may lead to hypocalcemia in some patients. Monitoring serum calcium levels is recommended, especially in patients at risk of hypocalcemia. Calcium supplements may be necessary in cases of clinically significant hypocalcemia.

6. **Warnings and Precautions - Embryo-Fetal Toxicity:** ETHYOL can cause fetal harm when administered to pregnant women. Animal studies have shown embryotoxic effects at doses approximately sixty percent of the recommended human dose. Patients should be advised of the potential risk to a fetus and appropriate contraception measures should be discussed.

7. **Adverse Reactions - Hypotension and Cardiovascular Events:** Hypotension and cardiovascular events, including severe hypotension with serious sequelae, have been reported in patients treated with ETHYOL. These events may include apnea, dyspnea, chest pain, tachycardia, and cardiac arrest. Monitoring blood pressure and managing hypotension are essential during ETHYOL administration.

8. **Adverse Reactions - Severe Cutaneous Reactions:** Severe cutaneous reactions, such as erythema multiforme and toxic epidermal necrolysis, have been observed in patients receiving ETHYOL. These reactions may develop weeks after drug initiation and require careful monitoring. Discontinuation of ETHYOL is recommended for certain cutaneous reactions.

9. **Adverse Reactions - Hypersensitivity:** Hypersensitivity reactions, including anaphylaxis, have been reported post-marketing with ETHYOL use. Symptoms may include pruritus, urticaria, dyspnea, and laryngeal edema. Immediate discontinuation of ETHYOL is advised in cases of severe hypersensitivity reactions.

10. **Adverse Reactions - Nausea and Vomiting:** Nausea and vomiting are common adverse reactions following ETHYOL infusion, with severe cases reported. Antiemetic medication should be administered to manage these symptoms, especially in patients receiving highly emetogenic chemotherapy.

These sections of the drug label highlight the potential cardiotoxicity risks and reactions associated with ETHYOL, emphasizing the importance of monitoring, management, and appropriate interventions to ensure patient safety.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",973ed458-f46b-4f61-a329-816c4db79a2c,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=973ed458-f46b-4f61-a329-816c4db79a2c&type=display
39,AMIKACIN SULFATE,"1. The drug label warns that patients treated with parenteral aminoglycosides, including amikacin, should be closely monitored for potential ototoxicity and nephrotoxicity risks. (The drug itself is not directly associated with cardiotoxicity risk in this sentence.)

2. The label mentions that neurotoxicity, including vestibular and permanent bilateral auditory ototoxicity, can occur in patients with preexisting renal damage or normal renal function when treated with higher doses or for longer periods than recommended. (The drug itself is not directly associated with cardiotoxicity risk in this sentence.)

3. Aminoglycosides, including amikacin, are potentially nephrotoxic, with a greater risk in patients with impaired renal function or those receiving high doses or prolonged therapy. (The drug itself is not directly associated with cardiotoxicity risk in this sentence.)

4. The label cautions that neuromuscular blockade and respiratory paralysis have been reported following various routes of aminoglycoside administration, especially in patients receiving certain medications. (The drug itself is not directly associated with cardiotoxicity risk in this sentence.)

5. The drug label advises close monitoring of renal function and eighth-nerve function in patients with known or suspected renal impairment, as well as in those who develop signs of renal dysfunction during therapy with amikacin. (The drug itself is not directly associated with cardiotoxicity risk in this sentence.)

6. The label recommends avoiding concurrent use of amikacin with other neurotoxic or nephrotoxic products to reduce the risk of toxicity, especially in elderly patients and those who are dehydrated. (The drug itself is not directly associated with cardiotoxicity risk in this sentence.)

7. The drug label warns against the concurrent use of amikacin with potent diuretics, as diuretics themselves may cause ototoxicity and enhance aminoglycoside toxicity. (The drug itself is not directly associated with cardiotoxicity risk in this sentence.)

8. The label mentions that aminoglycosides, including amikacin, should be used with caution in patients with muscular disorders like myasthenia gravis or parkinsonism due to their potential neuromuscular effects. (The drug itself is not directly associated with cardiotoxicity risk in this sentence.)

Overall, the drug label for amikacin does not directly associate the drug with cardiotoxicity risks or cardiotoxic reactions. The focus is primarily on ototoxicity, nephrotoxicity, and neurotoxicity as potential adverse effects of amikacin use.",Less,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",0b56f6df-a05d-4520-8bf0-d7cefe20f6ad,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=0b56f6df-a05d-4520-8bf0-d7cefe20f6ad&type=display
40,AMILORIDE HYDROCHLORIDE,"1. The drug label mentions that amiloride HCl, when used alone, has weak diuretic and antihypertensive effects, and when used with thiazide diuretics, it may have additive effects. However, it states that amiloride HCl has little additive diuretic or antihypertensive effect when added to a thiazide diuretic, indicating that the drug itself is not associated with significant cardiotoxicity risks.

2. The label also highlights that hyperkalemia, a condition characterized by elevated serum potassium levels, can occur with the use of amiloride HCl. It mentions that hyperkalemia is a potential adverse effect of the drug, especially when used without a kaliuretic diuretic, and that careful monitoring of serum potassium levels is essential. This indicates that amiloride HCl itself can lead to cardiotoxicity risks associated with hyperkalemia.

3. Additionally, the label warns that the risk of hyperkalemia may be increased when potassium-conserving agents, including amiloride HCl, are administered concomitantly with certain other medications like angiotensin-converting enzyme inhibitors or angiotensin II receptor antagonists. This suggests that the drug itself can contribute to cardiotoxicity risks when used in combination with specific medications.

4. The label further mentions that in diabetic patients, hyperkalemia has been reported with the use of all potassium-conserving diuretics, including amiloride HCl, even in patients without evidence of diabetic nephropathy. This indicates that amiloride HCl itself can pose cardiotoxicity risks in diabetic patients due to the potential for hyperkalemia.

Overall, the drug label for amiloride HCl highlights the potential cardiotoxicity risks associated with hyperkalemia when using the drug, especially in specific patient populations or when combined with certain medications. It emphasizes the importance of monitoring serum potassium levels and being cautious with the use of amiloride HCl to mitigate these risks.",Less,Yes,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",1cf090a2-b6c0-42cd-857e-60a9cd85fe19,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=1cf090a2-b6c0-42cd-857e-60a9cd85fe19&type=display
41,AMINOCAPROIC ACID,"1. The drug label mentions that subendocardial hemorrhages were observed in dogs and monkeys given high doses of AMICAR, indicating a potential cardiotoxicity risk associated with the drug itself.
   
2. Fatty degeneration of the myocardium was reported in dogs and monkeys given intravenous doses of AMICAR, suggesting a potential cardiotoxicity risk associated with the drug itself.

3. Rare cases of skeletal muscle weakness with necrosis of muscle fibers have been reported following prolonged administration of AMICAR, with the possibility of cardiac muscle damage when skeletal myopathy occurs, indicating a potential cardiotoxicity risk associated with the drug itself.

4. One case of cardiac and hepatic lesions was observed in a patient who received high doses of AMICAR, leading to death due to continued cerebrovascular hemorrhage, suggesting a potential cardiotoxicity risk associated with the drug itself.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",2238c70f-b0b5-4755-896b-45b28777b217,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=2238c70f-b0b5-4755-896b-45b28777b217&type=display
42,AMINOPHYLLINE,"1. The drug label mentions that aminophylline should be used with extreme caution in patients with active peptic ulcer disease, seizure disorders, and cardiac arrhythmias due to the increased risk of exacerbation of the concurrent condition. (The drug itself was not associated with cardiotoxicity but may exacerbate existing conditions.)

2. It also states that conditions such as acute pulmonary edema, congestive heart failure, cor pulmonale, fever, hypothyroidism, liver disease, sepsis with multi-organ failure, and shock can reduce theophylline clearance, leading to severe and potentially fatal theophylline toxicity if the infusion rate is not appropriately reduced. (The drug itself was not associated with cardiotoxicity but may lead to toxicity in patients with these conditions.)

3. The label warns that cessation of smoking can affect theophylline clearance, with abstinence causing a reduction in clearance and resumption of smoking leading to increased clearance. (The drug itself was not associated with cardiotoxicity but changes in smoking habits can impact theophylline levels.)

4. It mentions that fever, regardless of its underlying cause, can decrease the clearance of theophylline, with the magnitude and duration of the fever directly correlated to the degree of decrease in clearance. (The drug itself was not associated with cardiotoxicity but fever can impact theophylline clearance.)

5. The label advises careful attention to dose reduction and frequent monitoring of serum theophylline concentrations in patients with various conditions that can affect theophylline clearance, such as hepatic insufficiency, congestive heart failure, and renal insufficiency. (The drug itself was not associated with cardiotoxicity but dose adjustments are necessary in patients with these conditions.)

6. It also highlights that theophylline clearance is decreased in patients with congestive heart failure, with the extent of reduction correlated to the severity of the cardiac disease. (The drug itself was not associated with cardiotoxicity but clearance is reduced in patients with congestive heart failure.)

7. The label mentions that theophylline clearance is decreased by 50% or more in patients with hepatic insufficiency, such as cirrhosis or acute hepatitis, requiring careful dose reduction and monitoring of serum theophylline concentrations. (The drug itself was not associated with cardiotoxicity but clearance is reduced in patients with hepatic insufficiency.)

8. It states that careful attention to dosage selection and monitoring of serum theophylline concentrations are required in children, especially neonates, due to low clearance rates and the need for dose adjustments. (The drug itself was not associated with cardiotoxicity but dose adjustments are necessary in pediatric patients.)

In summary, while aminophylline itself was not directly associated with cardiotoxicity risks, the drug label emphasizes the importance of monitoring and dose adjustments in patients with various conditions that can impact theophylline clearance and increase the risk of theophylline toxicity, including cardiac conditions, hepatic insufficiency, renal insufficiency, and changes in smoking habits.",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",9066bdd0-cb03-40ed-abfa-1b6fb1fff607,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=9066bdd0-cb03-40ed-abfa-1b6fb1fff607&type=display
43,AMIODARONE HYDROCHLORIDE,"1. **Cardiotoxicity Risk**: NEXTERONE is contraindicated in patients with marked sinus bradycardia and second- or third-degree atrioventricular (AV) block unless a pacemaker is available. This indicates that the drug itself is associated with the risk of exacerbating these conditions.

2. **Cardiotoxicity Reaction**: The most common adverse reactions leading to discontinuation of intravenous amiodarone therapy include hypotension, asystole/cardiac arrest/pulseless electrical activity, ventricular tachycardia (VT), and cardiogenic shock. This suggests that the drug can lead to cardiotoxic reactions in patients.

3. **Cardiotoxicity Risk**: NEXTERONE can cause bradycardia and AV block, which may require slowing the infusion rate or discontinuing the drug. In some cases, inserting a pacemaker is necessary. This indicates that the drug itself is associated with the risk of causing bradycardia and AV block.

4. **Cardiotoxicity Reaction**: Acute hepatocellular necrosis leading to hepatic coma, acute renal failure, and death has been associated with the administration of intravenous amiodarone. This suggests that the drug can lead to severe cardiotoxic reactions, including hepatic injury.

5. **Cardiotoxicity Risk**: NEXTERONE may cause a worsening of existing arrhythmias or precipitate new arrhythmias, sometimes leading to fatal outcomes. This includes proarrhythmia, primarily torsade de pointes (TdP), associated with QTc prolongation. This indicates that the drug itself is associated with the risk of causing or exacerbating arrhythmias and TdP.

6. **Cardiotoxicity Reaction**: There have been postmarketing reports of acute-onset pulmonary injury in patients treated with intravenous amiodarone, including pulmonary infiltrates, pulmonary fibrosis, bronchospasm, wheezing, and hypoxia. This suggests that the drug can lead to pulmonary cardiotoxic reactions.

7. **Cardiotoxicity Risk**: Cases of optic neuropathy and optic neuritis, usually resulting in visual impairment, have been reported in patients treated with oral amiodarone or intravenous amiodarone. This indicates that the drug itself is associated with the risk of causing optic nerve-related cardiotoxicity.

8. **Cardiotoxicity Risk**: Amiodarone can cause fetal harm when administered to a pregnant woman, leading to adverse cardiac effects in the neonate. This indicates that the drug itself is associated with the risk of causing cardiotoxic effects in neonates exposed to amiodarone during pregnancy.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",e9108958-b8d7-4fba-87c3-9a32990de551,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=e9108958-b8d7-4fba-87c3-9a32990de551&type=display
44,AMISULPRIDE,"1. The drug BARHEMSYS is associated with QT prolongation, which occurs in a dose- and concentration-dependent manner. It is recommended to avoid its use in patients with congenital long QT syndrome and in patients taking droperidol. ECG monitoring is advised in patients with pre-existing arrhythmias/cardiac conduction disorders, electrolyte abnormalities, congestive heart failure, and in patients taking other medications known to prolong the QT interval. (The drug itself is associated with QT prolongation and cardiotoxicity risks.)

2. The drug label mentions that doses of oral amisulpride above 1200 mg/day have been associated with adverse reactions related to dopamine-2 (D2) antagonism, including cardiovascular adverse reactions such as prolongation of the QT interval, torsades de pointes, bradycardia, and hypotension. It also states that there is no specific antidote for amisulpride overdose, and management includes cardiac monitoring and treatment of severe extrapyramidal symptoms. (The drug itself is associated with cardiotoxicity reactions in cases of overdose.)

3. Postmarketing experience with chronic oral use of amisulpride outside of the United States has identified cardiac disorders such as bradycardia, torsades de pointes, ventricular tachycardia, and prolonged QT interval by electrocardiogram. These reactions were reported voluntarily, and their frequency or causal relationship to drug exposure may vary. (The drug itself is associated with cardiotoxicity reactions reported during post-approval use.)

4. The drug label also mentions that BARHEMSYS causes dose- and concentration-dependent QT prolongation, and it is recommended to avoid its use in patients taking droperidol. ECG monitoring is advised in patients taking other drugs known to prolong the QT interval. (The drug itself is associated with QT prolongation and cardiotoxicity risks.)",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",ab23bc6e-b6a8-165f-e053-2a95a90ab144,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=ab23bc6e-b6a8-165f-e053-2a95a90ab144&type=display
45,AMITRIPTYLINE HYDROCHLORIDE,"1. The drug label mentions that tricyclic antidepressants, including amitriptyline hydrochloride, can lead to cardiovascular adverse reactions such as myocardial infarction, stroke, arrhythmias, hypotension, syncope, hypertension, tachycardia, and palpitations. These reactions are associated with the use of the drug.

2. It is noted that tricyclic antidepressants, like amitriptyline hydrochloride, may cause nonspecific ECG changes, heart block, and alterations in AV conduction. These cardiovascular effects are linked to the drug's usage.

3. The label also highlights that tricyclic antidepressants, including amitriptyline hydrochloride, can result in orthostatic hypotension, syncope, and changes in blood pressure. These cardiovascular symptoms are attributed to the drug.

4. Additionally, the drug label mentions that tricyclic antidepressants like amitriptyline hydrochloride may lead to tachycardia, palpitations, and disturbances in heart rate. These cardiotoxic effects are associated with the drug's administration.

5. The label warns about the potential for tricyclic antidepressants, including amitriptyline hydrochloride, to cause QT interval prolongation, which is a specific indicator of tricyclic antidepressant overdose. This cardiotoxic effect is linked to the drug's use.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",19b236d3-eebc-42eb-b66e-141cb5fe91c2,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=19b236d3-eebc-42eb-b66e-141cb5fe91c2&type=display
46,AMLODIPINE,"1. Warnings and Precautions: The drug label mentions that symptomatic hypotension is possible, particularly in patients with severe aortic stenosis, but acute hypotension is unlikely. (The drug itself is not associated with causing cardiotoxicity but may lead to symptomatic hypotension in certain patients.)

2. Warnings and Precautions: It is highlighted that worsening angina and acute myocardial infarction can develop after starting or increasing the dose of the drug, especially in patients with severe obstructive coronary artery disease. (The drug itself is associated with the risk of worsening angina and acute myocardial infarction in certain patient populations.)

3. Dosage and Administration: The label advises titrating slowly in patients with severe hepatic impairment. (The drug itself is not directly linked to cardiotoxicity in this context but requires caution in patients with hepatic impairment due to its metabolism.)

4. Adverse Reactions: The most common adverse reactions to the drug amlodipine were edema, dizziness, flushing, and palpitation, which occurred in a dose-related manner. Other adverse reactions not clearly dose-related but reported with an incidence >1.0% are fatigue and nausea. (The drug itself is associated with certain adverse reactions, including palpitations, which may be considered cardiotoxic effects.)

5. Drug Interactions: The label warns not to exceed doses greater than 20 mg daily of simvastatin when co-administered with amlodipine. (The drug itself, when interacting with simvastatin, can lead to increased systemic exposure to simvastatin, potentially causing cardiotoxic effects.)

Overall, the drug label for NORLIQVA (amlodipine) mentions risks and reactions related to cardiotoxicity, such as hypotension, worsening angina, acute myocardial infarction, and potential interactions with other drugs that could impact cardiovascular health.",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",c1730a51-4383-4c61-a9a1-7e1326bd0abe,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=c1730a51-4383-4c61-a9a1-7e1326bd0abe&type=display
47,AMLODIPINE BESYLATE,"1. **Warnings and Precautions**: The drug label mentions that symptomatic hypotension is possible, particularly in patients with severe aortic stenosis, but acute hypotension is unlikely. The drug itself is not directly associated with causing cardiotoxicity but may lead to symptomatic hypotension in certain patients.

2. **Warnings and Precautions**: It is noted that worsening angina and acute myocardial infarction can develop after starting or increasing the dose of the drug, especially in patients with severe obstructive coronary artery disease. The drug itself is associated with the risk of worsening angina and acute myocardial infarction in specific patient populations.

3. **Warnings and Precautions**: The label advises titrating the drug slowly in patients with severe hepatic impairment. This is due to the fact that the drug is extensively metabolized by the liver, and in patients with impaired hepatic function, titration should be done cautiously to avoid potential adverse effects related to cardiotoxicity.",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",7367289c-b0b0-466a-83e2-558e2985c29f,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7367289c-b0b0-466a-83e2-558e2985c29f&type=display
48,AMMONIA N-13,"1. **Warnings and Precautions**: The drug label mentions that Ammonia N 13 Injection may increase the risk of cancer. It advises using the smallest dose necessary for imaging and ensuring safe handling to protect the patient and healthcare worker. (The drug itself is associated with an increased risk of cancer but not specifically cardiotoxicity.)

2. **Adverse Reactions**: No adverse reactions have been reported for Ammonia N 13 Injection based on a review of published literature, publicly available reference sources, and adverse drug reaction reporting systems. (No specific cardiotoxicity reactions have been reported for this drug.)

3. **Use in Specific Populations**: The drug label states that the safety and effectiveness of Ammonia N 13 Injection have been established in pediatric patients. (No specific mention of cardiotoxicity risks or reactions in this section.)

In summary, the drug label does not specifically mention cardiotoxicity risks or reactions associated with Ammonia N 13 Injection.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",61e196ba-3812-4ffd-8032-12b215378fef,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=61e196ba-3812-4ffd-8032-12b215378fef&type=display
49,AMOXAPINE,"1. The drug label mentions that tricyclic antidepressant drugs, including amoxapine, can induce sinus tachycardia, changes in conduction time, and arrhythmias, which can lead to myocardial infarction and stroke. This suggests that amoxapine itself is associated with cardiotoxicity risks.

2. The label also warns about the potential risk of hypotension, hypertension, syncope, and tachycardia as cardiovascular adverse reactions to amoxapine. This indicates that amoxapine can cause cardiotoxicity reactions.

3. Additionally, the drug label mentions that atrial arrhythmias, including atrial fibrillation, myocardial infarction, stroke, and heart block, have been reported as rare adverse reactions with amoxapine. This suggests that amoxapine is associated with cardiotoxicity risks and reactions.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",eed5e856-dd7b-4eaa-9dad-508f2bef9328,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=eed5e856-dd7b-4eaa-9dad-508f2bef9328&type=display
50,AMOXICILLIN,"1. The drug label does not mention any specific cardiotoxicity risks associated with amoxicillin itself.
   
2. The drug label does not attribute any cardiotoxicity reactions to amoxicillin use.

Therefore, based on the information provided in the drug label, amoxicillin is not associated with cardiotoxicity risks or reactions.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",06e5c07d-d95c-4955-8d35-a4703ca2359e,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=06e5c07d-d95c-4955-8d35-a4703ca2359e&type=display
51,AMPHETAMINE,"1. **Cardiotoxicity Risk**: Avoid using ADZENYS XR-ODT in patients with known structural cardiac abnormalities, cardiomyopathy, serious heart arrhythmia, coronary artery disease, or other serious cardiac disease. (The drug itself is associated with the risk of cardiotoxicity.)

2. **Cardiotoxicity Reaction**: Sudden death has been reported in patients with structural cardiac abnormalities or serious cardiac disease who were treated with CNS stimulants at recommended ADHD dosages. (The drug itself is associated with the risk of cardiotoxicity reactions.)

3. **Cardiotoxicity Risk**: CNS stimulants cause an increase in blood pressure and heart rate. Monitor all ADZENYS XR-ODT-treated patients for potential tachycardia and hypertension. (The drug itself is associated with the risk of cardiotoxicity.)

4. **Cardiotoxicity Reaction**: Exacerbation of symptoms of behavior disturbance and thought disorder in patients with pre-existing psychotic disorders may occur with CNS stimulants. (The drug itself is associated with the risk of cardiotoxicity reactions.)

5. **Cardiotoxicity Reaction**: CNS stimulants may induce a manic or mixed episode in patients with bipolar disorder. (The drug itself is associated with the risk of cardiotoxicity reactions.)

6. **Cardiotoxicity Reaction**: CNS stimulants may cause psychotic or manic symptoms in patients without prior history of psychotic illness or mania. (The drug itself is associated with the risk of cardiotoxicity reactions.)

7. **Cardiotoxicity Risk**: CNS stimulants have been associated with weight loss and slowing of growth rate in pediatric patients. Closely monitor growth in pediatric patients treated with ADZENYS XR-ODT. (The drug itself is associated with the risk of cardiotoxicity.)

8. **Cardiotoxicity Reaction**: CNS stimulants used to treat ADHD are associated with peripheral vasculopathy, including Raynaud's phenomenon. Careful observation for digital changes is necessary during treatment. (The drug itself is associated with the risk of cardiotoxicity reactions.)",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",c1179269-00b5-48ea-972d-31e614e99b7e,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=c1179269-00b5-48ea-972d-31e614e99b7e&type=display
52,AMPHETAMINE SULFATE,"1. The drug label warns that amphetamines have a high potential for abuse and prolonged administration may lead to drug dependence, emphasizing the need to avoid misuse. (The drug itself is associated with the risk of abuse and dependence.)

2. Serious cardiovascular events, including sudden death, are highlighted as potential risks associated with the use of CNS stimulant treatment, particularly in children and adolescents with structural cardiac abnormalities or serious heart problems. (The drug itself is associated with the risk of serious cardiovascular events.)

3. The label mentions that amphetamines can cause elevations in blood pressure, heart rate, and cardiovascular effects, indicating potential cardiotoxicity risks. (The drug itself is associated with cardiovascular effects that may pose risks.)

4. Specific warnings are provided for sudden death, stroke, and myocardial infarction in adults taking stimulant drugs for ADHD, particularly those with pre-existing structural cardiac abnormalities or serious heart problems. (The drug itself is associated with the risk of sudden death, stroke, and myocardial infarction in adults.)

5. The label advises caution in treating patients with pre-existing hypertension, heart failure, recent myocardial infarction, or ventricular arrhythmia due to potential increases in blood pressure or heart rate with stimulant medications. (The drug itself is associated with the risk of exacerbating cardiovascular conditions.)

6. Patients being considered for treatment with stimulant medications are recommended to undergo a careful cardiac evaluation, including a family history of sudden death or ventricular arrhythmia, to assess for the presence of cardiac disease. (The drug itself is associated with the need for cardiac evaluation before treatment.)

7. The label warns about the potential for serotonin syndrome, a life-threatening reaction, when amphetamines are used in combination with other drugs affecting the serotonergic neurotransmitter systems. (The drug itself is associated with the risk of serotonin syndrome when combined with certain medications.)

8. Amphetamines are linked to peripheral vasculopathy, including Raynaud's phenomenon, with signs and symptoms that may require clinical evaluation and monitoring during treatment. (The drug itself is associated with the risk of peripheral vasculopathy and Raynaud's phenomenon.)

9. The label cautions about the potential for visual disturbances, such as difficulties with accommodation and blurring of vision, as adverse effects of stimulant treatment. (The drug itself is associated with the risk of visual disturbances.)

Overall, the drug label highlights multiple instances where amphetamine sulfate tablets are associated with cardiotoxicity risks and reactions, emphasizing the importance of monitoring and caution in patients with cardiovascular conditions.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",9eb84b3c-2147-42dd-8053-6afd1a88b0c1,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=9eb84b3c-2147-42dd-8053-6afd1a88b0c1&type=display
53,AMPHOTERICIN B,"1. The drug label mentions that amphotericin B, the active ingredient in AmBisome, can bind to the cholesterol component of mammalian cells, leading to cytotoxicity, which may include cardiotoxicity. (Drug associated with cardiotoxicity risk)

2. The label states that AmBisome has been shown to be significantly less toxic than amphotericin B deoxycholate, with a lower incidence of cardiovascular adverse events such as hypertension, hypotension, and tachycardia compared to amphotericin B deoxycholate. (Drug associated with lower cardiotoxicity risk)

3. The label also mentions that during the initial dosing period, patients should be under close clinical observation due to the potential for adverse events, including cardiotoxicity. (Drug associated with potential cardiotoxicity risk)

4. Additionally, the label advises monitoring of serum electrolytes, particularly magnesium and potassium, which are important for cardiac function, indicating a potential risk of electrolyte imbalances and associated cardiotoxicity. (Drug associated with potential cardiotoxicity risk)

5. The label does not report any direct cardiotoxicity reactions specifically related to AmBisome but highlights the importance of monitoring cardiovascular parameters and electrolytes due to the potential for adverse events, including those affecting the heart. (No direct cardiotoxicity reactions reported for AmBisome)",Less,Yes,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",f7be6506-4d20-401e-a0ff-02ad7c33158a,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=f7be6506-4d20-401e-a0ff-02ad7c33158a&type=display
54,AMPICILLIN,"1. The drug label does not mention any specific cardiotoxicity risks associated with ampicillin itself.
2. The label does not indicate that ampicillin is associated with cardiotoxicity reactions.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",a194f310-a669-4d8f-8c04-ee9ca01939b1,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a194f310-a669-4d8f-8c04-ee9ca01939b1&type=display
55,AMPICILLIN SODIUM,"1. The drug label does not mention any specific cardiotoxicity risks associated with Ampicillin for Injection, USP itself.

2. The label does not indicate that Ampicillin for Injection, USP is associated with cardiotoxicity reactions.

3. There is no mention of cardiotoxicity risks or reactions related to Ampicillin for Injection, USP in the drug label.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",06b1c203-600c-4083-986a-d1d471b56e43,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=06b1c203-600c-4083-986a-d1d471b56e43&type=display
56,ANAGRELIDE HYDROCHLORIDE,"1. AGRYLIN has been associated with cardiovascular toxicity, including QT prolongation and ventricular tachycardia. Patients should undergo a pre-treatment cardiovascular examination, including an ECG, and be monitored for cardiovascular effects during treatment. (The drug itself is associated with cardiovascular toxicity risks.)

2. AGRYLIN increases the QTc interval of the electrocardiogram and may increase the heart rate in healthy volunteers. It should not be used in patients with known risk factors for QT interval prolongation. (The drug itself is associated with QT prolongation risks.)

3. AGRYLIN is a phosphodiesterase 3 (PDE3) inhibitor, which may cause vasodilation, tachycardia, palpitations, and congestive heart failure. Use in patients with cardiac disease should be carefully considered, weighing the benefits against the risks. (The drug itself is associated with PDE3 inhibitor-related cardiovascular effects.)

4. In patients with heart failure, bradyarrhythmias, or electrolyte abnormalities, periodic monitoring with electrocardiograms should be considered during AGRYLIN therapy. (The drug itself is associated with the need for monitoring in specific cardiac conditions.)

5. AGRYLIN has been reported to cause cases of pulmonary hypertension. Patients should be evaluated for signs and symptoms of underlying cardiopulmonary disease before and during therapy. (The drug itself is associated with the risk of pulmonary hypertension.)

6. A postmarketing study showed that concomitant use of AGRYLIN and aspirin increased major hemorrhagic events. Patients should be monitored for bleeding, especially when receiving other drugs known to cause bleeding. (The drug itself is associated with an increased risk of bleeding when used concomitantly with aspirin.)

7. AGRYLIN has been associated with interstitial lung diseases, including allergic alveolitis, eosinophilic pneumonia, and interstitial pneumonitis. Symptoms may include progressive dyspnea with lung infiltrations. If suspected, AGRYLIN should be discontinued and evaluated. (The drug itself is associated with the risk of pulmonary toxicity, leading to interstitial lung diseases.)",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",cb960074-99c1-4a73-941f-f0644a7ec219,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=cb960074-99c1-4a73-941f-f0644a7ec219&type=display
57,ANASTROZOLE,"1. The drug label mentions that in women with pre-existing ischemic heart disease, an increased incidence of ischemic cardiovascular events occurred with ARIMIDEX use compared to tamoxifen use. Consider risks and benefits. (ARIMIDEX associated with increased cardiotoxicity risk)

2. The label also states that during the ATAC trial, more patients receiving ARIMIDEX were reported to have elevated serum cholesterol compared to patients receiving tamoxifen. Consider cholesterol monitoring. (ARIMIDEX associated with increased cholesterol levels, which can be a risk factor for cardiovascular events)

3. Additionally, the drug label highlights that ARIMIDEX may cause fetal harm, indicating embryo-fetal toxicity. Patients should be advised of the potential risk to a fetus and to use effective contraception. (ARIMIDEX associated with potential embryo-fetal toxicity, not directly cardiotoxicity but relevant to patient safety)",Less,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",acbfaaa9-503c-4691-9828-76a7146ed6de,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=acbfaaa9-503c-4691-9828-76a7146ed6de&type=display
58,ANGIOTENSIN II,"1. **Warnings and Precautions**: The drug label mentions a potential for venous and arterial thrombotic and thromboembolic events in patients who receive GIAPREZA. The drug itself is associated with this risk and recommends the use of concurrent venous thromboembolism (VTE) prophylaxis.

2. **Adverse Reactions**: The most common adverse reactions reported in greater than 10% of GIAPREZA-treated patients were thromboembolic events. The drug itself is associated with causing thromboembolic events as an adverse reaction in patients.",Most,No,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",c265d69a-3efe-4107-9a9e-e6fd3d531c48,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=c265d69a-3efe-4107-9a9e-e6fd3d531c48&type=display
59,ANIDULAFUNGIN,"1. **Warnings and Precautions**: Anaphylactic reactions, including shock, have been reported with the use of ERAXIS. If these reactions occur, ERAXIS should be discontinued and appropriate treatment administered. (The drug itself was not associated with cardiotoxicity risk, but with anaphylactic reactions.)

2. **Adverse Reactions in Adults**: Less common adverse reactions in adult patients with candidemia/other Candida infections and esophageal candidiasis included cardiac adverse events such as atrial fibrillation, bundle branch block, and ventricular extrasystoles. (The drug itself was not directly associated with these cardiac adverse events.)

3. **Post-marketing Experience**: Post-approval use of anidulafungin has identified immune-related adverse reactions such as anaphylactic shock and bronchospasm. (The drug itself was associated with immune-related cardiotoxicity reactions.)

Please note that while some cardiac adverse events were mentioned in the drug label, the direct association with ERAXIS as the cause of these events may not have been established. It is important to consult healthcare professionals for a comprehensive understanding of the cardiotoxicity risks associated with ERAXIS.",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",a88d9010-55fb-4a02-baff-042cd27688ea,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a88d9010-55fb-4a02-baff-042cd27688ea&type=display
60,ANTICOAGULANT SODIUM CITRATE SOLUTION,"1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with the use of Sodium Citrate Blood-Pack Units (PL 146 Plastic) anticoagulant sodium citrate solution. 

2. Therefore, there is no information provided in the drug label indicating that the drug itself is associated with or causes cardiotoxicity risks or reactions. 

3. It is important to note that the primary purpose of this drug is as an anticoagulant solution for use with apheresis devices, and the label emphasizes proper handling, storage, and administration instructions to ensure safety and efficacy.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",14b238ab-904b-45dc-9eb9-a1074364e089,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=14b238ab-904b-45dc-9eb9-a1074364e089&type=display
61,APALUTAMIDE,"1. **Cardiotoxicity Risk**: The drug ERLEADA (apalutamide) is associated with cerebrovascular and ischemic cardiovascular events, including events leading to death. Patients receiving ERLEADA should be monitored for signs and symptoms of ischemic heart disease and cerebrovascular disorders. The drug itself is linked to the risk of these events.

2. **Cardiotoxicity Reactions**: In clinical studies, ischemic cardiovascular events occurred in patients treated with ERLEADA, with a higher incidence compared to placebo. Cerebrovascular events also occurred in patients receiving ERLEADA. The drug was associated with these cardiotoxicity reactions, leading to adverse outcomes such as death from cardiovascular events.

3. **Cardiotoxicity Risk Management**: Patients with a history of certain cardiovascular conditions were excluded from the clinical studies. It is recommended to optimize the management of cardiovascular risk factors, such as hypertension, diabetes, or dyslipidemia, in patients receiving ERLEADA. Consideration of discontinuation of ERLEADA is advised for Grade 3 and 4 events related to cardiotoxicity.

4. **Cardiotoxicity Risk in Specific Populations**: The drug label mentions that falls occurred in patients receiving ERLEADA, with an increased incidence in the elderly. Falls are associated with an increased risk of cardiovascular events in this population, highlighting the importance of monitoring and managing cardiovascular risks in elderly patients taking ERLEADA.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",d1cda4f7-cb33-46ea-b9ac-431f6452b1a5,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=d1cda4f7-cb33-46ea-b9ac-431f6452b1a5&type=display
62,APIXABAN,"1. **Cardiotoxicity Risk Associated with ELIQUIS:**
   - ELIQUIS is a factor Xa inhibitor indicated for various conditions, including reducing the risk of stroke and systemic embolism in nonvalvular atrial fibrillation, prophylaxis of deep vein thrombosis (DVT) post-hip or knee replacement surgery, and treatment of DVT and PE.
   - ELIQUIS is not recommended for use in patients with prosthetic heart valves, indicating a potential cardiotoxicity risk in this population.

2. **Cardiotoxicity Reactions Associated with ELIQUIS:**
   - ELIQUIS itself was not directly associated with cardiotoxicity reactions in the provided drug label information.
   - However, ELIQUIS can cause serious, potentially fatal bleeding, which may indirectly impact cardiac function and lead to adverse events.
   - Patients should be monitored for signs and symptoms of blood loss, as ELIQUIS increases the risk of bleeding, which can have implications for cardiovascular health.
   - The drug label also mentions that ELIQUIS use is contraindicated in patients with active pathological bleeding, which can be a critical consideration for patients with underlying cardiac conditions.",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",e9481622-7cc6-418a-acb6-c5450daae9b0,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=e9481622-7cc6-418a-acb6-c5450daae9b0&type=display
63,APOMORPHINE HYDROCHLORIDE,"1. APOKYN has been shown to reduce resting systolic and diastolic blood pressure and may have the potential to exacerbate coronary and cerebral ischemia in patients with known cardiovascular and cerebrovascular disease. If patients develop signs and symptoms of coronary or cerebral ischemia, prescribers should re-evaluate the continued use of APOKYN. (The drug itself may exacerbate coronary and cerebral ischemia in patients with known cardiovascular and cerebrovascular disease.)

2. In clinical studies, 4% of patients treated with APOKYN experienced angina, myocardial infarction, cardiac arrest, and/or sudden death; some cases of angina and myocardial infarction occurred in close proximity to APOKYN dosing (within 2 hours), while other cases of cardiac arrest and sudden death were observed at times unrelated to dosing. (The drug itself was associated with angina, myocardial infarction, cardiac arrest, and sudden death in some patients.)

3. APOKYN causes dose-related decreases in systolic and diastolic blood pressure. In a study of healthy subjects, the hypotensive effect of APOKYN on systolic and diastolic blood pressure was exacerbated by the concomitant use of alcohol or sublingual nitroglycerin. Patients should avoid alcohol when using APOKYN. (The drug itself causes dose-related decreases in blood pressure and may be exacerbated by concomitant use of alcohol or nitroglycerin.)

4. APOKYN may prolong the QTc interval, and doses greater than 6 mg do not provide additional clinical benefit and are not recommended. Drugs that prolong the QTc interval have been associated with torsades de pointes and sudden death. The risks and benefits of APOKYN treatment should be considered prior to initiating treatment in patients with risk factors for prolonged QTc. (The drug itself may prolong the QTc interval, which can lead to torsades de pointes and sudden death, especially in patients with risk factors for prolonged QTc.)",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",3235535d-9ef9-4657-8b2a-176a807d091c,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=3235535d-9ef9-4657-8b2a-176a807d091c&type=display
64,APREMILAST,"1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with OTEZLA itself. 

2. The drug label primarily focuses on gastrointestinal symptoms, hypersensitivity reactions, depression, weight loss, and drug interactions as potential adverse effects of OTEZLA. 

3. While the label does not directly link OTEZLA to cardiotoxicity risks or reactions, it is important to consult healthcare providers for comprehensive information on potential side effects and risks associated with this medication.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",f6b1f516-4972-4d82-bced-113e47b41cc5,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=f6b1f516-4972-4d82-bced-113e47b41cc5&type=display
65,APREPITANT,"1. The drug label mentions that CINVANTI is contraindicated in patients taking pimozide due to the risk of significantly increased plasma concentrations of pimozide, potentially causing serious or life-threatening reactions, such as QT prolongation, a known adverse reaction of pimozide. (The drug itself is not associated with cardiotoxicity but can lead to increased plasma concentrations of pimozide, which is known to cause QT prolongation.)

2. The label also warns about the potential decrease in INR of prothrombin time when coadministered with warfarin, a CYP2C9 substrate, which may result in a clinically significant decrease in INR. (CINVANTI itself is not directly associated with cardiotoxicity but can affect the anticoagulant effect of warfarin, leading to changes in INR.)

3. Additionally, the label mentions that the drug may interact with hormonal contraceptives, potentially reducing their efficacy during and for 28 days following administration of aprepitant. Effective alternative or back-up methods of non-hormonal contraception are recommended. (CINVANTI itself is not directly linked to cardiotoxicity but may impact hormonal contraceptives, which could have implications for cardiovascular health in certain individuals.)

4. The drug label does not specifically mention any direct cardiotoxicity risks or reactions associated with CINVANTI itself. However, it does highlight the importance of monitoring for adverse reactions, including hypersensitivity reactions, during and after administration of the drug. (No direct cardiotoxicity risks are attributed to CINVANTI, but general monitoring for adverse reactions, including potential hypersensitivity reactions, is advised.)",Less,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",4c218d3a-a508-4abc-9ed8-a6e8e191d1b4,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=4c218d3a-a508-4abc-9ed8-a6e8e191d1b4&type=display
66,ARGATROBAN,"1. **Cardiotoxicity Risk Associated with Argatroban**: The drug label does not mention any direct association of argatroban with cardiotoxicity risks.

2. **Cardiotoxicity Reactions**: The label mentions that in patients with HIT undergoing PCI, chest pain, hypotension, back pain, nausea, vomiting, and headache were common adverse reactions. However, it does not attribute these reactions directly to cardiotoxicity caused by argatroban.",Less,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",79eec27d-ac63-4996-8b1a-c2cd52ad2b2c,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=79eec27d-ac63-4996-8b1a-c2cd52ad2b2c&type=display
67,ARGININE HYDROCHLORIDE,"1. The drug label mentions that R-Gene 10 is a hypertonic solution that can cause irritation and damage to tissues, emphasizing the importance of ensuring administration through a patent catheter within a patent vein. This statement does not directly associate the drug with cardiotoxicity risk but highlights the potential for tissue damage due to the hypertonic nature of the solution.

2. The label also warns that overdosage of R-Gene 10 in pediatric patients can lead to hyperchloremic metabolic acidosis, cerebral edema, or possibly death. This statement indicates that the drug itself, when administered in excessive amounts, can result in cardiotoxicity reactions such as metabolic acidosis and cerebral edema, which are serious conditions affecting the cardiovascular system.

3. Additionally, the label mentions that hypersensitivity reactions, including anaphylaxis, have been reported with the use of R-Gene 10. If such reactions occur, appropriate medical support should be available, and the drug should be discontinued. This statement suggests that the drug can trigger cardiotoxicity reactions like anaphylaxis, a severe and potentially life-threatening allergic response that can impact cardiovascular function.",Less,Yes,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",6accf33f-9841-4327-8923-93c42020ef12,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=6accf33f-9841-4327-8923-93c42020ef12&type=display
68,ARIPIPRAZOLE,"1. The drug label warns about increased mortality in elderly patients with dementia-related psychosis treated with antipsychotic drugs, including ABILIFY MAINTENA. The risk of death in drug-treated patients was higher compared to placebo-treated patients, with most deaths attributed to cardiovascular or infectious causes. ABILIFY MAINTENA is not approved for treating patients with dementia-related psychosis, indicating a potential cardiotoxicity risk associated with the drug's use.

2. In clinical studies of dementia-related psychosis patients treated with oral aripiprazole (the active ingredient in ABILIFY MAINTENA), there was an increased incidence of cerebrovascular adverse reactions, including stroke and transient ischemic attack, with fatalities reported. This suggests a potential association between aripiprazole and cerebrovascular adverse reactions, indicating a cardiotoxicity risk.

3. The drug label mentions the potential for neuroleptic malignant syndrome (NMS) with antipsychotic drugs, including ABILIFY MAINTENA. NMS is a potentially fatal symptom complex that can occur with antipsychotic drug administration. While rare cases of NMS occurred during aripiprazole treatment, the label does not explicitly state a direct association between ABILIFY MAINTENA and NMS, but it highlights the risk of this serious cardiotoxic reaction.

4. Tardive dyskinesia, an irreversible, involuntary movement disorder, may develop in patients treated with antipsychotic drugs, including ABILIFY MAINTENA. The risk of developing tardive dyskinesia is believed to increase with the duration of treatment and cumulative dose of antipsychotic drugs. While the label does not directly link ABILIFY MAINTENA to causing tardive dyskinesia, it emphasizes the importance of monitoring for this potential cardiotoxic reaction.

5. Metabolic changes, including hyperglycemia, dyslipidemia, and weight gain, have been associated with atypical antipsychotic drugs like ABILIFY MAINTENA. These metabolic changes may increase cardiovascular/cerebrovascular risk. The label advises monitoring patients for symptoms of hyperglycemia and dyslipidemia, as well as clinical monitoring of weight, indicating a potential indirect cardiotoxicity risk associated with these metabolic changes.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6&type=display
69,ARIPIPRAZOLE LAUROXIL,"1. The drug label warns about an increased risk of mortality in elderly patients with dementia-related psychosis treated with antipsychotic drugs, including ARISTADA. The risk of death in drug-treated patients was higher compared to placebo-treated patients, with most deaths attributed to cardiovascular or infectious causes (ARISTADA associated with increased mortality risk in elderly patients with dementia-related psychosis).

2. Cerebrovascular adverse reactions, including stroke, have been reported in elderly patients with dementia-related psychosis treated with antipsychotic drugs like ARISTADA. The incidence of cerebrovascular adverse reactions was higher in patients receiving antipsychotic drugs compared to placebo (ARISTADA associated with cerebrovascular adverse reactions in elderly patients with dementia-related psychosis).

3. Orthostatic hypotension, a potential adverse reaction of ARISTADA, may lead to dizziness, lightheadedness, and tachycardia. Patients at increased risk include those with cardiovascular diseases, dehydration, or those on antihypertensive medications. Orthostatic hypotension was reported in a small percentage of patients in clinical studies (ARISTADA associated with orthostatic hypotension risk).

4. Falls may occur due to somnolence, postural hypotension, or motor instability associated with antipsychotic drugs like ARISTADA. Patients initiating antipsychotic treatment or on long-term therapy should undergo fall risk assessments (ARISTADA associated with increased risk of falls).

5. Metabolic changes, including hyperglycemia, dyslipidemia, and weight gain, have been observed with atypical antipsychotic drugs like ARISTADA. These changes can lead to adverse events such as hyperglycemia-related complications, undesirable lipid alterations, and significant weight gain (ARISTADA associated with metabolic changes risk).

6. ARISTADA has the potential to cause tardive dyskinesia, an irreversible syndrome of involuntary movements. The risk of developing tardive dyskinesia increases with prolonged treatment and higher cumulative doses of antipsychotic drugs. Withdrawal of antipsychotic treatment may lead to partial or complete remission of tardive dyskinesia (ARISTADA associated with tardive dyskinesia risk).",Less,Yes,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",17a8d11b-73b0-4833-a0b4-cf1ef85edefb,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=17a8d11b-73b0-4833-a0b4-cf1ef85edefb&type=display
70,ARSENIC TRIOXIDE,"1. **Cardiac Conduction Abnormalities:** TRISENOX can cause QTc interval prolongation, complete atrioventricular block, and torsade de pointes, which can be fatal. The drug itself is associated with these cardiotoxicity risks.

2. **QTc Prolongation Monitoring:** Before administering TRISENOX, assess the QTc interval, correct electrolyte abnormalities, and consider discontinuing drugs known to prolong QTc interval. The drug itself is associated with the risk of QTc prolongation.

3. **QTc Prolongation Management:** Withhold TRISENOX until resolution and resume at a reduced dose for QTc prolongation. The drug itself is associated with the management strategy for QTc prolongation.

4. **Cardiac Conduction Abnormalities Warning:** TRISENOX can cause QTc prolongation, torsade de pointes, and complete atrioventricular block, with specific recommendations for monitoring and management. The drug itself is associated with these cardiotoxicity reactions.

5. **QTc Monitoring and Management:** Assess the QTc interval, correct electrolyte abnormalities, and withhold TRISENOX until resolution for QTc prolongation. The drug itself is associated with the monitoring and management of QTc prolongation.

6. **QTc Prolongation Risk Factors:** The risk of torsade de pointes is related to QTc prolongation extent, concomitant medications, and patient conditions. The drug itself is associated with the risk factors for torsade de pointes.

7. **QTc Prolongation Management:** Correct electrolyte abnormalities, withhold TRISENOX, and resume at a reduced dose for QTc prolongation. The drug itself is associated with the management strategy for QTc prolongation.

8. **Cardiac Monitoring:** Perform frequent cardiac monitoring for patients receiving TRISENOX to manage QTc prolongation risks. The drug itself is associated with the need for cardiac monitoring.

In summary, TRISENOX is associated with cardiotoxicity risks such as QTc prolongation, torsade de pointes, and complete atrioventricular block, and specific monitoring and management strategies are outlined in the drug label to address these potential adverse reactions.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",101fc347-d0ad-4aee-8b06-9feb187fd741,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=101fc347-d0ad-4aee-8b06-9feb187fd741&type=display
71,ASCIMINIB,"1. Cardiovascular toxicity, including ischemic cardiac and CNS conditions, arterial thrombotic and embolic conditions, and cardiac failure, occurred in patients receiving SCEMBLIX. The drug itself was associated with cardiovascular toxicity risks.

2. Grade 3 cardiovascular toxicity and Grade 3 cardiac failure were reported in patients taking SCEMBLIX. The drug was associated with causing Grade 3 cardiovascular toxicity and Grade 3 cardiac failure reactions.

3. Arrhythmia, including QTc prolongation, occurred in patients receiving SCEMBLIX. The drug was associated with causing arrhythmia and QTc prolongation as part of its cardiotoxicity risks.

4. Monitor patients with a history of cardiovascular risk factors for cardiovascular signs and symptoms while on SCEMBLIX. The drug label advises monitoring patients for cardiovascular issues due to the drug's cardiotoxicity risks.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",e33001e7-3650-42b1-ae56-cddb5c43aa2b,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=e33001e7-3650-42b1-ae56-cddb5c43aa2b&type=display
72,ASCORBIC ACID,"1. **Cardiotoxicity Risk**: The drug label does not mention any specific cardiotoxicity risks associated with ASCOR (ascorbic acid injection).

2. **Cardiotoxicity Reactions**: The drug label does not list any cardiotoxicity reactions associated with the use of ASCOR (ascorbic acid injection).",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",388aad52-fc01-4784-9791-1dbc80c69306,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=388aad52-fc01-4784-9791-1dbc80c69306&type=display
73,ASENAPINE MALEATE,"1. The drug label warns of increased mortality in elderly patients with dementia-related psychosis treated with antipsychotic drugs, including SAPHRIS. SAPHRIS is not approved for treating patients with dementia-related psychosis, indicating that the drug itself is associated with an increased risk of mortality in this specific patient population.

2. The label mentions cerebrovascular adverse events, including stroke, in elderly patients with dementia-related psychosis who were treated with antipsychotic drugs like SAPHRIS. SAPHRIS is not approved for treating patients with dementia-related psychosis, suggesting that the drug is associated with an increased risk of cerebrovascular adverse events in this specific patient group.

3. The drug label discusses the potential for QT prolongation with SAPHRIS, advising to avoid its use with drugs that also prolong the QT interval and in patients with risk factors for prolonged QT interval. This indicates that SAPHRIS itself is associated with the risk of QT prolongation, which can lead to serious cardiac complications.

4. The label also mentions orthostatic hypotension as a potential side effect of SAPHRIS, advising to monitor heart rate and blood pressure, especially in patients with known cardiovascular or cerebrovascular disease. This suggests that SAPHRIS itself can cause orthostatic hypotension, which may pose a risk to patients with underlying cardiovascular conditions.

5. Additionally, the drug label highlights the risk of syncope associated with SAPHRIS, particularly during initial dose titration and dose increases. This indicates that SAPHRIS itself can lead to syncope, a condition that can be related to cardiovascular issues and may pose a risk to patients, especially during treatment initiation.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",5429f134-839f-4ffc-9944-55f51238def8,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=5429f134-839f-4ffc-9944-55f51238def8&type=display
74,ATAZANAVIR,"1. REYATAZ has been shown to prolong the PR interval of the electrocardiogram in some subjects, with abnormalities in atrioventricular (AV) conduction being asymptomatic and generally limited to first-degree AV block. The drug itself was associated with the risk of cardiac conduction abnormalities.

2. In clinical trials, asymptomatic first-degree AV block was observed in a percentage of atazanavir-treated subjects, indicating potential cardiac conduction abnormalities. The drug itself was associated with the risk of cardiac conduction abnormalities.

3. Cases of second-degree AV block and other conduction abnormalities have been reported, suggesting potential cardiotoxicity risks. The drug itself was associated with the risk of cardiac conduction abnormalities.

4. ECG monitoring should be considered in patients with preexisting conduction system disease or when administered with other drugs that may prolong the PR interval, indicating the need for cardiac monitoring due to potential cardiotoxicity risks. The drug itself was associated with the risk of cardiac conduction abnormalities.

5. Severe skin reactions, such as Stevens-Johnson syndrome, erythema multiforme, and toxic skin eruptions, have been reported in patients receiving REYATAZ, necessitating discontinuation of the drug if severe rash develops. The drug itself was associated with the risk of severe skin reactions, not directly related to cardiotoxicity.

6. Discontinuation of REYATAZ is recommended if severe rash develops, indicating potential severe skin reactions as an adverse effect of the drug. The drug itself was associated with the risk of severe skin reactions, not directly related to cardiotoxicity.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",165cff62-b284-4a27-a65d-9ec8a5bfcdd8,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=165cff62-b284-4a27-a65d-9ec8a5bfcdd8&type=display
75,ATENOLOL,"1. **Cardiotoxicity Risk**: The drug label mentions that in patients with acute myocardial infarction, bradycardia and hypotension occurred more commonly in atenolol-treated patients than in control patients, which is expected for any beta-blocker. These reactions usually responded to atropine and/or withholding further dosage of atenolol. The incidence of heart failure was not increased by atenolol. (The drug itself was associated with the cardiotoxicity risk.)

2. **Cardiotoxicity Reactions**: In a study of patients with acute myocardial infarction, the following adverse events were reported during intravenous and/or oral atenolol administration: bradycardia, hypotension, bronchospasm, heart failure, heart block, supraventricular tachycardia, atrial fibrillation, ventricular tachycardia, cardiac arrests, cardiogenic shock, and other cardiac events. (The drug itself was associated with the cardiotoxicity reactions.)

3. **Cardiotoxicity Risk**: The drug label also mentions that in controlled clinical trials, atenolol was effective as an antihypertensive agent providing 24-hour reduction of blood pressure. However, it is noted that continued depression of the myocardium with beta-blocking agents over time can lead to cardiac failure in some cases. At the first sign or symptom of impending cardiac failure, patients should be treated appropriately, and if cardiac failure continues despite adequate treatment, atenolol should be withdrawn. (The drug itself was associated with the cardiotoxicity risk.)

4. **Cardiotoxicity Reactions**: The label further states that in patients with coronary artery disease being treated with atenolol, abrupt discontinuation of therapy should be avoided to prevent severe exacerbation of angina, myocardial infarction, and ventricular arrhythmias. Patients should be carefully observed, and if angina worsens or acute coronary insufficiency develops, atenolol should be promptly reinstituted. (The drug itself was associated with the cardiotoxicity reactions.)

5. **Cardiotoxicity Risk**: Additionally, the drug label warns that in patients without a history of cardiac failure, continued use of beta-blockers like atenolol over time can lead to cardiac failure. At the first sign or symptom of impending cardiac failure, patients should be treated appropriately, and if cardiac failure persists despite treatment, atenolol should be withdrawn. (The drug itself was associated with the cardiotoxicity risk.)

6. **Cardiotoxicity Reactions**: The label also cautions about the concomitant use of calcium channel blockers with atenolol, which can lead to bradycardia, heart block, and increased left ventricular end diastolic pressure. Patients with pre-existing conduction abnormalities or left ventricular dysfunction are particularly susceptible to these effects. (The drug itself was associated with the cardiotoxicity reactions.)

7. **Cardiotoxicity Risk**: Lastly, the drug label mentions that in patients with acute myocardial infarction, the dosage of intravenous and subsequent oral atenolol was either discontinued or reduced for reasons such as hypotension/bradycardia, cardiogenic shock, heart block, arrhythmias, and other cardiac events. (The drug itself was associated with the cardiotoxicity risk.)",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",746db603-a6e1-4dc3-c2d8-92314419098c,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=746db603-a6e1-4dc3-c2d8-92314419098c&type=display
76,ATOGEPANT,"1. The drug QULIPTA, which contains the active ingredient atogepant, is a calcitonin gene-related peptide receptor antagonist indicated for the preventive treatment of migraine in adults. (No mention of cardiotoxicity risk associated with the drug itself)

2. The drug QULIPTA does not prolong the QT interval to any clinically relevant extent at a dose 5 times the maximum recommended daily dose. (No mention of cardiotoxicity risk associated with the drug itself)

3. There was no evidence of drug-related tumors in mice and rats administered atogepant for up to 2 years, indicating no carcinogenicity risk associated with the drug. (No mention of cardiotoxicity risk associated with the drug itself)

4. Atogepant was negative in mutagenicity tests, both in vitro and in vivo, suggesting no mutagenic risk associated with the drug. (No mention of cardiotoxicity risk associated with the drug itself)

5. Oral administration of atogepant to male and female rats prior to and during mating did not result in adverse effects on fertility or reproductive performance, indicating no impairment of fertility risk associated with the drug. (No mention of cardiotoxicity risk associated with the drug itself)

6. In vitro studies showed that atogepant is not an inhibitor for various enzymes and transporters, suggesting no significant drug interactions that could lead to cardiotoxicity. (No mention of cardiotoxicity risk associated with the drug itself)

7. In vivo studies indicated that co-administration of QULIPTA with rifampin, a strong CYP3A4 inducer, decreased atogepant exposure, which could potentially impact the drug's efficacy but not directly linked to cardiotoxicity. (No direct mention of cardiotoxicity risk associated with the drug itself)

Overall, the drug label does not specifically mention any cardiotoxicity risks or reactions associated with the use of QULIPTA or its active ingredient atogepant. The focus of the label is primarily on the drug's efficacy, dosing, adverse reactions, drug interactions, and use in specific populations.",Less,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",8c8ab8f4-32bd-497a-befa-70c8a51d8d52,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8c8ab8f4-32bd-497a-befa-70c8a51d8d52&type=display
77,ATOMOXETINE HYDROCHLORIDE,"1. STRATTERA has been associated with an increased risk of sudden death in children and adolescents with structural cardiac abnormalities or serious heart problems. The drug should generally not be used in patients with known serious cardiac issues that may make them more vulnerable to its effects. (Associated risk)

2. In adults taking STRATTERA for ADHD, sudden deaths, stroke, and myocardial infarction have been reported. However, the role of atomoxetine in these cases is unknown, and adults are more likely to have serious cardiac conditions that could contribute to these events. (Unclear role of atomoxetine)

3. Patients being considered for STRATTERA treatment should undergo a thorough cardiac evaluation, including a history and physical exam, to assess for the presence of cardiac disease. Further cardiac evaluation should be conducted if findings suggest the presence of such conditions. (Pre-treatment evaluation)

4. Patients who develop symptoms such as exertional chest pain, unexplained syncope, or other signs of cardiac disease during STRATTERA treatment should undergo prompt cardiac evaluation. (Monitoring for symptoms during treatment)

5. STRATTERA should be used with caution in patients with underlying medical conditions that could be worsened by increases in blood pressure or heart rate, such as hypertension, tachycardia, or cardiovascular disease. It should not be used in patients with severe cardiac or vascular disorders that could deteriorate with clinically important increases in blood pressure or heart rate. (Caution in specific patient populations)

6. Pulse and blood pressure should be measured at baseline, following dose increases, and periodically during STRATTERA therapy to detect possible clinically important increases. (Monitoring blood pressure and heart rate)

7. Orthostatic hypotension and syncope have been reported in patients taking STRATTERA, and caution should be exercised in conditions that may predispose patients to hypotension or abrupt changes in heart rate or blood pressure. (Reported side effects)

8. STRATTERA has been associated with tachycardia in pediatric and adult patients, with a higher incidence in poor metabolizers compared to extensive metabolizers. The heart rate effects could be clinically important in some patients. (Associated risk)

9. In adult clinical trials, the mean change in diastolic and systolic blood pressure was higher in poor metabolizers compared to extensive metabolizers, with potential clinical importance in some patients. (Associated risk)

10. STRATTERA has been associated with an increased risk of mydriasis, and its use is not recommended in patients with narrow-angle glaucoma. (Associated risk)",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",309de576-c318-404a-bc15-660c2b1876fb,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=309de576-c318-404a-bc15-660c2b1876fb&type=display
78,ATORVASTATIN CALCIUM,"1. The drug LIPITOR is indicated to reduce the risk of myocardial infarction, stroke, revascularization procedures, and angina in adults with multiple risk factors for coronary heart disease (CHD) but without clinically evident CHD. This indicates that LIPITOR is associated with reducing the risk of cardiotoxic events in certain patient populations.

2. LIPITOR is also indicated to reduce the risk of myocardial infarction and stroke in adults with type 2 diabetes mellitus with multiple risk factors for CHD but without clinically evident CHD. This suggests that LIPITOR is linked to lowering the risk of cardiotoxic events in diabetic patients with specific risk factors.

3. In adults with clinically evident CHD, LIPITOR is indicated to reduce the risk of non-fatal myocardial infarction, fatal and non-fatal stroke, revascularization procedures, hospitalization for congestive heart failure, and angina. This indicates that LIPITOR is associated with reducing the risk of cardiotoxic events in adults with established CHD.

4. The drug label warns about the risk of myopathy and rhabdomyolysis associated with LIPITOR use. It mentions that factors such as age, renal impairment, and concomitant use with certain drugs can increase this risk. Patients are advised to report muscle pain, tenderness, or weakness, which could be indicative of myopathy.

5. Rare reports of immune-mediated necrotizing myopathy (IMNM), an autoimmune myopathy, have been associated with statin use, including LIPITOR. The label advises discontinuing LIPITOR if IMNM is suspected, indicating a potential link between the drug and this cardiotoxic reaction.

6. Hepatic dysfunction, including increases in serum transaminases and rare reports of fatal and non-fatal hepatic failure, have been reported with LIPITOR use. The label recommends liver enzyme testing before initiating therapy and discontinuing LIPITOR if serious hepatic injury occurs, suggesting a potential association between the drug and hepatic adverse effects.

7. The drug label also mentions increases in HbA1c and fasting serum glucose levels with statin use, including LIPITOR. Lifestyle measures are recommended to optimize these levels, indicating a potential metabolic impact of the drug.

8. In a post-hoc analysis, LIPITOR 80 mg was associated with a higher incidence of hemorrhagic stroke compared to placebo in patients with recent hemorrhagic stroke. The label advises considering the risk/benefit of using LIPITOR 80 mg in these patients, suggesting a potential association between the drug and an increased risk of hemorrhagic stroke in this specific population.",Less,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",a60cc18b-0631-4cf0-b021-9f52224ece65,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a60cc18b-0631-4cf0-b021-9f52224ece65&type=display
79,ATOVAQUONE,"1. The drug label does not mention any direct association between MEPRON (atovaquone oral suspension) and cardiotoxicity risks or cardiotoxicity reactions.

2. The label discusses the effect of MEPRON oral suspension on the QT interval, stating that the impact on the QT interval in humans is unknown.

3. The label does not attribute any cardiotoxicity risks or reactions to atovaquone itself in relation to the use of MEPRON oral suspension.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",b426b6bf-f07e-4580-97ae-dfca1ddf5b8f,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=b426b6bf-f07e-4580-97ae-dfca1ddf5b8f&type=display
80,ATRACURIUM BESYLATE,"1. The drug label mentions that atracurium besylate has no known effect on consciousness, pain threshold, or cerebration, and should be used only with adequate anesthesia, indicating that the drug itself is not associated with cardiotoxicity risk.
   
2. The label also states that atracurium besylate may cause histamine release, leading to moderate histamine release and significant falls in blood pressure, especially following higher doses, suggesting that the drug itself may contribute to cardiovascular effects such as hypotension.

3. Additionally, the label warns that atracurium besylate has been associated with hypotension, vasodilatation, tachycardia, and bradycardia as observed in clinical trials, indicating that the drug itself may lead to cardiovascular reactions.

4. The label mentions that atracurium besylate has been reported to cause substantial vital sign changes, including alterations in mean arterial pressure and heart rate, further suggesting that the drug itself may have cardiotoxic effects.

5. Furthermore, the label highlights that atracurium besylate has been associated with rare spontaneous reports of seizures in ICU patients, which may be linked to cardiovascular changes, indicating that the drug itself could potentially lead to cardiotoxic reactions.",Less,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",de1c2dcd-295b-47ce-b7a1-a8be59939a54,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=de1c2dcd-295b-47ce-b7a1-a8be59939a54&type=display
81,ATROPINE SULFATE,"1. The drug label mentions that when the recurrent use of atropine is essential in patients with coronary artery disease, the total dose should be restricted to avoid the detrimental effects of atropine-induced tachycardia on myocardial oxygen demand. (The drug itself is associated with the cardiotoxicity risk due to tachycardia in patients with coronary artery disease.)

2. It is noted that atropine may cause acute glaucoma, which can be a cardiotoxicity risk. (The drug itself is associated with the risk of acute glaucoma, which can indirectly impact cardiovascular health.)

3. The label also warns that atropine may convert partial organic pyloric stenosis into complete obstruction, which could lead to cardiotoxicity. (The drug itself is associated with the risk of pyloric obstruction, which can have cardiotoxic effects.)

4. Additionally, it is mentioned that atropine may lead to complete urinary retention in patients with prostatic hypertrophy, which can indirectly impact cardiovascular health. (The drug itself is associated with the risk of worsening urinary retention, which can have secondary cardiotoxic effects.)

5. The label states that atropine may cause inspissation of bronchial secretions and the formation of viscid plugs in patients with chronic lung disease, which can lead to cardiotoxicity. (The drug itself is associated with the risk of viscid bronchial plugs, which can impact cardiovascular function.)",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",d5e07279-48ca-4f83-9633-299e65a7f821,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=d5e07279-48ca-4f83-9633-299e65a7f821&type=display
82,AURANOFIN,"1. The drug RIDAURA (auranofin) contains gold and, like other gold-containing drugs, can cause gold toxicity, which may include cardiotoxicity risks such as a fall in hemoglobin, leukopenia, and decrease in platelets. (The drug itself is associated with cardiotoxicity risks.)

2. Thrombocytopenia, a condition characterized by a decrease in platelets, has occurred in 1-3% of patients treated with RIDAURA, leading to bleeding. The onset of thrombocytopenia is not related to the duration of RIDAURA therapy and may require immediate withdrawal of the drug. (The drug itself is associated with thrombocytopenia, which can lead to cardiotoxicity.)

3. Proteinuria, a condition involving the presence of abnormal amounts of protein in the urine, has developed in 3-9% of patients treated with RIDAURA. Clinically significant proteinuria should prompt immediate discontinuation of RIDAURA due to potential cardiotoxicity risks. (The drug itself is associated with proteinuria, which can indicate cardiotoxicity.)

4. The drug label mentions that RIDAURA therapy should be weighed against the potential risks of gold toxicity on organ systems, including the heart, in patients with certain medical conditions such as progressive renal disease or significant hepatocellular disease. (The drug itself is associated with potential cardiotoxicity risks in patients with specific medical conditions.)",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",43ba3de1-ab2e-06f6-e054-00144ff8d46c,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=43ba3de1-ab2e-06f6-e054-00144ff8d46c&type=display
83,AVACOPAN,"1. The drug TAVNEOS (avacopan) does not prolong the QT interval to any clinically relevant extent. (The drug itself is not associated with cardiotoxicity risk.)

2. Avacopan blocks the C5a-induced upregulation of CD11b on neutrophils, but the clinical significance of this pharmacodynamic effect on cardiotoxicity is unclear. (The drug itself is not directly associated with cardiotoxicity risk.)

3. In the clinical trial, there were no specific mentions of cardiotoxicity risks or reactions associated with TAVNEOS or avacopan. (No direct cardiotoxicity risks or reactions were reported in relation to the drug in the clinical trial data provided.)

Please note that while the drug label did not highlight any direct cardiotoxicity risks or reactions associated with TAVNEOS, it is essential to consult the full prescribing information and discuss any concerns with a healthcare provider for a comprehensive understanding of potential risks.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",c93cbc0b-29a3-46a5-9c85-41815ea5cf4a,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=c93cbc0b-29a3-46a5-9c85-41815ea5cf4a&type=display
84,AVANAFIL,"1. The drug STENDRA is not recommended for use in men with pre-existing cardiovascular disease or those for whom sexual activity is inadvisable due to their underlying cardiovascular status. This indicates that the drug itself is associated with a cardiotoxicity risk.

2. STENDRA has systemic vasodilatory properties and may augment the blood pressure-lowering effect of other anti-hypertensive medications. The drug can result in transient decreases in blood pressure, especially in combination with other medications. This suggests that the drug itself is associated with a cardiotoxicity risk.

3. STENDRA should be used with caution in patients with anatomical deformation of the penis or conditions predisposing them to priapism, as prolonged erection and priapism have been reported with other PDE5 inhibitors. This indicates that the drug itself is associated with a cardiotoxicity risk.

4. Physicians should advise patients to stop using STENDRA and seek medical attention in the event of a sudden loss of vision in one or both eyes, as this may be a sign of Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION). The drug should be used with caution in patients with underlying NAION risk factors. This suggests that the drug itself is associated with a cardiotoxicity risk.

5. Use of PDE5 inhibitors, including STENDRA, has been associated with sudden decrease or loss of hearing, which may be accompanied by tinnitus or dizziness. Patients experiencing these symptoms should stop taking STENDRA and seek prompt medical attention. This indicates that the drug itself is associated with a cardiotoxicity risk.

6. Serious cardiovascular and cerebrovascular events, including myocardial infarction, sudden cardiac death, cerebrovascular accident, and subarachnoid hemorrhage, have been reported post-marketing in temporal association with the use of STENDRA. These events occurred in patients with preexisting cardiovascular risk factors. This suggests that the drug itself is associated with cardiotoxicity reactions.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",fa7d93e3-b69b-4e02-8146-89760cd8e9d6,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fa7d93e3-b69b-4e02-8146-89760cd8e9d6&type=display
85,AVAPRITINIB,"1. The drug label does not mention any specific cardiotoxicity risks or cardiotoxicity reactions associated with AYVAKIT (avapritinib) itself.

2. There is no indication in the drug label that AYVAKIT is associated with cardiotoxicity risks or cardiotoxicity reactions.

3. Cardiotoxicity risks or cardiotoxicity reactions are not listed as adverse reactions or warnings in the drug label for AYVAKIT.

4. AYVAKIT does not appear to be linked to any cardiotoxicity risks or cardiotoxicity reactions based on the information provided in the drug label.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",645c887c-8cd4-4623-8da9-ac223d71a8b9,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=645c887c-8cd4-4623-8da9-ac223d71a8b9&type=display
86,AVATROMBOPAG MALEATE,"1. The drug DOPTELET, containing avatrombopag, is a thrombopoietin receptor agonist that has been associated with thrombotic and thromboembolic complications in patients with chronic liver disease or chronic immune thrombocytopenia. The drug itself is associated with the risk of thrombotic and thromboembolic complications. Patients with chronic liver disease experienced thromboembolic events, such as portal vein thrombosis, in 0.4% of cases when receiving DOPTELET. In patients with chronic immune thrombocytopenia, thromboembolic events occurred in 7% of cases when taking DOPTELET. The drug DOPTELET is associated with an increased risk of thrombotic complications in patients with known risk factors for thromboembolism.

2. The drug label advises monitoring platelet counts and following dosing guidelines to achieve target platelet counts to minimize the risk of thromboembolic events when administering DOPTELET to patients with chronic liver disease or chronic immune thrombocytopenia. The drug itself is associated with the risk of thromboembolic events, and monitoring platelet counts is recommended to manage this risk effectively. 

3. The drug label also mentions that DOPTELET should not be administered to patients with chronic liver disease or chronic immune thrombocytopenia in an attempt to normalize platelet counts, as this could increase the risk of thrombotic complications. The drug itself is associated with the risk of thrombotic complications if used inappropriately to normalize platelet counts. Monitoring for signs and symptoms of thromboembolic events and prompt treatment are essential when using DOPTELET.",Most,No,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",e2d5960d-6c18-46cc-86bd-089222b09852,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=e2d5960d-6c18-46cc-86bd-089222b09852&type=display
87,AXITINIB,"1. **Cardiotoxicity Risk**: The drug label for INLYTA (axitinib) mentions that cardiac failure has been observed in patients receiving the drug, indicating a potential risk of cardiotoxicity associated with INLYTA.

2. **Cardiotoxicity Reaction**: The label states that in a controlled clinical study with INLYTA for the treatment of patients with RCC, cardiac failure was reported in patients receiving INLYTA, suggesting a direct association between the drug and the occurrence of cardiac failure.

3. **Cardiotoxicity Risk**: The label advises monitoring for signs or symptoms of cardiac failure throughout treatment with INLYTA, indicating a potential risk of cardiotoxicity associated with the drug.

4. **Cardiotoxicity Reaction**: The label further mentions that management of cardiac failure may require dose reduction, dose interruption, or permanent discontinuation of INLYTA, suggesting that the drug can lead to cardiac failure as a reaction.

In summary, the drug label for INLYTA highlights the risk of cardiac failure as a potential adverse reaction associated with the use of the drug, emphasizing the importance of monitoring and managing cardiotoxicity during treatment.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",8a903e31-936e-4ed7-8a59-59f32374f338,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8a903e31-936e-4ed7-8a59-59f32374f338&type=display
88,AZACITIDINE,"1. **Warnings and Precautions - Hepatotoxicity:** The drug label mentions that patients with severe preexisting hepatic impairment are at higher risk for toxicity, indicating a potential risk of hepatotoxicity. The drug itself is not directly associated with cardiotoxicity in this section.

2. **Warnings and Precautions - Renal Toxicity:** The label states that renal toxicity, ranging from elevated serum creatinine to renal failure and death, has been reported in patients treated with intravenous azacitidine in combination with other chemotherapeutic agents for non-MDS conditions. While this section does not specifically mention cardiotoxicity, it highlights the potential for renal toxicity, which can indirectly impact cardiovascular health.

3. **Warnings and Precautions - Tumor Lysis Syndrome:** The drug label warns that VIDAZA may cause fatal or serious tumor lysis syndrome, including in patients with MDS. While tumor lysis syndrome primarily affects metabolic and electrolyte balance, it can indirectly lead to cardiac complications due to electrolyte imbalances.

4. **Warnings and Precautions - Embryo-Fetal Toxicity:** The label indicates that VIDAZA can cause fetal harm when administered to a pregnant woman. While this section does not directly relate to cardiotoxicity, it highlights potential risks to fetal development, which can indirectly impact cardiovascular health in the developing fetus.

Overall, while the drug label does not explicitly mention direct cardiotoxicity risks or reactions associated with VIDAZA, certain warnings and precautions highlight potential risks to other organ systems that could indirectly impact cardiovascular function. It is essential for healthcare providers to monitor patients for any signs of organ toxicity, including cardiac effects, during treatment with VIDAZA.",Less,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",3495a71a-cc04-4776-851f-f185956f32af,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=3495a71a-cc04-4776-851f-f185956f32af&type=display
89,AZATHIOPRINE,"1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with Imuran (azathioprine).

2. Imuran is primarily associated with hematologic and gastrointestinal toxic effects, with no direct mention of cardiotoxicity risks or reactions.

3. The drug label focuses on risks such as malignancy, infections, and bone marrow suppression, but does not attribute any cardiotoxicity risks or reactions to Imuran.

Overall, the drug label for Imuran does not indicate any direct association between the drug and cardiotoxicity risks or reactions.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",606101a0-6244-7eff-e053-2a91aa0acadd,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=606101a0-6244-7eff-e053-2a91aa0acadd&type=display
90,AZATHIOPRINE SODIUM,"1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with azathioprine itself. 

2. Azathioprine is not directly linked to cardiotoxicity risks or reactions in the drug label. 

3. The drug label does not attribute any cardiotoxicity risks or reactions to azathioprine. 

4. There are no mentions of azathioprine causing cardiotoxicity risks or reactions in the drug label. 

5. Azathioprine is not stated to be associated with cardiotoxicity risks or reactions in the drug label.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",9ffe79a1-ac91-4a7b-a9e3-7c84bfa9ddf0,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=9ffe79a1-ac91-4a7b-a9e3-7c84bfa9ddf0&type=display
91,AZILSARTAN KAMEDOXOMIL,"1. **Fetal Toxicity Warning**: The drug label warns that drugs directly affecting the renin-angiotensin system, like Edarbi, can cause injury and death to the developing fetus. The drug itself is associated with the risk of fetal toxicity.

2. **Hypotension in Volume- or Salt-Depleted Patients**: In patients with an activated renin-angiotensin system, such as volume- and/or salt-depleted patients, symptomatic hypotension may occur after initiation of treatment with Edarbi. The drug itself is associated with the risk of hypotension in these specific patient populations.

3. **Impaired Renal Function**: Changes in renal function may be anticipated in susceptible individuals treated with Edarbi due to inhibiting the renin-angiotensin system. The drug itself is associated with the risk of impaired renal function in certain patient populations.

4. **Adverse Reactions**: While not directly cardiotoxic, adverse reactions such as dizziness and hypotension can occur with Edarbi use. These reactions may indirectly impact cardiovascular health and should be monitored.",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",52b27c75-9f5a-4816-bafd-dace9d7d2063,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=52b27c75-9f5a-4816-bafd-dace9d7d2063&type=display
92,AZITHROMYCIN,"1. The drug label mentions that prolonged cardiac repolarization and QT interval, which can lead to cardiac arrhythmia and torsades de pointes, have been observed with other macrolides, and a similar effect with azithromycin cannot be completely ruled out in patients at increased risk for prolonged cardiac repolarization. (The drug itself was associated with the risk of prolonged cardiac repolarization and QT interval.)

2. The label also warns about serious allergic reactions, including angioedema, anaphylaxis, and dermatologic reactions like Stevens Johnson Syndrome and toxic epidermal necrolysis, which have been reported rarely in patients on azithromycin therapy. Although rare, fatalities have been reported, and the relationship of these episodes to the long tissue half-life of azithromycin and subsequent prolonged exposure to antigen is unknown at present. (The drug itself was associated with the risk of serious allergic reactions.)

3. Additionally, the label mentions that despite initially successful symptomatic treatment of allergic symptoms, when symptomatic therapy was discontinued, the allergic symptoms recurred soon thereafter in some patients without further azithromycin exposure. These patients required prolonged periods of observation and symptomatic treatment. (The drug itself was associated with the risk of recurrent allergic symptoms upon discontinuation of symptomatic therapy.)

4. The label also highlights the potential for exacerbation of symptoms of myasthenia gravis and new onset of myasthenic syndrome in patients receiving azithromycin therapy. (The drug itself was associated with the risk of exacerbating myasthenia gravis symptoms and causing new onset myasthenic syndrome.)",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",5a96f4e1-6b80-42a2-8d85-95a1ff892099,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=5a96f4e1-6b80-42a2-8d85-95a1ff892099&type=display
93,AZTREONAM,"1. The drug label does not mention any direct association of AZACTAM (aztreonam) with cardiotoxicity risks or cardiotoxicity reactions. 

2. The label does not indicate any specific cardiotoxicity risks or reactions related to the use of AZACTAM. 

3. There are no mentions of cardiotoxicity risks or reactions attributed to AZACTAM in the drug label. 

Overall, the drug label for AZACTAM does not highlight any cardiotoxicity risks or reactions associated with the use of this medication.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",9a105eaf-ee77-4016-beeb-d425a5565db2,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=9a105eaf-ee77-4016-beeb-d425a5565db2&type=display
94,BACLOFEN,"1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with FLEQSUVY (baclofen oral suspension).

Therefore, based on the information provided in the drug label, there are no mentions of cardiotoxicity risks or reactions linked to the use of FLEQSUVY.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",9076d6ce-bbc2-4a9f-9cb9-2de1b675b9aa,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=9076d6ce-bbc2-4a9f-9cb9-2de1b675b9aa&type=display
95,BALOXAVIR MARBOXIL,"1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with XOFLUZA (baloxavir marboxil) itself.

2. XOFLUZA (baloxavir marboxil) is an influenza virus PA endonuclease inhibitor, and there is no information provided in the drug label linking this drug to cardiotoxicity risks or reactions.

3. The drug label does not include any data or warnings regarding cardiotoxicity risks or reactions related to the use of XOFLUZA (baloxavir marboxil).

Overall, based on the information provided in the drug label, XOFLUZA (baloxavir marboxil) is not associated with any cardiotoxicity risks or reactions.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",e49e1a61-1b7c-4be5-ac84-af6240b511e7,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=e49e1a61-1b7c-4be5-ac84-af6240b511e7&type=display
96,BALSALAZIDE DISODIUM,"1. The drug label mentions that mesalamine, the active moiety of COLAZAL, has been associated with acute intolerance syndrome, which includes symptoms like cramping, acute abdominal pain, and bloody diarrhea, potentially indicating cardiotoxicity risk. The drug itself is associated with this risk.

2. Hypersensitivity reactions to mesalamine, the active moiety of COLAZAL, may present as internal organ involvement, including myocarditis and pericarditis, suggesting a potential cardiotoxicity risk. The drug itself is associated with this risk.

3. Severe cutaneous adverse reactions, such as Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), have been reported with the use of mesalamine, the active moiety of COLAZAL, indicating a potential risk of cardiotoxicity. The drug itself is associated with this risk.

4. The drug label also mentions that there have been reports of hepatic failure in patients with pre-existing liver disease who have been administered mesalamine, the active moiety of COLAZAL, which could potentially lead to cardiotoxicity. The drug itself is associated with this risk.

5. Postmarketing experience with mesalamine-containing products, including COLAZAL, has identified adverse reactions like myocarditis and pericarditis, which suggest a potential risk of cardiotoxicity. The drug itself is associated with this risk.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",22f41e83-b9fb-4c9e-8cc3-f457034191a8,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=22f41e83-b9fb-4c9e-8cc3-f457034191a8&type=display
97,BARICITINIB,"1. The drug OLUMIANT (baricitinib) is associated with a higher rate of major adverse cardiovascular events (MACE) compared to TNF blockers in rheumatoid arthritis patients. The use of another JAK inhibitor in RA patients 50 years of age and older with cardiovascular risk factors was linked to an increased risk of all-cause mortality, including sudden cardiovascular death.

2. OLUMIANT has been associated with an increased incidence of thrombosis, including deep venous thrombosis and pulmonary embolism, compared to placebo. Another JAK inhibitor in RA patients 50 years of age and older with cardiovascular risk factors showed a higher rate of thrombosis compared to TNF blockers.

3. Patients treated with OLUMIANT are at risk for developing serious infections, including bacterial, fungal, viral, and opportunistic infections, which may lead to hospitalization or death. The risks and benefits of treatment with OLUMIANT should be carefully considered in patients with chronic or recurrent infections, as well as those with underlying conditions that may predispose them to infection.

4. In a large, randomized, postmarketing safety study, another JAK inhibitor in RA patients 50 years of age and older with cardiovascular risk factors was associated with a higher rate of all-cause mortality, including sudden cardiovascular death. The decision to initiate or continue therapy with OLUMIANT should be based on an assessment of the benefits and risks for each individual patient.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",866e9f35-9035-4581-a4b1-75a621ab55cf,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=866e9f35-9035-4581-a4b1-75a621ab55cf&type=display
98,BARIUM SULFATE,"1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with VARIBAR THIN HONEY (barium sulfate) itself.

2. The drug label focuses on gastrointestinal risks and reactions, such as perforation, obstruction, and aspiration, but does not mention any direct cardiotoxicity risks or reactions related to the use of VARIBAR THIN HONEY.

3. Therefore, based on the information provided in the drug label, VARIBAR THIN HONEY is not associated with or known to cause cardiotoxicity risks or reactions.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",37bf7f08-5486-e570-7f80-0e0ee5cd33e8,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=37bf7f08-5486-e570-7f80-0e0ee5cd33e8&type=display
99,BEDAQUILINE FUMARATE,"1. The drug SIRTURO (bedaquiline) is associated with an increased risk of mortality, with an increased risk of death observed in the SIRTURO treatment group compared to the placebo group in one trial. The imbalance in deaths is unexplained, and the drug should only be used when an effective treatment regimen cannot be provided.

2. SIRTURO can cause QT prolongation, which may lead to ventricular arrhythmias. Use with caution, as QT prolongation can occur with the drug. Monitoring of ECGs is recommended, and the drug should be discontinued if significant ventricular arrhythmia or QTcF interval >500 ms develops.

3. The drug label mentions that SIRTURO has not been studied in patients with ventricular arrhythmias or recent myocardial infarction. The drug itself is associated with QT prolongation, and caution is advised in patients with certain risk factors for QT prolongation.

4. In a drug interaction study, it was observed that co-administration of SIRTURO with other drugs that prolong the QT interval, such as clofazimine, may lead to additive or synergistic QT prolongation. Monitoring of ECGs is recommended if SIRTURO is co-administered with other QT-prolonging drugs, and the drug should be discontinued if evidence of serious ventricular arrhythmia or QTcF interval >500 ms is detected.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",1534c9ae-4948-4cf4-9f66-222a99db6d0e,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=1534c9ae-4948-4cf4-9f66-222a99db6d0e&type=display
100,BELINOSTAT,"1. **Clinical Pharmacology Section**: Beleodaq, a histone deacetylase inhibitor, did not show any meaningful effect on cardiac repolarization, heart rate, or other cardiac parameters in multiple clinical trials. There were no cases of Torsades de Pointes associated with Beleodaq use.

2. **Adverse Reactions Section**: The drug label does not mention any direct association of Beleodaq with cardiotoxicity reactions. The most common adverse reactions reported were nausea, fatigue, pyrexia, anemia, and vomiting. No specific cardiotoxicity reactions were highlighted in this section.

3. **Drug Interaction Studies**: In vitro studies indicated that belinostat, the active ingredient in Beleodaq, did not increase the AUC or Cmax of warfarin, a known CYP2C9 substrate. This suggests that Beleodaq did not have a significant impact on the pharmacokinetics of warfarin, a drug with potential cardiac implications.

Overall, while the drug label does not directly associate Beleodaq with cardiotoxicity risks or reactions, it is important to monitor patients for any signs or symptoms of cardiac issues during treatment with this medication.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",2e8ef36b-71fa-4492-a16f-577d5f7d111d,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=2e8ef36b-71fa-4492-a16f-577d5f7d111d&type=display
101,BELUMOSUDIL,"1. The drug REZUROCK (belumosudil) is a kinase inhibitor indicated for the treatment of chronic graft-versus-host disease (chronic GVHD) in adult and pediatric patients after failure of prior systemic therapy. (No mention of cardiotoxicity risk associated with the drug itself)
   
2. The drug label does not mention any specific cardiotoxicity risks or reactions associated with REZUROCK. (No mention of cardiotoxicity risks or reactions)

3. The drug label states that at 2.4 times the maximum exposure for the approved recommended dose, REZUROCK does not prolong the QT interval to any clinically relevant extent. (No cardiotoxicity risk associated with the drug itself)

4. The drug label does not report any specific cardiotoxicity risks or reactions related to REZUROCK treatment in patients with chronic GVHD. (No mention of cardiotoxicity risks or reactions)

In summary, the drug label for REZUROCK does not indicate any direct association with cardiotoxicity risks or reactions. The drug has not been reported to cause cardiotoxic effects in patients with chronic GVHD.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",102e4ef4-7f84-4e34-8df1-479c24d1575d,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=102e4ef4-7f84-4e34-8df1-479c24d1575d&type=display
102,BELZUTIFAN,"1. **Cardiotoxicity Risk**: The drug label does not mention any specific cardiotoxicity risks associated with WELIREG (belzutifan).
   
2. **Cardiotoxicity Reactions**: The drug label does not indicate any direct association of WELIREG (belzutifan) with cardiotoxicity reactions.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",13e15ee0-d679-4fa9-9430-e2e2170474da,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=13e15ee0-d679-4fa9-9430-e2e2170474da&type=display
103,BEMPEDOIC ACID,"1. The drug NEXLETOL (bempedoic acid) is associated with an increased risk of tendon rupture or injury, including events such as tendon rupture in patients taking the medication. This risk was observed in both primary hyperlipidemia trials and the cardiovascular outcomes trial. (Source: Warnings and Precautions, 5.2)

2. NEXLETOL has been linked to elevations in serum uric acid levels, which may lead to the development of gout. The drug itself is associated with hyperuricemia and gout, as reported in the primary hyperlipidemia trials and the cardiovascular outcomes trial. (Source: Warnings and Precautions, 5.1)

3. In the primary hyperlipidemia trials, NEXLETOL was associated with persistent changes in multiple laboratory tests, including increases in liver enzymes, creatinine, blood urea nitrogen, and platelet count. These changes occurred within the first 4 weeks of treatment and returned to baseline following discontinuation of the drug. (Source: Adverse Reactions, 6.1)

4. The drug label also mentions that NEXLETOL was associated with adverse reactions such as anemia, renal impairment, and muscle spasms in the cardiovascular outcomes trial. These reactions were reported in patients taking NEXLETOL and were greater than those observed in the placebo group. (Source: Adverse Reactions, 6.1)

5. NEXLETOL has been linked to an increased risk of tendon rupture, with events occurring in patients taking the medication. Tendon rupture events were reported in both the primary hyperlipidemia trials and the cardiovascular outcomes trial. (Source: Adverse Reactions, 6.1)",Less,No,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",88d06d89-a3da-40b4-b273-8f4f7d56c4c9,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=88d06d89-a3da-40b4-b273-8f4f7d56c4c9&type=display
104,BENAZEPRIL HYDROCHLORIDE,"1. The drug label warns about fetal toxicity associated with Lotensin, stating that drugs acting on the renin-angiotensin system can cause injury and death to the developing fetus. Lotensin should be discontinued as soon as pregnancy is detected to avoid potential fetal harm.

2. The drug label mentions that angioedema, a serious allergic reaction, can occur in patients treated with Lotensin. It advises prompt discontinuation of Lotensin and appropriate treatment if angioedema occurs. Lotensin itself is associated with the risk of angioedema.

3. Lotensin can cause impaired renal function, including acute renal failure, especially in patients whose renal function depends on the renin-angiotensin system. The label recommends monitoring renal function periodically in patients taking Lotensin. Lotensin is associated with the risk of impaired renal function.

4. Symptomatic hypotension, which can lead to complications like acute renal failure or death, may occur with Lotensin use, particularly in patients with certain conditions or characteristics. Close monitoring is advised, especially during the initial weeks of treatment. Lotensin itself is associated with the risk of symptomatic hypotension.

5. Lotensin can cause hyperkalemia, characterized by high levels of potassium in the blood. Monitoring serum potassium levels periodically is recommended in patients taking Lotensin. The drug label states that drugs inhibiting the renin-angiotensin system can lead to hyperkalemia. Lotensin is associated with the risk of hyperkalemia.

6. The drug label mentions that ACE inhibitors, including Lotensin, have been associated with hepatic failure, starting with cholestatic jaundice and potentially progressing to fulminant hepatic necrosis and death. Patients should discontinue Lotensin and seek appropriate medical follow-up if jaundice or elevated liver enzymes occur. Lotensin is associated with the risk of hepatic failure.",Less,No,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",2abb091b-a53e-46b0-9b84-e5ee8f2bdd8e,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=2abb091b-a53e-46b0-9b84-e5ee8f2bdd8e&type=display
105,BENDAMUSTINE HYDROCHLORIDE,"1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with bendamustine hydrochloride injection itself.

2. The drug label does not attribute any cardiotoxicity risks or reactions to bendamustine hydrochloride injection in the sections related to warnings and precautions, adverse reactions, or drug interactions. 

3. No information regarding cardiotoxicity risks or reactions related to bendamustine hydrochloride injection is provided in the drug label sections discussing clinical trials experience or postmarketing experience.

Overall, based on the information provided in the drug label, there are no mentions of cardiotoxicity risks or reactions directly associated with bendamustine hydrochloride injection.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",085dd54c-4212-d879-afef-ee52732a48c0,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=085dd54c-4212-d879-afef-ee52732a48c0&type=display
106,BENZNIDAZOLE,"1. **Cardiotoxicity Risk Associated with Benznidazole Tablets**: The drug label mentions that benznidazole, a nitroimidazole antimicrobial, has been associated with genotoxicity and carcinogenicity in humans, in vitro bacterial species, mammalian cell systems, and in vivo in rodents. However, it is noted that the data on benznidazole's association with carcinogenicity in humans is not known.

2. **Cardiotoxicity Reactions**: The drug label does not specifically mention direct cardiotoxicity reactions associated with benznidazole. However, it does highlight potential risks for genotoxicity and carcinogenicity, which could indirectly impact cardiac health. 

3. **Cardiotoxicity Risk in Pregnancy**: The label states that based on animal studies, benznidazole may cause fetal harm when administered to pregnant women. It mentions fetal malformations observed in animal studies at doses approximately 1-3 times the maximum recommended human dose in rats and doses approximately 0.3-1 times the MRHD in rabbits. These malformations include anasarca, anophthalmia, microphthalmia, and ventricular septal defect.

4. **Cardiotoxicity Risk in Lactation**: Limited data suggest that benznidazole is present in human milk at infant doses of 5.5 to 17% of the maternal weight-adjusted dosage. While there are no reports of adverse effects on breastfed infants, the label advises against breastfeeding during treatment with Benznidazole Tablets due to potential serious adverse reactions and the risk of transmitting Chagas disease.

In summary, while the drug label does not explicitly mention direct cardiotoxicity reactions associated with benznidazole, it does highlight potential risks for genotoxicity, carcinogenicity, and fetal harm in relation to cardiac health.",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",8983d6a0-f63f-4f8e-bba4-38223f39e29b,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8983d6a0-f63f-4f8e-bba4-38223f39e29b&type=display
107,BENZONATATE,"1. Severe hypersensitivity reactions, including bronchospasm, laryngospasm, and cardiovascular collapse, have been reported possibly related to local anesthesia from sucking or chewing the capsule instead of swallowing it. (The drug itself was not directly associated with cardiotoxicity risk, but the method of administration could lead to cardiovascular collapse.)

2. Accidental ingestion of benzonatate capsules resulting in death has been reported in children below age 10, with signs and symptoms of overdose reported within 15-20 minutes and death within one hour of ingestion. (The drug itself was not directly associated with cardiotoxicity risk, but accidental ingestion in children can lead to cardiovascular collapse and death.)

3. Deliberate or accidental overdose of benzonatate capsules has resulted in death, particularly in children, with signs and symptoms of overdose reported within 15-20 minutes. (The drug itself was associated with cardiotoxicity risk, as overdose can lead to cardiovascular collapse and death.)

4. Intentional and unintentional overdose of benzonatate capsules may result in death, particularly in children, with signs and symptoms of overdose reported within 15-20 minutes. (The drug itself was associated with cardiotoxicity risk, as overdose can lead to cardiovascular collapse and death.)

5. Convulsions, coma, cerebral edema, and cardiac arrest leading to death have been reported within 1 hour of ingestion of benzonatate capsules in cases of overdose. (The drug itself was associated with cardiotoxicity reactions, as overdose can lead to cardiovascular collapse and death.)",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",324f65ae-09d1-4bd6-9d2b-593035201ecd,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=324f65ae-09d1-4bd6-9d2b-593035201ecd&type=display
108,BENZPHETAMINE HYDROCHLORIDE,"1. The drug label mentions that benzphetamine hydrochloride tablets have been associated with cardiovascular effects such as palpitation, tachycardia, and elevation of blood pressure. (The drug itself was associated with these cardiovascular effects.)

2. The label also notes isolated reports of cardiomyopathy and ischemic cardiac events linked to chronic amphetamine use. (The drug itself was not specifically mentioned in these reports, but they are associated with chronic amphetamine use.)

3. Valvular heart disease has been reported with some anorectic agents, but no cases have been reported when benzphetamine hydrochloride tablets are used alone. (The drug itself was not associated with valvular heart disease when used alone.)

4. The label advises that baseline cardiac evaluation should be considered before initiating benzphetamine treatment to detect pre-existing valvular heart diseases or pulmonary hypertension. (The drug itself was not directly linked to causing valvular heart diseases or pulmonary hypertension.)

5. It is recommended to discontinue benzphetamine hydrochloride tablets if symptoms such as exertional dyspnea, angina pectoris, syncope, or lower extremity edema occur, as they may suggest the possibility of pulmonary hypertension. (The drug itself was not stated to cause pulmonary hypertension but should be discontinued if symptoms arise.)

6. The label emphasizes that the potential risks of serious adverse effects like valvular heart disease and pulmonary hypertension should be carefully weighed against the benefits of weight loss. (The drug itself was not directly implicated in causing valvular heart disease or pulmonary hypertension.)

7. Echocardiograms during and after treatment are recommended to detect any valvular disorders that may occur. (The drug itself was not mentioned as causing valvular disorders but monitoring is advised.)

8. Treatment with benzphetamine hydrochloride tablets should only continue if satisfactory weight loss is achieved within the first 4 weeks of treatment. (The drug itself was not directly linked to cardiotoxicity in this statement but is related to treatment continuation based on weight loss.)",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",14d4589d-7f1c-4b6e-9557-59dad39b0960,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=14d4589d-7f1c-4b6e-9557-59dad39b0960&type=display
109,BEROTRALSTAT HYDROCHLORIDE,"1. The drug label mentions that an increase in QT prolongation can occur at dosages higher than the recommended 150 mg once daily dosage, and additional doses or doses of ORLADEYO higher than 150 mg once daily are not recommended. This indicates that the drug itself is associated with the risk of QT prolongation.

2. The label also states that ORLADEYO should not be used for the treatment of acute HAE attacks, and additional doses or doses of ORLADEYO higher than 150 mg once daily are not recommended due to the potential for QT prolongation. This highlights that the drug itself is linked to the risk of QT prolongation.

3. Furthermore, the adverse reactions section mentions that the most common adverse reactions, including abdominal pain, vomiting, diarrhea, back pain, and gastroesophageal reflux disease, were observed. While these adverse reactions are not directly related to cardiotoxicity, they are important to monitor as they may impact the overall well-being of the patient.

Overall, the drug label clearly emphasizes the risk of QT prolongation associated with ORLADEYO, particularly at dosages higher than the recommended 150 mg once daily dosage. It is crucial for healthcare providers and patients to be aware of this cardiotoxicity risk when prescribing or taking ORLADEYO.",Less,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",3527ece1-e7e0-40b1-b0c5-6baeb0deabeb,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=3527ece1-e7e0-40b1-b0c5-6baeb0deabeb&type=display
110,BETAINE,1. The drug label for Cystadane does not mention any cardiotoxicity risks or cardiotoxicity reactions associated with the use of the drug.,No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",31a684d0-cd98-4e46-b43a-ccbd17c41559,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=31a684d0-cd98-4e46-b43a-ccbd17c41559&type=display
111,BETHANECHOL CHLORIDE,"1. The drug label mentions that Bethanechol chloride may cause a fall in blood pressure with reflex tachycardia as an adverse reaction following oral administration. The drug itself is associated with this cardiotoxicity risk.

2. Additionally, the label states that special care is required when administering Bethanechol chloride to patients receiving ganglion blocking compounds, as a critical fall in blood pressure may occur. The drug itself is associated with this cardiotoxicity risk.

3. The label also mentions that Bethanechol chloride can cause bronchial constriction and asthmatic attacks as adverse reactions. The drug itself is associated with this cardiotoxicity risk.

4. Furthermore, the drug label indicates that Bethanechol chloride may lead to a vasomotor response as an adverse reaction. The drug itself is associated with this cardiotoxicity risk.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",80393410-dd51-4cac-b27c-50ece00cca37,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=80393410-dd51-4cac-b27c-50ece00cca37&type=display
112,BETIATIDE,"1. The drug label does not mention any specific cardiotoxicity risks associated with the drug itself.
2. The drug label does not mention any cardiotoxicity reactions caused by the drug itself.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",0ad62039-f848-4f3d-b489-2524e6b6b86e,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=0ad62039-f848-4f3d-b489-2524e6b6b86e&type=display
113,BEXAROTENE,"1. **Cardiotoxicity Risk**: TARGRETIN is not associated with cardiotoxicity risks based on the provided drug label information.

2. **Cardiotoxicity Reactions**: The drug label does not mention any cardiotoxicity reactions associated with TARGRETIN use.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",1d056725-0576-4338-8089-6336e768ccdc,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=1d056725-0576-4338-8089-6336e768ccdc&type=display
114,BICALUTAMIDE,"1. **Warnings and Precautions (5.2):** There have been reports of excessive prolongation of the prothrombin time (PT) and International Normalized Ratio (INR) when bicalutamide is used concomitantly with coumarin anticoagulants, leading to serious bleeding. This suggests that bicalutamide can interact with coumarin anticoagulants to increase the risk of hemorrhage.

2. **Adverse Reactions (6.1):** In clinical trials, adverse reactions such as hypertension and cardiovascular events were reported in patients receiving bicalutamide plus an LHRH analog. This indicates that there is a potential association between bicalutamide use and cardiovascular adverse events.

3. **Postmarketing Experience (6.2):** Post-approval use of bicalutamide has identified cases of interstitial lung disease, including interstitial pneumonitis and pulmonary fibrosis, particularly at doses greater than 50 mg. This suggests a potential risk of cardiopulmonary toxicity associated with bicalutamide use.

In summary, bicalutamide has been associated with cardiotoxicity risks such as hemorrhage with coumarin anticoagulants, hypertension, and cardiovascular events in clinical trials, as well as cases of interstitial lung disease in postmarketing reports. These findings highlight the importance of monitoring patients for cardiotoxicity reactions during bicalutamide therapy.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",7a08d88b-051a-4c16-9560-12685c500c58,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7a08d88b-051a-4c16-9560-12685c500c58&type=display
115,BICISATE DIHYDROCHLORIDE,"1. The drug label does not mention any cardiotoxicity risks or cardiotoxicity reactions associated with Neurolite (bicisate dihydrochloride) in the ""WARNINGS"" section.
   
2. The drug label does not mention any cardiotoxicity risks or cardiotoxicity reactions associated with Neurolite (bicisate dihydrochloride) in the ""PRECAUTIONS"" section.

3. The drug label does not mention any cardiotoxicity risks or cardiotoxicity reactions associated with Neurolite (bicisate dihydrochloride) in the ""ADVERSE REACTIONS"" section.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",f9adbcd5-1ac1-42d8-b18a-a76c9204014c,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=f9adbcd5-1ac1-42d8-b18a-a76c9204014c&type=display
116,BINIMETINIB,"1. MEKTOVI, in combination with encorafenib, has been associated with cardiomyopathy, which manifests as left ventricular dysfunction with symptomatic or asymptomatic decreases in ejection fraction. The drug has been linked to cardiomyopathy in patients with BRAF V600 mutation-positive unresectable or metastatic melanoma.

2. The safety of MEKTOVI in combination with encorafenib has not been established in patients with a baseline ejection fraction below 50% or below the institutional lower limit of normal. Patients with cardiovascular risk factors should be closely monitored when treated with MEKTOVI. The drug itself is associated with the risk of cardiomyopathy.

3. Assessing ejection fraction by echocardiogram or MUGA scan before treatment initiation, one month after starting treatment, and every 2 to 3 months during treatment is recommended. The drug has been linked to left ventricular dysfunction and cardiomyopathy.

4. Withholding, reducing the dose, or permanently discontinuing MEKTOVI is advised based on the severity of the cardiomyopathy adverse reaction. The drug itself is associated with the risk of cardiomyopathy and left ventricular dysfunction.

5. In clinical trials, evidence of cardiomyopathy, including a decrease in left ventricular ejection fraction below the institutional lower limit of normal with an absolute decrease from baseline, occurred in a percentage of patients receiving MEKTOVI in combination with encorafenib. The drug has been associated with cardiomyopathy in clinical trials.

6. Cardiomyopathy resolved in a percentage of patients receiving MEKTOVI plus encorafenib. The drug has been associated with reversible cardiomyopathy in some patients.

7. The median time to the first occurrence of left ventricular dysfunction in patients receiving MEKTOVI in combination with encorafenib was reported. The drug has been associated with left ventricular dysfunction in a specific timeframe in clinical trials.

8. In another trial, evidence of cardiomyopathy occurred in a percentage of patients receiving MEKTOVI in combination with encorafenib. The drug has been associated with cardiomyopathy in a different clinical trial.

9. Cardiomyopathy resolved in a percentage of patients receiving MEKTOVI plus encorafenib in the trial. The drug has been associated with reversible cardiomyopathy in a specific trial setting.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",6c3408ac-d401-4925-8a03-26591afbc240,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=6c3408ac-d401-4925-8a03-26591afbc240&type=display
117,BISOPROLOL FUMARATE,"1. The drug label mentions that bisoprolol fumarate is contraindicated in patients with cardiogenic shock, overt cardiac failure, second or third degree AV block, and marked sinus bradycardia. (The drug itself is associated with the cardiotoxicity risk.)

2. The label warns about the potential for further depression of myocardial contractility and more severe heart failure with beta-blockade in patients with congestive heart failure. It states that beta-blocking agents should generally be avoided in patients with overt congestive heart failure. (The drug itself is associated with the cardiotoxicity risk.)

3. The label advises that in patients without a history of cardiac failure, continued depression of the myocardium with beta-blockers can precipitate cardiac failure. It suggests considering discontinuation of bisoprolol fumarate at the first signs or symptoms of heart failure. (The drug itself is associated with the cardiotoxicity risk.)

4. The label warns against the abrupt cessation of therapy with beta-blockers, as it may lead to exacerbation of angina pectoris, myocardial infarction, or ventricular arrhythmia in patients with coronary artery disease. It recommends cautioning patients against interrupting or discontinuing therapy without a physician's advice. (The drug itself is associated with the cardiotoxicity risk.)

5. The label cautions that beta-blockers can precipitate or worsen symptoms of arterial insufficiency in patients with peripheral vascular disease. It advises exercising caution in such individuals. (The drug itself is associated with the cardiotoxicity risk.)

6. The label mentions that patients with bronchospastic disease should generally not receive beta-blockers. However, it notes that bisoprolol fumarate, due to its relative beta1-selectivity, may be cautiously used in patients with bronchospastic disease who do not respond to or cannot tolerate other antihypertensive treatments. (The drug itself is associated with the cardiotoxicity risk.)

7. The label advises that chronically administered beta-blocking therapy should not be routinely withdrawn before major surgery, as the impaired ability of the heart to respond to reflex adrenergic stimuli may increase the risk of general anesthesia and surgical procedures. (The drug itself is associated with the cardiotoxicity risk.)

8. The label mentions that beta-blockers may mask some manifestations of hypoglycemia, particularly tachycardia, and that nonselective beta-blockers may potentiate insulin-induced hypoglycemia and delay recovery of serum glucose levels. It states that this is less likely with bisoprolol fumarate due to its beta1-selectivity. (The drug itself is associated with the cardiotoxicity risk.)

9. The label warns that beta-adrenergic blockade may mask clinical signs of hyperthyroidism, such as tachycardia, and that abrupt withdrawal of beta-blockade may exacerbate symptoms of hyperthyroidism or precipitate thyroid storm. (The drug itself is associated with the cardiotoxicity risk.)",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",c8fa858c-7e42-4134-9fc6-604a11a66fe2,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=c8fa858c-7e42-4134-9fc6-604a11a66fe2&type=display
118,BIVALIRUDIN,"1. The drug label mentions a thrombotic risk with coronary artery brachytherapy, indicating an increased risk of thrombus formation, including fatal outcomes, in gamma brachytherapy. The drug, bivalirudin, is associated with this thrombotic risk (5.2).

2. Postmarketing experience reports mention adverse reactions related to cardiotoxicity, such as fatal bleeding, lack of anticoagulant effect, thrombus formation during percutaneous coronary intervention (PCI) with and without intracoronary brachytherapy, pulmonary hemorrhage, and cardiac tamponade. These reactions were observed in patients who used bivalirudin, indicating a potential association with cardiotoxicity (6.2).",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",1ed8c822-6fe1-49c1-a59f-31a4c72818c8,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=1ed8c822-6fe1-49c1-a59f-31a4c72818c8&type=display
119,BLEOMYCIN,"1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with bleomycin. 

2. The label primarily focuses on pulmonary toxicity as the most severe toxicity associated with bleomycin, with a warning about pulmonary fibrosis being the most frequent presentation. Cardiotoxicity risks or reactions are not mentioned in this context.

3. The label does not contain any information about cardiotoxicity risks or reactions related to bleomycin use. 

Overall, the drug label for bleomycin does not highlight any specific cardiotoxicity risks or reactions associated with the drug. The focus is primarily on pulmonary toxicity and other adverse effects.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",cccfb763-79fa-4186-89fb-d8d061d3c161,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=cccfb763-79fa-4186-89fb-d8d061d3c161&type=display
120,BORTEZOMIB,"1. **Cardiac Toxicity Risk**: Bortezomib therapy has been associated with acute development or exacerbation of congestive heart failure and new onset of decreased left ventricular ejection fraction. Patients with risk factors for, or existing heart disease should be frequently monitored for cardiac toxicity. The incidence of any treatment-related cardiac disorder was 8% in patients receiving bortezomib.

2. **Cardiac Toxicity Reactions**: Reports have indicated worsening of and development of cardiac failure during bortezomib therapy, including in patients with no risk factors for decreased left ventricular ejection fraction. The incidence of adverse reactions suggestive of heart failure was 1% for each individual reaction in the bortezomib group. Isolated cases of QT-interval prolongation have been reported, although causality has not been established.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",e6718f64-b39e-fcc3-e053-2995a90ab69e,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=e6718f64-b39e-fcc3-e053-2995a90ab69e&type=display
121,BOSENTAN,"1. The drug TRACLEER is associated with a risk of fluid retention, which may require intervention, and is a known clinical consequence of pulmonary arterial hypertension (PAH) and worsening PAH, as well as an effect of TRACLEER and other endothelin receptor antagonists.

2. TRACLEER should be discontinued if signs of pulmonary edema occur, as it may indicate associated pulmonary veno-occlusive disease, prompting consideration of discontinuing TRACLEER.

3. TRACLEER has been associated with decreased sperm counts in patients receiving the drug, and preclinical data suggest that TRACLEER, like other endothelin receptor antagonists, may have an adverse effect on spermatogenesis.

4. Treatment with TRACLEER can cause a dose-related decrease in hemoglobin and hematocrit, with postmarketing reports of decreases in hemoglobin concentration and hematocrit that have resulted in anemia requiring transfusion. Monitoring of hemoglobin levels is recommended during treatment with TRACLEER to detect any marked decrease that may require further evaluation and specific treatment.",Less,No,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",749e42fb-2fe0-45dd-9268-b43bb3f4081c,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=749e42fb-2fe0-45dd-9268-b43bb3f4081c&type=display
122,BREMELANOTIDE,"1. The drug VYLEESI is contraindicated in patients with uncontrolled hypertension or known cardiovascular disease, indicating that the drug itself is associated with cardiotoxicity risks.

2. VYLEESI may transiently increase blood pressure and reduce heart rate after each dose, with effects usually resolving within 12 hours. The drug is not recommended for patients at high risk for cardiovascular disease, suggesting that the drug itself can cause cardiotoxicity reactions.

3. Focal hyperpigmentation, including involvement of the face, gingiva, and breasts, was reported in some patients who received VYLEESI, particularly with daily dosing. Resolution of hyperpigmentation was not confirmed in all patients, indicating a potential cardiotoxicity reaction associated with the drug.

4. Nausea was reported by a significant percentage of patients who received VYLEESI, with some requiring anti-emetic therapy and others discontinuing treatment due to severe nausea. Persistent or severe nausea may necessitate discontinuation of VYLEESI, suggesting a potential cardiotoxicity reaction linked to the drug.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",8c9607a2-5b57-4a59-b159-cf196deebdd9,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8c9607a2-5b57-4a59-b159-cf196deebdd9&type=display
123,BREXANOLONE,"1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with ZULRESSO (brexanolone) itself. 

2. The label does not indicate any direct association between ZULRESSO and cardiotoxicity risks or reactions. 

3. ZULRESSO (brexanolone) does not appear to be linked to any cardiotoxicity risks or reactions based on the information provided in the drug label. 

4. There is no mention of ZULRESSO (brexanolone) causing cardiotoxicity risks or reactions in the drug label. 

5. The drug label for ZULRESSO does not highlight any cardiotoxicity risks or reactions attributed to the medication.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",b40f3b2a-1859-4ed6-8551-444300806d13,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=b40f3b2a-1859-4ed6-8551-444300806d13&type=display
124,BREXPIPRAZOLE,"1. The drug label warns about increased mortality in elderly patients with dementia-related psychosis treated with antipsychotic drugs, including REXULTI. The risk of death in drug-treated elderly patients was higher compared to placebo-treated patients, with causes of death including cardiovascular events like heart failure and infectious conditions like pneumonia. REXULTI is not approved for treating dementia-related psychosis without agitation associated with dementia due to Alzheimer's disease, indicating a potential cardiotoxicity risk associated with the drug.

2. The label mentions that in placebo-controlled trials, elderly patients with dementia treated with certain antipsychotic drugs, including REXULTI, had a higher incidence of stroke and transient ischemic attack, including fatal stroke. REXULTI is not approved for treating dementia-related psychosis without agitation associated with dementia due to Alzheimer's disease, suggesting a potential association with cerebrovascular adverse reactions, including stroke.

3. The drug label does not specifically mention cardiotoxicity risks or reactions related to REXULTI itself.",Less,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",2d301358-6291-4ec1-bd87-37b4ad9bd850,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=2d301358-6291-4ec1-bd87-37b4ad9bd850&type=display
125,BRIGATINIB,"1. **Cardiotoxicity Risk**: ALUNBRIG has been associated with the risk of hypertension, with Grade 3 hypertension occurring in a percentage of patients in clinical trials. The drug itself is linked to the risk of hypertension.
   
2. **Cardiotoxicity Reaction**: Patients receiving ALUNBRIG may experience bradycardia, with symptomatic bradycardia reported in a percentage of patients. The drug itself is associated with the occurrence of bradycardia.

3. **Cardiotoxicity Risk**: ALUNBRIG has been linked to visual disturbances, including blurred vision and reduced visual acuity, which can impact cardiac health through potential effects on blood pressure and heart rate. The drug itself is associated with the risk of visual disturbances that may affect cardiovascular function.

4. **Cardiotoxicity Reaction**: ALUNBRIG has been associated with creatine phosphokinase (CPK) elevation, which can indicate muscle damage including cardiac muscle. The drug itself is linked to the elevation of CPK levels, which can have implications for cardiac health.

5. **Cardiotoxicity Risk**: ALUNBRIG has been associated with hepatotoxicity, including elevations in liver enzymes such as AST and ALT, which can impact cardiac function. The drug itself is linked to the risk of hepatotoxicity, which can have implications for cardiovascular health.

6. **Cardiotoxicity Reaction**: ALUNBRIG may lead to hyperglycemia, with Grade 3 hyperglycemia reported in a percentage of patients, which can impact cardiovascular health through effects on blood glucose levels. The drug itself is associated with the occurrence of hyperglycemia, which can affect cardiac function.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",0fe9ff20-d402-41f3-bc1e-7002ea7007db,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=0fe9ff20-d402-41f3-bc1e-7002ea7007db&type=display
126,BRILLIANT BLUE G,There is no mention of cardiotoxicity risks or cardiotoxicity reactions in the provided drug label for TissueBlue 0.025%.,No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",9d4b28b4-c582-4e2c-abd9-f7e203378e2d,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=9d4b28b4-c582-4e2c-abd9-f7e203378e2d&type=display
127,BRIVARACETAM,"1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with BRIVIACT (brivaracetam) itself.

2. There is no information provided in the drug label regarding any cardiotoxicity risks or reactions related to the use of BRIVIACT (brivaracetam). 

3. BRIVIACT (brivaracetam) is not reported to be associated with any cardiotoxicity risks or reactions in the drug label. 

Overall, the drug label for BRIVIACT does not indicate any cardiotoxicity risks or reactions linked to the use of this medication.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",3cf2f439-0e97-443e-8e33-25ecef616f6c,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=3cf2f439-0e97-443e-8e33-25ecef616f6c&type=display
128,BROMOCRIPTINE MESYLATE,"1. Parlodel (bromocriptine mesylate) has been associated with symptomatic hypotension, which can occur in patients treated for any indication, including postpartum patients, with decreases in supine systolic and diastolic pressures observed in almost 30% of patients. The drop in supine systolic pressure can be as much as 50-59 mm of Hg. (The drug itself is associated with symptomatic hypotension.)

2. Rare cases of serious adverse events, including hypertension, myocardial infarction, seizures, and stroke, have been reported in postpartum women treated with Parlodel for the inhibition of lactation. Hypertension may develop at the initiation of therapy or in the second week of therapy, with seizures reported with or without prior hypertension, and strokes mostly in postpartum patients. (The drug itself is associated with serious adverse events including hypertension, seizures, and stroke.)

3. Among patients on Parlodel, particularly on long-term and high-dose treatment, pleural and pericardial effusions, as well as pleural and pulmonary fibrosis and constrictive pericarditis, have been reported. Patients with unexplained pleuropulmonary disorders should be examined thoroughly, and discontinuation of Parlodel therapy should be considered. (The drug itself is associated with pleural and pericardial effusions, pleural and pulmonary fibrosis, and constrictive pericarditis.)

4. In a few patients on Parlodel, particularly on long-term and high-dose treatment, retroperitoneal fibrosis has been reported. It is recommended to watch for manifestations of retroperitoneal fibrosis, such as back pain, edema of the lower limbs, and impaired kidney function, and to withdraw Parlodel if fibrotic changes in the retroperitoneum are diagnosed or suspected. (The drug itself is associated with retroperitoneal fibrosis.)

5. Patients with a history of peptic ulcer or gastrointestinal bleeding should be observed carefully during treatment with Parlodel, as severe gastrointestinal bleeding from peptic ulcers has been reported, some of which were fatal. Symptoms suggestive of peptic ulcer should be investigated thoroughly and treated appropriately. (The drug itself is associated with severe gastrointestinal bleeding from peptic ulcers.)

6. Possible tumor expansion while receiving Parlodel therapy has been reported in a few patients. All patients should be carefully monitored, and if evidence of tumor expansion develops, discontinuation of treatment and alternative procedures should be considered. (The drug itself is associated with possible tumor expansion.)

7. Cold-sensitive digital vasospasm has been observed in some acromegalic patients treated with Parlodel. The response, if it occurs, can be reversed by reducing the dose of Parlodel and may be prevented by keeping the fingers warm. (The drug itself is associated with cold-sensitive digital vasospasm.)

8. Patients with a history of psychosis or cardiovascular disease should use Parlodel with caution. If acromegalic patients or patients with prolactinoma or Parkinsons disease are treated with Parlodel during pregnancy, they should be cautiously observed, particularly during the postpartum period if they have a history of cardiovascular disease. (The drug itself is associated with caution in patients with a history of psychosis or cardiovascular disease.)",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",fc2a08dd-4fb6-4ac4-9082-f99552fae25c,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fc2a08dd-4fb6-4ac4-9082-f99552fae25c&type=display
129,BUMETANIDE,"1. The drug Bumex (bumetanide) is a potent diuretic that can lead to profound diuresis with water and electrolyte depletion if given in excessive amounts. This risk is associated with the drug itself.

2. Hypokalemia, a condition where potassium levels in the blood are low, can occur as a consequence of Bumex administration. This risk is associated with the drug itself.

3. In patients with hepatic cirrhosis and ascites, sudden alterations of electrolyte balance due to Bumex administration may precipitate hepatic encephalopathy and coma. This risk is associated with the drug itself.

4. Bumetanide has been shown to produce ototoxicity in test animals, although the potential for ototoxicity in humans is rare due to the blood levels necessary to achieve this effect. This risk is associated with the drug itself.

5. Patients allergic to sulfonamides may show hypersensitivity to Bumex, indicating a potential risk of allergic reactions. This risk is associated with the drug itself.

6. Serious skin reactions, such as Stevens-Johnson syndrome and toxic epidermal necrolysis, have been reported in association with bumetanide use. This risk is associated with the drug itself.

7. Less frequent clinical adverse reactions to Bumex include impaired hearing, electrocardiogram changes, and weakness. This risk is associated with the drug itself.

8. Laboratory abnormalities reported with Bumex use include deviations in hemoglobin, prothrombin time, and hematocrit. This risk is associated with the drug itself.

In summary, the drug label for Bumex discusses various cardiotoxicity risks and reactions associated with the use of bumetanide, highlighting the importance of monitoring and managing these potential adverse effects during treatment.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",32dfbea3-eb2b-4070-8605-57ce3e6d5a2f,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=32dfbea3-eb2b-4070-8605-57ce3e6d5a2f&type=display
130,BUPRENORPHINE,"1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with BRIXADI itself.

2. However, it is important to note that buprenorphine, the active ingredient in BRIXADI, is a partial opioid agonist that can cause respiratory depression, which indirectly can lead to cardiotoxicity in severe cases if not managed properly.

3. Patients with compromised respiratory function, such as chronic obstructive pulmonary disease, cor pulmonale, or decreased respiratory reserve, may be at higher risk for respiratory depression, which can potentially lead to cardiotoxic events if not monitored closely.

4. The label advises caution in using BRIXADI in patients with compromised respiratory function and emphasizes the importance of monitoring patients for ongoing buprenorphine effects, including potential respiratory depression, which can indirectly impact cardiac function.

5. Educating patients and caregivers on recognizing signs of respiratory depression and emphasizing the need for immediate medical help in case of overdose is crucial to prevent any potential cardiotoxic events that may arise from severe respiratory depression associated with opioid use.",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",5d8a8fd0-8619-422a-a664-d1d2e8970f48,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=5d8a8fd0-8619-422a-a664-d1d2e8970f48&type=display
131,BUPROPION HYDROBROMIDE,"1. APLENZIN is associated with an increased risk of hypertension, which can result in elevated blood pressure. Assess blood pressure before starting treatment and monitor periodically during treatment. The risk of hypertension is increased if APLENZIN is used with certain medications that increase dopaminergic or noradrenergic activity.

2. In a clinical trial of bupropion immediate-release in patients with stable congestive heart failure, bupropion was associated with an exacerbation of pre-existing hypertension in some subjects, leading to discontinuation of bupropion treatment.

3. In the trials of bupropion HCl extended-release for seasonal affective disorder, there were significant elevations in blood pressure reported as an adverse reaction in some patients. Hypertension was observed in a small percentage of patients treated with bupropion, leading to discontinuation in some cases.

4. APLENZIN itself was not directly associated with cardiotoxicity risks or reactions such as arrhythmias or heart failure in the provided drug label information. The focus was primarily on the risk of hypertension as a potential cardiotoxicity concern.",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",6494d2d9-0ce4-4126-b1c7-49684395942b,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=6494d2d9-0ce4-4126-b1c7-49684395942b&type=display
132,BUPROPION HYDROCHLORIDE,"1. **Hypertension Risk**: Wellbutrin XL treatment can lead to elevated blood pressure and hypertension. Assess blood pressure before starting treatment and monitor periodically during treatment. The risk of hypertension is increased if Wellbutrin XL is used with MAOIs or other drugs that increase dopaminergic or noradrenergic activity. The drug itself is associated with the risk of hypertension.

2. **Hypertension in Smoking Cessation**: In a comparative trial, the combination of sustained-release bupropion and nicotine transdermal system (NTS) showed a higher incidence of treatment-emergent hypertension compared to bupropion alone, NTS alone, or placebo. The majority of subjects with treatment-emergent hypertension had pre-existing hypertension. The drug itself is associated with an increased risk of hypertension in combination with NTS.

3. **Elevations in Blood Pressure**: In trials for seasonal affective disorder, significant elevations in blood pressure were reported with bupropion HCl extended-release. Hypertension was reported as an adverse reaction in the bupropion group compared to the placebo group. The mean increase in systolic and diastolic blood pressure was higher in the bupropion group. The drug itself is associated with elevations in blood pressure.

4. **Exacerbation of Pre-existing Hypertension**: In a clinical trial with stable congestive heart failure patients, bupropion was associated with an exacerbation of pre-existing hypertension in some subjects, leading to discontinuation of bupropion treatment. The drug itself is associated with exacerbating pre-existing hypertension in certain patient populations.

Overall, Wellbutrin XL has been associated with cardiotoxicity risks such as elevated blood pressure, hypertension, and exacerbation of pre-existing hypertension in certain patient populations. Monitoring blood pressure before and during treatment is recommended to manage these potential cardiotoxicity reactions.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",a435da9d-f6e8-4ddc-897d-8cd2bf777b21,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a435da9d-f6e8-4ddc-897d-8cd2bf777b21&type=display
133,BUSPIRONE HYDROCHLORIDE,"1. The drug label does not mention any direct association of buspirone hydrochloride with cardiotoxicity risks or cardiotoxicity reactions. 

2. The label does not indicate any specific cardiotoxicity risks or reactions related to the use of buspirone hydrochloride. 

3. There is no mention of buspirone hydrochloride causing cardiotoxicity risks or cardiotoxicity reactions in the drug label. 

Overall, the drug label for buspirone hydrochloride does not highlight any cardiotoxicity risks or reactions associated with the use of this medication.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",ed2b56fe-e02f-46bc-808a-352f9bbb5b57,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=ed2b56fe-e02f-46bc-808a-352f9bbb5b57&type=display
134,BUSULFAN,"1. Cardiac tamponade has been reported in pediatric patients with thalassemia who received high doses of oral busulfan and cyclophosphamide. Abdominal pain and vomiting preceded the tamponade in most patients. (The drug itself was not directly associated with causing cardiac tamponade, but it was part of the preparatory regimen along with cyclophosphamide.)

2. Bronchopulmonary dysplasia with pulmonary fibrosis is a rare but serious complication following chronic busulfan therapy. The average onset of symptoms is 4 years after therapy. (The drug itself is associated with the risk of bronchopulmonary dysplasia and pulmonary fibrosis.)

3. Cellular dysplasia may occur in various organs due to busulfan treatment. Cytologic abnormalities have been reported in lymph nodes, pancreas, thyroid, adrenal glands, liver, lungs, and bone marrow. (The drug itself is associated with causing cellular dysplasia in multiple organs.)

4. Cardiac tamponade has been reported in pediatric patients with thalassemia who received high doses of oral busulfan and cyclophosphamide. Abdominal pain and vomiting preceded the tamponade in most patients. (The drug itself was not directly associated with causing cardiac tamponade, but it was part of the preparatory regimen along with cyclophosphamide.)",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",5cb9d285-1803-4a99-946a-d0b239b32df6,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=5cb9d285-1803-4a99-946a-d0b239b32df6&type=display
135,CABAZITAXEL,"1. **Warnings and Precautions (5.7):** Respiratory Disorders: The drug label mentions interstitial pneumonia/pneumonitis, interstitial lung disease, and acute respiratory distress syndrome as potential adverse reactions associated with JEVTANA. These respiratory disorders may be associated with fatal outcomes. The drug itself is not directly associated with cardiotoxicity risks in this section.

2. **Adverse Reactions (6.2):** Urinary Disorders Including Cystitis: The label discusses cystitis, radiation cystitis, and hematuria as potential adverse reactions associated with JEVTANA in patients who previously received pelvic radiation. While not directly related to cardiotoxicity, these urinary disorders are mentioned as potential reactions to the drug.

3. **Adverse Reactions (6.1):** Clinical Trials Experience: The TROPIC trial data mentions renal failure as an adverse reaction associated with JEVTANA. The label reports that renal failure occurred in 4% of patients treated with JEVTANA, including cases with fatal outcomes. While not specifically cardiotoxicity, renal failure is a serious adverse reaction that can impact cardiovascular health indirectly.",Less,No,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",de3d9c26-572b-4ea4-9b2d-dd58a2b3e8fa,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=de3d9c26-572b-4ea4-9b2d-dd58a2b3e8fa&type=display
136,CABERGOLINE,"1. The drug label states that cabergoline is contraindicated in patients with a history of cardiac valvular disorders, as suggested by anatomical evidence of valvulopathy of any valve, determined by pre-treatment evaluation including echocardiographic demonstration of valve leaflet thickening, valve restriction, or mixed valve restriction-stenosis. This indicates that cabergoline itself is associated with a risk of cardiac valvulopathy.

2. The label also mentions that post-marketing cases of cardiac valvulopathy have been reported in patients receiving cabergoline, particularly during administration of high doses (>2 mg/day) for the treatment of Parkinson's disease. This suggests that cabergoline use has been linked to the development of cardiac valvulopathy.

3. Furthermore, the label discusses a multi-country retrospective cohort study that found an increased risk of cardiac valvular regurgitation associated with the use of cabergoline in patients with Parkinson's disease compared to non-ergot-derived dopamine agonists and levodopa. This study provides additional evidence linking cabergoline to cardiac valvular complications.

4. The label also warns about extracardiac fibrotic reactions, such as pleural, pericardial, and retroperitoneal fibrosis, that have been reported following cabergoline administration. It specifies that cabergoline should not be used in patients with a history of cardiac or extracardiac fibrotic disorders, indicating a potential risk of fibrotic reactions associated with cabergoline use.

5. Post-marketing surveillance data mentioned in the label reports cases of alopecia, aggression, and psychotic disorder in patients taking cabergoline, suggesting a possible association between cabergoline use and these adverse reactions.

6. The label also highlights the importance of monitoring patients for signs and symptoms of fibrotic disorders, such as pleuro-pulmonary disease, renal insufficiency, and cardiac failure, during cabergoline treatment. This indicates that cabergoline use may lead to the development of fibrotic complications.

Overall, the drug label provides comprehensive information on the cardiotoxicity risks and reactions associated with cabergoline use, emphasizing the need for careful monitoring and evaluation of patients for potential cardiac and fibrotic complications during treatment.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",57cbd81e-fdb9-4060-80ee-6e8581c463a4,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=57cbd81e-fdb9-4060-80ee-6e8581c463a4&type=display
137,CABOTEGRAVIR,"1. **Warnings and Precautions**: The drug label mentions the potential risk of developing resistance to APRETUDE if an individual acquires HIV-1 either before or while taking APRETUDE or following discontinuation of APRETUDE. This risk is not directly associated with cardiotoxicity.

2. **Warnings and Precautions**: The label also highlights the potential risk of reduced drug concentration of APRETUDE due to drug interactions, which may indirectly impact cardiotoxicity risks by affecting the drug's efficacy.

3. **Adverse Reactions**: The most common adverse reactions observed in subjects receiving APRETUDE included injection site reactions, diarrhea, headache, pyrexia, fatigue, sleep disorders, nausea, dizziness, flatulence, abdominal pain, vomiting, myalgia, rash, decreased appetite, somnolence, back pain, and upper respiratory tract infection. Cardiotoxicity reactions are not specifically mentioned in this list.

Overall, the drug label does not directly associate APRETUDE with cardiotoxicity risks or cardiotoxicity reactions. However, the potential risk of reduced drug concentration due to drug interactions could indirectly impact cardiovascular health.",Less,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",4338428e-43d4-4e02-ac9d-bd98e738a7da,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=4338428e-43d4-4e02-ac9d-bd98e738a7da&type=display
138,CABOZANTINIB,"1. CABOMETYX is associated with an increased risk of thrombotic events, including venous thromboembolism and arterial thromboembolism, which can be fatal. Discontinuation of CABOMETYX is recommended for patients who develop acute myocardial infarction or serious arterial or venous thromboembolic events that require medical intervention.

2. Hypertension, including hypertensive crisis, can occur with CABOMETYX treatment. Patients should be monitored regularly for blood pressure changes, and the drug should not be initiated in patients with uncontrolled hypertension. CABOMETYX should be withheld for hypertension that is not adequately controlled with medical management, and a reduced dose should be considered upon resumption.

3. CABOMETYX may cause reversible posterior leukoencephalopathy syndrome (RPLS), a syndrome of subcortical vasogenic edema. Patients presenting with symptoms such as seizures, headache, visual disturbances, confusion, or altered mental function should be evaluated for RPLS, and CABOMETYX should be discontinued if RPLS is diagnosed.

4. Adverse reactions such as thrombotic events, hypertension, and RPLS were observed in patients treated with CABOMETYX, indicating that the drug itself is associated with cardiotoxicity risks and reactions. Close monitoring and appropriate management are essential to mitigate these risks in patients undergoing treatment with CABOMETYX.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",3850cce2-6137-42e5-a792-d318c4a4b3b5,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=3850cce2-6137-42e5-a792-d318c4a4b3b5&type=display
139,CAFFEINE CITRATE,"1. The drug label mentions that caffeine has been shown to increase heart rate, left ventricular output, and stroke volume in published studies, indicating a potential cardiotoxicity risk associated with the drug itself.

2. Although no cases of cardiac toxicity were reported in the placebo-controlled trial, the label advises caution in using caffeine citrate in infants with cardiovascular disease, suggesting a potential cardiotoxicity risk associated with the drug itself.

3. Adverse events described in the published literature include cardiovascular effects such as tachycardia, increased left ventricular output, and increased stroke volume, indicating potential cardiotoxicity reactions associated with the drug itself.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",21489401-f2a7-47d3-897a-4b7efa04dd7a,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=21489401-f2a7-47d3-897a-4b7efa04dd7a&type=display
140,CALCIFEDIOL,"1. **Warnings and Precautions - Hypercalcemia:** The drug RAYALDEE itself is associated with the risk of hypercalcemia, which can lead to cardiac arrhythmias and seizures. Patients should be informed about the symptoms of elevated calcium levels, which can include various cardiac-related symptoms. The drug can cause hypercalcemia, a condition that may require emergency attention due to its potential cardiotoxic effects.

2. **Warnings and Precautions - Digitalis Toxicity:** Hypercalcemia, which can be caused by RAYALDEE, increases the risk of digitalis toxicity. Patients using digitalis compounds concomitantly with RAYALDEE should be monitored for signs and symptoms of digitalis toxicity, especially when initiating or adjusting the dose of RAYALDEE. The drug's potential to induce hypercalcemia can potentiate the effects of digitalis on the heart, leading to an increased risk of digitalis toxicity.

3. **Adverse Reactions - Clinical Trial Experience:** An adverse reaction reported in the clinical trials was congestive heart failure, which was more frequent in patients taking RAYALDEE compared to placebo. This suggests a potential cardiotoxic effect associated with the drug. Congestive heart failure is a serious cardiac condition that requires monitoring and management, indicating a possible cardiotoxic reaction to RAYALDEE treatment.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",6a95effd-32a5-46b6-a30e-7f4f9bf8cc77,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=6a95effd-32a5-46b6-a30e-7f4f9bf8cc77&type=display
141,CALCITONIN SALMON,"1. The drug label mentions that in a meta-analysis of 21 clinical trials, an increased risk of overall malignancies was reported in calcitonin salmon-treated patients, suggesting a potential association between the drug and malignancies, including cardiotoxicity risks. (Associated risk)

2. The label also states that the incidence of pituitary adenomas was increased in rats after exposure to synthetic calcitonin salmon, indicating a potential risk of pituitary adenomas, which could have implications for cardiotoxicity. (Associated risk)

3. Additionally, the label mentions that calcitonin salmon reduced the latency period for the development of non-functioning pituitary adenomas in rats, suggesting a potential impact on pituitary function that could lead to cardiotoxic effects. (Associated risk)

4. The drug label does not directly state that calcitonin salmon is associated with cardiotoxicity reactions. However, the potential risks of malignancies and pituitary adenomas highlighted in the label could indirectly impact cardiac function and lead to cardiotoxic effects. (Potential indirect impact on cardiotoxicity)",Less,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",753ecc6a-07be-4fc6-9032-cc6ad116a662,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=753ecc6a-07be-4fc6-9032-cc6ad116a662&type=display
142,CALCITRIOL,"1. The drug Rocaltrol is a synthetic vitamin D analog that is active in regulating calcium absorption and utilization in the body. Rocaltrol itself is not associated with an accelerated rate of renal function deterioration or radiographic evidence of extraskeletal calcification in predialysis patients following treatment.

2. Rocaltrol can cause hypercalcemia, hypercalciuria, and hyperphosphatemia if given in excess of daily requirements, leading to cardiotoxicity risks. Chronic hypercalcemia due to Rocaltrol overdose can result in generalized vascular calcification, nephrocalcinosis, and other soft-tissue calcification.

3. Rocaltrol is the most potent metabolite of vitamin D available, and excessive dosage can cause hypercalcemia, hypercalciuria, and hyperphosphatemia, leading to cardiotoxicity risks. Progressive hypercalcemia due to Rocaltrol overdosage may require emergency attention and can lead to various cardiotoxic reactions such as cardiac arrhythmias.

4. Rocaltrol therapy should be started at the lowest possible dose and carefully monitored to avoid hypercalcemia and cardiotoxicity risks. Patients on Rocaltrol should be monitored for signs and symptoms of hypercalcemia, which can include cardiac arrhythmias, hypertension, and other cardiovascular complications.

5. Rocaltrol can induce hypercalcemia and hypercalciuria, leading to cardiotoxicity risks. If hypercalcemia develops, treatment with Rocaltrol should be stopped immediately, and serum calcium levels should be monitored closely. Adequate fluid intake should be maintained to prevent dehydration and associated cardiotoxic effects.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",d1013494-bf62-4e68-9f0c-e6571137f20f,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=d1013494-bf62-4e68-9f0c-e6571137f20f&type=display
143,CALCIUM ACETATE,"1. The drug label warns that patients with end-stage renal failure may develop hypercalcemia when given calcium with meals, and no other calcium supplements should be taken concurrently with PhosLo. This indicates that the drug itself is associated with the risk of hypercalcemia, which can lead to cardiotoxicity.

2. Progressive hypercalcemia due to an overdose of PhosLo may be severe enough to require emergency measures, and chronic hypercalcemia may lead to vascular and soft tissue calcification. This suggests that the drug itself can cause cardiotoxicity through the development of hypercalcemia.

3. The label advises monitoring serum calcium levels twice weekly during the early dose adjustment period, with a caution that the serum calcium times phosphate product should not exceed 66. This indicates that the drug itself can lead to cardiotoxicity by causing hypercalcemia, which can have adverse effects on the cardiovascular system.

4. Patients on digitalis should not be given PhosLo due to the risk of hypercalcemia precipitating cardiac arrhythmias. This suggests that the drug itself can contribute to cardiotoxicity by potentially causing dangerous heart rhythm disturbances in patients on digitalis therapy.

5. The label recommends starting PhosLo therapy at a low dose and not increasing it without careful monitoring of serum calcium levels to prevent hypercalcemia. This indicates that the drug itself can lead to cardiotoxicity by causing elevated calcium levels, which can have detrimental effects on the heart and blood vessels.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",6b0e60bb-0e9a-45a7-8f92-a43d939f8deb,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=6b0e60bb-0e9a-45a7-8f92-a43d939f8deb&type=display
144,CALCIUM CHLORIDE,"1. **Warnings and Precautions - Hypotension, Bradycardia, Arrhythmias, and Syncope with Rapid Administration:** The rapid injection of Calcium Chloride Injection may lead to vasodilation, decreased blood pressure, bradycardia, arrhythmias, syncope, and cardiac arrest. The drug itself is associated with the risk of cardiotoxicity due to rapid administration.

2. **Warnings and Precautions - Arrhythmias with Concomitant Digoxin Use:** Arrhythmias may occur if Calcium Chloride Injection and digoxin are administered together. The use of Calcium Chloride Injection may result in hypercalcemia, increasing the risk of digoxin toxicity. The drug itself is associated with the risk of arrhythmias when used concomitantly with digoxin.

3. **Warnings and Precautions - Tissue Necrosis and Calcinosis:** Administration of Calcium Chloride Injection may result in calcinosis cutis, tissue necrosis, ulceration, and secondary infection. The drug itself is associated with the risk of tissue necrosis and calcinosis if not administered properly.

4. **Warnings and Precautions - Aluminum Toxicity:** Calcium Chloride Injection contains aluminum that may be toxic, especially with prolonged administration in patients with impaired kidney function. The drug itself is associated with the risk of aluminum toxicity, particularly in patients with renal impairment.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",c4c65e48-85f8-4dcf-6281-06e40959cc79,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=c4c65e48-85f8-4dcf-6281-06e40959cc79&type=display
145,CALCIUM GLUCONATE,"1. **Warnings and Precautions - Arrhythmias with Concomitant Cardiac Glycoside Use:**
   - The drug itself is associated with the risk of cardiotoxicity when administered concomitantly with cardiac glycosides. Cardiac arrhythmias may occur if calcium and cardiac glycosides are administered together. Hypercalcemia increases the risk of digoxin toxicity. Administration of Calcium Gluconate in Sodium Chloride Injection should be avoided in patients receiving cardiac glycosides.

2. **Warnings and Precautions - End-Organ Damage due to Intravascular Ceftriaxone-Calcium Precipitates:**
   - The drug itself is not directly associated with cardiotoxicity in this section. However, it mentions that concomitant use of ceftriaxone and Calcium Gluconate in Sodium Chloride Injection can lead to the formation of ceftriaxone-calcium precipitates, which may result in vascular spasm or infarction.

3. **Warnings and Precautions - Tissue Necrosis and Calcinosis:**
   - The drug itself is associated with the risk of cardiotoxicity in this section. Intravenous administration of Calcium Gluconate in Sodium Chloride Injection and local trauma may result in calcinosis cutis due to a transient increase in local calcium concentration. Tissue necrosis, ulceration, and secondary infection are the most serious complications related to cardiotoxicity.

4. **Warnings and Precautions - Hypotension, Bradycardia, and Cardiac Arrhythmias with Rapid Administration:**
   - The drug itself is associated with the risk of cardiotoxicity in this section. Rapid injection of Calcium Gluconate in Sodium Chloride Injection may cause vasodilation, decreased blood pressure, bradycardia, cardiac arrhythmias, syncope, and cardiac arrest. To avoid adverse reactions that may follow rapid intravenous administration, the drug should be infused slowly, with careful ECG monitoring for cardiac arrhythmias.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",7f5101e0-abf9-4fcf-8986-c799e3333434,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7f5101e0-abf9-4fcf-8986-c799e3333434&type=display
146,CANAGLIFLOZIN,"1. INVOKANA is indicated to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease. (The drug itself is associated with reducing the risk of cardiovascular events.)

2. An increased risk of lower limb amputations was observed in patients using INVOKANA compared to placebo in clinical trials. (The drug itself is associated with an increased risk of lower limb amputations.)

3. Patients treated with INVOKANA may experience intravascular volume contraction, which can manifest as symptomatic hypotension or acute transient changes in creatinine. (The drug itself is associated with volume depletion-related adverse reactions.)

4. INVOKANA has been associated with an increased risk of urinary tract infections, including urosepsis and pyelonephritis, which may require hospitalization. (The drug itself is associated with an increased risk of urinary tract infections.)

5. When used in combination with insulin or insulin secretagogues, INVOKANA may increase the risk of hypoglycemia, necessitating a lower dose of insulin to minimize this risk. (The drug itself is associated with an increased risk of hypoglycemia when combined with insulin or insulin secretagogues.)

6. Reports of necrotizing fasciitis of the perineum (Fournier's gangrene), a rare but serious infection, have been identified in patients with diabetes mellitus receiving SGLT2 inhibitors like INVOKANA. (The drug itself is associated with the risk of necrotizing fasciitis of the perineum.)

7. INVOKANA increases the risk of genital mycotic infections, particularly in patients with a history of such infections or uncircumcised males. (The drug itself is associated with an increased risk of genital mycotic infections.)

8. Hypersensitivity reactions, including angioedema and anaphylaxis, have been reported with INVOKANA. (The drug itself is associated with hypersensitivity reactions.)

9. An increased risk of bone fracture has been observed in patients using INVOKANA, with factors contributing to fracture risk being considered before initiating treatment. (The drug itself is associated with an increased risk of bone fracture.)",Less,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",b9057d3b-b104-4f09-8a61-c61ef9d4a3f3,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=b9057d3b-b104-4f09-8a61-c61ef9d4a3f3&type=display
147,CANGRELOR,"1. **Warnings and Precautions**: The drug KENGREAL can increase the risk of bleeding, including significant active bleeding, as it inhibits platelet P2Y12 function. This indicates that KENGREAL itself is associated with the risk of bleeding, which can be considered a form of cardiotoxicity.

2. **Adverse Reactions**: The most common adverse reaction associated with KENGREAL is bleeding. This confirms that KENGREAL is linked to the adverse reaction of bleeding, which can be a form of cardiotoxicity.

3. **Adverse Reactions**: Serious cases of hypersensitivity, including anaphylactic reactions, were more frequent with KENGREAL than with the control group. While hypersensitivity reactions are not directly cardiotoxic, they can lead to cardiovascular complications in severe cases.

4. **Adverse Reactions**: Worsening renal function was reported in a small percentage of KENGREAL patients with severe renal impairment compared to the control group. Renal impairment can contribute to cardiotoxicity by affecting the cardiovascular system's ability to function properly.

5. **Adverse Reactions**: Dyspnea was reported more frequently in patients treated with KENGREAL than with the control group. Dyspnea, or difficulty breathing, can be a sign of heart or lung issues, indicating a potential cardiotoxic effect associated with KENGREAL.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",88b434fa-8891-4fd5-9d86-7ea64667c08f,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=88b434fa-8891-4fd5-9d86-7ea64667c08f&type=display
148,CANNABIDIOL,"1. EPIDIOLEX is associated with hepatic injury, including dose-related elevations of liver transaminases (alanine aminotransferase [ALT] and/or aspartate aminotransferase [AST]). The drug can cause transaminase elevations, with the incidence of ALT elevations above 3 times the upper limit of normal (ULN) being higher in EPIDIOLEX-treated patients compared to those on placebo. This indicates that EPIDIOLEX itself is associated with the risk of hepatic injury.

2. EPIDIOLEX has been linked to cases of cholestatic or mixed patterns of liver injury, as reported in patients treated with the drug. These patterns of liver injury were observed in patients taking EPIDIOLEX, suggesting a potential association between the drug and these hepatic reactions.

3. EPIDIOLEX can cause hypersensitivity reactions, with some subjects in clinical trials experiencing pruritus, erythema, and angioedema requiring treatment. Patients with known or suspected hypersensitivity to any ingredients of EPIDIOLEX were excluded from the trials. This indicates that EPIDIOLEX itself may lead to hypersensitivity reactions.

4. EPIDIOLEX is contraindicated in patients with a history of hypersensitivity to cannabidiol or any of the ingredients in the product, including sesame seed oil. This contraindication highlights the potential for EPIDIOLEX to trigger hypersensitivity reactions in susceptible individuals.",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",8bf27097-4870-43fb-94f0-f3d0871d1eec,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8bf27097-4870-43fb-94f0-f3d0871d1eec&type=display
149,CAPECITABINE,"1. Cardiotoxicity can occur with XELODA, including adverse reactions such as myocardial infarction/ischemia, angina, dysrhythmias, cardiac arrest, cardiac failure, sudden death, electrocardiographic changes, and cardiomyopathy.
   - The drug XELODA is associated with the risk of cardiotoxicity and the mentioned adverse reactions.

2. Patients with a prior history of coronary artery disease may be more susceptible to cardiotoxicity with XELODA.
   - XELODA is associated with an increased risk of cardiotoxicity in patients with a history of coronary artery disease.

3. The safety of resuming XELODA in patients with resolved cardiotoxicity has not been established.
   - XELODA may pose a risk of cardiotoxicity, and the safety of restarting the drug in patients with resolved cardiotoxicity is uncertain.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",e702d84d-7162-4751-bf37-d724cc7e45a5,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=e702d84d-7162-4751-bf37-d724cc7e45a5&type=display
150,CAPMATINIB,1. The drug label does not mention any specific cardiotoxicity risks or cardiotoxicity reactions associated with TABRECTA (capmatinib).,No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",455892c3-d144-4ba8-9ab4-79cabff9876d,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=455892c3-d144-4ba8-9ab4-79cabff9876d&type=display
151,CAPTOPRIL,"1. The drug label warns of fetal toxicity associated with drugs that act directly on the renin-angiotensin system, potentially causing injury and death to the developing fetus. The drug itself is associated with this risk. (WARNING: FETAL TOXICITY)

2. The label mentions that captopril tablets have been used in the treatment of hypertension, heart failure, and left ventricular dysfunction after myocardial infarction. The drug has shown beneficial effects in these conditions, including improved survival and clinical outcomes in heart failure patients. The drug itself is associated with these therapeutic effects. (INDICATIONS AND USAGE)

3. The label discusses the potential risk of hypotension as a side effect of captopril use, particularly in patients with heart failure, salt/volume depleted individuals, and those undergoing renal dialysis. The drug itself is associated with the risk of hypotension. (PRECAUTIONS: General)

4. Captopril use has been linked to rare cases of hepatic failure, starting with cholestatic jaundice and progressing to fulminant hepatic necrosis. The drug itself is associated with this rare syndrome. (WARNINGS: Hepatic Failure)

5. The label highlights the risk of neutropenia/agranulocytosis associated with captopril use, particularly in patients with renal failure, collagen vascular diseases, or those receiving immunosuppressant therapy. The drug itself is associated with the risk of neutropenia. (WARNINGS: Neutropenia/Agranulocytosis)

6. Captopril use has been associated with proteinuria in some patients, with total urinary proteins greater than 1 g per day observed in about 0.7% of patients. The drug itself is associated with the risk of proteinuria. (WARNINGS: Proteinuria)

7. The label mentions that elevations in serum potassium have been observed in some patients treated with ACE inhibitors, including captopril. The drug itself is associated with the risk of hyperkalemia. (PRECAUTIONS: Hyperkalemia)

8. Persistent nonproductive cough has been reported with all ACE inhibitors, including captopril, presumably due to the inhibition of the degradation of endogenous bradykinin. The drug itself is associated with the risk of cough. (PRECAUTIONS: Cough)",Less,No,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",65ed6e70-f1ee-437e-965c-d1b1fdadd832,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=65ed6e70-f1ee-437e-965c-d1b1fdadd832&type=display
152,CARBAMAZEPINE,"1. Tegretol has been associated with AV heart block, including second- and third-degree block, particularly in patients with underlying EKG abnormalities or risk factors for conduction disturbances. (The drug itself was associated with the risk of AV heart block.)

2. Patients with a history of cardiac conduction disturbance, including second- and third-degree AV heart block, should use Tegretol with caution. (The drug itself was not the cause but may exacerbate existing cardiac conditions.)

3. Rare cases of hepatic effects, including slight elevations in liver enzymes to hepatic failure, have been reported with Tegretol use. Some cases may progress despite discontinuation of the drug, and vanishing bile duct syndrome has been reported. (The drug itself was associated with rare cases of hepatic effects, including vanishing bile duct syndrome.)

4. Hepatic effects reported with Tegretol may overlap with other immunoallergenic syndromes, such as multiorgan hypersensitivity (DRESS syndrome) and serious dermatologic reactions. (The drug itself was associated with hepatic effects that may overlap with other syndromes.)

5. Tegretol suspension should be started at lower doses and increased slowly to avoid unwanted side effects, as it produces higher peak levels than the tablet form. (The drug itself was associated with the need for caution in dosing to prevent side effects.)

6. Tegretol suspension contains sorbitol and should not be given to patients with rare hereditary fructose intolerance. (The drug itself was associated with a contraindication for patients with fructose intolerance.)",Less,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",8d409411-aa9f-4f3a-a52c-fbcb0c3ec053,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8d409411-aa9f-4f3a-a52c-fbcb0c3ec053&type=display
153,CARBIDOPA,"1. The drug label states that carbidopa, the active ingredient in LODOSYN, has not been demonstrated to have any overt pharmacodynamic actions in the recommended doses. No cardiotoxicity risk is associated with carbidopa itself.

2. Adverse reactions reported with levodopa and carbidopa-levodopa combination products, which may also occur with LODOSYN, include cardiac irregularities, hypertension, myocardial infarction, hypotension including orthostatic hypotension, palpitation, phlebitis, and syncope. These reactions suggest a potential cardiotoxicity risk associated with the combination products, not specifically with carbidopa.

3. The drug label also mentions that LODOSYN, when administered concomitantly with levodopa or carbidopa-levodopa combination products, may cause dyskinesias such as choreiform, dystonic, and other involuntary movements, as well as nausea. While dyskinesias are not directly cardiotoxic, they can indirectly impact cardiovascular function. This suggests a potential indirect cardiotoxicity risk associated with the use of LODOSYN in combination with levodopa or carbidopa-levodopa products.",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",ff8e105b-7415-42d4-bbb2-b36cfb8945a5,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=ff8e105b-7415-42d4-bbb2-b36cfb8945a5&type=display
154,CARBINOXAMINE MALEATE,"1. The drug label mentions that Karbinal ER, which contains carbinoxamine maleate, has anticholinergic properties and should be used with caution in patients with cardiovascular disease, hypertension, and other related conditions. This suggests that the drug itself may pose a cardiotoxicity risk due to its anticholinergic effects.

2. The label also states that common adverse reactions of Karbinal ER include hypotension, headache, palpitations, tachycardia, and extrasystoles, which are cardiovascular-related symptoms. This indicates that the drug may be associated with cardiotoxicity reactions.

3. Additionally, the label mentions that carbinoxamine may cause dizziness, hypotension, confusion, or over-sedation in elderly patients, advising to start them on lower doses and monitor closely. This suggests that the drug itself may lead to cardiotoxicity reactions in the elderly population.

Overall, the drug label highlights potential cardiotoxicity risks and reactions associated with Karbinal ER, particularly in patients with cardiovascular conditions and the elderly population.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",c40b3f4e-2d71-41a1-a1fc-f64f38724879,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=c40b3f4e-2d71-41a1-a1fc-f64f38724879&type=display
155,CARBOPLATIN,"1. Carboplatin injection has been associated with cardiovascular events such as cardiac failure, embolism, and cerebrovascular accidents, which were fatal in less than 1% of patients and did not appear to be related to chemotherapy.

2. High dosages of carboplatin, more than 4 times the recommended dose, have resulted in severe abnormalities of liver function tests, indicating potential cardiotoxicity risks.

3. Cardiovascular events, including cardiac failure, embolism, and cerebrovascular accidents, were reported as adverse reactions in less than 1% of patients, suggesting a potential cardiotoxicity risk associated with carboplatin injection.

4. The drug label mentions that cardiovascular events were fatal in less than 1% of patients and did not appear to be related to chemotherapy, indicating a potential cardiotoxicity risk associated with carboplatin injection.",Less,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",1c275825-0275-4c73-b650-e4c1519f13b8,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=1c275825-0275-4c73-b650-e4c1519f13b8&type=display
156,CARBOPROST TROMETHAMINE,"1. The drug label mentions that carboprost tromethamine, the active ingredient in Hemabate, can raise blood pressure in laboratory animals and humans, likely by contracting vascular smooth muscle. However, with the clinical doses used for terminating pregnancy, this effect has not been clinically significant. (The drug itself is associated with a potential risk of raising blood pressure but is not considered clinically significant at the doses used for pregnancy termination.)

2. The label also notes that large doses of carboprost tromethamine can elevate body temperature in laboratory animals and humans. Some patients may experience transient temperature increases with the clinical doses used for pregnancy termination. (The drug itself is associated with a potential risk of elevating body temperature, which may be transient in some patients.)

3. Additionally, the drug label mentions that in some patients, carboprost tromethamine may cause transient bronchoconstriction. (The drug itself is associated with a potential risk of causing transient bronchoconstriction in some patients.)

4. The label states that during clinical trials with Hemabate, chorioamnionitis was identified as a complication contributing to postpartum uterine atony and hemorrhage in some cases. This complication may have an inhibitory effect on the uterine response to Hemabate, similar to what has been reported for other oxytocic agents. (The drug itself is not directly associated with chorioamnionitis but may be affected by this condition, potentially impacting its efficacy in managing postpartum hemorrhage.)

5. In the postpartum hemorrhage series, a small percentage of patients experienced an increase in blood pressure as a side effect, which was moderate and may have been due to a direct effect of Hemabate or a return to pregnancy-associated hypertension. These cases did not require specific therapy for the elevated blood pressure. (The drug itself is associated with a potential risk of increasing blood pressure in a small percentage of patients, which may not require specific treatment.)

6. The label also mentions that Hemabate may augment the activity of other oxytocic agents and that concomitant use with other oxytocic agents is not recommended. (The drug itself is associated with a potential risk of enhancing the activity of other oxytocic agents when used concomitantly.)

Overall, Hemabate (carboprost tromethamine) has been associated with potential cardiotoxicity risks such as raising blood pressure, elevating body temperature, causing bronchoconstriction, and interacting with other oxytocic agents. However, these risks are generally manageable and may not be clinically significant at the recommended doses for pregnancy termination and postpartum hemorrhage.",Less,Yes,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",3d282998-ff0c-480a-bd80-155606ef0a65,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=3d282998-ff0c-480a-bd80-155606ef0a65&type=display
157,CARFILZOMIB,"1. Cardiac Toxicities: Kyprolis is associated with new onset or worsening of pre-existing cardiac failure, cardiomyopathy, myocardial ischemia, and myocardial infarction, including fatalities. Patients should be monitored for signs or symptoms of cardiac failure or ischemia, and Kyprolis should be withheld for Grade 3 or 4 cardiac adverse reactions until recovery. The drug itself is associated with these cardiac toxicities.

2. Hypertension: Kyprolis has been observed to cause hypertension, including hypertensive crisis and hypertensive emergency. Patients should have their blood pressure optimized before starting Kyprolis, and blood pressure should be regularly monitored during treatment. If hypertension cannot be controlled, Kyprolis should be withheld and evaluated. The drug itself is associated with causing hypertension.

3. Pulmonary Hypertension: Pulmonary arterial hypertension has been reported in patients receiving Kyprolis, with Grade 3 or greater cases occurring in less than 1% of patients. Evaluation with cardiac imaging and/or other tests is recommended, and Kyprolis should be withheld for pulmonary hypertension until resolved or returned to baseline. The drug itself is associated with causing pulmonary hypertension.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",ea66eb30-e665-4693-99a1-a9d3b4bbe2d6,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=ea66eb30-e665-4693-99a1-a9d3b4bbe2d6&type=display
158,CARGLUMIC ACID,"1. **Clinical Pharmacology Section (12.2):** The Phase 1 study in healthy volunteers suggested a lack of clinically relevant QT prolongation effect at the highest therapeutic dose level of CARBAGLU, indicating no direct association of the drug with cardiotoxicity risks.

2. **Nonclinical Toxicology Section (13.1):** The nonclinical studies did not report any cardiotoxic effects or risks associated with CARBAGLU, indicating no observed cardiotoxicity concerns in animal studies.

3. **Adverse Reactions Section (6.1):** The clinical trials experience did not list any cardiotoxicity reactions as common adverse events associated with CARBAGLU use, indicating no reported cardiotoxic effects in patients treated with the drug.

In summary, based on the information provided in the drug label, there is no direct association or reported cases of cardiotoxicity risks or cardiotoxic reactions linked to the use of CARBAGLU.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",10175e73-5172-4dde-a508-8a88b7afc0a1,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=10175e73-5172-4dde-a508-8a88b7afc0a1&type=display
159,CARIPRAZINE,"1. The drug label warns about increased mortality in elderly patients with dementia-related psychosis treated with antipsychotic drugs, including VRAYLAR, which is associated with an increased risk of death in this population (VRAYLAR is not approved for treating dementia-related psychosis).
   
2. The label mentions that antipsychotic drugs, including VRAYLAR, can increase the all-cause risk of death in elderly patients with dementia-related psychosis, with a higher risk of cardiovascular and infectious causes of death observed in drug-treated patients compared to placebo-treated patients.

3. VRAYLAR's label highlights the potential for cerebrovascular adverse reactions, such as stroke, in elderly patients with dementia-related psychosis, which has been observed with other antipsychotic drugs in clinical trials.

4. The drug label also mentions the risk of orthostatic hypotension and syncope with atypical antipsychotics, including VRAYLAR, particularly during initial dose titration and dose increases, which can pose a risk to patients with cardiovascular diseases or conditions.

5. Additionally, the label discusses the potential for tardive dyskinesia, an involuntary movement disorder, which may develop in patients treated with antipsychotic drugs like VRAYLAR, although the specific risk profile for VRAYLAR is unknown.

6. VRAYLAR's label advises monitoring for metabolic changes, including hyperglycemia, dyslipidemia, and weight gain, which have been reported with atypical antipsychotics, including VRAYLAR, although each drug in the class may have a different risk profile for these metabolic effects.",Less,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",4b5f7c65-aa2d-452a-b3db-bc85c06ff12f,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=4b5f7c65-aa2d-452a-b3db-bc85c06ff12f&type=display
160,CARISOPRODOL,"1. The drug label mentions that post-marketing experience with SOMA has reported cardiovascular adverse reactions such as tachycardia, postural hypotension, and facial flushing. The drug itself was associated with these cardiovascular adverse reactions.

2. Additionally, the label states that there have been post-marketing reports of drowsiness, dizziness, vertigo, ataxia, tremor, agitation, irritability, headache, depressive reactions, syncope, insomnia, and seizures related to central nervous system effects. The drug itself was associated with these central nervous system effects, which may indirectly impact cardiovascular function.

3. The label also mentions that carisoprodol, the active ingredient in SOMA, has been subject to abuse, dependence, and withdrawal, which can lead to CNS and respiratory depression, hypotension, seizures, and other disorders. While not directly stated as cardiotoxicity, these effects can have implications on cardiovascular function.

Overall, the drug label does not explicitly state cardiotoxicity risks or reactions associated with SOMA, but it does mention adverse effects that could potentially impact cardiovascular health indirectly.",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",6297cf20-830a-11dc-94c8-0002a5d5c51b,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=6297cf20-830a-11dc-94c8-0002a5d5c51b&type=display
161,CARMUSTINE,"1. The drug label for GLIADEL WAFER does not mention any specific cardiotoxicity risks or reactions associated with the drug itself. 

2. The label primarily focuses on the indications, dosage, administration, contraindications, warnings, precautions, adverse reactions, and use in specific populations related to intracranial use of the drug carmustine in the form of wafers for the treatment of high-grade glioma.

3. While the label does not directly mention cardiotoxicity risks or reactions, it is important to consult the full prescribing information and discuss any concerns about potential cardiotoxic effects with a healthcare provider when considering the use of GLIADEL WAFER.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",38962a55-a514-4c48-bea5-f99a8da4beec,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=38962a55-a514-4c48-bea5-f99a8da4beec&type=display
162,CARVEDILOL,"1. The drug COREG (carvedilol) is indicated for the treatment of mild to severe chronic heart failure, left ventricular dysfunction following myocardial infarction, and hypertension. (No direct mention of cardiotoxicity risk associated with the drug itself)
   
2. COREG should be taken with food to slow the rate of absorption and reduce the incidence of orthostatic effects. (No direct mention of cardiotoxicity risk associated with the drug itself)

3. In clinical trials, COREG caused bradycardia in about 2% of hypertensive subjects, 9% of subjects with heart failure, and 6.5% of subjects with myocardial infarction and left ventricular dysfunction. If pulse rate drops below 55 beats per minute, the dosage should be reduced. (COREG is associated with the risk of bradycardia, a cardiotoxicity reaction)

4. In clinical trials of primarily mild-to-moderate heart failure, hypotension and postural hypotension occurred in subjects receiving COREG. Starting with a low dose, administration with food, and gradual up-titration should decrease the likelihood of syncope or excessive hypotension. (COREG is associated with the risk of hypotension, a cardiotoxicity reaction)

5. Worsening heart failure or fluid retention may occur during up-titration of carvedilol. If such symptoms occur, diuretics should be increased, and the carvedilol dose should not be advanced until clinical stability resumes. (COREG is associated with the risk of worsening heart failure or fluid retention, a cardiotoxicity reaction)

6. Patients with bronchospastic disease should generally not receive -blockers like COREG. However, if deemed necessary, use with caution and at the lowest effective dose. (No direct mention of cardiotoxicity risk associated with the drug itself)

7. Beta-blockers like COREG may prevent early warning signs of hypoglycemia, increase the risk for severe or prolonged hypoglycemia, and may lead to worsening hyperglycemia in patients with diabetes. Blood glucose should be monitored when initiating, adjusting, or discontinuing carvedilol dosing. (No direct mention of cardiotoxicity risk associated with the drug itself)

8. -blockers can precipitate or aggravate symptoms of arterial insufficiency in patients with peripheral vascular disease. Caution should be exercised in such individuals. (No direct mention of cardiotoxicity risk associated with the drug itself)

9. Rarely, use of carvedilol in patients with heart failure has resulted in deterioration of renal function. Renal function should be monitored during up-titration of carvedilol, and the drug discontinued or dosage reduced if worsening of renal function occurs. (No direct mention of cardiotoxicity risk associated with the drug itself)

10. Chronically administered -blocking therapy should not be routinely withdrawn prior to major surgery, as the impaired ability of the heart to respond to reflex adrenergic stimuli may augment the risks of general anesthesia and surgical procedures. (No direct mention of cardiotoxicity risk associated with the drug itself)

11. -adrenergic blockade may mask clinical signs of hyperthyroidism, such as tachycardia. Abrupt withdrawal of -blockade may exacerbate the symptoms of hyperthyroidism or precipitate thyroid storm. (No direct mention of cardiotoxicity risk associated with the drug itself)

12. In patients with pheochromocytoma, an -blocking agent should be initiated prior to the use of any -blocking agent. Caution should be taken in the administration of carvedilol to patients suspected of having pheochromocytoma. (No direct mention of cardiotoxicity risk associated with the drug itself)

13. Agents with non-selective -blocking activity may provoke chest pain in patients with Prinzmetal's variant angina. Caution should be taken in the administration of carvedilol to patients suspected of having Prinzmetal's variant angina. (No direct mention of cardiotoxicity risk associated with the drug itself)",Less,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",07c619c6-4a0c-445e-94fa-664a54f68a39,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=07c619c6-4a0c-445e-94fa-664a54f68a39&type=display
163,CASIMERSEN,"1. **Warnings and Precautions:** The drug label mentions that hypersensitivity reactions, including angioedema and anaphylaxis, have occurred in patients treated with AMONDYS 45. If a hypersensitivity reaction occurs, appropriate medical treatment should be instituted, and the infusion of AMONDYS 45 may need to be slowed, interrupted, or discontinued. **(The drug itself was not associated with cardiotoxicity in this section.)**

2. **Warnings and Precautions:** The label also states that based on animal data, AMONDYS 45 may cause kidney toxicity. Kidney function should be monitored, and creatinine may not be a reliable measure of renal function in DMD patients. **(The drug itself was not associated with cardiotoxicity in this section.)**

3. **Warnings and Precautions:** The drug label advises monitoring for kidney toxicity during treatment with AMONDYS 45. Serum cystatin C, urine dipstick, and urine protein-to-creatinine ratio should be measured before starting the treatment. **(The drug itself was not associated with cardiotoxicity in this section.)**

4. **Warnings and Precautions:** The label emphasizes that kidney toxicity, including potentially fatal glomerulonephritis, has been observed after administration of some antisense oligonucleotides. Kidney function should be monitored in patients taking AMONDYS 45. **(The drug itself was not associated with cardiotoxicity in this section.)**

5. **Warnings and Precautions:** The drug label instructs that if a persistent increase in serum cystatin C or proteinuria is detected, patients should be referred to a pediatric nephrologist for further evaluation. **(The drug itself was not associated with cardiotoxicity in this section.)**",Less,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",e9e5fd44-eeda-4580-bba1-a734828bbcc3,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=e9e5fd44-eeda-4580-bba1-a734828bbcc3&type=display
164,CASPOFUNGIN ACETATE,"1. The drug label does not mention any specific cardiotoxicity risks or cardiotoxicity reactions associated with CANCIDAS (caspofungin acetate) itself.

2. The label discusses adverse reactions such as hypotension, tachycardia, and hypertension, which are general cardiovascular-related issues reported in patients receiving CANCIDAS. However, it does not attribute these reactions specifically to cardiotoxicity risks associated with the drug.

3. In the clinical trials experience section for adults, the label mentions tachycardia as a cardiac disorder reported in patients receiving CANCIDAS. However, it does not directly link this to a cardiotoxicity risk associated with the drug.

4. The label also reports hypotension as a vascular disorder observed in patients receiving CANCIDAS in the clinical trials. While hypotension is a cardiovascular-related issue, the label does not state that it is a direct cardiotoxicity risk of the drug.

Overall, the drug label for CANCIDAS does not explicitly mention cardiotoxicity risks or cardiotoxicity reactions directly associated with the use of the medication.",Less,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",3bad23a6-09a6-4194-9182-093ed61bc71c,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=3bad23a6-09a6-4194-9182-093ed61bc71c&type=display
165,CEFACLOR,"1. The drug label does not mention any specific cardiotoxicity risks associated with cefaclor itself.

2. The drug label does not mention any cardiotoxicity reactions associated with cefaclor itself.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",d79a4b28-ef2b-4f0f-baec-002df7d06dd4,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=d79a4b28-ef2b-4f0f-baec-002df7d06dd4&type=display
166,CEFADROXIL,"1. The drug label does not mention any specific cardiotoxicity risks associated with cefadroxil itself.
2. The label does not indicate that cefadroxil is associated with cardiotoxicity reactions.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",ab9cf28c-7c16-4bfa-879d-c360b4d1d5a6,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=ab9cf28c-7c16-4bfa-879d-c360b4d1d5a6&type=display
167,CEFADROXIL HEMIHYDRATE,"1. The drug label does not mention any specific cardiotoxicity risks associated with Cefadroxil itself.
2. The drug label does not mention any cardiotoxicity reactions caused by Cefadroxil.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",a3a7d398-59a7-468b-b05e-fb87e8311b32,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a3a7d398-59a7-468b-b05e-fb87e8311b32&type=display
168,CEFAZOLIN,"1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with cefazolin itself.

2. The label does not indicate any direct association between cefazolin and cardiotoxicity risks or reactions.

3. There is no mention in the drug label of cefazolin being linked to cardiotoxicity risks or reactions.

4. The drug label does not list any cardiotoxicity risks or reactions attributed to cefazolin.

5. No information is provided in the drug label regarding cefazolin causing cardiotoxicity risks or reactions.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",6c7761d3-c154-4802-9876-627cd42913f0,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=6c7761d3-c154-4802-9876-627cd42913f0&type=display
169,CEFDINIR,1. The drug label does not mention any cardiotoxicity risks or cardiotoxicity reactions associated with cefdinir capsules.,No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",3c2130f9-a0d8-4a4e-bcad-36379202b7bb,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=3c2130f9-a0d8-4a4e-bcad-36379202b7bb&type=display
170,CEFDITOREN PIVOXIL,"1. The drug label does not mention any specific cardiotoxicity risks or cardiotoxicity reactions associated with Cefditoren Pivoxil itself.

2. The drug label does not attribute any cardiotoxicity risks or reactions to Cefditoren Pivoxil. 

3. Cefditoren Pivoxil is not linked to any cardiotoxicity risks or reactions in the drug label.

4. No cardiotoxicity risks or reactions are mentioned in relation to Cefditoren Pivoxil in the drug label.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",d5050d0e-81d1-4707-a38a-e80de2aebf09,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=d5050d0e-81d1-4707-a38a-e80de2aebf09&type=display
171,CEFEPIME,"1. **Warnings and Precautions (5.2):** Serious adverse reactions, including encephalopathy, aphasia, myoclonus, seizures, and nonconvulsive status epilepticus, have been reported with the use of Cefepime Injection. The drug itself was associated with neurotoxicity risks, which could lead to cardiotoxicity if not managed appropriately.

2. **Warnings and Precautions (5.3):** Clostridioides difficile-associated diarrhea (CDAD) has been reported with the use of Cefepime Injection. While CDAD primarily affects the gastrointestinal system, severe cases can lead to systemic effects, including potential cardiotoxicity. The drug itself was not directly associated with cardiotoxicity but could indirectly contribute to it in severe cases of CDAD.

3. **Warnings and Precautions (5.4):** Prescribing cefepime in the absence of a proven or strongly suspected bacterial infection may increase the risk of developing drug-resistant bacteria. Overgrowth of nonsusceptible microorganisms due to prolonged use of cefepime can lead to systemic infections, potentially causing cardiotoxicity. The drug itself was not directly linked to cardiotoxicity but could indirectly contribute to it through the development of drug-resistant bacterial infections.",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",be5f8ca6-7232-423a-a2d5-cccb7abe7921,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=be5f8ca6-7232-423a-a2d5-cccb7abe7921&type=display
172,CEFIDEROCOL SULFATE TOSYLATE,"1. **Increase in All-Cause Mortality in Patients with Carbapenem-Resistant Gram-Negative Bacterial Infections:** FETROJA was associated with an increase in all-cause mortality compared to best available therapy in patients with carbapenem-resistant Gram-negative bacterial infections. The 28-Day all-cause mortality was higher in patients treated with FETROJA than in those treated with best available therapy, particularly in patients with nosocomial pneumonia, bloodstream infections, sepsis, or complicated urinary tract infections. The cause of the increase in mortality has not been established, but most deaths were in patients with infections caused by Gram-negative organisms, including non-fermenters like Acinetobacter baumannii complex, Stenotrophomonas maltophilia, and Pseudomonas aeruginosa.

2. **Hypersensitivity Reactions:** Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients receiving beta-lactam antibacterial drugs, including FETROJA. Hypersensitivity reactions were observed in FETROJA-treated patients in clinical trials. These reactions are more likely to occur in individuals with a history of beta-lactam hypersensitivity and/or a history of sensitivity to multiple allergens. There have been reports of individuals with a history of penicillin hypersensitivity who have experienced severe reactions when treated with cephalosporins.

3. **Seizures and Other Central Nervous System (CNS) Adverse Reactions:** Cephalosporins, including FETROJA, have been implicated in triggering seizures. Nonconvulsive status epilepticus, encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins, particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment. Adjusting FETROJA dosing based on creatinine clearance is recommended. Anticonvulsant therapy should be continued in patients with known seizure disorders. If CNS adverse reactions, including seizures, occur, patients should undergo a neurological evaluation to determine whether FETROJA should be discontinued.

4. **Development of Drug-Resistant Bacteria:** Prescribing FETROJA in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.",Most,No,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",75c0c785-38e0-4049-a6fb-b77581f5b35c,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=75c0c785-38e0-4049-a6fb-b77581f5b35c&type=display
173,CEFIXIME,1. The drug label for SUPRAX (cefixime) does not mention any cardiotoxicity risks or cardiotoxicity reactions associated with the use of this medication.,No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",d0fd45bd-7d52-4fa6-a5f7-f46d5651ffa2,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=d0fd45bd-7d52-4fa6-a5f7-f46d5651ffa2&type=display
174,CEFOTETAN,"1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with Cefotan (Cefotetan for Injection, USP).",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",f1510f5e-d001-44e0-accb-27cf79fd4f9a,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=f1510f5e-d001-44e0-accb-27cf79fd4f9a&type=display
175,CEFOTETAN DISODIUM,"1. The drug label does not mention any specific cardiotoxicity risks associated with CEFOTAN (cefotetan for injection, USP).

2. The drug label does not attribute any cardiotoxicity reactions to the use of CEFOTAN (cefotetan for injection, USP). 

3. No information is provided in the drug label regarding cardiotoxicity risks or cardiotoxicity reactions related to the use of CEFOTAN (cefotetan for injection, USP).",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",0860bfe0-da3e-4460-da57-2411db14c426,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=0860bfe0-da3e-4460-da57-2411db14c426&type=display
176,CEFOXITIN,"1. The drug label does not mention any direct association of cefoxitin with cardiotoxicity risks or cardiotoxicity reactions. 

2. The label does not indicate any specific cardiotoxicity risks or reactions related to cefoxitin use. 

3. There is no mention of cefoxitin being linked to cardiotoxicity risks or cardiotoxicity reactions in the drug label. 

Overall, the drug label for cefoxitin does not highlight any cardiotoxicity risks or reactions associated with the use of this medication.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",6a4a2afa-4f00-41d4-bd6d-baa0a95f6929,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=6a4a2afa-4f00-41d4-bd6d-baa0a95f6929&type=display
177,CEFPODOXIME PROXETIL,"1. The drug label does not mention any direct association or causation of cardiotoxicity risks with cefpodoxime proxetil.
2. The label states that several cephalosporins, including cefpodoxime proxetil, have been implicated in triggering seizures, particularly in patients with renal impairment when the dosage was not reduced. If seizures associated with drug therapy occur, the drug should be discontinued. Anticonvulsant therapy can be given if clinically indicated. (The drug is not directly associated with cardiotoxicity but may trigger seizures in certain conditions.)
3. The label mentions that in acute rodent toxicity studies, a single 5 g/kg oral dose of cefpodoxime proxetil produced no adverse effects. In the event of serious toxic reaction from overdosage, hemodialysis or peritoneal dialysis may aid in the removal of cefpodoxime from the body, particularly if renal function is compromised. The toxic symptoms following an overdose of beta-lactam antibiotics may include nausea, vomiting, epigastric distress, and diarrhea. (The drug itself is not associated with cardiotoxicity risks but may cause adverse effects in case of overdose.)
4. The label does not report any specific cardiotoxicity reactions associated with cefpodoxime proxetil use.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",fb313728-09f1-aff8-e053-6394a90a30a8,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fb313728-09f1-aff8-e053-6394a90a30a8&type=display
178,CEFPROZIL,"1. The drug label does not mention any specific cardiotoxicity risks associated with cefprozil itself.
2. The drug label does not attribute any cardiotoxicity reactions to cefprozil use.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",af24a86f-8072-49a6-94ec-2f17fe81812b,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=af24a86f-8072-49a6-94ec-2f17fe81812b&type=display
179,CEFTAROLINE FOSAMIL,"1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with Teflaro (ceftaroline fosamil).

2. The label states that there were no drug-induced malformations in the offspring of rabbits given ceftaroline fosamil during organogenesis, despite maternal toxicity. This indicates that the drug itself was not associated with cardiotoxicity risks in this animal study.

3. The label also mentions that signs of maternal toxicity in rabbits exposed to ceftaroline fosamil included changes in fecal output, reductions in body weight gain, and food consumption, as well as an increase in spontaneous abortion at higher doses. However, there is no direct mention of cardiotoxicity risks or reactions in relation to these maternal toxicities.

4. Overall, based on the information provided in the drug label, there is no clear indication that Teflaro (ceftaroline fosamil) is associated with cardiotoxicity risks or cardiotoxic reactions.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",3ecde48b-75a2-4beb-9999-369f3f61bb8a,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=3ecde48b-75a2-4beb-9999-369f3f61bb8a&type=display
180,CEFTAZIDIME,"1. The drug label mentions that ceftazidime, the active ingredient in FORTAZ, has been associated with rare cases of hemolytic anemia, which is a hematologic adverse reaction. Ceftazidime itself is not directly linked to cardiotoxicity in this context.

2. The label also states that cephalosporin-class antibacterial drugs, to which ceftazidime belongs, have been associated with adverse reactions such as toxic nephropathy and hepatic dysfunction, including cholestasis and aplastic anemia. These reactions are not specifically related to cardiotoxicity.

3. Additionally, the drug label mentions that ceftazidime has been reported to cause central nervous system reactions, including seizures, encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia in renally impaired patients due to elevated levels of the drug. While these reactions involve the central nervous system, they are not directly related to cardiotoxicity.",Less,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",78982c98-7866-49f1-989f-a289c4242358,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=78982c98-7866-49f1-989f-a289c4242358&type=display
181,CEFTIBUTEN DIHYDRATE,"1. The drug label does not mention any cardiotoxicity risks or cardiotoxicity reactions associated with the use of Ceftibuten capsules or oral suspension.

2. Ceftibuten has not been reported to be associated with any cardiotoxicity risks or cardiotoxicity reactions in clinical trials or post-marketing surveillance.

3. No information is provided in the drug label regarding any cardiotoxicity risks or cardiotoxicity reactions linked to the use of Ceftibuten in adult or pediatric patients.

Overall, based on the information provided in the drug label, Ceftibuten does not appear to be associated with any cardiotoxicity risks or cardiotoxicity reactions.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",2dd58c88-142f-41ad-bc31-0a4fff074970,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=2dd58c88-142f-41ad-bc31-0a4fff074970&type=display
182,CEFTRIAXONE,"1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with Ceftriaxone for Injection and Dextrose Injection itself.

2. The drug label primarily focuses on indications, dosages, administration, contraindications, warnings, and precautions related to the use of Ceftriaxone for various infections caused by susceptible bacteria.

3. While the label discusses adverse reactions such as hypersensitivity, neurological adverse reactions, Clostridioides difficile-associated diarrhea, hemolytic anemia, and other potential side effects, it does not attribute any cardiotoxicity risks or reactions to Ceftriaxone for Injection and Dextrose Injection.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",67153914-16bc-490d-82d7-638061618467,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=67153914-16bc-490d-82d7-638061618467&type=display
183,CEFUROXIME AXETIL,"1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with cefuroxime axetil tablets.
2. There is no information provided in the drug label regarding cardiotoxicity risks or reactions related to the use of cefuroxime axetil tablets.
3. Cardiotoxicity risks or reactions are not listed as potential adverse effects or concerns in the drug label for cefuroxime axetil tablets.
4. The drug label does not attribute any cardiotoxicity risks or reactions to the use of cefuroxime axetil tablets.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",59f19579-f813-4102-b030-c55505b3551b,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=59f19579-f813-4102-b030-c55505b3551b&type=display
184,CEFUROXIME SODIUM,"1. The drug label does not mention any specific cardiotoxicity risks associated with cefuroxime itself.
2. The label does not indicate that cefuroxime is associated with cardiotoxicity reactions.
3. There is no mention of cefuroxime causing any cardiotoxicity risks or reactions in the drug label.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",0a145288-733a-4966-b7ae-dc96eb103d8c,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=0a145288-733a-4966-b7ae-dc96eb103d8c&type=display
185,CELECOXIB,"1. The drug label warns that nonsteroidal anti-inflammatory drugs (NSAIDs), including ELYXYB, are associated with an increased risk of serious cardiovascular thrombotic events, such as myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with the duration of use. (The drug itself is associated with the cardiotoxicity risk.)

2. ELYXYB is contraindicated in patients who have undergone coronary artery bypass graft (CABG) surgery due to the increased risk of cardiovascular thrombotic events. (The drug itself is associated with the cardiotoxicity risk.)

3. The label mentions that patients treated with celecoxib, the active ingredient in ELYXYB, had a threefold increased risk of cardiovascular death, myocardial infarction, or stroke compared to placebo. The increased risk was mainly due to a higher incidence of myocardial infarction. (The drug itself is associated with the cardiotoxicity risk.)

4. The label advises physicians to use ELYXYB for the fewest number of days per month as needed to minimize the potential risk of adverse cardiovascular events. Patients should be monitored for symptoms of serious cardiovascular events throughout the treatment course. (The drug itself is associated with the cardiotoxicity risk.)

5. The label also mentions that there is no consistent evidence that concurrent use of aspirin mitigates the increased risk of serious cardiovascular thrombotic events associated with NSAID use. Concurrent use of aspirin and an NSAID like ELYXYB increases the risk of serious gastrointestinal events. (The drug itself is associated with the cardiotoxicity risk.)

6. ELYXYB is contraindicated in patients with a recent myocardial infarction unless the benefits are expected to outweigh the risk of recurrent cardiovascular thrombotic events. Patients with a recent myocardial infarction should be monitored for signs of cardiac ischemia if ELYXYB is used. (The drug itself is associated with the cardiotoxicity risk.)",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",c8a5de07-9f27-4a54-a885-8089f0307bd7,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=c8a5de07-9f27-4a54-a885-8089f0307bd7&type=display
186,CENOBAMATE,"1. The drug XCOPRI is associated with a risk of QT shortening, as indicated by a higher percentage of subjects experiencing QT shortening of greater than 20 msec compared to placebo in a placebo-controlled study. This QT shortening was observed at different dosage levels of XCOPRI (200 mg and 500 mg) and was not seen in the placebo group. The drug itself is associated with the risk of QT shortening.

2. Familial Short QT syndrome is mentioned as a contraindication for the use of XCOPRI due to the increased risk of sudden death and ventricular arrhythmias associated with this syndrome when the corrected QT interval falls below 300 msec. Patients with Familial Short QT syndrome should not be treated with XCOPRI. The drug itself is not causing the syndrome but is contraindicated in patients with this pre-existing condition.

3. The drug label also warns about the potential synergistic effect on the QT interval when administering XCOPRI with other drugs that shorten the QT interval, which could increase the risk of QT shortening. This indicates that XCOPRI can interact with other drugs to further impact the QT interval. The drug itself is associated with the risk of QT shortening when used in combination with other QT-shortening drugs.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",565c2126-57ae-4e29-b443-723bbe7e2072,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=565c2126-57ae-4e29-b443-723bbe7e2072&type=display
187,CEPHALEXIN,1. The drug label for Cephalexin capsules does not mention any specific cardiotoxicity risks or cardiotoxicity reactions associated with the use of this drug.,No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",e54df878-c235-4aa3-af33-fe5287c73138,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=e54df878-c235-4aa3-af33-fe5287c73138&type=display
188,CERITINIB,"1. ZYKADIA can cause QTc interval prolongation, which may lead to an increased risk for ventricular tachyarrhythmia or sudden death. The drug itself is associated with QTc interval prolongation, leading to potential cardiotoxicity risks.

2. ZYKADIA can cause concentration-dependent increases in the QTc interval, with approximately 6% of patients experiencing an increase from baseline of QTc > 60 msec. The drug itself is associated with QTc interval prolongation, indicating a potential risk for cardiotoxicity.

3. ZYKADIA was found to cause QTc interval prolongation in approximately 1.3% of patients with a QTc > 500 msec. The drug itself is linked to QTc interval prolongation, posing a risk for cardiotoxicity reactions.

4. ZYKADIA should be avoided in patients with congenital long QT syndrome, and regular monitoring with ECGs and electrolytes is recommended for patients with specific cardiac conditions. The drug itself is associated with QTc interval prolongation, emphasizing the importance of monitoring and caution in patients with underlying cardiac issues.

5. Bradycardia, including sinus bradycardia, was noted in a small percentage of patients treated with ZYKADIA. The drug itself is associated with bradycardia, indicating a potential cardiotoxicity risk.

6. ZYKADIA should be avoided in combination with other products known to cause bradycardia, and regular monitoring of heart rate and blood pressure is recommended. The drug itself is linked to bradycardia, highlighting the need for caution and monitoring to prevent potential cardiotoxicity reactions.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",fff5d805-4ffd-4e8e-8e63-6f129697563e,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fff5d805-4ffd-4e8e-8e63-6f129697563e&type=display
189,CETIRIZINE HYDROCHLORIDE,"1. The drug label mentions that in clinical trials with QUZYTTIR and cetirizine hydrochloride tablets, somnolence/sedation has been reported in some patients, and it advises caution when driving or operating machinery due to this effect. The label does not directly associate this with cardiotoxicity risk.

2. The label states that in four clinical studies in healthy adult males, no clinically significant mean increases in QTc were observed with cetirizine hydrochloride oral tablets. It mentions that there was no significant effect on QTc with cetirizine hydrochloride alone or in combination with other medications. This suggests that the drug itself was not associated with cardiotoxicity risk in these studies.

3. The label also mentions that in a one-week clinical trial of cetirizine hydrochloride oral syrup in pediatric patients, ECG measurements did not show any abnormalities or increases in QTc interval compared to baseline assessments. This indicates that the drug did not cause cardiotoxicity reactions in this specific study.

Overall, the drug label does not indicate any direct association between QUZYTTIR or cetirizine hydrochloride and cardiotoxicity risks or reactions based on the information provided.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",f33e859d-ebc9-4d4f-a57d-204c48760d20,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=f33e859d-ebc9-4d4f-a57d-204c48760d20&type=display
190,CETRORELIX ACETATE,1. The drug label does not mention any cardiotoxicity risks or cardiotoxicity reactions associated with Cetrotide (cetrorelix acetate for injection).,No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",aca7768e-28a7-4027-b1d8-e66247665f79,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=aca7768e-28a7-4027-b1d8-e66247665f79&type=display
191,CEVIMELINE,"1. **Contraindications**: Cevimeline is contraindicated in patients with uncontrolled asthma, known hypersensitivity to cevimeline, and when miosis is undesirable, e.g., in acute iritis and in narrow-angle (angle-closure) glaucoma. **(Drug-associated cardiotoxicity risk not mentioned)**

2. **Warnings - Cardiovascular Disease**: Cevimeline can potentially alter cardiac conduction and/or heart rate. Patients with significant cardiovascular disease may potentially be unable to compensate for transient changes in hemodynamics or rhythm induced by cevimeline. Cevimeline should be used with caution and under close medical supervision in patients with a history of cardiovascular disease evidenced by angina pectoris or myocardial infarction. **(Drug-associated cardiotoxicity risk mentioned)**

3. **Warnings - Pulmonary Disease**: Cevimeline can potentially increase airway resistance, bronchial smooth muscle tone, and bronchial secretions. Cevimeline should be administered with caution and with close medical supervision to patients with controlled asthma, chronic bronchitis, or chronic obstructive pulmonary disease. **(No direct mention of cardiotoxicity risk)**

4. **Warnings - Ocular**: Ophthalmic formulations of muscarinic agonists have been reported to cause visual blurring which may result in decreased visual acuity, especially at night and in patients with central lens changes, and to cause impairment of depth perception. Caution should be advised while driving at night or performing hazardous activities in reduced lighting. **(No direct mention of cardiotoxicity risk)**

5. **Precautions - General**: Cevimeline toxicity is characterized by an exaggeration of its parasympathomimetic effects. These may include various symptoms, including cardiovascular effects like tachycardia, bradycardia, hypotension, hypertension, and cardiac arrhythmia. **(Drug-associated cardiotoxicity risk mentioned)**

6. **Adverse Reactions**: Adverse events associated with muscarinic agonism observed in clinical trials of cevimeline included cardiovascular-related events such as palpitations, arrhythmias, and myocardial infarction. **(Drug-associated cardiotoxicity reactions mentioned)**

7. **Post-Marketing Adverse Events**: Post-marketing reports included cardiovascular disorders such as arrhythmias, angina pectoris, myocardial infarction, and hypertension. **(Drug-associated cardiotoxicity reactions mentioned)**",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",773a19e8-4c3e-4414-99a6-aea98c9790ee,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=773a19e8-4c3e-4414-99a6-aea98c9790ee&type=display
192,CHENODIOL,"1. The drug label mentions that Chenodal is associated with potential hepatoxicity, poor response rates in some patient subgroups, and an increased rate of needing cholecystectomy in other subgroups, but it does not directly mention cardiotoxicity risks. The label states that Chenodal is not an appropriate treatment for many patients with gallstones due to these reasons.

2. The label describes that Chenodiol, the active ingredient in Chenodal, is unequivocally hepatotoxic in many animal species, including sub-human primates, at doses close to the human dose. It mentions that the hepatotoxicity is partly due to chenodiol itself and that it is characterized biochemically and morphologically as cholestatic, but it does not directly associate Chenodal with cardiotoxicity risks.

3. The label further discusses that patients who develop chenodiol-induced serum aminotransferase elevations are poor sulfators of lithocholic acid, which is a metabolite known to be a hepatotoxin. While this information relates to liver function, it does not specifically mention cardiotoxicity risks associated with Chenodal.

4. The label warns about the potential for bile acids, including chenodiol and lithocholic acid, to contribute to human colon cancer based on epidemiologic studies. It mentions that bile acids have no carcinogenic potential in animal models but may increase tumor numbers when administered with certain carcinogens. However, this information does not directly link Chenodal to cardiotoxicity risks.

In summary, the drug label for Chenodal primarily focuses on hepatotoxicity risks associated with the drug, with no direct mention of cardiotoxicity risks or reactions.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",769e0a3b-826d-4faf-9129-5eeb7ebe0b67,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=769e0a3b-826d-4faf-9129-5eeb7ebe0b67&type=display
193,CHLORAMBUCIL,1. The drug label does not specifically mention cardiotoxicity risks or cardiotoxicity reactions associated with LEUKERAN (chlorambucil) tablets.,No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",58a3c995-5ad6-465d-8437-5970c9088213,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=58a3c995-5ad6-465d-8437-5970c9088213&type=display
194,CHLORAMPHENICOL SODIUM SUCCINATE,"1. The drug label warns of serious and fatal blood dyscrasias, including aplastic anemia, hypoplastic anemia, thrombocytopenia, and granulocytopenia, known to occur after the administration of chloramphenicol. The drug itself is associated with these blood dyscrasias.

2. The label mentions reports of aplastic anemia attributed to chloramphenicol, which later terminated in leukemia. The drug itself is associated with these severe blood disorders.

3. The label advises that blood studies should be conducted during treatment with chloramphenicol to detect early peripheral blood changes. While these studies may detect certain blood abnormalities, they cannot reliably detect bone marrow depression before the development of aplastic anemia. The drug itself is associated with the potential risk of bone marrow depression and subsequent blood dyscrasias.

4. The label states that excessive blood levels may result from administering the recommended dose to patients with impaired liver or kidney function. Dosage adjustments or monitoring of blood concentration are recommended in such cases. The drug itself can lead to elevated blood levels in patients with impaired liver or kidney function.

5. The label cautions that chloramphenicol, like other antibiotics, may result in an overgrowth of nonsusceptible organisms, including fungi. Appropriate measures should be taken if infections caused by nonsusceptible organisms appear during therapy. The drug itself can contribute to the overgrowth of nonsusceptible organisms, potentially leading to adverse reactions.

6. The label mentions that chloramphenicol has been associated with neurotoxic reactions, including headache, mild depression, mental confusion, and delirium. Optic and peripheral neuritis have also been reported, usually following long-term therapy. The drug itself is linked to neurotoxic reactions, which can impact the central and peripheral nervous systems.

7. The label highlights the potential for hypersensitivity reactions with chloramphenicol, such as fever, rashes, angioedema, urticaria, and anaphylaxis. Herxheimers reactions have also been reported during therapy for typhoid fever. The drug itself is associated with hypersensitivity reactions that can manifest as various symptoms.

8. The label warns of ""Gray Syndrome,"" a toxic reaction that has occurred in premature and neonatal infants exposed to chloramphenicol. Symptoms associated with Gray Syndrome include abdominal distension, pallid cyanosis, vasomotor collapse, and death. The drug itself is linked to the development of Gray Syndrome in neonates and infants.",Less,No,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",aed29594-211d-49ef-813f-131975a8d0e3,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=aed29594-211d-49ef-813f-131975a8d0e3&type=display
195,CHLORDIAZEPOXIDE HYDROCHLORIDE,"1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with chlordiazepoxide hydrochloride itself. 

2. The label primarily focuses on the risks of concomitant use with opioids, abuse, misuse, addiction, dependence, and withdrawal reactions. 

3. While the drug label does not directly link chlordiazepoxide hydrochloride to cardiotoxicity, it does highlight the importance of monitoring patients for signs of respiratory depression and sedation, which can indirectly impact cardiovascular function. 

4. Additionally, the label advises caution in patients with impaired renal or hepatic function, suggesting that these conditions may indirectly affect cardiovascular health. 

5. Overall, the drug label does not specifically attribute cardiotoxicity risks or reactions to chlordiazepoxide hydrochloride, but it underscores the need for careful monitoring and consideration of individual patient factors that could impact cardiovascular health.",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",3cbd7cee-c4d7-4c95-93d8-09428169b937,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=3cbd7cee-c4d7-4c95-93d8-09428169b937&type=display
196,CHLORHEXIDINE GLUCONATE,1. The drug label does not mention any cardiotoxicity risks or cardiotoxicity reactions associated with the use of Peridex (Chlorhexidine Gluconate 0.12%) Oral Rinse.,No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",3fcd41c4-875a-4e54-b533-261f198011af,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=3fcd41c4-875a-4e54-b533-261f198011af&type=display
197,CHLOROQUINE PHOSPHATE,"1. The drug label warns that chloroquine phosphate tablets are associated with QT interval prolongation, which was studied in healthy subjects receiving chloroquine alone or in combination with azithromycin. Co-administration of azithromycin increased the QTc interval, indicating a dose- and concentration-dependent effect. (The drug itself was associated with the risk of QT interval prolongation.)

2. The label mentions that fatal and life-threatening cardiotoxicity, including cardiomyopathy and arrhythmias, have been reported with the use of chloroquine. Endomyocardial biopsy showed an association of cardiomyopathy with phospholipidosis in the absence of inflammation, infiltration, or necrosis. Patients may present with ventricular hypertrophy and conduction disorders. (The drug itself caused fatal and life-threatening cardiotoxicity.)

3. Additionally, the label states that QT interval prolongation, torsades de pointes, and ventricular arrhythmias have been reported with the use of chloroquine, with a greater risk at high doses. It is advised to use chloroquine with caution in patients with cardiac disease, a history of ventricular arrhythmias, or other specific conditions. (The drug itself was associated with the risk of QT interval prolongation and ventricular arrhythmias.)

4. The label also mentions that cardiac arrhythmias, conduction disorders such as bundle branch block/atrio-ventricular block, and other cardiac effects have been reported with therapeutic doses of chloroquine as well as with overdose. The risk is greater if chloroquine is administered at high doses, and fatal cases have been reported. (The drug itself was associated with the risk of cardiac arrhythmias and conduction disorders.)

5. Furthermore, the label warns that chloroquine may increase the risk of convulsions in patients with a history of epilepsy and should be used with caution in patients with preexisting auditory damage. In case of any defects in hearing, chloroquine should be immediately discontinued. (The drug itself was associated with the risk of convulsions and auditory damage.)

In summary, the drug label clearly indicates that chloroquine phosphate tablets are associated with various cardiotoxicity risks and reactions, including QT interval prolongation, cardiomyopathy, arrhythmias, and other cardiac effects. It is emphasized that these risks should be carefully considered and monitored during chloroquine therapy.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",cc0cb812-48f9-a138-e053-2a95a90a7666,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=cc0cb812-48f9-a138-e053-2a95a90a7666&type=display
198,CHLOROTHIAZIDE,"1. The drug label mentions that hypokalemia may develop, especially with brisk diuresis, when severe cirrhosis is present or after prolonged therapy. This electrolyte imbalance can lead to cardiac arrhythmias and may sensitize or exaggerate the response of the heart to the toxic effects of digitalis. The drug itself is associated with the risk of hypokalemia-induced cardiotoxicity.

2. The label also states that thiazides may cause intermittent and slight elevation of serum calcium in the absence of known disorders of calcium metabolism, which could potentially lead to cardiotoxic effects. The drug itself is associated with the risk of hypercalcemia-induced cardiotoxicity.

3. Additionally, the drug label mentions that thiazides may decrease urinary calcium excretion, which could impact calcium levels and potentially contribute to cardiotoxicity. The drug itself is associated with the risk of altered calcium metabolism and potential cardiotoxic effects.

4. The label warns that interference with adequate oral electrolyte intake can contribute to hypokalemia, which may cause cardiac arrhythmias and sensitize the heart to digitalis toxicity. The drug itself is associated with the risk of hypokalemia-induced cardiotoxicity.

5. Furthermore, the drug label cautions that hypokalemia may accentuate cardiac arrhythmias if digitalis has also been administered. This highlights the potential for synergistic cardiotoxic effects when the drug is used in combination with digitalis. The drug itself is associated with the risk of exacerbating digitalis-induced cardiotoxicity.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",bd936e35-1af8-42da-bcc0-f22489d68574,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=bd936e35-1af8-42da-bcc0-f22489d68574&type=display
199,CHLORPROMAZINE HYDROCHLORIDE,"1. The drug label warns of increased mortality in elderly patients with dementia-related psychosis treated with antipsychotic drugs, including chlorpromazine hydrochloride. The risk of death in drug-treated patients was found to be between 1.6 to 1.7 times higher compared to placebo-treated patients, with most deaths attributed to cardiovascular causes or infections.

2. Chlorpromazine hydrochloride may cause hypotensive effects, including postural hypotension, simple tachycardia, fainting, and dizziness, particularly after the first oral dose. Recovery is usually spontaneous, but severe and prolonged effects may lead to a shock-like condition.

3. EKG changes, such as nonspecific Q and T wave distortions, have been observed in some patients receiving phenothiazine tranquilizers, including chlorpromazine. Sudden death, apparently due to cardiac arrest, has also been reported in association with antipsychotic drugs.

4. Cardiovascular adverse reactions, including hypotensive effects, EKG changes, and sudden death, have been noted in patients taking chlorpromazine. These reactions may occur more intensely in patients with specific medical conditions, such as mitral insufficiency or pheochromocytoma.

5. Autonomic reactions, such as dry mouth, nasal congestion, nausea, constipation, urinary retention, and priapism, have been reported with chlorpromazine use. These reactions may impact cardiovascular function and warrant monitoring for cardiotoxicity risks.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",d3b09b67-e8da-450d-8a52-b3c40605de26,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=d3b09b67-e8da-450d-8a52-b3c40605de26&type=display
200,CHLORTHALIDONE,"1. The drug THALITONE (chlorthalidone) is indicated for the treatment of hypertension to lower blood pressure, reducing the risk of fatal and nonfatal cardiovascular events such as strokes and myocardial infarctions. The benefits of cardiovascular risk reduction have been observed in controlled trials of antihypertensive drugs, including THALITONE, but there are no controlled trials demonstrating risk reduction specifically with THALITONE itself.

2. THALITONE may cause symptomatic hypotension, particularly in patients with impaired sympathetic response, volume depletion, or salt restriction. However, a transient hypotensive response is not a contraindication to further treatment, and therapy can usually be continued once blood pressure stabilizes.

3. Changes in renal function, including acute renal failure, can be caused by diuretics like THALITONE. Patients with pre-existing kidney disease, heart failure, or volume depletion may be at higher risk of developing acute renal failure while on THALITONE. Monitoring renal function periodically is recommended, and therapy may need to be withheld or discontinued in patients with a significant decrease in renal function.

4. THALITONE can cause electrolyte abnormalities such as hypokalemia, hyponatremia, hypochloremic alkalosis, and hypomagnesemia. Hypomagnesemia can lead to difficult-to-treat hypokalemia despite potassium repletion. Monitoring serum electrolytes periodically is advised to manage and prevent these electrolyte imbalances effectively.

5. Chlorthalidone, the active ingredient in THALITONE, may raise serum levels of cholesterol and triglycerides, alter glucose tolerance, and increase serum uric acid levels. These metabolic disturbances can lead to hyperuricemia and precipitate gout in susceptible patients. Additionally, chlorthalidone decreases urinary calcium excretion, potentially causing elevations in serum calcium levels. Monitoring these metabolic parameters is essential during THALITONE therapy to address any abnormalities promptly.",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",bc5a0299-115b-4e60-bb3f-c75a95c51c15,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=bc5a0299-115b-4e60-bb3f-c75a95c51c15&type=display
201,CHLORZOXAZONE,"1. The drug label does not mention any specific cardiotoxicity risks associated with Chlorzoxazone.
2. The label does not indicate that Chlorzoxazone is directly associated with cardiotoxicity reactions.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",20ec792b-116b-4dae-82f9-4c77c3e5f196,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=20ec792b-116b-4dae-82f9-4c77c3e5f196&type=display
202,CHOLESTYRAMINE,"1. The drug label mentions that cholestyramine resin has been shown to reduce the combined rate of coronary heart disease death plus non-fatal myocardial infarction in hypercholesterolemic subjects. The study results indicated a 19% reduction in this combined rate in the cholestyramine resin group compared to the placebo group. (The drug itself was associated with a reduced risk of coronary heart disease events.)

2. Controlled clinical trials using coronary arteriography demonstrated that cholestyramine resin monotherapy slowed the progression and promoted regression of atherosclerotic lesions in the coronary arteries of patients with coronary artery disease. (The drug itself was associated with beneficial effects on atherosclerotic lesions in the coronary arteries.)

3. The label also mentions that the lipid-lowering effects of cholestyramine on total and LDL-cholesterol may be enhanced when combined with other medications such as HMG-CoA reductase inhibitors or nicotinic acid. (The drug itself was not directly associated with cardiotoxicity risks in this context, but its effects in combination therapy were discussed.)

Overall, the drug label indicates that cholestyramine resin has shown positive effects on reducing coronary heart disease events and atherosclerotic lesions in clinical studies, without directly mentioning any cardiotoxicity risks associated with the drug itself.",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",8c7fc9c8-318c-42de-a736-c439047d8af8,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8c7fc9c8-318c-42de-a736-c439047d8af8&type=display
203,CHOLIC ACID,"1. **Warnings and Precautions**: The drug label mentions the exacerbation of liver impairment as a potential risk associated with CHOLBAM. It states that liver function should be monitored, and CHOLBAM should be discontinued if liver function worsens while on treatment. (The drug itself is not directly associated with cardiotoxicity risk in this section.)

2. **Adverse Reactions**: The label lists malaise as one of the adverse reactions reported with CHOLBAM use. (The drug itself is not directly associated with cardiotoxicity risk in this section.)

3. **Clinical Studies**: The label reports on deaths in patients with bile acid synthesis disorders due to single enzyme defects (SEDs) and peroxisomal disorders (PDs) including Zellweger spectrum disorders. It mentions that some patients experienced worsening liver impairment during treatment with CHOLBAM. (The drug itself is not directly associated with cardiotoxicity risk in this section.)

4. **Postmarketing Experience**: The label mentions gastrointestinal disorders, including discomfort and distention, as adverse reactions identified during post-approval use of CHOLBAM. (The drug itself is not directly associated with cardiotoxicity risk in this section.)

Overall, the drug label does not directly associate CHOLBAM with cardiotoxicity risks or reactions. The focus is primarily on liver impairment and related adverse effects.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",e5b67402-8550-4604-97a0-c7b149fbf753,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=e5b67402-8550-4604-97a0-c7b149fbf753&type=display
204,CHOLINE C-11,"1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with Choline C 11 Injection.
2. There is no information provided in the drug label regarding cardiotoxicity risks or reactions related to the use of Choline C 11 Injection.
3. Cardiotoxicity risks or reactions are not mentioned in the drug label for Choline C 11 Injection.
4. The drug label does not indicate any cardiotoxicity risks or reactions attributed to Choline C 11 Injection.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",8e046642-5038-4094-b1bb-a1915558fb1c,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8e046642-5038-4094-b1bb-a1915558fb1c&type=display
205,CHROMIC CHLORIDE,"1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with Chromium (Chromic Chloride Injection, USP).
2. There is no indication in the drug label that the drug itself is associated with cardiotoxicity risks or reactions.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",b4d01ebb-a36e-44b7-028c-43c0ab2d13b4,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=b4d01ebb-a36e-44b7-028c-43c0ab2d13b4&type=display
206,CIDOFOVIR DIHYDRATE,1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with cidofovir injection.,No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",44966a7e-d777-40fb-956f-d0f31f737848,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=44966a7e-d777-40fb-956f-d0f31f737848&type=display
207,CILOSTAZOL,"1. **Cardiotoxicity Risk**: Cilostazol is contraindicated in patients with heart failure of any severity due to its inhibition of phosphodiesterase III, which has been associated with decreased survival in patients with class III-IV heart failure.

2. **Cardiotoxicity Reaction**: Cilostazol may induce tachycardia, palpitation, tachyarrhythmia, or hypotension. The increase in heart rate associated with cilostazol is approximately 5 to 7 bpm. Patients with a history of ischemic heart disease may be at risk for exacerbations of angina pectoris or myocardial infarction.

3. **Cardiotoxicity Reaction**: Left ventricular outflow tract obstruction has been reported in patients with a sigmoid-shaped interventricular septum. Monitoring for the development of a new systolic murmur or cardiac symptoms after starting cilostazol is recommended.

4. **Cardiotoxicity Reaction**: Cases of thrombocytopenia or leukopenia progressing to agranulocytosis have been reported with cilostazol use. Agranulocytosis is reversible upon discontinuation of cilostazol. Platelets and white blood cell counts should be monitored periodically.

5. **Cardiotoxicity Reaction**: Cilostazol inhibits platelet aggregation in a reversible manner, and it has not been studied in patients with hemostatic disorders or active pathologic bleeding. Therefore, the use of cilostazol is advised to be avoided in patients with these conditions.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",db0278e9-4ece-4aaf-9216-6bcbec58206a,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=db0278e9-4ece-4aaf-9216-6bcbec58206a&type=display
208,CIMETIDINE,"1. The drug label mentions rare cases of bradycardia, tachycardia, and A-V heart block associated with H2-receptor antagonists, including cimetidine. (The drug itself was associated with cardiotoxicity risks.)

2. The label also reports rare instances of cardiac arrhythmias and hypotension following rapid administration of cimetidine hydrochloride by intravenous bolus. (The drug itself was associated with cardiotoxicity risks.)

3. Additionally, the drug label states that a large epidemiological study suggested an increased risk of developing pneumonia in current users of histamine-2-receptor antagonists (H2RAs) compared to patients who had stopped H2RA treatment. However, a causal relationship between the use of H2RAs and pneumonia has not been established. (The drug itself was not directly associated with cardiotoxicity risks, but with an increased risk of pneumonia.)

4. The label mentions rare cases of fever and allergic reactions, including anaphylaxis and hypersensitivity vasculitis, which cleared on withdrawal of the drug. (The drug itself was associated with hypersensitivity reactions, which can have cardiovascular manifestations.)

5. Lastly, the drug label reports rare cases of pancreatitis, which cleared on withdrawal of the drug. (The drug itself was associated with the risk of pancreatitis, which can have cardiovascular implications.)",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",5c2e1f52-4021-4f70-9b2b-63af17094187,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=5c2e1f52-4021-4f70-9b2b-63af17094187&type=display
209,CIMETIDINE HYDROCHLORIDE,"1. The drug label mentions rare cases of bradycardia, tachycardia, and A-V heart block associated with H2-receptor antagonists, including cimetidine. (The drug itself was associated with cardiotoxicity risks.)

2. The label also reports that there have been reports of severe CNS symptoms, including unresponsiveness, following ingestion of cimetidine, particularly at high doses. (The drug itself was associated with cardiotoxicity risks.)

3. Additionally, the label mentions that there have been two deaths in adults reported to have ingested over 40 grams of cimetidine orally on a single occasion. (The drug itself was associated with cardiotoxicity risks.)

4. The label further states that cimetidine has been reported to reduce the hepatic metabolism of certain drugs, potentially leading to increased blood levels and adverse clinical effects. (The drug itself was associated with cardiotoxicity risks.)

5. Lastly, the label notes that there have been rare cases of pancreatitis reported with cimetidine, which cleared upon withdrawal of the drug. (The drug itself was associated with cardiotoxicity risks.)",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",d1d73350-4e7e-428a-90a5-6000fd373a4f,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=d1d73350-4e7e-428a-90a5-6000fd373a4f&type=display
210,CINACALCET,"1. **Warnings and Precautions - Hypocalcemia**: Cinacalcet is associated with a risk of hypocalcemia, which can lead to life-threatening events and fatal outcomes, including prolonging the QT interval, lowering the threshold for seizures, and causing hypotension, worsening heart failure, and arrhythmia. The drug itself is linked to these cardiotoxicity risks.

2. **Warnings and Precautions - Hypocalcemia**: Cinacalcet can lower serum calcium levels, potentially causing paresthesias, myalgias, muscle spasms, tetany, seizures, QT interval prolongation, and ventricular arrhythmia. Life-threatening events and fatal outcomes associated with hypocalcemia have been reported in patients treated with cinacalcet, including in pediatric patients. The drug itself is associated with these cardiotoxicity reactions.

3. **Warnings and Precautions - Hypocalcemia**: Cinacalcet is not indicated for patients with chronic kidney disease (CKD) who are not on dialysis due to an increased risk of hypocalcemia. Cinacalcet-treated patients with CKD not on dialysis have an increased risk for hypocalcemia compared to those on dialysis, potentially due to lower baseline calcium levels. The drug itself is linked to an increased risk of hypocalcemia in patients with CKD not on dialysis.

4. **Warnings and Precautions - Hypocalcemia**: Cinacalcet can lower serum calcium levels, potentially prolonging the QT interval and resulting in ventricular arrhythmia. Patients with conditions predisposing to QT interval prolongation may be at increased risk if they develop hypocalcemia due to cinacalcet. The drug itself is associated with QT interval prolongation and ventricular arrhythmias.

5. **Warnings and Precautions - Hypocalcemia**: Cinacalcet-treated patients with CKD not on dialysis have an increased risk of hypocalcemia compared to those on dialysis, potentially due to lower baseline calcium levels. The drug itself is linked to an increased risk of hypocalcemia in patients with CKD not on dialysis.

6. **Warnings and Precautions - Hypocalcemia**: Cinacalcet can lower serum calcium levels, potentially causing seizures, particularly in patients with seizure disorders. The threshold for seizures is lowered by significant reductions in serum calcium levels. The drug itself is associated with an increased risk of seizures due to hypocalcemia.

7. **Warnings and Precautions - Hypocalcemia**: Cinacalcet should be used cautiously with other calcium-lowering drug products, as concurrent administration could result in severe hypocalcemia. The drug itself is associated with an increased risk of severe hypocalcemia when used with other calcium-lowering therapies.

8. **Warnings and Precautions - Hypotension, Worsening Heart Failure, and/or Arrhythmias**: Isolated cases of hypotension, worsening heart failure, and arrhythmia have been reported in patients with impaired cardiac function in postmarketing safety surveillance. While a causal relationship to cinacalcet could not be completely excluded, these cardiotoxicity reactions may be mediated by reductions in serum calcium levels. The drug itself is associated with isolated cases of these cardiotoxicity reactions.

9. **Warnings and Precautions - Hypotension, Worsening Heart Failure, and/or Arrhythmias**: Cinacalcet is associated with isolated, idiosyncratic cases of hypotension, worsening heart failure, and arrhythmia in patients with impaired cardiac function. The drug itself is linked to these cardiotoxicity reactions.

10. **Warnings and Precautions - Hypotension, Worsening Heart Failure, and/or Arrhythmias**: Cinacalcet is associated with isolated cases of hypotension, worsening heart failure, and arrhythmia in patients with impaired cardiac function. While a complete exclusion of a causal relationship to cinacalcet could not be made, these cardiotoxicity reactions may be mediated by reductions in serum calcium levels. The drug itself is linked to these cardiotoxicity reactions.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",0837aabc-e796-0e07-8958-71f1ff6e89bf,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=0837aabc-e796-0e07-8958-71f1ff6e89bf&type=display
211,CIPROFLOXACIN,1. The drug label for Cetraxal (Ciprofloxacin otic solution) 0.2% does not mention any cardiotoxicity risks or cardiotoxicity reactions associated with the use of this otic solution.,No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",213b339a-75e0-4b1d-9052-8ee82a65d713,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=213b339a-75e0-4b1d-9052-8ee82a65d713&type=display
212,CISATRACURIUM BESYLATE,"1. The drug label mentions bradycardia as an adverse reaction associated with Cisatracurium Besylate Injection, occurring at a rate of 0.4% in surgical patients. The drug itself is associated with the risk of bradycardia as an adverse reaction.

2. Additionally, hypotension is listed as an adverse reaction linked to Cisatracurium Besylate Injection, with an incidence rate of 0.2% in surgical patients. The drug itself is associated with the risk of hypotension as an adverse reaction.

3. The drug label also mentions flushing as an adverse reaction related to Cisatracurium Besylate Injection, occurring at a rate of 0.2% in surgical patients. The drug itself is associated with the risk of flushing as an adverse reaction.

4. Bronchospasm is identified as an adverse reaction associated with Cisatracurium Besylate Injection, with an incidence rate of 0.2% in surgical patients. The drug itself is associated with the risk of bronchospasm as an adverse reaction.

5. Lastly, the drug label mentions rash as an adverse reaction linked to Cisatracurium Besylate Injection, occurring at a rate of 0.1% in surgical patients. The drug itself is associated with the risk of rash as an adverse reaction.",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",7073cb55-f766-4092-a10b-c2cb2863a044,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7073cb55-f766-4092-a10b-c2cb2863a044&type=display
213,CISPLATIN,"1. Cisplatin for injection is associated with cardiovascular disorders such as venous thromboembolism, arterial thromboembolism, myocardial infarction, cerebrovascular accident, and cardiac failure, among others. (The drug itself is associated with cardiovascular disorders.)

2. Cisplatin for injection may cause ototoxicity, which includes vestibular toxicity and hearing loss in the high frequency range. Ototoxicity can be more severe in pediatric patients, especially those under 5 years of age. (The drug itself may cause ototoxicity, which can affect the vestibular function and hearing.)

3. Ocular toxicity reactions, such as optic neuritis, papilledema, cortical blindness, blurred vision, and altered color perception, have been reported with the use of cisplatin for injection. (The drug itself is associated with ocular toxicity reactions.)

4. Cisplatin for injection has been reported to cause local soft tissue toxicity following extravasation, leading to tissue cellulitis, fibrosis, necrosis, pain, edema, and erythema. The severity of these reactions is related to the concentration of the cisplatin solution. (The drug itself can cause local soft tissue toxicity reactions.)

5. Cisplatin for injection is associated with cardiovascular disorders, including pericardial effusion, ventricular dysfunction, Raynauds phenomenon, and thrombotic microangiopathy. (The drug itself is associated with cardiovascular disorders.)

6. Cisplatin for injection can cause pulmonary embolism and pneumonitis/interstitial lung disease as respiratory adverse reactions. (The drug itself is associated with respiratory adverse reactions.)

7. Cisplatin for injection has been reported to cause cardiovascular disorders such as thrombotic thrombocytopenic purpura, hemolytic uremic syndrome, and Coombs-positive hemolytic anemia. (The drug itself is associated with cardiovascular disorders.)

8. Cisplatin for injection may lead to hepatic disorders, including elevations of aminotransferases, lactate dehydrogenase, and bilirubin, as well as hepatic failure. (The drug itself is associated with hepatic disorders.)

Please note that these summaries are based on the information provided in the drug label and do not constitute medical advice. It is important to consult healthcare professionals for personalized medical guidance.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",508496cb-3441-46b3-a4fe-e0d440e6adc6,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=508496cb-3441-46b3-a4fe-e0d440e6adc6&type=display
214,CITALOPRAM,"1. CELEXA is associated with dose-dependent QTc prolongation, Torsade de Pointes, ventricular tachycardia, and sudden death, as observed in postmarketing reports for citalopram. The drug should be avoided in patients with certain cardiac conditions and those taking other medications that prolong the QTc interval.

2. The drug label recommends limiting the citalopram dose to 20 mg once daily in patients who are CYP2C19 poor metabolizers, those receiving concomitant CYP2C19 inhibitors, patients with hepatic impairment, and those over 60 years of age due to expected higher exposures and increased risk of QT prolongation.

3. Electrolyte and ECG monitoring is advised for patients at risk of significant electrolyte disturbances, and baseline serum potassium and magnesium measurements should be obtained with periodic monitoring. Discontinue CELEXA in patients with persistent QTc measurements >500 ms and evaluate further if symptoms of cardiac arrhythmias occur.

4. CELEXA may precipitate serotonin syndrome, a potentially life-threatening condition, especially when co-administered with other serotonergic drugs or MAOIs. Serotonin syndrome symptoms include mental status changes, autonomic instability, neuromuscular symptoms, seizures, and gastrointestinal symptoms.

5. The drug label warns of an increased risk of bleeding events with CELEXA, particularly when used concomitantly with aspirin, NSAIDs, antiplatelet drugs, warfarin, or other anticoagulants. Patients should be informed about this risk, and those taking warfarin should have their international normalized ratio carefully monitored.

6. CELEXA may cause activation of mania or hypomania in patients with bipolar disorder. Prior screening for bipolar disorder, mania, or hypomania is recommended before initiating treatment with CELEXA to prevent the precipitation of a mixed/manic episode.

7. Adverse reactions, including seizures, angle-closure glaucoma, hyponatremia, and sexual dysfunction, have been reported with CELEXA use. Patients with a history of seizures should use CELEXA with caution, and the drug should be avoided in patients with untreated narrow angles or at risk of hyponatremia.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",4259d9b1-de34-43a4-85a8-41dd214e9177,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=4259d9b1-de34-43a4-85a8-41dd214e9177&type=display
215,CLADRIBINE,"1. The drug label for MAVENCLAD does not mention any specific cardiotoxicity risks or cardiotoxicity reactions associated with the use of the drug itself. 

2. The label primarily focuses on warnings related to malignancies, teratogenicity, lymphopenia, infections, hematologic toxicity, liver injury, and hypersensitivity. 

3. While the label does not directly link MAVENCLAD to cardiotoxicity, it is important to consult the full prescribing information for comprehensive details on potential adverse effects and risks associated with the medication.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",9c75e30a-a410-40f1-b653-04d532bd9144,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=9c75e30a-a410-40f1-b653-04d532bd9144&type=display
216,CLARITHROMYCIN,"1. Clarithromycin, the active ingredient in BIAXIN, was not directly associated with cardiotoxicity risks or reactions in the drug label.

2. The drug label did not mention any cardiotoxicity risks or reactions related to the use of BIAXIN in the sections provided. 

3. No specific information regarding cardiotoxicity risks or reactions was outlined in the drug label for BIAXIN.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",2e899f4a-a2e9-445c-a0ed-6ad811e997e6,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=2e899f4a-a2e9-445c-a0ed-6ad811e997e6&type=display
217,CLEMASTINE FUMARATE,"1. The drug label mentions that antihistamines, including clemastine fumarate, should be used with caution in patients with cardiovascular disease, hypertension, and other related conditions. This indicates that the drug itself is associated with a cardiotoxicity risk due to its potential effects on the cardiovascular system.

2. Adverse reactions listed in the label include cardiovascular system-related effects such as hypotension, headache, palpitations, tachycardia, and extrasystoles. These reactions suggest that the drug itself can cause cardiotoxicity reactions in patients, manifesting as cardiovascular symptoms.

3. The label also highlights that in cases of antihistamine overdosage, cardiovascular collapse may occur, especially in infants and children, leading to potential fatalities. This indicates that the drug can lead to severe cardiotoxicity reactions, including cardiovascular collapse and death, particularly in vulnerable populations like infants and children.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",63a3789a-8fe9-4149-8b7d-d7e6d32aadc5,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=63a3789a-8fe9-4149-8b7d-d7e6d32aadc5&type=display
218,CLEVIPIDINE,"1. **Warnings and Precautions**: Cleviprex may lead to hypotension and reflex tachycardia, with the potential for systemic hypotension and tachycardia. The drug itself is associated with these cardiotoxicity risks.

2. **Warnings and Precautions**: Dihydropyridine calcium channel blockers like Cleviprex can have negative inotropic effects and worsen heart failure. The drug itself is linked to the risk of exacerbating heart failure, indicating cardiotoxicity potential.

3. **Warnings and Precautions**: Cleviprex does not provide protection against the effects of abrupt beta-blocker withdrawal. The drug itself does not mitigate the consequences of sudden beta-blocker cessation, highlighting a cardiotoxicity concern.

4. **Warnings and Precautions**: Patients receiving prolonged Cleviprex infusions should be monitored for rebound hypertension for at least 8 hours after stopping the infusion. The drug itself is associated with the potential for rebound hypertension, indicating a cardiotoxicity risk.

5. **Adverse Reactions**: Less common adverse reactions in patients with severe or essential hypertension included cardiac events like myocardial infarction and cardiac arrest. The drug itself is linked to these less common cardiotoxicity reactions.

6. **Clinical Pharmacology**: Clevidipine, the active ingredient in Cleviprex, is a dihydropyridine calcium channel blocker that reduces mean arterial blood pressure by decreasing systemic vascular resistance. The drug itself is associated with hemodynamic effects that can impact cardiac function, indicating a cardiotoxicity risk.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",f9290625-b723-4eda-bab8-a97bef6041f6,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=f9290625-b723-4eda-bab8-a97bef6041f6&type=display
219,CLINDAMYCIN HYDROCHLORIDE,"1. The drug label warns about the risk of Clostridioides difficile-associated diarrhea (CDAD) with the use of nearly all antibacterial agents, including CLEOCIN HCl. This is due to the alteration of normal colon flora, leading to overgrowth of C. difficile. The drug itself is not directly associated with cardiotoxicity in this warning.

2. The label mentions that clindamycin therapy has been associated with severe colitis, which may be fatal, and should be reserved for serious infections where less toxic antimicrobial agents are inappropriate. This severe colitis is not directly related to cardiotoxicity.

3. The drug label does not mention any specific cardiotoxicity risks or reactions associated with the use of clindamycin hydrochloride (CLEOCIN HCl).",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",df9a2a41-b132-4f43-8940-b2d773b1369a,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=df9a2a41-b132-4f43-8940-b2d773b1369a&type=display
220,CLINDAMYCIN IN 5 PERCENT DEXTROSE,"1. The drug label warns that rapid intravenous administration of clindamycin may lead to cardiopulmonary arrest and hypotension, indicating that the drug itself is associated with cardiotoxicity risks.
   
2. The label also mentions that significant mortality was observed in animal studies at high doses of clindamycin, with symptoms such as convulsions and depression, suggesting that the drug itself can cause cardiotoxic reactions at high doses.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",231d95a6-5e5f-4a45-a92b-d3d16ef0a7ca,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=231d95a6-5e5f-4a45-a92b-d3d16ef0a7ca&type=display
221,CLINDAMYCIN PALMITATE HYDROCHLORIDE,"1. The drug label does not mention any specific cardiotoxicity risks or cardiotoxicity reactions associated with clindamycin palmitate hydrochloride for oral solution (Pediatric) itself. 

2. The label does not indicate any direct association between clindamycin palmitate hydrochloride for oral solution (Pediatric) and cardiotoxicity risks or reactions. 

3. There is no mention in the drug label of clindamycin palmitate hydrochloride for oral solution (Pediatric) being linked to cardiotoxicity risks or cardiotoxicity reactions. 

4. The drug label does not attribute any cardiotoxicity risks or reactions to clindamycin palmitate hydrochloride for oral solution (Pediatric). 

5. No specific cardiotoxicity risks or cardiotoxicity reactions are stated in the drug label for clindamycin palmitate hydrochloride for oral solution (Pediatric).",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",28ba03fd-0f9c-49c6-9bfb-cda5417801c6,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=28ba03fd-0f9c-49c6-9bfb-cda5417801c6&type=display
222,CLINDAMYCIN PHOSPHATE,"1. Clindamycin Phosphate in Sodium Chloride Injection has been associated with cardiopulmonary arrest and hypotension following too rapid intravenous administration, indicating a potential risk of cardiotoxicity associated with the drug's administration. 

2. The drug label warns about the potential risk of cardiotoxicity reactions, such as cardiopulmonary arrest and hypotension, which have been reported following the rapid intravenous administration of Clindamycin Phosphate in Sodium Chloride Injection. 

3. Clindamycin itself is not directly linked to cardiotoxicity risks, but the label advises caution in administering the drug intravenously to avoid potential cardiopulmonary arrest and hypotension reactions.",Less,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",44fa506b-90ac-42de-831b-5f3f1a500fc0,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=44fa506b-90ac-42de-831b-5f3f1a500fc0&type=display
223,CLOBAZAM,"1. The drug label does not mention any specific cardiotoxicity risks or cardiotoxicity reactions associated with SYMPAZAN (clobazam) itself.

2. The drug label primarily focuses on risks related to concomitant use with opioids, abuse, misuse, addiction, dependence, and withdrawal reactions. These risks do not directly involve cardiotoxicity associated with SYMPAZAN.

3. While the drug label does not highlight any cardiotoxicity risks or reactions linked to SYMPAZAN, it is essential to consult the full prescribing information for a comprehensive understanding of potential adverse effects and safety considerations.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",5e3d8fcb-aa7d-4822-88fc-4f06264c3242,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=5e3d8fcb-aa7d-4822-88fc-4f06264c3242&type=display
224,CLOMIPHENE CITRATE,"1. The drug label does not mention any direct association or causation of cardiotoxicity risks by the drug itself.
2. The drug label does not mention any direct association or causation of cardiotoxicity reactions by the drug itself.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",6370e342-16a5-4339-a13f-ba275fd5de09,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=6370e342-16a5-4339-a13f-ba275fd5de09&type=display
225,CLOMIPRAMINE HYDROCHLORIDE CAPSULES,"1. Clomipramine hydrochloride capsules may cause modest orthostatic decreases in blood pressure and tachycardia in approximately 20% of patients, but patients were frequently asymptomatic. The drug itself was associated with these cardiovascular effects.

2. Among patients treated with clomipramine, approximately 1.5% developed ECG abnormalities during treatment, but these changes were rarely associated with significant clinical symptoms. The drug itself was associated with ECG abnormalities.

3. Clomipramine has been reported to precipitate acute psychotic episodes, delusions, hallucinations, confusion, and paranoia in some patients. The drug itself was associated with neuropsychiatric signs and symptoms.

4. Activation of mania or hypomania has been reported in several patients with affective disorders treated with clomipramine. The drug itself was associated with the precipitation of mania or hypomania.

5. Clomipramine was occasionally associated with elevations in liver enzymes, with a pooled incidence of approximately 1% and 3% for SGOT and SGPT, respectively. Rare reports of severe liver injury, some fatal, have been recorded in foreign postmarketing experience. The drug itself was associated with potential hepatic changes.

6. Although no severe hematologic toxicity was seen in premarketing experience, postmarketing reports have linked clomipramine use to leukopenia, agranulocytosis, thrombocytopenia, anemia, and pancytopenia. The drug itself was associated with hematologic changes.

7. Clomipramine has been associated with more than 30 cases of hyperthermia, particularly when used in combination with other drugs. The drug itself was associated with hyperthermia cases.

8. Weight gain was reported in 18% of patients receiving clomipramine, compared to 1% of patients receiving placebo. Weight loss was also observed in some patients. The drug itself was associated with weight changes.

9. Clomipramine should be used with caution in patients with certain conditions, including hyperthyroidism, increased intraocular pressure, tumors of the adrenal medulla, and significantly impaired renal function. The drug itself was associated with the need for caution in these concomitant illnesses.",Less,Yes,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",ebad19b5-e5dd-4f77-ab97-d20ce0f24cb9,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=ebad19b5-e5dd-4f77-ab97-d20ce0f24cb9&type=display
226,CLONAZEPAM,"1. The drug label for Klonopin (clonazepam) does not mention any specific cardiotoxicity risks or reactions associated with the drug itself. 

2. The label primarily focuses on warnings related to the risks of concomitant use with opioids, abuse, misuse, addiction, dependence, and withdrawal reactions. 

3. While the label does not directly link Klonopin to cardiotoxicity, it is important to note that benzodiazepines, including clonazepam, can have central nervous system depressant effects, which may indirectly impact cardiovascular function in certain individuals. 

4. Patients with pre-existing cardiovascular conditions or those taking medications that affect heart function should consult with their healthcare provider regarding the potential implications of using Klonopin. 

5. Overall, the label emphasizes the need for careful monitoring and individualized assessment of risks when prescribing Klonopin, particularly in patients with underlying cardiac issues.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",cfa0d79a-843c-4b88-95a1-e9511d649ca1,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=cfa0d79a-843c-4b88-95a1-e9511d649ca1&type=display
227,CLONIDINE HYDROCHLORIDE,"1. The drug label states that Duraclon (epidural clonidine) is not recommended for obstetrical, post-partum, or peri-operative pain management due to the risk of hemodynamic instability, especially hypotension and bradycardia, which may be unacceptable in these patients. The drug itself is associated with the cardiotoxicity risk.

2. Severe hypotension may follow the administration of clonidine, and it should be used with caution in all patients, especially those with severe cardiovascular disease or who are hemodynamically unstable. The benefit of its administration in these patients should be carefully balanced against the potential risks resulting from hypotension. The drug itself is associated with the cardiotoxicity risk.

3. The drug label mentions that clonidine decreases sympathetic outflow from the central nervous system, resulting in decreases in peripheral resistance, renal vascular resistance, heart rate, and blood pressure. However, in the absence of profound hypotension, renal blood flow and glomerular filtration rate remain essentially unchanged. The drug itself is associated with the cardiotoxicity risk.

4. The label also warns about the potential for rebound hypertension, cerebrovascular accidents, and death after abrupt discontinuation of clonidine treatment, particularly in patients with a history of hypertension and/or other underlying cardiovascular conditions. The drug itself is associated with the cardiotoxicity risk.

5. Additionally, the drug label mentions that clonidine frequently causes decreases in heart rate, and symptomatic bradycardia can be treated with atropine. Rarely, atrioventricular block greater than first degree has been reported. The drug itself is associated with the cardiotoxicity risk.

6. The label also states that clonidine does not alter the hemodynamic response to exercise but may mask the increase in heart rate associated with hypovolemia. The drug itself is associated with the cardiotoxicity risk.

7. Furthermore, the drug label mentions that clonidine administration may result in sedation through the activation of alpha-adrenoceptors in the brainstem. High doses of clonidine can cause sedation and ventilatory abnormalities that are usually mild. The drug itself is associated with the cardiotoxicity risk.

8. The label also notes that depression has been seen in a small percentage of patients treated with oral or transdermal clonidine, and it may be exacerbated by treatment with clonidine. The drug itself is associated with the cardiotoxicity risk.

9. Lastly, the drug label mentions that clonidine may potentiate the CNS-depressive effect of alcohol, barbiturates, or other sedating drugs, and that narcotic analgesics may potentiate the hypotensive effects of clonidine. The drug itself is associated with the cardiotoxicity risk.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",8c126bb8-732a-4949-8754-2f50b5543638,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8c126bb8-732a-4949-8754-2f50b5543638&type=display
228,CLOPIDOGREL,"1. The drug Plavix (clopidogrel) is indicated for reducing the rate of myocardial infarction (MI) and stroke in patients with acute coronary syndrome (ACS), including non-ST-segment elevation ACS and ST-elevation myocardial infarction (STEMI), when managed medically or with coronary revascularization. Plavix should be administered with aspirin. (The drug itself is not associated with cardiotoxicity risk.)

2. Plavix is also indicated to reduce the rate of MI and stroke in patients with recent MI, recent stroke, or established peripheral arterial disease. (The drug itself is not associated with cardiotoxicity risk.)

3. Plavix is a P2Y12 platelet inhibitor that works by inhibiting platelet activation and aggregation through irreversible binding to P2Y12 class of ADP receptors on platelets. (The drug itself is not associated with cardiotoxicity risk.)

4. Plavix has been evaluated for safety in over 54,000 patients, with bleeding being the most commonly reported adverse reaction, including life-threatening and fatal bleeding. (The drug itself is associated with an increased risk of bleeding, which can be a cardiotoxicity risk.)

5. Thrombotic thrombocytopenic purpura (TTP) has been reported following the use of Plavix, which is a serious condition requiring urgent treatment, including plasmapheresis. TTP is characterized by thrombocytopenia, microangiopathic hemolytic anemia, neurological findings, renal dysfunction, and fever. (The drug itself is associated with the risk of TTP, which can be a cardiotoxicity reaction.)

6. Plavix increases the risk of bleeding, including major bleeding events, which can be life-threatening. The risk factors for bleeding include concomitant use of other drugs that increase bleeding risk, such as anticoagulants, antiplatelet agents, and NSAIDs. (The drug itself is associated with an increased risk of bleeding, which can be a cardiotoxicity risk.)

7. Discontinuation of Plavix increases the risk of cardiovascular events, and premature discontinuation should be avoided. If temporary discontinuation is necessary, Plavix should be restarted as soon as possible. (The drug itself is not associated with cardiotoxicity risk but discontinuation can lead to cardiovascular events.)

8. Plavix is contraindicated in patients with active pathological bleeding, such as peptic ulcer or intracranial hemorrhage, due to the increased risk of bleeding associated with the drug. (The drug itself is associated with an increased risk of bleeding, which can be a cardiotoxicity risk.)

9. Plavix should be used with caution in patients with impaired CYP2C19 function, as this can lead to diminished antiplatelet activity of the drug. Tests are available to identify patients who are poor metabolizers of CYP2C19. (The drug itself is not associated with cardiotoxicity risk but may have reduced efficacy in patients with impaired CYP2C19 function.)

10. Cross-reactivity among thienopyridines, including Plavix, has been reported, with hypersensitivity reactions such as rash, angioedema, or hematologic reactions. (The drug itself is associated with cross-reactivity among thienopyridines, which can lead to cardiotoxicity reactions.)",Less,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",de8b0b67-eb25-4684-83b5-7ad785314227,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=de8b0b67-eb25-4684-83b5-7ad785314227&type=display
229,CLORAZEPATE DIPOTASSIUM,"1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with clorazepate dipotassium itself. 

2. However, it does highlight the potential for decreased systolic blood pressure as an observed side effect, which could indirectly impact cardiovascular function. 

3. It is important to note that the label emphasizes the need for caution in elderly or debilitated patients due to their potential sensitivity to the effects of benzodiazepines, including clorazepate dipotassium. This caution is likely due to the potential impact on cardiovascular function in these populations. 

Overall, while the drug label does not directly attribute cardiotoxicity risks to clorazepate dipotassium, it underscores the importance of monitoring patients for potential adverse effects, including those that may impact cardiovascular health, especially in vulnerable populations.",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",fb5c9e98-02b2-4c36-b436-25b58fe3c7d5,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fb5c9e98-02b2-4c36-b436-25b58fe3c7d5&type=display
230,CLOZAPINE,"1. Severe Neutropenia: CLOZARIL can cause severe neutropenia, which can lead to serious and fatal infections. Patients initiating and continuing treatment with CLOZARIL must have regular ANC monitoring during treatment. (CLOZARIL associated with severe neutropenia risk)
   
2. Orthostatic Hypotension, Bradycardia, and Syncope: Risk is dose-related. Starting dose is 12.5 mg. Titrate gradually and use divided dosages. (CLOZARIL associated with orthostatic hypotension, bradycardia, and syncope risk)

3. Seizure: Risk is dose-related. Titrate gradually and use divided doses. Use with caution in patients with history of seizure or risk factors for seizure. (CLOZARIL associated with seizure risk)

4. Myocarditis, Cardiomyopathy, and Mitral Valve Incompetence: Can be fatal. Discontinue and obtain cardiac evaluation if findings suggest these cardiac reactions. (CLOZARIL associated with myocarditis, cardiomyopathy, and mitral valve incompetence risk)",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",90876802-0e3a-44c9-9ff7-1754dfbe736a,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=90876802-0e3a-44c9-9ff7-1754dfbe736a&type=display
231,COBICISTAT,"1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with TYBOST itself.

2. However, the label does caution against coadministration of TYBOST with certain drugs that are known to have potential for serious and/or life-threatening events or loss of therapeutic effect, such as antiarrhythmic drugs like dronedarone, anti-gout medication colchicine, and phosphodiesterase-5 (PDE-5) inhibitors like sildenafil when used for pulmonary arterial hypertension. This is due to the potential for altered plasma concentrations of these drugs when coadministered with TYBOST, which could lead to adverse cardiac effects.

3. Additionally, the label mentions that coadministration of TYBOST with certain antiretrovirals that are not recommended, such as darunavir in combination with efavirenz, nevirapine, or etravirine, or atazanavir in combination with efavirenz in treatment-experienced patients, may result in decreased plasma concentrations of the antiretroviral agents, potentially leading to loss of therapeutic effect and development of resistance. While not directly related to cardiotoxicity, these interactions could impact the efficacy of the antiretroviral therapy in managing HIV-1 infection, including potential effects on the cardiovascular system.",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",3784c35c-e87f-410c-900b-8fd6313c6010,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=3784c35c-e87f-410c-900b-8fd6313c6010&type=display
232,COBIMETINIB,"1. **Cardiotoxicity Risk**: The drug COTELLIC can lead to an increased risk of cardiomyopathy in patients receiving it with vemurafenib compared to vemurafenib alone. The safety of COTELLIC has not been established in patients with decreased left ventricular ejection fraction (LVEF).

2. **Cardiotoxicity Reaction**: In Trial 1, patients receiving COTELLIC with vemurafenib experienced Grade 2 or 3 decreases in LVEF, with 26% of patients showing this adverse reaction. The median time to the first onset of LVEF decrease was 4 months, and 22% of affected patients required dose interruption or reduction, with 14% needing permanent discontinuation.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",c387579e-cee0-4334-bd1e-73f93ac1bde6,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=c387579e-cee0-4334-bd1e-73f93ac1bde6&type=display
233,CODEINE SULFATE,"1. The drug label does not specifically mention cardiotoxicity risks or cardiotoxicity reactions associated with Codeine Sulfate Tablets.
2. No information is provided in the drug label regarding any direct association of Codeine Sulfate Tablets with cardiotoxicity risks or reactions.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",010905f9-3bcb-4b50-9fe8-a3ad0010f14c,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=010905f9-3bcb-4b50-9fe8-a3ad0010f14c&type=display
234,COLCHICINE,"1. **Warnings and Precautions**: Fatal overdoses have been reported with colchicine in adults and children. Keep colchicine capsules out of the reach of children. (The drug itself is associated with the risk of fatal overdoses, including cardiotoxicity).

2. **Warnings and Precautions**: Neuromuscular toxicity and rhabdomyolysis have been reported from chronic treatment with colchicine in therapeutic doses, especially in combination with other drugs known to cause this effect. Patients with impaired renal function and elderly patients are at increased risk. (The drug itself is associated with the risk of neuromuscular toxicity, including cardiotoxicity).

3. **Adverse Reactions**: Toxic manifestations associated with colchicine include injury to cells in the circulatory system. These most often occur with excessive accumulation or overdosage. (The drug itself is associated with the risk of injury to cells in the circulatory system, indicating potential cardiotoxicity).

4. **Adverse Reactions**: The following reactions have been reported with colchicine: elevated AST, elevated ALT. (The drug itself is associated with the risk of liver enzyme elevation, which can be indicative of cardiotoxicity).

5. **Drug Interactions**: Some drugs such as HMG-CoA reductase inhibitors and fibrates may increase the risk of myopathy when combined with colchicine capsules. Complaints of muscle pain or weakness could be an indication to check serum creatinine kinase levels for signs of myopathy. (The drug itself is associated with the risk of myopathy, which can include cardiotoxic effects).

6. **Drug Interactions**: Signs and symptoms of colchicine toxicity should be evaluated promptly, and if toxicity is suspected, colchicine capsules should be discontinued immediately. (The drug itself is associated with the risk of toxicity, including potential cardiotoxicity).

7. **Drug Interactions**: Treatment of colchicine overdose should begin with gastric lavage and measures to prevent shock. Otherwise, treatment is symptomatic and supportive. No specific antidote is known. (The drug itself is associated with the risk of overdose, which can lead to cardiotoxic effects).

8. **Drug Interactions**: Colchicine is not effectively removed by hemodialysis. (The drug itself has characteristics that make it challenging to manage in cases of overdose, potentially leading to cardiotoxicity).

In summary, colchicine is associated with the risk of cardiotoxicity, including neuromuscular toxicity, liver enzyme elevation, myopathy, and potential overdose-related cardiotoxic effects. Close monitoring and prompt action are necessary to manage these risks effectively.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",ee1583ac-c308-4beb-b602-9ecac4977026,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=ee1583ac-c308-4beb-b602-9ecac4977026&type=display
235,COLESEVELAM,"1. **Cardiotoxicity Risk**: The drug label does not mention any direct association of Colesevelam Hydrochloride with cardiotoxicity risks.

2. **Cardiotoxicity Reactions**: The label does not list any cardiotoxicity reactions associated with the use of Colesevelam Hydrochloride.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",6a26e745-7e38-4af0-9bcc-566b2812df75,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=6a26e745-7e38-4af0-9bcc-566b2812df75&type=display
236,COLESTIPOL HYDROCHLORIDE,"1. The drug label mentions that chest pain, angina, and tachycardia have been infrequently reported as cardiovascular adverse reactions. The drug itself was not directly associated with causing these cardiotoxicity risks.

2. The label also notes that transient and modest elevations of certain liver enzymes were observed in various patients treated with the drug. While this is not a direct cardiotoxicity risk, liver enzyme elevations can sometimes be associated with underlying heart conditions, so it is important to monitor these levels closely.

3. Additionally, the drug label mentions that musculoskeletal pain, joint pains, and backache have been reported as musculoskeletal adverse reactions. These symptoms can sometimes be associated with underlying heart conditions, but the drug itself was not directly linked to causing cardiotoxicity in this context.",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",21b37725-fc0c-4365-a7dc-1a473d42502d,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=21b37725-fc0c-4365-a7dc-1a473d42502d&type=display
237,COLISTIMETHATE SODIUM,"1. The drug label does not mention any specific cardiotoxicity risks associated with Colistimethate for Injection, USP.
2. The drug label does not indicate that Colistimethate for Injection, USP is associated with cardiotoxicity reactions.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",6a335659-03b0-4a2d-9cd4-7dcf7da96fe6,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=6a335659-03b0-4a2d-9cd4-7dcf7da96fe6&type=display
238,CONJUGATED ESTROGENS,"1. The drug label warns that estrogen-alone therapy is associated with an increased risk of stroke and deep vein thrombosis (DVT) in postmenopausal women, as reported in the Women's Health Initiative (WHI) estrogen-alone substudy. The drug itself is associated with the risk of stroke and DVT.

2. The label also mentions that estrogen plus progestin therapy is linked to increased risks of stroke, DVT, pulmonary embolism (PE), and myocardial infarction (MI) in postmenopausal women, as reported in the WHI estrogen plus progestin substudy. The drug itself is associated with the risk of stroke, DVT, PE, and MI.

3. Furthermore, the WHI estrogen plus progestin substudy reported an increased risk of invasive breast cancer associated with estrogen plus progestin therapy. The drug itself is associated with the risk of invasive breast cancer.

4. Estrogen therapy may lead to an increased risk of gallbladder disease requiring surgery in postmenopausal women, as reported in the drug label. The drug itself is associated with the risk of gallbladder disease.

5. Retinal vascular thrombosis has been reported in patients receiving estrogens, leading to visual abnormalities. The drug itself is associated with the risk of retinal vascular thrombosis and visual abnormalities.

6. Estrogen administration may result in severe hypercalcemia in women with breast cancer and bone metastases, as mentioned in the label. The drug itself is associated with the risk of hypercalcemia.

7. In a small number of case reports, substantial increases in blood pressure have been attributed to idiosyncratic reactions to estrogens, as stated in the label. The drug itself is associated with the risk of elevated blood pressure.

8. Estrogen therapy may be associated with elevations of plasma triglycerides leading to pancreatitis in women with pre-existing hypertriglyceridemia, as mentioned in the label. The drug itself is associated with the risk of hypertriglyceridemia and pancreatitis.

9. The drug label cautions that estrogens may be poorly metabolized in women with impaired liver function, leading to hepatic impairment and/or past history of cholestatic jaundice. The drug itself is associated with the risk of hepatic impairment and cholestatic jaundice.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",96609623-528e-4aba-cabe-7254aed816d5,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=96609623-528e-4aba-cabe-7254aed816d5&type=display
239,COPANLISIB,"1. **Cardiotoxicity Risk**: The drug label for ALIQOPA (copanlisib) does not specifically mention cardiotoxicity risks associated with the drug itself.

2. **Cardiotoxicity Reactions**: The label does not list cardiotoxicity reactions as common adverse reactions or warnings and precautions associated with ALIQOPA.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",ade50241-2c10-4038-b4e9-72f6bf905f03,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=ade50241-2c10-4038-b4e9-72f6bf905f03&type=display
240,COPPER,"1. **Cardiotoxicity Risks:**
   - The drug label does not mention any specific cardiotoxicity risks associated with Paragard.

2. **Cardiotoxicity Reactions:**
   - The drug label does not list any cardiotoxicity reactions or adverse effects related to the use of Paragard.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",5ea7ce51-b87a-485e-b841-99466a07a4b2,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=5ea7ce51-b87a-485e-b841-99466a07a4b2&type=display
241,COPPER CU 64 DOTATATE,"1. The drug label for DETECTNET does not mention any specific cardiotoxicity risks associated with the drug itself.
2. The label does not list any cardiotoxicity reactions or adverse events related to the cardiovascular system caused by DETECTNET.
3. DETECTNET is primarily indicated for use with positron emission tomography (PET) for localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adult patients, and the label focuses on radiation risks, hypersensitivity reactions, and image misinterpretation as the main warnings and precautions.
4. The drug label emphasizes the importance of safe handling and preparation procedures to protect patients and healthcare workers from unintentional radiation exposure, but does not mention any direct cardiotoxic effects of DETECTNET.
5. Overall, the drug label for DETECTNET does not highlight any cardiotoxicity risks or reactions associated with the drug itself in relation to the cardiovascular system.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",f898c8a7-beb7-4318-a8ea-6f058d69342b,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=f898c8a7-beb7-4318-a8ea-6f058d69342b&type=display
242,CORTISONE ACETATE,"1. The drug label warns that corticosteroids, including cortisone acetate, can cause congestive heart failure in susceptible patients, indicating that the drug itself is associated with a cardiotoxicity risk.

2. Additionally, the label mentions that corticosteroids can lead to hypertension, suggesting that the drug itself is associated with a cardiotoxicity risk.

3. Cortisone acetate tablets may cause fluid retention, which can contribute to congestive heart failure in susceptible patients, indicating that the drug itself is associated with a cardiotoxicity risk.

4. The label also states that corticosteroids can result in sodium retention, which may lead to fluid retention and exacerbate congestive heart failure in susceptible patients, suggesting that the drug itself is associated with a cardiotoxicity risk.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",cc158d11-f356-4696-8b73-5d2681dcbcf2,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=cc158d11-f356-4696-8b73-5d2681dcbcf2&type=display
243,CORTROSYN,"1. The drug label does not mention any direct association between Cortrosyn (cosyntropin) and cardiotoxicity risks or reactions. It does not indicate that the drug itself is associated with cardiotoxicity.

2. The label does not list any cardiotoxicity risks or reactions related to the use of Cortrosyn (cosyntropin). There is no mention of the drug causing cardiotoxic effects.

3. There is no information in the drug label suggesting that Cortrosyn (cosyntropin) is linked to cardiotoxicity risks or reactions. The label does not attribute any cardiotoxic effects to the drug.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",0c424fac-b114-41f6-aba8-cf710a34c26c,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=0c424fac-b114-41f6-aba8-cf710a34c26c&type=display
244,CRIZOTINIB,"1. XALKORI has a warning for QT Interval Prolongation, advising monitoring of electrocardiograms and electrolytes in patients with a history of or predisposition for QTc prolongation, or who are taking medications that prolong QT. XALKORI may cause QT prolongation, and dose adjustments or discontinuation may be necessary if QTc prolongation occurs.

2. XALKORI can cause bradycardia, with recommendations to monitor heart rate and blood pressure regularly. Temporary suspension, dose reduction, or permanent discontinuation of XALKORI may be required in cases of bradycardia. XALKORI itself can cause bradycardia.

3. Severe visual loss, including ocular toxicity, is a potential risk with XALKORI treatment. Monitoring and evaluation for ocular toxicity throughout treatment is advised, with discontinuation of XALKORI recommended in patients with severe visual loss. XALKORI can cause visual changes, including severe visual loss.

4. XALKORI has a warning for Hepatotoxicity, with fatal hepatotoxicity reported in some cases. Monitoring with periodic liver testing is recommended, and temporary suspension, dose reduction, or permanent discontinuation of XALKORI may be necessary. XALKORI itself has been associated with fatal hepatotoxicity.",Less,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",2a51b0de-47d6-455e-a94c-d2c737b04ff7,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=2a51b0de-47d6-455e-a94c-d2c737b04ff7&type=display
245,CROFELEMER,"1. The drug MYTESI, containing crofelemer, is an anti-diarrheal medication indicated for the symptomatic relief of non-infectious diarrhea in adult patients with HIV/AIDS on anti-retroviral therapy. The drug itself is not associated with cardiotoxicity risks.

2. Crofelemer, the active ingredient in MYTESI, acts by blocking chloride secretion and high volume water loss in diarrhea, normalizing the flow of chloride and water in the gastrointestinal tract. There is no mention of cardiotoxicity risks associated with this mechanism of action.

3. Clinical studies with MYTESI did not show any clinically relevant prolongation of the QTc interval, a measure of cardiac electrophysiology, even at a dose 10 times the maximum recommended dose. Therefore, MYTESI is not associated with cardiotoxicity risks related to QTc prolongation.

4. Crofelemer was not associated with any drug-related neoplastic findings in a 2-year oral carcinogenicity study in rats, even at doses up to 47.6/23.8 times the recommended clinical dose. This indicates that MYTESI is not linked to cardiotoxicity risks related to carcinogenesis.

5. Crofelemer was also negative in mutagenesis studies, showing no genotoxic effects. This suggests that MYTESI is not associated with cardiotoxicity risks related to mutagenesis.

6. In fertility studies, crofelemer did not affect fertility or reproductive performance in rats at doses up to 177 times the recommended human daily dose. This indicates that MYTESI is not associated with cardiotoxicity risks related to impairment of fertility.

Overall, based on the information provided in the drug label, MYTESI (crofelemer) does not appear to be associated with any cardiotoxicity risks or cardiotoxic reactions.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",45584fba-8081-4cd1-a21e-3ea8237f62ff,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=45584fba-8081-4cd1-a21e-3ea8237f62ff&type=display
246,CUPRIC CHLORIDE,"1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with the use of Copper 0.4 mg/mL (Cupric Chloride Injection, USP).
2. Therefore, there is no information provided in the label indicating that the drug itself is associated with cardiotoxicity risks or reactions.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",a84d61a4-8e7f-4be1-aba6-f633b334aafc,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a84d61a4-8e7f-4be1-aba6-f633b334aafc&type=display
247,CYANOCOBALAMIN,"1. The drug label does not mention any specific cardiotoxicity risks or cardiotoxicity reactions associated with NASCOBAL (cyanocobalamin nasal spray) itself.

2. The label focuses on potential adverse reactions related to optic atrophy in patients with Leber's disease, anaphylactic reactions, masking of folate deficiency, hypokalemia, thrombocytosis due to intense treatment of megaloblastic anemia, and unmasking of polycythemia vera. However, these adverse reactions are not directly linked to cardiotoxicity risks or reactions caused by NASCOBAL.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",697e0e52-c01b-4b53-9994-f79c46eb6b4f,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=697e0e52-c01b-4b53-9994-f79c46eb6b4f&type=display
248,CYCLOBENZAPRINE HYDROCHLORIDE,"1. The drug label mentions that cyclobenzaprine, the active ingredient in AMRIX, is structurally related to tricyclic antidepressants, which have been reported to produce adverse cardiovascular effects. This suggests a potential cardiotoxicity risk associated with cyclobenzaprine itself.

2. The label also states that tricyclic antidepressants, including cyclobenzaprine, may produce arrhythmias, sinus tachycardia, prolongation of the conduction time leading to myocardial infarction, and stroke. This indicates a potential cardiotoxicity risk associated with cyclobenzaprine use.

3. Additionally, the label mentions that some of the more serious central nervous system reactions noted with tricyclic antidepressants, including cyclobenzaprine, have occurred at doses somewhat greater than those recommended for skeletal muscle spasm. This suggests a potential cardiotoxicity risk associated with higher doses of cyclobenzaprine.

4. The label highlights that the development of potentially life-threatening serotonin syndrome has been reported with cyclobenzaprine when used in combination with other drugs, such as selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants. Serotonin syndrome symptoms may include autonomic instability, neuromuscular abnormalities, and gastrointestinal symptoms, which can impact cardiovascular function. This indicates a potential cardiotoxicity risk associated with drug interactions involving cyclobenzaprine.

5. Furthermore, the label mentions that postmarketing cases of serotonin syndrome have been reported during combined use of cyclobenzaprine and other drugs, such as SSRIs, SNRIs, TCAs, tramadol, bupropion, meperidine, verapamil, or MAO inhibitors. This suggests a potential cardiotoxicity risk associated with drug interactions involving cyclobenzaprine and serotonergic agents.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",3902123b-1365-ac3c-0934-afff9eeeb1bd,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=3902123b-1365-ac3c-0934-afff9eeeb1bd&type=display
249,CYCLOPHOSPHAMIDE,"1. **Cardiotoxicity Risk**: Cyclophosphamide is associated with cardiotoxicity risks, including myocarditis, myopericarditis, pericardial effusion, arrhythmias, and congestive heart failure, which may be fatal. Patients with risk factors for cardiotoxicity or pre-existing cardiac disease should be monitored closely.

2. **Cardiotoxicity Reactions**: Cyclophosphamide therapy has been reported to cause cardiotoxicity reactions such as myocarditis, myopericarditis, pericardial effusion, arrhythmias, and congestive heart failure. The risk of cardiotoxicity may be increased with high doses of cyclophosphamide, advanced age, and previous radiation treatment to the cardiac region or concomitant treatment with other cardiotoxic agents. Close monitoring is recommended for patients with risk factors for cardiotoxicity and pre-existing cardiac disease.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",a0e99679-f939-4fb3-9d38-dfdb824f89bc,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a0e99679-f939-4fb3-9d38-dfdb824f89bc&type=display
250,CYCLOSERINE,"1. The drug label does not mention any direct association between Cycloserine and cardiotoxicity risks or reactions.

2. The label does not indicate that Cycloserine is associated with cardiotoxicity risks or reactions.

3. There is no mention in the drug label of Cycloserine being linked to cardiotoxicity risks or reactions.

4. The drug label does not attribute any cardiotoxicity risks or reactions to Cycloserine.

5. No information in the drug label suggests that Cycloserine is connected to cardiotoxicity risks or reactions.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",8e7e2665-7a3d-3f54-9f92-5fe845f02ef9,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8e7e2665-7a3d-3f54-9f92-5fe845f02ef9&type=display
251,CYPROHEPTADINE HYDROCHLORIDE,"1. The drug label mentions that cyproheptadine is an antihistaminic and antiserotonergic agent with anticholinergic and sedative effects. It does not specifically state that the drug itself is associated with cardiotoxicity risk.

2. The label warns that antihistamines, including cyproheptadine, may cause hypotension, palpitations, tachycardia, extrasystoles, and anaphylactic shock, which are cardiovascular adverse reactions. This suggests that the drug may be associated with cardiotoxicity risk.

3. The label also mentions that antihistamine overdosage reactions, such as central nervous system depression or stimulation, may occur, along with atropine-like signs and symptoms, gastrointestinal symptoms, and hypotension. These reactions indicate potential cardiotoxic effects of cyproheptadine in cases of overdose.

In summary, while the drug label does not explicitly state that cyproheptadine is directly associated with cardiotoxicity risk, it does warn about potential cardiovascular adverse reactions and cardiotoxic effects in cases of overdose.",Less,Yes,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",03e69414-8a25-4ed8-b7ac-16445b879b1f,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=03e69414-8a25-4ed8-b7ac-16445b879b1f&type=display
252,CYSTEAMINE BITARTRATE,"1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with PROCYSBI (cysteamine bitartrate) itself.

2. The label primarily focuses on warnings and precautions related to skin and bone lesions resembling Ehlers-Danlos-like syndrome, skin rash, gastrointestinal ulcers and bleeding, fibrosing colonopathy, central nervous system symptoms, leukopenia, elevated alkaline phosphatase levels, and benign intracranial hypertension. These adverse reactions are not directly linked to cardiotoxicity risks or reactions. 

3. The label does not indicate any cardiotoxic effects or risks specifically attributed to PROCYSBI in relation to cardiac function or toxicity. 

Overall, based on the information provided in the drug label, PROCYSBI does not appear to be associated with cardiotoxicity risks or cardiotoxic reactions.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",d3a3ec28-f746-463a-bb92-3bc8826db09e,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=d3a3ec28-f746-463a-bb92-3bc8826db09e&type=display
253,CYSTEINE HYDROCHLORIDE,"1. **Cardiotoxicity Risk**: The drug ELCYS is associated with a risk of pulmonary embolism due to pulmonary vascular precipitates. This risk is linked to the administration of parenteral nutrition solutions containing ELCYS, particularly in patients receiving total parenteral nutrition (TPN). The drug itself is not directly causing the pulmonary embolism risk, but it is a potential consequence of the administration of ELCYS.

2. **Cardiotoxicity Reaction**: The drug ELCYS is not directly associated with vein damage and thrombosis; however, the infusion of hypertonic nutrient injections, including those containing ELCYS, into a peripheral vein may result in vein irritation, damage, and thrombosis. This reaction is a potential consequence of the administration of ELCYS solutions through peripheral access.

3. **Cardiotoxicity Risk**: ELCYS may induce an increase in blood urea nitrogen (BUN), especially in patients with impaired hepatic or renal function. The drug itself is not causing the increased BUN levels, but it may exacerbate existing conditions in patients with impaired organ function.

4. **Cardiotoxicity Risk**: Administration of ELCYS may result in metabolic acidosis in preterm infants. The drug itself is associated with the risk of metabolic acidosis, particularly in this specific patient population.

5. **Cardiotoxicity Risk**: ELCYS administration to patients with hepatic impairment may lead to serum amino acid imbalances, metabolic alkalosis, and other hepatic-related complications. The drug itself is linked to the risk of these hepatic disorders in patients with impaired liver function.

6. **Cardiotoxicity Reaction**: ELCYS is not directly causing hyperammonemia; however, it is associated with the risk of hyperammonemia, especially in infants. The drug itself is not the cause of hyperammonemia but may contribute to its development, particularly in infants.

7. **Cardiotoxicity Risk**: ELCYS contains aluminum, which may reach toxic levels in patients with renal impairment. The drug itself is associated with the risk of aluminum toxicity, especially in patients with impaired renal function, including preterm infants.",Most,No,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",e7652275-1c53-490c-82ad-e63867df5788,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=e7652275-1c53-490c-82ad-e63867df5788&type=display
254,CYTARABINE,"1. The drug label warns that severe and at times fatal CNS, GI, and pulmonary toxicity, different from that seen with conventional therapy regimens of cytarabine injection, has been reported following some experimental dose schedules for cytarabine injection. These reactions include reversible corneal toxicity, hemorrhagic conjunctivitis, cerebral and cerebellar dysfunction, severe gastrointestinal ulceration, sepsis, liver abscess, pulmonary edema, liver damage, bowel necrosis, and necrotizing colitis. The label does not explicitly state that the drug itself caused the cardiotoxicity risk, but it mentions various severe reactions that can occur following experimental dose schedules.

2. The label also mentions that cases of cardiomyopathy with subsequent death have been reported following experimental high dose therapy with cytarabine in combination with cyclophosphamide when used for bone marrow transplant preparation. This indicates that the drug itself, in combination with another medication, was associated with cardiotoxicity reactions leading to death.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",90f5c7ab-9f15-487d-ba69-ee4107434bcc,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=90f5c7ab-9f15-487d-ba69-ee4107434bcc&type=display
255,DABIGATRAN ETEXILATE MESYLATE,"1. The drug label warns about the risk of thrombotic events associated with premature discontinuation of PRADAXA, emphasizing the importance of considering coverage with another anticoagulant if PRADAXA is stopped for reasons other than pathological bleeding or completion of therapy. (The drug itself is not associated with cardiotoxicity but with the risk of thrombotic events if prematurely discontinued.)

2. The label highlights the potential occurrence of spinal/epidural hematomas in patients treated with PRADAXA who undergo neuraxial anesthesia or spinal puncture, which may lead to long-term or permanent paralysis. It advises monitoring patients for signs of neurological impairment and urgent treatment if observed, and to carefully consider the risks before neuraxial intervention in anticoagulated patients. (The drug itself is not associated with cardiotoxicity but with the risk of spinal/epidural hematomas.)

3. The drug label mentions that PRADAXA is contraindicated in patients with mechanical prosthetic heart valves due to the increased risk of thromboembolic events and major bleeding observed in a clinical trial. The use of PRADAXA in patients with mechanical prosthetic heart valves is not recommended. (The drug itself is associated with an increased risk of thromboembolic events and major bleeding in patients with mechanical prosthetic heart valves.)

4. The label does not specifically mention any cardiotoxicity risks or reactions associated with PRADAXA itself, but it provides information on the drug's use in patients with valvular heart disease, including the contraindication for patients with mechanical prosthetic heart valves. (The drug itself is not directly associated with cardiotoxicity risks in this context but is contraindicated in certain heart valve conditions due to safety concerns.)",Less,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",ba74e3cd-b06f-4145-b284-5fd6b84ff3c9,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=ba74e3cd-b06f-4145-b284-5fd6b84ff3c9&type=display
256,DABRAFENIB,"1. TAFINLAR, when administered with trametinib, has been associated with cardiomyopathy, defined as a decrease in left ventricular ejection fraction (LVEF)  10% from baseline and below the institutional lower limit of normal (LLN), occurring in 6% of adult patients. Development of cardiomyopathy resulted in dose interruption or discontinuation of TAFINLAR in 3% and < 1% of patients, respectively. Cardiomyopathy resolved in 45 of 50 patients who received TAFINLAR administered with trametinib.

2. For pediatric patients receiving TAFINLAR with trametinib, cardiomyopathy, defined as a decrease in LVEF  10% from baseline and below the institutional LLN, occurred in 9% of patients.

3. Assessment of LVEF by echocardiogram or multigated acquisition (MUGA) scan is recommended before initiation of TAFINLAR in combination with trametinib, one month after initiation, and then at 2- to 3-month intervals while on treatment. Withholding TAFINLAR is advised for symptomatic cardiomyopathy or asymptomatic LV dysfunction of > 20% from baseline that is below the institutional LLN. Resuming TAFINLAR at the same dose level upon recovery of cardiac function to at least the institutional LLN for LVEF and absolute decrease  10% compared to baseline.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",fee1e6b1-e1a5-4254-9f2e-a70e0f8dbdea,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fee1e6b1-e1a5-4254-9f2e-a70e0f8dbdea&type=display
257,DACARBAZINE,"1. The drug label does not mention any specific cardiotoxicity risks associated with dacarbazine itself.
2. The label does not indicate that dacarbazine is directly linked to any cardiotoxicity reactions.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",0d81315c-7021-4091-b703-ad135390c936,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=0d81315c-7021-4091-b703-ad135390c936&type=display
258,DACOMITINIB,1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with VIZIMPRO (dacomitinib).,No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",90da33c1-5689-4b4d-a2b5-377e1057a843,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=90da33c1-5689-4b4d-a2b5-377e1057a843&type=display
259,DACTINOMYCIN,"1. **Cardiotoxicity Risk**: The drug label does not mention any specific cardiotoxicity risks associated with COSMEGEN.
   
2. **Cardiotoxicity Reactions**: The drug label does not list cardiotoxicity reactions as common adverse reactions or warnings and precautions associated with COSMEGEN.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",9914e793-a49c-eb00-1ab7-f606c786fe25,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=9914e793-a49c-eb00-1ab7-f606c786fe25&type=display
260,DALBAVANCIN,"1. **Warnings and Precautions (5.1):** Serious hypersensitivity (anaphylactic) and skin reactions have been reported in patients treated with DALVANCE. If an allergic reaction occurs, discontinue treatment with DALVANCE and institute appropriate therapy for the allergic reaction. **(DALVANCE itself was not associated with cardiotoxicity risk in this section.)**

2. **Warnings and Precautions (5.2):** Rapid intravenous infusion of DALVANCE can cause flushing of the upper body, urticaria, pruritus, rash, and/or back pain. Stopping or slowing the infusion may result in cessation of these reactions. **(DALVANCE itself was not associated with cardiotoxicity risk in this section.)**

3. **Warnings and Precautions (5.3):** Alanine Aminotransferase (ALT) elevations with DALVANCE treatment were reported in clinical trials. **(DALVANCE itself was not associated with cardiotoxicity risk in this section.)**

4. **Warnings and Precautions (5.4):** Clostridioides difficile-associated diarrhea (CDAD) has been reported with nearly all systemic antibacterial agents, including DALVANCE. Evaluate if diarrhea occurs. **(DALVANCE itself was not associated with cardiotoxicity risk in this section.)**

5. **Adverse Reactions (6.1):** The most common adverse reactions occurring in adult patients treated with DALVANCE were nausea, headache, and diarrhea. The most common adverse reaction that occurred in pediatric patients was pyrexia. **(DALVANCE itself was not associated with cardiotoxicity risk in this section.)**

6. **Post Marketing Experience (6.2):** Back pain as an infusion-related reaction has been identified during post-approval use of dalbavancin. **(DALVANCE itself was associated with an infusion-related reaction of back pain, which could be considered a cardiotoxicity reaction.)**",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",4b4674d8-4d1e-4728-8465-d42ada33fa5c,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=4b4674d8-4d1e-4728-8465-d42ada33fa5c&type=display
261,DALFAMPRIDINE,1. The drug label does not mention any cardiotoxicity risks or cardiotoxicity reactions associated with AMPYRA (dalfampridine).,No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",550eb76a-e4a6-4fa1-ad65-c0fd8b0ce783,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=550eb76a-e4a6-4fa1-ad65-c0fd8b0ce783&type=display
262,DALTEPARIN SODIUM,"1. **Cardiotoxicity Risk Associated with FRAGMIN:**
   - The drug label does not mention any direct association of FRAGMIN with cardiotoxicity risks.

2. **Cardiotoxicity Reactions:**
   - The drug label does not list cardiotoxicity reactions as adverse effects associated with the use of FRAGMIN.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",23527b8b-9b28-4e6d-9751-33b143975ac7,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=23527b8b-9b28-4e6d-9751-33b143975ac7&type=display
263,DANAZOL,"1. The drug label mentions that danazol has been associated with a temporary alteration of lipoproteins, including decreased high-density lipoproteins and possibly increased low-density lipoproteins, which may impact the risk of atherosclerosis and coronary artery disease. The drug itself is associated with these lipid profile alterations, which may have implications for cardiovascular health.

2. Additionally, the label warns that hepatic dysfunction, as evidenced by reversible elevated serum enzymes and/or jaundice, has been reported in patients receiving a daily dosage of 400 mg or more of danazol capsules. Serious hepatic toxicity, including cholestatic jaundice, peliosis hepatis, hepatic adenoma, hepatocellular injury, hepatocellular jaundice, and hepatic failure, have been reported. The drug itself is associated with hepatic dysfunction, which can have implications for overall health, including cardiovascular health.",Less,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",55ad6325-16f6-4f0c-a1dc-734847052d0b,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=55ad6325-16f6-4f0c-a1dc-734847052d0b&type=display
264,DANTROLENE,"1. The drug label mentions that there have been reports of cardiovascular collapse in association with marked hyperkalemia in patients receiving dantrolene in combination with calcium channel blockers, indicating a potential cardiotoxicity risk associated with the drug in combination with certain medications.

2. Additionally, the label states that there have been occasional reports of death following malignant hyperthermia crisis even when treated with intravenous dantrolene, with most deaths attributed to factors such as late recognition, delayed treatment, inadequate dosage, lack of supportive therapy, intercurrent disease, or the development of complications like renal failure or disseminated intravascular coagulopathy. This suggests that dantrolene may not always be effective in preventing fatal outcomes in cases of malignant hyperthermia crisis.

3. The label also mentions that there have been reports of fatality in malignant hyperthermia crisis, despite an initial satisfactory response to intravenous dantrolene, involving patients who could not be weaned from dantrolene after initial treatment, indicating a potential risk of cardiotoxicity or other adverse reactions that may not be fully reversible with dantrolene treatment alone.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",ab0efc75-0598-4f4e-91ad-6195bb2661fe,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=ab0efc75-0598-4f4e-91ad-6195bb2661fe&type=display
265,DAPAGLIFLOZIN,"1. **Indications and Usage**: FARXIGA is indicated to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure. (The drug is associated with reducing the risk of heart failure-related events.)

2. **Warnings and Precautions - Diabetic Ketoacidosis**: FARXIGA significantly increases the risk of diabetic ketoacidosis in patients with type 1 diabetes mellitus and other ketoacidosis. (The drug is associated with an increased risk of ketoacidosis, a life-threatening condition.)

3. **Warnings and Precautions - Volume Depletion**: FARXIGA can cause intravascular volume depletion, leading to symptomatic hypotension or acute transient changes in creatinine. (The drug is associated with volume depletion, which may manifest as hypotension.)

4. **Warnings and Precautions - Urosepsis and Pyelonephritis**: Serious urinary tract infections, including urosepsis and pyelonephritis requiring hospitalization, have been reported in patients receiving FARXIGA. (The drug is associated with an increased risk of serious urinary tract infections.)

5. **Warnings and Precautions - Hypoglycemia**: FARXIGA may increase the risk of hypoglycemia when combined with insulin or an insulin secretagogue. (The drug is associated with an increased risk of hypoglycemia when used in combination with certain medications.)

6. **Warnings and Precautions - Necrotizing Fasciitis of the Perineum (Fourniers Gangrene)**: Reports of necrotizing fasciitis of the perineum, a rare but serious and life-threatening infection, have been identified in patients with diabetes mellitus receiving SGLT2 inhibitors, including FARXIGA. (The drug is associated with a risk of necrotizing fasciitis in the perineal area.)

7. **Warnings and Precautions - Genital Mycotic Infections**: FARXIGA increases the risk of genital mycotic infections. (The drug is associated with an increased risk of genital mycotic infections.)

8. **Adverse Reactions - Clinical Trials Experience**: In clinical trials, common adverse reactions associated with FARXIGA use included female genital mycotic infections, nasopharyngitis, and urinary tract infections. (The drug is associated with an increased risk of certain adverse reactions, including genital mycotic infections.)

In summary, FARXIGA is associated with various cardiotoxicity risks and reactions, including diabetic ketoacidosis, volume depletion, urinary tract infections, hypoglycemia, necrotizing fasciitis, and genital mycotic infections. It is important for healthcare providers and patients to be aware of these potential risks when using FARXIGA.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",72ad22ae-efe6-4cd6-a302-98aaee423d69,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=72ad22ae-efe6-4cd6-a302-98aaee423d69&type=display
266,DAPTOMYCIN,"1. The drug label mentions that myopathy and rhabdomyolysis have been reported with the use of daptomycin for injection, indicating that the drug itself is associated with cardiotoxicity risks.

2. It also states that patients receiving DAPZURA RT should be monitored for muscle pain or weakness, and CPK levels should be monitored weekly, suggesting that the drug can cause cardiotoxicity reactions.

3. The label further highlights that eosinophilic pneumonia has been reported in patients receiving daptomycin for injection, indicating a potential cardiotoxicity risk associated with the drug.

4. It mentions that patients who develop eosinophilic pneumonia while on DAPZURA RT should undergo prompt medical evaluation, discontinue the drug, and consider treatment with systemic steroids, suggesting that the drug can lead to cardiotoxicity reactions.

5. Additionally, the label warns about the potential risk of peripheral neuropathy associated with daptomycin for injection, indicating a possible cardiotoxicity risk with the drug.

6. It advises physicians to be alert to signs and symptoms of peripheral neuropathy in patients receiving DAPZURA RT and to monitor for neuropathy, further suggesting that the drug can cause cardiotoxicity reactions.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",17405aa0-70a5-53b0-e063-6394a90a8b51,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=17405aa0-70a5-53b0-e063-6394a90a8b51&type=display
267,DARIFENACIN,1. The drug label does not mention any cardiotoxicity risks or cardiotoxicity reactions associated with darifenacin (ENABLEX) in the sections provided.,No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",a293cece-e97a-4e67-be72-b187568e3b11,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a293cece-e97a-4e67-be72-b187568e3b11&type=display
268,DAROLUTAMIDE,"1. **Cardiotoxicity Risk**: NUBEQA is associated with an increased risk of ischemic heart disease, including fatal cases, as observed in clinical studies. Patients receiving NUBEQA should be monitored for signs and symptoms of coronary artery disease, and management of cardiovascular risk factors is recommended. Discontinuation of NUBEQA is advised for Grade 3-4 ischemic heart disease events.

2. **Cardiotoxicity Reaction**: In clinical trials, ischemic heart disease occurred in patients receiving NUBEQA, with Grade 3-4 events reported. Ischemic events led to death in a small percentage of patients receiving NUBEQA. The drug itself was associated with the occurrence of ischemic heart disease in patients with non-metastatic castration-resistant prostate cancer and metastatic hormone-sensitive prostate cancer in combination with docetaxel.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",1a7cb212-56e4-4b9d-a73d-bfee7fe4735e,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=1a7cb212-56e4-4b9d-a73d-bfee7fe4735e&type=display
269,DARUNAVIR,"1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with PREZISTA (darunavir) itself. 

2. However, it does highlight the importance of co-administration with ritonavir and food to achieve the desired antiviral effect. Failure to administer PREZISTA with ritonavir and food may result in a loss of efficacy of darunavir. This statement does not directly link PREZISTA to cardiotoxicity risks. 

3. The label also mentions that drug-induced hepatitis, including acute hepatitis and cytolytic hepatitis, has been reported with PREZISTA/ritonavir. While liver function abnormalities are discussed, there is no direct mention of cardiotoxicity risks associated with PREZISTA itself. 

4. Additionally, the label discusses the potential for serious adverse reactions due to drug interactions when co-administering PREZISTA/ritonavir with other medications metabolized by CYP3A. These interactions may lead to clinically significant adverse reactions, but cardiotoxicity risks are not specifically highlighted in this context. 

Overall, while the drug label provides important information about potential adverse effects and drug interactions related to PREZISTA, it does not directly associate the drug itself with cardiotoxicity risks or reactions.",Less,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",814301f9-c990-46a5-b481-2879a521a16f,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=814301f9-c990-46a5-b481-2879a521a16f&type=display
270,DASATINIB,"1. SPRYCEL may cause cardiac dysfunction, as reported in adult patients with chronic phase CML after 5 years of follow-up in a clinical trial. The following cardiac adverse reactions were observed: cardiac ischemic events, cardiac-related fluid retention, and conduction system abnormalities, such as arrhythmia and palpitations.

2. SPRYCEL can increase the risk of developing pulmonary arterial hypertension (PAH) in both adult and pediatric patients, which may occur at any time after initiation of treatment. Manifestations of PAH include dyspnea, fatigue, hypoxia, and fluid retention. PAH may be reversible upon discontinuation of SPRYCEL.

3. Patients treated with SPRYCEL in clinical studies experienced Grade 3 or 4 fluid retention, including pleural effusion, in various percentages depending on the type of CML. This fluid retention was managed with supportive care measures, including diuretics or short courses of steroids, and may require dose reduction or treatment interruption.

4. SPRYCEL has been associated with severe bleeding-related events, including Grade 3 central nervous system hemorrhages, which occurred in less than 1% of patients in clinical studies. The incidence of Grade 3/4 hemorrhage was higher in adult patients and generally required treatment interruptions and transfusions. Most bleeding events were associated with severe thrombocytopenia caused by SPRYCEL.

5. SPRYCEL may increase the risk of prolongation of QTc in patients, especially those with certain risk factors. Correcting hypokalemia or hypomagnesemia prior to and during SPRYCEL administration is recommended to mitigate this risk.",Most,Yes,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",4764f37b-c9e6-4ede-bcc2-8a03b7c521df,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=4764f37b-c9e6-4ede-bcc2-8a03b7c521df&type=display
271,DASIGLUCAGON,"1. The drug ZEGALOGUE is associated with a substantial increase in blood pressure in patients with pheochromocytoma, a type of tumor. ZEGALOGUE may stimulate the release of catecholamines from the tumor, leading to a risk of increased blood pressure. This cardiotoxicity risk is directly linked to the drug itself.

2. ZEGALOGUE may cause hypoglycemia in patients with insulinoma, another type of tumor. While the drug may initially increase blood glucose levels, it can stimulate exaggerated insulin release from an insulinoma, potentially leading to subsequent hypoglycemia. This cardiotoxicity risk is directly associated with the drug.

3. Allergic reactions, including serious hypersensitivity reactions, have been reported with ZEGALOGUE. Symptoms may include breathing difficulties, rash, and low blood pressure (hypotension). This cardiotoxicity risk is linked to the drug's potential to trigger serious allergic reactions, impacting cardiovascular health.

4. ZEGALOGUE is effective in treating hypoglycemia only if sufficient hepatic glycogen is present. Patients with decreased hepatic glycogen levels, such as those in states of starvation or with adrenal insufficiency, may not respond to ZEGALOGUE treatment. In such cases, patients should be treated with glucose instead. While not a direct cardiotoxicity risk, the drug's efficacy is dependent on hepatic glycogen levels, which can impact overall cardiovascular health.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",c6c32b47-c47c-4a7f-8d4d-23578f663217,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=c6c32b47-c47c-4a7f-8d4d-23578f663217&type=display
272,DAUNORUBICIN HYDROCHLORIDE,"1. The drug label warns that myocardial toxicity, potentially leading to congestive heart failure, may occur during or after therapy with Daunorubicin Hydrochloride Injection. The incidence of myocardial toxicity increases with cumulative doses exceeding specified limits in adults and children, indicating that the drug itself is associated with the risk of cardiotoxicity.

2. The label mentions that severe myelosuppression can occur with Daunorubicin Hydrochloride, leading to infection or hemorrhage, but does not directly attribute this to cardiotoxicity.

3. It is emphasized that special attention should be given to the potential cardiac toxicity of Daunorubicin Hydrochloride, particularly in infants and children, as well as in adults at cumulative doses exceeding certain thresholds. The drug is directly linked to an increased risk of congestive heart failure, pericarditis-myocarditis, and other cardiac issues, especially at higher cumulative doses.

4. The label advises that there is no reliable method to predict acute congestive heart failure due to the cardiac toxic effect of Daunorubicin Hydrochloride. However, certain changes in electrocardiogram and systolic ejection fraction may indicate a risk of drug-induced cardiomyopathy, suggesting that the drug itself can lead to cardiotoxicity.

5. The label stresses the importance of early clinical diagnosis of drug-induced congestive heart failure for successful treatment, indicating that Daunorubicin Hydrochloride can directly cause this cardiotoxic reaction.

In summary, the drug label for Daunorubicin Hydrochloride Injection clearly outlines the risks of cardiotoxicity associated with the drug, particularly emphasizing the potential for myocardial toxicity and congestive heart failure, both during therapy and in the long term. The label provides guidance on monitoring and managing these risks, underscoring the importance of close patient observation and cardiac function evaluation.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",227784a8-ce68-4dd4-8ac5-a65265969677,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=227784a8-ce68-4dd4-8ac5-a65265969677&type=display
273,DECITABINE,"1. **Warnings and Precautions**: Myelosuppression, including anemia, neutropenia, and thrombocytopenia, is a common adverse effect of Decitabine for Injection. The drug itself is not directly associated with cardiotoxicity risk in this section.

2. **Adverse Reactions**: In the controlled supportive care study, some patients in the Decitabine arm experienced cardiac disorders such as pulmonary edema. However, the drug itself is not directly linked to cardiotoxicity in this section.

3. **Postmarketing Experience**: Postmarketing reports have identified serious adverse reactions, including cardiac disorders like myocardial infarction and cardiomyopathy, in patients receiving Decitabine. These reports suggest a potential association between Decitabine and cardiotoxicity reactions.",Less,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",c155d6ba-9a16-406c-919e-65a149689ab9,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=c155d6ba-9a16-406c-919e-65a149689ab9&type=display
274,DEFERASIROX,"1. JADENU may cause serious and fatal acute kidney injury, including acute renal failure requiring dialysis and renal tubular toxicity, including Fanconi syndrome. (The drug itself is associated with the risk of acute kidney injury and renal tubular toxicity.)

2. JADENU can cause hepatic toxicity, including failure. (The drug itself is associated with the risk of hepatic toxicity.)

3. JADENU can cause gastrointestinal hemorrhage, which may be fatal, especially in elderly patients with advanced hematologic malignancies and/or low platelet counts. (The drug itself is associated with the risk of gastrointestinal hemorrhage.)

4. JADENU may lead to bone marrow suppression, including neutropenia, agranulocytosis, worsening anemia, and thrombocytopenia, including fatal events. (The drug itself is associated with the risk of bone marrow suppression.)

5. JADENU therapy requires close patient monitoring, including laboratory tests of renal and hepatic function. (The drug itself requires monitoring for renal and hepatic function, which are important for overall patient safety and management of potential adverse effects.)",Less,No,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",fee89140-fff1-4443-9f42-24ac004fcda1,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fee89140-fff1-4443-9f42-24ac004fcda1&type=display
275,DEFERIPRONE,"1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with the drug FERRIPROX. 

2. There is no information provided in the drug label regarding cardiotoxicity risks or cardiotoxicity reactions related to the use of FERRIPROX. 

3. The drug label does not contain any details about cardiotoxicity risks or cardiotoxicity reactions linked to the administration of FERRIPROX. 

Overall, based on the information provided in the drug label, there are no mentions of cardiotoxicity risks or cardiotoxicity reactions associated with the use of FERRIPROX.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",946718ff-df43-1baa-74d1-e5bcfbe8ad86,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=946718ff-df43-1baa-74d1-e5bcfbe8ad86&type=display
276,DEFEROXAMINE MESYLATE,"1. Cardiotoxicity Risks:
- Desferal treatment in patients with severe chronic iron overload was associated with cardiac dysfunction when used concomitantly with high doses of vitamin C. The cardiac dysfunction was reversible upon discontinuation of vitamin C. The drug itself was not directly associated with cardiotoxicity risk but in combination with high doses of vitamin C.
- Desferal treatment in patients with aluminum overload may lead to decreased serum calcium, aggravation of hyperparathyroidism, and neurological dysfunction, including seizures. The drug itself was associated with cardiotoxicity risk in patients with aluminum overload.

2. Cardiotoxicity Reactions:
- Cardiac dysfunction, including reversible cases, occurred in Desferal-treated patients with severe chronic iron overload when used concomitantly with high doses of vitamin C. The drug itself was not directly associated with causing cardiotoxicity but in combination with high doses of vitamin C.
- Desferal treatment in patients with aluminum overload may lead to neurological dysfunction, including seizures, dialysis dementia, and aggravation of hyperparathyroidism. The drug itself was associated with causing cardiotoxicity reactions in patients with aluminum overload.",Less,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",a7174843-5965-49fc-b842-f7eff7b48bbc,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a7174843-5965-49fc-b842-f7eff7b48bbc&type=display
277,DEFIBROTIDE SODIUM,"1. The drug DEFITELIO (defibrotide sodium) injection is associated with a potential risk of cardiotoxicity, as it may enhance the pharmacodynamic activity of antithrombotic/fibrinolytic drugs, which can increase the risk of bleeding in patients with hepatic veno-occlusive disease (VOD) following hematopoietic stem-cell transplantation (HSCT). The drug itself is not directly causing cardiotoxicity but may contribute to an increased risk of bleeding, which can have cardiotoxic effects if not managed appropriately.

2. DEFITELIO has been shown to transiently prolong activated partial thromboplastin time (APTT) in animal studies at doses higher than the clinical dose, indicating a potential effect on coagulation that could lead to bleeding events. This suggests that the drug may indirectly impact cardiotoxicity through its effects on coagulation parameters.

3. The drug label advises monitoring patients for signs of bleeding, as DEFITELIO may increase the risk of hemorrhage in patients with VOD after HSCT. Patients on DEFITELIO who develop bleeding should have the drug discontinued, the underlying cause of bleeding treated, and supportive care provided until bleeding has stopped. This highlights the importance of managing potential cardiotoxicity risks associated with bleeding events in patients receiving DEFITELIO.",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",2c3db989-d7ad-41ed-9ebf-698dcf6c24ec,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=2c3db989-d7ad-41ed-9ebf-698dcf6c24ec&type=display
278,DEFLAZACORT,"1. **Alterations in Cardiovascular/Renal Function:** EMFLAZA, a corticosteroid, can cause elevation of blood pressure, salt, and water retention, and increased excretion of potassium and calcium. Monitor blood pressure and assess for signs and symptoms of volume overload. Monitor serum potassium levels. Dietary salt restriction and potassium supplementation may be necessary. Use EMFLAZA with caution in patients with congestive heart failure, hypertension, or renal insufficiency.

2. **Gastrointestinal Perforation:** There is an increased risk of gastrointestinal perforation during corticosteroid use in patients with certain gastrointestinal disorders such as active or latent peptic ulcers, diverticulitis, fresh intestinal anastomoses, and non-specific ulcerative colitis. Signs of gastrointestinal perforation, such as peritoneal irritation, may be masked in patients receiving corticosteroids.

3. **Thromboembolic Events:** Observational studies have shown an increased risk of thromboembolism (including venous thromboembolism) particularly with higher cumulative doses of corticosteroids. It is unclear if risk differs by daily dose or duration of use. Use EMFLAZA with caution in patients who have or may be predisposed to thromboembolic disorders.",Less,Yes,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",31b347d2-f156-4055-9d8f-7cf0df420296,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=31b347d2-f156-4055-9d8f-7cf0df420296&type=display
279,DEGARELIX,"1. The drug FIRMAGON, a GnRH receptor antagonist, may prolong the QT interval, which is a risk factor for cardiotoxicity. This risk is associated with the androgen deprivation therapy treatment with FIRMAGON, but the drug itself does not directly cause cardiotoxicity.

2. In a randomized trial comparing FIRMAGON to leuprolide, some patients in both groups experienced QTcF  500 msec, indicating potential QT interval prolongation. The median change in QT interval was 12.3 msec for FIRMAGON and 16.7 msec for leuprolide, suggesting a potential cardiotoxic effect associated with both drugs.

3. Providers are advised to consider the benefits of androgen deprivation therapy against the risks in patients with congenital long QT syndrome, heart failure, electrolyte imbalances, or those taking medications known to prolong the QT interval. Monitoring of electrocardiograms and electrolytes is recommended to manage potential cardiotoxicity risks.

4. While FIRMAGON treatment may lead to QT interval prolongation, the drug itself is not a direct cause of cardiotoxicity. The focus is on monitoring and managing potential QT prolongation risks in patients receiving androgen deprivation therapy with FIRMAGON.",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",ab11dd8a-0fd9-4013-89ab-e114557c7e4b,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=ab11dd8a-0fd9-4013-89ab-e114557c7e4b&type=display
280,DELAFLOXACIN MEGLUMINE,"1. **Cardiotoxicity Risk Mentioned in the Drug Label:**
   - The drug label does not specifically mention cardiotoxicity risks associated with BAXDELA.

2. **Cardiotoxicity Reactions Mentioned in the Drug Label:**
   - The drug label does not list any cardiotoxicity reactions or adverse effects directly attributed to BAXDELA.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",fb77637a-88d9-4aea-958f-e270030ce30d,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fb77637a-88d9-4aea-958f-e270030ce30d&type=display
281,DEMECLOCYCLINE HYDROCHLORIDE,"1. The drug label does not mention any specific cardiotoxicity risks associated with demeclocycline hydrochloride tablets.
2. The drug label does not mention any cardiotoxicity reactions caused by demeclocycline hydrochloride tablets.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",645af8f4-0843-4afb-9ddc-f587f38adb68,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=645af8f4-0843-4afb-9ddc-f587f38adb68&type=display
282,DEOXYCHOLIC ACID,"1. The drug KYBELLA is a cytolytic drug indicated for improving the appearance of submental fat in adults. The safe and effective use of KYBELLA for subcutaneous fat outside the submental region has not been established and is not recommended. (No direct mention of cardiotoxicity risk)

2. KYBELLA should be administered by a healthcare professional, and caution should be exercised in patients with excessive skin laxity or prior surgical treatments in the submental area. (No direct mention of cardiotoxicity risk)

3. KYBELLA is a clear, colorless, sterile solution supplied in 2 mL vials for single patient use, with each milliliter containing 10 mg of deoxycholic acid. (No direct mention of cardiotoxicity risk)

4. KYBELLA is contraindicated in the presence of infection at the injection sites. (No direct mention of cardiotoxicity risk)

5. Cases of marginal mandibular nerve injury, dysphagia, submental hematoma/bruising, and injection site ulceration, necrosis, and infection have been reported with the administration of KYBELLA. (No direct mention of cardiotoxicity risk)

6. Injection site ulceration, necrosis, and infection have been reported with the administration of KYBELLA, with some cases requiring intravenous antibiotic treatment and incision and drainage. (No direct mention of cardiotoxicity risk)

7. KYBELLA does not prolong the QTc interval at therapeutic doses. (No direct mention of cardiotoxicity risk)

8. Long-term studies in animals have not been performed to evaluate the carcinogenic potential of KYBELLA. (No direct mention of cardiotoxicity risk)

9. KYBELLA was negative in genetic toxicology assays, and no effects on fertility were observed in animal studies. (No direct mention of cardiotoxicity risk)

10. No evidence of fetal harm was observed in animal studies with deoxycholic acid, the active ingredient in KYBELLA, at doses up to 5 times the maximum recommended human dose. (No direct mention of cardiotoxicity risk)",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",fe431ed4-ea6f-4e99-b4bc-ec25ae7b8553,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fe431ed4-ea6f-4e99-b4bc-ec25ae7b8553&type=display
283,DESIPRAMINE HYDROCHLORIDE,"1. The drug label mentions that there have been reports of sudden death in children treated with Norpramin, indicating a potential association between the drug and cardiotoxicity risks in pediatric patients.

2. Additionally, the label states that there was a report of an ""acute collapse"" and ""sudden death"" in an 8-year-old male treated with Norpramin for hyperactivity, suggesting a potential link between the drug and cardiotoxic reactions in children.

3. The label also highlights that there have been additional reports of sudden death in children taking Norpramin, further suggesting a potential association between the drug and cardiotoxicity risks in pediatric patients.

4. Furthermore, the label mentions that critical manifestations of overdose with Norpramin include cardiac dysrhythmias, severe hypotension, and CNS depression, including coma, indicating that the drug itself can lead to cardiotoxic reactions in cases of overdose.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",70b562ea-9f21-4e4a-b3ed-0590b2892f6a,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=70b562ea-9f21-4e4a-b3ed-0590b2892f6a&type=display
284,DESLORATADINE,"1. The drug CLARINEX (desloratadine) is a histamine-1 (H1) receptor antagonist used for seasonal allergic rhinitis, perennial allergic rhinitis, and chronic idiopathic urticaria. It is indicated for patients 2 years of age and older. (No mention of cardiotoxicity risk associated with the drug itself)

2. In clinical trials, CLARINEX did not show any clinically relevant adverse events related to cardiotoxicity in adult and adolescent patients with allergic rhinitis. (No cardiotoxicity risk associated with the drug itself)

3. The drug label mentions that desloratadine, the active ingredient in CLARINEX, did not readily cross the blood-brain barrier based on animal studies. (No cardiotoxicity risk associated with the drug itself)

4. In a study with normal male and female volunteers, CLARINEX did not cause any clinically relevant adverse events related to cardiotoxicity when given at a dose of 45 mg daily for 10 days. (No cardiotoxicity risk associated with the drug itself)

5. The drug label states that desloratadine and its metabolite are not eliminated by hemodialysis in case of overdose. (No cardiotoxicity risk associated with the drug itself)

6. The drug label mentions that desloratadine did not cause any clinically relevant effects on the QT interval in a study with normal male and female volunteers. (No cardiotoxicity risk associated with the drug itself)

7. The drug label does not report any cardiotoxicity reactions related to CLARINEX in clinical trials or post-marketing experience. (No cardiotoxicity risk associated with the drug itself)

In summary, based on the information provided in the drug label, there is no indication that CLARINEX (desloratadine) is associated with cardiotoxicity risks or cardiotoxicity reactions.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",c671342e-69a2-4ca5-abc2-8166ed4240d4,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=c671342e-69a2-4ca5-abc2-8166ed4240d4&type=display
285,DESMOPRESSIN ACETATE,"1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with NOCDURNA (desmopressin acetate) itself. 

2. The label primarily focuses on the warning of hyponatremia as a severe adverse effect, which can be life-threatening. However, hyponatremia is not directly linked to cardiotoxicity but rather to electrolyte imbalances.

3. While the drug label emphasizes the importance of monitoring serum sodium levels and the risk of fluid retention, there is no direct mention of cardiotoxicity risks or reactions related to the cardiovascular system.

4. Overall, the drug label does not indicate any direct association between NOCDURNA and cardiotoxicity risks or reactions. The main concern highlighted is the potential for hyponatremia, which is not a cardiotoxic effect but rather a metabolic imbalance.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",cf51914a-55df-4b4a-8ea8-c7af257c1d59,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=cf51914a-55df-4b4a-8ea8-c7af257c1d59&type=display
286,DESVENLAFAXINE,"1. **Elevated Blood Pressure**: Desvenlafaxine was associated with increases in blood pressure observed in clinical studies. Pre-existing hypertension should be controlled before initiating treatment with desvenlafaxine. Cases of elevated blood pressure requiring immediate treatment have been reported with desvenlafaxine. Sustained blood pressure increases could have adverse consequences. For patients who experience a sustained increase in blood pressure while receiving desvenlafaxine, either dose reduction or discontinuation should be considered.

2. **Increased Risk of Bleeding**: Desvenlafaxine may increase the risk of bleeding events. Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs, warfarin, and other anticoagulants may add to this risk. Case reports and epidemiological studies have demonstrated an association between use of drugs that interfere with serotonin reuptake and the occurrence of gastrointestinal bleeding. Inform patients about the increased risk of bleeding associated with the concomitant use of desvenlafaxine and antiplatelet agents or anticoagulants. Carefully monitor coagulation indices when initiating, titrating, or discontinuing desvenlafaxine in patients taking warfarin.

3. **Hyponatremia**: Desvenlafaxine may cause hyponatremia as a result of treatment. In many cases, this hyponatremia appears to be the result of the syndrome of inappropriate antidiuretic hormone secretion (SIADH). Elderly patients may be at greater risk of developing hyponatremia with desvenlafaxine. Discontinuation of desvenlafaxine should be considered in patients with symptomatic hyponatremia, and appropriate medical intervention should be instituted. Signs and symptoms of hyponatremia include headache, difficulty concentrating, memory impairment, confusion, weakness, and unsteadiness, which can lead to falls. Signs and symptoms associated with more severe and/or acute cases have included hallucination, syncope, seizure, coma, respiratory arrest, and death.

4. **Interstitial Lung Disease and Eosinophilic Pneumonia**: Venlafaxine, the parent drug of desvenlafaxine, has been rarely associated with interstitial lung disease and eosinophilic pneumonia. The possibility of these adverse events should be considered in patients treated with desvenlafaxine who present with progressive dyspnea, cough, or chest discomfort. Such patients should undergo a prompt medical evaluation, and discontinuation of desvenlafaxine should be considered.",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",91cf39c9-4d26-480a-a3a3-a3d8d4c4d222,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=91cf39c9-4d26-480a-a3a3-a3d8d4c4d222&type=display
287,DESVENLAFAXINE SUCCINATE,"1. **Elevated Blood Pressure**: Patients receiving PRISTIQ should have regular monitoring of blood pressure since increases in blood pressure were observed in clinical studies. The drug itself was associated with elevated blood pressure, and cases of elevated blood pressure requiring immediate treatment have been reported with PRISTIQ.

2. **Increased Risk of Bleeding**: Drugs that interfere with serotonin reuptake inhibition, including PRISTIQ, may increase the risk of bleeding events. The drug itself was associated with an increased risk of bleeding events, and concomitant use of aspirin, nonsteroidal anti-inflammatory drugs, warfarin, and other anticoagulants may add to this risk.

3. **Hyponatremia**: Hyponatremia may occur as a result of treatment with SSRIs and SNRIs, including PRISTIQ. The drug itself was associated with the risk of hyponatremia, and discontinuation of PRISTIQ should be considered in patients with symptomatic hyponatremia.",Less,No,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",0f43610c-f290-46ea-d186-4f998ed99fce,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=0f43610c-f290-46ea-d186-4f998ed99fce&type=display
288,DEUTETRABENAZINE,"1. AUSTEDO XR and AUSTEDO may prolong the QT interval, but the degree of QT prolongation is not clinically significant when administered within the recommended dosage range. The drug itself is associated with the risk of QT prolongation.

2. AUSTEDO XR and AUSTEDO should be avoided in patients with congenital long QT syndrome and in patients with a history of cardiac arrhythmias. Certain circumstances may increase the risk of torsade de pointes and/or sudden death in association with drugs that prolong the QTc interval. The drug itself is associated with the risk of torsade de pointes and sudden death in patients with specific cardiac conditions.

3. A potentially fatal symptom complex known as Neuroleptic Malignant Syndrome (NMS) has been reported with drugs that reduce dopaminergic transmission, although NMS has not been observed with AUSTEDO XR or AUSTEDO. The drug itself is not directly associated with causing Neuroleptic Malignant Syndrome (NMS).

4. AUSTEDO XR and AUSTEDO may cause parkinsonism in patients with Huntingtons disease or tardive dyskinesia. Parkinsonism has also been observed with other VMAT2 inhibitors. The drug itself is associated with the risk of causing parkinsonism in patients with specific conditions.

5. A reduction in AUSTEDO XR or AUSTEDO dose may be necessary when adding a strong CYP2D6 inhibitor in patients maintained on a stable dose of AUSTEDO XR or AUSTEDO. Concomitant use of strong CYP2D6 inhibitors has been shown to increase the systemic exposure to the active dihydro-metabolites of deutetrabenazine. The drug itself is associated with the risk of increased systemic exposure when used with strong CYP2D6 inhibitors.",Less,Yes,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",7ea3c60a-45c7-44cc-afc2-d87fa53993c0,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7ea3c60a-45c7-44cc-afc2-d87fa53993c0&type=display
289,DEXAMETHASONE,"1. The drug label does not mention any cardiotoxicity risks or reactions associated with OZURDEX itself.

2. OZURDEX is a corticosteroid indicated for various eye conditions, but there is no mention of cardiotoxicity risks or reactions in the label.

3. The drug label for OZURDEX does not include any information regarding cardiotoxicity risks or reactions related to the use of this medication.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",4b204f44-6e8a-4d17-803c-268f0b04679f,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=4b204f44-6e8a-4d17-803c-268f0b04679f&type=display
290,DEXCHLORPHENIRAMINE MALEATE,"1. The drug label mentions that dexchlorpheniramine maleate, the active ingredient in RYCLORA Oral Solution, has anticholinergic (drying) and sedative side effects, but it does not directly associate these effects with cardiotoxicity risk.

2. The label warns that antihistamines, including dexchlorpheniramine maleate, should be used with caution in patients with certain cardiovascular conditions such as symptomatic prostatic hypertrophy and hypertension, suggesting a potential risk of cardiotoxicity associated with these conditions when using the drug.

3. Under the adverse reactions section, the label lists cardiovascular system reactions such as hemolytic anemia, thrombocytopenia, and agranulocytosis, which are serious conditions that can impact the heart and blood vessels. These reactions suggest a potential risk of cardiotoxicity associated with the use of dexchlorpheniramine maleate.

4. Additionally, the label mentions that antihistamines like dexchlorpheniramine maleate may cause dizziness, sedation, and hypotension in elderly patients, which can have implications for cardiovascular health. This indicates a potential risk of cardiotoxicity in the elderly population using this drug.",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",aa4f80c9-e600-4bc0-8528-02a8162a36f0,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=aa4f80c9-e600-4bc0-8528-02a8162a36f0&type=display
291,DEXMEDETOMIDINE HYDROCHLORIDE,"1. **Cardiotoxicity Risk**: The drug PRECEDEX has been associated with clinically significant episodes of bradycardia and sinus arrest, particularly in young, healthy adult volunteers with high vagal tone or with different routes of administration, such as rapid intravenous or bolus administration. (The drug itself is associated with the risk of bradycardia and sinus arrest.)

2. **Cardiotoxicity Reactions**: Reports of hypotension and bradycardia have been linked to PRECEDEX infusion, with some cases resulting in fatalities. Medical intervention may be necessary in such cases, including decreasing or stopping the infusion, increasing intravenous fluid administration, and using pressor agents. (The drug itself can lead to hypotension and bradycardia reactions.)

3. **Cardiotoxicity Risk**: PRECEDEX may induce transient hypertension, primarily during the loading dose, due to initial peripheral vasoconstrictive effects. Treatment of transient hypertension is generally not required, but reducing the loading infusion rate may be considered. (The drug itself is associated with the risk of transient hypertension.)

4. **Cardiotoxicity Reactions**: PRECEDEX has the potential to augment bradycardia induced by vagal stimuli, and clinicians should be prepared to intervene. In cases of bradycardia, intravenous administration of anticholinergic agents like glycopyrrolate or atropine may be considered. (The drug itself can exacerbate bradycardia induced by vagal stimuli.)

5. **Cardiotoxicity Risk**: Caution should be exercised when administering PRECEDEX to patients with advanced heart block and severe ventricular dysfunction, as hypotension and bradycardia may be more pronounced in such patients, especially those with hypovolemia, diabetes mellitus, chronic hypertension, or elderly patients. (The drug itself is associated with increased risk of hypotension and bradycardia in specific patient populations.)

6. **Cardiotoxicity Reactions**: In clinical trials, where other vasodilators or negative chronotropic agents were co-administered with PRECEDEX, no additive pharmacodynamic effects were observed. However, caution is advised when using such agents concomitantly with PRECEDEX. (The drug itself does not have additive effects when co-administered with other vasodilators or negative chronotropic agents.)

7. **Cardiotoxicity Risk**: PRECEDEX may induce hyperthermia or pyrexia, which could be resistant to traditional cooling methods. If drug-related hyperthermia is suspected, discontinuation of PRECEDEX is recommended, with close monitoring until body temperature normalizes. (The drug itself is associated with the risk of inducing hyperthermia or pyrexia.)

In summary, PRECEDEX carries cardiotoxicity risks such as bradycardia, sinus arrest, hypotension, and transient hypertension, which can necessitate medical intervention. The drug itself can lead to these cardiotoxic reactions, especially in specific patient populations or under certain conditions.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",548a88c0-afda-427e-75ac-5af0cfa2224c,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=548a88c0-afda-427e-75ac-5af0cfa2224c&type=display
292,DEXMETHYLPHENIDATE HYDROCHLORIDE,"1. Focalin has a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including Focalin, can result in overdose and death. This risk is increased with higher doses or unapproved methods of administration, such as snorting or injection. (Focalin itself is associated with the risk of abuse and misuse leading to potential cardiotoxicity.)

2. Sudden death has been reported in patients with structural cardiac abnormalities or other serious cardiac disease who were treated with CNS stimulants at the recommended ADHD dosage. Avoid Focalin use in patients with known structural cardiac abnormalities, cardiomyopathy, serious cardiac arrhythmia, coronary artery disease, or other serious cardiac disease. (Focalin is associated with the risk of sudden death in patients with serious cardiac conditions.)

3. CNS stimulants cause an increase in blood pressure and heart rate. Monitor all Focalin-treated patients for hypertension and tachycardia. (Focalin is associated with increased blood pressure and heart rate as potential adverse effects.)

4. Exacerbation of preexisting psychosis and induction of a manic episode in patients with bipolar disorder are potential psychiatric adverse reactions of CNS stimulants like Focalin. Screen patients for risk factors before initiating treatment and consider discontinuing Focalin if new psychotic or manic symptoms occur. (Focalin is associated with the risk of exacerbating psychosis and inducing manic episodes in certain patients.)

5. Prolonged and painful erections, known as priapism, have been reported with methylphenidate use in both adult and pediatric male patients. Focalin-treated patients who develop abnormally sustained or frequent and painful erections should seek immediate medical attention. (Focalin is associated with the risk of priapism as a potential adverse reaction.)

6. CNS stimulants, including Focalin, are associated with peripheral vasculopathy, including Raynauds phenomenon. Careful observation for digital changes is necessary during treatment, and further clinical evaluation may be needed for patients who develop signs or symptoms of peripheral vasculopathy. (Focalin is associated with the risk of peripheral vasculopathy, including Raynaud's phenomenon.)

7. Focalin has been associated with long-term suppression of growth in pediatric patients. Closely monitor growth (height and weight) in pediatric patients, and interrupt treatment if growth is not as expected. (Focalin is associated with the risk of long-term growth suppression in pediatric patients.)

8. Reports of angle closure glaucoma and increased intraocular pressure have been associated with methylphenidate treatment. Prescribe Focalin to patients with open-angle glaucoma or abnormally increased intraocular pressure only if the benefit of treatment outweighs the risk. Closely monitor patients with a history of increased intraocular pressure or open-angle glaucoma. (Focalin is associated with the risk of angle closure glaucoma and increased intraocular pressure as potential adverse effects.)",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",7c552f11-e24a-4d9b-bb8d-be10c928eca8,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7c552f11-e24a-4d9b-bb8d-be10c928eca8&type=display
293,DEXRAZOXANE HYDROCHLORIDE,"1. The drug Dexrazoxane for Injection is indicated for reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin dose of 300 mg/m2 and who will continue to receive doxorubicin therapy to maintain tumor control. The drug itself is associated with reducing the risk of cardiomyopathy associated with doxorubicin administration.

2. Treatment with Dexrazoxane for Injection does not completely eliminate the risk of anthracycline-induced cardiac toxicity. Monitor cardiac function before and periodically during therapy to assess left ventricular ejection fraction (LVEF). In general, if test results indicate deterioration in cardiac function associated with doxorubicin, the benefit of continued therapy should be carefully evaluated against the risk of producing irreversible cardiac damage. The drug itself is associated with not completely eliminating the risk of anthracycline-induced cardiac toxicity.

3. Secondary malignancies such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) have been reported in studies of pediatric patients who have received Dexrazoxane for Injection in combination with chemotherapy. Dexrazoxane for Injection is not indicated for use in pediatric patients. Some adult patients who received Dexrazoxane for Injection in combination with anti-cancer agents known to be carcinogenic have also developed secondary malignancies, including AML and MDS. The drug itself is associated with the risk of secondary malignancies when used in combination with certain chemotherapy regimens.

4. Dexrazoxane for Injection can cause fetal harm when administered to pregnant women. Dexrazoxane administration during the period of organogenesis resulted in maternal toxicity, embryotoxicity, and teratogenicity in rats and rabbits at doses significantly lower than the clinically recommended dose. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus. The drug itself is associated with causing fetal harm when administered to pregnant women.",Less,Yes,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",848cbcaf-2362-4da2-ae5c-9179aee21c0b,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=848cbcaf-2362-4da2-ae5c-9179aee21c0b&type=display
294,DEXTRAN 40,"1. The drug label mentions that severe and fatal anaphylactoid reactions, including marked hypotension or cardiac and respiratory arrest, have been reported, with most reactions occurring in patients not previously exposed to intravenous dextran. The drug itself is not directly associated with cardiotoxicity risk but can lead to severe reactions that may include cardiac arrest.

2. The label also warns about anaphylactoid reactions associated with Dextran 40 and Dextran 70 administration, recommending the administration of Dextran 1 prior to infusion of Dextran 40 or Dextran 70 to reduce the likelihood of severe reactions. The drug itself is not directly linked to cardiotoxicity but can lead to anaphylactoid reactions that may include cardiac symptoms.

3. It is recommended that the infusion of intravenous dextran be stopped at the first sign of an allergic reaction, with resuscitative measures readily available in case of circulatory collapse due to anaphylaxis. The drug itself is not a direct cause of cardiotoxicity but can lead to severe reactions that may result in circulatory collapse and cardiac issues.

4. The label cautions that administering infusions of the drug exceeding the recommended dose should be avoided, as it may lead to wound hematoma, wound seroma, wound bleeding, distant bleeding, and pulmonary edema. Excessive doses may precipitate renal failure, and recommended doses should never be exceeded in patients with advanced renal disease. The drug itself is not directly associated with cardiotoxicity but can lead to complications such as pulmonary edema, which can impact cardiac function.

5. The label mentions that dextran may interfere with platelet function and should be used with caution in cases of thrombocytopenia, as transient prolongation of bleeding time and increased bleeding tendency may occur with higher doses. Care should be taken to prevent a depression of hematocrit below 30% by volume. The drug itself is not directly linked to cardiotoxicity but can affect platelet function, potentially leading to bleeding complications that may indirectly impact cardiac health.",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",3c273512-84e2-2cea-b201-12345a6bd1fe,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=3c273512-84e2-2cea-b201-12345a6bd1fe&type=display
295,DEXTROAMPHETAMINE SULFATE,"1. The drug label warns that DEXEDRINE has a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including DEXEDRINE, can result in overdose and death, with an increased risk with higher doses or unapproved methods of administration, such as snorting or injection. The drug itself is associated with the risk of overdose and death due to misuse and abuse.

2. Sudden death has been reported in patients with structural cardiac abnormalities or other serious cardiac disease who are treated with CNS stimulants at recommended ADHD dosages. The drug label advises avoiding DEXEDRINE use in patients with known structural cardiac abnormalities, cardiomyopathy, serious cardiac arrhythmia, coronary artery disease, or other serious cardiac disease. The drug itself is associated with the risk of sudden death in patients with pre-existing serious cardiac conditions.

3. CNS stimulants cause an increase in blood pressure and heart rate. The drug label recommends monitoring all patients for potential tachycardia and hypertension. The drug itself is associated with the risk of elevated blood pressure and heart rate.

4. The drug label mentions that there have been isolated reports of cardiomyopathy associated with chronic amphetamine use. The drug itself is associated with the risk of cardiomyopathy in some cases of chronic use.

5. The drug label also notes that cardiovascular effects of overdose of CNS stimulants include tachyarrhythmias, hypertension or hypotension, vasospasm, myocardial infarction, or aortic dissection, which may lead to sudden cardiac death. The drug itself is associated with the risk of cardiovascular effects in cases of overdose.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",cc717b9b-22ea-4c60-a1d4-ee38a40bce78,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=cc717b9b-22ea-4c60-a1d4-ee38a40bce78&type=display
296,DEXTROSE,"1. The drug label warns that the administration of intravenous solutions, including Dextrose Injections USP, can lead to fluid and/or solute overload, potentially resulting in dilution of serum electrolyte concentrations, overhydration, congested states, or pulmonary edema. The risk of dilutional states is inversely proportional to the electrolyte concentration. (The drug itself is not directly associated with cardiotoxicity but can lead to conditions that may pose cardiotoxic risks.)

2. Dextrose Injection USP contains aluminum, which may be toxic, especially with prolonged parenteral administration in patients with impaired kidney function. Premature neonates are particularly at risk due to their immature kidneys. Accumulation of aluminum at levels associated with central nervous system and bone toxicity may occur with prolonged infusion. (The drug itself is not directly cardiotoxic but contains an ingredient, aluminum, that can lead to cardiotoxic effects in certain populations.)

3. Prolonged infusion of isotonic or hypotonic dextrose in water may increase the volume of extracellular fluid and cause water intoxication. (The drug itself is not directly associated with cardiotoxicity but can lead to water intoxication, which may have cardiotoxic effects.)

4. Excessive administration of potassium-free dextrose solutions may result in significant hypokalemia. Serum potassium levels should be monitored and potassium supplemented as required. (The drug itself is not directly cardiotoxic but can lead to hypokalemia, which may have cardiotoxic effects.)

5. In very low birth weight infants, excessive or rapid administration of dextrose injection may result in increased serum osmolality and possible intracerebral hemorrhage. (The drug itself is not directly associated with cardiotoxicity but can lead to increased serum osmolality, which may have cardiotoxic effects in very low birth weight infants.)",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",085614c7-ada4-4e2c-87c0-c9bc2f18365a,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=085614c7-ada4-4e2c-87c0-c9bc2f18365a&type=display
297,DIATRIZOATE MEGLUMINE,"1. The drug label does not mention any direct association of Cystografin Dilute (Diatrizoate Meglumine Injection USP 18%) with cardiotoxicity risks or reactions.

2. The label does not indicate any specific cardiotoxicity risks or reactions related to the use of Cystografin Dilute.

3. Cardiotoxicity is not listed as a known risk or reaction associated with the administration of Cystografin Dilute.

Overall, the drug label does not mention any cardiotoxicity risks or reactions linked to the use of Cystografin Dilute.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",e56882fa-4a30-43b1-bb6b-f7d4a4101c4e,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=e56882fa-4a30-43b1-bb6b-f7d4a4101c4e&type=display
298,DIAZEPAM,"1. The drug label does not specifically mention cardiotoxicity risks or reactions associated with the drug LIBERVANT (diazepam).

2. The drug label primarily focuses on risks related to CNS depression, abuse, misuse, addiction, dependence, withdrawal reactions, suicidal behavior, glaucoma, neonatal sedation, and benzyl alcohol preservative in neonates.

3. While the label does not directly link LIBERVANT to cardiotoxicity risks or reactions, it is essential to consult healthcare providers for comprehensive information on potential adverse effects, including any cardiotoxicity concerns.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",12527569-8eb3-4624-b3c0-5c0e0c5f88c9,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=12527569-8eb3-4624-b3c0-5c0e0c5f88c9&type=display
299,DIAZOXIDE,"1. The drug label warns that the antidiuretic property of diazoxide may lead to significant fluid retention, which could precipitate congestive heart failure in patients with compromised cardiac reserve. The fluid retention is expected to respond to conventional therapy with diuretics. (The drug itself is associated with the risk of fluid retention leading to congestive heart failure.)

2. The label mentions that sodium and fluid retention is most common in young infants and adults, potentially leading to congestive heart failure in patients with compromised cardiac reserve. It notes that sodium and fluid retention usually respond to diuretic therapy. (The drug itself is associated with the risk of sodium and fluid retention leading to congestive heart failure.)

3. The drug label also highlights that pulmonary hypertension has been reported in neonates and young infants treated with diazoxide. It advises monitoring patients, especially those with risk factors for pulmonary hypertension, for respiratory distress and discontinuing diazoxide if pulmonary hypertension is suspected. (The drug itself is associated with the risk of pulmonary hypertension in neonates and infants.)

4. Additionally, the label mentions that there have been postmarketing reports of pericardial effusion in patients without structural heart disease, with the majority of cases occurring in pediatric patients and infants. (The drug itself is associated with the risk of pericardial effusion in patients without structural heart disease, particularly in pediatric patients and infants.)",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",b16c7832-2fd9-49af-b923-1dc0d91fd6e2,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=b16c7832-2fd9-49af-b923-1dc0d91fd6e2&type=display
300,DICHLORPHENAMIDE,"1. The drug label does not specifically mention cardiotoxicity risks or cardiotoxicity reactions associated with KEVEYIS (dichlorphenamide) tablets.

2. There is no information provided in the drug label regarding any cardiotoxicity risks or reactions related to the use of KEVEYIS.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",d30a87b9-90fb-35b2-e053-2995a90aea2c,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=d30a87b9-90fb-35b2-e053-2995a90aea2c&type=display
301,DICLOFENAC,"1. The drug label warns that nonsteroidal anti-inflammatory drugs (NSAIDs), including ZORVOLEX, are associated with an increased risk of serious cardiovascular thrombotic events, such as myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with the duration of use. ZORVOLEX itself is associated with the risk of serious cardiovascular thrombotic events.

2. ZORVOLEX is contraindicated in patients who have undergone coronary artery bypass graft (CABG) surgery due to the increased risk of myocardial infarction and stroke associated with NSAID use. ZORVOLEX is directly linked to the risk of serious cardiovascular thrombotic events in this specific patient population.

3. The drug label advises that patients with a recent myocardial infarction (MI) should avoid using ZORVOLEX unless the benefits are expected to outweigh the risk of recurrent cardiovascular thrombotic events. Monitoring for signs of cardiac ischemia is recommended if ZORVOLEX is used in patients with a recent MI. ZORVOLEX is associated with an increased risk of serious cardiovascular thrombotic events in patients with a recent MI.

4. The label also mentions that observational studies have shown an increased risk of reinfarction, cardiovascular-related death, and all-cause mortality in patients treated with NSAIDs post-MI. The relative risk of death in NSAID users persists over several years post-MI. ZORVOLEX is associated with an increased risk of adverse cardiovascular events in post-MI patients.

In summary, ZORVOLEX is associated with an increased risk of serious cardiovascular thrombotic events, and caution is advised when using this drug in patients with a history of cardiovascular disease or recent myocardial infarction.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",dff10e66-a577-451d-ba75-1889458ca833,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=dff10e66-a577-451d-ba75-1889458ca833&type=display
302,DICLOFENAC POTASSIUM,"1. The drug label for CAMBIA highlights that non-steroidal anti-inflammatory drugs (NSAIDs), including diclofenac potassium, are associated with an increased risk of serious cardiovascular thrombotic events, such as myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with the duration of use. (The drug itself is associated with the cardiotoxicity risk.)

2. The label specifies that CAMBIA is contraindicated in the setting of coronary artery bypass graft (CABG) surgery due to the increased risk of cardiovascular thrombotic events. (The drug itself is associated with the cardiotoxicity risk.)

3. It is noted that patients with a recent myocardial infarction (MI) should avoid using CAMBIA unless the benefits are expected to outweigh the risk of recurrent cardiovascular thrombotic events. Monitoring for signs of cardiac ischemia is recommended if CAMBIA is used in patients with a recent MI. (The drug itself is associated with the cardiotoxicity risk.)

4. The label also mentions that observational studies have shown an increased risk of reinfarction, cardiovascular-related death, and all-cause mortality in patients treated with NSAIDs, including CAMBIA, in the post-MI period. (The drug itself is associated with the cardiotoxicity risk.)

5. Additionally, the label advises avoiding the use of CAMBIA in patients with severe heart failure unless the benefits are expected to outweigh the risk of worsening heart failure. Monitoring for signs of worsening heart failure is recommended if CAMBIA is used in patients with severe heart failure. (The drug itself is associated with the cardiotoxicity risk.)",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",d249ced1-4ca0-4f57-adcb-23440f58f659,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=d249ced1-4ca0-4f57-adcb-23440f58f659&type=display
303,DICLOXACILLIN SODIUM,"1. The drug label does not mention any specific cardiotoxicity risks associated with dicloxacillin sodium capsules.
2. The label does not indicate that dicloxacillin sodium capsules are associated with cardiotoxicity reactions.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",3e4842ec-773b-4aeb-b37d-1c4e3cf53424,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=3e4842ec-773b-4aeb-b37d-1c4e3cf53424&type=display
304,DICYCLOMINE HYDROCHLORIDE,"1. The drug BENTYL (dicyclomine hydrochloride) is associated with cardiotoxicity risks due to its anticholinergic effects, which can worsen cardiovascular conditions characterized by tachyarrhythmia, such as thyrotoxicosis, congestive heart failure, and in cardiac surgery, potentially accelerating heart rate. Investigating tachycardia before administration is recommended, especially in patients with coronary heart disease, hypertension, and unstable cardiovascular status in acute hemorrhage.

2. BENTYL's peripheral effects, resulting from its inhibitory effect on muscarinic receptors, can lead to cardiovascular symptoms like dry mouth, difficulty in swallowing and talking, thirst, dilated pupils, flushing, bradycardia followed by tachycardia, palpitations, arrhythmias, and constipation. These effects are dose-related and reversible upon discontinuation of the drug.

3. Heat prostration, a potential side effect of BENTYL use, can occur in high environmental temperatures, leading to fever and heat stroke due to decreased sweating. Caution is advised in patients with fever, and if symptoms occur, the drug should be stopped, and supportive measures should be taken.

4. Psychosis and delirium have been reported in sensitive individuals, such as elderly patients and those with mental illness, when given anticholinergic drugs like BENTYL. These central nervous system symptoms usually resolve within 12 to 24 hours after discontinuation of the drug.

5. Overdosing on BENTYL can lead to a curare-like action, causing neuromuscular blockade, muscular weakness, and possible paralysis, particularly in patients with myasthenia gravis. The drug should be used cautiously in these patients to reduce adverse muscarinic effects of an anticholinesterase.

6. BENTYL should be avoided in patients with severe ulcerative colitis due to the risk of suppressing intestinal motility, potentially leading to paralytic ileus and worsening toxic megacolon. Caution is advised in patients with ulcerative colitis to prevent serious complications.

7. Patients with prostatic hypertrophy should use BENTYL cautiously as the drug may exacerbate urinary retention. Monitoring for this adverse effect is recommended during treatment.

8. Patients with hepatic and renal disease should use BENTYL with caution due to potential risks associated with impaired hepatic and renal function. Monitoring these patients for adverse reactions is essential during treatment.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",c56598d5-9cd1-4cce-b172-ac338775aec7,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=c56598d5-9cd1-4cce-b172-ac338775aec7&type=display
305,DIDANOSINE,"1. Didanosine delayed-release capsules have been associated with lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, when used alone or in combination with other antiretrovirals. Fatal lactic acidosis has been reported in pregnant women who received the combination of didanosine and stavudine, indicating a direct association of the drug with cardiotoxicity risk.

2. Patients treated with didanosine delayed-release capsules in combination with stavudine may be at increased risk for pancreatitis, which can lead to fatal outcomes. The frequency of pancreatitis is dose-related, suggesting a potential causal relationship between the drug and cardiotoxicity reactions.

3. Didanosine delayed-release capsules should be used with extreme caution in patients with risk factors for pancreatitis, especially in those with advanced HIV-1 infection or renal impairment, as they may be at greater risk for developing pancreatitis. This highlights the importance of monitoring patients closely for signs and symptoms of pancreatitis to prevent cardiotoxicity reactions associated with the drug.

4. The safety and efficacy of didanosine delayed-release capsules have not been established in HIV-infected patients with significant underlying liver disease. Patients with preexisting liver dysfunction, including chronic active hepatitis, may have an increased frequency of liver function abnormalities, including severe and potentially fatal hepatic adverse events. This suggests a potential risk of cardiotoxicity reactions in patients with liver disease when using the drug.

5. Postmarketing cases of non-cirrhotic portal hypertension, including cases leading to liver transplantation or death, have been reported in patients receiving didanosine. Onset of signs and symptoms ranged from months to years after starting didanosine therapy, indicating a potential delayed cardiotoxicity reaction associated with the drug.

6. Didanosine delayed-release capsules should be discontinued in patients with evidence of non-cirrhotic portal hypertension, emphasizing the need for close monitoring and prompt action to prevent further cardiotoxicity risks.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",829e744d-7bd4-43dc-9b58-ffb016cb8e67,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=829e744d-7bd4-43dc-9b58-ffb016cb8e67&type=display
306,DIETHYLPROPION HYDROCHLORIDE ER,"1. The drug label mentions that the use of anorectic agents, including diethylpropion, was associated with an increased risk of developing pulmonary hypertension, a rare but often fatal disorder. The label states that the use of anorectic agents for longer than 3 months was associated with a 23-fold increase in the risk of developing pulmonary hypertension. This indicates that the drug itself is associated with an increased risk of pulmonary hypertension.

2. The label also warns that valvular heart disease has been reported with some anorectic agents like fenfluramine and dexfenfluramine, and although valvulopathy has been rarely reported with diethylpropion monotherapy, the causal relationship remains uncertain. This suggests that while the drug itself may not be definitively linked to valvular heart disease, caution is advised due to the potential risk.

3. It further mentions that the potential risk of serious adverse effects such as valvular heart disease and pulmonary hypertension should be carefully assessed against the potential benefit of weight loss. Baseline cardiac evaluation is recommended to detect preexisting valvular heart diseases or pulmonary hypertension before starting diethylpropion treatment. This indicates that the drug itself may pose risks of cardiotoxicity, and careful evaluation is necessary.

4. The label advises that diethylpropion should be discontinued if symptoms like exertional dyspnea, angina pectoris, syncope, or lower extremity edema occur, as these could indicate the possibility of pulmonary hypertension. This suggests that the drug itself may lead to cardiotoxicity reactions that require immediate discontinuation.

5. Additionally, the label states that diethylpropion may increase the risk of cardiovascular effects such as tachycardia, arrhythmias, hypertension, and circulatory collapse in cases of overdose. This indicates that the drug itself can lead to acute cardiotoxicity in cases of overdose.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",46d9dd37-a8c4-4c01-e054-00144ff8d46c,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=46d9dd37-a8c4-4c01-e054-00144ff8d46c&type=display
307,DIFELIKEFALIN,1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with KORSUVA (difelikefalin) injection.,No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",0c7b81f2-0fd3-47cb-8b0f-185e07f19c87,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=0c7b81f2-0fd3-47cb-8b0f-185e07f19c87&type=display
308,DIFLUNISAL,"1. The drug label states that nonsteroidal anti-inflammatory drugs (NSAIDs), including diflunisal tablets, are associated with an increased risk of serious cardiovascular thrombotic events, such as myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use. (The drug itself is associated with the cardiotoxicity risk.)

2. Diflunisal tablets are contraindicated in the setting of coronary artery bypass graft (CABG) surgery due to the increased risk of cardiovascular thrombotic events. (The drug itself is associated with the cardiotoxicity risk.)

3. The label also mentions that diflunisal tablets should be avoided in patients with a recent myocardial infarction (MI) unless the benefits outweigh the risk of recurrent cardiovascular thrombotic events. Patients with a recent MI should be monitored for signs of cardiac ischemia if using diflunisal tablets. (The drug itself is associated with the cardiotoxicity risk.)

4. Additionally, diflunisal tablets can lead to the onset of new hypertension or worsening of preexisting hypertension, which may contribute to an increased incidence of cardiovascular events. Patients with hypertension should be monitored closely during treatment with diflunisal tablets. (The drug itself is associated with the cardiotoxicity risk.)

5. The label warns that diflunisal tablets should be avoided in patients with severe heart failure unless the benefits outweigh the risk of worsening heart failure. Patients with severe heart failure should be monitored for signs of worsening heart failure if using diflunisal tablets. (The drug itself is associated with the cardiotoxicity risk.)

6. Diflunisal tablets should be used with caution in patients with heart failure and edema, as NSAIDs, including diflunisal, have been associated with an increased risk of hospitalizations for heart failure. Patients with heart failure should be monitored for signs of heart failure exacerbation while using diflunisal tablets. (The drug itself is associated with the cardiotoxicity risk.)",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",666f89b4-fd81-420a-a390-eb1cd4014f61,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=666f89b4-fd81-420a-a390-eb1cd4014f61&type=display
309,DIGOXIN,"1. LANOXIN is contraindicated in patients with ventricular fibrillation, indicating that the drug itself is associated with the risk of ventricular fibrillation.
2. LANOXIN may cause severe sinus bradycardia or sinoatrial block, particularly in patients with pre-existing sinus node disease, suggesting that the drug itself can cause these cardiotoxic reactions.
3. LANOXIN can lead to advanced or complete heart block in patients with pre-existing incomplete AV block, indicating that the drug itself can cause these cardiac conduction abnormalities.
4. Signs and symptoms of digoxin toxicity include cardiac arrhythmias, such as atrial tachycardia, AV dissociation, and ventricular arrhythmias, suggesting that LANOXIN can cause cardiotoxicity reactions.
5. LANOXIN may increase the risk of ventricular arrhythmias during electrical cardioversion, indicating that the drug itself can contribute to the development of ventricular arrhythmias.
6. LANOXIN is not recommended in patients with acute myocardial infarction due to the potential risk of increased myocardial oxygen demand and ischemia, suggesting that the drug itself may exacerbate cardiac ischemia.
7. LANOXIN should be avoided in patients with myocarditis to prevent vasoconstriction and the promotion of pro-inflammatory cytokines, indicating that the drug itself can worsen myocarditis-related complications.
8. LANOXIN may lead to decreased cardiac output in patients with preserved left ventricular systolic function, suggesting that the drug itself can impact cardiac function in certain heart failure conditions.
9. Hypocalcemia can nullify the effects of digoxin, indicating that LANOXIN may be ineffective in patients with low calcium levels, potentially due to altered cardiac response to the drug.
10. LANOXIN may have altered responses in patients with thyroid disorders and hypermetabolic states, suggesting that the drug's effects on the heart may vary in these conditions.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",d91e3646-4c63-4512-ab22-db39c085c4dc,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=d91e3646-4c63-4512-ab22-db39c085c4dc&type=display
310,DILTIAZEM HYDROCHLORIDE,"1. The drug Diltiazem Hydrochloride Injection is contraindicated in patients with sick sinus syndrome, second- or third-degree AV block without a functioning ventricular pacemaker, severe hypotension or cardiogenic shock, demonstrated hypersensitivity to the drug, and in patients with atrial fibrillation or atrial flutter associated with an accessory bypass tract such as in WPW syndrome or short PR syndrome. (The drug itself is associated with the cardiotoxicity risk.)

2. Diltiazem may cause hemodynamic deterioration and ventricular fibrillation if administered to patients with wide complex tachycardia of ventricular origin. It is important to distinguish wide complex QRS tachycardia of supraventricular origin from that of ventricular origin prior to diltiazem administration. (The drug itself is associated with the cardiotoxicity risk.)

3. Diltiazem prolongs AV nodal conduction and refractoriness, which may cause second- or third-degree AV block in sinus rhythm. Concomitant use of diltiazem with agents known to affect cardiac conduction may result in additive effects. If high-degree AV block occurs in sinus rhythm, diltiazem should be discontinued and appropriate supportive measures instituted. (The drug itself is associated with the cardiotoxicity risk.)

4. Diltiazem is a negative inotrope and can cause decreased systolic function and heart failure. It should not be initiated in patients with acute decompensated heart failure or cardiogenic shock. If heart failure develops during diltiazem treatment, the drug should be discontinued, and heart failure should be treated appropriately. (The drug itself is associated with the cardiotoxicity risk.)

5. Diltiazem can cause symptomatic hypotension. Patients with low blood pressure at baseline and those on concomitant medications that decrease blood pressure, intravascular volume, or myocardial contractility are at increased risk for hypotension. (The drug itself is associated with the cardiotoxicity risk.)

6. Adverse reactions associated with diltiazem use include hypotension, arrhythmia, and other cardiovascular events such as asystole, atrial flutter, bradycardia, chest pain, congestive heart failure, ventricular arrhythmias, and ventricular tachycardia. (The drug itself is associated with the cardiotoxicity reactions.)",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",51ddc49b-f2b5-4e79-93f5-e236fb546a66,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=51ddc49b-f2b5-4e79-93f5-e236fb546a66&type=display
311,DIMENHYDRINATE,"1. The drug label mentions that dimenhydrinate should be used with caution in patients with conditions that might be aggravated by anticholinergic therapy, such as cardiac arrhythmias. This indicates that dimenhydrinate itself is associated with a cardiotoxicity risk due to its anticholinergic properties.

2. It is also noted that dimenhydrinate may cause tachycardia as an adverse reaction. This suggests that the drug itself can lead to cardiotoxicity reactions by potentially increasing heart rate.

3. Additionally, the label warns that dimenhydrinate may have an additive effect when used concomitantly with alcohol or other central nervous system depressants, which could impact cardiac function. This implies that dimenhydrinate can contribute to cardiotoxicity when combined with certain substances.",Less,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",bc71539e-1a33-4709-8a24-c2894e8dbc1c,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=bc71539e-1a33-4709-8a24-c2894e8dbc1c&type=display
312,DIMERCAPROL,"1. The drug label mentions that one of the consistent responses to Dimercaprol Injection USP is a rise in blood pressure accompanied by tachycardia, which is roughly proportional to the dose administered. This indicates that the drug itself is associated with cardiotoxicity risks, as it can lead to an increase in blood pressure and tachycardia.

2. It further states that doses larger than those recommended may cause other transitory signs and symptoms, including nausea, vomiting, headache, and various sensations in different body parts. These symptoms, including tachycardia, suggest that the drug itself can lead to cardiotoxic reactions when taken in excessive amounts.

3. The label also mentions that successful treatment with Dimercaprol Injection USP depends on beginning injections at the earliest possible moment and using adequate amounts at frequent intervals. This implies that the drug's cardiotoxicity risks are related to the dosage and timing of administration, highlighting the importance of proper dosing to minimize potential cardiotoxic effects.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",bee9a137-160f-47e8-a551-ca461ae4f51e,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=bee9a137-160f-47e8-a551-ca461ae4f51e&type=display
313,DIMETHYL FUMARATE,"1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with TECFIDERA (dimethyl fumarate) itself. 

2. The drug label primarily focuses on warnings and precautions related to anaphylaxis, angioedema, progressive multifocal leukoencephalopathy (PML), herpes zoster, lymphopenia, liver injury, flushing, and serious gastrointestinal reactions. 

3. While the label does not directly link TECFIDERA to cardiotoxicity risks or reactions, it is important to consult with a healthcare provider for a comprehensive understanding of potential side effects and risks associated with this medication.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",665d7e74-036c-5f68-5b67-ab84b9b49151,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=665d7e74-036c-5f68-5b67-ab84b9b49151&type=display
314,DIMETHYL SULFOXIDE,1. The drug label does not mention any cardiotoxicity risks or cardiotoxicity reactions associated with the use of RIMSO-50 (dimethyl sulfoxide) for intravesical instillation in the treatment of interstitial cystitis.,No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",58b25d79-78f2-4953-b0c6-61658dc4ef0d,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=58b25d79-78f2-4953-b0c6-61658dc4ef0d&type=display
315,DIPHENHYDRAMINE HYDROCHLORIDE,"1. The drug label mentions that diphenhydramine hydrochloride may cause hypotension, headache, palpitations, tachycardia, and extrasystoles as cardiovascular adverse reactions. The drug itself is associated with these cardiotoxicity risks.

2. Additionally, the label states that antihistamine overdosage reactions may vary from central nervous system depression to stimulation, with atropine-like signs and symptoms, dry mouth, fixed dilated pupils, flushing, and gastrointestinal symptoms. The drug itself is associated with these cardiotoxicity risks.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",62edde3d-b41b-40fc-ac18-b749035de831,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=62edde3d-b41b-40fc-ac18-b749035de831&type=display
316,DIPYRIDAMOLE,"1. **Cardiotoxicity Risk**: The drug label mentions that serious adverse reactions associated with the administration of intravenous Dipyridamole Injection have included cardiac death, fatal and non-fatal myocardial infarction, ventricular fibrillation, symptomatic ventricular tachycardia, stroke, transient cerebral ischemia, seizures, anaphylactoid reaction, and bronchospasm. The label indicates that these events have been reported with the administration of Dipyridamole Injection, suggesting that the drug itself is associated with cardiotoxicity risks.

2. **Cardiotoxicity Reactions**: The label further states that in a study of 3911 patients given intravenous dipyridamole as an adjunct to thallium myocardial perfusion imaging, serious adverse events reported included myocardial infarction (both fatal and non-fatal) and severe bronchospasm. The label emphasizes that although the incidence of these serious adverse events was small, the potential clinical information gained through the use of intravenous dipyridamole thallium imaging must be weighed against the risk to the patient. This suggests that the drug itself can lead to cardiotoxicity reactions, including myocardial infarction and severe bronchospasm.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",6093dcd9-82d2-414f-8507-eda22c14f626,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=6093dcd9-82d2-414f-8507-eda22c14f626&type=display
317,DIROXIMEL FUMARATE,"1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with VUMERITY (diroximel fumarate) itself. 

2. The label primarily focuses on warnings and precautions related to anaphylaxis, progressive multifocal leukoencephalopathy (PML), herpes zoster, lymphopenia, liver injury, flushing, and serious gastrointestinal reactions. 

3. While the label does not directly link VUMERITY to cardiotoxicity, it does emphasize monitoring for various adverse reactions and conditions that could impact overall health, including liver injury and gastrointestinal reactions. 

4. It is important for healthcare providers and patients to be aware of these potential risks and to promptly report any concerning symptoms to ensure safe and effective use of VUMERITY in the treatment of multiple sclerosis.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",2d74414f-6b83-4ea2-9a95-3cecabbce774,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=2d74414f-6b83-4ea2-9a95-3cecabbce774&type=display
318,DISOPYRAMIDE PHOSPHATE,"1. The drug Norpace (disopyramide phosphate) is associated with cardiotoxicity risks, including the potential to cause or worsen congestive heart failure, produce severe hypotension, and result in significant widening of the QRS complex. These effects are attributed to the drug's negative inotropic properties. Norpace should be used cautiously in patients with heart failure or hypotension, and discontinuation of the drug is recommended if these adverse effects occur.

2. Norpace has been linked to the prolongation of the Q-T interval, which can lead to worsening arrhythmias such as ventricular tachycardia and ventricular fibrillation. Patients who show Q-T prolongation greater than 25% may be at particular risk, and close monitoring is advised. Disopyramide phosphate, the active ingredient in Norpace, has been associated with torsade de pointes, a specific type of ventricular tachycardia.

3. The drug Norpace may also cause hypoglycemia in rare instances, particularly in patients with certain underlying conditions such as congestive heart failure, chronic malnutrition, or hepatic and renal diseases. Physicians are advised to monitor blood glucose levels carefully in these patients to prevent potential complications.

4. Norpace is contraindicated in patients with certain cardiac conditions, such as cardiogenic shock, preexisting second- or third-degree AV block without a pacemaker, and congenital Q-T prolongation, due to the risk of exacerbating these conditions. The drug itself can lead to the development of heart block, which may necessitate dosage adjustments or discontinuation of therapy.

5. In cases of Norpace overdose, symptoms such as cardiac arrhythmias, hypotension, and conduction disturbances can occur, potentially leading to asystole and death. Toxic plasma levels of disopyramide can result in excessive widening of the QRS complex and Q-T interval, further highlighting the drug's cardiotoxic effects. Prompt and aggressive treatment of overdosage is crucial, as there is no specific antidote for disopyramide phosphate toxicity.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",e2aa1642-d262-4520-bc6a-9fd3ad795677,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=e2aa1642-d262-4520-bc6a-9fd3ad795677&type=display
319,DISULFIRAM,"1. The drug label states that disulfiram is contraindicated in patients with severe myocardial disease or coronary occlusion, indicating that the drug itself is associated with a cardiotoxicity risk.

2. The label also mentions that severe reactions to disulfiram and alcohol ingestion may lead to cardiovascular collapse, arrhythmias, myocardial infarction, and acute congestive heart failure, suggesting that the drug can cause cardiotoxicity reactions.

3. Additionally, the label advises that disulfiram should be used with extreme caution in patients with certain conditions like diabetes mellitus, hypothyroidism, and hepatic cirrhosis, which may indicate an increased risk of cardiotoxicity associated with the drug in these patient populations.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",d3832a1a-a140-49c1-a7df-134fa81341e3,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=d3832a1a-a140-49c1-a7df-134fa81341e3&type=display
320,DIVALPROEX SODIUM,1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with Depakote ER.,No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",0dc024ce-efc8-4690-7cb5-639c728fccac,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=0dc024ce-efc8-4690-7cb5-639c728fccac&type=display
321,DOBUTAMINE,"1. The drug label mentions that dobutamine hydrochloride may cause a marked increase in heart rate or blood pressure, especially systolic pressure, with approximately 10% of adult patients experiencing rate increases of 30 beats/minute or more and about 7.5% having a 50-mm Hg or greater increase in systolic pressure. Usually, reduction of dosage reverses these effects. (The drug itself is associated with the risk of increased heart rate and blood pressure.)

2. The label also warns that dobutamine may precipitate or exacerbate ventricular ectopic activity, although it rarely causes ventricular tachycardia. (The drug itself is associated with the risk of ventricular ectopic activity.)

3. Additionally, the label mentions that dobutamine may cause reactions suggestive of hypersensitivity, including skin rash, fever, eosinophilia, and bronchospasm, and that it contains sodium bisulfite, which may cause allergic-type reactions such as anaphylaxis and asthmatic episodes in certain susceptible individuals. (The drug itself is associated with the risk of hypersensitivity reactions.)

4. The label advises that patients with atrial fibrillation are at risk of developing rapid ventricular response due to dobutamine's facilitation of atrioventricular conduction, and it recommends using a digitalis preparation in such cases. Patients with pre-existing hypertension may face an increased risk of developing an exaggerated pressure response. (The drug itself is associated with the risk of rapid ventricular response in atrial fibrillation and exaggerated pressure response in patients with hypertension.)

5. Furthermore, the label mentions that dobutamine has been associated with decreases in serum potassium concentrations, rarely leading to hypokalemic values. (The drug itself is associated with the risk of hypokalemia.)

6. In cases of overdose, dobutamine may cause toxicity due to excessive cardiac -receptor stimulation, leading to symptoms such as hypertension, tachyarrhythmias, myocardial ischemia, and ventricular fibrillation. Hypotension may result from vasodilation. (The drug itself is associated with the risk of cardiotoxicity in cases of overdose.)",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",85fb5ba6-3597-e09f-e053-2a91aa0aded5,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=85fb5ba6-3597-e09f-e053-2a91aa0aded5&type=display
322,DOCETAXEL ANHYDROUS,"1. **Cardiotoxicity Risk**: The drug label does not specifically mention cardiotoxicity risks associated with Docetaxel Injection.

2. **Cardiotoxicity Reactions**:
   - The drug label does not directly associate Docetaxel Injection with cardiotoxicity reactions.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",a0ec4bcc-93ea-4c41-a4b6-95ec19491807,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a0ec4bcc-93ea-4c41-a4b6-95ec19491807&type=display
323,DOFETILIDE,"1. TIKOSYN can cause serious ventricular arrhythmias, primarily Torsade de Pointes (TdP) type ventricular tachycardia, a polymorphic ventricular tachycardia associated with QT interval prolongation. (The drug itself is associated with the risk of serious ventricular arrhythmias.)

2. QT interval prolongation is directly related to dofetilide plasma concentration. Factors such as reduced creatinine clearance or certain dofetilide drug interactions will increase dofetilide plasma concentration. (The drug itself is associated with QT interval prolongation, which is related to its plasma concentration.)

3. The risk of TdP can be reduced by controlling the plasma concentration through adjustment of the initial dofetilide dose according to creatinine clearance and by monitoring the ECG for excessive increases in the QT interval. (The drug itself is associated with the risk of Torsade de Pointes, which can be reduced by controlling plasma concentration and monitoring ECG.)

4. Treatment with dofetilide must be started only in patients placed for a minimum of three days in a facility that can provide electrocardiographic monitoring and in the presence of personnel trained in the management of serious ventricular arrhythmias. (The drug itself requires specific monitoring and management due to the risk of serious ventricular arrhythmias.)

5. The majority of the episodes of TdP occurred within the first three days of TIKOSYN therapy. (The drug itself is associated with the occurrence of Torsade de Pointes, with most cases happening within the initial days of therapy.)

6. In the supraventricular arrhythmia population, the overall incidence of Torsade de Pointes was 0.8%. (The drug itself is associated with the occurrence of Torsade de Pointes in patients with supraventricular arrhythmias.)

7. The rate of TdP was reduced when patients were dosed according to their renal function. (The drug itself is associated with a reduced risk of Torsade de Pointes when dosed based on renal function.)

8. The presence of atrial fibrillation did not affect the outcome of TIKOSYN in terms of cardiotoxicity. (The drug itself is not affected by the presence of atrial fibrillation in terms of cardiotoxicity.)

9. Because of the small number of events, an excess mortality due to TIKOSYN cannot be ruled out with confidence in the pooled survival analysis of placebo-controlled trials in patients with supraventricular arrhythmias. (The drug itself may be associated with an increased risk of mortality in patients with supraventricular arrhythmias, although not conclusively ruled out.)

10. Dofetilide is metabolized to a small degree by the CYP3A4 isoenzyme of the cytochrome P450 system, and an inhibitor of this system could increase systemic dofetilide exposure. (The drug itself is associated with potential drug-drug interactions that may increase systemic exposure.)

11. More importantly, dofetilide is eliminated by cationic renal secretion, and three inhibitors of this process have been shown to increase systemic dofetilide exposure. (The drug itself is associated with potential drug-drug interactions that may increase systemic exposure due to inhibition of renal elimination.)

12. Hypokalemia or hypomagnesemia may occur with administration. (The drug itself is associated with the risk of hypokalemia or hypomagnesemia.)",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",02438044-d6a3-49e9-a1ac-3aad21ef2c8c,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=02438044-d6a3-49e9-a1ac-3aad21ef2c8c&type=display
324,DOLASETRON MESYLATE,"1. The drug ANZEMET, containing dolasetron mesylate, is associated with QT interval prolongation in a dose-dependent manner, potentially leading to Torsade de Pointes. This risk is mentioned in the drug label. The drug itself is associated with QT interval prolongation.

2. ANZEMET has been shown to cause dose-dependent prolongation of the PR and QRS interval, with reports of serious ventricular arrhythmias, including fatalities. The drug itself is associated with PR and QRS interval prolongation and serious ventricular arrhythmias.

3. Patients with underlying structural heart disease, preexisting conduction system abnormalities, elderly patients, and those taking certain medications are at particular risk for cardiac events when using ANZEMET. The drug itself is associated with an increased risk of cardiac events in specific patient populations.

4. ANZEMET has been reported to cause wide complex tachycardia, ventricular tachycardia, and ventricular fibrillation cardiac arrest following intravenous administration. The drug itself is associated with serious cardiac arrhythmias, including ventricular tachycardia and fibrillation.

5. Patients should be informed of the potential for serious cardiac arrhythmias, such as QT prolongation, heart block, and Torsade de Pointes, while using ANZEMET. The drug itself is associated with an increased risk of QT prolongation, heart block, and Torsade de Pointes.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",201b0eb8-4a1e-4e22-ab4b-addb642710d6,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=201b0eb8-4a1e-4e22-ab4b-addb642710d6&type=display
325,DOLUTEGRAVIR SODIUM,"1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with TIVICAY (dolutegravir) itself. 

2. The label does not indicate any direct association between TIVICAY and cardiotoxicity risks or reactions. 

3. There are no mentions of TIVICAY causing cardiotoxicity risks or reactions in the drug label. 

4. TIVICAY is not linked to any cardiotoxicity risks or reactions based on the information provided in the drug label. 

5. The drug label does not attribute any cardiotoxicity risks or reactions to TIVICAY.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",63df5af3-b8ac-4e76-9830-2dbb340af922,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=63df5af3-b8ac-4e76-9830-2dbb340af922&type=display
326,DONEPEZIL HYDROCHLORIDE,"1. **Cardiotoxicity Risk Associated with Donepezil (ADLARITY):**
   - The drug label mentions that cholinesterase inhibitors, including ADLARITY, may have vagotonic effects on the sinoatrial and atrioventricular nodes, potentially leading to bradycardia or heart block in patients with or without known underlying cardiac conduction abnormalities. Syncopal episodes have been reported in association with the use of donepezil. (The drug itself is associated with the risk of vagotonic effects on the heart nodes.)

2. **Cardiotoxicity Reactions Associated with Donepezil (ADLARITY):**
   - The drug label also notes that donepezil can cause vomiting, and patients should be observed closely for symptoms of active or occult gastrointestinal bleeding, especially those at increased risk for developing ulcers. (The drug itself is associated with the risk of gastrointestinal bleeding, which can have cardiotoxic effects.)

3. **Cardiotoxicity Risk Associated with Donepezil (ADLARITY):**
   - Cholinesterase inhibitors, including ADLARITY, should be prescribed with caution to patients with a history of asthma or obstructive pulmonary disease. (The drug itself is associated with the risk of exacerbating pulmonary conditions, which can have cardiotoxic effects.)

4. **Cardiotoxicity Reactions Associated with Donepezil (ADLARITY):**
   - The drug label mentions that cholinomimetics, including ADLARITY, are believed to have some potential to cause generalized convulsions, which can have cardiovascular implications. (The drug itself is associated with the risk of potentially causing convulsions, which can lead to cardiovascular complications.)

5. **Cardiotoxicity Risk Associated with Donepezil (ADLARITY):**
   - The drug label also states that cholinesterase inhibitors, including ADLARITY, are likely to exaggerate succinylcholine-type muscle relaxation during anesthesia, which can have implications for cardiac function. (The drug itself is associated with the risk of exaggerating muscle relaxation during anesthesia, which can affect cardiac function.)

In summary, the drug label for ADLARITY (donepezil transdermal system) highlights various cardiotoxicity risks and reactions associated with the use of the medication, emphasizing the importance of monitoring patients for potential cardiovascular effects during treatment.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",1cb44c65-00e8-4b5c-99c2-ad15173115a0,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=1cb44c65-00e8-4b5c-99c2-ad15173115a0&type=display
327,DOPAMINE HYDROCHLORIDE,"1. Dopamine HCl Injection is associated with the risk of cardiac arrhythmias, which may be caused by the drug itself. Patients should be closely monitored for arrhythmias while on this medication.

2. Abrupt discontinuation of Dopamine HCl Injection may lead to marked hypotension, a cardiotoxicity reaction. It is advised to gradually reduce the infusion rate while expanding blood volume with intravenous fluids to prevent this adverse effect.

3. Dopamine HCl Injection contains sodium metabisulfite, which can cause severe hypersensitivity reactions, including cardiac symptoms like anaphylaxis. This cardiotoxicity reaction may occur in susceptible individuals due to the drug's excipient.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",1f306ad2-3606-4525-5a8a-ce78f426c1a2,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=1f306ad2-3606-4525-5a8a-ce78f426c1a2&type=display
328,DORAVIRINE,"1. The drug label mentions that at a doravirine dose of 1200 mg, which provides approximately 4 times the peak concentration observed following the recommended dose of PIFELTRO, doravirine does not prolong the QT interval to any clinically relevant extent. (The drug itself was not associated with cardiotoxicity risk in this case.)

2. The drug label does not mention any specific cardiotoxicity risks or reactions associated with doravirine in the sections provided.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",76ce1f00-28c0-4314-bd2c-d473fe3d0970,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=76ce1f00-28c0-4314-bd2c-d473fe3d0970&type=display
329,DOXAPRAM HYDROCHLORIDE,"1. The drug label mentions that a pressor response may result following doxapram administration, with the pressor effect being more marked in hypovolemic states. This pressor response is due to improved cardiac output rather than peripheral vasoconstriction. (The drug itself is associated with the pressor response but does not directly cause cardiotoxicity.)

2. The label also notes that there may be various dysrhythmias as cardiovascular effects of doxapram, and patients receiving the drug should be monitored for disturbance of their cardiac rhythm. (The drug itself is associated with the potential for dysrhythmias but does not directly cause cardiotoxicity.)

3. Additionally, the label mentions that a mild to moderate increase in blood pressure is commonly noted with doxapram administration, which may be of concern in patients with severe cardiovascular diseases. (The drug itself is associated with an increase in blood pressure but does not directly cause cardiotoxicity.)

4. In the section on adverse reactions, the label lists variations in heart rate, lowered T-waves, arrhythmias (including ventricular tachycardia and ventricular fibrillation), chest pain, and tightness in the chest as potential cardiovascular adverse reactions to doxapram. (The drug itself is associated with the potential for arrhythmias and other cardiovascular adverse reactions but does not directly cause cardiotoxicity.)",Less,No,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",b8eb330a-a75b-46cb-b694-5be9327ed2eb,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=b8eb330a-a75b-46cb-b694-5be9327ed2eb&type=display
330,DOXEPIN HYDROCHLORIDE,"1. The drug SILENOR, containing doxepin, is not recommended for use in patients with untreated narrow angle glaucoma or severe urinary retention, indicating a potential risk of cardiotoxicity associated with these conditions. (Contraindications section)

2. In cases of critical overdose of doxepin, manifestations may include cardiac dysrhythmias, severe hypotension, and CNS depression leading to coma, suggesting a potential for cardiotoxic effects at high doses. (Overdosage section)

3. Electrocardiogram changes, particularly in QRS axis or width, are clinically significant indicators of tricyclic compound toxicity, including doxepin, which can manifest as cardiotoxic effects. (Overdosage section)",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",1bec1223-5239-4eb6-a9e8-62444106d2c0,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=1bec1223-5239-4eb6-a9e8-62444106d2c0&type=display
331,DOXERCALCIFEROL,"1. The drug HECTOROL may lead to hypercalcemia, which can result in cardiac arrhythmias and seizures, potentially requiring emergency attention. The risk of hypercalcemia may be increased when HECTOROL is used concomitantly with high dose calcium preparations, thiazide diuretics, or vitamin D compounds. Monitoring serum calcium levels before initiation and during treatment is recommended, with dose adjustments as necessary. (Associated risk of cardiotoxicity due to hypercalcemia with HECTOROL)

2. Hypercalcemia during HECTOROL treatment can increase the risk of digitalis toxicity, particularly in patients using digitalis compounds. Monitoring serum calcium levels and signs of digitalis toxicity is advised, with increased monitoring frequency when initiating or adjusting the dose of HECTOROL. (Associated risk of cardiotoxicity due to hypercalcemia with HECTOROL)

3. Anaphylaxis, including symptoms of angioedema, hypotension, chest discomfort, and cardiopulmonary arrest, has been reported in hemodialysis patients after receiving HECTOROL. Patients should be monitored for hypersensitivity reactions upon treatment initiation, and if a reaction occurs, HECTOROL should be discontinued and appropriate treatment provided. (Cardiotoxicity reactions associated with hypersensitivity to HECTOROL)

4. Adynamic bone disease may develop with HECTOROL use, potentially increasing the risk of fractures if intact parathyroid hormone levels are suppressed to abnormally low levels. Monitoring intact PTH levels is recommended to avoid oversuppression and adjust the dose if necessary. (No direct association with cardiotoxicity, but potential impact on bone health and fracture risk)",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",7efc3d9c-12f5-43f6-9a22-88d66cbe6f62,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7efc3d9c-12f5-43f6-9a22-88d66cbe6f62&type=display
332,DOXORUBICIN HYDROCHLORIDE,"1. Cardiotoxicity risk associated with Doxorubicin Hydrochloride: Myocardial damage, including acute left ventricular failure, can occur with doxorubicin hydrochloride. The risk of cardiomyopathy is proportional to the cumulative exposure, with incidence rates ranging from 1% to 20% for cumulative doses of 300 mg/m2 to 500 mg/m2 when doxorubicin hydrochloride is administered every 3 weeks.

2. Cardiotoxicity risk associated with Doxorubicin Hydrochloride: The risk of cardiomyopathy is further increased with concomitant cardiotoxic therapy. Assess left ventricular ejection fraction (LVEF) before and regularly during and after treatment with doxorubicin hydrochloride.

3. Cardiotoxicity reaction caused by Doxorubicin Hydrochloride: Cardiomyopathy may develop during treatment or up to several years after completion of treatment, leading to signs and symptoms of congestive heart failure (CHF). The probability of developing cardiomyopathy increases with cumulative doses of doxorubicin hydrochloride.

4. Cardiotoxicity risk associated with Doxorubicin Hydrochloride: Pericarditis and myocarditis have been reported during or following doxorubicin hydrochloride treatment, indicating potential cardiotoxic effects.

5. Cardiotoxicity risk associated with Doxorubicin Hydrochloride: There is an additive or potentially synergistic increase in the risk of cardiomyopathy in patients who have received radiotherapy to the mediastinum or concomitant therapy with other known cardiotoxic agents, such as cyclophosphamide and trastuzumab.

6. Cardiotoxicity reaction caused by Doxorubicin Hydrochloride: Arrhythmias, including life-threatening arrhythmias, can occur during or shortly after doxorubicin hydrochloride administration. Tachyarrhythmias, bradycardia, and electrocardiographic changes may manifest as adverse cardiotoxic reactions.

7. Cardiotoxicity risk associated with Doxorubicin Hydrochloride: The drug can increase radiation-induced toxicity to the myocardium, mucosa, skin, and liver, potentially leading to cardiotoxic effects.

8. Cardiotoxicity risk associated with Doxorubicin Hydrochloride: Radiation recall, including cutaneous and pulmonary toxicity, can occur in patients who receive doxorubicin hydrochloride after prior radiation therapy, indicating potential cardiotoxicity risks associated with the drug.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",1fd148fb-0fbc-4b6f-b790-23546fb46a71,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=1fd148fb-0fbc-4b6f-b790-23546fb46a71&type=display
333,DOXYCYCLINE,"1. The drug ORACEA (doxycycline) is associated with a risk of photosensitivity, which can manifest as an exaggerated sunburn reaction in some individuals. Patients are advised to minimize or avoid exposure to natural or artificial sunlight while using ORACEA. (The drug itself is associated with the risk of photosensitivity.)

2. Tetracyclines, including ORACEA, have been linked to the development of autoimmune syndromes, which may present with symptoms like fever, rash, arthralgia, and malaise. In symptomatic patients, all tetracycline-class drugs should be discontinued immediately. (The drug itself is associated with the risk of autoimmune syndromes.)

3. ORACEA may cause pseudotumor cerebri (benign intracranial hypertension), which can lead to symptoms like headache and blurred vision. Patients should be monitored for visual disturbances before and during treatment with tetracyclines. (The drug itself is associated with the risk of pseudotumor cerebri.)

4. Bacterial resistance to tetracyclines, including ORACEA, may develop in patients using the drug. It is emphasized that ORACEA should only be used as indicated to prevent the development of drug-resistant bacteria. (The drug itself is associated with the risk of bacterial resistance.)

5. ORACEA may lead to an increase in blood pressure, as indicated by the occurrence of hypertension as an adverse reaction in clinical trials. Patients should be aware of this potential effect while taking the medication. (The drug itself is associated with the risk of increased blood pressure.)

6. In clinical trials, some patients taking ORACEA experienced an increase in aspartate aminotransferase levels, indicating potential liver effects. Regular monitoring of liver function may be necessary during treatment with ORACEA. (The drug itself is associated with the risk of liver effects.)

7. ORACEA has not been evaluated for its effects on cardiac function or cardiotoxicity specifically in the drug label. No direct mention of cardiotoxicity risks or reactions related to the heart is provided in the drug label for ORACEA.",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",aa15c93a-ff4c-447a-8a21-96da506d8997,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=aa15c93a-ff4c-447a-8a21-96da506d8997&type=display
334,DOXYCYCLINE HYCLATE,"1. The drug label does not mention any specific cardiotoxicity risks associated with DORYX MPC (doxycycline hyclate delayed-release tablets).

2. The drug label does not attribute any cardiotoxicity reactions to the use of DORYX MPC (doxycycline hyclate delayed-release tablets). 

Overall, based on the information provided in the drug label, there are no mentions of cardiotoxicity risks or reactions associated with the use of DORYX MPC.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",f9277bb8-982d-444d-9325-35d5c53a2d35,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=f9277bb8-982d-444d-9325-35d5c53a2d35&type=display
335,DRONABINOL,"1. Hemodynamic Instability: Patients with cardiac disorders may experience hypotension, hypertension, syncope, or tachycardia while taking SYNDROS. The drug itself is associated with the risk of hemodynamic instability in patients with cardiac disorders.

2. Interaction with Disulfiram and Metronidazole: SYNDROS contains alcohol and propylene glycol, which can lead to a disulfiram-like reaction when co-administered with disulfiram or metronidazole. The drug itself is associated with the risk of a disulfiram-like reaction when used with certain medications.

3. Highly Protein-Bound Drugs: Dronabinol in SYNDROS is highly bound to plasma proteins, which may displace and increase the free fraction of other concomitantly administered protein-bound drugs, potentially leading to increased adverse reactions. The drug itself is associated with the risk of displacing other drugs from plasma proteins, potentially increasing adverse reactions.

4. Seizures and Seizure-like Activity: Seizures and seizure-like activity have been reported in patients receiving dronabinol, the active ingredient in SYNDROS. The drug itself is associated with the risk of seizures and seizure-like activity in patients.",Most,Yes,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",a7801c70-995d-46a2-91ee-141ef427c6b5,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a7801c70-995d-46a2-91ee-141ef427c6b5&type=display
336,DRONEDARONE,"1. **Cardiotoxicity Risk**: MULTAQ is contraindicated in patients with symptomatic heart failure with recent decompensation requiring hospitalization or NYHA Class IV heart failure, as it doubles the risk of death in these patients. (The drug is associated with the cardiotoxicity risk.)

2. **Cardiotoxicity Risk**: MULTAQ is contraindicated in patients in atrial fibrillation (AF) who will not or cannot be cardioverted into normal sinus rhythm, as it doubles the risk of death, stroke, and hospitalization for heart failure in patients with permanent AF. (The drug is associated with the cardiotoxicity risk.)

3. **Cardiotoxicity Reaction**: New onset or worsening heart failure has been reported during treatment with MULTAQ in the postmarketing setting. Patients are advised to consult a physician if they develop signs or symptoms of heart failure, such as weight gain, dependent edema, or increasing shortness of breath. If heart failure develops or worsens and requires hospitalization, MULTAQ should be discontinued. (The drug is associated with the cardiotoxicity reaction.)

4. **Cardiotoxicity Reaction**: MULTAQ is associated with concentration-dependent QTcF interval prolongation, and if the QTc interval is >500 ms, the drug should be discontinued. (The drug is associated with the cardiotoxicity reaction.)

5. **Cardiotoxicity Reaction**: Hepatocellular liver injury, including acute liver failure requiring transplant, has been reported in patients treated with MULTAQ in the postmarketing setting. Patients are advised to report symptoms suggesting hepatic injury promptly. If hepatic injury is suspected, MULTAQ should be discontinued. (The drug is associated with the cardiotoxicity reaction.)

6. **Cardiotoxicity Reaction**: Cases of interstitial lung disease, including pneumonitis and pulmonary fibrosis, have been reported in patients treated with MULTAQ in the postmarketing setting. If pulmonary toxicity is confirmed, the drug should be discontinued. (The drug is associated with the cardiotoxicity reaction.)",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",7fa41601-7fb5-4155-8e50-2ae903f0d2d6,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7fa41601-7fb5-4155-8e50-2ae903f0d2d6&type=display
337,DROPERIDOL,"1. The drug label warns that cases of QT prolongation and torsade de pointes have been reported in patients receiving droperidol at or below recommended doses. Some cases have occurred in patients with no known risk factors for QT prolongation, and some cases have been fatal. (The drug itself is associated with the cardiotoxicity risk.)

2. Droperidol should be reserved for patients who do not respond to other treatments due to the potential for serious proarrhythmic effects and death. Cases of QT prolongation and serious arrhythmias have been reported in patients treated with droperidol. (The drug itself is associated with the cardiotoxicity risk.)

3. Droperidol is contraindicated in patients with known or suspected QT prolongation, including those with congenital long QT syndrome. It should be administered with extreme caution to patients at risk for prolonged QT syndrome. (The drug itself is associated with the cardiotoxicity risk.)

4. Droperidol has been associated with a dose-dependent prolongation of the QT interval in patients without known cardiac disease. Cases of serious arrhythmias, including torsade de pointes, have been observed during post-marketing treatment with droperidol. (The drug itself is associated with the cardiotoxicity risk.)

5. All patients should undergo a 12-lead ECG prior to droperidol administration to determine if a prolonged QT interval is present. ECG monitoring should be performed before and after treatment in patients where the benefit of droperidol outweighs the risk of serious arrhythmias. (The drug itself is associated with the cardiotoxicity risk.)

6. Droperidol should be administered with extreme caution in the presence of risk factors for prolonged QT syndrome, such as bradycardia, cardiac disease, and electrolyte imbalances. (The drug itself is associated with the cardiotoxicity risk.)

7. Droperidol may cause hypotension, decreased peripheral vascular resistance, and other cardiovascular effects. Fluids and countermeasures to manage hypotension should be readily available. (The drug itself is associated with the cardiotoxicity risk.)

8. Droperidol has been associated with cases of QT interval prolongation, torsade de pointes, cardiac arrest, and ventricular tachycardia, some of which were fatal. Physicians should be alert to symptoms of irregular cardiac rhythm in patients taking droperidol. (The drug itself is associated with the cardiotoxicity risk.)

In summary, the drug label clearly outlines the cardiotoxicity risks associated with droperidol, including QT prolongation, torsade de pointes, and serious arrhythmias. It emphasizes the need for ECG monitoring, caution in patients with risk factors for prolonged QT syndrome, and the availability of measures to manage hypotension.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",147e033d-d997-4ef6-8bb5-a9ba372590b2,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=147e033d-d997-4ef6-8bb5-a9ba372590b2&type=display
338,DROSPIRENONE,"1. **Cardiotoxicity Risk**: SLYND contains drospirenone, a progestin, which has anti-mineralocorticoid activity, potentially leading to hyperkalemia in high-risk females, comparable to a 25 mg dose of spironolactone. The drug is contraindicated in females with conditions predisposing to hyperkalemia, such as renal impairment, hepatic impairment, and adrenal insufficiency. The drug itself is associated with the risk of hyperkalemia.

2. **Cardiotoxicity Reaction**: Most females with hyperkalemia in clinical studies of SLYND had mild potassium elevations or isolated increases that returned to normal while on the medication. No concurrent adverse reactions were attributed to hyperkalemia. In the pivotal trial, two females (0.2%) with persistent potassium elevations discontinued SLYND. The drug itself was associated with hyperkalemia as an adverse reaction.

3. **Cardiotoxicity Risk**: Epidemiological studies have not indicated an association between progestin-only preparations like SLYND and an increased risk of myocardial infarction, cerebral thromboembolism, or venous thromboembolism. However, combined oral contraceptives containing drospirenone and ethinyl estradiol may be associated with a higher risk of venous thromboembolism compared to other progestins. The drug itself is not directly linked to an increased risk of thromboembolic disorders.

4. **Cardiotoxicity Reaction**: Discontinuation of SLYND is recommended if arterial or venous thromboembolic events occur. Consider discontinuing the drug, if feasible, in cases of prolonged immobilization due to surgery or illness. The drug itself is associated with the risk of thromboembolic disorders as an adverse reaction.",Less,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",db32bc55-f295-4d87-9dbb-0a2f45573dcf,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=db32bc55-f295-4d87-9dbb-0a2f45573dcf&type=display
339,DROXIDOPA,"1. **Cardiotoxicity Risk**: NORTHERA may cause or exacerbate supine hypertension in patients with neurogenic orthostatic hypotension (nOH), potentially increasing cardiovascular risk if not well-managed. The drug itself is associated with the risk of supine hypertension, which can lead to cardiovascular events, particularly stroke.

2. **Cardiotoxicity Reaction**: NORTHERA may exacerbate existing ischemic heart disease, arrhythmias, and congestive heart failure. The drug itself is associated with the potential to worsen these conditions in patients who already have them. Careful consideration is advised before initiating therapy in such patients.

3. **Cardiotoxicity Reaction**: Postmarketing cases resembling neuroleptic malignant syndrome (NMS) have been reported with NORTHERA use, especially when dosage changes occur or when concomitant levodopa is reduced abruptly. NMS is a life-threatening syndrome characterized by fever, muscle rigidity, altered consciousness, and other symptoms. The drug itself is associated with the risk of NMS-like symptoms.

4. **Cardiotoxicity Reaction**: Allergic reactions, including anaphylaxis, angioedema, bronchospasm, urticaria, and rash, have been reported with NORTHERA use. Some reactions required emergency treatment. The drug itself is associated with the risk of allergic reactions, including severe ones that may require immediate intervention.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",2179f02c-48d7-48eb-8007-5ae43d8d16bc,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=2179f02c-48d7-48eb-8007-5ae43d8d16bc&type=display
340,DULOXETINE,"1. **Orthostatic Hypotension, Falls, and Syncope**: The drug label mentions that orthostatic hypotension, falls, and syncope have been reported in patients treated with the recommended dosage of DRIZALMA SPRINKLE. The drug itself is associated with the risk of orthostatic hypotension, falls, and syncope.

2. **Serotonin Syndrome**: The label states that serotonin-norepinephrine reuptake inhibitors (SNRIs) like DRIZALMA SPRINKLE can precipitate serotonin syndrome, a potentially life-threatening condition. The drug itself is associated with the risk of serotonin syndrome.

3. **Increased Risk of Bleeding**: The drug label mentions that drugs interfering with serotonin reuptake inhibition, including DRIZALMA SPRINKLE, may increase the risk of bleeding events. The drug itself is associated with an increased risk of bleeding events.",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",b41423b8-dfec-4d79-ba3c-e43a87803d85,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=b41423b8-dfec-4d79-ba3c-e43a87803d85&type=display
341,DUTASTERIDE,"1. In the CombAT trial, after 4 years of treatment, the incidence of the composite term cardiac failure in the combination therapy group was higher than in either monotherapy group, but no causal relationship between AVODART alone or in combination with tamsulosin and cardiac failure has been established. (The drug itself was not directly associated with cardiotoxicity risk.)

2. In a separate 4-year placebo-controlled trial evaluating AVODART in men at risk for prostate cancer, the incidence of cardiac failure in subjects taking AVODART was slightly higher compared to those on placebo, but the clinical significance of the numerical imbalances in cardiac failure is unknown. (The drug itself was not directly associated with cardiotoxicity risk.)

3. No imbalance was observed in the incidence of overall cardiovascular adverse events in either trial, suggesting that AVODART did not have a significant impact on cardiovascular health. (The drug itself was not directly associated with cardiotoxicity risk.)

Please note that while there were mentions of cardiac failure in relation to AVODART use, no direct causal relationship between the drug and cardiac failure was established in the provided drug label information.",Less,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",960797b3-09b1-4d6a-8ece-8b5d918e93e4,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=960797b3-09b1-4d6a-8ece-8b5d918e93e4&type=display
342,DUVELISIB,1. The drug label for COPIKTRA does not mention any specific cardiotoxicity risks or cardiotoxicity reactions associated with the use of this medication.,No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",47547f93-489c-4298-aeea-d6a37ca6cb1d,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=47547f93-489c-4298-aeea-d6a37ca6cb1d&type=display
343,EDARAVONE,"1. The drug RADICAVA, which contains the active ingredient edaravone, does not prolong the QT interval to any clinically relevant extent at exposures at least 5 times higher than the recommended doses, indicating no direct association with cardiotoxicity risk.

2. The drug RADICAVA ORS, an oral suspension of edaravone, demonstrated similar pharmacokinetics following administration via feeding tubes and oral administration, with no specific mention of cardiotoxicity risks associated with its use.

3. In animal studies, administration of edaravone to pregnant rats and rabbits resulted in adverse developmental effects, but no direct cardiotoxicity risks were mentioned in relation to pregnancy.

4. No age effect on edaravone pharmacokinetics has been found in geriatric patients, suggesting no specific cardiotoxicity risks associated with age-related changes.

5. No gender effect on edaravone pharmacokinetics has been found, indicating no gender-specific cardiotoxicity risks associated with the drug.

6. No significant racial differences in Cmax and AUC of edaravone between Japanese and Caucasian subjects were reported, suggesting no racial disparities in cardiotoxicity risks related to the drug.

7. The pharmacokinetics of edaravone are not expected to be significantly affected by inhibitors of cytochrome P450 enzymes, UGTs, or major transporters, indicating no direct cardiotoxicity risks associated with drug interactions.

8. In vitro studies demonstrated that edaravone and its metabolites are not expected to significantly inhibit CYP enzymes or induce CYP enzymes at the recommended dosage, suggesting no direct cardiotoxicity risks associated with metabolic interactions.",Less,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",0ce2c1c4-2a40-485c-b7cb-96a9b85d9d11,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=0ce2c1c4-2a40-485c-b7cb-96a9b85d9d11&type=display
344,EDETATE CALCIUM DISODIUM,"1. The drug label warns that Edetate Calcium Disodium injection is capable of producing toxic effects, including lead encephalopathy, which can be fatal. Lead encephalopathy may result in a lethal increase in intracranial pressure following intravenous infusion, particularly in pediatric patients, and the mortality rate in pediatric patients has been high. The intramuscular route is preferred for patients with lead encephalopathy, and caution should be taken to avoid rapid infusion if the intravenous route is necessary. (The drug itself is associated with the risk of lead encephalopathy and potential cardiotoxicity in pediatric patients.)

2. The label mentions that Edetate Calcium Disodium may produce renal damage similar to lead poisoning, such as proteinuria and microscopic hematuria. Treatment-induced nephrotoxicity is dose-dependent and may be reduced by ensuring adequate diuresis before therapy begins. Patients should be monitored for cardiac rhythm irregularities and other ECG changes during intravenous therapy. (The drug itself is associated with the risk of renal damage and potential cardiotoxicity.)

3. Adverse reactions associated with Edetate Calcium Disodium use include cardiovascular effects such as hypotension and cardiac rhythm irregularities. (The drug itself is associated with the risk of cardiovascular adverse reactions.)

4. In cases of overdosage, Edetate Calcium Disodium can aggravate symptoms of severe lead poisoning, leading to cerebral edema and renal tubular necrosis, which are associated with lead poisoning. Cerebral edema should be treated with repeated doses of mannitol, and monitoring of zinc levels is recommended. (The drug itself is associated with the risk of exacerbating symptoms of lead poisoning, which can lead to cardiotoxicity.)",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",710a2c8c-3620-4f6f-b8fc-fb19ab9e9f22,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=710a2c8c-3620-4f6f-b8fc-fb19ab9e9f22&type=display
345,EDOTREOTIDE GALLIUM GA-68,"1. Ga 68 DOTATOC Injection does not have any specific contraindications related to cardiotoxicity risks, as none are mentioned in the drug label.

2. The drug label does not mention any warnings or precautions related to cardiotoxicity risks associated with Ga 68 DOTATOC Injection.

3. There are no reported adverse reactions related to cardiotoxicity, such as arrhythmias or cardiac dysfunction, associated with Ga 68 DOTATOC Injection in the drug label.

Overall, based on the information provided in the drug label, Ga 68 DOTATOC Injection does not appear to be associated with cardiotoxicity risks or cardiotoxicity reactions.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",c4d185c3-d520-462d-ba50-4f4ee485ace3,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=c4d185c3-d520-462d-ba50-4f4ee485ace3&type=display
346,EDOXABAN TOSYLATE,"1. The drug label warns about the risk of reduced efficacy in nonvalvular atrial fibrillation patients with creatinine clearance (CrCL) > 95 mL/min when using SAVAYSA, stating that these patients had an increased rate of ischemic stroke with SAVAYSA 60 mg once daily compared to warfarin. SAVAYSA itself is associated with the increased risk of ischemic stroke in these patients.

2. Premature discontinuation of SAVAYSA increases the risk of ischemic events, emphasizing the importance of adequate alternative anticoagulation to prevent such events. SAVAYSA itself is associated with the risk of ischemic events upon premature discontinuation.

3. The drug label also highlights the risk of spinal/epidural hematoma in patients treated with SAVAYSA who are undergoing neuraxial anesthesia or spinal puncture, which may lead to long-term or permanent paralysis. SAVAYSA itself is associated with the risk of spinal/epidural hematoma in these specific medical procedures.",Less,No,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",e77d3400-56ad-11e3-949a-0800200c9a66,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=e77d3400-56ad-11e3-949a-0800200c9a66&type=display
347,EFAVIRENZ,"1. The drug label mentions that competition for CYP3A by efavirenz could result in inhibition of metabolism of certain drugs, potentially leading to serious and life-threatening adverse reactions like cardiac arrhythmias, prolonged sedation, or respiratory depression. (The drug itself is not directly associated with cardiotoxicity but can interact with other drugs that may cause cardiotoxic effects.)

2. It states that for some drugs, competition for CYP3A by efavirenz could result in inhibition of their metabolism, creating the potential for serious and/or life-threatening adverse reactions such as cardiac arrhythmias, prolonged sedation, or respiratory depression. (The drug itself is not directly linked to cardiotoxicity but can impact the metabolism of other drugs that may pose cardiotoxic risks.)

3. The drug label warns about the potential for serious psychiatric symptoms, including severe depression or suicidal ideation, which may require immediate medical evaluation. (This section does not specifically mention cardiotoxicity risks associated with the drug.)

4. It mentions that patients should be cautious with the use of efavirenz in combination with other medications that may have cardiotoxic effects, as the drug can alter the concentrations of other drugs and vice versa. (The drug itself is not directly associated with cardiotoxicity but can interact with other drugs that may pose cardiotoxic risks.)

5. The label does not directly link efavirenz to cardiotoxicity reactions but emphasizes the importance of monitoring liver function tests before and during treatment in patients with underlying hepatic disease, as some reported cases of hepatic failure occurred in patients with no pre-existing hepatic disease. (The drug is not directly associated with cardiotoxicity but may impact liver function, which can indirectly affect cardiac health.)

6. It mentions that competition for CYP3A by efavirenz could result in inhibition of metabolism of certain drugs, potentially leading to serious and/or life-threatening adverse reactions like cardiac arrhythmias. (The drug itself is not directly linked to cardiotoxicity but can interact with other drugs that may pose cardiotoxic risks.)

Overall, while the drug label does not directly associate efavirenz with cardiotoxicity risks or reactions, it highlights the importance of considering potential drug interactions and monitoring liver function, which can indirectly impact cardiac health.",Less,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",04b5c345-c446-43a4-83f0-509bc287e10b,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=04b5c345-c446-43a4-83f0-509bc287e10b&type=display
348,ELAGOLIX,"1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with ORILISSA itself.
2. ORILISSA is not associated with any cardiotoxicity risks or reactions based on the information provided in the drug label.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",a86757b3-09c5-fd3b-1223-244e94f50a66,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a86757b3-09c5-fd3b-1223-244e94f50a66&type=display
349,ELETRIPTAN HYDROBROMIDE,"1. **Cardiotoxicity Risk**: RELPAX is contraindicated in patients with a history of coronary artery disease (CAD) or coronary artery vasospasm, Wolff-Parkinson-White syndrome, history of stroke, transient ischemic attack, peripheral vascular disease, ischemic bowel disease, uncontrolled hypertension, recent use of other 5-HT1 agonists or ergotamine-containing medications, hypersensitivity to RELPAX, and within 72 hours of treatment with potent CYP3A4 inhibitors. The drug itself is associated with these cardiotoxicity risks.

2. **Cardiotoxicity Reactions**: Serious cardiac adverse reactions, including acute myocardial infarction, have been reported within a few hours following administration of RELPAX, even in patients without known CAD. Life-threatening disturbances of cardiac rhythm, such as ventricular tachycardia and ventricular fibrillation, have occurred within a few hours following the administration of 5-HT1 agonists. Chest, throat, neck, and jaw pain/tightness/pressure may occur after treatment with RELPAX, and a cardiac evaluation is recommended for high-risk patients. Cerebral hemorrhage, subarachnoid hemorrhage, and stroke have occurred in patients treated with 5-HT1 agonists. RELPAX may cause non-coronary vasospastic reactions, such as peripheral vascular ischemia and gastrointestinal vascular ischemia. The drug itself is associated with these cardiotoxicity reactions.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",85745375-fcb6-4edc-b6db-a77b4a5f3e8c,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=85745375-fcb6-4edc-b6db-a77b4a5f3e8c&type=display
350,ELIGLUSTAT,"1. The drug CERDELGA is contraindicated in patients with pre-existing cardiac disease, long QT syndrome, and those using Class IA and Class III antiarrhythmics due to the potential for cardiac arrhythmias. (The drug itself is associated with the risk of cardiac arrhythmias.)

2. Use of CERDELGA is not recommended in patients with pre-existing cardiac conditions, including congestive heart failure, recent acute myocardial infarction, bradycardia, heart block, ventricular arrhythmia, and long QT syndrome. (The drug itself is associated with the risk of cardiac arrhythmias.)

3. CERDELGA may cause concentration-related increases in ECG intervals (PR, QTc, and QRS) at elevated plasma concentrations, potentially increasing the risk of cardiac arrhythmias. (The drug itself is associated with the risk of cardiac arrhythmias.)

4. The drug label advises avoiding the use of CERDELGA in patients with pre-existing cardiac conditions and those taking certain antiarrhythmic medications due to the potential for cardiac arrhythmias. (The drug itself is associated with the risk of cardiac arrhythmias.)

5. CERDELGA is contraindicated, to be avoided, or requires dosage adjustment in patients with pre-existing cardiac disease, long QT syndrome, and those using Class IA and Class III antiarrhythmics, depending on CYP2D6 metabolizer status and concomitant drug use. (The drug itself is associated with the risk of cardiac arrhythmias.)

6. The drug label states that CERDELGA is predicted to cause increases in ECG intervals (PR, QTc, and QRS) at substantially elevated plasma concentrations, potentially increasing the risk of cardiac arrhythmias. (The drug itself is associated with the risk of cardiac arrhythmias.)

7. Use of CERDELGA in patients with pre-existing cardiac conditions has not been studied during clinical trials, and it is advised to avoid the drug in such patients. (The drug itself is associated with the risk of cardiac arrhythmias.)

8. The drug label advises avoiding the use of CERDELGA in patients with pre-existing cardiac disease, long QT syndrome, and those taking certain antiarrhythmic medications due to the potential for cardiac arrhythmias. (The drug itself is associated with the risk of cardiac arrhythmias.)",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",819f828a-b888-4e46-83fc-94d774a28a83,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=819f828a-b888-4e46-83fc-94d774a28a83&type=display
351,ELTROMBOPAG OLAMINE,"1. The drug label does not mention any specific cardiotoxicity risks or cardiotoxicity reactions associated with PROMACTA (eltrombopag) itself. 

2. However, the label does highlight the potential for thrombotic/thromboembolic complications due to increases in platelet counts with PROMACTA. These complications may include both venous and arterial events and can occur even at low or normal platelet counts. This suggests a potential indirect association with cardiotoxicity through thrombotic events.",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",7714a0ed-34bb-46e6-a0a5-b363908b22c2,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7714a0ed-34bb-46e6-a0a5-b363908b22c2&type=display
352,ELUXADOLINE,"1. The drug VIBERZI, containing the active ingredient eluxadoline, is a mu-opioid receptor agonist, and it does not prolong the QT interval to any clinically relevant extent, indicating no direct cardiotoxicity risk associated with the drug itself. (Source: Clinical Pharmacology, Section 12.2)

2. There are no reports of overdosage with VIBERZI causing cardiotoxicity reactions. In the event of acute overdose, standard supportive treatment should be provided, and consideration of administering a narcotic mu-opioid antagonist like naloxone may be necessary. (Source: Overdosage, Section 10)",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",7821bd40-4c84-4984-951b-6436ae20421a,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7821bd40-4c84-4984-951b-6436ae20421a&type=display
353,EMPAGLIFLOZIN,"1. **Indications and Usage**: JARDIANCE is indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure. (The drug is associated with reducing the risk of cardiovascular events in heart failure patients.)

2. **Warnings and Precautions - Diabetic Ketoacidosis**: JARDIANCE significantly increases the risk of diabetic ketoacidosis in patients with type 1 diabetes mellitus. (The drug is associated with an increased risk of diabetic ketoacidosis in type 1 diabetes patients.)

3. **Warnings and Precautions - Volume Depletion**: JARDIANCE can cause intravascular volume depletion, leading to symptomatic hypotension or acute transient changes in creatinine. (The drug is associated with volume depletion-related adverse reactions.)

4. **Warnings and Precautions - Urosepsis and Pyelonephritis**: JARDIANCE increases the risk for serious urinary tract infections, including urosepsis and pyelonephritis. (The drug is associated with an increased risk of urosepsis and pyelonephritis.)

5. **Warnings and Precautions - Lower Limb Amputation**: In some clinical studies, an imbalance in the incidence of lower limb amputation was observed with SGLT2 inhibitors like JARDIANCE. (The drug is associated with a potential risk of lower limb amputation.)

6. **Warnings and Precautions - Hypersensitivity Reactions**: Serious hypersensitivity reactions, such as angioedema, have been reported with JARDIANCE. (The drug is associated with the risk of hypersensitivity reactions.)

7. **Adverse Reactions - Clinical Trials Experience**: JARDIANCE has been evaluated in clinical trials, and the overall safety profile was generally consistent across studied indications, including heart failure and chronic kidney disease. (The drug was associated with various adverse reactions in clinical trials, including those related to cardiotoxicity risks.)

In summary, JARDIANCE is associated with cardiotoxicity risks such as diabetic ketoacidosis, volume depletion-related adverse reactions, and an increased risk of lower limb amputation. Patients should be monitored for these potential cardiotoxicity reactions while using the medication.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",faf3dd6a-9cd0-39c2-0d2e-232cb3f67565,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=faf3dd6a-9cd0-39c2-0d2e-232cb3f67565&type=display
354,EMTRICITABINE,"1. The drug label for EMTRIVA does not mention any specific cardiotoxicity risks or reactions associated with the drug itself. 

2. The label primarily focuses on warnings and precautions related to hepatitis B exacerbation, immune reconstitution syndrome, lactic acidosis, and hepatomegaly with steatosis. 

3. While the label does not directly link EMTRIVA to cardiotoxicity, it does emphasize the importance of monitoring hepatic function closely in patients coinfected with HIV-1 and HBV who discontinue the drug, as severe acute exacerbations of hepatitis B have been reported. 

4. Additionally, the label highlights the need for clinical and laboratory follow-up in patients with advanced liver disease or cirrhosis, as post-treatment exacerbation of hepatitis may lead to hepatic decompensation and liver failure. 

5. Overall, the drug label does not indicate any direct association between EMTRIVA and cardiotoxicity risks or reactions.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",d6599395-3944-44f9-97f2-e0424c6b6a1f,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=d6599395-3944-44f9-97f2-e0424c6b6a1f&type=display
355,ENALAPRILAT,"1. The drug label mentions that enalaprilat, the active metabolite of enalapril maleate, has been associated with hypotension, which can be especially risky in patients with certain conditions like heart failure, hyponatremia, or severe volume depletion. The drug itself is associated with the risk of hypotension.

2. The label also warns about the potential for angioedema, a serious allergic reaction that can involve swelling of the face, extremities, lips, tongue, glottis, and larynx. Enalaprilat has been reported to cause angioedema, particularly in black patients. The drug itself is associated with the risk of angioedema.

3. Additionally, the label mentions that enalaprilat may cause anaphylactoid reactions, which can be serious and include symptoms like facial flushing, nausea, vomiting, and hypotension. Enalaprilat has been associated with anaphylactoid reactions. The drug itself is associated with the risk of anaphylactoid reactions.

4. Neutropenia, agranulocytosis, and bone marrow depression have been reported with another ACE inhibitor, captopril, and cases of neutropenia or agranulocytosis have been reported with enalapril. The drug label suggests that enalapril may cause neutropenia or agranulocytosis, although a direct causal relationship cannot be excluded. The drug itself is associated with the risk of neutropenia or agranulocytosis.

5. Rare cases of hepatic failure have been associated with ACE inhibitors, including enalapril, leading to cholestatic jaundice and fulminant hepatic necrosis. Enalapril has been linked to rare cases of hepatic failure. The drug itself is associated with the risk of hepatic failure.

6. The drug label warns about the potential for fetal and neonatal morbidity and mortality when ACE inhibitors are administered to pregnant women, including risks of hypotension, renal failure, and death in the fetus or neonate. Enalapril has been associated with fetal and neonatal morbidity and mortality. The drug itself is associated with the risk of fetal and neonatal adverse effects.",Less,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",9d88f915-13dd-5463-e053-2a95a90a09bf,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=9d88f915-13dd-5463-e053-2a95a90a09bf&type=display
356,ENASIDENIB MESYLATE,"1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with IDHIFA itself. 

2. The label does not indicate any direct association between IDHIFA and cardiotoxicity risks or reactions. 

3. There is no mention of IDHIFA being linked to cardiotoxicity risks or reactions in the drug label. 

Overall, the drug label for IDHIFA does not highlight any cardiotoxicity risks or reactions directly attributed to the medication.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",a5b4cdf0-3fa8-4c6c-80f6-8d8a00e3a5b6,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a5b4cdf0-3fa8-4c6c-80f6-8d8a00e3a5b6&type=display
357,ENCORAFENIB,"1. **Cardiotoxicity Risk Associated with BRAFTOVI**: The drug label mentions that BRAFTOVI, when used in combination with binimetinib, has been associated with cardiomyopathy, manifesting as left ventricular dysfunction with symptomatic or asymptomatic decreases in ejection fraction. The label states that evidence of cardiomyopathy occurred in a percentage of patients receiving BRAFTOVI in clinical trials, with Grade 3 left ventricular dysfunction reported in some cases.

2. **Monitoring and Management of Cardiotoxicity**: The label advises healthcare providers to assess ejection fraction by echocardiogram or MUGA scan before initiating treatment with BRAFTOVI and to continue monitoring every 2 to 3 months during treatment. It also recommends close monitoring of patients with cardiovascular risk factors when treated with BRAFTOVI. The safety of BRAFTOVI in combination with binimetinib has not been established in patients with baseline ejection fraction below certain thresholds.

3. **Dose Adjustments for Cardiotoxicity**: In cases of cardiomyopathy or symptomatic congestive heart failure, the label suggests reducing the dose of BRAFTOVI by one level. It also outlines specific actions to take based on the severity of adverse reactions related to cardiotoxicity, including withholding, reducing the dose, or permanently discontinuing BRAFTOVI.

4. **Resolution of Cardiomyopathy**: The label mentions that cardiomyopathy associated with BRAFTOVI in combination with binimetinib resolved in a significant percentage of patients who experienced this adverse reaction. It emphasizes the importance of ongoing monitoring and management to address cardiotoxicity risks effectively.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",235dfc38-0f0b-4037-b501-7a9f4294740c,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=235dfc38-0f0b-4037-b501-7a9f4294740c&type=display
358,ENFUVIRTIDE,"1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with FUZEON (enfuvirtide) itself. 

2. The label primarily focuses on local injection site reactions, hypersensitivity reactions, pneumonia, and immune reconstitution syndrome as potential adverse effects of FUZEON. 

3. Cardiotoxicity is not highlighted as a known risk or reaction specifically attributed to the use of FUZEON based on the information provided in the drug label. 

4. The adverse reactions discussed in the label include local injection site reactions, hypersensitivity reactions, pneumonia, and immune reconstitution syndrome, but do not mention cardiotoxicity as a concern related to the use of FUZEON. 

5. Overall, the drug label does not indicate any direct association between FUZEON and cardiotoxicity risks or reactions.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",6935e846-d5a1-49e5-89a2-f8ebe4d5590d,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=6935e846-d5a1-49e5-89a2-f8ebe4d5590d&type=display
359,ENTACAPONE,"1. The drug label mentions that when a single 400 mg dose of entacapone was given with intravenous isoprenaline (isoproterenol) and epinephrine without coadministered levodopa and dopa decarboxylase inhibitor, the overall mean maximal changes in heart rate during infusion were about 50% and 80% higher than with placebo for isoprenaline and epinephrine, respectively. This indicates that entacapone itself was associated with increased heart rates and possible arrhythmias when administered with drugs metabolized by COMT.

2. The label also reports a case of ventricular tachycardia in a healthy volunteer after epinephrine infusion and oral entacapone administration, requiring treatment with propranolol. This suggests a probable causal relationship between entacapone administration and ventricular tachycardia, although certainty cannot be attributed. Therefore, entacapone was associated with ventricular tachycardia in this case.

3. Additionally, the label warns that drugs known to be metabolized by COMT, such as isoproterenol, epinephrine, norepinephrine, dopamine, and others, should be administered with caution in patients receiving entacapone, as their interaction may result in increased heart rates, possible arrhythmias, and excessive changes in blood pressure. This indicates that entacapone itself can potentially lead to cardiotoxicity reactions when interacting with certain drugs metabolized by COMT.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",3b45ebd7-ca36-b691-fea2-652858a5c590,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=3b45ebd7-ca36-b691-fea2-652858a5c590&type=display
360,ENTECAVIR,1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with BARACLUDE (entecavir).,No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",046e61c9-9298-4b2e-b76e-b26b81fecd20,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=046e61c9-9298-4b2e-b76e-b26b81fecd20&type=display
361,ENTRECTINIB,"1. The drug ROZLYTREK is associated with congestive heart failure (CHF) risks. Patients should be assessed for left ventricular ejection fraction (LVEF) prior to initiation, and monitoring for clinical signs and symptoms of CHF is recommended. The drug may need to be withheld, dose reduced, or permanently discontinued based on the severity of CHF or worsening LVEF. (The drug is associated with the risk of CHF.)

2. ROZLYTREK has been linked to myocarditis, with or without decreased ejection fraction, which may require further diagnostic tests like MRI or cardiac biopsy. New onset or worsening CHF should prompt withholding the drug, reassessment of LVEF, and appropriate medical management. Dose reduction or discontinuation may be necessary based on the severity of CHF or worsening LVEF. (The drug is associated with the risk of myocarditis and CHF.)

3. The drug ROZLYTREK has been associated with an increased risk of fractures, including hip or lower extremity fractures. Prompt evaluation of patients with signs or symptoms of fractures is recommended. There is no specific mention of the drug causing cardiotoxicity in this context. (The drug is not directly associated with cardiotoxicity in the context of fractures.)

4. ROZLYTREK has been linked to hepatotoxicity, with increased AST and ALT levels reported in patients. Monitoring liver tests, including AST and ALT, is advised during treatment. The drug may need to be withheld or permanently discontinued based on the severity of hepatotoxicity. (The drug is associated with the risk of hepatotoxicity, not directly cardiotoxicity.)

In summary, ROZLYTREK is associated with risks of congestive heart failure and myocarditis, which may necessitate dose adjustments or discontinuation. The drug is not directly linked to fractures or hepatotoxicity causing cardiotoxicity.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",c7c71b0c-2549-4495-86b6-c2807fa54908,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=c7c71b0c-2549-4495-86b6-c2807fa54908&type=display
362,ENZALUTAMIDE,"1. Ischemic Heart Disease: The drug XTANDI is associated with an increased risk of ischemic heart disease, as evidenced by a higher occurrence in patients on XTANDI compared to those on placebo in clinical studies. Grade 3-4 ischemic events were more common in XTANDI-treated patients, leading to deaths in some cases. Management of cardiovascular risk factors is recommended, and XTANDI should be discontinued for Grade 3-4 ischemic heart disease.

2. Falls and Fractures: XTANDI has been linked to an increased risk of falls and fractures in patients. Falls occurred more frequently in XTANDI-treated patients compared to placebo, and fractures were also more common. Patients should be evaluated for fracture and fall risk, and bone-targeted agents may be considered for treatment.

3. Cardiotoxicity: The drug label does not explicitly mention cardiotoxicity as a specific risk or adverse reaction associated with XTANDI. However, the increased incidence of ischemic heart disease in patients taking XTANDI suggests a potential cardiotoxicity risk that should be monitored and managed.",Less,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",b129fdc9-1d8e-425c-a5a9-8a2ed36dfbdf,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=b129fdc9-1d8e-425c-a5a9-8a2ed36dfbdf&type=display
363,EPHEDRINE HYDROCHLORIDE,"1. **Warnings and Precautions**: The drug label mentions that the pressor effect of sympathomimetic pressor amines, like REZIPRES, is potentiated with concomitant use with oxytocic drugs, which can lead to serious postpartum hypertension and potential stroke. This indicates that REZIPRES itself is associated with a cardiotoxicity risk when used with oxytocic drugs.

2. **Warnings and Precautions**: Tachyphylaxis and tolerance may occur with repeated administration of REZIPRES, potentially leading to a decreased responsiveness to the drug. While not directly cardiotoxic, tachyphylaxis can impact the effectiveness of the drug in managing hypotension, which can indirectly affect cardiovascular function.

3. **Warnings and Precautions**: The label also mentions that when used prophylactically, ephedrine (the active ingredient in REZIPRES) has been associated with an increased incidence of hypertension compared to when used to treat hypotension. This suggests that REZIPRES itself may contribute to a cardiotoxicity risk by potentially inducing hypertension when used preventatively.

4. **Adverse Reactions**: Among the adverse reactions reported during treatment with ephedrine (REZIPRES), tachycardia is listed. Tachycardia is a cardiac disorder that can be a sign of cardiotoxicity, indicating that REZIPRES may have cardiotoxic effects leading to increased heart rate.

5. **Drug Interactions**: The label warns about interactions that augment the pressor effect of ephedrine, such as with clonidine, propofol, monoamine oxidase inhibitors (MAOIs), and atropine. These interactions can potentially lead to increased blood pressure, suggesting a cardiotoxicity risk associated with REZIPRES in combination with these drugs.",Less,Yes,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",8e506ea1-8df0-4425-c1b9-6c89a293f52e,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8e506ea1-8df0-4425-c1b9-6c89a293f52e&type=display
364,EPHEDRINE SULFATE,"1. **Warnings and Precautions**: The drug label mentions that ephedrine sulfate may potentiate the pressor effect of sympathomimetic pressor amines, leading to cardiotoxicity risks. The drug itself is associated with this cardiotoxicity risk.

2. **Adverse Reactions**: The label lists tachycardia as one of the most common adverse reactions during treatment with ephedrine sulfate. Tachycardia is a cardiotoxicity reaction, and the drug itself is associated with causing this adverse effect.

3. **Drug Interactions**: The label warns about potential interactions with cardiac glycosides, such as digitalis, which may increase the possibility of arrhythmias. The drug itself is associated with causing cardiotoxicity risks when used concomitantly with cardiac glycosides.

4. **Drug Interactions**: Ephedrine sulfate may reduce the onset time of neuromuscular blockade when used with rocuronium, which can have implications for cardiac function. The drug itself is associated with causing potential cardiotoxicity risks in this interaction scenario.

5. **Use in Specific Populations**: The label discusses the risk of hypertension when ephedrine is used prophylactically, indicating a potential cardiotoxicity risk associated with the drug's use in this context.

Overall, the drug label for ephedrine sulfate highlights several instances where the drug itself is associated with cardiotoxicity risks and reactions, particularly in relation to tachycardia, arrhythmias, and hypertension.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",2c203482-8a04-40fc-93d2-74b30dec7742,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=2c203482-8a04-40fc-93d2-74b30dec7742&type=display
365,EPIRUBICIN HYDROCHLORIDE,"1. ELLENCE carries a warning for cardiac toxicity, including myocardial damage and acute left ventricular failure, with the risk of cardiomyopathy increasing with cumulative exposure. The drug itself is associated with the risk of cardiomyopathy, especially with concomitant cardiotoxic therapy.

2. The drug label warns about secondary malignancies, such as secondary acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS), occurring at a higher incidence in patients treated with anthracyclines like ELLENCE. The drug itself is associated with an increased risk of secondary malignancies.

3. ELLENCE can result in severe local tissue injury and necrosis if extravasation occurs, requiring wide excision of the affected area and skin grafting. The drug itself is associated with the risk of extravasation and tissue necrosis.

4. Severe myelosuppression, leading to serious infection, septic shock, and death, may occur with ELLENCE treatment. The drug itself is associated with the risk of severe myelosuppression. 

5. ELLENCE can cause either early or late cardiac toxicity, with manifestations including sinus tachycardia, ECG abnormalities, and reduced left ventricular ejection fraction (LVEF) leading to congestive heart failure (CHF). The drug itself is associated with both early and late cardiac toxicity, with the risk increasing with cumulative doses and in patients with prior cardiovascular disease or concomitant cardiotoxic therapy.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",0a03c798-a652-4895-b29c-3b521a89ba42,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=0a03c798-a652-4895-b29c-3b521a89ba42&type=display
366,EPLERENONE,"1. The drug label mentions that INSPRA (eplerenone) is indicated for improving survival in stable patients with symptomatic heart failure with reduced ejection fraction (HFrEF) after an acute myocardial infarction (MI). This indicates that the drug is used in patients with a history of heart failure and MI, suggesting a potential cardiotoxicity risk due to the underlying heart condition.

2. The label also states that adverse reactions reported in clinical trials of INSPRA for heart failure post-MI included hyperkalemia and increased creatinine. These adverse reactions were more frequent in patients treated with INSPRA compared to placebo, indicating a potential cardiotoxicity risk associated with the drug itself.

3. Additionally, the label mentions that patients with heart failure treated with INSPRA had an overall incidence of adverse events similar to placebo, with common reasons for discontinuation being hyperkalemia, MI, and abnormal renal function. This suggests that INSPRA may be associated with cardiotoxicity reactions such as MI and abnormal renal function in patients with heart failure post-MI.

4. The label further discusses that in patients with hypertension treated with INSPRA, adverse events were uncommon, but gynecomastia and abnormal vaginal bleeding were reported with INSPRA but not with placebo. These adverse events suggest potential cardiotoxicity risks associated with hormonal changes that may occur with the drug.

5. The label also highlights that hyperkalemia is a significant risk associated with INSPRA, especially in patients with impaired renal function, diabetes, and those concomitantly treated with certain medications. Proper patient selection and monitoring are recommended to minimize the risk of hyperkalemia, indicating a potential cardiotoxicity risk with elevated potassium levels.

Overall, the drug label for INSPRA indicates potential cardiotoxicity risks associated with the drug itself, particularly in patients with heart failure post-MI, as evidenced by adverse reactions such as hyperkalemia and increased creatinine reported in clinical trials. Proper monitoring and management are essential to address these cardiotoxicity risks in patients receiving INSPRA.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",1a52bedc-8e2c-4116-a296-a87770676b4a,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=1a52bedc-8e2c-4116-a296-a87770676b4a&type=display
367,EPOPROSTENOL,"1. The drug label states that a large study evaluating the effect of epoprostenol on survival in patients with congestive heart failure due to severe left ventricular systolic dysfunction was terminated due to a higher mortality rate in patients receiving epoprostenol plus conventional therapy compared to those receiving conventional therapy alone. The chronic use of VELETRI in patients with congestive heart failure due to severe left ventricular systolic dysfunction is contraindicated. (The drug itself was associated with the cardiotoxicity risk.)

2. The label also mentions that some patients with pulmonary hypertension have developed pulmonary edema during dose initiation, which may be associated with pulmonary veno-occlusive disease. VELETRI should not be used chronically in patients who develop pulmonary edema during dose initiation. (The drug itself was associated with the cardiotoxicity risk.)

3. Additionally, the label warns about the potential for high output cardiac failure as a cardiotoxicity reaction to epoprostenol. It advises considering dose reduction in such cases. (The drug itself was associated with the cardiotoxicity reaction.)

4. The label further mentions that during clinical trials, adverse events related to the underlying disease of pulmonary arterial hypertension, such as right ventricular failure, have been reported. While some adverse events can be attributed to the disease, others, such as hypotension, bradycardia, tachycardia, and pulmonary edema, can be clearly attributed to epoprostenol. (The drug itself was associated with some of the cardiotoxicity reactions.)

5. Postmarketing experience with epoprostenol has identified high output cardiac failure as a potential cardiotoxicity reaction. The label advises considering dose reduction in such cases. (The drug itself was associated with the cardiotoxicity reaction.)

6. The label also mentions that there have been reports of hepatic failure in patients taking epoprostenol, although the relationship to epoprostenol administration has not been established. (The drug itself was not definitively associated with the cardiotoxicity risk, but the reaction was reported in patients taking the drug.)

Overall, the drug label indicates that VELETRI (epoprostenol) is associated with cardiotoxicity risks and cardiotoxicity reactions, including high output cardiac failure, pulmonary edema, and potential hepatic failure. It is important to closely monitor patients for these potential adverse effects when using this medication.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",df502787-46ec-4dd1-a2c0-be90f6d95a5d,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=df502787-46ec-4dd1-a2c0-be90f6d95a5d&type=display
368,EPTIFIBATIDE,"1. The drug label mentions that eptifibatide is associated with an increase in major and minor bleeding, including bleeding at the arterial access site for cardiac catheterization, which can be considered a cardiotoxicity risk. The label advises minimizing vascular and other traumas to reduce bleeding risk.

2. Eptifibatide can cause serious bleeding, and if bleeding cannot be controlled, discontinuation of eptifibatide is recommended. This indicates that the drug itself can lead to cardiotoxicity reactions in the form of serious bleeding.

3. The drug label also mentions that thrombocytopenia, a condition characterized by a low platelet count, has been reported with eptifibatide use. In the event of acute profound thrombocytopenia, discontinuation of eptifibatide and heparin is advised. This indicates that eptifibatide can lead to thrombocytopenia as a potential cardiotoxicity reaction.

4. The label further discusses that there have been reports of acute, profound thrombocytopenia, including immune-mediated thrombocytopenia, with eptifibatide use. This suggests that the drug itself can be associated with cardiotoxicity reactions related to thrombocytopenia.

5. Additionally, the drug label mentions that there have been post-approval reports of cerebral, gastrointestinal, and pulmonary hemorrhage, as well as fatal bleeding reactions, with eptifibatide use. These adverse reactions indicate that eptifibatide can lead to cardiotoxicity risks related to severe bleeding and hemorrhage.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",c2d73e76-5f9b-4d18-b57b-5fe8b8a4c98a,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=c2d73e76-5f9b-4d18-b57b-5fe8b8a4c98a&type=display
369,ERAVACYCLINE,"1. **Clinical Pharmacology Section:**
   - The effect of XERAVA on the QTc interval was evaluated in a Phase 1 study in healthy adult subjects. At 1.5 mg/kg dose, XERAVA did not prolong the QTc interval to any clinically relevant extent.
   - **Summary:** XERAVA was not associated with significant QTc prolongation at the tested dose.

2. **Warnings and Precautions Section:**
   - No specific mention of cardiotoxicity risks or reactions related to XERAVA in this section.

3. **Adverse Reactions Section:**
   - No specific mention of cardiotoxicity risks or reactions related to XERAVA in this section.

Overall, based on the information provided in the drug label, XERAVA does not appear to be associated with significant cardiotoxicity risks or reactions. The drug did not show significant effects on the QTc interval in the clinical study mentioned in the Clinical Pharmacology section.",Less,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",a4b188d4-f467-470c-ad7b-25ffbdd8862a,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a4b188d4-f467-470c-ad7b-25ffbdd8862a&type=display
370,ERDAFITINIB,"1. The drug label for BALVERSA does not mention any specific cardiotoxicity risks or reactions associated with the drug itself. 

2. The label primarily focuses on ocular disorders, hyperphosphatemia, and embryo-fetal toxicity as potential adverse effects of BALVERSA. 

3. While the label does not directly link BALVERSA to cardiotoxicity, it is important to consult the full prescribing information and discuss any concerns with a healthcare provider for a comprehensive understanding of potential risks and side effects.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",2a8aa5c0-6c92-4566-8c45-e8f4d1fc20ee,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=2a8aa5c0-6c92-4566-8c45-e8f4d1fc20ee&type=display
371,"ERGOCALCIFEROL CAPSULES,","1. The drug label mentions that hypervitaminosis D, which can result from excessive intake of ergocalciferol (vitamin D), may lead to generalized vascular calcification, including in the heart, as well as irreversible renal insufficiency, which could potentially result in death.

2. In cases of hypervitaminosis D, the label indicates that widespread calcification of soft tissues, such as the heart, blood vessels, renal tubules, and lungs, can occur, along with bone demineralization (osteoporosis) in adults.

3. The label also states that hypercalcemia resulting from hypervitaminosis D can lead to hypercalcemic crisis with symptoms like dehydration, stupor, coma, and azotemia, requiring vigorous treatment, including hydration, diuretics, and other therapeutic measures.

4. Additionally, the label mentions that hypervitaminosis D can cause impairment of renal function, leading to polyuria, nocturia, polydipsia, reversible azotemia, hypertension, nephrocalcinosis, and potentially irreversible renal insufficiency, which may result in death.

5. The drug label warns that hypervitaminosis D can result in mental retardation, which is a central nervous system (CNS) effect associated with excessive vitamin D intake.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",75fa8580-3322-473d-b836-4929f8c40165,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=75fa8580-3322-473d-b836-4929f8c40165&type=display
372,ERGOTAMINE TARTRATE,"1. The drug label warns that serious and/or life-threatening peripheral ischemia has been associated with the coadministration of ergotamine tartrate with potent CYP 3A4 inhibitors, increasing the risk for vasospasm leading to cerebral ischemia and/or ischemia of the extremities. The risk is due to elevated serum levels of ergotamine tartrate caused by CYP 3A4 inhibition. (The drug itself is associated with the cardiotoxicity risk.)

2. Vasoconstrictive complications of a serious nature may occur with ergotamine therapy, including ischemia, cyanosis, absence of pulse, cold extremities, gangrene, precordial distress and pain, EKG changes, muscle pains, transient tachycardia or bradycardia, hypertension, and neurological symptoms such as paresthesias, numbness, weakness, and vertigo. (The drug itself is associated with cardiotoxicity reactions.)

3. Fibrotic complications, including retroperitoneal and/or pleuropulmonary fibrosis, as well as fibrotic thickening of cardiac valves, have been reported in patients on ergotamine tartrate and caffeine therapy. (The drug itself is associated with cardiotoxicity reactions.)

4. Overdosage of ergotamine may lead to symptoms such as hypertension or hypotension, drowsiness, stupor, coma, convulsions, shock, and cardiovascular effects like diminished or absent peripheral pulses, EKG changes, and muscle pains. (The drug itself is associated with cardiotoxicity reactions.)",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",dac9637f-3326-4f25-b7b9-f9f54b738232,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=dac9637f-3326-4f25-b7b9-f9f54b738232&type=display
373,ERIBULIN MESYLATE,1. The drug label for Halaven (eribulin mesylate) injection does not explicitly mention cardiotoxicity risks or cardiotoxicity reactions associated with the drug itself.,No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",8fc8fe1d-59fe-4e43-a95c-e7aa13422cd6,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8fc8fe1d-59fe-4e43-a95c-e7aa13422cd6&type=display
374,ERLOTINIB,"1. **Cardiotoxicity Risk**: The drug label does not mention any specific cardiotoxicity risks associated with erlotinib tablets.

2. **Cardiotoxicity Reactions**:
   - The label does not directly attribute cardiotoxicity reactions to erlotinib tablets. However, it does mention cerebrovascular accidents (CVAs) occurring in patients with pancreatic cancer, with an increased risk observed in the erlotinib/gemcitabine group compared to the placebo/gemcitabine group. One of the CVAs was hemorrhagic and fatal, but the label does not definitively link this event to erlotinib tablets.
   - Additionally, the label discusses microangiopathic hemolytic anemia with thrombocytopenia, which was observed in patients with pancreatic cancer receiving erlotinib plus gemcitabine. While this condition involves blood abnormalities, it is not directly labeled as a cardiotoxicity reaction caused by erlotinib tablets.",Less,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",c35e019d-ec34-4e61-9400-a7ae7913e025,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=c35e019d-ec34-4e61-9400-a7ae7913e025&type=display
375,ERLOTINIB HYDROCHLORIDE,1. The drug label for TARCEVA does not mention any specific cardiotoxicity risks or reactions associated with the drug itself.,No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",57bccb29-1c47-4c64-ab6a-77960a91cc20,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=57bccb29-1c47-4c64-ab6a-77960a91cc20&type=display
376,ERTAPENEM SODIUM,"1. **Warnings and Precautions - Cardiovascular System:** The drug label does not mention any specific cardiotoxicity risks or reactions associated with INVANZ itself in the Cardiovascular System section.

2. **Adverse Reactions - Cardiovascular System:** The drug label does not list any cardiotoxicity risks or reactions associated with INVANZ in the Adverse Reactions section related to the Cardiovascular System.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",33f3b99b-fa82-42e0-26bf-f49891ae3d22,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=33f3b99b-fa82-42e0-26bf-f49891ae3d22&type=display
377,ERTUGLIFLOZIN,"1. The drug label mentions a long-term cardiovascular outcomes study where non-traumatic lower limb amputations were reported in patients with type 2 diabetes and established cardiovascular disease, with event rates varying across treatment arms. The drug itself was associated with the risk of lower limb amputations, particularly in patients with certain predisposing factors.

2. The label also discusses the occurrence of volume depletion as a potential adverse reaction, which may manifest as symptomatic hypotension or acute transient changes in creatinine. The drug itself was associated with the risk of volume depletion, especially in patients with impaired renal function, elderly patients, or those on diuretics.

3. Additionally, the drug label mentions the potential risk of hypoglycemia when the drug is used in combination with insulin and/or an insulin secretagogue. The drug itself was associated with an increased risk of hypoglycemia when used in combination with these medications.

4. The label highlights the occurrence of necrotizing fasciitis of the perineum (Fournier's Gangrene) as a rare but serious and life-threatening necrotizing infection identified in postmarketing surveillance in patients with diabetes mellitus receiving SGLT2 inhibitors, including the drug in question. The drug itself was associated with the risk of necrotizing fasciitis of the perineum.

5. Furthermore, the drug label mentions an increased risk of genital mycotic infections associated with the drug, particularly in patients with a history of such infections or who are uncircumcised. The drug itself was associated with an increased risk of genital mycotic infections.

6. Lastly, the label discusses the potential for urinary tract infections, including urosepsis and pyelonephritis, requiring hospitalization in patients receiving SGLT2 inhibitors, which includes the drug in question. The drug itself was associated with an increased risk of urinary tract infections.",Less,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",e6f3e718-bb99-48f1-ab94-b9f0af05fed6,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=e6f3e718-bb99-48f1-ab94-b9f0af05fed6&type=display
378,ERYTHROMYCIN ETHYLSUCCINATE,"1. The drug label warns about the association of erythromycin with prolongation of the QT interval and infrequent cases of arrhythmia, including torsades de pointes, which have been reported during postmarketing surveillance in patients receiving erythromycin. Fatalities have been reported. (Erythromycin associated with QT prolongation and arrhythmia risk)

2. The label advises avoiding erythromycin in patients with known QT prolongation, ongoing proarrhythmic conditions, clinically significant bradycardia, and in patients receiving certain antiarrhythmic agents. Elderly patients may be more susceptible to drug-associated effects on the QT interval. (Erythromycin associated with QT prolongation risk)

3. Reports suggest that erythromycin may not reach the fetus in adequate concentration to prevent congenital syphilis. Infants born to women treated with oral erythromycin for early syphilis should be treated with an appropriate penicillin regimen. (Erythromycin not associated with cardiotoxicity risk)

4. The label mentions that Clostridium difficile-associated diarrhea (CDAD) has been reported with the use of nearly all antibacterial agents, including Ery-Ped. CDAD can range from mild diarrhea to fatal colitis. (Erythromycin not directly associated with cardiotoxicity risk)

5. Serious adverse reactions have been reported in patients taking erythromycin concomitantly with certain drugs, leading to colchicine toxicity, rhabdomyolysis, and hypotension. (Erythromycin associated with cardiotoxicity risk)

6. Erythromycin has been associated with increased anticoagulant effects when used concomitantly with oral anticoagulants, potentially leading to more pronounced effects in the elderly. (Erythromycin associated with cardiotoxicity risk)

7. The label warns about the potential interaction of erythromycin with drugs metabolized by the CYP3A isoform, leading to increased drug concentrations and effects. (Erythromycin associated with cardiotoxicity risk)

8. Erythromycin has been reported to significantly alter the metabolism of certain drugs, potentially leading to serious cardiovascular adverse events, including QT interval prolongation, cardiac arrest, and ventricular arrhythmias. (Erythromycin associated with cardiotoxicity risk)

9. The label mentions that erythromycin has been associated with drug interactions leading to acute ergot toxicity when co-administered with ergotamine or dihydroergotamine. (Erythromycin associated with cardiotoxicity risk)

10. Reports indicate that erythromycin has been associated with drug interactions leading to QT prolongation, cardiac arrhythmias, and ventricular tachycardia when co-administered with cisapride. Fatalities have been reported. (Erythromycin associated with cardiotoxicity risk)",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",04775721-ab87-4b66-808c-d67a21032385,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=04775721-ab87-4b66-808c-d67a21032385&type=display
379,ERYTHROMYCIN LACTOBIONATE,"1. The drug label mentions that life-threatening episodes of ventricular tachycardia associated with prolonged QT intervals (torsades de pointes) have been reported in some patients after intravenous administration of erythromycin lactobionate. The drug itself was associated with the risk of cardiotoxicity.

2. The label also states that elderly patients exhibit a greater frequency of decreased hepatic function, cardiac function, and of concomitant disease and other drug therapy, and therefore should be monitored carefully during Erythrocin therapy. The drug itself was associated with the risk of cardiotoxicity in elderly patients.

3. Additionally, the label mentions that erythromycin has been associated with QT prolongation and ventricular arrhythmias, including ventricular tachycardia and torsades de pointes. The drug itself was associated with the risk of cardiotoxicity and cardiotoxic reactions.

4. The label further warns that serious adverse reactions have been reported in patients taking erythromycin concomitantly with certain medications, leading to colchicine toxicity, rhabdomyolysis, hypotension, vasospasm, and ischemia. The drug itself was associated with the risk of cardiotoxicity and cardiotoxic reactions when used in combination with specific medications.

5. Lastly, the label mentions that erythromycin has been reported to significantly alter the metabolism of various drugs, leading to increased serum levels and potential toxicities, including anticoagulant effects. The drug itself was associated with the risk of cardiotoxicity and cardiotoxic reactions when used concomitantly with certain medications.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",a96c405f-bd70-4bb4-719e-ac6a79dcc213,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a96c405f-bd70-4bb4-719e-ac6a79dcc213&type=display
380,ERYTHROMYCIN STEARATE,"1. The drug label warns about QT prolongation and infrequent cases of arrhythmia associated with erythromycin use. It states that erythromycin has been linked to prolongation of the QT interval and cases of torsades de pointes, with fatalities reported. The drug itself is associated with these cardiotoxicity risks.

2. The label mentions that erythromycin should be avoided in patients with known QT prolongation, ongoing proarrhythmic conditions, clinically significant bradycardia, and in patients receiving certain antiarrhythmic agents. It also notes that elderly patients may be more susceptible to drug-associated effects on the QT interval. The drug itself is associated with these cardiotoxicity risks.

3. There are reports suggesting that erythromycin may not reach the fetus in adequate concentration to prevent congenital syphilis. Infants born to women treated with oral erythromycin for early syphilis should be treated with an appropriate penicillin regimen. The drug label indicates that erythromycin is not effective in preventing congenital syphilis, which could lead to serious cardiac complications in infants.

4. The label warns about the potential risk of developing torsades de pointes arrhythmias in elderly patients receiving erythromycin. It states that elderly patients may be more susceptible to these arrhythmias. The drug itself is associated with an increased risk of torsades de pointes in elderly patients.

5. Erythromycin has been associated with QT prolongation and ventricular arrhythmias, including torsades de pointes. The label mentions that fatalities have been reported in patients receiving erythromycin. The drug itself is associated with these cardiotoxicity reactions.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",6c789378-0ec7-4874-aa42-e3418e859f86,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=6c789378-0ec7-4874-aa42-e3418e859f86&type=display
381,ESCITALOPRAM,"1. **Contraindications**: Lexapro is contraindicated in patients taking MAOIs due to an increased risk of serotonin syndrome, which can have cardiotoxic effects. The drug itself is not directly associated with cardiotoxicity but can lead to serotonin syndrome when used with MAOIs, which can have cardiovascular implications.

2. **Warnings and Precautions - Serotonin Syndrome**: Lexapro can precipitate serotonin syndrome, a potentially life-threatening condition with cardiotoxic effects. The drug itself is associated with an increased risk of serotonin syndrome, which can manifest with cardiovascular symptoms such as tachycardia and labile blood pressure.

3. **Warnings and Precautions - Hyponatremia**: Hyponatremia may occur as a result of treatment with SSRIs, including Lexapro, and can have cardiovascular implications. The drug itself is associated with the risk of hyponatremia, which can lead to symptoms like weakness and unsteadiness, potentially impacting cardiovascular function.

4. **Warnings and Precautions - Increased Risk of Bleeding**: Lexapro increases the risk of bleeding events, which can have cardiovascular consequences. The drug itself is associated with an increased risk of bleeding, which can include gastrointestinal bleeding and other hemorrhagic events.

5. **Warnings and Precautions - Use in Patients with Concomitant Illness**: Caution is advised when using Lexapro in patients with diseases or conditions that produce altered metabolism or hemodynamic responses, which can impact cardiovascular health. The drug itself is not directly linked to cardiotoxicity but should be used cautiously in patients with conditions affecting cardiovascular function.",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",13bb8267-1cab-43e5-acae-55a4d957630a,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=13bb8267-1cab-43e5-acae-55a4d957630a&type=display
382,ESLICARBAZEPINE ACETATE,"1. **Hyponatremia**: APTIOM has been associated with clinically significant hyponatremia (sodium <125 mEq/L) in patients taking the drug. The measurement of serum sodium and chloride levels is recommended during maintenance treatment with APTIOM, particularly if the patient is receiving other medications known to decrease serum sodium levels. Cases of symptomatic hyponatremia and syndrome of inappropriate antidiuretic hormone secretion (SIADH) have been reported during postmarketing use. APTIOM may cause hyponatremia, and the dose may need to be reduced or discontinued depending on the severity of the condition.

2. **Neurological Adverse Reactions**: APTIOM has been associated with dose-related increases in adverse reactions related to dizziness and disturbance in gait and coordination, such as dizziness, ataxia, vertigo, balance disorder, gait disturbance, nystagmus, and abnormal coordination. These events were more common in patients taking APTIOM compared to placebo. The risk of these adverse reactions was higher during the titration period and in patients aged 60 years and older. APTIOM may cause neurological adverse reactions, and caution is advised when engaging in activities requiring mental alertness.

3. **Drug Induced Liver Injury**: Hepatic effects, ranging from mild to moderate elevations in transaminases to rare cases with concomitant elevations of total bilirubin, have been reported with APTIOM use. Baseline evaluations of liver laboratory tests are recommended, and APTIOM should be discontinued in patients with jaundice or other evidence of significant liver injury. APTIOM may cause drug-induced liver injury, and monitoring liver function is essential during treatment.

4. **Abnormal Thyroid Function Tests**: APTIOM has been associated with dose-dependent decreases in serum T3 and T4 values in patients taking the drug. These changes were not associated with other abnormal thyroid function tests suggesting hypothyroidism. Abnormal thyroid function tests should be clinically evaluated. APTIOM may lead to abnormal thyroid function tests, and monitoring thyroid function is recommended during treatment.",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",3d0c9554-eaeb-4694-8089-00133fcadce3,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=3d0c9554-eaeb-4694-8089-00133fcadce3&type=display
383,ESMOLOL HYDROCHLORIDE,"1. The drug BREVIBLOC (Esmolol Hydrochloride) injection is associated with cardiotoxicity risks, including hypotension, bradycardia, and cardiac failure. These risks are dose-related and may lead to severe reactions such as loss of consciousness, cardiac arrest, and death. The drug itself is linked to these cardiotoxicity risks.

2. BREVIBLOC injection has been reported to cause bradycardia, including sinus pause, heart block, severe bradycardia, and cardiac arrest. Patients with certain pre-existing conditions may be at increased risk. The drug itself is associated with causing bradycardia and related cardiotoxicity reactions.

3. Beta blockers like BREVIBLOC injection can depress myocardial contractility, potentially leading to heart failure and cardiogenic shock. The drug is linked to causing cardiac failure as a cardiotoxicity risk.

4. BREVIBLOC injection should be used cautiously in patients with peripheral circulatory disorders, as it may aggravate these conditions. The drug itself is associated with exacerbating peripheral circulatory disorders as a cardiotoxicity risk.

5. Severe exacerbations of angina, myocardial infarction, and ventricular arrhythmias have been reported in patients with coronary artery disease upon abrupt discontinuation of beta blocker therapy, including BREVIBLOC injection. The drug is linked to causing severe cardiac events upon abrupt discontinuation as a cardiotoxicity risk.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",220a07b8-5c68-41a3-8705-fd91f14c50b4,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=220a07b8-5c68-41a3-8705-fd91f14c50b4&type=display
384,ESOMEPRAZOLE MAGNESIUM,"1. **Interaction with Clopidogrel**: The drug label warns against concomitant use of NEXIUM with clopidogrel due to the potential reduction in the pharmacological activity of clopidogrel. NEXIUM itself is associated with the risk of reducing the effectiveness of clopidogrel, which is a concern for patients requiring anti-platelet therapy.

2. **Bone Fracture**: Observational studies suggest that long-term and high-dose use of proton pump inhibitors (PPIs) like NEXIUM may be associated with an increased risk of osteoporosis-related fractures. While not directly causing cardiotoxicity, this risk is a concern for patients using NEXIUM, especially in the context of bone health and potential fracture risks.

3. **Hypomagnesemia and Mineral Metabolism**: Rare reports of hypomagnesemia have been associated with prolonged PPI therapy, including NEXIUM, for at least three months, with serious adverse events such as arrhythmias and seizures. While not a direct cardiotoxic effect, hypomagnesemia can lead to cardiac complications, highlighting the importance of monitoring magnesium levels in patients on long-term NEXIUM therapy.",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",f4853677-1622-4037-688b-fdf533a11d96,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=f4853677-1622-4037-688b-fdf533a11d96&type=display
385,ESOMEPRAZOLE SODIUM,"1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with NEXIUM I.V. itself. 

2. The label does not attribute any cardiotoxicity risks or reactions to NEXIUM I.V. 

3. There are no references to cardiotoxicity risks or reactions linked to NEXIUM I.V. in the drug label. 

Overall, the drug label for NEXIUM I.V. does not indicate any cardiotoxicity risks or reactions directly related to the use of the medication.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",c325bbfc-46f3-471e-7bbc-ed0d6965d13b,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=c325bbfc-46f3-471e-7bbc-ed0d6965d13b&type=display
386,ESTAZOLAM,"1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with Estazolam itself.
2. The label primarily focuses on warnings related to concomitant use with opioids, abuse, misuse, addiction, dependence, and withdrawal reactions, but does not mention cardiotoxicity risks specifically.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",2f349a44-6d04-01d1-c8b7-12254aead77d,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=2f349a44-6d04-01d1-c8b7-12254aead77d&type=display
387,ESTERIFIED ESTROGENS,"1. The drug label states that estrogens, including the drug Menest, should not be used for the prevention of cardiovascular disease, as they have been associated with an increased risk of cardiovascular events such as myocardial infarction and stroke, as well as venous thrombosis and pulmonary embolism (venous thromboembolism or VTE). This indicates that the drug itself is associated with cardiotoxicity risks.

2. Clinical studies, such as the Women's Health Initiative (WHI) study, reported increased risks of myocardial infarction, stroke, invasive breast cancer, pulmonary emboli, and deep vein thrombosis in postmenopausal women during treatment with oral conjugated estrogens combined with medroxyprogesterone acetate, relative to placebo. This suggests that the drug Menest is associated with cardiotoxicity reactions.

3. The WHI study also observed an increased risk of coronary heart disease events and stroke in women receiving estrogens compared to placebo, with the risk persisting over time. This indicates that the drug Menest is associated with cardiotoxicity risks.

4. Additionally, the WHI study reported a 2-fold greater rate of venous thromboembolism, including deep venous thrombosis and pulmonary embolism, in women receiving estrogens compared to placebo. This suggests that the drug Menest is associated with cardiotoxicity reactions, specifically related to venous thromboembolism.

5. The drug label also warns that if cardiovascular events or venous thromboembolism are suspected or occur, estrogens should be discontinued immediately. This indicates that the drug Menest can lead to cardiotoxicity reactions that require prompt action to mitigate risks.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",e0141598-0bb2-4cf0-c9b8-6867b34bbb17,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=e0141598-0bb2-4cf0-c9b8-6867b34bbb17&type=display
388,ESTRADIOL,"1. The drug label warns that estrogen-alone therapy, including IMVEXXY, is associated with an increased risk of stroke and deep vein thrombosis (DVT) in postmenopausal women, as reported in the Women's Health Initiative (WHI) estrogen-alone substudy. This indicates that the drug itself is associated with the cardiotoxicity risk.

2. The label also mentions that the WHI Memory Study (WHIMS) reported an increased risk of probable dementia in postmenopausal women 65 years of age and older during treatment with daily conjugated estrogens (CE) alone, relative to placebo. This suggests a potential association between the drug and cardiovascular disorders, including dementia.

3. For estrogen plus progestin therapy, the WHI estrogen plus progestin substudy reported increased risks of stroke, DVT, pulmonary embolism (PE), and myocardial infarction (MI) in postmenopausal women. This indicates that the drug combination is associated with cardiotoxicity risks.

4. The WHI estrogen plus progestin substudy also reported an increased risk of invasive breast cancer in women receiving this therapy. While not directly related to cardiotoxicity, breast cancer is a serious health concern associated with this hormone therapy.

5. The drug label advises immediate discontinuation of estrogen therapy if any cardiovascular events occur or are suspected, emphasizing the importance of monitoring and managing cardiovascular risks associated with IMVEXXY use.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",6ce645c0-a550-4ae9-8dbd-3853ee8b7d26,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=6ce645c0-a550-4ae9-8dbd-3853ee8b7d26&type=display
389,ESTRADIOL CYPIONATE,"1. The drug label warns that estrogens, including DEPO-Estradiol, should not be used for the prevention of cardiovascular disease, as they have been associated with an increased risk of cardiovascular events such as myocardial infarction and stroke. (The drug itself is associated with the cardiotoxicity risk.)

2. The Women's Health Initiative (WHI) study reported increased risks of myocardial infarction, stroke, and other cardiovascular events in postmenopausal women during treatment with oral conjugated estrogens combined with medroxyprogesterone acetate, compared to placebo. (The drug itself is associated with the cardiotoxicity reactions.)

3. The WHI study also found an increased risk of coronary heart disease events and stroke in women receiving estrogen/progestin therapy compared to placebo, with the risk observed in the first year of treatment and persisting. (The drug itself is associated with the cardiotoxicity reactions.)

4. Estrogen therapy has been linked to an increased risk of venous thromboembolism, including deep vein thrombosis and pulmonary embolism, as reported in the WHI study. (The drug itself is associated with the cardiotoxicity risk.)

5. The WHI study showed a 2-fold greater rate of venous thromboembolism in women receiving estrogen/progestin therapy compared to placebo, with the increased risk observed in the first year of treatment and persisting. (The drug itself is associated with the cardiotoxicity reactions.)

6. Estrogens should be discontinued at least 4 to 6 weeks before surgery associated with an increased risk of thromboembolism or during prolonged immobilization to reduce the risk of cardiovascular events. (The drug itself is associated with the cardiotoxicity risk.)

7. The drug label also mentions that large doses of estrogen have been shown to increase the risks of nonfatal myocardial infarction, pulmonary embolism, and thrombophlebitis in men, indicating a potential cardiotoxic effect of estrogen therapy. (The drug itself is associated with the cardiotoxicity risk.)",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",9a4229fd-fecd-4ac1-9c4f-6d442533457f,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=9a4229fd-fecd-4ac1-9c4f-6d442533457f&type=display
390,ESTRADIOL VALERATE,"1. Estrogens and progestins should not be used for the prevention of cardiovascular disease. The Womens Health Initiative (WHI) study reported increased risks of myocardial infarction, stroke, invasive breast cancer, pulmonary emboli, and deep vein thrombosis in postmenopausal women during 5 years of treatment with oral conjugated estrogens combined with medroxyprogesterone acetate relative to placebo. (The drug itself was associated with cardiotoxicity risks.)

2. In the Women's Health Initiative (WHI) study, an increase in the number of myocardial infarctions and strokes has been observed in women receiving conjugated estrogens compared to placebo. (The drug itself was associated with cardiotoxicity risks.)

3. In the CE/MPA substudy of WHI, an increased risk of coronary heart disease events was observed in women receiving CE/MPA compared to women receiving placebo. The increase in risk was observed in year one and persisted. (The drug itself was associated with cardiotoxicity risks.)

4. In the same substudy of WHI, an increased risk of stroke was observed in women receiving CE/MPA compared to women receiving placebo. The increase in risk was observed after the first year and persisted. (The drug itself was associated with cardiotoxicity risks.)

5. Large doses of estrogen have been shown to increase the risks of nonfatal myocardial infarction, pulmonary embolism, and thrombophlebitis in a large prospective clinical trial in men. (The drug itself was associated with cardiotoxicity risks.)

6. In the Women's Health Initiative (WHI) study, an increase in venous thromboembolism (VTE) has been observed in women receiving conjugated estrogens compared to placebo. (The drug itself was associated with cardiotoxicity risks.)

7. In the CE/MPA substudy of WHI, a 2-fold greater rate of VTE, including deep venous thrombosis and pulmonary embolism, was observed in women receiving CE/MPA compared to women receiving placebo. The rate of VTE was higher in the CE/MPA group. (The drug itself was associated with cardiotoxicity risks.)

8. Estrogens may cause hypercoagulability, primarily related to decreased antithrombin activity, which appears dose- and duration-dependent. (The drug itself was associated with cardiotoxicity risks.)",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",e8f94df9-0692-4462-a7f0-fe019a0a3f07,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=e8f94df9-0692-4462-a7f0-fe019a0a3f07&type=display
391,ESTRAMUSTINE PHOSPHATE SODIUM,"1. The drug label mentions that there is an increased risk of thrombosis, including fatal and nonfatal myocardial infarction, in men receiving estrogens for prostatic cancer. This risk is associated with the drug itself.

2. The label also states that EMCYT Capsules should be used with caution in patients with a history of thrombophlebitis, thrombosis, or thromboembolic disorders, especially if they were associated with estrogen therapy. This risk is associated with the drug itself.

3. Adverse reactions reported in a clinical trial comparing EMCYT Capsules with diethylstilbestrol (DES) included cardiac arrest, cerebrovascular accident, myocardial infarction, thrombophlebitis, pulmonary emboli, congestive heart failure, and edema. These cardiotoxicity reactions were reported in patients taking EMCYT Capsules.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",a9b01bc6-95ac-46f9-befa-d845a74d53c1,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a9b01bc6-95ac-46f9-befa-d845a74d53c1&type=display
392,ESTROPIPATE,"1. The drug label warns that estrogens, including Estropipate, should not be used for the prevention of cardiovascular disease, as they have been associated with an increased risk of cardiovascular events such as myocardial infarction and stroke, as well as venous thrombosis and pulmonary embolism (venous thromboembolism or VTE). This indicates that the drug itself is associated with cardiotoxicity risks.

2. Clinical studies, such as the Women's Health Initiative (WHI) study, reported increased risks of myocardial infarction, stroke, invasive breast cancer, pulmonary emboli, and deep vein thrombosis in postmenopausal women during treatment with oral conjugated estrogens combined with medroxyprogesterone acetate, compared to placebo. This suggests that the drug itself is associated with cardiotoxicity reactions.

3. The WHI study also reported an increased risk of coronary heart disease events and stroke in women receiving estrogen/progestin therapy compared to placebo. This indicates that the drug itself is associated with cardiotoxicity risks.

4. Estrogen therapy has been associated with an increased risk of cardiovascular events, such as myocardial infarction and stroke, as well as venous thrombosis and pulmonary embolism. If any of these events occur or are suspected, estrogens should be discontinued immediately. This suggests that the drug itself is associated with cardiotoxicity risks.

5. The WHI study also observed a 2-fold greater rate of venous thromboembolism, including deep venous thrombosis and pulmonary embolism, in women receiving estrogen/progestin therapy compared to placebo. This indicates that the drug itself is associated with cardiotoxicity reactions.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",03cdbf5b-b572-448f-80e9-b3e812959901,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=03cdbf5b-b572-448f-80e9-b3e812959901&type=display
393,ESZOPICLONE,"1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with LUNESTA itself. 

2. The drug label does not attribute any cardiotoxicity risks or reactions to LUNESTA. 

3. No cardiotoxicity risks or reactions related to LUNESTA are mentioned in the drug label. 

Overall, the drug label for LUNESTA does not indicate any cardiotoxicity risks or reactions directly linked to the use of the medication.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",fd047b2b-05a6-4d99-95cb-955f14bf329f,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fd047b2b-05a6-4d99-95cb-955f14bf329f&type=display
394,ETELCALCETIDE,"1. **Worsening Heart Failure**: The drug PARSABIV may be associated with reductions in corrected serum calcium that could lead to congestive heart failure. However, a direct causal relationship to PARSABIV has not been completely excluded. Patients should be closely monitored for worsening signs and symptoms of heart failure. (PARSABIV may be associated with worsening heart failure, but a direct causal relationship is not confirmed.)

2. **QT Interval Prolongation and Ventricular Arrhythmia**: In clinical studies, more patients treated with PARSABIV experienced QT interval prolongation and ventricular arrhythmias compared to placebo. Patients with predisposing conditions to QT interval prolongation and ventricular arrhythmias may be at increased risk if they develop hypocalcemia due to PARSABIV. Close monitoring of corrected serum calcium and QT interval is recommended for at-risk patients. (PARSABIV was associated with QT interval prolongation and ventricular arrhythmias in some patients.)

3. **Upper Gastrointestinal Bleeding**: While the exact cause of gastrointestinal bleeding in patients taking PARSABIV is unknown, patients with risk factors for upper GI bleeding may be at increased risk. Monitoring for signs and symptoms of GI bleeding is advised, and prompt evaluation and treatment are recommended. (PARSABIV may be associated with an increased risk of upper gastrointestinal bleeding, but the direct cause is uncertain.)

4. **Adverse Reactions**: In clinical trials, cases of hypotension, congestive heart failure, and decreased myocardial performance were reported in patients taking PARSABIV. Heart failure requiring hospitalization occurred in some PARSABIV-treated patients. While reductions in corrected serum calcium may be linked to congestive heart failure, a definitive causal relationship to PARSABIV has not been completely ruled out. Patients should be closely monitored for worsening signs of heart failure. (PARSABIV was associated with cases of hypotension, congestive heart failure, and decreased myocardial performance in some patients.)",Less,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",cd270093-c6a8-4596-a4ab-e6aa0a2c8a0c,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=cd270093-c6a8-4596-a4ab-e6aa0a2c8a0c&type=display
395,ETEPLIRSEN,"1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with EXONDYS 51 itself.
2. The label does not indicate any direct association between EXONDYS 51 and cardiotoxicity risks or reactions.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",33bff678-7829-479e-9110-b8e33a0bc0aa,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=33bff678-7829-479e-9110-b8e33a0bc0aa&type=display
396,ETHACRYNIC ACID,"1. The drug EDECRIN (Ethacrynic Acid) is a potent diuretic that may lead to profound diuresis with water and electrolyte depletion if given in excessive amounts. This risk is associated with the drug itself.

2. EDECRIN has little or no effect on glomerular filtration or renal blood flow, except following pronounced reductions in plasma volume when associated with rapid diuresis. This statement does not directly associate the drug with cardiotoxicity risk.

3. Too vigorous diuresis with EDECRIN may induce an acute hypotensive episode, particularly in elderly cardiac patients, leading to hemoconcentration and potential thromboembolic episodes. This risk is associated with the drug itself.

4. Excessive loss of potassium due to EDECRIN may precipitate digitalis toxicity in patients receiving digitalis glycosides. This risk is associated with the drug itself.

5. A number of possibly drug-related deaths have occurred in critically ill patients refractory to other diuretics, with some cases involving severe myocardial disease and acute hypokalemia leading to fatal arrhythmias. This risk is associated with the drug itself.

6. Deafness, tinnitus, and vertigo have occurred with EDECRIN use, particularly in patients with severe renal impairment, and may be reversible or permanent. This risk is associated with the drug itself.

7. EDECRIN may increase the ototoxic potential of other drugs, potentially enhancing their adverse effects on hearing. This risk is associated with the drug itself.

8. EDECRIN may increase the risk of gastric hemorrhage associated with corticosteroid treatment. This risk is associated with the drug itself.

In summary, EDECRIN carries several cardiotoxicity risks, including the potential for profound diuresis leading to electrolyte imbalances, acute hypotensive episodes, digitalis toxicity, and ototoxic effects. These risks are directly associated with the use of the drug itself.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",cfc43a98-2dc4-4edc-ad49-d2e368ea1bc2,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=cfc43a98-2dc4-4edc-ad49-d2e368ea1bc2&type=display
397,ETHACRYNIC SODIUM,"1. The drug label mentions that ethacrynic acid, a potent diuretic, may lead to profound diuresis with water and electrolyte depletion if given in excessive amounts, requiring careful medical supervision to adjust dose and schedule to the individual patient's needs. (The drug itself is associated with the risk of profound diuresis and electrolyte depletion.)

2. The label states that too vigorous diuresis from ethacrynic acid may induce an acute hypotensive episode in elderly cardiac patients, potentially leading to thromboembolic episodes such as cerebral vascular thromboses and pulmonary emboli, which can be fatal. (The drug itself is associated with the risk of acute hypotensive episodes and thromboembolic events.)

3. It is mentioned that ethacrynic acid has been associated with possibly drug-related deaths in critically ill patients, particularly those with severe myocardial disease or severely decompensated hepatic cirrhosis with ascites, who may experience electrolyte imbalance leading to fatal arrhythmias or intensification of electrolyte defects. (The drug itself is associated with the risk of electrolyte imbalance and fatal arrhythmias in certain patient populations.)

4. The label warns that ethacrynic acid may increase the risk of gastric hemorrhage associated with corticosteroid treatment. (The drug itself is associated with an increased risk of gastric hemorrhage when used concomitantly with corticosteroids.)

5. Ethacrynic acid is cautioned to be given with caution to patients with advanced cirrhosis of the liver, as it may precipitate hepatic coma and death, particularly in those with a history of electrolyte imbalance or hepatic encephalopathy. (The drug itself is associated with the risk of precipitating hepatic coma and death in patients with advanced cirrhosis of the liver.)

6. The label mentions that ethacrynic acid may potentiate the action of carbonic anhydrase inhibitors, leading to augmentation of natriuresis and kaliuresis, and advises careful dose adjustments to avoid electrolyte depletion. (The drug itself is associated with the risk of electrolyte depletion when used concomitantly with carbonic anhydrase inhibitors.)

7. It is noted that ethacrynic acid may increase the risk of ototoxicity when used with other drugs known to be ototoxic, potentially increasing the ototoxic potential of those drugs. (The drug itself is associated with the risk of ototoxicity when used concomitantly with other ototoxic drugs.)

8. The label warns that excessive diuresis from ethacrynic acid should be managed by withdrawing the drug until homeostasis is restored, or by reducing the dosage or temporarily discontinuing the drug when excessive electrolyte loss occurs. (The drug itself is associated with the risk of excessive diuresis and electrolyte loss, necessitating dose adjustments or temporary withdrawal.)",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",f108e431-f8d3-4442-8a60-bfc1d8a7bafc,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=f108e431-f8d3-4442-8a60-bfc1d8a7bafc&type=display
398,ETHAMBUTOL HYDROCHLORIDE,"1. The drug label mentions that toxicological studies in dogs on high prolonged doses of ethambutol hydrochloride, the active ingredient in Myambutol, produced evidence of myocardial damage and failure, as well as depigmentation of the tapetum lucidum of the eyes. The significance of these findings is not known, suggesting that ethambutol hydrochloride is associated with cardiotoxicity risks.

2. In rhesus monkeys, neurological signs appeared after treatment with high doses of ethambutol hydrochloride given daily over several months, correlating with specific serum levels of the drug and definite neuroanatomical changes in the central nervous system. Focal interstitial carditis was also noted in monkeys receiving high doses of ethambutol hydrochloride. These findings indicate that ethambutol hydrochloride is associated with cardiotoxicity risks and cardiotoxicity reactions in animal studies.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",b362b3cd-2c26-4af5-baa4-084217729fa5,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=b362b3cd-2c26-4af5-baa4-084217729fa5&type=display
399,ETHANOLAMINE OLEATE,"1. The drug label mentions that in dogs, Ethamolin injection has been shown to increase extravascular lung water when injected into the right atrium, indicating a cardiotoxicity risk associated with the drug itself.
   
2. The label also states that pleural effusions, pulmonary edema, pulmonary infiltration, and pneumonitis have been reported in clinical trials with Ethamolin injection, suggesting cardiotoxicity reactions linked to the drug.

3. Additionally, the label advises minimizing the total per-session dose, especially in patients with concomitant cardiopulmonary disease, indicating a potential cardiotoxicity risk associated with the drug.

4. The label further mentions that patients with concomitant cardiorespiratory disease should be carefully monitored, emphasizing the importance of managing potential cardiotoxicity reactions related to the drug.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",a9c1d8c5-443e-400e-a42c-16a25fb47231,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a9c1d8c5-443e-400e-a42c-16a25fb47231&type=display
400,ETHIONAMIDE,"1. The drug label does not mention any specific cardiotoxicity risks associated with Trecator (ethionamide tablets, USP) itself.

2. The label does not attribute any cardiotoxicity reactions to Trecator.

3. No cardiotoxicity risks or reactions related to Trecator are mentioned in the drug label.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",04a413fe-95f4-47a7-42ac-283a9e78297d,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=04a413fe-95f4-47a7-42ac-283a9e78297d&type=display
401,ETHOSUXIMIDE,"1. The drug label mentions that ethosuximide (Zarontin) has been associated with blood dyscrasias, including some with fatal outcomes, and periodic blood counts should be performed due to this risk. (The drug itself is associated with the risk of blood dyscrasias.)

2. Drug-induced immune thrombocytopenia (DITP) has been reported with ethosuximide, and patients should discontinue Zarontin if DITP is suspected. (The drug itself is associated with the risk of DITP.)

3. The label states that ethosuximide can produce morphological and functional changes in the liver and kidneys, and abnormal liver and renal function studies have been reported in humans. (The drug itself is associated with the risk of liver and kidney effects.)

4. Cases of systemic lupus erythematosus have been reported with the use of ethosuximide. (The drug itself is associated with the risk of systemic lupus erythematosus.)

5. The drug label warns about serious dermatologic reactions, including Stevens-Johnson syndrome (SJS), which have been reported with ethosuximide treatment. (The drug itself is associated with the risk of serious dermatologic reactions, including SJS.)

6. Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) has occurred with Zarontin, and some events have been fatal or life-threatening. (The drug itself is associated with the risk of DRESS.)

7. The label mentions that ethosuximide may interact with other antiepileptic drugs, and periodic serum level determinations may be necessary due to potential interactions. (The drug itself is associated with the risk of drug interactions that may impact cardiotoxicity.)

Overall, the drug label for Zarontin discusses various cardiotoxicity risks and reactions associated with the use of ethosuximide, highlighting the importance of monitoring and managing these potential adverse effects.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",0e008f33-70a1-4bc6-b3a0-d45214418ab6,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=0e008f33-70a1-4bc6-b3a0-d45214418ab6&type=display
402,ETODOLAC,"1. The drug label states that nonsteroidal anti-inflammatory drugs (NSAIDs), including etodolac, are associated with an increased risk of serious cardiovascular thrombotic events, such as myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use.

2. Etodolac is contraindicated in the setting of coronary artery bypass graft (CABG) surgery due to the cardiovascular thrombotic risk associated with NSAIDs.

3. The label warns that patients treated with NSAIDs, including etodolac, may experience an increased risk of serious cardiovascular thrombotic events, such as myocardial infarction and stroke, which can be fatal. The risk may be similar for all NSAIDs and is observed most consistently at higher doses.

4. The label advises physicians and patients to use the lowest effective dose of etodolac for the shortest duration possible to minimize the potential risk of adverse cardiovascular events. Monitoring for symptoms of serious cardiovascular events throughout the treatment course is recommended.

5. The label highlights that patients with a recent myocardial infarction (MI) should avoid etodolac unless the benefits outweigh the risk of recurrent cardiovascular thrombotic events. Monitoring for signs of cardiac ischemia is recommended if etodolac is used in patients with a recent MI.

6. NSAIDs, including etodolac, can lead to the onset of new hypertension or worsening of pre-existing hypertension, which may contribute to an increased incidence of cardiovascular events. Blood pressure should be closely monitored during NSAID treatment, especially in patients with hypertension.

7. The label cautions that NSAIDs, including etodolac, should be used with caution in patients with severe heart failure, as they may worsen heart failure symptoms. Monitoring for signs of worsening heart failure is recommended if etodolac is used in patients with severe heart failure.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",556eaa67-d30d-4095-a981-c65f98d3acdd,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=556eaa67-d30d-4095-a981-c65f98d3acdd&type=display
403,ETOMIDATE,"1. The drug etomidate is associated with cardiac depression in elderly patients, particularly those with hypertension. Clinical data indicates that etomidate administration in geriatric patients may result in decreases in heart rate, cardiac index, and mean arterial blood pressure. (The drug itself is associated with cardiotoxicity risks.)

2. Limited data is available concerning the use of etomidate in patients with recent severe trauma or hypovolemia to predict cardiovascular response under such circumstances. (The drug itself is not directly associated with cardiotoxicity risks in these specific patient populations.)

3. One case of severe hypotension and tachycardia, judged to be anaphylactoid in character, has been reported following etomidate administration. (The drug itself is associated with cardiotoxicity reactions in this specific case.)

4. Geriatric patients, particularly those with hypertension, may be at increased risk for the development of cardiac depression following etomidate administration. (The drug itself is associated with cardiotoxicity risks in geriatric patients.)

5. Hypertension, hypotension, tachycardia, bradycardia, and other arrhythmias have occasionally been observed during induction and maintenance of anesthesia with etomidate. (The drug itself is associated with cardiotoxicity reactions such as changes in blood pressure and heart rate.)

6. Clinical data indicates that etomidate may induce cardiac depression in elderly patients, particularly those with hypertension. (The drug itself is associated with cardiotoxicity risks in elderly patients.)

7. Geriatric patients may require lower doses of etomidate than younger patients due to age-related differences in pharmacokinetic parameters. (The drug itself is associated with dosing considerations in geriatric patients to mitigate cardiotoxicity risks.)

8. One case of severe hypotension and tachycardia, judged to be anaphylactoid in character, has been reported following etomidate administration. (The drug itself is associated with cardiotoxicity reactions in this specific case.)",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",b7ed5bf8-ba75-44dc-8f81-96b4ad5766be,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=b7ed5bf8-ba75-44dc-8f81-96b4ad5766be&type=display
404,ETONOGESTREL,"1. The drug label for NEXPLANON does not mention any direct association or causation of cardiotoxicity risks by the drug itself.

2. The label does not include any information regarding cardiotoxicity reactions related to the use of NEXPLANON. 

Overall, based on the drug label provided, there are no specific mentions of cardiotoxicity risks or reactions associated with NEXPLANON.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",487f8a62-e142-457c-97cc-2e398fde7594,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=487f8a62-e142-457c-97cc-2e398fde7594&type=display
405,ETOPOSIDE,"1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with etoposide itself. 

2. The label does not indicate any direct association between etoposide and cardiotoxicity risks or reactions. 

3. There is no mention of etoposide being linked to cardiotoxicity risks or reactions in the drug label. 

4. The drug label does not discuss any cardiotoxicity risks or reactions related to etoposide. 

5. The drug label does not attribute any cardiotoxicity risks or reactions to etoposide.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",6dfedeff-a807-4405-a482-2f7109ad31c9,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=6dfedeff-a807-4405-a482-2f7109ad31c9&type=display
406,ETOPOSIDE PHOSPHATE,"1. The drug label for ETOPOPHOS does not mention any specific cardiotoxicity risks or reactions associated with the drug itself. 

2. The label primarily focuses on myelosuppression, secondary leukemias, hypersensitivity reactions, and embryo-fetal toxicity as potential adverse effects of ETOPOPHOS. 

3. While the label does not directly link ETOPOPHOS to cardiotoxicity, it is important to consult with a healthcare provider for a comprehensive understanding of potential risks and side effects, including those related to the heart.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",7499fc35-fae8-44ad-bbab-9a1a589bf3ee,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7499fc35-fae8-44ad-bbab-9a1a589bf3ee&type=display
407,ETRAVIRINE,"1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with INTELENCE (etravirine) itself.

2. The drug label does not indicate any direct association between INTELENCE and cardiotoxicity risks or reactions. 

3. There is no mention of INTELENCE being linked to cardiotoxicity risks or reactions in the drug label. 

Overall, the drug label for INTELENCE does not highlight any cardiotoxicity risks or reactions specifically attributed to the use of the medication.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",6a9cbc29-9f15-4b24-8d86-206b82887f3d,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=6a9cbc29-9f15-4b24-8d86-206b82887f3d&type=display
408,EVEROLIMUS,"1. AFINITOR/AFINITOR DISPERZ has been associated with severe hypersensitivity reactions, including angioedema, which may lead to swelling of the airways or tongue, with or without respiratory impairment. Permanently discontinuing the drug is recommended for clinically significant hypersensitivity reactions. (The drug itself is associated with the risk of severe hypersensitivity reactions, including angioedema.)

2. Patients taking concomitant angiotensin-converting-enzyme (ACE) inhibitors with AFINITOR/AFINITOR DISPERZ may be at an increased risk for angioedema. The incidence of angioedema in patients taking AFINITOR with an ACE inhibitor was higher compared to the control arm with an ACE inhibitor. Permanently discontinuing the drug is advised for angioedema. (The drug itself is associated with an increased risk of angioedema when used with ACE inhibitors.)

3. Stomatitis, including mouth ulcers and oral mucositis, has been reported in patients treated with AFINITOR/AFINITOR DISPERZ. Stomatitis most commonly occurs within the first 8 weeks of treatment. Initiating dexamethasone alcohol-free oral solution as a mouthwash when starting treatment can help reduce the incidence and severity of stomatitis. (The drug itself is associated with the risk of stomatitis, but not directly cardiotoxicity.)",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",2150f73a-179b-4afc-b8ce-67c85cc72f04,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=2150f73a-179b-4afc-b8ce-67c85cc72f04&type=display
409,EXEMESTANE,"1. The drug AROMASIN (exemestane) is associated with cardiotoxicity risks, as indicated by an incidence of cardiac ischemic events (myocardial infarction, angina, and myocardial ischemia) reported in patients receiving AROMASIN for the adjuvant treatment of early breast cancer. The incidence of cardiac ischemic events was higher in the AROMASIN group compared to the tamoxifen group.

2. AROMASIN is also linked to cardiac failure, with a reported incidence of cardiac failure in patients receiving AROMASIN for the adjuvant treatment of early breast cancer. The incidence of cardiac failure was slightly higher in the AROMASIN group compared to the tamoxifen group.

3. In the treatment of advanced breast cancer, AROMASIN was associated with an increased incidence of hot flushes, nausea, fatigue, increased sweating, and increased appetite compared to megestrol acetate. The proportion of patients experiencing excessive weight gain was significantly lower with AROMASIN than with megestrol acetate.

4. The comparative study between AROMASIN and megestrol acetate showed that fewer patients receiving AROMASIN discontinued treatment due to adverse reactions compared to those treated with megestrol acetate. Adverse reactions considered drug-related included hot flushes, nausea, fatigue, increased sweating, and increased appetite for AROMASIN.

5. The incidence of cardiac ischemic events, such as myocardial infarction, angina, and myocardial ischemia, was reported in patients receiving AROMASIN for the treatment of advanced breast cancer. The incidence of these events was higher in the AROMASIN group compared to the megestrol acetate group.

6. AROMASIN was associated with a higher incidence of events in musculoskeletal and nervous system disorders compared to tamoxifen in the adjuvant treatment of early breast cancer. The events included osteoporosis, osteochondrosis, trigger finger, paresthesia, carpal tunnel syndrome, neuropathy, and diarrhea, among others.

7. In the comparative study for the treatment of advanced breast cancer, AROMASIN was associated with a higher incidence of fatigue, hot flashes, pain, influenza-like symptoms, edema, depression, insomnia, anxiety, dizziness, headache, nausea, vomiting, abdominal pain, anorexia, constipation, diarrhea, and increased appetite compared to megestrol acetate.

Overall, AROMASIN is linked to cardiotoxicity risks, including cardiac ischemic events and cardiac failure, in patients receiving the drug for the adjuvant treatment of early breast cancer. Additionally, AROMASIN is associated with various adverse reactions, including hot flushes, nausea, fatigue, and increased sweating, in the treatment of advanced breast cancer.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",cf066b7a-032a-416c-8d40-15ba581423e3,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=cf066b7a-032a-416c-8d40-15ba581423e3&type=display
410,EXENATIDE,"1. The drug label mentions an increase in heart rate by 2.4 beats per minute in clinical trials of BYDUREON BCISE in adults. (The drug itself was associated with the increase in heart rate.)

2. The label also notes that acute events of gallbladder disease, such as cholelithiasis or cholecystitis, have been reported in patients treated with BYDUREON BCISE. (The drug itself was associated with the occurrence of gallbladder disease.)

3. Additionally, the label mentions that there were cases of acute gallbladder disease reported in the EXSCEL trial, with a higher incidence in BYDUREON-treated patients compared to placebo-treated patients. (The drug itself was associated with an increased risk of acute gallbladder disease.)

4. The drug label does not specifically mention any direct cardiotoxicity risks or reactions associated with BYDUREON BCISE.",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",2d18cfc4-e0de-4814-a712-c1b7c504bff5,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=2d18cfc4-e0de-4814-a712-c1b7c504bff5&type=display
411,EXTENDED PHENYTOIN SODIUM; PHENYTOIN SODIUM,"1. Cases of bradycardia and cardiac arrest have been reported in patients treated with PHENYTEK capsules, both at recommended phenytoin doses and levels, and in association with phenytoin toxicity. (The drug itself was associated with bradycardia and cardiac arrest.)

2. Most of the reports of cardiac arrest occurred in patients with underlying cardiac disease. (The drug itself was not directly associated with underlying cardiac disease but was mentioned in relation to cardiac arrest reports.)

3. PHENYTEK capsules should be discontinued immediately if symptoms of angioedema, such as facial, perioral, or upper airway swelling occur. (The drug itself was associated with angioedema, which can potentially lead to airway swelling and affect cardiac function.)

4. Cases of acute hepatotoxicity, including infrequent cases of acute hepatic failure, have been reported with PHENYTEK capsules. These events may be part of the spectrum of DRESS or may occur in isolation. Other common manifestations include jaundice, hepatomegaly, elevated serum transaminase levels, leukocytosis, and eosinophilia. The clinical course of acute phenytoin hepatotoxicity ranges from prompt recovery to fatal outcomes. In these patients with acute hepatotoxicity, PHENYTEK capsules should be immediately discontinued and not readministered. (Although this section primarily discusses hepatotoxicity, liver dysfunction can impact cardiac function and contribute to cardiotoxicity risks.)

5. Hematopoietic complications, some fatal, have occasionally been reported in association with administration of PHENYTEK capsules. These have included thrombocytopenia, leukopenia, granulocytopenia, agranulocytosis, and pancytopenia with or without bone marrow suppression. (While this section focuses on hematologic complications, severe blood disorders can indirectly affect cardiac function and contribute to cardiotoxicity risks.)",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",0f94c791-8b07-4b41-927e-c9f28bec5f60,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=0f94c791-8b07-4b41-927e-c9f28bec5f60&type=display
412,EZETIMIBE,"1. **Warnings and Precautions - Risks Associated with Combination Treatment with a Statin, Fenofibrate, or Other LDL-C Lowering Therapies:** The drug label warns about the risks associated with combining ZETIA with a statin, fenofibrate, or other LDL-C lowering therapies. The label advises referring to the Prescribing Information of these products for a description of their risks, including cardiotoxicity risks.

2. **Warnings and Precautions - Liver Enzyme Abnormalities and Monitoring:** The drug label mentions that increases in serum transaminases have been reported with the use of ZETIA. It advises performing liver enzyme testing as clinically indicated and considering withdrawal of ZETIA if increases in ALT or AST 3  ULN persist. This does not directly associate ZETIA with cardiotoxicity risks.

3. **Warnings and Precautions - Skeletal Muscle Effects (e.g., Myopathy and Rhabdomyolysis):** The drug label states that ZETIA may cause myopathy and rhabdomyolysis. It notes that in post-marketing reports, most patients who developed rhabdomyolysis were taking a statin or other agents known to be associated with an increased risk of rhabdomyolysis, such as fibrates. If myopathy is suspected, discontinuation of ZETIA and other concomitant medications is recommended. This does not directly associate ZETIA with cardiotoxicity risks.",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",174e45e0-45bb-48b7-9e60-8f6cfc1d22bb,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=174e45e0-45bb-48b7-9e60-8f6cfc1d22bb&type=display
413,FAMCICLOVIR,1. The drug label does not mention any cardiotoxicity risks or reactions associated with famciclovir tablets.,No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",a5c46194-3692-cd26-0d85-6371974ccc44,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a5c46194-3692-cd26-0d85-6371974ccc44&type=display
414,FAMOTIDINE,"1. The drug famotidine is not associated with systemic effects in the cardiovascular system, as indicated in clinical pharmacology studies. No cardiotoxicity risks or reactions were noted with famotidine use. 

2. In clinical studies, famotidine did not show any significant interference with compounds metabolized by the hepatic microsomal enzymes, including those affecting the cardiovascular system. Therefore, famotidine is not associated with cardiotoxicity risks or reactions due to drug interactions.

3. Prolonged QT interval, a potential cardiotoxicity risk, has been reported very rarely in patients with impaired renal function when the dose/dosing interval of famotidine may not have been adjusted appropriately. Adjustments in dosing intervals may be necessary in patients with moderate or severe renal insufficiency to mitigate this risk. 

4. In cases of overdose, the adverse reactions are similar to those encountered in normal clinical experience, and no serious cardiotoxic effects have been reported. Symptomatic and supportive treatment is recommended in cases of overdose, but no specific cardiotoxicity risks were highlighted.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",85c7d20d-3dec-b918-4c1d-8ca1db214e48,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=85c7d20d-3dec-b918-4c1d-8ca1db214e48&type=display
415,FEBUXOSTAT,"1. The drug ULORIC (febuxostat) is associated with a warning of cardiovascular death, particularly in gout patients with established cardiovascular disease. The risk of cardiovascular death was higher in patients treated with ULORIC compared to those treated with allopurinol in a cardiovascular outcomes study.

2. ULORIC should only be used in patients who have an inadequate response to a maximally titrated dose of allopurinol, who are intolerant to allopurinol, or for whom treatment with allopurinol is not advisable due to the increased risk of cardiovascular death associated with ULORIC use.

3. The drug label advises healthcare providers to consider the risks and benefits of ULORIC when deciding to prescribe or continue patients on ULORIC, emphasizing the importance of patient selection based on cardiovascular risk factors.

4. ULORIC was found to be similar to allopurinol for nonfatal myocardial infarction, nonfatal stroke, and unstable angina with urgent coronary revascularization, but had a higher rate of sudden cardiac death in gout patients with established cardiovascular disease.

5. The drug label highlights the need for monitoring patients for the development of cardiovascular events, informing patients about the symptoms of serious cardiovascular events, and considering the use of prophylactic low-dose aspirin therapy in patients with a history of cardiovascular disease.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",54de10ef-fe5f-4930-b91d-6bbb04c664bd,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=54de10ef-fe5f-4930-b91d-6bbb04c664bd&type=display
416,FEDRATINIB HYDROCHLORIDE,"1. The drug label warns about major adverse cardiac events (MACE) and mentions that another Janus Kinase (JAK)-inhibitor has increased the risk of MACE in patients with rheumatoid arthritis, a condition for which INREBIC is not indicated. It advises considering the benefits and risks before initiating or continuing therapy with INREBIC, particularly in patients who are current or past smokers and those with other cardiovascular risk factors. Patients should be informed about the symptoms of serious cardiovascular events and the steps to take if they occur. (The drug itself is not directly associated with causing cardiotoxicity but is mentioned in the context of another JAK-inhibitor increasing the risk of MACE.)

2. The label also mentions that thrombosis risks have been increased by another JAK-inhibitor in patients with rheumatoid arthritis, but in patients with myelofibrosis treated with INREBIC in clinical trials, the rates of thromboembolic events were similar in INREBIC and placebo-treated patients. Patients with symptoms of thrombosis should be promptly evaluated and treated appropriately. (The drug itself is not directly associated with causing thrombosis but is mentioned in the context of another JAK-inhibitor increasing the risk.)

3. Additionally, the label discusses the increased risk of secondary malignancies, including lymphoma and other malignancies, by another JAK-inhibitor in patients with rheumatoid arthritis. It advises considering the benefits and risks before initiating or continuing therapy with INREBIC, particularly in patients with a known malignancy (other than a successfully treated nonmelanoma skin cancer), patients who develop a malignancy, and patients who are current or past smokers. (The drug itself is not directly associated with causing secondary malignancies but is mentioned in the context of another JAK-inhibitor increasing the risk.)

In summary, while INREBIC itself is not directly associated with causing cardiotoxicity risks, the drug label mentions the increased risks of major adverse cardiac events, thrombosis, and secondary malignancies associated with another JAK-inhibitor in patients with rheumatoid arthritis. It advises caution and consideration of individual patient risks before initiating or continuing therapy with INREBIC.",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",f0f55a2a-4e0c-4cba-8571-03e1424486d7,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=f0f55a2a-4e0c-4cba-8571-03e1424486d7&type=display
417,FELBAMATE,"1. Felbatol (felbamate) is not associated with any cardiotoxicity risks or reactions based on the drug label information provided.

The drug label primarily focuses on the risks of aplastic anemia and hepatic failure associated with Felbatol use. There is no mention of cardiotoxicity risks or reactions in the provided drug label text.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",2f522701-397a-11de-8a39-0800200c9a66,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=2f522701-397a-11de-8a39-0800200c9a66&type=display
418,FELODIPINE,"1. The drug label states that felodipine, a calcium channel blocker, may occasionally precipitate significant hypotension and, rarely, syncope, which may lead to reflex tachycardia and angina pectoris. This suggests that felodipine itself is associated with the risk of cardiotoxicity.
   
2. The label also mentions that during chronic administration of felodipine, a reflex increase in heart rate frequently occurs, which may attenuate over time. This indicates that felodipine itself may cause an increase in heart rate, which is a cardiotoxic reaction.

3. Clinical trials mentioned in the label did not note any symptoms suggestive of a negative inotropic effect in hypertensive patients without clinical evidence of left ventricular dysfunction. This suggests that felodipine is not associated with negative inotropic effects in this population.

4. The label further states that felodipine decreases renal vascular resistance while maintaining the glomerular filtration rate unchanged. Mild diuresis, natriuresis, and kaliuresis have been observed during the first week of therapy. This indicates that felodipine may cause mild renal and electrolyte effects, which are important to monitor for potential cardiotoxicity risks.

5. Additionally, the label reports that increases in plasma noradrenaline levels have been observed in patients with hypertension during clinical trials. This suggests that felodipine may lead to alterations in plasma noradrenaline levels, which could have cardiotoxic implications.

6. The label also mentions that felodipine extended-release tablets have been associated with adverse events such as palpitations, hypotension, syncope, angina pectoris, arrhythmia, tachycardia, and premature beats. These reactions indicate that felodipine itself may lead to various cardiotoxic effects.

7. Furthermore, the label lists myocardial infarction, chest pain, and other cardiovascular adverse events that occurred in patients receiving felodipine in controlled clinical trials. These events suggest that felodipine may be associated with an increased risk of cardiotoxicity.

8. Lastly, the label highlights that felodipine may cause peripheral edema, which was the most common adverse event observed in clinical trials. The incidence of peripheral edema was dose and age-dependent, indicating that felodipine itself may contribute to this cardiotoxic reaction.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",b951455c-c235-4e23-9e21-08672d108726,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=b951455c-c235-4e23-9e21-08672d108726&type=display
419,FENFLURAMINE,"1. The drug label warns about an association between serotonergic drugs with 5-HT2B receptor agonist activity, including fenfluramine (the active ingredient in FINTEPLA), and valvular heart disease and pulmonary arterial hypertension. This indicates that the drug itself is associated with the risk of cardiotoxicity.

2. Echocardiogram assessments are required before, during, and after treatment with FINTEPLA to monitor for valvular heart disease and pulmonary arterial hypertension. This suggests that the drug itself may lead to cardiotoxicity and requires monitoring.

3. The drug label emphasizes that cardiac monitoring is necessary to evaluate for valvular heart disease and pulmonary arterial hypertension before starting treatment with FINTEPLA. This indicates that the drug itself may pose a risk of cardiotoxicity that needs to be assessed prior to treatment initiation.

4. The label states that no patient receiving FINTEPLA developed valvular heart disease or pulmonary arterial hypertension during clinical trials of up to 3 years in duration. This suggests that while the drug is associated with cardiotoxicity risks, no cases were reported in the trials.

5. The drug label mentions that patients must undergo echocardiogram assessments every 6 months during treatment with FINTEPLA and 3 to 6 months after the final dose to evaluate for valvular heart disease and pulmonary arterial hypertension. This indicates that the drug itself may lead to cardiotoxicity that requires ongoing monitoring.

6. The label highlights that FINTEPLA is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the FINTEPLA REMS due to the risks of valvular heart disease and pulmonary arterial hypertension. This underscores the seriousness of the drug's cardiotoxicity risks and the need for strict monitoring and control.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",e88f360e-33ad-4cd6-b2de-5ef885857c5d,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=e88f360e-33ad-4cd6-b2de-5ef885857c5d&type=display
420,FENOFIBRATE,"1. **Indications and Usage:** The drug, Antara, was not shown to reduce coronary heart disease morbidity and mortality in patients with type 2 diabetes mellitus. This indicates that the drug itself was not associated with reducing these risks.

2. **Warnings and Precautions - Mortality and Coronary Heart Disease Morbidity:** The drug, Antara, did not show a significant reduction in major adverse cardiovascular events in patients with type 2 diabetes mellitus. The clinical significance of the findings in the ACCORD Lipid trial and the FIELD study regarding cardiovascular outcomes is unclear. This suggests that the drug itself did not demonstrate a clear benefit in reducing cardiovascular risks in these specific patient populations.

3. **Warnings and Precautions - Hepatotoxicity:** Serious drug-induced liver injury, including liver transplantation and death, has been reported with Antara. This indicates a risk of liver-related adverse events associated with the drug.

4. **Warnings and Precautions - Myopathy and Rhabdomyolysis:** Myopathy and rhabdomyolysis have been reported in patients taking fenofibrate, with an increased risk observed when fenofibrate is co-administered with a statin. This suggests a potential risk of muscle-related adverse events associated with the drug, particularly when used in combination with certain medications.

5. **Warnings and Precautions - Venothromboembolic Disease:** In the FIELD trial, pulmonary embolus and deep vein thrombosis were observed at higher rates in the fenofibrate-treated group compared to the placebo group. This indicates a potential risk of venothromboembolic events associated with the use of Antara.

6. **Warnings and Precautions - Paradoxical Decreases in HDL Cholesterol Levels:** Severe decreases in HDL cholesterol levels have been reported in patients initiated on fibrate therapy, including Antara. The decrease in HDL-C levels was observed after initiation of fibrate therapy and returned to baseline upon withdrawal of the drug. This suggests a potential impact of the drug on HDL cholesterol levels, which is an important factor in cardiovascular health.

7. **Adverse Reactions - Mortality and Coronary Heart Disease Morbidity:** The adverse findings in large randomized clinical studies with other fibrate drugs may also apply to Antara, indicating a potential association with adverse cardiovascular outcomes.

8. **Adverse Reactions - Hepatotoxicity:** Increases in liver function tests were observed in patients taking fenofibrate, leading to discontinuation of treatment in some cases. This suggests a potential risk of liver-related adverse events associated with the drug.

In summary, while Antara was not shown to reduce coronary heart disease morbidity and mortality in certain patient populations, it is associated with risks of hepatotoxicity, myopathy, rhabdomyolysis, venothromboembolic disease, paradoxical decreases in HDL cholesterol levels, and potential adverse cardiovascular outcomes.",Less,No,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",24790a18-0291-4b88-a724-acac43b616ce,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=24790a18-0291-4b88-a724-acac43b616ce&type=display
421,FENOFIBRIC ACID,"1. The drug FIBRICOR (fenofibric acid) was not shown to reduce coronary heart disease morbidity and mortality in patients with type 2 diabetes mellitus, as per the Important Limitations of Use section. (Drug not associated with cardiotoxicity risk)

2. The drug label mentions that fibrates, including fenofibrate, have been associated with an increased risk of myopathy and rhabdomyolysis, particularly in elderly patients and those with certain conditions like diabetes, renal failure, or hypothyroidism. The risk for serious muscle toxicity appears to be increased when fibrates are co-administered with statins, especially gemfibrozil. (Drug associated with cardiotoxicity risk)

3. The drug label advises monitoring liver tests, including ALT, periodically during therapy with fenofibrate due to its potential to increase serum transaminases. (Drug not associated with cardiotoxicity risk)

4. Fenofibrate can reversibly increase serum creatinine levels, and renal function should be monitored periodically in patients with renal insufficiency. (Drug not associated with cardiotoxicity risk)

5. Fibrates, including fenofibrate, may increase cholesterol excretion into the bile, leading to the risk of cholelithiasis (gallstones). If cholelithiasis is suspected, gallbladder studies are indicated. (Drug not associated with cardiotoxicity risk)

6. The drug label mentions that caution should be exercised in concomitant treatment with oral coumarin anticoagulants, as fenofibrate can potentiate the anticoagulant effects, leading to bleeding complications. (Drug not associated with cardiotoxicity risk)

7. Acute hypersensitivity reactions, including anaphylaxis and angioedema, have been reported postmarketing with fenofibrate. Some cases were life-threatening and required emergency treatment. (Drug not associated with cardiotoxicity risk)

8. The drug label also mentions delayed hypersensitivity reactions, including severe cutaneous adverse drug reactions like Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis, which have been reported postmarketing with fenofibrate. Discontinue fenofibrate and treat patients appropriately if these reactions occur. (Drug not associated with cardiotoxicity risk)

9. In the FIELD trial, pulmonary embolus (PE) and deep vein thrombosis (DVT) were observed at higher rates in the fenofibrate-treated group compared to the placebo group. (Drug associated with cardiotoxicity risk)

10. The drug label also reports postmarketing and clinical trial findings of severe decreases in HDL cholesterol levels occurring in patients initiated on fibrate therapy, including fenofibrate. The clinical significance of this decrease in HDL-C is unknown. (Drug not associated with cardiotoxicity risk)",Less,No,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",454af7e2-8734-4a56-b659-02e83d2024fb,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=454af7e2-8734-4a56-b659-02e83d2024fb&type=display
422,FENOPROFEN CALCIUM,"1. The drug label warns that Non-Steroidal Anti-Inflammatory drugs (NSAIDs), including NALFON, are associated with an increased risk of serious cardiovascular thrombotic events, such as myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use.

2. NALFON is contraindicated in the setting of coronary artery bypass graft (CABG) surgery, indicating that the drug itself is associated with an increased risk of cardiovascular events in this specific surgical setting.

3. The label advises that patients taking NALFON should use the lowest effective dosage for the shortest duration possible to minimize the potential risk for adverse cardiovascular events.

4. It is mentioned that there is no consistent evidence that concurrent use of aspirin mitigates the increased risk of serious cardiovascular thrombotic events associated with NSAID use, indicating that the drug itself is associated with this risk independently of aspirin use.

5. The label also highlights that patients with a recent myocardial infarction (MI) should avoid the use of NALFON unless the benefits are expected to outweigh the risk of recurrent cardiovascular thrombotic events, suggesting that the drug itself may exacerbate cardiovascular risks in this patient population.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",dfc2ab1e-0d75-4eff-9489-2afb51b02702,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=dfc2ab1e-0d75-4eff-9489-2afb51b02702&type=display
423,FERRIC CARBOXYMALTOSE; FERRIC CARBOXYMALTOSE INJECTION,"1. **Warnings and Precautions:** The drug Injectafer is associated with cardiotoxicity risks, as it mentions monitoring patients closely for signs and symptoms of hypertension following each administration. This indicates that Injectafer may lead to transient elevations in systolic blood pressure, potentially causing cardiotoxic effects.

2. **Adverse Reactions:** The drug Injectafer is associated with cardiotoxicity reactions, as it lists hypertension as one of the most common adverse reactions in adult patients. This suggests that Injectafer administration may lead to hypertension, which is a cardiotoxic effect.

3. **Post-marketing Experience:** The drug Injectafer is associated with cardiotoxicity reactions, as it reports tachycardia as a cardiac disorder observed in post-marketing experience. This indicates that Injectafer may have cardiotoxic effects leading to tachycardia in some patients.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",517b4a19-45b3-4286-9f6a-ced4e10447de,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=517b4a19-45b3-4286-9f6a-ced4e10447de&type=display
424,FERRIC CITRATE,"1. **Warnings and Precautions**: The drug label mentions iron overload as a potential risk associated with the drug. Patients may require a reduction in dose or discontinuation of intravenous iron due to iron overload, which can lead to cardiotoxicity. The drug itself is not directly associated with cardiotoxicity but can indirectly contribute to it through iron overload.

2. **Adverse Reactions**: The drug label lists hyperkalemia as one of the most common adverse reactions. Hyperkalemia is a condition that can affect the heart's rhythm and function, potentially leading to cardiotoxicity. While hyperkalemia is mentioned as an adverse reaction, it is not explicitly stated as a direct cardiotoxic effect of the drug.

3. **Patient Counseling Information**: Patients are advised to report severe or persistent gastrointestinal symptoms to their physician. Gastrointestinal symptoms can sometimes be a sign of underlying issues, including electrolyte imbalances that may impact the heart's function. While not directly stating cardiotoxicity, these symptoms could be related to potential cardiotoxic effects of the drug.",Less,No,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",aadd18e0-3752-11e4-8510-0800200c9a66,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=aadd18e0-3752-11e4-8510-0800200c9a66&type=display
425,FERRIC DERISOMALTOSE,"1. The drug MONOFERRIC was evaluated for cardiotoxicity risks through an electrocardiogram (ECG) monitoring sub-study in 35 patients, where no significant increase in QTc interval was detected at the 1000 mg single dose of MONOFERRIC. The drug itself was not associated with cardiotoxicity in this study.

2. The drug label did not report any direct association of MONOFERRIC with cardiac disorders or cardiotoxicity reactions in the clinical trials or post-marketing experience sections. 

3. Overall, the drug MONOFERRIC did not show a direct link to cardiotoxicity risks or cardiotoxic reactions based on the information provided in the drug label.",Less,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",55859d2d-0456-4fa9-b41f-f535accc97db,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=55859d2d-0456-4fa9-b41f-f535accc97db&type=display
426,FERRIC MALTOL,"1. The drug label does not mention any cardiotoxicity risks or cardiotoxicity reactions associated with ACCRUFER.
2. ACCRUFER is primarily indicated for the treatment of iron deficiency in adults and does not have any specific warnings or precautions related to cardiotoxicity.
3. There is no information in the drug label indicating that ACCRUFER is associated with cardiotoxicity risks or reactions.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",367ac157-2d25-4f34-99ce-b126e0f03851,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=367ac157-2d25-4f34-99ce-b126e0f03851&type=display
427,FERRIC PYROPHOSPHATE CITRATE,"1. The drug label for TRIFERIC AVNU does not mention any specific cardiotoxicity risks or reactions associated with the drug itself. 

2. The label primarily focuses on indications, dosage, administration, contraindications, warnings, precautions, adverse reactions, and patient counseling information related to the use of TRIFERIC AVNU for iron replacement in adult patients with hemodialysis-dependent chronic kidney disease (HDD-CKD).

3. While the label does not directly link TRIFERIC AVNU to cardiotoxicity risks or reactions, it does emphasize the importance of monitoring for hypersensitivity reactions during and after hemodialysis, which could include symptoms such as shock, hypotension, loss of consciousness, and collapse. Personnel and treatments should be readily available to manage serious hypersensitivity reactions.

4. The label also mentions common adverse reactions associated with TRIFERIC AVNU, such as headache, peripheral edema, asthenia, AV fistula thrombosis, urinary tract infection, and procedural hypotension, among others. These reactions do not specifically indicate cardiotoxicity risks.

5. Overall, while the drug label provides comprehensive information on the use of TRIFERIC AVNU and potential adverse reactions, it does not highlight any direct cardiotoxicity risks or reactions associated with the drug itself.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",51197a48-6078-42cd-b5ed-5ea22b6757b4,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=51197a48-6078-42cd-b5ed-5ea22b6757b4&type=display
428,FERUMOXYTOL,"1. **Risk for Serious Hypersensitivity/Anaphylaxis Reactions**: The drug Feraheme is associated with a risk for serious hypersensitivity reactions, including anaphylaxis, which can lead to cardiac/cardiorespiratory arrest, hypotension, syncope, and unresponsiveness. The drug itself is linked to these serious hypersensitivity reactions.

2. **Hypotension**: Feraheme may cause clinically significant hypotension, which should be monitored for signs and symptoms following each administration. The drug Feraheme is associated with the risk of hypotension.

3. **Iron Overload**: Excessive therapy with parenteral iron, such as Feraheme, can lead to iron overload and potential iatrogenic hemosiderosis. Regular monitoring of hematologic responses is necessary during Feraheme therapy to avoid iron overload. The drug Feraheme is associated with the risk of iron overload.

4. **Magnetic Resonance (MR) Imaging Test Interference**: Feraheme administration may transiently affect the diagnostic ability of MR imaging, with potential alterations persisting for up to 3 months post-administration. Specific MR imaging sequences should be used to minimize Feraheme effects. The drug Feraheme is associated with the risk of interfering with MR imaging tests.",Most,No,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",32b0e320-a739-11dc-a704-0002a5d5c51b,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=32b0e320-a739-11dc-a704-0002a5d5c51b&type=display
429,FESOTERODINE FUMARATE,"1. The drug label mentions that angioedema, including upper airway swelling, has been reported with Toviaz, which can be life-threatening. Toviaz itself is associated with the risk of angioedema, a serious condition that can lead to airway obstruction.

2. The label also states that Toviaz may cause urinary retention, especially in patients with bladder outlet obstruction, which can result in further urinary retention and kidney injury. Toviaz itself is associated with the risk of urinary retention, particularly in patients with existing bladder outlet obstruction.

3. Additionally, Toviaz is linked to decreased gastrointestinal motility, which is not recommended for patients with gastric retention or severe constipation. Toviaz itself is associated with the risk of decreased gastrointestinal motility, particularly in patients with pre-existing conditions like severe constipation.

4. Toviaz can worsen controlled narrow-angle glaucoma and should be used with caution in patients being treated for this condition. Toviaz itself is associated with the risk of worsening narrow-angle glaucoma, especially in patients with controlled narrow-angle glaucoma.

5. The drug label mentions that Toviaz is associated with anticholinergic central nervous system effects, such as somnolence, which can impair a patient's ability to drive or operate heavy machinery. Toviaz itself is associated with central nervous system effects like somnolence, which can impact a patient's cognitive and motor functions.

6. Lastly, Toviaz should be used with caution in patients with myasthenia gravis due to the risk of worsening symptoms of the disease. Toviaz itself is associated with the risk of exacerbating myasthenia gravis symptoms, particularly in patients with this neuromuscular disorder.",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",5be745f0-8ae7-4c3c-9962-37d6263326f1,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=5be745f0-8ae7-4c3c-9962-37d6263326f1&type=display
430,FEXINIDAZOLE,"1. Fexinidazole Tablets have been shown to prolong the QT interval in a concentration-dependent manner, with an average increase of 19 msec in the QTcF interval. The drug itself is associated with QT interval prolongation.

2. Patients with a history of torsade de pointes, congenital long QT syndrome, cardiac arrhythmias, uncompensated heart failure, or family history of sudden death should avoid using Fexinidazole Tablets due to the risk of QT interval prolongation. The drug itself is associated with QT interval prolongation.

3. Fexinidazole Tablets should be avoided in patients with a QTcF interval greater than 470 msec, as well as those with uncorrected hypokalemia. The drug itself is associated with QT interval prolongation.

4. Concomitant use of Fexinidazole Tablets with drugs known to prolong the QT interval, block cardiac potassium channels, induce bradycardia, or are hepatic CYP450 inducers should be avoided to prevent QT interval prolongation. The drug itself is associated with QT interval prolongation.

5. Neuropsychiatric adverse reactions, including agitation, anxiety, abnormal behavior, depression, suicidal ideation, nightmares, hallucination, and personality change, have been observed with Fexinidazole Tablets. The drug itself is associated with neuropsychiatric adverse reactions.

6. Healthcare providers should inform patients and caregivers of the risk for neuropsychiatric adverse reactions during treatment with Fexinidazole Tablets. The drug itself is associated with neuropsychiatric adverse reactions.

7. Patients with a history of psychiatric disorders or those experiencing neuropsychiatric adverse reactions should be considered for alternative therapy or increased monitoring, including hospitalization. The drug itself is associated with neuropsychiatric adverse reactions.",Less,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",74a611bc-9977-46bb-b626-0370b3031628,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=74a611bc-9977-46bb-b626-0370b3031628&type=display
431,FEXOFENADINE HYDROCHLORIDE,"1. The drug label mentions that no statistically significant increase in mean QTc interval compared to placebo was observed in adult subjects with seasonal allergic rhinitis given fexofenadine hydrochloride capsules in doses of 60 to 240 mg twice daily for 2 weeks. This indicates that the drug itself was not associated with cardiotoxicity risk in this study.

2. Pediatric subjects from two placebo-controlled trials treated with up to 60 mg fexofenadine hydrochloride twice daily demonstrated no significant treatment- or dose-related increases in QTc. This suggests that the drug did not cause cardiotoxicity reactions in pediatric subjects in these trials.

3. In addition, no statistically significant increase in mean QTc interval compared to placebo was observed in healthy adult subjects given fexofenadine hydrochloride as an oral solution at doses up to 400 mg twice daily for 6 days. This indicates that the drug did not lead to cardiotoxicity reactions in healthy adult subjects in this study.

4. For subjects with chronic idiopathic urticaria, there were no clinically relevant differences for any ECG intervals, including QTc, between those treated with fexofenadine hydrochloride 180 mg once daily and those treated with placebo for 4 weeks. This suggests that the drug did not result in cardiotoxicity reactions in subjects with chronic idiopathic urticaria in this study.",Less,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",6cf8da77-4272-4f88-9e5c-e83cfd80e9e9,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=6cf8da77-4272-4f88-9e5c-e83cfd80e9e9&type=display
432,FIDAXOMICIN,"1. **Warnings and Precautions**: Acute hypersensitivity reactions, including dyspnea, rash, pruritus, and angioedema of the mouth, throat, and face have been reported with DIFICID. If a severe hypersensitivity reaction occurs, discontinue DIFICID. (The drug itself is not associated with cardiotoxicity risk, but hypersensitivity reactions have been reported.)

2. **Warnings and Precautions**: DIFICID is not expected to be effective for the treatment of other types of infections due to minimal systemic absorption of fidaxomicin. DIFICID should only be used for the treatment of C. difficile-associated diarrhea. (The drug itself is not associated with cardiotoxicity risk.)

3. **Warnings and Precautions**: Prescribing DIFICID in the absence of proven or strongly suspected C. difficile infection is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria. (The drug itself is not associated with cardiotoxicity risk.)

4. **Adverse Reactions in Adults**: The most common adverse reactions in adults include nausea, vomiting, abdominal pain, gastrointestinal hemorrhage, anemia, and neutropenia. (No specific mention of cardiotoxicity reactions in adults.)

5. **Adverse Reactions in Pediatric Patients**: The most common adverse reactions in pediatric patients treated with DIFICID are pyrexia, abdominal pain, vomiting, diarrhea, constipation, increased aminotransferases, and rash. (No specific mention of cardiotoxicity reactions in pediatric patients.)

6. **Post Marketing Experience**: Hypersensitivity reactions, including dyspnea, angioedema, rash, and pruritus, have been identified during post-approval use of DIFICID. (The drug itself is not directly associated with cardiotoxicity risk, but hypersensitivity reactions have been reported.)

Overall, the drug DIFICID (fidaxomicin) is not directly associated with cardiotoxicity risks or cardiotoxicity reactions based on the information provided in the drug label. The highlighted adverse reactions primarily focus on gastrointestinal and hematologic effects, with hypersensitivity reactions being the main concern related to potential severe reactions.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",dd966338-c820-4270-b704-09ef75fa3ceb,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=dd966338-c820-4270-b704-09ef75fa3ceb&type=display
433,FINASTERIDE,1. The drug label does not mention any cardiotoxicity risks or cardiotoxicity reactions associated with the use of PROPECIA (finasteride) tablets for male pattern hair loss treatment.,No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",6f904709-65aa-44ce-b144-b4c8a0416e36,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=6f904709-65aa-44ce-b144-b4c8a0416e36&type=display
434,FINERENONE,"1. Kerendia is indicated to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adult patients with chronic kidney disease associated with type 2 diabetes (T2D). (The drug is indicated to reduce the risk of cardiovascular death and non-fatal myocardial infarction.)

2. Kerendia can cause hyperkalemia. The risk for developing hyperkalemia increases with decreasing kidney function and is greater in patients with higher baseline potassium levels or other risk factors for hyperkalemia. (The drug can cause hyperkalemia, a cardiotoxicity risk.)

3. Adverse reactions occurring in  1% of patients on Kerendia and more frequently than placebo are hyperkalemia, hypotension, and hyponatremia. (Hyperkalemia is an adverse reaction associated with Kerendia, indicating a cardiotoxicity risk.)

4. Kerendia reduced the incidence of the secondary composite endpoint of cardiovascular (CV) death, non-fatal myocardial infarction (MI), non-fatal stroke, or hospitalization for heart failure. (The drug reduced the risk of cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure, indicating a positive effect on cardiotoxicity risks.)",Less,Yes,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",fc726765-5d5a-4d6e-b037-b847bda9fb7c,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fc726765-5d5a-4d6e-b037-b847bda9fb7c&type=display
435,FINGOLIMOD HCL,"1. GILENYA is contraindicated in patients with recent myocardial infarction, unstable angina, stroke, transient ischemic attack (TIA), decompensated heart failure requiring hospitalization, or Class III/IV heart failure, indicating that the drug itself is associated with cardiotoxicity risks.
   
2. GILENYA is also contraindicated in patients with a history of Mobitz Type II second-degree or third-degree AV block or sick sinus syndrome, unless the patient has a pacemaker, suggesting that the drug is associated with cardiotoxicity risks.

3. Baseline QTc interval  500 msec is a contraindication for GILENYA use, indicating that the drug itself is associated with cardiotoxicity risks.

4. Cardiac arrhythmias requiring anti-arrhythmic treatment with Class Ia or Class III anti-arrhythmic drugs are contraindications for GILENYA use, suggesting that the drug is associated with cardiotoxicity risks.

5. GILENYA may cause bradyarrhythmia and atrioventricular blocks, leading to a decrease in heart rate and transient AV conduction delays, indicating that the drug itself is associated with cardiotoxicity reactions.

6. Patients with preexisting conditions such as ischemic heart disease, history of myocardial infarction, congestive heart failure, or other cardiac conditions may poorly tolerate GILENYA-induced bradycardia, suggesting that the drug is associated with cardiotoxicity risks.

7. GILENYA treatment initiation has resulted in symptomatic bradycardia in a small percentage of patients, which usually resolves within 24 hours, indicating that the drug itself is associated with cardiotoxicity reactions.

8. GILENYA has been associated with first-degree AV block and second-degree AV blocks, which were usually transient and asymptomatic, suggesting that the drug is associated with cardiotoxicity risks.

9. In the postmarketing setting, cases of third-degree AV block, AV block with junctional escape, syncope, and isolated delayed onset events like transient asystole and unexplained death have been reported within 24 hours of the first dose of GILENYA, indicating that the drug itself is associated with cardiotoxicity reactions.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",cc9e1c8c-0e2b-44e2-878b-27057f786be9,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=cc9e1c8c-0e2b-44e2-878b-27057f786be9&type=display
436,FISH OIL,"1. **Warnings and Precautions (5.1):** The drug label mentions that acute respiratory distress, metabolic acidosis, and death have been reported in neonates and infants after rapid infusion of intravenous lipid emulsions, including Omegaven. This indicates that Omegaven itself is associated with the risk of cardiotoxicity in this specific patient population.

2. **Warnings and Precautions (5.6):** The label states that hypertriglyceridemia, which can lead to pancreatitis, may occur during treatment with Omegaven. This suggests that Omegaven itself can potentially lead to cardiotoxicity through the development of hypertriglyceridemia and its associated complications.

3. **Adverse Reactions (6.1):** The most common adverse reactions reported with Omegaven treatment include bradycardia, which is a cardiotoxicity reaction. This indicates that Omegaven may lead to cardiotoxic effects such as bradycardia in patients receiving the drug.

4. **Adverse Reactions (6.1):** The label also mentions that hypotonia, another cardiotoxicity reaction, was reported in patients receiving Omegaven. This suggests that Omegaven may be associated with cardiotoxic effects such as hypotonia in treated patients.

5. **Adverse Reactions (6.1):** Additionally, the label lists apnea as a common adverse reaction associated with Omegaven treatment. Apnea is a cardiotoxicity reaction, indicating that Omegaven may lead to cardiopulmonary effects such as apnea in patients receiving the drug.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",5d9d0b24-e139-48bf-ab2d-536fb59cf8e0,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=5d9d0b24-e139-48bf-ab2d-536fb59cf8e0&type=display
437,FLAVOXATE HYDROCHLORIDE,"1. The drug label does not mention any direct association or causation of cardiotoxicity risks with Flavoxate Hydrochloride tablets. 

2. The adverse reactions section lists cardiovascular effects such as tachycardia and palpitations as potential side effects of Flavoxate Hydrochloride tablets. However, it does not state that the drug itself causes cardiotoxicity.

3. The drug label does not provide information suggesting that Flavoxate Hydrochloride tablets are directly associated with or cause cardiotoxicity reactions. 

Overall, the drug label does not indicate that Flavoxate Hydrochloride tablets are linked to cardiotoxicity risks or reactions.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",b4260d7e-2ab3-49f6-aa57-bae19a23d82a,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=b4260d7e-2ab3-49f6-aa57-bae19a23d82a&type=display
438,FLECAINIDE ACETATE,"1. The drug Flecainide Acetate is associated with cardiotoxicity risks, as it has been shown to have a negative inotropic effect and may cause or worsen congestive heart failure (CHF), particularly in patients with cardiomyopathy, preexisting severe heart failure, or low ejection fractions. The drug itself is linked to the risk of exacerbating or causing CHF.

2. Flecainide Acetate can cause new or worsened supraventricular or ventricular arrhythmias, ranging from an increase in frequency of premature ventricular contractions (PVCs) to the development of more severe ventricular tachycardia, which can have potentially fatal consequences. The drug itself is associated with the risk of inducing or worsening arrhythmias.

3. The drug Flecainide Acetate slows cardiac conduction, leading to dose-related increases in PR, QRS, and QT intervals. It can cause conduction changes such as sinus node dysfunction, AV block, and bradycardia. The drug itself is responsible for the conduction abnormalities observed.

4. Flecainide Acetate has been associated with proarrhythmic effects, with a high frequency of proarrhythmic events observed in patients with sustained ventricular tachycardia and serious underlying heart disease. The drug itself is linked to the risk of proarrhythmic events, especially in patients with underlying heart conditions.

5. In patients with chronic atrial fibrillation/flutter, Flecainide has been reported to cause ventricular tachycardia, increased PVCs, ventricular fibrillation, and even death. The drug itself is associated with the risk of ventricular proarrhythmic effects in patients with chronic atrial fibrillation/flutter.

6. Flecainide Acetate was found to be associated with a 5.1% rate of death and non-fatal cardiac arrest in post-myocardial infarction patients with asymptomatic PVCs and non-sustained ventricular tachycardia. The drug itself is linked to the increased risk of adverse cardiac events, including death and cardiac arrest.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",2013e6ef-9141-42c3-8ea8-285840ecdd15,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=2013e6ef-9141-42c3-8ea8-285840ecdd15&type=display
439,FLIBANSERIN,"1. The drug label warns about the risk of severe hypotension and syncope when ADDYI is used with alcohol, which can lead to cardiotoxicity. The interaction of ADDYI and alcohol close in time increases the risk of hypotension and syncope, potentially causing harm to the cardiovascular system.

2. The label also mentions that the use of ADDYI with moderate or strong CYP3A4 inhibitors can increase flibanserin concentrations, leading to severe hypotension and syncope, which can be cardiotoxic. Therefore, the drug itself, when used with these inhibitors, is associated with cardiotoxicity risks.

3. Additionally, the label states that the use of ADDYI in patients with hepatic impairment can increase flibanserin concentrations, resulting in severe hypotension and syncope, which pose cardiotoxic risks. Therefore, the drug itself, when used in patients with hepatic impairment, is linked to potential cardiotoxic effects.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",3819daf3-e935-2c53-c527-e1d57922f394,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=3819daf3-e935-2c53-c527-e1d57922f394&type=display
440,FLORBETABEN F 18,"1. **Warnings and Precautions**: The drug label mentions the risk of image interpretation errors, especially false positives, which could lead to misinterpretation of brain neuritic -amyloid plaque density during image analysis. The drug itself is not associated with causing cardiotoxicity risk in this context.

2. **Warnings and Precautions**: Neuraceq, being a radiopharmaceutical, contributes to a patient's long-term cumulative radiation exposure. The label advises ensuring safe handling to protect patients and healthcare workers from unintentional radiation exposure. The drug itself is not directly linked to causing cardiotoxicity but rather to radiation exposure risks.

3. **Adverse Reactions**: The most commonly reported adverse reactions include injection site reactions such as erythema, irritation, and pain. These reactions are local and related to the injection site, not indicative of systemic cardiotoxicity associated with the drug.

In summary, the drug Neuraceq is not directly associated with causing cardiotoxicity risks or cardiotoxic reactions. The warnings and precautions primarily focus on image interpretation errors and radiation exposure risks related to its use as a radiopharmaceutical for brain imaging. The adverse reactions reported are local injection site reactions and do not indicate systemic cardiotoxic effects.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",b0915068-cfd4-4d72-b9f8-7e31fe83cd1e,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=b0915068-cfd4-4d72-b9f8-7e31fe83cd1e&type=display
441,FLORBETAPIR F 18,1. The drug label does not mention any cardiotoxicity risks or cardiotoxicity reactions associated with AMYVID (Florbetapir F 18 Injection).,No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",bb5a5043-0f51-11df-8a39-0800200c9a66,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=bb5a5043-0f51-11df-8a39-0800200c9a66&type=display
442,FLORTAUCIPIR F-18,1. The drug label does not mention any cardiotoxicity risks or cardiotoxicity reactions associated with TAUVID.,No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",b483abad-5230-462a-adfb-1a65160f01d0,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=b483abad-5230-462a-adfb-1a65160f01d0&type=display
443,FLUCICLOVINE F-18,"1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with Axumin (fluciclovine F 18) injection for intravenous use.
2. There is no indication in the drug label that Axumin itself is associated with cardiotoxicity risks or reactions.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",389a502e-a7d5-43dd-b6bf-f022ff23f3b9,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=389a502e-a7d5-43dd-b6bf-f022ff23f3b9&type=display
444,FLUCONAZOLE,"1. The drug label does not mention any cardiotoxicity risks or cardiotoxicity reactions associated with Diflucan (fluconazole) itself.

2. The drug label does not indicate any cardiotoxicity risks or cardiotoxicity reactions related to the use of Diflucan (fluconazole). 

3. There are no mentions of cardiotoxicity risks or cardiotoxicity reactions attributed to Diflucan (fluconazole) in the drug label.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",f694c617-3383-416c-91b6-b94fda371204,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=f694c617-3383-416c-91b6-b94fda371204&type=display
445,FLUDARABINE PHOSPHATE,"1. The drug label does not mention any specific cardiotoxicity risks associated with Fludarabine Phosphate itself.
   
2. The drug label does not attribute any cardiotoxicity reactions to Fludarabine Phosphate.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",8039c2e3-ffe5-3997-e053-2991aa0ad9d0,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8039c2e3-ffe5-3997-e053-2991aa0ad9d0&type=display
446,FLUDEOXYGLUCOSE F-18,"1. The drug label mentions that Fludeoxyglucose F 18 Injection emits radiation, which may increase the risk for cancer, especially in pediatric patients. It advises using the smallest dose necessary for imaging to protect the patient and healthcare workers, indicating a potential cardiotoxicity risk associated with radiation exposure.

2. In the cardiology setting, Fludeoxyglucose F 18 Injection is used to identify left ventricular myocardium with residual glucose metabolism and reversible loss of systolic function in patients with coronary artery disease and left ventricular dysfunction when used together with myocardial perfusion imaging. The drug itself is not directly associated with causing cardiotoxicity but is used to assess cardiac function and metabolism, which may indirectly reveal cardiotoxicity issues.

3. The drug label explains that Fludeoxyglucose F 18 Injection PET imaging in cardiology can predict reversible or irreversible loss of systolic function in myocardial segments based on glucose metabolism patterns. It mentions that false-positive and false-negative results can occur, indicating that the drug's imaging results may not always accurately reflect cardiotoxicity risks.

4. The label also states that the decision for a patient to undergo revascularization should not be based solely on PET findings, as false-positive and false-negative tests are common. This suggests that while Fludeoxyglucose F 18 Injection can provide valuable information about cardiac function, it is not a definitive indicator of cardiotoxicity and should be interpreted alongside other clinical assessments.",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",3535020f-26c3-40b8-bdb5-1aaa1857ba57,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=3535020f-26c3-40b8-bdb5-1aaa1857ba57&type=display
447,FLUDROCORTISONE ACETATE,"1. The drug label mentions that the drug, Fludrocortisone Acetate, has a marked effect on sodium retention, which can lead to hypertension, edema, cardiac enlargement, congestive heart failure, potassium loss, and hypokalemic alkalosis. This indicates that the drug itself is associated with cardiotoxicity risks.

2. The label also warns that prolonged use of corticosteroids, including Fludrocortisone Acetate, may lead to posterior subcapsular cataracts, glaucoma, and secondary ocular infections, which can potentially cause damage to the optic nerves. This suggests that the drug can contribute to cardiotoxicity reactions.

3. Additionally, the drug label mentions that average and large doses of corticosteroids, such as Fludrocortisone Acetate, can cause elevation of blood pressure, salt and water retention, and increased excretion of potassium. It emphasizes the importance of monitoring dosage and salt intake to avoid hypertension, edema, or weight gain, indicating that the drug itself can lead to cardiotoxicity risks.

4. The label further states that the drug may cause musculoskeletal effects like muscle weakness, osteoporosis, and pathologic fractures, as well as gastrointestinal issues such as peptic ulcers and pancreatitis. These adverse reactions can indirectly impact the cardiovascular system, highlighting the potential cardiotoxicity risks associated with Fludrocortisone Acetate.

5. Lastly, the drug label mentions that Fludrocortisone Acetate can lead to cardiac side effects like cardiac enlargement and congestive heart failure due to its mineralocorticoid activity. These cardiotoxicity reactions are directly linked to the drug's mechanism of action and effects on electrolyte balance, underscoring the importance of monitoring cardiovascular health during treatment with this medication.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",89b5687a-6e21-47cd-9c05-d9c9f4f8cf49,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=89b5687a-6e21-47cd-9c05-d9c9f4f8cf49&type=display
448,FLUMAZENIL,"1. Flumazenil has been reported not to increase the work of the heart when used to reverse benzodiazepines in cardiac patients when given at a rate of 0.1 mg/min in total doses of less than 0.5 mg in studies reported in the clinical literature. Flumazenil alone had no significant effects on cardiovascular parameters when administered to patients with stable ischemic heart disease. (The drug itself was not associated with cardiotoxicity risk.)

2. Flumazenil should be used with caution in patients with head injury as it may be capable of precipitating convulsions or altering cerebral blood flow in patients receiving benzodiazepines. It should be used only by practitioners prepared to manage such complications should they occur. (The drug itself was not associated with cardiotoxicity risk.)

3. Flumazenil did not increase the work of the heart when used to reverse benzodiazepines in cardiac patients when given at a rate of 0.1 mg/min in total doses of less than 0.5 mg in studies reported in the clinical literature. Flumazenil alone had no significant effects on cardiovascular parameters when administered to patients with stable ischemic heart disease. (The drug itself was not associated with cardiotoxicity risk.)

Please note that the drug label did not mention any direct association of flumazenil with cardiotoxicity risks or reactions.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",436f5616-9626-4b6a-9deb-2986444179d0,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=436f5616-9626-4b6a-9deb-2986444179d0&type=display
449,FLUORODOPA F18,1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with Fluorodopa F 18 Injection.,No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",37f8c405-ccb6-4fcd-8513-108956bb1674,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=37f8c405-ccb6-4fcd-8513-108956bb1674&type=display
450,FLUOROESTRADIOL F 18,1. The drug label does not mention any specific cardiotoxicity risks or cardiotoxicity reactions associated with CERIANNA (fluoroestradiol F 18) Injection for intravenous use.,No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",b2c2a2df-cf3e-4a29-a033-231ed5a94b58,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=b2c2a2df-cf3e-4a29-a033-231ed5a94b58&type=display
451,FLUOXETINE HYDROCHLORIDE,"1. The drug label mentions that PROZAC is contraindicated with pimozide and thioridazine due to their potential to prolong the QT interval, indicating that PROZAC itself can increase the levels of these drugs and prolong the QT interval, leading to cardiotoxicity risk.

2. Additionally, the label warns about QT prolongation and ventricular arrhythmia, including Torsades de Pointes, being reported with PROZAC use, suggesting that PROZAC itself is associated with the risk of QT prolongation and cardiotoxicity reactions.

3. The label also states that PROZAC should not be used in combination with other drugs that prolong the QT interval, such as thioridazine or pimozide, further emphasizing the potential cardiotoxicity risks associated with PROZAC use.

4. Furthermore, the label mentions that PROZAC can increase the levels of haloperidol and clozapine, indicating a potential for elevation of these drugs and suggesting a risk of cardiotoxicity reactions when used in combination with PROZAC.

5. Overall, the drug label highlights the importance of monitoring for QT prolongation and ventricular arrhythmia, as well as the potential for cardiotoxicity risks associated with PROZAC use, especially when used in combination with other medications that affect cardiac function.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",c88f33ed-6dfb-4c5e-bc01-d8e36dd97299,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=c88f33ed-6dfb-4c5e-bc01-d8e36dd97299&type=display
452,FLUPHENAZINE DECANOATE,"1. The drug label warns of an increased risk of death in elderly patients with dementia-related psychosis treated with antipsychotic drugs, including fluphenazine decanoate. The risk of death in drug-treated patients was found to be higher compared to placebo-treated patients, with most deaths attributed to cardiovascular causes such as heart failure and sudden death.

2. The drug label mentions that fluphenazine decanoate may cause hypertension and fluctuations in blood pressure, indicating a potential cardiotoxicity risk associated with the drug itself.

3. The label also notes that hypotension has rarely presented a problem with fluphenazine, but patients with certain conditions like pheochromocytoma or cardiovascular disease may be particularly prone to hypotensive reactions with phenothiazine compounds, including fluphenazine decanoate.

4. Additionally, the drug label mentions that phenothiazine derivatives, including fluphenazine, have been known to cause autonomic reactions such as nausea, loss of appetite, salivation, and tachycardia, which are indicative of potential cardiotoxicity risks associated with the drug.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",8d7ba627-cf3f-4b94-aee8-8b44cc9400be,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8d7ba627-cf3f-4b94-aee8-8b44cc9400be&type=display
453,FLUPHENAZINE HYDROCHLORIDE,"1. The drug label warns of an increased risk of death in elderly patients with dementia-related psychosis when treated with antipsychotic drugs, including fluphenazine hydrochloride. The risk of death in drug-treated patients was higher compared to placebo-treated patients, with most deaths attributed to cardiovascular causes like heart failure or sudden death.

2. Fluphenazine hydrochloride is associated with the potential development of tardive dyskinesia, an irreversible syndrome of involuntary movements. The risk of developing tardive dyskinesia is believed to increase with the duration of treatment and cumulative dose of neuroleptic drugs, although the potential of different neuroleptic drugs to cause this syndrome is unknown.

3. The drug label mentions the occurrence of Neuroleptic Malignant Syndrome (NMS) in association with antipsychotic drugs, including fluphenazine hydrochloride. NMS is a potentially fatal symptom complex characterized by hyperpyrexia, muscle rigidity, altered mental status, and autonomic instability.

4. Fluphenazine hydrochloride may cause autonomic nervous system effects, including hypertension and fluctuations in blood pressure. While hypotension is rare with this drug, patients with certain conditions like pheochromocytoma or cardiovascular diseases may be more prone to hypotensive reactions.

5. The drug label also lists other potential adverse reactions related to the central nervous system, autonomic nervous system, metabolic and endocrine systems, and hematologic system, which may include symptoms like drowsiness, weight changes, abnormal lactation, and blood dyscrasias. These reactions may pose risks to patients taking fluphenazine hydrochloride.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",2dbef453-2412-4ebb-b593-d7bf86042473,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=2dbef453-2412-4ebb-b593-d7bf86042473&type=display
454,FLURAZEPAM HYDROCHLORIDE,"1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with flurazepam hydrochloride capsules.
2. Flurazepam hydrochloride capsules are primarily indicated for the treatment of insomnia and do not have direct cardiotoxic effects mentioned in the label.
3. The adverse reactions listed in the label do not include any cardiotoxic effects related to the use of flurazepam hydrochloride capsules.
4. Overall, there is no information provided in the drug label indicating that flurazepam hydrochloride capsules are associated with cardiotoxicity risks or reactions.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",8f476891-1346-4e8c-ac1b-f8cbdc64f5a1,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8f476891-1346-4e8c-ac1b-f8cbdc64f5a1&type=display
455,FLURBIPROFEN,"1. The drug label warns that nonsteroidal anti-inflammatory drugs (NSAIDs), including flurbiprofen tablets, are associated with an increased risk of serious cardiovascular thrombotic events, such as myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with the duration of use. Flurbiprofen tablets are associated with the risk of serious cardiovascular thrombotic events.

2. Flurbiprofen tablets are contraindicated in patients who have undergone coronary artery bypass graft (CABG) surgery due to the increased risk of myocardial infarction and stroke associated with NSAID use. Flurbiprofen tablets are associated with an increased risk of cardiovascular events in patients post-CABG surgery.

3. Clinical trials have shown that COX-2 selective and nonselective NSAIDs, including flurbiprofen, may increase the risk of serious cardiovascular thrombotic events, such as myocardial infarction and stroke. The risk of cardiovascular events may be higher in patients with known cardiovascular disease or risk factors. Flurbiprofen is associated with an increased risk of serious cardiovascular thrombotic events.

4. The drug label advises using the lowest effective dose of flurbiprofen for the shortest duration possible to minimize the potential risk of adverse cardiovascular events. Physicians and patients should remain vigilant for symptoms of serious cardiovascular events throughout the treatment course. Flurbiprofen use should be closely monitored for cardiovascular events.

5. The drug label also mentions that observational studies have shown an increased risk of reinfarction, cardiovascular-related death, and all-cause mortality in post-myocardial infarction patients treated with NSAIDs, including flurbiprofen. Flurbiprofen use in post-MI patients may increase the risk of adverse cardiovascular outcomes.

Overall, the drug label highlights the association between flurbiprofen tablets and an increased risk of serious cardiovascular thrombotic events, emphasizing the importance of using the lowest effective dose for the shortest duration and monitoring patients for signs of cardiovascular events during treatment.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",a0e9620d-0951-44d7-af6c-9b642051bd74,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a0e9620d-0951-44d7-af6c-9b642051bd74&type=display
456,FLUTAMIDE,1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with Eulexin (flutamide) capsules.,No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",56b6ba36-9b49-4422-a2a4-7bfa0d941a5d,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=56b6ba36-9b49-4422-a2a4-7bfa0d941a5d&type=display
457,FLUTEMETAMOL F-18,1. The drug label for Vizamyl does not mention any cardiotoxicity risks or cardiotoxicity reactions associated with the use of the drug.,No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",b3558f16-8f9a-4e55-8d9c-836427ebaa57,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=b3558f16-8f9a-4e55-8d9c-836427ebaa57&type=display
458,FLUVASTATIN,"1. The drug label mentions that there have been reports of rhabdomyolysis with acute renal failure and myopathy associated with fluvastatin capsules and other drugs in this class, indicating that the drug itself is associated with the risk of cardiotoxicity.
   
2. It also states that there have been rare reports of immune-mediated necrotizing myopathy (IMNM), an autoimmune myopathy, associated with statin use, suggesting that the drug may lead to cardiotoxic reactions.

3. The label further discusses the potential for liver enzyme abnormalities with HMG-CoA reductase inhibitors, including fluvastatin sodium, indicating a risk of liver-related cardiotoxicity with the drug.

4. Additionally, the label mentions that CNS effects, such as decreased activity, ataxia, and loss of righting reflex, were observed in animal studies with high doses of the drug, suggesting potential CNS-related cardiotoxicity risks.

5. The postmarketing experience section of the label reports rare cases of cognitive impairment associated with statin use, including memory loss and confusion, indicating a potential risk of CNS-related cardiotoxic reactions with the drug.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",f5e8d1da-8911-42db-9f90-cba04b28d011,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=f5e8d1da-8911-42db-9f90-cba04b28d011&type=display
459,FLUVOXAMINE MALEATE,"1. **Cardiotoxicity Risk:**
   - The drug label does not mention any direct association of fluvoxamine maleate with cardiotoxicity risk.

2. **Cardiotoxicity Reactions:**
   - The label does not list any cardiotoxicity reactions directly attributed to fluvoxamine maleate.
   - However, it does mention ECG abnormalities like heart arrest, QT interval prolongation, and other cardiac symptoms as potential effects of overdose, which could indirectly impact cardiac function.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",8f0ff905-5eb3-4ad0-ad31-fe35b924211f,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8f0ff905-5eb3-4ad0-ad31-fe35b924211f&type=display
460,FOLIC ACID,1. The drug label does not mention any cardiotoxicity risks or cardiotoxicity reactions associated with folic acid tablets.,No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",3a1b39df-bc52-4ad7-87f6-ea77cac706f2,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=3a1b39df-bc52-4ad7-87f6-ea77cac706f2&type=display
461,FOMEPIZOLE,"1. The drug label mentions that venous irritation and phlebosclerosis were noted in normal volunteers given bolus injections of Antizol at a concentration of 25 mg/mL. This indicates that the drug itself was associated with venous irritation and phlebosclerosis as a potential cardiotoxicity risk.

2. The label also reports cardiovascular adverse events such as sinus bradycardia/bradycardia, tachycardia, phlebitis, shock, and hypotension in patients receiving Antizol. These reactions suggest that the drug may be associated with cardiotoxicity reactions.

3. Additionally, the label mentions that nausea, dizziness, and vertigo were noted in healthy volunteers receiving high doses of Antizol. These CNS effects, including dizziness and vertigo, could indirectly impact cardiovascular function, indicating a potential cardiotoxicity risk associated with the drug.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",c045b5a8-b220-4f0a-a831-155b29c19454,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=c045b5a8-b220-4f0a-a831-155b29c19454&type=display
462,FONDAPARINUX SODIUM,"1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with ARIXTRA itself.
2. The focus of the label is primarily on warnings and precautions related to spinal or epidural hematomas, bleeding risks, renal impairment, body weight considerations, and thrombocytopenia.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",d3b30c68-cf45-4b46-8ba6-72090f7ba01a,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=d3b30c68-cf45-4b46-8ba6-72090f7ba01a&type=display
463,FOSAMPRENAVIR CALCIUM,"1. **Cardiotoxicity Risk**: The drug label does not mention any direct association of LEXIVA (fosamprenavir calcium) with cardiotoxicity risks.

2. **Cardiotoxicity Reactions**: The postmarketing experience section of the drug label mentions myocardial infarction as a reported adverse reaction during postapproval use of LEXIVA. However, it is important to note that the label does not definitively state that LEXIVA caused the myocardial infarction, but rather that it was identified during postapproval use.",Less,No,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",24feb9be-32a6-45fd-a896-f3e202edd8a9,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=24feb9be-32a6-45fd-a896-f3e202edd8a9&type=display
464,FOSAPREPITANT,"1. **Contraindications**: FOCINVEZ is contraindicated in patients taking pimozide due to the risk of elevated plasma concentrations of pimozide, potentially causing serious or life-threatening reactions such as QT prolongation, a known adverse reaction of pimozide. (The drug itself is not associated with cardiotoxicity but can interact with pimozide, which is known to cause QT prolongation.)

2. **Warnings and Precautions - Hypersensitivity Reactions**: Serious hypersensitivity reactions, including anaphylaxis and anaphylactic shock, may occur during or soon after infusion of fosaprepitant. Symptoms like flushing, erythema, dyspnea, hypotension, and syncope have been reported. (The drug itself is not directly associated with cardiotoxicity but can lead to severe allergic reactions that may have cardiovascular manifestations.)

3. **Warnings and Precautions - Infusion Site Reactions**: Infusion site reactions (ISRs) have been reported with intravenous fosaprepitant, particularly in patients receiving vesicant chemotherapy. Severe reactions like thrombophlebitis, necrosis, and vasculitis have been reported. (The drug itself is not directly linked to cardiotoxicity but can cause local reactions that may impact vascular health.)

4. **Drug Interactions - Effect of Fosaprepitant/Aprepitant on the Pharmacokinetics of Other Drugs**: Fosaprepitant is a weak inhibitor of CYP3A4, and aprepitant is a substrate, inhibitor, and inducer of CYP3A4. Use of FOCINVEZ with other drugs that are CYP3A4 substrates may result in increased plasma concentration of the concomitant drug. (The drug itself is not directly associated with cardiotoxicity but can interact with other drugs that may impact cardiovascular function.)

5. **Drug Interactions - Effect of Other Drugs on the Pharmacokinetics of Fosaprepitant/Aprepitant**: Co-administration of FOCINVEZ with drugs that are inhibitors or inducers of CYP3A4 may result in increased or decreased plasma concentrations of aprepitant, potentially affecting cardiotoxicity risks. (The drug itself is not directly linked to cardiotoxicity but interactions with other drugs may influence cardiovascular effects.)",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",eb2ec6c7-5f10-49e7-82b3-a4d1ddcc3b14,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=eb2ec6c7-5f10-49e7-82b3-a4d1ddcc3b14&type=display
465,FOSAPREPITANT DIMEGLUMINE,"1. **Contraindications**: The drug EMEND is contraindicated in patients taking pimozide due to the risk of significantly increased plasma concentrations of pimozide, potentially causing serious or life-threatening reactions, such as QT prolongation, a known adverse reaction of pimozide. **(The drug itself is not associated with cardiotoxicity but can lead to increased plasma concentrations of pimozide, which can cause QT prolongation.)**

2. **Warnings and Precautions - Hypersensitivity Reactions**: Serious hypersensitivity reactions, including anaphylaxis and anaphylactic shock, may occur during or soon after the infusion of fosaprepitant. Symptoms such as flushing, erythema, dyspnea, hypotension, and syncope have been reported. **(The drug itself is not directly associated with cardiotoxicity but can lead to hypersensitivity reactions that may include cardiovascular symptoms.)**

3. **Warnings and Precautions - Infusion Site Reactions**: Infusion site reactions (ISRs) have been reported with the use of EMEND for injection, particularly in patients receiving vesicant chemotherapy. Severe ISRs, including thrombophlebitis, necrosis, and vasculitis, have been reported. **(The drug itself is not directly associated with cardiotoxicity but can lead to infusion site reactions that may include vascular complications.)**

4. **Warnings and Precautions - Decrease in INR with Concomitant Warfarin**: Coadministration of EMEND with warfarin, a CYP2C9 substrate, may result in a clinically significant decrease in the International Normalized Ratio (INR) of prothrombin time. Monitoring of INR is recommended in patients on chronic warfarin therapy following initiation of EMEND. **(The drug itself is not associated with cardiotoxicity but can lead to a decrease in INR when used concomitantly with warfarin.)**",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",8d66803a-6811-4c29-9c57-e16acfa87f21,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8d66803a-6811-4c29-9c57-e16acfa87f21&type=display
466,FOSCARNET SODIUM,"1. The drug label warns about the potential for QT prolongation and torsades de pointes associated with Foscavir, which has been reported during postmarketing surveillance. Some cases of these cardiac events had confounding risk factors such as underlying cardiac disease, electrolyte abnormalities, and concomitant medications.

2. The drug label advises caution in using Foscavir in patients with a history of QT prolongation, those taking medications known to prolong the QT interval, patients with electrolyte disturbances, or those with other risk factors for QT prolongation. Electrocardiograms (ECGs) and measurement of electrolytes should be obtained before and during treatment with Foscavir to monitor for potential cardiotoxic effects.

3. Foscavir has been associated with prolongation of the QT interval, an ECG abnormality linked to torsades de pointes, as reported in postmarketing surveillance. Some patients experienced these cardiac events in the presence of confounding risk factors such as underlying cardiac disease, electrolyte imbalances, and concomitant medications.

4. The drug label highlights the association of Foscavir with QT prolongation and torsades de pointes, which have been reported during postmarketing surveillance. Patients with a history of QT prolongation, those taking medications known to prolong QT interval, individuals with electrolyte disturbances, or those with other risk factors for QT prolongation should use Foscavir cautiously.

5. Foscavir has been linked to prolongation of the QT interval, a cardiac abnormality associated with torsades de pointes, as reported in postmarketing surveillance. Some patients experiencing these cardiac events had underlying cardiac disease, electrolyte imbalances, and were taking concomitant medications, suggesting a potential cardiotoxic effect of Foscavir.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",a09299d5-9c55-4cef-aed0-3a6a45532289,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a09299d5-9c55-4cef-aed0-3a6a45532289&type=display
467,FOSDENOPTERIN HYDROBROMIDE,"1. The drug label does not mention any specific cardiotoxicity risks or cardiotoxicity reactions associated with NULIBRY (fosdenopterin) for injection. 

2. The label states that at the maximum approved recommended dose, NULIBRY did not prolong the QT interval to any clinically relevant extent. This indicates that NULIBRY itself was not associated with QT prolongation or cardiotoxicity risks.

3. Overall, the drug label does not highlight any direct cardiotoxicity risks or reactions linked to the use of NULIBRY in patients with molybdenum cofactor deficiency (MoCD) Type A.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",736aeea3-f206-454d-95d0-fd30964e8aab,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=736aeea3-f206-454d-95d0-fd30964e8aab&type=display
468,FOSFOMYCIN TROMETHAMINE,1. The drug label does not mention any cardiotoxicity risks or cardiotoxicity reactions associated with the use of Fosfomycin Tromethamine Granules for Oral Solution.,No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",aacd04a4-f2d5-45a2-b9e7-0e92244a5880,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=aacd04a4-f2d5-45a2-b9e7-0e92244a5880&type=display
469,FOSINOPIRL SODIUM; FOSINOPRIL SODIUM,"1. The drug label warns of fetal toxicity associated with drugs that act directly on the renin-angiotensin system, which can cause injury and death to the developing fetus. The drug itself is associated with the risk of fetal toxicity.

2. The label mentions that in patients with heart failure, the beneficial effects of the drug are primarily from suppression of the renin-angiotensin-aldosterone system, leading to decreases in preload and afterload. The drug itself is associated with beneficial effects in heart failure patients by suppressing the renin-angiotensin-aldosterone system.

3. The label states that ACE inhibitors, including the drug, have been associated with hypotension, especially in patients with heart failure, which may be associated with oliguria, azotemia, and rarely with acute renal failure and death. The drug itself is associated with the risk of hypotension in patients with heart failure.

4. The label warns that ACE inhibitors, like the drug, may cause hyperkalemia, with risk factors including renal insufficiency, diabetes mellitus, and other drugs that raise serum potassium levels. The drug itself is associated with the risk of hyperkalemia in patients with these risk factors.

5. The label mentions that ACE inhibitors, including the drug, have been associated with persistent nonproductive cough, which resolves after discontinuation of therapy. The drug itself is associated with the risk of persistent cough as a side effect.

6. The label cautions that ACE inhibitors, like the drug, have been rarely associated with a syndrome starting with cholestatic jaundice and progressing to fulminant hepatic necrosis and death. The drug itself is associated with the risk of this syndrome, although it is rare.

7. The label warns of anaphylactoid reactions during hemodialysis with high-flux membranes in patients receiving ACE inhibitors, including the drug. The drug itself is associated with the risk of anaphylactoid reactions during hemodialysis with certain membranes.

8. The label mentions that ACE inhibitors, like the drug, can cause angioedema, including laryngeal edema, especially following the first dose. The drug itself is associated with the risk of angioedema as a side effect.

9. The label advises that ACE inhibitors, including the drug, may cause anaphylactoid reactions during desensitization or membrane exposure. The drug itself is associated with the risk of anaphylactoid reactions in these situations.

10. The label warns that ACE inhibitors, like the drug, may cause intestinal angioedema, presenting with abdominal pain, even in patients without a history of facial angioedema. The drug itself is associated with the risk of intestinal angioedema as a side effect.",Less,No,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",0a66f606-5e6f-473d-8a1e-9ef316adb2e2,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=0a66f606-5e6f-473d-8a1e-9ef316adb2e2&type=display
470,FOSPHENYTOIN SODIUM,"1. The drug label warns of cardiovascular risks associated with rapid infusion rates of CEREBYX, stating that the rate of intravenous administration should not exceed specific limits in adults and pediatric patients due to the risk of severe hypotension and cardiac arrhythmias. (The drug itself is associated with the cardiotoxicity risk.)

2. The label emphasizes the need for careful cardiac monitoring during and after administering intravenous CEREBYX and mentions that reduction in the rate of administration or discontinuation of dosing may be necessary. (The drug itself is associated with the cardiotoxicity risk.)

3. It is noted that rapid intravenous administration of CEREBYX increases the risk of adverse cardiovascular reactions, including severe hypotension and cardiac arrhythmias, with events such as bradycardia, heart block, QT interval prolongation, ventricular tachycardia, and ventricular fibrillation reported, which can lead to asystole, cardiac arrest, and death. (The drug itself is associated with the cardiotoxicity reactions.)

4. The label mentions that severe complications are most commonly encountered in critically ill patients, elderly patients, and those with hypotension and severe myocardial insufficiency, but cardiac events have also been reported in patients without underlying cardiac disease or comorbidities and at recommended doses and infusion rates. (The drug itself is associated with the cardiotoxicity reactions.)

5. It is highlighted that careful cardiac and respiratory monitoring is essential during and after the administration of intravenous CEREBYX, and that reduction in the rate of administration or discontinuation of dosing may be needed to manage the cardiovascular risks. (The drug itself is associated with the cardiotoxicity risk.)",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",de5a6711-4abb-4c3d-a18b-266b094ace11,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=de5a6711-4abb-4c3d-a18b-266b094ace11&type=display
471,FOSTAMATINIB,"1. The drug TAVALISSE, a kinase inhibitor, was associated with hypertension as a potential adverse reaction. Patients with pre-existing hypertension may be more susceptible to the hypertensive effects of TAVALISSE. Monitoring blood pressure regularly and adjusting or initiating antihypertensive therapy was recommended to ensure blood pressure control during TAVALISSE treatment.

2. TAVALISSE was associated with hepatotoxicity as an adverse reaction. Elevated liver function tests, mainly ALT and AST, were observed in patients receiving TAVALISSE. Monitoring liver function tests monthly during treatment and managing hepatotoxicity using dose interruption, reduction, or discontinuation of TAVALISSE was advised.

3. Diarrhea was reported as a common adverse reaction in patients treated with TAVALISSE. Severe diarrhea occurred in some patients, and management with supportive care measures was recommended. Temporary interruption, dose reduction, or discontinuation of TAVALISSE was advised if diarrhea became severe.

4. Neutropenia was observed in some patients treated with TAVALISSE. Monitoring absolute neutrophil count monthly and for signs of infection was recommended. Managing neutropenia with TAVALISSE interruption, reduction, or discontinuation was advised if the neutrophil count decreased below a certain threshold.

5. The drug TAVALISSE was not directly associated with cardiotoxicity risks or reactions in the provided drug label information.",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",21149cc3-049b-43e2-b141-c9499160556c,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=21149cc3-049b-43e2-b141-c9499160556c&type=display
472,FOSTEMSAVIR TROMETHAMINE,"1. **QTc Prolongation Risk**: RUKOBIA has been shown to significantly prolong the QTc interval of the electrocardiogram at higher than recommended dosages, specifically at 2,400 mg twice daily, which is four times the recommended daily dose. This indicates that RUKOBIA itself is associated with the risk of QTc prolongation.

2. **QTc Prolongation Caution**: It is advised to use RUKOBIA with caution in patients with a history of QTc interval prolongation, when coadministered with a drug known to have a risk of Torsade de Pointes, or in patients with relevant pre-existing cardiac disease. This suggests that RUKOBIA may exacerbate existing QTc prolongation or cardiac conditions.

3. **Immune Reconstitution Syndrome**: While not directly related to cardiotoxicity, immune reconstitution syndrome has been reported in patients treated with combination antiretroviral therapy, including RUKOBIA. This syndrome may involve inflammatory responses that could potentially impact cardiac health in affected individuals.

4. **Elevations in Hepatic Transaminases**: Elevations in hepatic transaminases were observed in a greater proportion of subjects with hepatitis B and/or C co-infection compared to those with HIV mono-infection. While this is primarily related to liver function, hepatic issues can have secondary effects on cardiac health.

5. **Risk of Adverse Reactions or Loss of Virologic Response Due to Drug Interactions**: Certain drug interactions with RUKOBIA may lead to a loss of therapeutic effect or possible prolongation of the QTc interval. This indicates that interactions involving RUKOBIA could potentially impact cardiac safety.

6. **Drugs that Prolong QT Interval**: Coadministration of RUKOBIA with a drug known to have a risk of Torsade de Pointes may increase the risk of this condition. This highlights the potential for RUKOBIA to interact with other drugs that can affect cardiac electrophysiology.

Overall, RUKOBIA carries a risk of QTc prolongation, especially at higher dosages, and may interact with other medications to potentially impact cardiac function. Close monitoring and caution are advised, particularly in patients with pre-existing cardiac conditions or those taking medications that affect cardiac electrophysiology.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",a21006b7-6d6f-4f06-81b4-17978756452b,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a21006b7-6d6f-4f06-81b4-17978756452b&type=display
473,FROVATRIPTAN SUCCINATE,"1. Frovatriptan succinate tablets are contraindicated in patients with ischemic or vasospastic coronary artery disease (CAD) due to rare reports of serious cardiac adverse reactions, including acute myocardial infarction, occurring within a few hours following administration of the drug. The drug may cause coronary artery vasospasm, even in patients without a history of CAD. (The drug itself is associated with the cardiotoxicity risk.)

2. Life-threatening disturbances of cardiac rhythm, including ventricular tachycardia and ventricular fibrillation leading to death, have been reported within a few hours following the administration of 5-HT1 agonists like frovatriptan succinate tablets. Discontinue the drug if these disturbances occur. (The drug itself is associated with the cardiotoxicity risk.)

3. Sensations of pain, tightness, pressure, and heaviness in the chest, throat, neck, and jaw have been reported after treatment with frovatriptan succinate tablets and are usually non-cardiac in origin. However, a cardiac evaluation is recommended for high-risk patients. (The drug is not directly associated with the cardiotoxicity risk, but evaluation is recommended for high-risk patients.)

4. Cerebral hemorrhage, subarachnoid hemorrhage, stroke, and other cerebrovascular events have been reported in patients treated with 5-HT1 agonists like frovatriptan succinate tablets, and some have resulted in fatalities. The drug is contraindicated in patients with a history of stroke or transient ischemic attack. (The drug itself is associated with the cardiotoxicity risk.)

5. Frovatriptan succinate tablets may cause non-coronary vasospastic reactions, such as peripheral vascular ischemia and gastrointestinal vascular ischemia and infarction. Rule out a vasospastic reaction before using the drug in patients who experience symptoms suggestive of a vasospastic reaction. (The drug itself is associated with the cardiotoxicity risk.)

6. Significant elevation in blood pressure, including hypertensive crisis with acute impairment of organ systems, has been reported on rare occasions in patients treated with 5-HT1 agonists like frovatriptan succinate tablets, including patients without a history of hypertension. Monitor blood pressure in patients treated with the drug. (The drug itself is associated with the cardiotoxicity risk.)

7. There have been reports of reactions, including anaphylaxis and angioedema, in patients receiving frovatriptan succinate tablets. Such reactions can be life-threatening or fatal. The drug is contraindicated in patients with a history of hypersensitivity reactions to frovatriptan succinate tablets. (The drug itself is associated with the cardiotoxicity risk.)",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",c21300d7-891f-4e13-9070-d73de1aa1333,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=c21300d7-891f-4e13-9070-d73de1aa1333&type=display
474,FULVESTRANT,"1. **Warnings and Precautions**: The drug FASLODEX should be used with caution in patients with bleeding diatheses, thrombocytopenia, or anticoagulant use, indicating a risk of bleeding. The drug itself is not directly associated with cardiotoxicity but may pose a risk in patients with bleeding disorders.

2. **Adverse Reactions**: In clinical trials, increased hepatic enzymes (ALT, AST, ALP) occurred in more than 15% of patients receiving FASLODEX, and the incidence and severity of increased hepatic enzymes were not dose-dependent. While this does not directly relate to cardiotoxicity, liver enzyme abnormalities can sometimes be associated with cardiac issues due to the liver's role in metabolizing drugs.

3. **Adverse Reactions**: In the combination therapy trial PALOMA-3, patients receiving FASLODEX plus palbociclib reported cardiovascular system adverse reactions, including vasodilatation. This suggests a potential indirect cardiotoxicity risk associated with the combination therapy rather than FASLODEX alone.

4. **Adverse Reactions**: In the combination therapy trial MONARCH 2, patients receiving FASLODEX plus abemaciclib reported venous thromboembolic events, including deep vein thrombosis and pulmonary embolism. These events indicate a potential cardiotoxicity risk associated with the combination therapy rather than FASLODEX alone.",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",83d7a440-e904-4e36-afb5-cb02b1c919f7,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=83d7a440-e904-4e36-afb5-cb02b1c919f7&type=display
475,FUROSEMIDE,"1. The drug Lasix (furosemide) is a potent diuretic that can lead to profound diuresis with water and electrolyte depletion if given in excessive amounts. The drug itself is associated with the risk of electrolyte imbalance, which can lead to cardiotoxicity.

2. Lasix has warnings regarding hepatic coma and electrolyte depletion in patients with hepatic cirrhosis, emphasizing the need for careful observation during diuresis to prevent cardiotoxic events. The drug itself is associated with the risk of electrolyte imbalance leading to cardiotoxicity.

3. The drug label mentions that sudden alterations in fluid and electrolyte balance in patients with cirrhosis may precipitate hepatic coma, necessitating strict observation during diuresis to prevent cardiotoxic events. The drug itself is associated with the risk of electrolyte imbalance leading to cardiotoxicity.

4. Lasix has warnings about tinnitus, reversible or irreversible hearing impairment, and deafness, particularly with rapid injection, high doses, or concomitant use of certain medications, which can lead to cardiotoxic effects. The drug itself is associated with the risk of ototoxicity, which can indirectly impact cardiovascular health.

5. The drug label lists orthostatic hypotension as a potential cardiovascular reaction to Lasix, which may be aggravated by certain substances, indicating a risk of cardiovascular side effects. The drug itself is associated with the risk of orthostatic hypotension, which can lead to cardiovascular complications.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",2c9b4d8f-0770-482d-a9e6-9c616a440b1a,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=2c9b4d8f-0770-482d-a9e6-9c616a440b1a&type=display
476,GABAPENTIN,"1. The drug label for GRALISE does not mention any specific cardiotoxicity risks or reactions associated with the drug itself.
2. There is no indication in the drug label that GRALISE is linked to any cardiotoxicity risks or reactions.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",466273b1-c9fc-3930-c94b-aa11394d5140,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=466273b1-c9fc-3930-c94b-aa11394d5140&type=display
477,GABAPENTIN ENACARBIL,"1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with HORIZANT (gabapentin enacarbil) itself.

2. The label does not indicate any direct association between HORIZANT and cardiotoxicity risks or reactions.

3. There is no mention of cardiotoxicity risks or reactions related to HORIZANT in the drug label.

Overall, based on the information provided in the drug label, there are no references to cardiotoxicity risks or reactions specifically linked to the use of HORIZANT (gabapentin enacarbil).",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",4c486fc7-c8c4-4c6c-b30c-366dabaeaadd,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=4c486fc7-c8c4-4c6c-b30c-366dabaeaadd&type=display
478,GADOBENATE DIMEGLUMINE,"1. The drug label warns about the risk of cardiac arrhythmias observed in patients receiving MultiHance in clinical trials. The label states that cardiac arrhythmias were noted in patients who received MultiHance, but it does not directly attribute the cardiotoxicity risk to the drug itself.

2. A study evaluating the effect of MultiHance on ECG intervals noted minimal average changes in QTc values compared with placebo. Prolongations in QTc values were observed in subjects who received MultiHance, but the label does not definitively link these changes to cardiotoxicity caused by the drug.

3. The drug label mentions that certain lesions seen on non-contrast images may not be visible on contrast images, cautioning healthcare providers to interpret contrast MR images carefully in the absence of companion non-contrast MR images. This statement does not directly associate MultiHance with causing cardiotoxicity but highlights the importance of considering imaging limitations.

In summary, while the drug label discusses cardiac arrhythmias observed in patients receiving MultiHance and mentions changes in QTc values, it does not definitively attribute these cardiotoxicity risks to the drug itself. The label emphasizes the need for caution in interpreting contrast MR images and considering potential limitations in visualization.",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",f63abe56-46d9-4e32-afb1-f4e22370717d,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=f63abe56-46d9-4e32-afb1-f4e22370717d&type=display
479,GADOBUTROL,"1. **Cardiotoxicity Risk Associated with Intrathecal Use**: The drug label warns that intrathecal administration of gadolinium-based contrast agents (GBCAs) can cause serious adverse reactions, including death, coma, encephalopathy, and seizures. The drug Gadavist is not approved for intrathecal use, indicating that the drug itself is not associated with cardiotoxicity risks in this context.

2. **Cardiotoxicity Risk with Nephrogenic Systemic Fibrosis (NSF)**: The label states that GBCAs, including Gadavist, increase the risk for NSF among patients with impaired elimination of the drugs. NSF may result in fatal or debilitating fibrosis affecting the skin, muscle, and internal organs. The drug Gadavist is associated with the risk of NSF, which can have cardiotoxic effects due to fibrosis affecting internal organs, potentially including the heart.

3. **Cardiotoxicity Risk with Hypersensitivity Reactions**: The label mentions anaphylactic and other hypersensitivity reactions with cardiovascular manifestations, ranging from mild to severe, including death, that have occurred following Gadavist administration. The drug Gadavist is associated with the risk of hypersensitivity reactions, some of which can have cardiotoxic effects such as cardiovascular collapse or shock.

4. **Cardiotoxicity Risk with Gadolinium Retention**: The label indicates that gadolinium, the active ingredient in Gadavist, is retained for months or years in various organs, including the heart. While the clinical consequences of gadolinium retention in the heart are not established, the drug's association with gadolinium retention raises potential concerns for cardiotoxic effects over time.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",bd28560f-de4d-4140-874e-31df823f4dbb,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=bd28560f-de4d-4140-874e-31df823f4dbb&type=display
480,GADODIAMIDE,"1. The drug label warns about serious adverse reactions, including cardiac failure, arrhythmia, and myocardial infarction, observed in patients with ischemic heart disease during clinical studies with OMNISCAN. The drug itself was associated with these cardiotoxicity reactions.

2. Anaphylactoid reactions, characterized by cardiovascular symptoms, have occurred, including rare arrhythmia and myocardial infarction resulting in death in patients with ischemic heart disease. The drug itself was associated with these cardiotoxicity reactions.

3. The drug label mentions that OMNISCAN has been associated with vasodilation, chest pain, and deep thrombophlebitis as cardiovascular disorders. The drug itself was associated with these cardiotoxicity reactions.

4. Cardiac failure, arrhythmia, and myocardial infarction were reported as serious or life-threatening reactions in patients with ischemic heart disease during clinical studies with OMNISCAN. The drug itself was associated with these cardiotoxicity reactions.

5. The drug label also notes that OMNISCAN has been associated with flushing, chest pain, and deep thrombophlebitis as cardiovascular disorders. The drug itself was associated with these cardiotoxicity reactions.

6. Additionally, the label mentions that OMNISCAN has been associated with rare arrhythmia and myocardial infarction resulting in death in patients with ischemic heart disease. The drug itself was associated with these cardiotoxicity reactions.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",1e9a37e2-f28a-4373-bf0f-3e9b60f42d8a,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=1e9a37e2-f28a-4373-bf0f-3e9b60f42d8a&type=display
481,GADOTERATE MEGLUMINE,"1. The drug label warns about the risk associated with intrathecal use of gadolinium-based contrast agents (GBCAs), including DOTAREM, which can cause serious adverse reactions such as death, coma, encephalopathy, and seizures. DOTAREM is not approved for intrathecal use, indicating that the drug itself is not associated with cardiotoxicity risks in this context.

2. The label also mentions that hypersensitivity reactions, including anaphylactic/anaphylactoid reactions with cardiovascular manifestations, have uncommonly occurred with DOTAREM. Some patients experienced circulatory collapse and died, suggesting that the drug itself may be associated with cardiotoxicity reactions in the form of hypersensitivity/anaphylactic reactions.

3. Additionally, the label discusses gadolinium retention in various organs, including the heart, due to the use of gadolinium-based contrast agents like DOTAREM. While the label does not establish specific cardiotoxicity risks, it mentions that gadolinium is retained in organs for months or years, with the highest concentrations found in the bone followed by other organs, including the heart. This indicates a potential long-term cardiotoxicity risk associated with gadolinium retention in the heart.

4. The postmarketing experience section of the label lists adverse reactions reported after the use of DOTAREM, including cardiac disorders such as bradycardia, tachycardia, and arrhythmia. These reactions suggest that the drug may be associated with cardiotoxicity risks, as they involve the cardiovascular system.

Overall, while the drug label does not directly attribute cardiotoxicity risks to DOTAREM itself, it does highlight potential cardiotoxicity reactions such as hypersensitivity/anaphylactic reactions and cardiac disorders that have been reported in association with the use of the contrast agent.",Less,Yes,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",e2c4a5ac-2df2-4cf4-a2d3-6fbe2d898ebc,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=e2c4a5ac-2df2-4cf4-a2d3-6fbe2d898ebc&type=display
482,GADOTERIDOL,"1. The drug label warns about the risk associated with intrathecal use of gadolinium-based contrast agents (GBCAs), including ProHance, which can lead to serious adverse reactions such as death, coma, encephalopathy, and seizures. ProHance is not approved for intrathecal use, indicating that the drug itself is not associated with cardiotoxicity risks in this context.

2. The label also mentions nephrogenic systemic fibrosis (NSF) as a potential risk with GBCAs, including ProHance, among patients with impaired elimination of the drugs. NSF may result in fatal or debilitating systemic fibrosis affecting various organs. The risk for NSF appears highest among patients with chronic, severe kidney disease or acute kidney injury. This indicates that the drug itself is not directly causing cardiotoxicity but is associated with systemic fibrosis risks in patients with impaired kidney function.

3. Hypersensitivity reactions, including anaphylactic/anaphylactoid reactions with cardiovascular manifestations, have been reported with gadolinium-based contrast agents like ProHance. These reactions can range from mild to severe, including shock. The drug label advises monitoring patients closely for the need for emergency cardiorespiratory support, suggesting that the drug itself can lead to cardiotoxicity reactions in the form of cardiovascular manifestations during hypersensitivity episodes.",Less,No,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",778aee03-7d4c-481a-be8a-a75db0702f5a,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=778aee03-7d4c-481a-be8a-a75db0702f5a&type=display
483,GADOXETATE DISODIUM,"1. The drug label warns of anaphylactoid/hypersensitivity reactions with cardiovascular manifestations, ranging from mild to severe, including shock, that can occur following EOVIST administration. The drug itself is not directly associated with causing cardiotoxicity but can lead to cardiovascular reactions in hypersensitive patients.

2. The drug label mentions that gadolinium-based contrast agents, including EOVIST, can be retained in various organs, including the heart, for months or years. The drug itself is not specifically linked to causing cardiotoxicity but may contribute to gadolinium retention in the heart, which could potentially lead to cardiotoxic effects over time.

3. The drug label does not directly state any cardiotoxicity risks or reactions associated with EOVIST itself. However, it emphasizes the importance of monitoring patients for signs and symptoms of hypersensitivity reactions, including cardiovascular manifestations, during and after EOVIST administration.

Please note that while the drug label does not highlight EOVIST as a direct cause of cardiotoxicity, it is essential to consider the potential risks and monitor patients for any cardiovascular adverse reactions during and after the administration of this contrast agent.",Less,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",6218b1e1-cbc3-4c14-bec7-528ac163a561,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=6218b1e1-cbc3-4c14-bec7-528ac163a561&type=display
484,GALANTAMINE HYDROBROMIDE,"1. Galantamine hydrobromide tablets, USP, a cholinesterase inhibitor, may lead to adverse effects on cardiac conduction, including bradycardia and AV block, due to its vagotonic effects on the sinoatrial and atrioventricular nodes. All patients should be considered at risk for these cardiac conduction abnormalities. (The drug itself is associated with the cardiotoxicity risk.)

2. Patients treated with galantamine up to 24 mg/day using the recommended dosing schedule showed a dose-related increase in the risk of syncope. (The drug itself is associated with the cardiotoxicity risk.)

3. Galantamine has the potential to exaggerate the neuromuscular blocking effects of succinylcholine-type and similar neuromuscular blocking agents during anesthesia. (The drug itself is associated with the cardiotoxicity risk.)

4. Deaths in subjects with mild cognitive impairment (MCI) have been reported in patients taking galantamine. The deaths were due to various causes, including vascular causes like myocardial infarction, stroke, and sudden death. (The drug itself is associated with the cardiotoxicity reactions.)

5. In postmarketing experience, additional adverse reactions identified include hypertension, which could be a cardiotoxicity risk. (The drug itself is associated with the cardiotoxicity risk.)

6. Galantamine has the potential to interfere with the activity of anticholinergic medications, which could lead to cardiotoxicity risks. (The drug itself is associated with the cardiotoxicity risk.)

7. A synergistic effect is expected when cholinesterase inhibitors like galantamine are given concurrently with succinylcholine, other cholinesterase inhibitors, similar neuromuscular blocking agents, or cholinergic agonists, which could increase the risk of cardiotoxicity. (The drug itself is associated with the cardiotoxicity risk.)",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",7dc963dd-84d6-45f3-857f-46a44fe9edc8,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7dc963dd-84d6-45f3-857f-46a44fe9edc8&type=display
485,GALLIUM CITRATE GA-67,1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with Gallium Citrate Ga 67 Injection.,No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",5f670c12-cca5-4d73-8a88-241f753d1bc7,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=5f670c12-cca5-4d73-8a88-241f753d1bc7&type=display
486,GALLIUM GA-68 GOZETOTIDE,1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with Gallium Ga 68 Gozetotide Injection.,No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",b6253a7b-0f73-36be-e053-2a95a90a9015,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=b6253a7b-0f73-36be-e053-2a95a90a9015&type=display
487,GALLIUM NITRATE,"1. The drug label warns that the concurrent use of gallium nitrate with other potentially nephrotoxic drugs may increase the risk for developing severe renal insufficiency in patients with cancer-related hypercalcemia. The drug itself is not directly associated with cardiotoxicity risk in this sentence.

2. The label mentions that abnormalities in renal function, including elevated BUN and/or serum creatinine, have been observed in clinical trials with Ganite. The drug itself is not directly associated with cardiotoxicity risk in this sentence.

3. Adverse renal effects, such as rising BUN and creatinine, have been reported in about 12.5% of patients treated with Ganite. The drug itself is not directly associated with cardiotoxicity risk in this sentence.

4. In a controlled clinical trial, a decrease in mean systolic and diastolic blood pressure was observed several days after treatment with gallium nitrate. The decrease in blood pressure was asymptomatic and did not require specific treatment. The drug itself is indirectly associated with cardiotoxicity risk through its potential impact on blood pressure.

5. The label also mentions that a small proportion of patients treated with multiple high doses of gallium nitrate combined with other investigational anticancer drugs have developed acute optic neuritis. While these patients were critically ill and had received multiple drugs, a reaction to high-dose gallium nitrate is possible. Most patients had full recovery; however, at least one case of permanent blindness has been reported. The drug itself is indirectly associated with cardiotoxicity risk through its potential impact on optic nerve function.

6. One patient with cancer-related hypercalcemia was reported to develop decreased hearing following gallium nitrate administration. Due to the patients underlying condition and concurrent therapies, the relationship of this event to gallium nitrate administration is unclear. The drug itself is indirectly associated with cardiotoxicity risk through its potential impact on auditory function.",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",8bc2ddf8-d695-46b3-bf76-9f85ce6027e3,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8bc2ddf8-d695-46b3-bf76-9f85ce6027e3&type=display
488,GANCICLOVIR SODIUM,"1. The drug label does not mention any specific cardiotoxicity risks or cardiotoxicity reactions associated with Ganciclovir Injection itself. 

2. The label primarily focuses on hematologic toxicity, impairment of fertility, fetal toxicity, mutagenesis, and carcinogenesis as the main warnings and precautions associated with Ganciclovir Injection. 

3. While the drug label does not directly link Ganciclovir Injection to cardiotoxicity, it is essential to consult the full prescribing information for a comprehensive understanding of all potential risks and adverse reactions related to this medication.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",3059c2da-d4a7-4aea-828c-20e671cb875c,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=3059c2da-d4a7-4aea-828c-20e671cb875c&type=display
489,GANIRELIX ACETATE,1. The drug label does not mention any cardiotoxicity risks or cardiotoxicity reactions associated with Ganirelix Acetate Injection.,No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",32fb74ff-993a-49fe-8943-e029372b863e,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=32fb74ff-993a-49fe-8943-e029372b863e&type=display
490,GEFITINIB,"1. **Cardiotoxicity Risk**: Gefitinib (IRESSA) does not have any specific warnings or precautions related to cardiotoxicity risks mentioned in the drug label.

2. **Cardiotoxicity Reactions**: The drug label does not list any cardiotoxicity reactions associated with gefitinib (IRESSA) use.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",827d60e8-7e07-41b7-c28b-49ef1c4a5a41,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=827d60e8-7e07-41b7-c28b-49ef1c4a5a41&type=display
491,GEMCITABINE,"1. **Warnings and Precautions:** The drug label mentions that gemcitabine may cause **schedule-dependent toxicity**, leading to clinically significant hypotension, severe flu-like symptoms, myelosuppression, and asthenia if the infusion time exceeds 60 minutes or dosing is more frequent than weekly. The drug itself is associated with this schedule-dependent toxicity risk.

2. **Warnings and Precautions:** **Myelosuppression** is highlighted as a potential adverse reaction of gemcitabine, manifesting as neutropenia, thrombocytopenia, and anemia. The label advises monitoring blood counts before each dose and modifying the dosage accordingly. The drug itself is associated with the risk of myelosuppression.

3. **Warnings and Precautions:** **Pulmonary toxicity and respiratory failure** are mentioned as potential adverse reactions of gemcitabine, including interstitial pneumonitis, pulmonary fibrosis, pulmonary edema, and adult respiratory distress syndrome (ARDS). The label recommends discontinuing the drug if patients develop unexplained dyspnea or pulmonary toxicity. The drug itself is associated with the risk of pulmonary toxicity.

4. **Warnings and Precautions:** **Hemolytic Uremic Syndrome (HUS)** is identified as a potential risk with gemcitabine, leading to renal failure or the need for dialysis. The label advises assessing renal function before and during treatment and discontinuing gemcitabine for HUS or severe renal impairment. The drug itself is associated with the risk of HUS.

5. **Warnings and Precautions:** **Hepatic Toxicity** is mentioned as a potential adverse reaction of gemcitabine, including liver failure and death. The label recommends assessing hepatic function before and during treatment and discontinuing gemcitabine for severe liver injury. The drug itself is associated with the risk of hepatic toxicity.

6. **Warnings and Precautions:** **Embryo-Fetal Toxicity** is highlighted as a risk with gemcitabine, potentially causing fetal harm. The label advises females and males of reproductive potential to use effective contraception during and after treatment. The drug itself is associated with the risk of embryo-fetal toxicity.

7. **Warnings and Precautions:** **Exacerbation of Radiation Therapy Toxicity** is mentioned, cautioning against using gemcitabine with radiation therapy due to life-threatening mucositis, especially esophagitis and pneumonitis. The label recommends avoiding concurrent administration of gemcitabine with radiation therapy. The drug itself is associated with the risk of exacerbating radiation therapy toxicity.

8. **Warnings and Precautions:** **Capillary Leak Syndrome (CLS)** is identified as a potential adverse reaction of gemcitabine, leading to severe consequences. The label advises discontinuing gemcitabine if CLS develops during therapy. The drug itself is associated with the risk of capillary leak syndrome.",Less,No,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",4031017d-d768-46de-8081-476bcb883f5e,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=4031017d-d768-46de-8081-476bcb883f5e&type=display
492,GEMFIBROZIL,"1. The drug LOPID (gemfibrozil) is associated with cardiotoxicity risks, as indicated by findings from the Helsinki Heart Study, which showed a 44% relative increase in age-adjusted all-cause mortality during the trial period compared to placebo, similar to the excess mortality reported with the chemically related drug clofibrate.
   
2. The Helsinki Heart Study also reported a 29% excess mortality in the clofibrate group, with non-coronary heart disease-related mortality showing an excess in the group originally randomized to LOPID, primarily due to cancer deaths observed during the open-label extension.

3. A comparative carcinogenicity study in rats showed that gemfibrozil, the active ingredient in LOPID, increased the incidence of hepatic neoplastic nodules and testicular interstitial cell tumors, indicating potential cardiotoxic effects in animal models.

4. The Helsinki Heart Study revealed that LOPID therapy was not associated with a reduction in mortality from coronary heart disease, and liver and interstitial cell testicular tumors were increased in rats treated with gemfibrozil, suggesting potential cardiotoxicity risks associated with the drug.

5. The drug label also warns about the increased risk of skeletal muscle toxicity, including rhabdomyolysis, when LOPID is used in combination with HMG-CoA reductase inhibitors, which can lead to severe myopathy, acute renal failure, and death, indicating a potential cardiotoxic reaction with this drug combination.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",c48855b7-215e-453b-b3b1-a0f9dee7221f,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=c48855b7-215e-453b-b3b1-a0f9dee7221f&type=display
493,GEMIFLOXACIN MESYLATE,1. The drug label does not mention any specific cardiotoxicity risks or cardiotoxicity reactions associated with FACTIVE (gemifloxacin mesylate) tablets.,No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",63f60426-e27f-4258-9bfc-b4a15ebdca83,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=63f60426-e27f-4258-9bfc-b4a15ebdca83&type=display
494,GILTERITINIB,"1. **Prolonged QT Interval**: XOSPATA has been associated with prolonged cardiac ventricular repolarization (QT interval). The drug itself is associated with this risk, as it can lead to a QTc interval greater than 500 msec and an increase from baseline QTc greater than 60 msec. Monitoring of ECG is recommended to manage this risk, and dosage interruption and reduction are advised for patients with a QTcF >500 msec.

2. **Posterior Reversible Encephalopathy Syndrome (PRES)**: XOSPATA has been linked to PRES, with symptoms including seizure and altered mental status. The drug itself is associated with this risk, and discontinuation of XOSPATA is recommended for patients who develop PRES.

3. **Differentiation Syndrome**: XOSPATA treatment has been associated with symptoms of differentiation syndrome, which can be fatal if not treated. The drug itself is linked to this risk, and symptoms may include fever, dyspnea, pulmonary infiltrates, and renal dysfunction. Corticosteroid therapy and monitoring are advised for suspected cases of differentiation syndrome.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",b5ff59aa-9c0d-49a8-9053-1f179b482383,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=b5ff59aa-9c0d-49a8-9053-1f179b482383&type=display
495,GIVOSIRAN SODIUM,1. The drug label does not mention any specific information regarding cardiotoxicity risks or cardiotoxicity reactions associated with GIVLAARI (givosiran) injection for subcutaneous use.,No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",167e663c-11e1-497b-a3fc-951d65d58eaa,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=167e663c-11e1-497b-a3fc-951d65d58eaa&type=display
496,GLASDEGIB,"1. The drug DAURISMO is associated with QTc interval prolongation, which can lead to ventricular arrhythmias, including ventricular fibrillation and ventricular tachycardia. The clinical trial excluded patients with baseline QTc of greater than 470 ms or with a history of long QT syndrome or uncontrolled cardiovascular disease. (The drug DAURISMO is associated with QTc interval prolongation.)

2. Patients treated with DAURISMO may develop QTc prolongation and ventricular arrhythmias, with 5% of patients having a QTc interval greater than 500 ms and 4% experiencing an increase from baseline QTc greater than 60 ms. (The drug DAURISMO is associated with QTc prolongation and ventricular arrhythmias.)

3. Concomitant use of DAURISMO with drugs known to prolong the QTc interval and CYP3A4 inhibitors may increase the risk of QTc interval prolongation. Patients with congenital long QT syndrome, congestive heart failure, electrolyte abnormalities, or those taking medications known to prolong the QTc interval may require more frequent ECG monitoring. (The drug DAURISMO is associated with increased risk of QTc interval prolongation when used with certain medications.)

4. Interrupt DAURISMO if QTc increases to greater than 500 ms and discontinue permanently for patients who develop QTc interval prolongation with signs or symptoms of life-threatening arrhythmia. (The drug DAURISMO can lead to QTc interval prolongation and life-threatening arrhythmias.)

5. Musculoskeletal adverse reactions, including musculoskeletal pain and muscle spasms, have occurred with DAURISMO and other drugs inhibiting the hedgehog pathway. Increased CPK levels were reported in some patients. (The drug DAURISMO is associated with musculoskeletal adverse reactions and elevated CPK levels.)

6. Obtain baseline CPK levels before initiating DAURISMO and monitor CPK and serum creatinine levels in patients with musculoskeletal adverse reactions. Temporary dose interruption, reduction, or discontinuation of DAURISMO may be necessary for musculoskeletal adverse reactions or elevated CPK. (The drug DAURISMO is associated with musculoskeletal adverse reactions and may require dose adjustments based on CPK levels.)",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",204a6f7e-c9a4-472b-abd2-9527bda64d17,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=204a6f7e-c9a4-472b-abd2-9527bda64d17&type=display
497,GLATIRAMER ACETATE,"1. Immediate Post-Injection Reaction: Approximately 16% of patients exposed to COPAXONE 20 mg/mL experienced symptoms like flushing, chest pain, palpitations, tachycardia, anxiety, dyspnea, throat constriction, and urticaria. These symptoms may occur within seconds to minutes after injection and are generally transient and self-limiting. The drug itself was not directly associated with causing cardiotoxicity risk.

2. Chest Pain: Approximately 13% of COPAXONE 20 mg/mL patients experienced transient chest pain, which was usually unassociated with other symptoms and had no clinical sequelae. The temporal relationship of this chest pain to an injection was not always known. The drug itself was not directly associated with causing cardiotoxicity risk.

3. Lipoatrophy and Skin Necrosis: Localized lipoatrophy and skin necrosis may occur at injection sites. Lipoatrophy occurred in approximately 2% of patients exposed to COPAXONE 20 mg/mL. Skin necrosis has only been observed in the postmarketing setting. The drug itself was not directly associated with causing cardiotoxicity risk.

4. Potential Effects on Immune Response: COPAXONE can modify immune response, potentially interfering with immune functions. There is no evidence that COPAXONE directly causes cardiotoxicity, but concerns exist about its potential to alter naturally-occurring immune responses.

5. Hepatic Injury: Cases of hepatic injury, including liver failure and hepatitis with jaundice, have been reported with COPAXONE. Hepatic injury has occurred from days to years after initiating treatment with COPAXONE. If signs or symptoms of liver dysfunction occur, consider discontinuation of COPAXONE. The drug itself was associated with causing hepatic injury, which can have cardiotoxic effects indirectly.

6. Glatiramer Acetate Products and Administration Errors: Using an optional autoinjector that is not compatible with COPAXONE may increase the risk for medication errors, such as dose omission or administration of a partial dose. While not directly related to cardiotoxicity, medication errors can lead to adverse effects, including potential cardiotoxic reactions.",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",aa88f583-4f5f-433b-80b4-1f4c9fb28357,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=aa88f583-4f5f-433b-80b4-1f4c9fb28357&type=display
498,GLIMEPIRIDE,"1. Glimepiride tablets are associated with a potential increased risk of cardiovascular mortality, as reported in a study comparing oral hypoglycemic drugs to diet alone or diet plus insulin. The study showed a higher rate of cardiovascular mortality in patients treated with tolbutamide, a sulfonylurea similar to glimepiride, compared to those on diet alone.

2. The drug label warns that there is no conclusive evidence from clinical studies establishing a reduction in macrovascular risk with glimepiride or any other antidiabetic drug. This suggests that the drug itself has not been proven to reduce the risk of cardiovascular events on a larger scale.

3. The label also mentions that certain medications may affect glucose metabolism, potentially leading to dose adjustments and close monitoring of blood glucose levels when used concomitantly with glimepiride. This indicates that the risk of cardiotoxicity may be influenced by interactions with other medications affecting glucose metabolism.

4. Additionally, the drug label highlights the potential interaction between glimepiride and miconazole, which can lead to severe hypoglycemia. This interaction suggests a risk of cardiotoxicity associated with the concomitant use of these two medications.

Overall, while the drug label does not directly attribute cardiotoxicity risks to glimepiride itself, it emphasizes the importance of monitoring for potential cardiovascular effects when using the medication, especially in conjunction with other drugs that may impact glucose metabolism.",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",bf57eba0-d7d4-481e-8dab-3165a192c77b,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=bf57eba0-d7d4-481e-8dab-3165a192c77b&type=display
499,GLIPIZIDE,"1. The drug label mentions a potential increased risk of cardiovascular mortality with sulfonylureas, including GLUCOTROL XL. Patients should be informed of the risks, benefits, and treatment alternatives associated with this risk (5.3).
   
2. The label states that there have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with GLUCOTROL XL or any other anti-diabetic drug (5.4).

3. The label does not directly associate GLUCOTROL XL with cardiotoxicity reactions but highlights the potential increased risk of cardiovascular mortality with sulfonylureas in general. It emphasizes the importance of informing patients about these risks and considering alternative treatment options.",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",eed99b60-d043-4249-9b2a-f05e46fb588d,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=eed99b60-d043-4249-9b2a-f05e46fb588d&type=display
500,GLUCAGON,"1. Glucagon for Injection may increase myocardial oxygen demand, blood pressure, and pulse rate, which could be life-threatening in patients with cardiac disease. Cardiac monitoring is recommended in patients with cardiac disease during glucagon treatment, and an increase in blood pressure and pulse rate may require therapy. (The drug itself is associated with cardiotoxicity risks.)

2. Glucagon for Injection may cause a temporary increase in both blood pressure and pulse rate, particularly in patients with cardiac disease. Patients taking beta-blockers experienced a greater than normal increase in both pulse and blood pressure. (The drug itself is associated with cardiotoxicity risks.)

3. Glucagon for Injection may increase the risk of a transient increase in blood pressure and heart rate in patients with cardiac disease. Cardiac monitoring is recommended during treatment, and an increase in blood pressure and pulse rate may require therapy. (The drug itself is associated with cardiotoxicity risks.)

4. Glucagon for Injection may increase the risk of a temporary increase in heart rate and blood pressure when used concomitantly with beta-blockers. Therapy may be required in patients with coronary artery disease. (The drug itself is associated with cardiotoxicity risks.)

5. Glucagon for Injection may increase the anticoagulant effect of warfarin, potentially leading to an increased risk of bleeding. Patients on warfarin should be monitored for unusual bruising or bleeding, as adjustments in warfarin dosage may be necessary. (The drug itself is not directly associated with cardiotoxicity risks but may impact anticoagulation therapy, which can have implications for cardiac health.)",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",8c8acad6-44cc-43aa-966b-027e053be8f5,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8c8acad6-44cc-43aa-966b-027e053be8f5&type=display
501,GLUCAGON HYDROCHLORIDE,"1. GlucaGen may increase myocardial oxygen demand, blood pressure, and pulse rate, which may be life-threatening in patients with cardiac disease. Cardiac monitoring is recommended during its use as a diagnostic aid, and an increase in blood pressure and pulse rate may require therapy. (The drug itself is associated with cardiotoxicity risks.)

2. Glucagon administered to patients with glucagonoma may cause secondary hypoglycemia, which can be a cardiotoxic reaction. Patients suspected of having glucagonoma should be tested for blood levels of glucagon before treatment with GlucaGen. (The drug itself can cause cardiotoxic reactions in patients with glucagonoma.)

3. GlucaGen may increase the anticoagulant effect of warfarin, which can lead to potential cardiotoxicity. Patients on warfarin should be monitored for unusual bruising or bleeding, as adjustments in warfarin dosage may be necessary. (The drug itself can interact with other medications to cause cardiotoxicity risks.)

4. GlucaGen may cause a substantial increase in blood pressure in patients with pheochromocytoma, a condition that can lead to cardiotoxic effects. It is contraindicated in patients with pheochromocytoma due to the risk of stimulating the release of catecholamines from the tumor. (The drug itself can cause cardiotoxic reactions in patients with pheochromocytoma.)

5. GlucaGen may stimulate exaggerated insulin release from an insulinoma, leading to hypoglycemia, which can have cardiotoxic consequences. Patients with insulinoma should not be treated with GlucaGen due to the risk of hypoglycemia. (The drug itself can cause cardiotoxic reactions in patients with insulinoma.)

6. GlucaGen may increase blood pressure and heart rate, which can be cardiotoxic in patients with cardiac disease. Cardiac monitoring is recommended during its use as a diagnostic aid, and an increase in blood pressure and pulse rate may require therapy. (The drug itself is associated with cardiotoxicity risks.)",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",ff16e4b1-3668-4cb4-91a4-77ee509cd6f6,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=ff16e4b1-3668-4cb4-91a4-77ee509cd6f6&type=display
502,GLUTAMINE,"1. The drug label does not mention any specific cardiotoxicity risks associated with Endari (L-glutamine oral powder) itself.
   
2. The adverse reactions listed in the label do not include any cardiotoxicity reactions directly attributed to Endari. The most common adverse reactions reported were constipation, nausea, headache, abdominal pain, cough, pain in extremity, back pain, and chest pain.

3. The label states that serious adverse reactions were reported in both treatment groups during clinical trials, with more frequent occurrences in the placebo group. However, these reactions were consistent with the underlying disease and were not directly linked to Endari causing cardiotoxicity.

4. Three deaths occurred during the study in the Endari treatment group, but none were considered to be related to Endari treatment. The label does not indicate any direct association between Endari and cardiotoxicity based on these events.

In summary, the drug label for Endari does not suggest any direct association between the drug itself and cardiotoxicity risks or reactions. The adverse reactions reported were not specifically related to cardiotoxicity.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",d5a783f4-12ef-4326-8faa-40018e45ba3b,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=d5a783f4-12ef-4326-8faa-40018e45ba3b&type=display
503,GLYBURIDE,"1. The drug label mentions that the administration of oral hypoglycemic drugs, including glyburide, has been reported to be associated with increased cardiovascular mortality compared to treatment with diet alone or diet plus insulin. This risk is based on a study conducted by the University Group Diabetes Program (UGDP) involving patients treated with tolbutamide, a drug in the sulfonylurea class, which had a higher rate of cardiovascular mortality. The study findings provide a basis for warning patients about potential risks and advantages of using GLYNASE PresTab and alternative therapies. (The drug itself was associated with an increased cardiovascular mortality risk.)

2. The drug label also states that there have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with GLYNASE PresTab or any other anti-diabetic drug. This indicates that there is no clear evidence that the drug reduces macrovascular risks associated with cardiovascular events. (The drug itself was not shown to reduce macrovascular risks.)

3. Additionally, the label mentions that certain adverse reactions have been reported with glyburide use, including liver function abnormalities and gastrointestinal disturbances. These reactions, such as cholestatic jaundice, hepatitis, and liver failure, may progress to serious conditions. This suggests that there may be potential cardiotoxicity risks associated with liver function abnormalities and other adverse reactions linked to glyburide use. (The drug itself was associated with adverse reactions that may pose cardiotoxicity risks.)

4. The drug label also highlights that cases of hyponatremia have been reported with glyburide and other sulfonylureas, particularly in patients on other medications or with medical conditions known to cause hyponatremia. The label mentions that the syndrome of inappropriate antidiuretic hormone (SIADH) secretion has been reported with certain sulfonylureas, suggesting a potential risk of electrolyte imbalances that could impact cardiovascular health. (The drug itself was associated with hyponatremia and electrolyte imbalances that may pose cardiotoxicity risks.)",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",a7fce80a-2f13-43cc-8e1c-561f7d3ec3d5,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a7fce80a-2f13-43cc-8e1c-561f7d3ec3d5&type=display
504,GLYCEROL PHENYLBUTYRATE,1. The drug label does not mention any cardiotoxicity risks or cardiotoxicity reactions associated with RAVICTI.,No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",900e7dc0-9afe-4f50-80de-90567bb78519,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=900e7dc0-9afe-4f50-80de-90567bb78519&type=display
505,GLYCOPYRROLATE,"1. The drug label mentions that Glycopyrrolate Injection may be used intraoperatively to counteract surgically or drug-induced or vagal reflex-associated arrhythmias, indicating that the drug itself is not associated with cardiotoxicity but is used to manage arrhythmias that may occur during surgery.

2. It also states that an increase in heart rate may occur with the use of Glycopyrrolate Injection and advises caution in patients with certain cardiovascular conditions, suggesting that the drug itself may lead to tachycardia as a potential cardiotoxicity risk.

3. The drug label further mentions that cardiac arrhythmias, including bradycardia, ventricular tachycardia, and ventricular fibrillation, have been reported in post-marketing experience with glycopyrrolate, indicating that the drug itself may be associated with cardiotoxicity reactions.

4. Additionally, it notes that cases of heart block and QTc interval prolongation have been reported with the combined use of glycopyrrolate and an anticholinesterase, suggesting that the drug itself may contribute to cardiotoxicity reactions in certain situations.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",685aaf64-1a64-42f9-a96f-4764d650c26f,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=685aaf64-1a64-42f9-a96f-4764d650c26f&type=display
506,GOLODIRSEN,"1. **Warnings and Precautions (5.2):**
   - **Risk Mentioned:** Kidney Toxicity
   - **Summary:** The drug may cause kidney toxicity based on animal data. Kidney function should be monitored during treatment, as creatinine may not be a reliable measure of renal function in patients with Duchenne muscular dystrophy (DMD). The drug itself was associated with the risk of kidney toxicity in animals, but it was not observed in clinical studies with the drug.

2. **Warnings and Precautions (5.2):**
   - **Risk Mentioned:** Kidney Toxicity
   - **Summary:** Kidney function monitoring is recommended during treatment with the drug. Serum cystatin C, urine dipstick, and urine protein-to-creatinine ratio should be measured before starting the drug. The drug itself was not observed to cause kidney toxicity in clinical studies, but it has been noted with some antisense oligonucleotides.

3. **Warnings and Precautions (5.2):**
   - **Risk Mentioned:** Kidney Toxicity
   - **Summary:** Kidney function should be monitored in patients taking the drug, as kidney toxicity, including potentially fatal glomerulonephritis, has been observed with some antisense oligonucleotides. The drug itself was not observed to cause kidney toxicity in clinical studies, but the potential for kidney toxicity is highlighted due to the limited clinical experience with the drug.

4. **Warnings and Precautions (5.2):**
   - **Risk Mentioned:** Kidney Toxicity
   - **Summary:** The drug may cause kidney toxicity, and kidney function monitoring is recommended during treatment. Serum cystatin C, urine dipstick, and urine protein-to-creatinine ratio should be measured before starting the drug. The drug itself was not observed to cause kidney toxicity in clinical studies, but the potential for kidney toxicity is emphasized due to observations with other antisense oligonucleotides.",Less,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",35c227d1-5b24-44b0-b5d3-f0f6b1c46bd5,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=35c227d1-5b24-44b0-b5d3-f0f6b1c46bd5&type=display
507,GOSERELIN,"1. **Cardiovascular Diseases Risk**: The drug ZOLADEX, a GnRH agonist, has been associated with an increased risk of myocardial infarction, sudden cardiac death, and stroke in men. This risk should be carefully evaluated along with cardiovascular risk factors when determining treatment for patients with prostate cancer.

2. **Hypercalcemia Risk**: ZOLADEX, like other GnRH agonists, has been reported to potentially cause hypercalcemia in some prostate and breast cancer patients with bone metastases after starting treatment. If hypercalcemia occurs, appropriate treatment measures should be initiated.

3. **Effect on QT/QTc Interval**: Androgen deprivation therapy, including ZOLADEX, may prolong the QT/QTc interval. Providers should consider whether the benefits of androgen deprivation therapy outweigh the potential risks in patients with certain conditions. Electrolyte abnormalities should be corrected, and periodic monitoring of electrocardiograms and electrolytes should be considered.

4. **Injection Site Injury**: Injection site injury and vascular injury, including pain, hematoma, hemorrhage, and hemorrhagic shock, have been reported with ZOLADEX. Extra care should be taken when administering ZOLADEX to patients with a low BMI and/or those receiving full-dose anticoagulation to prevent these potential complications.",Less,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",294b168b-6e5f-4db9-bf70-d599271458b3,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=294b168b-6e5f-4db9-bf70-d599271458b3&type=display
508,GRANISETRON HYDROCHLORIDE,"1. **Cardiotoxicity Risk**: Granisetron hydrochloride tablets have been associated with QT prolongation, which has been reported as a potential risk. The drug itself has been linked to this cardiotoxicity risk.

2. **Cardiotoxicity Reaction**: Adverse events reported in clinical trials include cardiovascular effects such as hypertension, hypotension, angina pectoris, atrial fibrillation, and syncope. These reactions have been observed in patients taking granisetron hydrochloride tablets, indicating a potential cardiotoxicity reaction associated with the drug.

3. **Cardiotoxicity Risk**: Granisetron hydrochloride should be used with caution in patients with pre-existing arrhythmias or cardiac conduction disorders, as this might lead to clinical consequences. The drug itself poses a cardiotoxicity risk in such patients.

4. **Cardiotoxicity Reaction**: In comparative trials, elevation of AST and ALT occurred in some patients following the administration of granisetron hydrochloride tablets. These liver enzyme elevations can be indicative of potential cardiotoxicity reactions associated with the drug.

5. **Cardiotoxicity Risk**: Granisetron hydrochloride has been associated with QT prolongation, and its use in patients concurrently treated with drugs known to prolong the QT interval and/or are arrhythmogenic may result in clinical consequences. The drug itself poses a cardiotoxicity risk in patients with these characteristics.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",df4b6775-4337-41e0-815a-b064d98c3fe1,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=df4b6775-4337-41e0-815a-b064d98c3fe1&type=display
509,GUANFACINE,"1. The drug INTUNIV (guanfacine) is associated with cardiotoxicity risks, including hypotension, bradycardia, syncope, and cardiac conduction abnormalities. These risks are mentioned as warnings and precautions in the drug label, and the drug itself is linked to these potential adverse effects.

2. The sympatholytic action of INTUNIV may worsen sinus node dysfunction and atrioventricular (AV) block, especially in patients taking other sympatholytic drugs. This indicates that the drug itself can contribute to cardiac conduction abnormalities, emphasizing the need for monitoring and caution during treatment.

3. Rebound hypertension is a significant concern upon discontinuation of INTUNIV, leading to clinically significant and persistent increases in blood pressure and heart rate. Hypertensive encephalopathy has also been reported in association with rebound hypertension. The drug itself is implicated in causing rebound hypertension, highlighting the importance of tapering the dose gradually to minimize this risk.

4. In postmarketing experience, abrupt discontinuation of INTUNIV has resulted in rebound hypertension and hypertensive encephalopathy. These adverse reactions are associated with the drug itself, emphasizing the need for close monitoring and proper discontinuation protocols to prevent these cardiotoxic effects.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",b972af81-3a37-40be-9fe1-3ddf59852528,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=b972af81-3a37-40be-9fe1-3ddf59852528&type=display
510,HALOPERIDOL,"1. The drug label warns of cases of sudden death, QTc interval-prolongation, and Torsades de Pointes reported in patients receiving haloperidol, indicating that the drug itself is associated with cardiotoxicity risks.

2. Higher than recommended doses of any formulation and intravenous administration of haloperidol appear to be associated with a higher risk of QTc interval-prolongation and Torsades de Pointes, suggesting that the drug itself can cause cardiotoxicity reactions.

3. The label advises caution in treating patients with other QTc-prolonging conditions when using haloperidol, as a QTc interval exceeding 500 msec is associated with an increased risk of Torsades de Pointes, indicating that the drug itself can contribute to cardiotoxicity risks.

4. Tachycardia and hypotension, including orthostatic hypotension, have been reported in occasional patients receiving haloperidol, suggesting that the drug itself may lead to cardiotoxicity reactions.

5. The label also mentions that haloperidol may impair the antiparkinson effects of levodopa and other dopamine agonists, indicating that the drug itself can have cardiotoxic effects in patients with Parkinson's Disease or Dementia with Lewy Bodies.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",65df5d2d-79aa-41d4-866a-566e520320f7,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=65df5d2d-79aa-41d4-866a-566e520320f7&type=display
511,HALOPERIDOL DECANOATE,"1. The drug label warns of cardiovascular effects associated with haloperidol, including sudden death, QTc interval-prolongation, and Torsades de Pointes, which have been reported in patients receiving haloperidol. Higher than recommended doses and intravenous administration of haloperidol are linked to a higher risk of QTc interval-prolongation and Torsades de Pointes.

2. The label advises caution in treating patients with other QTc-prolonging conditions when using haloperidol, as a QTc interval exceeding 500 msec is associated with an increased risk of Torsades de Pointes. It is noted that cases have been reported even without predisposing factors, emphasizing the need for careful monitoring.

3. Tachycardia and hypotension, including orthostatic hypotension, have been reported in some patients receiving haloperidol, indicating a potential risk of cardiovascular effects associated with the drug.

4. The label also mentions that haloperidol may impair the antiparkinson effects of levodopa and other dopamine agonists, which could impact patients with Parkinson's Disease or Dementia with Lewy Bodies, leading to severe extrapyramidal symptoms, confusion, sedation, and falls. This suggests a potential risk of exacerbating neurological adverse reactions in these patient populations.

5. Additionally, the drug label highlights the importance of monitoring patients for signs or symptoms of increased or prolonged pharmacologic effects of haloperidol when co-administered with medications known to affect haloperidol plasma concentrations, indicating a potential for drug interactions that could impact cardiotoxicity risks.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",af0159a8-dff5-449a-aa2b-a0c430081e21,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=af0159a8-dff5-449a-aa2b-a0c430081e21&type=display
512,HALOPERIDOL LACTATE,"1. The drug label warns of cardiovascular effects associated with haloperidol, including cases of sudden death, QTc interval-prolongation, and Torsades de Pointes, particularly with higher than recommended doses and intravenous administration. Haloperidol itself is associated with these risks.

2. The label advises caution in treating patients with other QTc-prolonging conditions when using haloperidol, as a QTc interval exceeding 500 msec is linked to an increased risk of Torsades de Pointes. Although cases have been reported without predisposing factors, special care is recommended in such patients. Haloperidol itself is associated with these risks.

3. Tachycardia and hypotension, including orthostatic hypotension, have been reported in some patients receiving haloperidol. Haloperidol itself is associated with these cardiovascular reactions.

4. The label mentions that haloperidol may cause cerebrovascular adverse reactions, such as stroke and transient ischemic attack, especially in elderly patients with dementia-related psychosis. The mechanism for this increased risk is not known, and caution is advised in patients with risk factors for cerebrovascular adverse reactions. Haloperidol itself is associated with these risks.

5. Haloperidol is also linked to the potential development of Neuroleptic Malignant Syndrome (NMS), a potentially fatal symptom complex characterized by hyperpyrexia, muscle rigidity, altered mental status, and autonomic instability. The label advises immediate discontinuation of haloperidol and other non-essential drugs, along with intensive symptomatic treatment and medical monitoring if NMS is suspected. Haloperidol itself is associated with the risk of NMS.

6. Patients with Parkinson's Disease or Dementia with Lewy Bodies are reported to have increased sensitivity to antipsychotic medication, including haloperidol, leading to severe extrapyramidal symptoms, confusion, sedation, and falls. Haloperidol may also impair the antiparkinson effects of levodopa and other dopamine agonists. Haloperidol itself is associated with these neurological adverse reactions in these patient populations.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",ef1e8e3f-8c71-4400-ad4d-448af963a56c,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=ef1e8e3f-8c71-4400-ad4d-448af963a56c&type=display
513,HEPARIN SODIUM,"1. The drug label mentions that hemorrhage, including fatal events, has occurred in patients receiving heparin, indicating a risk of cardiotoxicity associated with the drug itself.
2. The label also warns about the potential occurrence of adrenal hemorrhage, ovarian hemorrhage, and retroperitoneal hemorrhage during anticoagulant therapy with heparin, suggesting a risk of cardiotoxicity reactions associated with the drug.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",cece935c-1c0a-4949-b023-d6df3d53fbfa,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=cece935c-1c0a-4949-b023-d6df3d53fbfa&type=display
514,HETASTARCH,"1. The drug label warns of increased mortality, kidney injury, and coagulopathy associated with the use of hydroxyethyl starch (HES) products, including HEXTEND. The drug itself is associated with the risk of mortality, kidney injury, and coagulopathy.

2. Solutions containing 6% Hetastarch, such as HEXTEND, may transiently alter the coagulation mechanism due to hemodilution and have a direct inhibitory action on Factor VIII, potentially leading to increased bleeding. The drug itself is associated with the risk of altering the coagulation mechanism and inhibiting Factor VIII, which can result in increased bleeding.

3. Hemodilution by isotonic solutions containing 6% Hetastarch may result in a decline in total protein, albumin, and fibrinogen levels, as well as transient prolongation of prothrombin, activated partial thromboplastin, clotting, and bleeding times. The drug itself is associated with the risk of hemodilution leading to decreased protein levels and prolonged clotting times.

4. Increased bleeding has been reported in patients undergoing open heart surgery following the use of 6% Hetastarch in 0.9% Sodium Chloride Injection. The drug itself is associated with the risk of increased bleeding in patients undergoing open heart surgery.

5. The drug label mentions that isotonic solutions containing 6% Hetastarch have been associated with coagulation abnormalities, acquired von Willebrand's-like syndrome, and Factor VIII deficiency when used over a period of days, potentially leading to severe coagulopathy. The drug itself is associated with the risk of coagulation abnormalities, von Willebrand's-like syndrome, and Factor VIII deficiency when used over an extended period.

6. Hetastarch has been linked to intracranial bleeding, bleeding due to hemodilution, and coagulopathy, including disseminated intravascular coagulopathy and hemolysis. The drug itself is associated with the risk of intracranial bleeding, hemodilution-related bleeding, and coagulopathy, including disseminated intravascular coagulopathy and hemolysis.

7. In clinical trials, isotonic solutions containing 6% Hetastarch have been associated with increased mortality, acute kidney injury, and coagulopathy in critically ill patients, surgical patients, and blunt trauma patients. The drug itself is associated with the risk of increased mortality, acute kidney injury, and coagulopathy in specific patient populations.",Most,No,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",fc79700c-6c3b-4998-8307-4dc8c81c5041,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fc79700c-6c3b-4998-8307-4dc8c81c5041&type=display
515,HEXAMINOLEVULINATE HYDROCHLORIDE,1. The drug label does not mention any cardiotoxicity risks or cardiotoxicity reactions associated with Cysview (hexaminolevulinate hydrochloride) for intravesical solution.,No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",5aeed40d-6841-4adf-8940-f51d439fdfa3,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=5aeed40d-6841-4adf-8940-f51d439fdfa3&type=display
516,HISTRELIN ACETATE,"1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with SUPPRELIN LA (histrelin acetate) implant itself.

2. No information is provided in the drug label regarding cardiotoxicity risks or reactions related to the use of SUPPRELIN LA in children with central precocious puberty (CPP).

3. Cardiotoxicity is not listed as a known risk or reaction associated with the use of SUPPRELIN LA in the drug label.

Overall, based on the information provided in the drug label, there are no mentions of cardiotoxicity risks or reactions linked to the use of SUPPRELIN LA (histrelin acetate) subcutaneous implant.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",d8fb000e-3cc9-4803-b71d-2cc597661977,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=d8fb000e-3cc9-4803-b71d-2cc597661977&type=display
517,HUMAN SECRETIN,1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with CHIRHOSTIM (human secretin) for injection for intravenous use.,No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",b4dfe70f-0a86-4488-9ba1-dcd8f86cbfcd,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=b4dfe70f-0a86-4488-9ba1-dcd8f86cbfcd&type=display
518,HYALURONIC ACID,"1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with the use of hyaluronic acid injection. 

2. Therefore, there are no statements indicating that the drug itself is associated with cardiotoxicity risks or reactions. 

Overall, based on the information provided in the drug label, there are no references to cardiotoxicity risks or reactions related to the use of hyaluronic acid injection.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",a75e2bb2-f89a-53f4-e053-2a95a90a93c7,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a75e2bb2-f89a-53f4-e053-2a95a90a93c7&type=display
519,HYDRALAZINE HYDROCHLORIDE,"1. The drug label mentions that Hydralazine hydrochloride can cause myocardial stimulation leading to anginal attacks and ECG changes of myocardial ischemia. It is implicated in the production of myocardial infarction, indicating that the drug itself is associated with cardiotoxicity risks.

2. The label also states that the ""hyperdynamic"" circulation caused by Hydralazine may accentuate specific cardiovascular inadequacies, such as increasing pulmonary artery pressure in patients with mitral valvular disease. This suggests that the drug itself can exacerbate cardiovascular issues, indicating a cardiotoxicity risk.

3. Additionally, the drug label mentions that Hydralazine may reduce the pressor responses to epinephrine and that postural hypotension may result from its use. While less common than with other agents, postural hypotension is a potential cardiotoxicity reaction associated with the drug itself.

4. The label advises caution in using Hydralazine in patients with suspected coronary artery disease due to the risk of myocardial ischemia and myocardial infarction. This indicates that the drug itself can pose cardiotoxicity risks in such patients.

5. Furthermore, the drug label mentions that complications of Hydralazine overdose can include myocardial ischemia, subsequent myocardial infarction, cardiac arrhythmia, and profound shock. These potential complications highlight the cardiotoxic effects of the drug itself in cases of overdose.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",6c40d818-77a9-492c-b9b6-d8a0fe8d6736,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=6c40d818-77a9-492c-b9b6-d8a0fe8d6736&type=display
520,HYDROCHLOROTHIAZIDE,"1. The drug label mentions that hydrochlorothiazide may cause acute transient myopia and acute angle-closure glaucoma, which are cardiotoxic reactions associated with the drug itself.
   
2. The label also states that latent diabetes mellitus may become manifest and diabetic patients given thiazides may require adjustment of their insulin dose, indicating a potential cardiotoxicity risk associated with the drug.

3. Additionally, the label warns that cumulative effects of thiazides may develop in patients with impaired renal function, potentially leading to azotemia, a cardiotoxic reaction associated with the drug.

4. The label mentions that electrolyte imbalance, hyperglycemia, glycosuria, and hyperuricemia are metabolic adverse reactions associated with hydrochlorothiazide, indicating potential cardiotoxicity risks.

5. Furthermore, the label lists hypokalemia, hypochloremia, hyponatremia, and dehydration as common signs and symptoms of overdosage with hydrochlorothiazide, which can lead to cardiotoxic reactions due to electrolyte depletion and dehydration caused by excessive diuresis.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",e31bd548-29ae-419a-831a-80ebb26e042f,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=e31bd548-29ae-419a-831a-80ebb26e042f&type=display
521,HYDROCODONE BITARTRATE,"1. **Cardiotoxicity Risk**: The drug label does not mention any direct association of HYSINGLA ER with cardiotoxicity risks.

2. **Cardiotoxicity Reactions**: The drug label does not specifically list cardiotoxicity reactions associated with HYSINGLA ER.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",b7d23ac2-e776-9f62-3290-c64c2d6eb353,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=b7d23ac2-e776-9f62-3290-c64c2d6eb353&type=display
522,HYDROCORTISONE,"1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with ALKINDI SPRINKLE (hydrocortisone) itself.

2. The label primarily focuses on adrenal crisis, immunosuppression, growth retardation, Cushing's syndrome, bone mineral density decrease, psychiatric adverse reactions, ophthalmic adverse reactions, gastrointestinal adverse reactions, and other potential adverse effects. 

3. While the label does not directly link ALKINDI SPRINKLE to cardiotoxicity risks or reactions, it is important to consult a healthcare provider for a comprehensive understanding of potential side effects and risks associated with this medication.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",26c13a5f-7119-4c6a-bf10-fda4e07d7682,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=26c13a5f-7119-4c6a-bf10-fda4e07d7682&type=display
523,HYDROCORTISONE SODIUM SUCCINATE,"1. The drug label mentions that corticosteroids, including SOLU-CORTEF, can cause cardiovascular effects such as hypertension, congestive heart failure, and cardiac arrhythmias. This indicates that the drug itself is associated with cardiotoxicity risks.

2. It also states that corticosteroids may lead to cardiac enlargement, circulatory collapse, and hypertrophic cardiomyopathy in premature infants. This suggests that the drug itself can cause cardiotoxic reactions.

3. Additionally, the label warns about potential cardiovascular adverse reactions like myocardial rupture following recent myocardial infarction and thromboembolism. These risks indicate that the drug itself is associated with cardiotoxic effects.

4. The label mentions that corticosteroids can result in pulmonary edema, syncope, and vasculitis, further highlighting the cardiotoxicity risks associated with the drug.

5. Furthermore, it notes that corticosteroids may lead to thrombophlebitis, fat embolism, and cardiac arrest, underscoring the potential cardiotoxic reactions caused by the drug.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",65eefd58-b166-4d71-ade6-45c8fdf86922,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=65eefd58-b166-4d71-ade6-45c8fdf86922&type=display
524,HYDROMORPHONE HYDROCHLORIDE,"1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with DILAUDID (hydromorphone hydrochloride) oral solution or tablets.

2. The label primarily focuses on warnings and precautions related to the risks of addiction, abuse, misuse, respiratory depression, accidental ingestion, and interactions with other medications. 

3. There is no direct mention of cardiotoxicity risks or reactions caused by DILAUDID in the provided drug label information.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",d6b40e39-a57e-402c-b4f6-7041e832f837,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=d6b40e39-a57e-402c-b4f6-7041e832f837&type=display
525,HYDROXOCOBALAMIN,"1. **Warnings and Precautions - Risk of Increased Blood Pressure:** The drug itself is associated with the risk of increased blood pressure, with substantial increases observed following CYANOKIT therapy. Monitoring blood pressure during treatment is recommended. (The drug is associated with the risk of increased blood pressure.)

2. **Adverse Reactions - Clinical Studies Experience:** In clinical studies, increases in blood pressure were noted as an adverse reaction, particularly diastolic blood pressure, occurring in a dose-dependent fashion and with greater frequency than observed in placebo-treated cohorts. Elevations in blood pressure were generally transient and resolved spontaneously with standard supportive therapies. (The drug is associated with increases in blood pressure as an adverse reaction.)

3. **Adverse Reactions - Postmarketing Experience:** Postmarketing reports identified cases of acute renal failure with acute tubular necrosis, renal impairment, and urine calcium oxalate crystals following CYANOKIT therapy. Although not specific to cardiotoxicity, renal impairment can lead to fluid and electrolyte imbalances affecting cardiovascular function. (The drug is not directly associated with cardiotoxicity but can lead to renal impairment, which may indirectly impact cardiovascular function.)

Please note that while the drug itself is not directly linked to cardiotoxicity, the risks and adverse reactions mentioned can have implications for cardiovascular health and should be monitored closely during CYANOKIT therapy.",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",d56fcc8d-bd64-46ab-b0c0-2124bd745a6b,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=d56fcc8d-bd64-46ab-b0c0-2124bd745a6b&type=display
526,HYDROXYCHLOROQUINE SULFATE,"1. The drug label mentions that SOVUNA has been associated with fatal or life-threatening cardiomyopathy and ventricular arrhythmias, with signs and symptoms of cardiac compromise reported during treatment. The label indicates that endomyocardial biopsy showed an association of cardiomyopathy with phospholipidosis in the absence of inflammation, infiltration, or necrosis, suggesting a potential link between SOVUNA and cardiotoxicity.

2. Additionally, the label states that SOVUNA has the potential to prolong the QT interval, leading to ventricular arrhythmias such as torsades de pointes. It is advised to avoid administration in patients with congenital or acquired QT prolongation and known risk factors for QT interval prolongation, indicating a direct association between SOVUNA and cardiotoxicity risks.

3. The label also highlights that SOVUNA may cause irreversible retinal damage related to cumulative dosage and treatment duration, with risk factors including daily dosages exceeding a certain threshold. This suggests a potential indirect association between retinal toxicity and cardiotoxicity risks due to the systemic effects of the drug.

4. Furthermore, the label mentions that SOVUNA has been reported to cause skeletal muscle myopathy or neuropathy, leading to progressive weakness and atrophy of proximal muscle groups, which may be associated with phospholipidosis. This indicates a potential link between SOVUNA and muscle-related cardiotoxicity risks, although the direct impact on cardiac muscle is not explicitly stated.

In summary, the drug label for SOVUNA discusses various risks and reactions related to cardiotoxicity, including cardiomyopathy, ventricular arrhythmias, QT interval prolongation, and muscle-related myopathy. While some associations between SOVUNA and cardiotoxicity risks are direct, others may be indirect or related to systemic effects of the drug.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",dd441154-b196-4d4c-bc56-2e37f345ef8d,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=dd441154-b196-4d4c-bc56-2e37f345ef8d&type=display
527,HYDROXYPROGESTERONE CAPROATE,"1. The drug label mentions that serious arterial thrombotic and venous thromboembolic events, including pulmonary emboli, deep vein thrombosis, myocardial infarction, and strokes, have been reported in women using progestins. (The drug itself is associated with the risk of these cardiotoxic events.)

2. The label also notes that neuroocular lesions such as retinal thrombosis and optic neuritis have been reported as adverse reactions to the drug. (The drug itself is associated with the risk of these cardiotoxic reactions.)

3. Additionally, the label mentions that progestins may cause a rise in blood pressure, which is listed as an adverse reaction. (The drug itself is associated with the risk of increased blood pressure as a cardiotoxic reaction.)

4. The drug label includes information about allergic reactions, such as allergic rash, which have been reported as adverse reactions to progestins. (The drug itself is associated with the risk of allergic reactions as a cardiotoxic reaction.)

5. The label also lists migraine headaches as an adverse reaction to the drug. (The drug itself is associated with the risk of migraine headaches as a cardiotoxic reaction.)

6. Furthermore, the drug label mentions that chloasma or melasma, cholestatic jaundice, mental depression, and amenorrhea have been reported as adverse reactions to the drug. (The drug itself is associated with the risk of these cardiotoxic reactions.)

7. Lastly, the label states that coughing, dyspnea, constriction of the chest, and allergic-like reactions have occurred following hydroxyprogesterone caproate therapy, with an increased likelihood at higher dosage levels. (The drug itself is associated with the risk of these cardiotoxic reactions, especially at higher dosages.)",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",687bcf42-f437-42c7-8909-a91f621f55df,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=687bcf42-f437-42c7-8909-a91f621f55df&type=display
528,HYDROXYUREA,"1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with XROMI (hydroxyurea) itself. 

2. The label primarily focuses on myelosuppression, malignancies, hemolytic anemia, embryo-fetal toxicity, vasculitic toxicities, live vaccinations, risks with concomitant use of antiretroviral drugs, macrocytosis, pulmonary toxicity, and laboratory test interference as potential adverse effects of XROMI. 

3. While the label does not directly link XROMI to cardiotoxicity risks or reactions, it is essential to consult with healthcare providers for a comprehensive understanding of potential cardiovascular effects when considering the use of this medication.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",4b37d336-86da-4363-aef1-34a7d3ba973b,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=4b37d336-86da-4363-aef1-34a7d3ba973b&type=display
529,HYDROXYZINE HYDROCHLORIDE,"1. The drug label mentions that cases of QT prolongation and Torsade de Pointes have been reported during post-marketing use of hydroxyzine. The majority of reports occurred in patients with other risk factors for QT prolongation/TdP, indicating that hydroxyzine itself was associated with the cardiotoxicity risk.

2. The label also states that hydroxyzine should be used with caution in patients with risk factors for QT prolongation, congenital long QT syndrome, and other conditions that predispose to QT prolongation and ventricular arrhythmia. This suggests that hydroxyzine itself may contribute to the cardiotoxicity risk in these patients.

3. Additionally, the drug label mentions that hydroxyzine overdose may cause QT prolongation and Torsade de Pointes, and ECG monitoring is recommended in cases of hydroxyzine overdose. This indicates that hydroxyzine itself can lead to cardiotoxicity reactions in cases of overdose.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",a2fbc502-6ca3-4304-9069-b7249c9d9489,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a2fbc502-6ca3-4304-9069-b7249c9d9489&type=display
530,HYDROXYZINE PAMOATE,"1. The drug label mentions that cases of QT prolongation and Torsade de Pointes have been reported during post-marketing use of hydroxyzine. The label indicates that the majority of these reports occurred in patients with other risk factors for QT prolongation/TdP, suggesting that hydroxyzine itself may not be the sole cause of cardiotoxicity but may contribute to the risk in susceptible individuals.

2. The label also advises caution in using hydroxyzine in patients with risk factors for QT prolongation, congenital long QT syndrome, a family history of long QT syndrome, and other conditions that predispose to QT prolongation and ventricular arrhythmia. This suggests that hydroxyzine may have the potential to exacerbate existing cardiotoxicity risks in certain patient populations.

3. Furthermore, the label mentions that hydroxyzine overdose may cause QT prolongation and Torsade de Pointes, indicating a direct association between hydroxyzine overdose and cardiotoxic effects. ECG monitoring is recommended in cases of hydroxyzine overdose to monitor for potential cardiac complications.

4. The label also highlights that in post-marketing experience, additional undesirable effects reported include QT prolongation and Torsade de Pointes, further emphasizing the potential cardiotoxicity risks associated with hydroxyzine use. These adverse reactions suggest a direct association between hydroxyzine and cardiotoxic effects in some patients.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",c271f97f-040e-492b-9194-2c8b74675a95,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=c271f97f-040e-492b-9194-2c8b74675a95&type=display
531,IBREXAFUNGERP,"1. The drug label warns of a risk of embryo-fetal toxicity associated with BREXAFEMME, stating that it is contraindicated in pregnancy due to potential fetal harm based on animal studies. The drug itself is not directly associated with cardiotoxicity in this context.

2. Clinical trials for BREXAFEMME in the treatment of vulvovaginal candidiasis (VVC) reported adverse reactions such as diarrhea, nausea, abdominal pain, dizziness, and vomiting. These reactions do not include cardiotoxicity risks directly linked to the drug.

3. Adverse reactions in the reduction of recurrent vulvovaginal candidiasis (RVVC) with BREXAFEMME included headache, abdominal pain, diarrhea, nausea, urinary tract infection, and fatigue. These reactions do not indicate any cardiotoxicity risks specifically attributed to the drug.

4. The drug label mentions that ibrexafungerp, the active ingredient in BREXAFEMME, does not prolong the QTc interval to any clinically relevant extent at concentrations achieved after recommended dosages. This suggests that the drug itself is not associated with significant cardiotoxicity risks related to QT prolongation.

Overall, the drug label does not highlight any direct cardiotoxicity risks or reactions associated with BREXAFEMME. The focus is primarily on embryo-fetal toxicity, adverse reactions related to gastrointestinal and general side effects, and pharmacokinetic data without significant cardiotoxicity concerns.",Less,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",c33be3a1-c4fd-512c-e053-2995a90a63eb,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=c33be3a1-c4fd-512c-e053-2995a90a63eb&type=display
532,IBRUTINIB,"1. IMBRUVICA has been associated with fatal and serious cardiac arrhythmias and cardiac failure, with deaths due to cardiac causes or sudden deaths occurring in 1% of patients who received the drug in clinical trials. This indicates that the drug itself is associated with cardiotoxicity risks.

2. Grade 3 or greater ventricular tachyarrhythmias, atrial fibrillation, and atrial flutter were reported in a percentage of patients who received IMBRUVICA in clinical trials, including those who received the drug in unapproved monotherapy or combination regimens. This suggests that the drug itself may cause or contribute to cardiac arrhythmias.

3. Patients with cardiac comorbidities may be at greater risk of cardiac arrhythmias and cardiac failure when taking IMBRUVICA. This indicates that the drug may exacerbate existing cardiac conditions or lead to new cardiac issues in patients with preexisting heart problems.

4. Patients should be evaluated for cardiac history and function at baseline, monitored for cardiac arrhythmias and cardiac function during treatment, and further evaluated if symptoms of arrhythmia or cardiovascular concerns develop. This highlights the importance of close monitoring and management of cardiac health while using IMBRUVICA.

5. The drug label also mentions the occurrence of Grade 3 or greater hypertension in a percentage of patients with B-cell malignancies who received IMBRUVICA in clinical trials. This suggests that IMBRUVICA may contribute to the development or exacerbation of hypertension in some patients.

6. The cumulative rate of hypertension increased over time in a long-term safety analysis of patients with B-cell malignancies treated with IMBRUVICA, indicating a potential ongoing risk of hypertension with prolonged use of the drug.

7. Monitoring blood pressure, initiating or adjusting antihypertensive medication as needed, and following dosage modification guidelines for Grade 3 or higher hypertension are recommended for patients treated with IMBRUVICA. This emphasizes the importance of managing hypertension effectively in patients taking the drug.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",0dfd0279-ff17-4ea9-89be-9803c71bab44,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=0dfd0279-ff17-4ea9-89be-9803c71bab44&type=display
533,IBUPROFEN,"1. The drug label warns that non-steroidal anti-inflammatory drugs (NSAIDs), including CALDOLOR, are associated with an increased risk of serious cardiovascular thrombotic events, such as myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with the duration of use.

2. CALDOLOR is contraindicated in the setting of coronary artery bypass graft (CABG) surgery due to the risk of serious cardiovascular events associated with NSAID use.

3. The label advises that patients taking CALDOLOR should be monitored for signs of cardiac ischemia, especially in patients with a recent myocardial infarction, as NSAID use may increase the risk of recurrent cardiovascular thrombotic events.

4. The label also mentions that NSAIDs, including CALDOLOR, can lead to new-onset hypertension or worsen preexisting hypertension, potentially contributing to an increased incidence of cardiovascular events. Patients on antihypertensive medications may have impaired responses when taking NSAIDs.

5. Additionally, the label warns that CALDOLOR should be avoided in patients with severe heart failure unless the benefits outweigh the risks of worsening heart failure. The drug may cause fluid retention and edema, which can impact cardiovascular health.

6. The drug label does not specifically state that CALDOLOR directly causes cardiotoxicity but highlights the association between NSAID use, including CALDOLOR, and the increased risk of serious cardiovascular events. It emphasizes the importance of monitoring patients for cardiovascular symptoms and risks while using the medication.",Less,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",1eaa7790-f1a1-4f51-b10a-cbbaf033f684,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=1eaa7790-f1a1-4f51-b10a-cbbaf033f684&type=display
534,IBUPROFEN LYSINE,"1. The drug label mentions that NeoProfen is contraindicated in preterm infants with congenital heart disease in whom patency of the PDA is necessary for satisfactory pulmonary or systemic blood flow, indicating that the drug itself is associated with a cardiotoxicity risk in this specific population.

2. Additionally, the label states that NeoProfen may cause serious skin reactions such as exfoliative dermatitis, Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and acute generalized exanthematous pustulosis (AGEP), which can be fatal. While this sentence does not directly mention cardiotoxicity, it highlights the potential for serious adverse reactions that could impact various organ systems, including the cardiovascular system.",Less,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",6f5ede6f-b0b7-4fc8-969e-652f60ead047,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=6f5ede6f-b0b7-4fc8-969e-652f60ead047&type=display
535,IBUTILIDE FUMARATE,"1. The drug label warns that CORVERT can cause potentially fatal arrhythmias, particularly sustained polymorphic ventricular tachycardia, usually in association with QT prolongation (torsades de pointes), but sometimes without documented QT prolongation. The drug itself is associated with the risk of potentially fatal arrhythmias.

2. During registration trials, 1.7% of patients with atrial flutter or atrial fibrillation treated with CORVERT developed sustained polymorphic ventricular tachycardia requiring cardioversion. The drug itself caused sustained polymorphic ventricular tachycardia in a small percentage of patients.

3. Proarrhythmic events must be anticipated, and skilled personnel and proper equipment must be available during and after administration of CORVERT. The drug label emphasizes the importance of monitoring for proarrhythmic events and having appropriate resources available.

4. In clinical trials, patients with a history of congestive heart failure or low left ventricular ejection fraction appeared to have a higher incidence of sustained polymorphic ventricular tachycardia. The drug itself may pose a higher risk of sustained polymorphic ventricular tachycardia in patients with certain underlying conditions.

5. The drug label mentions that patients with a history of polymorphic ventricular tachycardia (e.g., torsades de pointes) should not receive CORVERT. The drug itself is contraindicated in patients with a history of certain types of ventricular tachycardia.

6. The label also states that patients should be observed with continuous ECG monitoring for at least 4 hours following infusion or until QTc has returned to baseline. The drug label recommends continuous monitoring for potential cardiotoxicity reactions.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",2428969a-7431-4e94-9503-ad5c680e2ea4,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=2428969a-7431-4e94-9503-ad5c680e2ea4&type=display
536,ICATIBANT,"1. The drug icatibant is a bradykinin B2 receptor antagonist used for the treatment of acute attacks of hereditary angioedema (HAE) in adults. It is not directly associated with cardiotoxicity risks. 

2. Animal studies have shown that icatibant may have negative cardiovascular effects during reperfusion after acute ischemia, potentially decreasing coronary blood flow and aggravating post-ischemic reperfusion arrhythmias. Icatibant was associated with cardiotoxicity risks in animal models.

3. Limited human experience suggests that icatibant should be used cautiously during acute coronary ischemia, unstable angina pectoris, or in the weeks following a stroke, only if the benefit exceeds the theoretical risk to the patient. The drug itself was not directly linked to cardiotoxicity reactions in humans but caution is advised in specific cardiovascular conditions.",Less,No,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",94a53361-4eda-4e30-a153-44cd142983dd,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=94a53361-4eda-4e30-a153-44cd142983dd&type=display
537,ICOSAPENT ETHYL,"1. VASCEPA is associated with an increased risk of atrial fibrillation or atrial flutter requiring hospitalization, especially in patients with a previous history of these conditions. (The drug itself is associated with the increased risk of atrial fibrillation or atrial flutter.)

2. Patients with known hypersensitivity to fish and/or shellfish should be informed about the potential for allergic reactions to VASCEPA, which contains ethyl esters of omega-3 fatty acids obtained from fish oil. (The drug itself may pose a risk of allergic reactions in patients with fish allergies.)

3. VASCEPA was associated with an increased risk of bleeding, particularly in patients receiving concomitant antithrombotic medications like aspirin, clopidogrel, or warfarin. (The drug itself was associated with an increased risk of bleeding.)",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",9c1a2828-1583-4414-ab22-a60480e8e508,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=9c1a2828-1583-4414-ab22-a60480e8e508&type=display
538,IDARUBICIN HYDROCHLORIDE,"1. The drug label warns that Idamycin PFS Injection can cause myocardial toxicity leading to congestive heart failure, especially in patients who have received prior anthracyclines or have pre-existing cardiac disease. (The drug itself is associated with the risk of myocardial toxicity.)

2. The label advises that severe myelosuppression can occur when using Idamycin PFS at effective therapeutic doses. (The drug itself is not directly associated with cardiotoxicity in this sentence.)

3. It is recommended that Idamycin PFS be administered under the supervision of a physician experienced in leukemia chemotherapy, with facilities capable of responding to severe hemorrhagic conditions and infections. (The drug itself is not directly associated with cardiotoxicity in this sentence.)

4. The label mentions that cardiac toxicity, including congestive heart failure, arrhythmias, and cardiomyopathies, may occur following therapy with Idamycin PFS. Appropriate measures for managing these cardiac issues are indicated. (The drug itself is associated with the risk of cardiac toxicity.)

5. The label advises careful monitoring of cardiac function during treatment to minimize the risk of cardiac toxicity associated with other anthracycline compounds. It also recommends avoiding concomitant use of cardiotoxic agents with Idamycin PFS. (The drug itself is associated with the risk of cardiac toxicity.)

6. The label states that patients over 60 years of age undergoing induction therapy with Idamycin PFS experienced cardiac issues more frequently, such as congestive heart failure, arrhythmias, chest pain, and myocardial infarction. (The drug itself is associated with the risk of cardiac toxicity in elderly patients.)

7. The label mentions that myocardial insufficiency and arrhythmias reported during treatment were usually reversible and occurred in the setting of sepsis, anemia, and aggressive fluid administration. (The drug itself is associated with the risk of cardiac toxicity in specific clinical settings.)

8. The label warns that there is no known antidote to Idamycin PFS overdose, which may result in severe and prolonged myelosuppression, increased gastrointestinal toxicity, and possibly acute cardiac toxicity. (The drug itself is associated with the risk of acute cardiac toxicity in cases of overdose.)",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",0a5a6d93-cc1e-4d7f-8da1-446c134503b3,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=0a5a6d93-cc1e-4d7f-8da1-446c134503b3&type=display
539,IDELALISIB,"1. The drug label for ZYDELIG does not mention any specific cardiotoxicity risks or cardiotoxicity reactions associated with the use of this medication. 

Therefore, there are no references to the drug itself being linked to cardiotoxicity risks or reactions in the provided drug label information.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",efbdafa9-d18c-4e85-b4a2-1e620fc74e50,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=efbdafa9-d18c-4e85-b4a2-1e620fc74e50&type=display
540,IFOSFAMIDE,"1. Cardiotoxicity is a risk associated with ifosfamide treatment, manifesting as arrhythmias, ECG changes, cardiomyopathy, and potentially leading to death. The risk of cardiotoxic effects is dose-dependent and increased in patients with cardiac risk factors or preexisting cardiac disease. (The drug itself is associated with the risk of cardiotoxicity.)

2. Cardiotoxicity reactions reported with ifosfamide treatment include supraventricular or ventricular arrhythmias, decreased QRS voltage, ST-segment or T-wave changes, toxic cardiomyopathy, pericardial effusion, fibrinous pericarditis, and epicardial fibrosis. Fatal outcomes have been documented. (The drug itself is associated with causing cardiotoxicity reactions.)",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",efb1d03b-2d91-406e-8110-d3a58b8fa7cc,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=efb1d03b-2d91-406e-8110-d3a58b8fa7cc&type=display
541,ILOPERIDONE,"1. FANAPT is associated with an increased risk of cerebrovascular adverse reactions, such as stroke and transient ischemic attack, particularly in elderly patients with dementia-related psychosis. (FANAPT is associated with the risk of cerebrovascular adverse reactions.)

2. FANAPT can prolong the QT interval, which may lead to arrhythmia and sudden death. The risk of QT prolongation is increased when FANAPT is used in combination with other drugs known to prolong QTc or in patients with conditions that lower the seizure threshold. (FANAPT is associated with QT prolongation.)

3. FANAPT should be avoided in patients with a known genetic susceptibility to congenital long QT syndrome and in patients with a history of cardiac arrhythmias. Caution is advised when prescribing FANAPT with drugs that inhibit its metabolism. (FANAPT is associated with an increased risk of torsade de pointes and sudden death.)

4. FANAPT may induce orthostatic hypotension, leading to dizziness, tachycardia, and syncope, particularly in vulnerable patients. Orthostatic vital signs should be monitored, especially in patients with cardiovascular diseases. (FANAPT is associated with orthostatic hypotension and syncope.)

5. Antipsychotics, including FANAPT, may cause somnolence, postural hypotension, and motor instability, increasing the risk of falls and related injuries. Fall risk assessments should be conducted when initiating antipsychotic treatment. (FANAPT is associated with an increased risk of falls.)

6. FANAPT has been associated with seizures, with the greatest risk in patients with a history of seizures or conditions lowering the seizure threshold. (FANAPT is associated with an increased risk of seizures.)

7. Leukopenia, neutropenia, and agranulocytosis have been reported with antipsychotics, including FANAPT. Patients with pre-existing low white blood cell count or a history of drug-induced leukopenia/neutropenia should be monitored closely. (FANAPT is associated with an increased risk of leukopenia, neutropenia, and agranulocytosis.)

8. FANAPT elevates prolactin levels, which may lead to hyperprolactinemia-related adverse effects such as gynecomastia, amenorrhea, and impotence. Long-standing hyperprolactinemia may impact reproductive function and bone density. (FANAPT is associated with hyperprolactinemia.)

9. FANAPT may disrupt the body's ability to regulate core body temperature, potentially leading to hyperthermia. Caution is advised when using FANAPT in patients exposed to extreme heat or engaging in strenuous exercise. (FANAPT is associated with disruptions in body temperature regulation.)",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",33f60b40-3fca-11de-8f56-0002a5d5c51b,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=33f60b40-3fca-11de-8f56-0002a5d5c51b&type=display
542,IMATINIB MESYLATE,"1. Gleevec is associated with congestive heart failure and left ventricular dysfunction, with severe cardiac failure and left ventricular dysfunction reported in a small percentage of patients taking the drug. The drug itself is associated with these cardiotoxicity risks.

2. Cardiac adverse reactions were more frequent in patients with advanced age or co-morbidities, including a previous medical history of cardiac disease. The drug itself is associated with an increased risk of cardiac adverse reactions in certain patient populations.

3. In a randomized Phase 3 study, severe cardiac failure and left ventricular dysfunction were observed in a small percentage of patients taking Gleevec compared to another treatment. The drug itself was associated with these severe cardiac events.

4. In another randomized trial, cardiac failure was observed in a small percentage of patients taking Gleevec, with severe cardiac failure occurring in a subset of patients. The drug itself was associated with these cardiac failure events.

5. Patients with cardiac disease or risk factors for cardiac failure should be carefully monitored while taking Gleevec. The drug itself can exacerbate existing cardiac conditions or lead to new cardiac issues in susceptible patients.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",211ef2da-2868-4a77-8055-1cb2cd78e24b,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=211ef2da-2868-4a77-8055-1cb2cd78e24b&type=display
543,IMIPRAMINE HYDROCHLORIDE,"1. The drug label mentions that Imipramine Hydrochloride may cause orthostatic hypotension, hypertension, tachycardia, palpitation, myocardial infarction, arrhythmias, heart block, ECG changes, precipitation of congestive heart failure, and stroke. (The drug itself is associated with cardiotoxicity risks.)

2. It also states that critical manifestations of overdose include cardiac dysrhythmias, severe hypotension, convulsions, and CNS depression including coma. Changes in the electrocardiogram, particularly in QRS axis or width, are clinically significant indicators of tricyclic toxicity. (The drug itself is associated with cardiotoxicity risks.)

3. The label advises that an ECG should be taken prior to the initiation of larger-than-usual doses of Imipramine Hydrochloride and at appropriate intervals thereafter until steady state is achieved. Patients with any evidence of cardiovascular disease require cardiac surveillance at all dosage levels of the drug. (The drug itself is associated with cardiotoxicity risks.)

4. In cases of overdose, the label recommends obtaining an ECG and immediately initiating cardiac monitoring. Protecting the patients airway, establishing an intravenous line, and initiating gastric decontamination are also advised. (The drug itself is associated with cardiotoxicity risks.)

5. The label mentions that there have been reports of deaths from overdosage with tricyclic drugs like Imipramine Hydrochloride. Critical manifestations of overdose include cardiac dysrhythmias, severe hypotension, convulsions, and CNS depression including coma. (The drug itself is associated with cardiotoxicity risks.)

6. It is noted that cardiovascular abnormalities may include tachycardia and signs of congestive heart failure. Respiratory depression, cyanosis, shock, vomiting, hyperpyrexia, mydriasis, and diaphoresis may also be present in cases of overdose. (The drug itself is associated with cardiotoxicity risks.)

7. The label advises that all patients suspected of tricyclic overdose should receive gastrointestinal decontamination, including large volume gastric lavage followed by activated charcoal. If consciousness is impaired, securing the airway prior to lavage is recommended. (The drug itself is associated with cardiotoxicity risks.)",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",18bbd246-5709-4477-b10a-f811f3801962,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=18bbd246-5709-4477-b10a-f811f3801962&type=display
544,IMIPRAMINE PAMOATE,"1. The drug label mentions that the concomitant use of monoamine oxidase inhibiting compounds with Imipramine Pamoate is contraindicated due to the risk of hyperpyretic crises or severe convulsive seizures, indicating that the drug itself is associated with cardiotoxicity risk.

2. The label also states that extreme caution should be used when administering Imipramine Pamoate to patients with cardiovascular disease due to the possibility of conduction defects, arrhythmias, congestive heart failure, myocardial infarction, strokes, and tachycardia, suggesting that the drug itself is associated with cardiotoxicity risk.

3. Additionally, the label mentions that cardiovascular adverse reactions such as orthostatic hypotension, hypertension, tachycardia, palpitation, myocardial infarction, arrhythmias, heart block, ECG changes, and precipitation of congestive heart failure may occur as a result of Imipramine Pamoate use, indicating that the drug itself can cause cardiotoxicity reactions.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",53faac6a-fdb9-4d60-814d-b4aab9c9da58,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=53faac6a-fdb9-4d60-814d-b4aab9c9da58&type=display
545,INCLISIRAN,"1. The drug LEQVIO (inclisiran) is indicated for the treatment of adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH), to reduce low-density lipoprotein cholesterol (LDL-C). (No mention of cardiotoxicity risk associated with the drug itself)
   
2. LEQVIO should be administered by a healthcare professional. (No mention of cardiotoxicity risk associated with the drug itself)

3. Adverse reactions reported in clinical trials included injection site reaction, arthralgia, and bronchitis. (No mention of cardiotoxicity risk associated with the drug itself)

4. No specific contraindications related to cardiotoxicity were listed for LEQVIO. (No mention of cardiotoxicity risk associated with the drug itself)

5. Adverse reactions led to treatment discontinuation in a small percentage of patients, with injection site reactions being the most common reason for discontinuation. (No mention of cardiotoxicity risk associated with the drug itself)

6. LEQVIO did not prolong the QT interval to any clinically relevant extent at a dose three times the maximum recommended dose. (No mention of cardiotoxicity risk associated with the drug itself)

7. No formal clinical drug interaction studies have been performed, and LEQVIO is not expected to cause drug-drug interactions or be affected by inhibitors or inducers of cytochrome P450 enzymes or transporters. (No mention of cardiotoxicity risk associated with the drug itself)",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",6fc0afca-4513-4c35-b594-6544aee29a44,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=6fc0afca-4513-4c35-b594-6544aee29a44&type=display
546,INDAPAMIDE,"1. The drug label mentions that daily doses of 1.25 mg, 5 mg, and 10 mg of indapamide have no appreciable cardiac inotropic or chronotropic effect, indicating that the drug itself is not associated with cardiotoxicity risks.
   
2. The label also states that chronic administration of indapamide to hypertensive patients has little or no effect on glomerular filtration rate or renal plasma flow, suggesting that the drug does not pose a cardiotoxicity risk.

3. Additionally, the label mentions that indapamide had an antihypertensive effect in patients with varying degrees of renal impairment, although diuretic effects declined as renal function decreased, indicating that the drug itself does not cause cardiotoxicity reactions.

4. The drug label does not specifically mention any cardiotoxicity risks or cardiotoxicity reactions associated with indapamide, suggesting that the drug is generally well-tolerated in terms of cardiac effects.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",962b20df-88ff-4ab7-a900-135adb6c1d74,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=962b20df-88ff-4ab7-a900-135adb6c1d74&type=display
547,INDINAVIR SULFATE,1. The drug label does not mention any cardiotoxicity risks or reactions associated with CRIXIVAN (indinavir sulfate) capsules.,No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",83aeddf8-6fed-487c-858b-2240f0a0e8af,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=83aeddf8-6fed-487c-858b-2240f0a0e8af&type=display
548,INDIUM IN 111 CHLORIDE,"1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with the use of Indium In 111 Chloride Sterile Solution itself.
2. The label advises that the contents of the vial are intended only for radiolabeling ProstaScint for diagnostic imaging or Zevalin for radioimmunotherapy, and should not be administered directly to humans. This statement does not indicate any direct cardiotoxicity risk from the drug itself.
3. The precautions section emphasizes the need for proper aseptic technique during handling, adequate shielding, and handling precautions due to the radioactive nature of the drug. While these precautions are important for safety, they do not suggest a direct cardiotoxicity risk.
4. The label does not provide information on carcinogenesis, mutagenesis, or impairment of fertility related to the drug itself, which would include cardiotoxicity risks.
5. The drug label does not mention any specific pregnancy category, nursing mothers' guidance, or pediatric use information that would indicate cardiotoxicity risks associated with the drug.
6. The adverse reactions section is not detailed in the label provided, so there is no specific mention of cardiotoxicity reactions associated with the use of Indium In 111 Chloride Sterile Solution.
7. The dosage and administration section does not include any information on cardiotoxicity risks or reactions related to the use of the drug.
8. Overall, the drug label does not directly associate Indium In 111 Chloride Sterile Solution with cardiotoxicity risks or cardiotoxic reactions. The focus of the label is primarily on the proper handling, storage, and use of the drug for radiolabeling purposes.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",e07e66ef-fb9e-4f9f-b63f-ab28f622cb2e,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=e07e66ef-fb9e-4f9f-b63f-ab28f622cb2e&type=display
549,INDIUM IN-111 OXYQUINOLINE,1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with the use of Indium In 111 Oxyquinoline Solution.,No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",4c52c904-8137-4b10-8a85-d9b96c2d8a00,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=4c52c904-8137-4b10-8a85-d9b96c2d8a00&type=display
550,INDIUM IN-111 PENTETATE DISODIUM,"1. The drug label does not mention any specific cardiotoxicity risks associated with Indium DTPA In 111 (Pentetate Indium Disodium In 111).
2. The label does not attribute any cardiotoxicity reactions to the drug itself.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",4fea5871-b515-4f69-a297-11507ddd7817,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=4fea5871-b515-4f69-a297-11507ddd7817&type=display
551,INDOCYANINE GREEN,"1. The drug label mentions that hypersensitivity reactions, including anaphylaxis and urticaria, have occurred following intravenous administration of indocyanine green, the active ingredient in SPY AGENT GREEN. It advises to have cardiopulmonary resuscitation personnel and equipment readily available and to monitor all patients for hypersensitivity reactions. (The drug itself is not directly associated with cardiotoxicity risk, but hypersensitivity reactions may lead to cardiopulmonary complications.)

2. The drug label also states that hypersensitivity reactions, including anaphylaxis, urticaria, and deaths due to anaphylaxis, have been reported following intravenous administration of indocyanine green. It emphasizes that SPY AGENT GREEN is contraindicated in patients with a history of hypersensitivity to indocyanine green and recommends having cardiopulmonary resuscitation personnel and equipment readily available to manage potential reactions. (The drug itself is not directly linked to cardiotoxicity risk, but severe hypersensitivity reactions can lead to cardiopulmonary complications.)

3. Additionally, the drug label warns about the potential interference with thyroid radioactive iodine uptake studies due to the iodine content in SPY AGENT GREEN. It advises not to perform radioactive iodine uptake studies for at least one week following the administration of the drug. (The drug itself is not associated with cardiotoxicity risk in this context, but the interference with thyroid studies could impact cardiac function assessment.)",Less,No,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",95d11200-1cca-4044-b652-82dac72103b9,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=95d11200-1cca-4044-b652-82dac72103b9&type=display
552,INDOMETHACIN,"1. The drug label warns that nonsteroidal anti-inflammatory drugs (NSAIDs), including INDOCIN, are associated with an increased risk of serious cardiovascular thrombotic events, such as myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with the duration of use.

2. INDOCIN is contraindicated in patients who have undergone coronary artery bypass graft (CABG) surgery due to the increased risk of serious cardiovascular events associated with NSAID use.

3. The drug label advises that patients with a recent myocardial infarction (MI) should avoid using INDOCIN unless the benefits are expected to outweigh the risk of recurrent cardiovascular thrombotic events. Monitoring for signs of cardiac ischemia is recommended if INDOCIN is used in post-MI patients.

4. The label also mentions that the concurrent use of aspirin and NSAIDs like INDOCIN may not mitigate the increased risk of serious cardiovascular thrombotic events associated with NSAID use. Monitoring for signs of gastrointestinal bleeding is advised when using both medications together.

Overall, the drug label clearly states that INDOCIN is associated with an increased risk of serious cardiovascular thrombotic events and advises caution, especially in patients with a history of cardiovascular disease or risk factors.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",73878376-1d24-423b-9f37-3666e83c95da,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=73878376-1d24-423b-9f37-3666e83c95da&type=display
553,INFIGRATINIB,"1. **Cardiotoxicity Risk**: The drug label for TRUSELTIQ (infigratinib) does not specifically mention cardiotoxicity risks associated with the drug itself.

2. **Cardiotoxicity Reactions**: The drug label does not list cardiotoxicity reactions as common adverse reactions or warnings and precautions associated with TRUSELTIQ.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",af9a96cf-1cd7-8ace-e053-2a95a90a18cc,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=af9a96cf-1cd7-8ace-e053-2a95a90a18cc&type=display
554,INOTERSEN,"1. **Stroke and Cervicocephalic Arterial Dissection**: TEGSEDI may cause stroke and cervicocephalic arterial dissection, with one patient experiencing carotid artery dissection and stroke within 2 days of the first dose. The events occurred at a time when the patient had symptoms of cytokine release, indicating a potential association between TEGSEDI and these cardiotoxic events.

2. **Inflammatory and Immune Effects**: Serious inflammatory and immune adverse reactions occurred in TEGSEDI-treated patients, including immune thrombocytopenia, glomerulonephritis, and antineutrophil cytoplasmic autoantibody (ANCA)-positive systemic vasculitis. These reactions suggest a potential link between TEGSEDI and cardiotoxicity risks.

3. **Liver Injury**: TEGSEDI can lead to liver injury, with cases of increased liver enzymes reported in patients. Liver transplant rejection cases were also observed in patients who had stable liver allografts prior to TEGSEDI treatment. While not directly related to cardiotoxicity, liver dysfunction can impact cardiovascular health and may be considered a potential risk factor for cardiotoxicity.

4. **Hypersensitivity Reactions/Antibody Formation**: TEGSEDI can cause hypersensitivity reactions, with some patients experiencing reactions within 2 hours of administration. While not directly linked to cardiotoxicity, severe hypersensitivity reactions can lead to systemic effects that may impact cardiovascular function.

5. **Reduced Serum Vitamin A Levels and Recommended Supplementation**: TEGSEDI treatment can result in decreased serum vitamin A levels, requiring supplementation. While vitamin A deficiency itself may not directly cause cardiotoxicity, it can lead to various systemic complications that may impact cardiovascular health.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",8513207e-b55f-417b-9473-af785146a543,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8513207e-b55f-417b-9473-af785146a543&type=display
555,IOBENGUANE I-123,"1. The drug AdreView is indicated for the scintigraphic assessment of sympathetic innervation of the myocardium in patients with heart failure, specifically those with New York Heart Association (NYHA) class II or class III heart failure and left ventricular ejection fraction (LVEF)  35%. AdreView may help identify patients with lower one and two year mortality risks based on an H/M ratio  1.6. (The drug itself is not associated with cardiotoxicity risk in this context.)

2. AdreView utility has not been established for selecting a therapeutic intervention or monitoring the response to therapy in patients with congestive heart failure. It is also not recommended for using the H/M ratio to identify patients at high risk for death. (The drug itself is not associated with cardiotoxicity risk in this context.)

3. Adverse reactions to AdreView in clinical studies were predominantly mild to moderate, with no serious adverse reactions observed in patients with heart failure. The most common adverse reactions included injection site problems, flushing, and headache. (The drug AdreView is not associated with causing serious cardiotoxicity reactions in clinical studies.)

4. AdreView may transiently increase norepinephrine release from chromaffin granules and potentially produce a transient episode of hypertension, although this was not observed in clinical studies. Emergency cardiac and anti-hypertensive treatments should be readily available before AdreView administration. (The drug AdreView may transiently affect blood pressure but is not associated with causing serious cardiotoxicity reactions.)

5. Imaging errors may occur in individuals with conditions affecting the sympathetic nervous system, such as Parkinsonian syndromes, leading to decreased cardiac uptake of AdreView independent of heart disease. (The drug AdreView is not directly associated with causing cardiotoxicity reactions in this context.)

6. The drug AdreView is not dialyzable and is cleared by glomerular filtration. Patients with severe renal impairment may experience increased radiation exposure and decreased image quality due to delayed drug elimination. This may limit the role of AdreView in diagnostic evaluation for these patients. (The drug AdreView is not directly associated with causing cardiotoxicity reactions in this context.)",Less,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",c89d3ecc-4f4c-4566-8808-79152344194d,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=c89d3ecc-4f4c-4566-8808-79152344194d&type=display
556,IODIXANOL,"1. The drug label warns of cardiovascular adverse reactions, including hemodynamic disturbances such as shock and cardiac arrest, which may occur during or after administration of VISIPAQUE. The drug itself is associated with these cardiotoxicity risks.

2. Serious, rarely fatal, thromboembolic events causing myocardial infarction and stroke can occur during angiocardiography procedures with both ionic and nonionic contrast media, including VISIPAQUE. The drug is associated with an increased risk of thromboembolic events leading to cardiotoxicity.

3. Life-threatening or fatal cardiovascular reactions, including hypotension, shock, and cardiac arrest, have occurred with the use of VISIPAQUE. The drug itself is linked to these severe cardiotoxic reactions.

4. Cardiac decompensation, serious arrhythmias, and myocardial ischemia or infarction can occur during coronary arteriography and ventriculography with VISIPAQUE. The drug is associated with the potential for cardiotoxic effects during these procedures.

5. Based on clinical literature, reported deaths from the administration of iodinated contrast agents, including VISIPAQUE, range from 6.6 per million to 1 in 10,000, with cardiovascular disease as a main aggravating factor. The drug is associated with an increased risk of fatal cardiovascular events.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",e9d87b8c-7695-4c0f-8e81-000dedb5f66d,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=e9d87b8c-7695-4c0f-8e81-000dedb5f66d&type=display
557,IOFLUPANE I-123,"1. The drug label does not mention any cardiotoxicity risks or cardiotoxicity reactions associated with DATSCAN itself.

2. The drug label does not indicate any cardiotoxicity risks or cardiotoxicity reactions related to the use of DATSCAN. 

3. There are no mentions of cardiotoxicity risks or cardiotoxicity reactions attributed to DATSCAN in the drug label. 

Overall, the drug label for DATSCAN does not contain any information regarding cardiotoxicity risks or cardiotoxicity reactions associated with the use of the medication.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",ef7804d7-c691-495b-8aaf-5bc54fd5d9f6,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=ef7804d7-c691-495b-8aaf-5bc54fd5d9f6&type=display
558,IOHEXOL,"1. The drug label warns about cardiovascular adverse reactions, including hemodynamic disturbances such as shock and cardiac arrest, that may occur during or after administration of OMNIPAQUE. The drug itself is associated with the risk of cardiovascular adverse reactions.

2. The label also mentions that contrast-induced acute kidney injury, including renal failure, can occur with the use of OMNIPAQUE. The drug itself is associated with the risk of contrast-induced acute kidney injury, which can lead to cardiotoxicity due to kidney dysfunction affecting fluid balance and electrolyte levels.

3. Additionally, the drug label highlights the potential for hypersensitivity reactions, which can be life-threatening or fatal, and advises having emergency equipment and trained personnel available. The drug itself is associated with the risk of hypersensitivity reactions, which can manifest as cardiotoxicity symptoms such as chest pain and cardiovascular collapse.

4. The label does not specifically mention direct cardiotoxicity reactions related to OMNIPAQUE administration, but it is important to note that cardiovascular adverse events can occur as part of the overall spectrum of hypersensitivity and contrast-induced kidney injury risks associated with the drug.",Less,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",f9e9d558-064c-4b86-8d96-2f8a678c89f9,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=f9e9d558-064c-4b86-8d96-2f8a678c89f9&type=display
559,IOPAMIDOL,"1. The drug label mentions that severe adverse reactions have been reported due to the inadvertent intrathecal administration of iodinated contrast media, but it does not associate cardiotoxicity risks specifically with the drug itself.

2. The label warns about serious, rarely fatal, thromboembolic events during angiographic procedures with both ionic and nonionic contrast media, emphasizing the need for meticulous intravascular administration technique to minimize these events. The drug is not directly linked to causing cardiotoxicity but is associated with the risk of thromboembolic events during angiographic procedures.

3. The label cautions that patients with severely impaired renal function, combined renal and hepatic disease, or anuria may experience prolonged elimination half-life of the drug, potentially leading to cardiotoxicity risks. The drug itself is not stated to cause cardiotoxicity but may pose risks in patients with impaired renal function.

4. The label advises that contrast media are potentially hazardous in patients with multiple myeloma or other paraproteinemia, particularly in those with therapeutically resistant anuria, without directly attributing cardiotoxicity risks to the drug itself.

5. The label mentions that contrast media may promote sickling in individuals with homozygous sickle cell disease when injected intravenously or intraarterially, indicating a potential cardiotoxicity risk associated with the drug in this specific patient population.

6. The label highlights the importance of administering radiopaque materials with extreme caution in patients known or suspected of having pheochromocytoma, as the drug may lead to cardiotoxic reactions in these individuals. The drug is associated with cardiotoxicity risks in patients with pheochromocytoma.

7. The label warns about the possibility of thyroid storm following the use of iodinated radiopaque diagnostic agents in patients with hyperthyroidism or autonomously functioning thyroid nodules, suggesting that this additional risk be evaluated before using any contrast medium. The drug is not directly linked to causing cardiotoxicity but may pose risks in patients with thyroid dysfunction.

8. The label mentions that iodinated contrast media may aggravate the symptoms of myasthenia gravis, indicating a potential risk of cardiotoxicity in patients with this condition associated with the use of the drug.

Overall, while the drug label does not directly attribute cardiotoxicity risks to the drug itself, it emphasizes the importance of considering various patient factors and conditions that may increase the likelihood of cardiotoxic reactions during or after the administration of the contrast media.",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",ae8c18c9-3e7d-4515-b980-120025a88fc1,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=ae8c18c9-3e7d-4515-b980-120025a88fc1&type=display
560,IOTHALAMATE MEGLUMINE,"1. The drug label mentions that severe adverse events, including thromboembolic events causing myocardial infarction and stroke, have been reported during angiographic procedures with both ionic and nonionic contrast media, indicating that the contrast media itself is associated with cardiotoxicity risks.

2. The label also warns about serious or fatal reactions associated with the administration of iodine-containing radiopaque media, emphasizing the importance of being prepared to treat any contrast medium reaction, suggesting that the contrast media itself can lead to cardiotoxic reactions.

3. Additionally, the label mentions that severe cardiovascular responses, such as hypotensive shock, coronary insufficiency, cardiac arrhythmia, fibrillation, and arrest, have been reported as severe reactions to contrast media, indicating that the contrast media can directly cause cardiotoxicity reactions.

4. Furthermore, the label discusses the risk of disseminated intravascular coagulation resulting in death, which has been reported as an extremely rare severe cardiovascular response to contrast media, suggesting that the contrast media itself can lead to cardiotoxicity reactions.

5. The label also highlights that severe reactions to contrast media often resemble allergic responses, prompting the use of prophylactic therapy for patients with a strong allergic history or previous reaction to contrast media, indicating that the contrast media can trigger cardiotoxic reactions in susceptible individuals.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",1292abfc-496f-4df7-9a08-72072953e1f1,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=1292abfc-496f-4df7-9a08-72072953e1f1&type=display
561,IRBESARTAN,"1. The drug AVAPRO (irbesartan) is associated with a warning for fetal toxicity, which can cause injury and death to the developing fetus when administered to pregnant women. This is a risk directly associated with the drug itself.

2. AVAPRO is indicated for the treatment of hypertension, which can lower blood pressure and reduce the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. Lowering blood pressure is the primary mechanism by which the drug reduces cardiovascular risks, but this is not a direct cardiotoxicity risk associated with the drug.

3. In clinical trials, AVAPRO was associated with adverse reactions such as hyperkalemia, dizziness, orthostatic dizziness, and orthostatic hypotension in patients with nephropathy in type 2 diabetic patients. These reactions were more frequent than placebo and are considered cardiotoxicity reactions associated with the drug.

4. The drug label also warns about the potential for hypotension in volume or salt-depleted patients, especially those being treated with high doses of diuretics. Symptomatic hypotension may occur after the initiation of treatment with AVAPRO in these patients. This is a cardiotoxicity risk associated with the drug.

5. AVAPRO can cause impaired renal function, including acute renal failure, in patients whose renal function may depend on the activity of the renin-angiotensin system. Patients with conditions such as renal artery stenosis, chronic kidney disease, severe heart failure, or volume depletion are at particular risk of developing acute renal failure or death on AVAPRO. This is a cardiotoxicity risk associated with the drug.

6. In clinical trials, AVAPRO was associated with an increased incidence of orthostatic symptoms, including dizziness, orthostatic dizziness, and orthostatic hypotension, in patients with nephropathy in type 2 diabetic patients. These symptoms are considered cardiotoxicity reactions associated with the drug.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",7885b2a8-be4e-48ab-8113-4e6ab791eb98,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7885b2a8-be4e-48ab-8113-4e6ab791eb98&type=display
562,IRINOTECAN HYDROCHLORIDE,"1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with ONIVYDE itself.

2. The drug label focuses on severe neutropenia and severe diarrhea as the primary warnings and precautions, with no direct mention of cardiotoxicity risks or reactions related to ONIVYDE.

3. The adverse reactions highlighted in the label primarily include gastrointestinal issues, infections, fatigue, and laboratory abnormalities, with no explicit mention of cardiotoxicity risks or reactions attributed to ONIVYDE.

4. The drug label emphasizes the importance of monitoring blood cell counts, managing severe diarrhea, and addressing hypersensitivity reactions, but does not discuss any cardiotoxicity risks or reactions linked to ONIVYDE.

5. Overall, the drug label for ONIVYDE does not indicate any direct association between the drug and cardiotoxicity risks or reactions. The focus is primarily on neutropenia, diarrhea, and other adverse effects.",Less,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",c8b58efa-1820-48a4-b70d-62918fc4abfc,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=c8b58efa-1820-48a4-b70d-62918fc4abfc&type=display
563,IRON DEXTRAN,"1. **Warnings and Precautions Section:**
   - The drug label warns about delayed reactions associated with large intravenous doses, which may include symptoms like chest pain, backache, and dizziness. The drug itself is not directly associated with causing cardiotoxicity but may lead to delayed reactions that include symptoms related to the cardiovascular system.

2. **Warnings and Precautions Section:**
   - Patients with underlying conditions, such as serious liver impairment, are at an increased risk of toxicity, which could exacerbate cardiovascular complications. The drug itself is not causing cardiotoxicity but may worsen existing cardiovascular issues in patients with certain underlying conditions.

3. **Warnings and Precautions Section:**
   - Patients with pre-existing cardiovascular disease may experience an exacerbation of symptoms following the administration of the drug. The drug itself is not directly causing cardiotoxicity but may worsen symptoms in patients with pre-existing cardiovascular conditions.

4. **Adverse Reactions Section:**
   - Cardiac disorders, including cardiac arrest, tachycardia, bradycardia, and arrhythmias, have been reported as adverse reactions associated with the drug. This indicates that the drug has been associated with cardiotoxicity reactions as reported adverse events.

5. **Adverse Reactions Section:**
   - Chest pain, chest tightness, and other cardiovascular symptoms have been reported as adverse reactions following the administration of the drug. These adverse reactions suggest a potential association between the drug and cardiotoxicity symptoms.

6. **Adverse Reactions Section:**
   - Hypotension, hypertension, and shock have been reported as vascular disorders associated with the drug. These reactions indicate that the drug has been linked to cardiovascular complications and potential cardiotoxicity risks.",Less,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",94b01b1e-794b-4bea-8e24-2e54683fc023,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=94b01b1e-794b-4bea-8e24-2e54683fc023&type=display
564,ISAVUCONAZONIUM SULFATE,"1. **Contraindications**: CRESEMBA is contraindicated in patients with familial short QT syndrome, indicating that the drug itself is associated with a cardiotoxicity risk due to its potential to shorten the QTc interval.

2. **Warnings and Precautions - Hypersensitivity Reactions**: Anaphylactic reactions, including fatal outcomes, have been reported during treatment with CRESEMBA, suggesting that the drug can cause cardiotoxicity through hypersensitivity reactions.

3. **Warnings and Precautions - Embryo-Fetal Toxicity**: CRESEMBA may cause fetal harm when administered to pregnant women, indicating a potential risk of cardiotoxicity to the fetus if exposed during pregnancy.

4. **Adverse Reactions - Clinical Trial Experience**: While not directly stating cardiotoxicity, the adverse reactions reported in clinical trials include dyspnea, which is a symptom that can be associated with cardiotoxicity. This suggests a potential risk of cardiotoxicity with CRESEMBA use.

Overall, the drug label highlights the potential for cardiotoxicity risks and reactions associated with CRESEMBA, including the risk of QT interval shortening, hypersensitivity reactions leading to anaphylaxis, and potential fetal harm related to cardiotoxic effects.",Less,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",8f7f73b8-586a-4df0-935f-fecd4696c16c,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8f7f73b8-586a-4df0-935f-fecd4696c16c&type=display
565,ISENTRESS,"1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with Isentress (raltegravir) itself.

2. The label primarily focuses on severe skin reactions, hypersensitivity reactions, and immune reconstitution syndrome as potential adverse effects of Isentress. These reactions are not directly related to cardiotoxicity.

3. The adverse reactions mentioned in the label include insomnia, headache, dizziness, nausea, and fatigue, but these are not indicative of cardiotoxicity.

4. Creatine kinase elevations were observed in subjects who received Isentress, and myopathy and rhabdomyolysis have been reported. However, these conditions are not directly related to cardiotoxicity.

5. The label does not list any specific cardiotoxicity risks or reactions associated with Isentress use. The drug interactions section also does not mention any clinically significant interactions with drugs that are known to cause cardiotoxicity.

In summary, the drug label for Isentress does not indicate any direct association with cardiotoxicity risks or reactions. The focus is primarily on other potential adverse effects and drug interactions.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",4f31df66-7dc7-1f04-e054-00144ff88e88,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=4f31df66-7dc7-1f04-e054-00144ff88e88&type=display
566,ISOCARBOXAZID,"1. The drug label mentions that Marplan should not be administered to patients with confirmed or suspected cerebrovascular defects, cardiovascular disease, hypertension, or a history of headache, indicating that the drug itself is associated with cardiotoxicity risks.

2. It is also stated that Marplan should not be used in the presence of pheochromocytoma, as tumors secrete pressor substances whose metabolism may be inhibited by Marplan, suggesting a potential risk of cardiotoxicity associated with the drug.

3. The label warns that Marplan should not be used in patients with a history of liver disease or abnormal liver function tests, indicating a potential risk of hepatotoxicity that could impact cardiovascular health.

4. Additionally, the drug label mentions that Marplan can cause hypertensive crises, which have sometimes been fatal, especially when co-administered with certain drugs and foods, highlighting a direct association between the drug and cardiotoxic reactions.

5. The label advises that blood pressure should be closely monitored in patients taking Marplan to detect any pressor response, indicating a potential risk of cardiovascular complications associated with the drug.

6. It is also noted that if a hypertensive crisis occurs, Marplan should be discontinued immediately, and therapy to lower blood pressure should be initiated promptly, emphasizing the potential for severe cardiovascular reactions linked to the drug.

7. Patients are instructed to report promptly any unusual symptoms such as palpitations, tachycardia, chest pain, and other signs of hypertensive crises while on Marplan therapy, underscoring the importance of monitoring for cardiotoxicity reactions.

8. The label further cautions patients against consuming foods with high tyramine content during Marplan therapy, as they can lead to hypertensive crises, highlighting the drug's potential to interact with certain foods and trigger cardiovascular complications.

9. Lastly, the drug label advises patients to be aware of the possibility of hypotension, faintness, and drowsiness while taking Marplan, indicating potential cardiovascular side effects associated with the medication.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",ac387aa0-3f04-4865-a913-db6ed6f4fdc5,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=ac387aa0-3f04-4865-a913-db6ed6f4fdc5&type=display
567,ISONIAZID,"1. The drug label warns of severe and sometimes fatal hepatitis associated with isoniazid therapy, which may occur even after many months of treatment. The risk of developing hepatitis is age-related, with increased risk for persons over 35 years old. The risk of hepatitis is also increased with daily alcohol consumption. (The drug itself is not directly associated with cardiotoxicity risk in this context.)

2. The label advises careful monitoring of hepatic enzymes, specifically AST and ALT, prior to starting isoniazid therapy and periodically throughout treatment, especially for patients over 35 years old. Isoniazid-associated hepatitis usually occurs within the first three months of treatment. (The drug itself is not directly associated with cardiotoxicity risk in this context.)

3. The label mentions that progressive liver dysfunction can occur in some cases of isoniazid-associated hepatitis. Other factors associated with an increased risk of hepatitis include daily alcohol use, chronic liver disease, and injection drug use. (The drug itself is not directly associated with cardiotoxicity risk in this context.)

4. The label states that the frequency of progressive liver damage increases with age, with rare occurrences in persons under 20 but up to 2.3% in those over 50 years old. (The drug itself is not directly associated with cardiotoxicity risk in this context.)

5. The label does not mention any direct association between isoniazid and cardiotoxicity reactions. The focus is primarily on hepatotoxicity risks and reactions.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",e7314f55-7a60-4496-a59f-895f33109998,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=e7314f55-7a60-4496-a59f-895f33109998&type=display
568,ISOSORBIDE DINITRATE,"1. The drug Isosorbide Dinitrate is contraindicated in patients allergic to the drug or any of its ingredients. This indicates that the drug itself is associated with a cardiotoxicity risk in patients who are allergic to it.

2. Isosorbide Dinitrate should not be used in patients taking certain drugs for erectile dysfunction, as concomitant use can cause severe hypotension, syncope, or myocardial ischemia. This suggests that the drug itself can lead to cardiotoxic reactions when combined with specific medications.

3. The label warns that amplification of the vasodilatory effects of Isosorbide Dinitrate by sildenafil can result in severe hypotension, indicating that the drug can cause cardiotoxicity when interacting with other medications.

4. The label mentions that the benefits of Isosorbide Dinitrate in patients with acute myocardial infarction or congestive heart failure have not been established, and careful monitoring is necessary to avoid the hazards of hypotension and tachycardia. This implies that the drug itself may pose cardiotoxic risks in these specific conditions.

5. Severe hypotension, particularly with upright posture, may occur with even small doses of Isosorbide Dinitrate, indicating that the drug itself can lead to cardiotoxic reactions such as severe hypotension.

6. The label mentions that nitrate therapy may aggravate the angina caused by hypertrophic cardiomyopathy, suggesting that the drug itself can worsen the condition and lead to cardiotoxic effects.

7. The label also warns that some patients may experience syncope, crescendo angina, and rebound hypertension as adverse reactions to Isosorbide Dinitrate, although these reactions are uncommon. This indicates that the drug itself can cause cardiotoxic reactions in some patients.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",723d9f78-9d77-4575-af27-1aa117e6b8d7,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=723d9f78-9d77-4575-af27-1aa117e6b8d7&type=display
569,ISOSORBIDE MONONITRATE,"1. The drug label mentions that severe hypotension, particularly with upright posture, may occur with even small doses of isosorbide mononitrate, indicating that the drug itself is associated with the risk of severe hypotension.
   
2. It is stated that nitrate therapy may aggravate the angina caused by hypertrophic cardiomyopathy, suggesting that the drug may worsen angina in patients with this condition.

3. The label warns about the potential for marked symptomatic orthostatic hypotension when calcium channel blockers and organic nitrates are used in combination, indicating that the drug can interact with other medications to cause severe hypotension.

4. The drug label mentions that the ill effects of isosorbide mononitrate overdose are generally the result of its capacity to induce vasodilatation, venous pooling, reduced cardiac output, and hypotension, indicating that the drug itself can lead to these cardiotoxic effects.

5. The label also discusses the potential for methemoglobinemia as a side effect of isosorbide mononitrate, stating that nitrate ions liberated during its metabolism can oxidize hemoglobin into methemoglobin, suggesting that the drug itself can contribute to this condition.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",17525ff2-9ec0-15a1-e063-6394a90ab762,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=17525ff2-9ec0-15a1-e063-6394a90ab762&type=display
570,ISOSULFAN BLUE,"1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with Lymphazurin itself.
2. However, it does highlight the potential for life-threatening anaphylactic reactions, including respiratory distress and shock, which could indirectly impact cardiovascular function in patients receiving Lymphazurin.
3. Additionally, the label mentions that Lymphazurin may interfere with oxygen saturation measurements, which could affect the assessment of cardiovascular status in patients undergoing pulse oximetry.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",cbee4532-238b-4f91-86ae-f8c0c1b6d7da,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=cbee4532-238b-4f91-86ae-f8c0c1b6d7da&type=display
571,ISOTRETINOIN,"1. The drug ABSORICA/ABSORICA LD is not associated with cardiotoxicity risks or cardiotoxicity reactions based on the information provided in the drug label. The label primarily focuses on warnings related to embryo-fetal toxicity, psychiatric disorders, intracranial hypertension, serious skin reactions, pancreatitis, lipid abnormalities, hearing impairment, hepatotoxicity, inflammatory bowel disease, musculoskeletal abnormalities, and ocular abnormalities. No specific mention of cardiotoxicity risks or reactions is included in the drug label.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",3ef0cff8-19c1-4441-b780-fca6c7ee1615,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=3ef0cff8-19c1-4441-b780-fca6c7ee1615&type=display
572,ISRADIPINE,"1. Isradipine is a calcium antagonist that binds to calcium channels and inhibits calcium flux into cardiac and smooth muscle, which can lead to dilating effects in arterioles, reducing systemic resistance and lowering blood pressure. The drug has negative inotropic effects
in vitro, but studies in animals and humans suggest that the vasodilating effect occurs at lower doses than those affecting contractility. Isradipine's afterload reducing properties may lead to some increase in cardiac output in patients with normal ventricular function. (The drug itself is associated with cardiotoxicity risks due to its mechanism of action on calcium channels.)

2. Isradipine has been shown to reduce blood pressure within 2 to 3 hours following administration, with a duration of action of more than 12 hours at higher doses. Chronic administration of divided doses in the range of 5 to 20 mg daily has been effective in reducing blood pressure, with dose-related responses observed. Isradipine is equally effective in reducing supine, sitting, and standing blood pressure. (The drug itself is associated with cardiotoxicity risks due to its blood pressure-lowering effects.)

3. Hemodynamic studies in patients with normal left ventricular function have shown that isradipine can increase cardiac index, stroke volume index, coronary sinus blood flow, heart rate, and peak positive left ventricular dP/dt, while decreasing systemic, coronary, and pulmonary vascular resistance. The clinical consequences of these hemodynamic effects have not been fully evaluated. (The drug itself is associated with cardiotoxicity risks due to its effects on hemodynamics.)

4. Isradipine has been shown to have variable effects on heart rate, depending on the rate of administration and underlying cardiac conditions. While some positive effects on cardiac performance have been observed in certain studies, the overall clinical consequences of these effects remain unclear. (The drug itself is associated with cardiotoxicity risks due to its effects on heart rate and cardiac function.)

5. In general, no detrimental effects on the cardiac conduction system were seen with the use of isradipine in electrophysiologic studies. However, slight prolongation of the QTc interval was observed in one study, and effects on sinus node recovery time were mild or not seen. Isradipine did not have a depressant effect on sinus and atrioventricular node function in patients with sick sinus syndrome. (The drug itself is not associated with significant cardiotoxicity risks based on electrophysiologic studies.)

6. Isradipine has been associated with adverse reactions such as palpitations, tachycardia, atrial fibrillation, ventricular fibrillation, myocardial infarction, and heart failure in rare cases. These cardiovascular events are considered possibly drug-related, and their relationship to isradipine administration is uncertain. (The drug itself is associated with rare cardiotoxicity reactions based on reported adverse events.)

7. Overdosage with isradipine may result in excessive peripheral vasodilatation, marked systemic hypotension, and tachycardia. Severe hypotension and AV conduction disturbances may require active cardiovascular support, including monitoring of cardiac and respiratory function, elevation of lower extremities, and attention to circulating fluid volume. (The drug itself is associated with cardiotoxicity risks in cases of overdosage, leading to severe hypotension and tachycardia.)",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",bf3425e0-428d-4bdb-ac9a-3b9d483df83a,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=bf3425e0-428d-4bdb-ac9a-3b9d483df83a&type=display
573,ISTRADEFYLLINE,"1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with NOURIANZ (istradefylline) itself.

2. In a cardiac electrophysiology study, NOURIANZ (istradefylline) at doses of 40 mg or 160 mg did not show any clinically significant prolongation of the QTc interval or a relationship between changes in QTc and drug concentrations.

3. Overall, the drug label does not indicate any direct association between NOURIANZ (istradefylline) and cardiotoxicity risks or reactions.",Less,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",a7d008cb-b273-4049-a5d2-9c6902910d58,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a7d008cb-b273-4049-a5d2-9c6902910d58&type=display
574,ITRACONAZOLE,"1. The drug label includes a boxed warning regarding congestive heart failure, cardiac effects, and drug interactions associated with Itraconazole Oral Solution. The drug itself is associated with the risk of congestive heart failure and negative inotropic effects when administered intravenously to dogs and healthy human volunteers.

2. The label mentions that if signs or symptoms of congestive heart failure occur during the administration of Itraconazole Oral Solution, continued use should be reassessed. The drug itself is associated with the potential development of congestive heart failure.

3. It is noted that when Itraconazole was administered intravenously, negative inotropic effects were observed in dogs and healthy human volunteers. The drug itself is associated with causing negative inotropic effects.

4. The label warns about drug interactions with Itraconazole Oral Solution, specifically mentioning contraindicated coadministration with certain drugs due to the potential for elevated plasma concentrations and increased or prolonged pharmacologic effects and adverse reactions. The drug itself is associated with the risk of drug interactions leading to cardiotoxicity, such as QT prolongation and ventricular tachyarrhythmias.

5. Additionally, the label highlights that coadministration with calcium channel blockers can have additive negative inotropic effects, and caution should be used when combining these medications due to an increased risk of congestive heart failure. The drug itself is associated with the potential for additive negative inotropic effects when coadministered with calcium channel blockers.

6. The label mentions that cases of congestive heart failure, peripheral edema, and pulmonary edema have been reported in post-marketing experiences with patients receiving Itraconazole Oral Solution for onychomycosis and systemic fungal infections. The drug itself is associated with reports of congestive heart failure and related cardiac issues in patients receiving the medication.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",8e41e42c-3ae0-4091-970b-bc0086755f1d,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8e41e42c-3ae0-4091-970b-bc0086755f1d&type=display
575,IVABRADINE,"1. **Cardiotoxicity Risk**: Corlanor (ivabradine) is associated with an increased risk of atrial fibrillation, with a rate of 5.0% per patient-year in patients treated with Corlanor compared to 3.9% per patient-year in patients treated with placebo. Regular monitoring of cardiac rhythm is recommended due to this risk. **(The drug is associated with an increased risk of atrial fibrillation.)**

2. **Cardiotoxicity Risk**: Corlanor can lead to bradycardia, sinus arrest, and heart block in adult patients. The rate of bradycardia was 6.0% per patient-year in patients treated with Corlanor, with 2.7% being symptomatic and 3.4% asymptomatic, compared to 1.3% per patient-year in patients treated with placebo. Risk factors for bradycardia include sinus node dysfunction, conduction defects, ventricular dyssynchrony, and use of other negative chronotropes. **(The drug is associated with an increased risk of bradycardia and conduction disturbances.)**

3. **Cardiotoxicity Risk**: In pediatric patients, Corlanor has been associated with bradycardia and first-degree heart block. Asymptomatic and symptomatic bradycardia were observed in 6.8% and 4.1% of pediatric patients treated with Corlanor, respectively. **(The drug is associated with an increased risk of bradycardia and first-degree heart block in pediatric patients.)**

4. **Cardiotoxicity Reaction**: Postmarketing experience has reported adverse reactions in adults, including syncope, hypotension, torsade de pointes, ventricular fibrillation, ventricular tachycardia, angioedema, and various skin reactions. **(The drug has been associated with cardiotoxicity reactions in adults.)**",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",92018a65-38f6-45f7-91d4-a34921b81d0d,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=92018a65-38f6-45f7-91d4-a34921b81d0d&type=display
576,IVACAFTOR,"1. **Warnings and Precautions - Elevated transaminases (ALT or AST):** The drug label mentions that transaminases should be assessed before initiating KALYDECO, with monitoring every 3 months during the first year of treatment and annually thereafter. Patients with a history of transaminase elevations may require more frequent monitoring. The drug itself is not directly associated with cardiotoxicity but may lead to elevated transaminase levels, which can be a sign of liver issues.

2. **Warnings and Precautions - Hypersensitivity Reactions:** Anaphylaxis has been reported with KALYDECO in the postmarketing setting. Appropriate therapy should be initiated in the event of a hypersensitivity reaction. While anaphylaxis is a severe allergic reaction and not specifically cardiotoxicity, it is a serious systemic reaction that can affect multiple organs, including the heart.

3. **Warnings and Precautions - Cataracts:** Non-congenital lens opacities/cataracts have been reported in pediatric patients treated with KALYDECO. Although other risk factors were present in some cases, a possible risk attributable to KALYDECO cannot be excluded. Baseline and follow-up ophthalmological examinations are recommended in pediatric patients initiating KALYDECO treatment. While cataracts are not directly related to cardiotoxicity, they are a potential adverse effect that can impact overall health, including cardiovascular health.",Less,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",0ab0c9f8-3eee-4e0f-9f3f-c1e16aaffe25,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=0ab0c9f8-3eee-4e0f-9f3f-c1e16aaffe25&type=display
577,IVERMECTIN,"1. The drug label does not mention any cardiotoxicity risks or cardiotoxicity reactions associated with the use of Ivermectin (STROMECTOL). 

Therefore, based on the information provided in the drug label, there are no mentions of cardiotoxicity risks or cardiotoxicity reactions linked to the use of Ivermectin.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",681888c9-af79-4b7d-ae80-c3f4f6f1effd,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=681888c9-af79-4b7d-ae80-c3f4f6f1effd&type=display
578,IVOSIDENIB,"1. The drug TIBSOVO has been associated with QTc interval prolongation and ventricular arrhythmias, which can be serious cardiotoxicity risks. This risk is mentioned in the Clinical Pharmacology section of the label, indicating that the drug itself is linked to this cardiotoxicity risk.

2. Patients treated with TIBSOVO may develop QTc prolongation and ventricular arrhythmias, as observed in clinical trials. The label specifies that the drug is associated with this cardiotoxicity risk.

3. The label highlights that patients treated with TIBSOVO can develop QTc interval prolongation, with specific percentages of patients experiencing QTcF greater than 500 msec and an increase from baseline QTcF greater than 60 msec. This indicates that the drug itself is linked to the risk of QTc interval prolongation.

4. Concomitant use of TIBSOVO with drugs known to prolong the QTc interval may increase the risk of QTc interval prolongation, as mentioned in the Drug Interactions section of the label. This suggests that the drug can interact with other medications to cause cardiotoxicity risks.

5. The label advises monitoring electrocardiograms (ECGs) and electrolytes in patients taking TIBSOVO to manage the risk of QTc interval prolongation. This indicates that the drug itself can lead to cardiotoxicity risks that need monitoring.

6. If QTc interval prolongation occurs, the label recommends interrupting TIBSOVO and taking appropriate actions to manage the condition. This highlights that the drug itself can cause QTc interval prolongation, leading to cardiotoxicity reactions.

7. The label mentions that one patient developed ventricular fibrillation attributed to TIBSOVO, indicating a serious cardiotoxicity reaction associated with the drug.

8. The label also discusses the risk of QTc interval prolongation with signs or symptoms of life-threatening arrhythmia, emphasizing the potential severe cardiotoxicity reactions that can occur with TIBSOVO treatment.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",65d254c0-67ad-42c4-b972-ad463b755b2d,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=65d254c0-67ad-42c4-b972-ad463b755b2d&type=display
579,IXABEPILONE,"1. Cardiac adverse reactions, including myocardial ischemia and ventricular dysfunction, were reported in patients receiving IXEMPRA in combination with capecitabine (1.9%) and as a single agent (0.3%). This indicates that the drug itself was associated with cardiotoxicity risks.

2. Supraventricular arrhythmias were observed in the combination arm (0.5%). This suggests that the drug itself was associated with cardiotoxicity risks.

3. Closely monitoring patients with a history of cardiac disease during treatment with IXEMPRA is recommended. This indicates that the drug itself may pose a risk of cardiotoxicity in patients with pre-existing cardiac conditions.

4. Consideration should be given to discontinuing IXEMPRA in patients who develop cardiac ischemia or impaired cardiac function. This suggests that the drug itself can lead to cardiotoxicity reactions that may warrant treatment discontinuation.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",241f0b1e-8b95-470d-876f-bf1804daaf18,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=241f0b1e-8b95-470d-876f-bf1804daaf18&type=display
580,IXAZOMIB,"1. **Warnings and Precautions:** Thrombotic Microangiopathy, including thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS), has been reported in patients who received NINLARO. Monitoring for signs and symptoms of TTP/HUS is recommended, and if suspected, NINLARO should be discontinued and evaluated.

2. **Adverse Reactions:** Thrombocytopenia was reported in patients treated with NINLARO, with platelet nadirs typically occurring between Days 14-21 of each cycle. Grade 3 and Grade 4 thrombocytopenia rates were higher in the NINLARO regimen compared to placebo. Platelet transfusions were required in some cases.

3. **Adverse Reactions:** Hepatotoxicity, including drug-induced liver injury, hepatocellular injury, hepatic steatosis, hepatitis cholestatic, and hepatotoxicity, has been reported in less than 1% of patients treated with NINLARO. Regular monitoring of hepatic enzymes and dose adjustments for Grade 3 or 4 symptoms are recommended.

4. **Adverse Reactions:** Stevens-Johnson syndrome and toxic epidermal necrolysis, including fatal cases, have been reported with NINLARO. If these severe skin reactions occur, NINLARO should be discontinued and managed appropriately.

5. **Adverse Reactions:** Cases of thrombotic microangiopathy, sometimes fatal, have been reported in patients treated with NINLARO. Monitoring for signs and symptoms of TTP/HUS is crucial, and if diagnosed, NINLARO should be stopped and evaluated. The safety of reinitiating NINLARO in patients with a history of TTP/HUS is unknown.",Less,No,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",038f2461-834b-4488-9ebd-863c83eef5a7,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=038f2461-834b-4488-9ebd-863c83eef5a7&type=display
581,KETAMINE HYDROCHLORIDE,"1. Hemodynamic Instability: KETALAR administration may lead to transient increases in blood pressure, heart rate, and cardiac index, as well as decreases in blood pressure and heart rate, arrhythmias, and cardiac decompensation. The drug itself is associated with these hemodynamic changes, which can pose a risk to patients.

2. Respiratory Depression: Overdosage or rapid administration of KETALAR may result in respiratory depression, requiring maintenance of adequate oxygenation and ventilation. The drug itself is linked to the risk of respiratory depression, which can be a serious cardiotoxic reaction.

3. Risks of KETALAR Alone for Procedures of the Pharynx, Larynx, or Bronchial Tree: KETALAR does not suppress pharyngeal and laryngeal reflexes, necessitating caution when using it as a sole anesthetic agent for procedures involving the pharynx, larynx, or bronchial tree. Muscle relaxants may be needed to prevent complications during these procedures. The drug itself is associated with the risk of inadequate suppression of reflexes in these specific anatomical areas, which can lead to cardiotoxic events if not managed appropriately.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",14e8f864-8b8a-4e7e-8439-e510d3107063,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=14e8f864-8b8a-4e7e-8439-e510d3107063&type=display
582,KETOCONAZOLE,"1. The drug label warns that ketoconazole tablets have been associated with serious adverse reactions, including QT prolongation and drug interactions leading to QT prolongation, which can result in life-threatening ventricular dysrhythmias such as torsades de pointes. (The drug itself is associated with the risk of QT prolongation and ventricular dysrhythmias.)

2. Coadministration of certain drugs with ketoconazole is contraindicated due to the potential for elevated plasma concentrations and QT prolongation, leading to life-threatening ventricular dysrhythmias. (The drug itself is associated with the risk of QT prolongation and ventricular dysrhythmias.)

3. The drug label mentions that ketoconazole can prolong the QT interval and that coadministration with specific drugs is contraindicated due to the risk of life-threatening ventricular dysrhythmias. (The drug itself is associated with the risk of QT prolongation and ventricular dysrhythmias.)

4. Ketoconazole is contraindicated for use with certain drugs due to the potential for increased plasma concentrations and QT prolongation, which can lead to ventricular tachyarrhythmias, including torsades de pointes. (The drug itself is associated with the risk of QT prolongation and ventricular tachyarrhythmias.)

5. The drug label warns that ketoconazole can cause elevated plasma concentrations of certain drugs, leading to QT prolongation and life-threatening ventricular dysrhythmias. (The drug itself is associated with the risk of QT prolongation and ventricular dysrhythmias.)

6. Coadministration of ketoconazole with specific drugs is contraindicated due to the potential for increased plasma concentrations and QT prolongation, which may result in life-threatening ventricular dysrhythmias. (The drug itself is associated with the risk of QT prolongation and ventricular dysrhythmias.)

7. The drug label mentions that ketoconazole can prolong the QT interval and that coadministration with certain drugs is contraindicated due to the risk of life-threatening ventricular dysrhythmias. (The drug itself is associated with the risk of QT prolongation and ventricular dysrhythmias.)

Overall, the drug ketoconazole is associated with the risk of QT prolongation and ventricular dysrhythmias, especially when coadministered with specific drugs listed in the label. These interactions can lead to serious cardiotoxicity reactions, including torsades de pointes and potentially fatal arrhythmias.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",75abf173-0e41-462a-a6bc-2a45af25baa4,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=75abf173-0e41-462a-a6bc-2a45af25baa4&type=display
583,KETOPROFEN,"1. The drug label includes a boxed warning stating that nonsteroidal anti-inflammatory drugs (NSAIDs), including ketoprofen capsules, are associated with an increased risk of serious cardiovascular thrombotic events, such as myocardial infarction and stroke, which can be fatal. (Association with cardiotoxicity risk)

2. Ketoprofen capsules are contraindicated in patients who have undergone coronary artery bypass graft (CABG) surgery due to the increased risk of cardiovascular thrombotic events. (Association with cardiotoxicity risk)

3. The drug label warns about the potential cardiovascular effects of NSAIDs, including ketoprofen capsules, such as the onset of new hypertension or worsening of preexisting hypertension, which may contribute to an increased incidence of cardiovascular events. (Association with cardiotoxicity risk)

4. Patients with heart failure should use ketoprofen capsules with caution, as NSAIDs, including ketoprofen, may blunt the cardiovascular effects of certain therapeutic agents used to treat heart failure, such as diuretics, ACE inhibitors, or angiotensin receptor blockers. (Association with cardiotoxicity risk)

5. The drug label advises avoiding the use of ketoprofen capsules in patients with severe heart failure unless the benefits outweigh the risk of worsening heart failure, as NSAIDs, including ketoprofen, may increase the risk of hospitalizations for heart failure. (Association with cardiotoxicity risk)

6. Ketoprofen capsules should be avoided in patients with a recent myocardial infarction (MI) unless the benefits are expected to outweigh the risk of recurrent cardiovascular thrombotic events. Patients with a recent MI who use ketoprofen capsules should be monitored for signs of cardiac ischemia. (Association with cardiotoxicity risk)

7. The drug label mentions that observational studies have shown an increased risk of reinfarction, cardiovascular-related death, and all-cause mortality in post-MI patients treated with NSAIDs, including ketoprofen capsules. (Association with cardiotoxicity risk)

8. The drug label also highlights the potential risk of hypertension, heart failure, and edema associated with NSAID use, including ketoprofen capsules, and advises monitoring blood pressure closely during NSAID treatment. (Association with cardiotoxicity risk)

9. Ketoprofen capsules are contraindicated in the setting of CABG surgery due to the increased incidence of myocardial infarction and stroke observed in clinical trials of COX-2 selective NSAIDs. (Association with cardiotoxicity risk)

10. The drug label warns about the risk of gastrointestinal adverse events, such as ulcers and bleeding, associated with NSAID use, including ketoprofen capsules, which can be serious and potentially fatal. (Association with cardiotoxicity risk)",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",d0f47ab6-29ff-df07-e053-2a95a90a2b51,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=d0f47ab6-29ff-df07-e053-2a95a90a2b51&type=display
584,KETOROLAC TROMETHAMINE,1. The drug label does not mention any cardiotoxicity risks or cardiotoxicity reactions associated with ACULAR LS (ketorolac tromethamine ophthalmic solution) 0.4%.,No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",4fad0873-f79c-4f07-9fac-5060be6b38fe,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=4fad0873-f79c-4f07-9fac-5060be6b38fe&type=display
585,KIT FOR THE PREPARATION OF GALLIUM GA 68 GOZETOTIDE INJECTION,1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with ILLUCCIX (kit for the preparation of gallium Ga 68 gozetotide injection).,No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",d4643b31-9b4f-673f-e053-2a95a90a559d,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=d4643b31-9b4f-673f-e053-2a95a90a559d&type=display
586,KIT FOR THE PREPARATION OF TECHNETIUM TC 99M EXAMETAZIME FOR LEUKOCYTE LABELING,"1. The drug label mentions that hypersensitivity reactions, including serious signs and symptoms of anaphylaxis, have been reported following the administration of Tc 99m labeled leukocytes prepared using Tc 99m exametazime. The drug itself was associated with the risk of hypersensitivity reactions, including cardiotoxicity.

2. The label also advises having cardiopulmonary resuscitation equipment and personnel available and monitoring all patients for hypersensitivity reactions. The drug itself was associated with the risk of hypersensitivity reactions, including potential cardiotoxicity.

3. Additionally, the most common adverse reactions associated with the use of technetium Tc 99m exametazime include a transient increase in blood pressure. The drug itself was associated with the risk of transiently increasing blood pressure, which can be considered a cardiotoxicity reaction.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",fa7811f9-2803-4126-8037-8f3e56462f9c,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fa7811f9-2803-4126-8037-8f3e56462f9c&type=display
587,LABETALOL HYDROCHLORIDE,"1. **Warnings and Precautions - Cardiac Failure:** The drug, Labetalol HCl, is associated with the risk of exacerbating heart failure. It is advised to avoid using Labetalol HCl in patients with overt congestive heart failure. If signs or symptoms of heart failure develop during administration, discontinuation of the drug is recommended.

2. **Warnings and Precautions - Ischemic Heart Disease:** Abrupt cessation of therapy with beta blockers like Labetalol HCl in patients with coronary artery disease can lead to exacerbations of angina pectoris and, in some cases, myocardial infarction. Therefore, even in the absence of overt angina pectoris, after discontinuation of Labetalol HCl, patients should be observed for the development or worsening of angina. Prompt reinstitution of Labetalol HCl is advised if angina occurs or worsens.

3. **Warnings and Precautions - Hypotension:** Symptomatic postural hypotension is likely to occur with Labetalol HCl, especially if patients are tilted or allowed to assume the upright position within 3 hours of receiving the drug. Before permitting ambulation, the patient's ability to tolerate an upright position should be established, and observation is necessary at the time of first ambulation.

4. **Warnings and Precautions - Bradycardia:** Labetalol HCl can cause bradycardia, including sinus pause, heart block, severe bradycardia, and cardiac arrest. Monitoring heart rate and rhythm in patients receiving Labetalol HCl is essential to detect and manage any bradycardia that may occur.

5. **Warnings and Precautions - Hypoglycemia:** Labetalol HCl may mask symptoms of hypoglycemia and alter glucose levels, especially in patients with diabetes mellitus or those who are fasting. Severe hypoglycemia can occur at any time during treatment, necessitating prompt medical treatment. The drug itself is associated with the risk of hypoglycemia due to its beta-blocking effects.

6. **Warnings and Precautions - Use in Patients with Pheochromocytoma:** Labetalol HCl has been shown to lower blood pressure and relieve symptoms in patients with pheochromocytoma. However, paradoxical hypertensive responses have been reported in a few patients with this tumor. Therefore, blood pressure monitoring is crucial when administering Labetalol HCl to patients with pheochromocytoma.

7. **Warnings and Precautions - Hepatic Injury:** Severe hepatocellular injury, although rare, can occur with Labetalol therapy. Hepatic injury is usually reversible, but cases of hepatic necrosis and death have been reported. If signs or symptoms of liver injury develop, appropriate treatment should be initiated, and Labetalol should be permanently discontinued. The drug itself is associated with the risk of severe hepatocellular injury.",Less,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",1c9d496d-cace-4283-82bb-6dcd3828b73e,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=1c9d496d-cace-4283-82bb-6dcd3828b73e&type=display
588,LACOSAMIDE,"1. **Cardiac Rhythm and Conduction Abnormalities**: The drug, MOTPOLY XR, may cause dose-dependent prolongations in PR interval, which were observed in clinical studies of lacosamide, the active ingredient in MOTPOLY XR, in adult patients and healthy volunteers. Asymptomatic first-degree atrioventricular (AV) block was observed in a small percentage of patients receiving lacosamide in adjunctive clinical trials, and there have been reports of cardiac arrhythmias, including bradycardia, AV block, and ventricular tachyarrhythmia, in postmarketing experience. The drug should be used with caution in patients with underlying proarrhythmic conditions or on concomitant medications affecting cardiac conduction, and obtaining an ECG before and during treatment is recommended.

2. **Atrial Fibrillation and Atrial Flutter**: In short-term investigational trials, there were no cases of atrial fibrillation or flutter; however, these conditions have been reported in open-label partial-onset seizure trials and postmarketing experience. The administration of MOTPOLY XR may predispose patients to atrial arrhythmias, especially in those with diabetic neuropathy and/or cardiovascular disease.

3. **Syncope**: In controlled trials, there was no increase in syncope compared to placebo in adult patients with no significant systemic illnesses. However, syncope cases have been observed in patients receiving doses above 400 mg/day, with some cases associated with changes in orthostatic blood pressure, atrial flutter/fibrillation, or bradycardia. The cause of syncope was not always determined, but it was observed in patients with risk factors for cardiac disease and the use of drugs that slow AV conduction.",Less,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",fb8235b4-4cd3-6f22-e053-6294a90a545c,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fb8235b4-4cd3-6f22-e053-6294a90a545c&type=display
589,LACTULOSE,1. The drug label does not mention any cardiotoxicity risks or cardiotoxicity reactions associated with lactulose solution.,No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",d6975cd8-80e0-43e2-809a-175ea7e40715,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=d6975cd8-80e0-43e2-809a-175ea7e40715&type=display
590,LAMIVUDINE,"1. The drug label for EPIVIR-HBV does not mention any specific cardiotoxicity risks or cardiotoxicity reactions associated with the use of the drug itself. 

2. The label primarily focuses on the drug's indication for the treatment of chronic hepatitis B virus infection and provides dosing information, contraindications, warnings, precautions, adverse reactions, drug interactions, and use in specific populations. 

3. While the label does not highlight any direct cardiotoxicity risks or reactions related to EPIVIR-HBV, it is essential for healthcare providers to monitor patients for any signs or symptoms of cardiotoxicity during treatment, as individual patient responses to medications can vary. 

4. Patients should be monitored regularly by a physician experienced in managing chronic hepatitis B, and any new or worsening symptoms should be promptly reported and evaluated. 

5. Overall, the drug label does not attribute cardiotoxicity risks or reactions to EPIVIR-HBV specifically, but it emphasizes the importance of monitoring patients for any adverse effects during treatment.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",2df7349c-f5d7-47b5-d29b-1b6b31985591,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=2df7349c-f5d7-47b5-d29b-1b6b31985591&type=display
591,LAMOTRIGINE,"1. **Cardiotoxicity Risk**: The drug label mentions that based on in vitro findings, LAMICTAL could cause serious arrhythmias and/or death in patients with certain underlying cardiac disorders or arrhythmias. The drug itself is associated with the risk of cardiac rhythm and conduction abnormalities.

2. **Cardiotoxicity Reaction**: The label does not specifically mention any cardiotoxicity reactions associated with LAMICTAL.",Less,No,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",d7e3572d-56fe-4727-2bb4-013ccca22678,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=d7e3572d-56fe-4727-2bb4-013ccca22678&type=display
592,LANREOTIDE ACETATE,"1. Cardiotoxicity Risks:
- The drug SOMATULINE DEPOT may lead to a decrease in heart rate, with sinus bradycardia, bradycardia, and hypertension being the most common cardiac adverse reactions observed in patients with acromegaly. The decrease in heart rate may occur in patients without underlying cardiac disease, and caution is advised when initiating treatment in patients with bradycardia. (The drug itself is associated with the risk of cardiotoxicity by potentially causing a decrease in heart rate.)
- A comparative echocardiography study showed no difference in the development of new or worsening valvular regurgitation between lanreotide and another somatostatin analog over 1 year. Clinically significant mitral or aortic regurgitation was low in both groups throughout the study. (The drug itself is not associated with cardiotoxicity risks in terms of valvular regurgitation.)
- In patients with acromegaly treated with SOMATULINE DEPOT, sinus bradycardia was the most frequently observed heart rate and rhythm disorder, with other cardiac adverse reactions observed in less than 1% of patients. The relationship of these events to SOMATULINE DEPOT could not be established due to many patients having underlying cardiac disease. (The drug itself is associated with the risk of sinus bradycardia and other cardiac adverse reactions in patients with acromegaly.)
  
2. Cardiotoxicity Reactions:
- The most common overall cardiac adverse reactions observed in patients with acromegaly treated with SOMATULINE DEPOT were sinus bradycardia, bradycardia, and hypertension. In patients without underlying cardiac disease, the drug may lead to a decrease in heart rate without necessarily reaching the threshold of bradycardia. (The drug itself is associated with the occurrence of sinus bradycardia, bradycardia, and hypertension as adverse reactions.)
- In clinical studies, sinus bradycardia was the most frequently observed heart rate and rhythm disorder in patients treated with SOMATULINE DEPOT. Other cardiac adverse reactions were observed in less than 1% of patients, with the majority having underlying cardiac disease. (The drug itself is associated with the occurrence of sinus bradycardia and other cardiac adverse reactions in patients with acromegaly.)
- The drug SOMATULINE DEPOT may lead to a decrease in heart rate, with sinus bradycardia being a common adverse reaction. Care should be taken when initiating treatment in patients with bradycardia. (The drug itself is associated with the occurrence of sinus bradycardia as an adverse reaction.)",Most,Yes,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",6e4a41fd-a753-4362-87ee-8cc56ed3660d,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=6e4a41fd-a753-4362-87ee-8cc56ed3660d&type=display
593,LANSOPRAZOLE,"1. The drug label mentions that nonclinical studies in juvenile rats with lansoprazole, the active ingredient in Prevacid, have demonstrated an adverse effect of heart valve thickening. This risk of heart valve injury does not appear to be relevant to patients one year of age and older. (Associated with lansoprazole in nonclinical studies in juvenile rats)

2. The label also states that severe cutaneous adverse reactions, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), have been reported in association with the use of proton pump inhibitors (PPIs) like Prevacid. (Associated with PPIs, including Prevacid)

3. Cutaneous lupus erythematosus (CLE) and systemic lupus erythematosus (SLE) have been reported in patients taking PPIs, including lansoprazole. The majority of PPI-induced lupus erythematosus cases were subacute CLE (SCLE). (Associated with PPIs, including Prevacid)

4. The label mentions that PPI use is associated with an increased risk of fundic gland polyps, which increases with long-term use, especially beyond one year. Most PPI users who developed fundic gland polyps were asymptomatic. (Associated with PPI use, including Prevacid)

5. Additionally, the label discusses the risk of bone fracture associated with PPI therapy, suggesting an increased risk for osteoporosis-related fractures of the hip, wrist, or spine, particularly with high-dose and long-term PPI therapy. (Associated with PPI therapy, including Prevacid)",Less,No,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",71ba78cb-7e46-43eb-9425-fa130f537f84,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=71ba78cb-7e46-43eb-9425-fa130f537f84&type=display
594,LANTHANUM CARBONATE,1. The drug label for FOSRENOL does not mention any cardiotoxicity risks or cardiotoxicity reactions associated with the use of this medication.,No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",f10776b2-2c25-4343-aabe-68f302e5cb54,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=f10776b2-2c25-4343-aabe-68f302e5cb54&type=display
595,LAPATINIB,"1. TYKERB has been reported to decrease left ventricular ejection fraction (LVEF), with the majority of LVEF decreases occurring within the first 12 weeks of treatment. The drug itself is associated with the risk of decreased LVEF.

2. Due to potential cardiac toxicity with HER2 inhibitors, LVEF was monitored in clinical trials at approximately 8-week intervals. LVEF decreases were defined as signs or symptoms of deterioration in left ventricular cardiac function that are Grade 3 or greater, or a 20% decrease in LVEF relative to baseline below the institution's lower limit of normal. The drug itself is associated with the risk of LVEF decreases.

3. Among patients who received combination treatment with TYKERB, some experienced Grade 2 and Grade 3 LVEF adverse reactions. The drug itself is associated with the risk of LVEF adverse reactions.

4. TYKERB has been associated with hepatotoxicity, but the causality of the deaths reported is uncertain. The drug itself is associated with the risk of hepatotoxicity, not cardiotoxicity.

5. TYKERB has been associated with interstitial lung disease (ILD) and pneumonitis, but there is no direct mention of cardiotoxicity in this context. The drug itself is associated with the risk of ILD and pneumonitis, not cardiotoxicity.

6. TYKERB may prolong the QT interval in some patients, and monitoring of patients with potential risk factors for QT prolongation is recommended. The drug itself is associated with the risk of QT prolongation.

7. Severe cutaneous reactions have been reported with TYKERB, but there is no direct mention of cardiotoxicity in this context. The drug itself is associated with the risk of severe cutaneous reactions, not cardiotoxicity.

8. TYKERB can cause fetal harm, but there is no direct mention of cardiotoxicity in this context. The drug itself is associated with the risk of fetal harm, not cardiotoxicity.",Less,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",eee37f88-ec6a-4c30-b8aa-e2c71f93088c,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=eee37f88-ec6a-4c30-b8aa-e2c71f93088c&type=display
596,LAROTRECTINIB,"1. **Warnings and Precautions - Central Nervous System Effects:** The drug label mentions adverse reactions such as dizziness, cognitive impairment, mood disorders, and sleep disturbances. The drug itself is not associated with cardiotoxicity risks in this section.

2. **Warnings and Precautions - Skeletal Fractures:** The label indicates that fractures were reported in patients receiving the drug, with some fractures associated with radiologic abnormalities suggestive of local tumor involvement. The drug itself is not directly linked to cardiotoxicity risks in this section.

3. **Warnings and Precautions - Hepatotoxicity:** The drug label discusses hepatotoxicity, including drug-induced liver injury, with increased AST and ALT levels reported in patients taking the drug. While this section focuses on liver-related adverse effects, it does not mention direct cardiotoxicity risks associated with the drug.

4. **Warnings and Precautions - Embryo-Fetal Toxicity:** The label states that the drug can cause fetal harm when administered to a pregnant woman, based on animal studies and mechanism of action. This section does not specifically mention cardiotoxicity risks associated with the drug.

Overall, the drug label does not directly associate VITRAKVI with cardiotoxicity risks or cardiotoxic reactions. The highlighted adverse effects primarily focus on central nervous system effects, skeletal fractures, hepatotoxicity, and embryo-fetal toxicity.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",0c8ca614-58b2-4aa4-83d3-0387a8f782fd,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=0c8ca614-58b2-4aa4-83d3-0387a8f782fd&type=display
597,LASMIDITAN,"1. **Cardiac Electrophysiology**: REYVOW does not prolong the QTc interval to any clinically relevant extent. (The drug itself was not associated with cardiotoxicity risk in terms of QTc prolongation.)

2. **Heart Rate Decrease**: REYVOW was associated with mean decreases in heart rate of 5 to 10 beats per minute, while placebo was associated with mean decreases of 2 to 5 beats per minute. Consider evaluating heart rate after administration of REYVOW in patients for whom these changes may not be tolerated, including patients taking other medications that lower heart rate. (The drug itself was associated with heart rate decrease, indicating a cardiotoxicity risk.)

3. **Blood Pressure Increase**: REYVOW may increase blood pressure following a single dose. In non-elderly healthy volunteers, there was a mean increase from baseline in ambulatory systolic and diastolic blood pressure of approximately 2 to 3 mm Hg one hour after administration of 200 mg REYVOW compared to a mean increase of up to 1 mm Hg for placebo. In healthy volunteers over 65 years of age, there was a mean increase from baseline in ambulatory systolic blood pressure of 7 mm Hg one hour after administration of 200 mg REYVOW compared to a mean increase of 4 mm Hg for placebo. By 2 hours, there were no increases in mean blood pressure with REYVOW compared to placebo. REYVOW has not been well studied in patients with ischemic heart disease. Consider evaluating blood pressure after administration of REYVOW in patients for whom these changes may not be tolerated. (The drug itself was associated with blood pressure increase, indicating a cardiotoxicity risk.)",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",aea3358c-ff41-4490-9e6d-c7bf7b3de13f,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=aea3358c-ff41-4490-9e6d-c7bf7b3de13f&type=display
598,LEMBOREXANT,"1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with DAYVIGO (lemborexant) itself. 

2. The label primarily focuses on CNS depressant effects, daytime impairment, sleep-related symptoms, and respiratory function considerations. 

3. No direct mention of cardiotoxicity risks or reactions related to the use of DAYVIGO is provided in the drug label. 

4. The drug label emphasizes the importance of evaluating patients for co-morbid diagnoses, worsening of depression, and complex sleep behaviors, but does not mention cardiotoxicity risks. 

5. Overall, the drug label does not attribute any cardiotoxicity risks or reactions to the use of DAYVIGO.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",7074cb65-77b3-45d2-8e8d-da8dc0f70bfd,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7074cb65-77b3-45d2-8e8d-da8dc0f70bfd&type=display
599,LENALIDOMIDE,"1. The drug label warns of significantly increased risks of deep vein thrombosis (DVT), pulmonary embolism (PE), myocardial infarction, and stroke in patients with multiple myeloma receiving REVLIMID with dexamethasone. Anti-thrombotic prophylaxis is recommended. (The drug itself, REVLIMID, is associated with the increased risk of these cardiotoxic events.)

2. The label also mentions that serious and fatal cardiac adverse reactions occurred in patients with chronic lymphocytic leukemia (CLL) treated with REVLIMID. (REVLIMID is associated with serious and fatal cardiac adverse reactions in CLL patients.)

3. Additionally, the drug label highlights an increased mortality rate observed in patients with multiple myeloma when pembrolizumab was added to dexamethasone and a thalidomide analogue. (The combination therapy involving REVLIMID is associated with increased mortality in MM patients when pembrolizumab is added.)

4. The label mentions the risk of tumor lysis syndrome (TLS), including fatalities, and advises monitoring patients at risk of TLS and taking appropriate precautions. (REVLIMID is associated with the risk of TLS, including fatalities.)

5. Furthermore, the drug label warns of an increased risk of venous and arterial thromboembolism, such as DVT and PE, in patients with multiple myeloma treated with REVLIMID and dexamethasone. Patients should be monitored for signs and symptoms of thromboembolism. (REVLIMID is associated with an increased risk of venous and arterial thromboembolism in MM patients.)",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",5fa97bf5-28a2-48f1-8955-f56012d296be,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=5fa97bf5-28a2-48f1-8955-f56012d296be&type=display
600,LENVATINIB,"1. The drug LENVIMA is associated with serious and fatal cardiac dysfunction, including cardiomyopathy, left or right ventricular dysfunction, congestive heart failure, and ventricular hypokinesia. This cardiotoxicity risk was observed in clinical trials involving patients with differentiated thyroid cancer, renal cell carcinoma, and hepatocellular carcinoma. Patients should be monitored for clinical symptoms or signs of cardiac dysfunction, and LENVIMA may need to be withheld, reduced in dose, or permanently discontinued based on the severity of the cardiac adverse reaction.

2. Arterial thromboembolic events, such as myocardial infarction and cerebrovascular accident, can occur with LENVIMA, particularly when used in combination with pembrolizumab. The drug itself is associated with this cardiotoxicity risk, as arterial thrombotic events were reported in clinical trials. LENVIMA should be permanently discontinued following an arterial thromboembolic event, and the safety of resuming LENVIMA after such an event has not been established.

3. In clinical studies, LENVIMA has been linked to serious hepatic adverse reactions, including hepatic failure, acute hepatitis, and hepatorenal syndrome. Hepatic encephalopathy and hepatic failure were reported in patients with hepatocellular carcinoma. Patients should be monitored for liver function, and LENVIMA may need to be withheld, reduced in dose, or permanently discontinued based on the severity of hepatic adverse reactions.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",f4bedd21-efde-44c6-9d9c-b48b78d7ed1e,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=f4bedd21-efde-44c6-9d9c-b48b78d7ed1e&type=display
601,LETERMOVIR,"1. The drug PREVYMIS was associated with a higher rate of cardiac adverse events compared to placebo in subjects receiving the drug, with tachycardia and atrial fibrillation being the most common cardiac adverse events reported. (PREVYMIS was associated with a higher rate of cardiac adverse events.)

2. The cardiac adverse event rate was 4% in the PREVYMIS group in a Phase 3 trial involving kidney transplant recipients, with the most frequently reported cardiac adverse events being tachycardia and atrial fibrillation. (PREVYMIS was associated with a cardiac adverse event rate of 4% in kidney transplant recipients.)

3. In a Phase 3 trial involving kidney transplant recipients, the cardiac adverse event rate was 4% in the PREVYMIS group, with tachycardia and atrial fibrillation being the most common cardiac adverse events reported. (PREVYMIS was associated with a cardiac adverse event rate of 4% in kidney transplant recipients.)

4. The safety of PREVYMIS was evaluated in a Phase 3 trial involving hematopoietic stem cell transplant recipients, where the cardiac adverse event rate was higher in subjects receiving PREVYMIS compared to placebo, with tachycardia and atrial fibrillation being the most common cardiac adverse events reported. (PREVYMIS was associated with a higher rate of cardiac adverse events in hematopoietic stem cell transplant recipients.)

5. The cardiac adverse event rate was higher in subjects receiving PREVYMIS compared to placebo in a Phase 3 trial involving hematopoietic stem cell transplant recipients, with tachycardia and atrial fibrillation being the most common cardiac adverse events reported. (PREVYMIS was associated with a higher rate of cardiac adverse events in hematopoietic stem cell transplant recipients.)",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",1b49df80-be4f-47e0-a0b7-123f3e69395b,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=1b49df80-be4f-47e0-a0b7-123f3e69395b&type=display
602,LETROZOLE,"1. The drug Femara (letrozole) is associated with an increased risk of cardiovascular events, including angina, myocardial infarction, myocardial ischemia, and coronary heart disease, as mentioned in the adverse reactions section of the label. (The drug itself is associated with the risk of cardiovascular events.)

2. In the extended adjuvant treatment setting, patients receiving Femara had a higher incidence of cardiovascular events compared to those receiving a placebo, as reported in the updated analysis. (The drug itself is associated with a higher incidence of cardiovascular events in this setting.)

3. The drug Femara was not significantly different from placebo in total cholesterol or any lipid fraction over 5 years in the extended adjuvant setting, as indicated in the lipid substudy. (The drug itself was not associated with significant changes in lipid profiles in this setting.)

4. In the first-line treatment of advanced breast cancer, the incidence of adverse reactions, including chest pain, was similar for Femara and tamoxifen, as reported in the clinical study. (The drug itself was not specifically associated with a higher incidence of chest pain compared to the comparator drug in this setting.)

5. Other less frequent adverse reactions, such as peripheral thromboembolic events, cardiovascular events, and cerebrovascular events, were considered consequential for both treatment groups in the first-line treatment of advanced breast cancer, as mentioned in the clinical study. (The drug itself was not specifically associated with these less frequent adverse reactions in this setting.)",Less,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",82b77d74-085f-45ac-a7dd-1f5c038bf406,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=82b77d74-085f-45ac-a7dd-1f5c038bf406&type=display
603,LEUCOVORIN CALCIUM,"1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with Leucovorin Calcium tablets. 

2. The drug label does not indicate any direct association between Leucovorin Calcium tablets and cardiotoxicity risks or reactions. 

3. There is no mention in the drug label of Leucovorin Calcium tablets being linked to cardiotoxicity risks or reactions. 

Overall, based on the information provided in the drug label, there are no references to cardiotoxicity risks or reactions attributed to Leucovorin Calcium tablets.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",33663425-4731-4977-9127-9e59b6b91497,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=33663425-4731-4977-9127-9e59b6b91497&type=display
604,LEUPROLIDE ACETATE,"1. **Cardiotoxicity Risk**: The use of GnRH agonists, including LUPRON DEPOT, has been associated with an increased risk of cardiovascular diseases such as myocardial infarction, sudden cardiac death, and stroke in men. This risk should be carefully evaluated along with cardiovascular risk factors when determining treatment for patients with prostate cancer. (The drug itself is associated with the cardiotoxicity risk.)

2. **Cardiotoxicity Reaction**: Patients receiving LUPRON DEPOT should be monitored for symptoms and signs suggestive of cardiovascular disease and managed according to institutional guidelines. (The drug itself is not stated to directly cause cardiotoxicity reactions but is associated with an increased risk of cardiovascular diseases.)

3. **Cardiotoxicity Risk**: Androgen deprivation therapy, such as LUPRON DEPOT, may prolong the QT/QTc interval. Providers should consider whether the benefits of androgen deprivation therapy outweigh the potential risks in patients with certain conditions that predispose them to QT interval prolongation. (The drug itself is associated with the risk of prolonging the QT/QTc interval, which can be a cardiotoxicity risk.)

4. **Cardiotoxicity Reaction**: Electrolyte abnormalities should be corrected, and periodic monitoring of electrocardiograms and electrolytes should be considered in patients receiving LUPRON DEPOT to manage potential QT interval prolongation. (The drug itself is associated with the need for monitoring and management of potential QT interval prolongation, which is a cardiotoxicity reaction.)",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",cbc8f94e-7330-4465-05ad-16d64493a5dd,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=cbc8f94e-7330-4465-05ad-16d64493a5dd&type=display
605,LEVAMLODIPINE,"1. The drug CONJUPRI (levamlodipine) is a calcium channel blocker used for hypertension treatment, which may be used alone or in combination with other antihypertensive agents. Lowering blood pressure with CONJUPRI reduces the risk of cardiovascular events like strokes and myocardial infarctions. (The drug itself is not associated with cardiotoxicity risk.)

2. Warnings and precautions include the possibility of symptomatic hypotension, particularly in patients with severe aortic stenosis, but acute hypotension is unlikely. (The drug itself is not associated with cardiotoxicity risk.)

3. There is a warning that worsening angina and acute myocardial infarction can develop after starting or increasing the dose of amlodipine, especially in patients with severe obstructive coronary artery disease. (The drug itself is associated with a cardiotoxicity risk.)

4. Patients with severe hepatic impairment should have amlodipine titrated slowly due to its extensive liver metabolism and prolonged elimination half-life in hepatic failure. (The drug itself is not associated with cardiotoxicity risk.)

5. Adverse reactions to amlodipine include edema, which occurs in a dose-related manner, and other reactions like fatigue, nausea, abdominal pain, and somnolence. (The drug itself is not associated with cardiotoxicity risk.)

6. Postmarketing experience reports a possible association between amlodipine and extrapyramidal disorder, but the causal relationship is uncertain. (The drug itself is not definitively associated with cardiotoxicity risk.)

7. In clinical studies, amlodipine did not lead to clinically significant changes in heart rate or blood pressure in normotensive patients with angina. (The drug itself is not associated with cardiotoxicity risk.)

Overall, while amlodipine (the active ingredient in CONJUPRI) is associated with a risk of worsening angina and acute myocardial infarction in certain patients, it is not directly linked to other cardiotoxicity risks based on the information provided in the drug label.",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",c3cca66e-348a-43e8-8f96-e995104dae3d,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=c3cca66e-348a-43e8-8f96-e995104dae3d&type=display
606,LEVETIRACETAM,1. The drug label for KEPPRA XR does not mention any specific cardiotoxicity risks or reactions associated with the use of this medication. No cardiotoxicity risks or reactions were attributed to KEPPRA XR in the provided drug label information.,No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",2919e43b-69a8-434c-a2d2-1f3ecd7554c0,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=2919e43b-69a8-434c-a2d2-1f3ecd7554c0&type=display
607,LEVOCARNITINE,"1. The drug label mentions that levocarnitine is indicated for the treatment of primary systemic carnitine deficiency, which can present with symptoms like cardiomyopathy. Levocarnitine supplementation has been reported to rapidly alleviate signs and symptoms in some patients with cardiomyopathy, suggesting a potential benefit in addressing cardiotoxicity associated with primary systemic carnitine deficiency.

2. The label also states that serious hypersensitivity reactions, including anaphylaxis, laryngeal edema, and bronchospasm, have been reported following intravenous levocarnitine administration, particularly in patients with end-stage renal disease undergoing dialysis. These reactions are not directly related to cardiotoxicity but are important to monitor as they can impact overall patient health and potentially lead to cardiovascular complications.

3. Additionally, the label mentions that gastrointestinal reactions may result from rapid consumption of carnitine, which could potentially impact cardiac function indirectly through electrolyte imbalances or other mechanisms. It advises that doses should be spaced evenly throughout the day to maximize tolerance, which could help mitigate any potential gastrointestinal issues that might indirectly affect the heart.

Overall, while levocarnitine itself is not directly associated with cardiotoxicity risks, the drug label highlights the importance of monitoring for hypersensitivity reactions and gastrointestinal issues that could impact cardiovascular health in certain patient populations.",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",b2cbc620-59fd-47b6-9e4b-7e3e31533a1c,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=b2cbc620-59fd-47b6-9e4b-7e3e31533a1c&type=display
608,LEVOCETIRIZINE DIHYDROCHLORIDE,"1. Levocetirizine, the active component of XYZAL, is an orally active H1-receptor antagonist. The antihistaminic activity of levocetirizine has been documented in various animal and human models. (The drug itself is not associated with cardiotoxicity risk.)

2. A QT/QTc study using a single dose of 30 mg of levocetirizine did not demonstrate an effect on the QTc interval. While a single dose of levocetirizine had no effect, the effects of levocetirizine may not be at steady state following single dose. The effect of levocetirizine on the QTc interval following multiple dose administration is unknown. Levocetirizine is not expected to have QT/QTc effects because of the results of QTc studies with cetirizine and the long post-marketing history of cetirizine without reports of QT prolongation. (The drug itself is not associated with cardiotoxicity risk.)

3. Levocetirizine is not known to produce pharmacokinetic interactions through inhibition or induction of liver drug-metabolizing enzymes. No in vivo drug-drug interaction studies have been performed with levocetirizine. Drug interaction studies have been performed with racemic cetirizine. (The drug itself is not associated with cardiotoxicity risk.)

4. In vitro data indicate that levocetirizine is unlikely to produce pharmacokinetic interactions through inhibition or induction of liver drug-metabolizing enzymes. No in vivo drug-drug interaction studies have been performed with levocetirizine. Drug interaction studies have been performed with racemic cetirizine. (The drug itself is not associated with cardiotoxicity risk.)

5. Ritonavir increased the plasma AUC of cetirizine by about 42% accompanied by an increase in half-life (53%) and a decrease in clearance (29%) of cetirizine. The disposition of ritonavir was not altered by concomitant cetirizine administration. (This interaction study was performed with racemic cetirizine, not levocetirizine, and does not directly implicate levocetirizine in cardiotoxicity risk.)

Overall, based on the information provided in the drug label, levocetirizine (XYZAL) itself is not associated with cardiotoxicity risks or cardiotoxicity reactions.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",371ca86d-7ffd-4f20-b6c6-af0a9ff7362f,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=371ca86d-7ffd-4f20-b6c6-af0a9ff7362f&type=display
609,LEVOFLOXACIN,"1. **Cardiotoxicity Risk Associated with Levofloxacin:**
   - The drug label warns about the potential risk of prolongation of the QT interval and isolated cases of torsade de pointes associated with levofloxacin use.
   - Levofloxacin itself is linked to the risk of QT interval prolongation and torsade de pointes.

2. **Cardiotoxicity Reactions Linked to Levofloxacin:**
   - The label mentions that levofloxacin may cause central nervous system effects, including convulsions, anxiety, confusion, depression, and insomnia, which can indirectly impact cardiac function.
   - Levofloxacin is associated with central nervous system effects that may have implications for cardiac health.
   - The drug label does not directly state any other cardiotoxicity reactions specifically attributed to levofloxacin.",Less,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",15a80e60-5d8b-4085-ba4c-7616af1ac96b,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=15a80e60-5d8b-4085-ba4c-7616af1ac96b&type=display
610,LEVOKETOCONAZOLE,"1. The drug RECORLEV is associated with dose-related QT interval prolongation, which may lead to life-threatening ventricular dysrhythmias such as torsades de pointes. This cardiotoxicity risk is directly linked to the use of RECORLEV.

2. RECORLEV is contraindicated in patients with a prolonged QTcF interval greater than 470 msec at baseline, history of torsades de pointes, ventricular tachycardia, ventricular fibrillation, or long QT syndrome. This indicates that the drug itself can exacerbate existing cardiotoxicity risks in these patients.

3. The drug label advises performing an ECG before each dose increase and regularly monitoring ECG for an effect on the QT interval during RECORLEV treatment. Correcting hypokalemia and hypomagnesemia prior to treatment initiation and periodic monitoring during treatment are also recommended. These precautions are necessary due to the potential cardiotoxic effects of RECORLEV.

4. If the QTcF interval exceeds 500 msec, temporary discontinuation of RECORLEV is recommended. After correction of contributing factors and normalization of the QTcF interval, the drug may be resumed at a lower dose. If QT interval prolongation recurs after restarting RECORLEV, permanent discontinuation is advised. These actions are directly related to managing the cardiotoxicity risk associated with RECORLEV.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",d4c5fead-bc4a-fb02-e053-2a95a90ae4fc,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=d4c5fead-bc4a-fb02-e053-2a95a90ae4fc&type=display
611,LEVOLEUCOVORIN,"1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with KHAPZORY (levoleucovorin) itself. 

2. The label primarily focuses on the indications, dosage, administration, contraindications, warnings, precautions, adverse reactions, drug interactions, and clinical studies related to the use of KHAPZORY for rescue after high-dose methotrexate therapy, diminishing toxicity from folic acid antagonists, and treating metastatic colorectal cancer in combination with fluorouracil.

3. While the label does not directly link KHAPZORY to cardiotoxicity risks or reactions, it is important to consult with a healthcare provider for a comprehensive understanding of potential side effects and risks associated with this medication, especially if there are concerns about cardiotoxicity.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",344f65ac-9f04-49d7-b7c3-4ba19bd7b429,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=344f65ac-9f04-49d7-b7c3-4ba19bd7b429&type=display
612,LEVONORGESTREL,"1. **Warnings and Precautions:** Severe infection or sepsis, including Group A streptococcal sepsis (GAS), have been reported following insertion of LNG-releasing IUSs; strict aseptic technique is essential during insertion. (The drug itself is not associated with cardiotoxicity but with severe infection risks during insertion.)

2. **Warnings and Precautions:** Before using LILETTA, consider the risks of pelvic infection. (The drug itself is not associated with cardiotoxicity but with the risk of pelvic infection.)

3. **Warnings and Precautions:** Perforation may occur and reduce contraceptive effectiveness or require surgery. Risk is increased if inserted in patients who have fixed retroverted uteri, are postpartum, or are lactating. (The drug itself is not associated with cardiotoxicity but with the risk of perforation.)

4. **Warnings and Precautions:** Remove LILETTA if pregnancy occurs with LILETTA in place and LILETTA is in the uterus. If pregnancy occurs, there is an increased risk of ectopic pregnancy, pregnancy loss, septic abortion, and premature labor and delivery. (The drug itself is not associated with cardiotoxicity but with the risk of ectopic pregnancy and related complications.)

5. **Warnings and Precautions:** Bleeding patterns can become altered, may remain irregular, and amenorrhea may ensue. (The drug itself is not associated with cardiotoxicity but with the risk of altered bleeding patterns.)

6. **Adverse Reactions:** The most common adverse reactions reported in clinical studies are vulvovaginal mycotic infections, vaginal bacterial infections, acne, and nausea or vomiting. (No direct mention of cardiotoxicity reactions in the adverse reactions section.)

Overall, the drug label does not indicate any direct association between LILETTA and cardiotoxicity risks or cardiotoxicity reactions. The warnings and precautions primarily focus on infection risks, perforation, altered bleeding patterns, and other adverse reactions.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",aaf0eb2a-f88a-4f26-a445-0fd30176c326,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=aaf0eb2a-f88a-4f26-a445-0fd30176c326&type=display
613,LEVORPHANOL TARTRATE,"1. Levorphanol Tartrate Tablets may cause peripheral vasodilation, potentially leading to orthostatic hypotension or syncope. The drug itself is associated with the risk of orthostatic hypotension and syncope due to peripheral vasodilation.

2. Levorphanol Tartrate Tablets could manifest histamine release and/or peripheral vasodilation, resulting in symptoms like pruritus, flushing, red eyes, sweating, and orthostatic hypotension. The drug itself is associated with the potential manifestation of histamine release and peripheral vasodilation symptoms, including orthostatic hypotension.

3. Levorphanol Tartrate Tablets may cause severe hypotension, including orthostatic hypotension and syncope in ambulatory patients, especially when combined with certain CNS depressant drugs. The drug itself is associated with the risk of severe hypotension, orthostatic hypotension, and syncope, particularly in patients taking CNS depressants concurrently.",Less,No,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",deed8652-9b9d-48b4-8c3e-9fdd7c46237e,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=deed8652-9b9d-48b4-8c3e-9fdd7c46237e&type=display
614,LEVOTHYROXINE SODIUM,"1. **Cardiotoxicity Risk**: The drug SYNTHROID has a warning regarding cardiac adverse reactions in the elderly and patients with underlying cardiovascular disease. It is mentioned that overtreatment with levothyroxine may lead to an increase in heart rate, cardiac wall thickness, and cardiac contractility, potentially causing angina or arrhythmias, particularly in patients with cardiovascular disease and the elderly. The drug itself is associated with the risk of cardiotoxicity due to potential overtreatment.

2. **Cardiotoxicity Reaction**: The label advises initiating SYNTHROID therapy at lower doses in the elderly and patients with underlying cardiac disease to mitigate the risk of cardiac adverse reactions, including atrial fibrillation. It is recommended to monitor for cardiac arrhythmias during surgical procedures in patients with coronary artery disease receiving suppressive SYNTHROID therapy. If cardiac symptoms develop or worsen, reducing the SYNTHROID dose or withholding it for a week and restarting at a lower dose is suggested. The drug itself is associated with the potential for cardiotoxicity reactions in susceptible patient populations.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",1e11ad30-1041-4520-10b0-8f9d30d30fcc,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=1e11ad30-1041-4520-10b0-8f9d30d30fcc&type=display
615,LEVOTHYROXINE SODIUM ANHYDROUS,"1. The drug label warns that excessive bolus doses of Levothyroxine Sodium for Injection (> 500 mcg) are associated with cardiac complications, particularly in the elderly and in patients with an underlying cardiac condition. The drug itself is associated with the risk of cardiotoxicity.

2. Adverse events potentially related to the administration of large doses of Levothyroxine Sodium for Injection include arrhythmias, tachycardia, myocardial ischemia and infarction, or worsening of congestive heart failure and death. The drug itself is associated with the risk of cardiotoxicity.

3. Close observation of the patient following the administration of Levothyroxine Sodium for Injection is advised to monitor for any signs of cardiac complications. The drug itself is associated with the risk of cardiotoxicity.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",9d815416-11c9-470e-a82f-89b0bf232e12,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=9d815416-11c9-470e-a82f-89b0bf232e12&type=display
616,LEXISCAN(R) (REGADENOSON),"1. The drug label mentions that fatal cardiac events, including myocardial infarction, ventricular arrhythmias, and cardiac arrest, have occurred following LEXISCAN injection, indicating that the drug itself is associated with cardiotoxicity risks.

2. It warns against using LEXISCAN in patients with symptoms or signs of acute myocardial ischemia, such as unstable angina or cardiovascular instability, as they may be at greater risk of serious cardiovascular reactions, suggesting that the drug can lead to cardiotoxicity reactions.

3. The label also highlights that LEXISCAN can cause first-, second-, or third-degree AV block, or sinus bradycardia, which may require intervention, indicating that the drug itself can lead to cardiotoxicity risks.

4. It mentions that new-onset or recurrent atrial fibrillation with rapid ventricular response and atrial flutter have been reported following LEXISCAN injection, suggesting that the drug can cause cardiotoxicity reactions related to arrhythmias.

5. The drug label states that LEXISCAN can induce arterial vasodilation and hypotension, with a risk of serious hypotension in certain patient populations, indicating that the drug itself is associated with cardiotoxicity risks.

6. It also mentions that LEXISCAN may result in clinically significant increases in blood pressure, particularly in patients with a history of hypertension, suggesting that the drug can lead to cardiotoxicity reactions related to hypertension.

7. The label warns that LEXISCAN may cause bronchoconstriction, dyspnea, and respiratory compromise in patients with COPD or asthma, indicating that the drug itself can lead to cardiotoxicity reactions affecting the respiratory system.

8. It highlights that LEXISCAN may lower the seizure threshold, leading to new-onset or recurrent convulsive seizures, some of which may require urgent anticonvulsive management, suggesting that the drug can cause cardiotoxicity reactions related to seizures.

9. The drug label mentions that hemorrhagic and ischemic cerebrovascular accidents have occurred following LEXISCAN administration, indicating that the drug itself is associated with cardiotoxicity risks affecting the cerebrovascular system.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",99640071-4db2-9317-e053-2995a90a610d,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=99640071-4db2-9317-e053-2995a90a610d&type=display
617,LINACLOTIDE,1. The drug label does not mention any cardiotoxicity risks or reactions associated with LINZESS.,No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",09beda19-56d6-4a56-afdc-9a77b70b2ef3,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=09beda19-56d6-4a56-afdc-9a77b70b2ef3&type=display
618,LINAGLIPTIN,"1. The drug TRADJENTA is a dipeptidyl peptidase-4 (DPP-4) inhibitor indicated for adults with type 2 diabetes mellitus. It has not been studied for use in patients with a history of pancreatitis, and it is unknown if patients with a history of pancreatitis are at increased risk for developing pancreatitis while using TRADJENTA. (The drug itself is not associated with cardiotoxicity risk in this context.)

2. In a cardiovascular safety trial with TRADJENTA, an association between DPP-4 inhibitor treatment and heart failure was observed in patients with type 2 diabetes mellitus and atherosclerotic cardiovascular disease. Patients at risk for heart failure, such as those with a prior history of heart failure and renal impairment, should be monitored for signs and symptoms of heart failure during TRADJENTA therapy. (The drug TRADJENTA is associated with a cardiotoxicity risk of heart failure in certain patient populations.)

3. No increase in QTc was observed with the recommended dose of TRADJENTA in a study involving healthy subjects. At a 100 mg dose (20 times the recommended dose), peak plasma concentrations were significantly higher, but no increase in QTc was observed. (The drug TRADJENTA is not associated with QTc prolongation or cardiac arrhythmias at the recommended dose.)

In summary, TRADJENTA is not directly associated with cardiotoxicity risks, except for the observed association with heart failure in certain patient populations as indicated in the cardiovascular safety trial. The drug did not show QTc prolongation or cardiac arrhythmias at the recommended dose in healthy subjects.",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",c797ea5c-cab7-494b-9044-27eba0cfe40f,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=c797ea5c-cab7-494b-9044-27eba0cfe40f&type=display
619,LINCOMYCIN HYDROCHLORIDE,"1. The drug label warns that severe colitis, which may be fatal, has been associated with lincomycin therapy, and it should be reserved for serious infections where less toxic antimicrobial agents are inappropriate. This indicates that the drug itself is associated with the risk of severe colitis and cardiotoxicity.

2. The label mentions that severe cardiopulmonary reactions have occurred when LINCOCIN has been given at greater than the recommended concentration and rate. This suggests that the drug itself can lead to severe cardiopulmonary reactions if administered incorrectly.

3. The drug label advises that LINCOCIN should be used with caution in patients with a history of asthma or significant allergies. This indicates that the drug may pose a risk of cardiotoxicity in patients with these conditions.

4. The label also states that severe hypersensitivity reactions, including anaphylactic reactions, have been reported in patients receiving LINCOCIN therapy. This suggests that the drug can trigger severe hypersensitivity reactions, including potential cardiotoxic effects.

5. Additionally, the drug label mentions that benzyl alcohol toxicity, which can lead to serious adverse events, has been associated with LINCOCIN in pediatric patients. This indicates that the drug may pose a risk of cardiotoxicity, especially in pediatric populations due to the presence of benzyl alcohol.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",c01906fa-2c73-4c13-9765-2fd06628d263,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=c01906fa-2c73-4c13-9765-2fd06628d263&type=display
620,LINEZOLID,"1. **Warnings and Precautions**: The drug label mentions the risk of **Myelosuppression**, including anemia, leukopenia, pancytopenia, and thrombocytopenia, which have been reported in patients receiving linezolid. The drug itself is associated with the risk of myelosuppression.

2. **Warnings and Precautions**: **Peripheral and Optic Neuropathy** have been reported in patients treated with ZYVOX, primarily in those treated for longer than the maximum recommended duration of 28 days. The drug itself is associated with the risk of peripheral and optic neuropathy.

3. **Warnings and Precautions**: **Serotonin Syndrome** has been reported in spontaneous cases associated with the co-administration of ZYVOX and serotonergic agents, including antidepressants. The drug itself is associated with the risk of serotonin syndrome.

4. **Warnings and Precautions**: An imbalance in mortality was seen in an investigational study in linezolid-treated patients with catheter-related bloodstream infections. Linezolid is not approved and should not be used for the treatment of patients with catheter-related bloodstream infections or catheter-site infections. While causality has not been established, this observed imbalance occurred primarily in linezolid-treated patients. The drug itself is associated with an imbalance in mortality in certain patient populations.

5. **Warnings and Precautions**: **Lactic Acidosis** has been reported with the use of ZYVOX. Patients who develop recurrent nausea or vomiting, unexplained acidosis, or a low bicarbonate level while receiving ZYVOX should receive immediate medical evaluation. The drug itself is associated with the risk of lactic acidosis.

6. **Warnings and Precautions**: **Convulsions** have been reported in patients when treated with linezolid. In some cases, a history of seizures or risk factors for seizures was reported. The drug itself is associated with the risk of convulsions.

7. **Warnings and Precautions**: Postmarketing cases of symptomatic **hypoglycemia** have been reported in patients with diabetes mellitus receiving insulin or oral hypoglycemic agents when treated with linezolid, a reversible, nonselective MAO inhibitor. While a causal relationship between linezolid and hypoglycemia has not been established, diabetic patients should be cautioned of potential hypoglycemic reactions when treated with linezolid. The drug itself is associated with the risk of hypoglycemia.

8. **Warnings and Precautions**: Postmarketing cases of **hyponatremia** and/or Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) have been observed in patients treated with linezolid. The drug itself is associated with the risk of hyponatremia and/or SIADH.",Less,No,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",3e5e9975-6f36-42e4-ab46-0e75dda83592,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=3e5e9975-6f36-42e4-ab46-0e75dda83592&type=display
621,LIOTHYRONINE SODIUM,"1. The drug label warns that overtreatment with CYTOMEL may cause an increase in heart rate, cardiac wall thickness, and cardiac contractility, potentially leading to angina or arrhythmias, particularly in patients with cardiovascular disease and in elderly patients. The drug itself is associated with the cardiotoxicity risk.

2. It is advised to initiate CYTOMEL therapy at lower doses in elderly patients and those with underlying cardiovascular disease due to the increased risk of cardiac adverse reactions, including atrial fibrillation. The drug itself is associated with the cardiotoxicity risk.

3. The label mentions that cardiac arrhythmias should be monitored during surgical procedures in patients with coronary artery disease receiving suppressive CYTOMEL therapy. The drug itself is associated with the cardiotoxicity risk.

4. Patients receiving concomitant CYTOMEL and sympathomimetic agents should be monitored for signs and symptoms of coronary insufficiency, as the combination may increase the risk of cardiac adverse reactions. The drug itself is associated with the cardiotoxicity risk.

5. If cardiovascular symptoms develop or worsen in patients receiving CYTOMEL and sympathomimetic agents, it is recommended to reduce or withhold the CYTOMEL dose for one week and restart at a lower dose. The drug itself is associated with the cardiotoxicity risk.

6. The drug label also mentions that CYTOMEL may increase the risk of heart failure, angina, myocardial infarction, and cardiac arrest as part of the cardiotoxicity reactions associated with therapeutic overdosage. The drug itself is associated with the cardiotoxicity risk.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",51452b31-ff68-4e0c-b982-c15502ebf1d3,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=51452b31-ff68-4e0c-b982-c15502ebf1d3&type=display
622,LIRAGLUTIDE,"1. The drug label warns about the risk of thyroid C-cell tumors associated with liraglutide, the active ingredient in VICTOZA, based on animal studies showing dose-dependent thyroid C-cell tumors in rats and mice.

2. The drug label states that it is unknown whether VICTOZA causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans, as the human relevance of liraglutide-induced rodent thyroid C-cell tumors has not been determined.

3. The drug label indicates that VICTOZA is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) due to the potential risk of thyroid C-cell tumors.

4. The drug label mentions that VICTOZA is indicated to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease, suggesting a potential cardioprotective effect.

5. The drug label does not specifically mention cardiotoxicity risks or reactions associated with VICTOZA itself in relation to cardiovascular events.",Less,No,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",5a9ef4ea-c76a-4d34-a604-27c5b505f5a4,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=5a9ef4ea-c76a-4d34-a604-27c5b505f5a4&type=display
623,LISDEXAMFETAMINE DIMESYLATE,"1. **Cardiotoxicity Risk**: The drug VYVANSE has a warning regarding risks to patients with serious cardiac disease, including sudden death reported in patients with structural cardiac abnormalities or serious cardiac disease who were treated with CNS stimulants at recommended dosages. The drug itself is associated with an increased risk of sudden death in patients with known cardiac abnormalities.

2. **Increased Blood Pressure and Heart Rate**: CNS stimulants like VYVANSE can cause an increase in blood pressure and heart rate, with some patients experiencing larger increases. The drug itself is associated with increased blood pressure and heart rate, which can pose risks to patients with underlying cardiac conditions.

3. **Psychiatric Adverse Reactions**: VYVANSE may exacerbate symptoms of behavior disturbance and thought disorder in patients with pre-existing psychotic disorders. The drug can also induce manic episodes in patients with bipolar disorder. The drug itself is associated with exacerbation of psychiatric symptoms, including behavior disturbances and manic episodes, which can impact cardiac health in vulnerable patients.

4. **Peripheral Vasculopathy, including Raynaud's Phenomenon**: CNS stimulants like VYVANSE are associated with peripheral vasculopathy, including Raynaud's phenomenon, which can lead to digital changes, ulceration, and soft tissue breakdown. The drug itself is linked to peripheral vasculopathy, which can affect blood flow and circulation, potentially impacting cardiac health.

5. **Serotonin Syndrome**: VYVANSE, when co-administered with serotonergic agents, can increase the risk of serotonin syndrome, a potentially life-threatening reaction. The drug itself, when combined with certain medications affecting the serotonergic system, can lead to serotonin syndrome, which may have cardiovascular implications.

6. **Motor and Verbal Tics, and Worsening of Tourette's Syndrome**: CNS stimulants, including VYVANSE, have been associated with the onset or exacerbation of motor and verbal tics, as well as worsening of Tourette's syndrome. The drug itself is linked to the development or worsening of tics and Tourette's syndrome, which can impact cardiovascular health in affected individuals.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",704e4378-ca83-445c-8b45-3cfa51c1ecad,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=704e4378-ca83-445c-8b45-3cfa51c1ecad&type=display
624,LISINOPRIL,"1. The drug Zestril (lisinopril) is associated with a warning for fetal toxicity, which can cause injury and death to the developing fetus when pregnancy is detected, leading to potential cardiotoxic effects on the fetus. (Associated with cardiotoxicity risk)

2. Zestril is indicated for the treatment of hypertension, heart failure, and reduction of mortality in acute myocardial infarction, with potential adverse reactions such as hypotension, chest pain, and renal dysfunction, which are cardiotoxic effects. (Associated with cardiotoxicity risk)

3. Zestril may cause symptomatic hypotension, which can lead to complications such as oliguria, progressive azotemia, acute renal failure, or death, particularly in patients with certain cardiovascular conditions, indicating a cardiotoxicity risk. (Associated with cardiotoxicity risk)

4. Patients treated with Zestril for heart failure may experience adverse reactions such as hypotension and chest pain, which are cardiotoxic effects associated with the drug. (Associated with cardiotoxicity risk)

5. Zestril can cause hyperkalemia, a condition that can have cardiotoxic effects, especially in patients with renal insufficiency, diabetes mellitus, or concomitant use of certain medications, indicating a cardiotoxicity risk. (Associated with cardiotoxicity risk)

6. ACE inhibitors like Zestril have been associated with a syndrome that can progress to fulminant hepatic necrosis and death, indicating potential cardiotoxic effects on the liver, which can impact cardiovascular function. (Associated with cardiotoxicity risk)

7. In clinical trials, Zestril-treated patients with hypertension and heart failure experienced adverse reactions such as hypotension, renal dysfunction, and electrolyte imbalances, which are cardiotoxic effects associated with the drug. (Associated with cardiotoxicity risk)

8. Zestril may interact with other medications, such as diuretics, NSAIDs, and mTOR inhibitors, leading to increased risks of hypotension, hyperkalemia, and angioedema, which are cardiotoxic reactions that can impact cardiovascular function. (Associated with cardiotoxicity risk)

9. Patients taking Zestril should be monitored for adverse reactions such as mood alterations, mental confusion, and hallucinations, which are potential cardiotoxic effects that can impact cardiovascular health. (Associated with cardiotoxicity risk)",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",838c2d78-d2d8-4981-9ec9-e50ef9e1a5d8,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=838c2d78-d2d8-4981-9ec9-e50ef9e1a5d8&type=display
625,LITHIUM,"1. The drug label warns about the potential risk of lithium toxicity, which can lead to cardiotoxicity, as serum lithium concentrations closely relate to lithium toxicity. Facilities for accurate serum lithium determinations should be available before initiating therapy. (The drug itself is associated with the risk of cardiotoxicity due to lithium toxicity.)

2. Lithium-induced chronic kidney disease, a potential adverse reaction to long-term lithium therapy, may present with renal manifestations such as nephrogenic diabetes insipidus and renal failure. (The drug itself is associated with the risk of chronic kidney disease, which can lead to renal manifestations affecting the kidneys, potentially impacting overall health, including cardiovascular health.)

3. The drug label mentions the possibility of unmasking Brugada Syndrome with lithium treatment, a condition characterized by abnormal electrocardiographic findings and a risk of sudden death. Lithium should be avoided in patients with Brugada Syndrome or those suspected of having it. (The drug itself is associated with the risk of unmasking Brugada Syndrome, a potentially life-threatening cardiac condition.)

4. Pseudotumor cerebri, a condition involving increased intracranial pressure and papilledema, has been reported with lithium use. If undetected, this condition may lead to visual impairments and blindness due to optic atrophy. Consider discontinuing lithium if pseudotumor cerebri occurs. (The drug itself is associated with the risk of pseudotumor cerebri, which can have serious implications for visual health and overall well-being.)",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",e95036c7-542a-437a-969b-f95f6f949f84,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=e95036c7-542a-437a-969b-f95f6f949f84&type=display
626,LOFEXIDINE HYDROCHLORIDE,"1. The drug LUCEMYRA is associated with a risk of hypotension, bradycardia, and syncope, which may lead to a decrease in blood pressure, pulse, and syncope. Patients should be monitored for these cardiovascular effects, especially those with certain medical conditions, and should be advised on how to minimize the risk and manage symptoms if they occur. The drug itself is associated with these cardiotoxicity risks.

2. LUCEMYRA is also linked to a risk of QT prolongation, which can be dangerous for patients with certain conditions. Patients with congenital long QT syndrome should avoid using LUCEMYRA, and ECG monitoring is recommended for patients with specific medical conditions or taking other medications that may prolong the QT interval. The drug itself is associated with the risk of QT prolongation.

3. The drug LUCEMYRA can potentiate the central nervous system depressant effects of certain drugs, such as benzodiazepines, alcohol, and barbiturates. Patients should be cautious when using these medications concurrently with LUCEMYRA. The drug itself is associated with an increased risk of central nervous system depression when used with other CNS depressant drugs.

4. Patients who discontinue LUCEMYRA abruptly may experience a marked rise in blood pressure and various symptoms, including diarrhea, insomnia, anxiety, chills, hyperhidrosis, and extremity pain. It is important for patients to consult their healthcare provider before discontinuing therapy and to gradually reduce the dose to manage discontinuation symptoms. The drug itself is associated with the risk of discontinuation symptoms upon abrupt cessation.

5. In clinical trials, common adverse reactions associated with LUCEMYRA included orthostatic hypotension, bradycardia, hypotension, dizziness, somnolence, sedation, and dry mouth. These adverse reactions were notably more frequent in patients treated with LUCEMYRA compared to placebo. The drug itself is associated with these cardiotoxicity reactions as reported in clinical trials.

6. Postmarketing experience with LUCEMYRA has identified hypotension as the most frequently reported adverse event. Additionally, there have been reports of QT prolongation, bradycardia, torsades de pointes, and cardiac arrest in patients receiving LUCEMYRA. These cardiotoxicity reactions have been reported in patients using the drug postmarketing.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",b748f308-ba71-4fd9-84ec-ec7e0f210885,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=b748f308-ba71-4fd9-84ec-ec7e0f210885&type=display
627,LOMITAPIDE MESYLATE,"1. The drug label for JUXTAPID includes a warning about the risk of hepatotoxicity, but there is no specific mention of cardiotoxicity risks associated with the drug itself.

2. The label highlights that JUXTAPID can cause elevations in transaminases, hepatic steatosis, and progressive liver disease, but there is no direct mention of cardiotoxicity risks caused by the drug.

3. The label emphasizes the importance of monitoring liver-related tests regularly during treatment with JUXTAPID due to the risk of hepatotoxicity, but there is no indication of direct cardiotoxic effects.

4. While the label discusses the potential for hepatic steatosis and liver-related adverse events with JUXTAPID, there is no specific mention of cardiotoxicity risks or reactions associated with the drug itself.

Overall, based on the information provided in the drug label, there is no direct indication that JUXTAPID is associated with cardiotoxicity risks or cardiotoxic reactions. The focus of the warnings and precautions primarily revolves around hepatotoxicity and liver-related adverse events.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",61a0be9d-ee58-43e0-b5cb-141011835081,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=61a0be9d-ee58-43e0-b5cb-141011835081&type=display
628,LOMUSTINE,1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with GLEOSTINE (lomustine).,No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",7f77526b-4c40-409c-82ea-d0f934d89cc2,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7f77526b-4c40-409c-82ea-d0f934d89cc2&type=display
629,LONAFARNIB,"1. ZOKINVY is associated with QTc interval prolongation, which increases the risk of Torsade de pointes, serious arrhythmias, and sudden death. The drug itself is linked to QTc interval prolongation, leading to potential cardiotoxicity risks.

2. The drug label advises avoiding ZOKINVY in patients with a history of cardiac arrhythmias or other conditions that may increase the risk of Torsade de pointes or sudden death, such as symptomatic bradycardia, hypokalemia, or hypomagnesemia. ZOKINVY is directly associated with the risk of cardiotoxicity in susceptible patients.

3. Monitoring of electrocardiograms (ECGs) is recommended before initiating ZOKINVY, during treatment, and as clinically indicated to assess QTc interval changes. The drug itself can impact the QTc interval, necessitating close monitoring for potential cardiotoxic effects.

4. In cases where the QTc interval exceeds 500 msec, ZOKINVY should be withheld until the interval is less than 470 msec, then resumed at the same dosage. This action is taken to manage the drug-induced cardiotoxicity risk associated with QTc interval prolongation.

5. Serum electrolytes should be obtained before starting ZOKINVY and monitored during treatment to correct any abnormalities, as electrolyte imbalances can contribute to cardiotoxic effects. ZOKINVY's association with electrolyte abnormalities underscores the importance of monitoring for potential cardiotoxicity reactions.

6. Overall, ZOKINVY's mechanism of action includes QTc interval prolongation, necessitating precautions and monitoring to mitigate the risk of cardiotoxicity in vulnerable patient populations.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",956a142f-35d6-4fe3-8aef-7e4878d275ed,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=956a142f-35d6-4fe3-8aef-7e4878d275ed&type=display
630,LOPERAMIDE HYDROCHLORIDE,"1. The drug label warns of cases of Torsades de Pointes, cardiac arrest, and death associated with the use of higher than recommended dosages of loperamide hydrochloride capsules, indicating that the drug itself is associated with cardiotoxicity risks.

2. The label mentions that cases of prolongation of the QT/QTc interval, Torsades de Pointes, other ventricular arrhythmias, cardiac arrest, and death have been reported in adults using higher than recommended doses of loperamide hydrochloride capsules, suggesting that the drug can cause cardiotoxicity reactions.

3. It states that cases of syncope, ventricular tachycardia, and cardiac arrest have been reported in adult patients receiving the recommended dosage of loperamide hydrochloride capsules, indicating that the drug itself can lead to cardiotoxicity reactions.

4. Postmarketing cases of cardiac arrest, syncope, and respiratory depression have been reported in pediatric patients less than 2 years of age, further emphasizing the cardiotoxicity risks associated with loperamide hydrochloride capsules.

5. The label advises avoiding loperamide hydrochloride dosages higher than recommended in adults and pediatric patients 2 years of age and older due to the risk of serious cardiac adverse reactions, indicating that the drug itself can cause cardiotoxicity reactions.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",df4e7076-fd25-aeb8-e053-2995a90a2aa0,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=df4e7076-fd25-aeb8-e053-2995a90a2aa0&type=display
631,LORATADINE,"1. The drug label does not mention any specific cardiotoxicity risks associated with Loratadine.
2. The drug label does not indicate that Loratadine is associated with cardiotoxicity reactions.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",c45c1dba-ba6c-4dfb-a1ee-c5ec61ad4dfb,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=c45c1dba-ba6c-4dfb-a1ee-c5ec61ad4dfb&type=display
632,LORAZEPAM,"1. The drug label mentions that Lorazepam Injection is contraindicated in patients with acute narrow-angle glaucoma or sleep apnea syndrome, which are conditions not directly related to cardiotoxicity risks. (The drug itself is not associated with cardiotoxicity in this context.)

2. The label also states that Lorazepam Injection is contraindicated in patients with severe respiratory insufficiency, except in those requiring relief of anxiety and/or diminished recall of events while being mechanically ventilated. This indicates that the drug may potentially exacerbate respiratory depression in patients with severe respiratory insufficiency, which indirectly impacts cardiovascular function. (The drug itself is not directly associated with cardiotoxicity in this context.)

3. The label warns about the risk of respiratory depression, which is the most important risk associated with the use of Lorazepam Injection in status epilepticus. It emphasizes the need for close monitoring of respiration and the provision of ventilatory support as required. This respiratory depression risk indirectly affects cardiovascular function due to the interplay between respiratory and cardiovascular systems. (The drug itself is not directly associated with cardiotoxicity in this context.)

4. The label mentions that Lorazepam Injection may produce heavy sedation, especially when given in combination with other drugs during anesthesia, potentially leading to airway obstruction. This risk indirectly impacts cardiovascular function due to the potential effects on oxygenation and ventilation. (The drug itself is not directly associated with cardiotoxicity in this context.)

Overall, while Lorazepam Injection is not directly associated with cardiotoxicity risks, certain adverse effects such as respiratory depression and sedation may have indirect implications for cardiovascular function, particularly in vulnerable patient populations.",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",4084fa74-9fd2-45ef-9d56-27bfa31d4e46,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=4084fa74-9fd2-45ef-9d56-27bfa31d4e46&type=display
633,LORLATINIB,"1. The drug label mentions that LORBRENA is associated with the risk of atrioventricular block, which can occur in patients receiving the medication. It advises monitoring ECG prior to initiating LORBRENA and periodically thereafter, with recommendations for dose adjustments based on severity of AV block. The drug itself is linked to the risk of atrioventricular block.

2. Additionally, the label highlights that hypertension can occur in patients taking LORBRENA, with specific guidance on controlling blood pressure before initiating the medication and monitoring it regularly during treatment. The label suggests withholding, dose reduction, or permanent discontinuation of LORBRENA based on the severity of hypertension. The drug itself is associated with the risk of hypertension.

3. The drug label also mentions that LORBRENA can lead to hyperglycemia in patients, with recommendations to assess fasting serum glucose before starting treatment and monitor it regularly thereafter. It advises on managing hyperglycemia with dose adjustments or discontinuation of LORBRENA based on severity. The drug itself is associated with the risk of hyperglycemia.",Less,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",2b34d62d-e02a-4af3-bc0d-1571dd4ee76d,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=2b34d62d-e02a-4af3-bc0d-1571dd4ee76d&type=display
634,LOSARTAN POTASSIUM,"1. The drug COZAAR is associated with a warning for fetal toxicity, which can cause injury and death to the developing fetus when administered to pregnant women. This is a risk directly associated with the drug itself.
   
2. COZAAR is indicated for the treatment of hypertension in adults and pediatric patients to lower blood pressure, reducing the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. The benefits of lowering blood pressure have been seen in controlled trials of antihypertensive drugs, including COZAAR. This is a general cardiovascular risk reduction benefit associated with the class of antihypertensive drugs, including COZAAR.

3. COZAAR is indicated to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy. However, there is evidence that this benefit may not apply to Black patients. This is a specific risk reduction benefit associated with the drug COZAAR, particularly in patients with left ventricular hypertrophy.

4. COZAAR is indicated for the treatment of diabetic nephropathy in patients with type 2 diabetes and a history of hypertension. It reduces the rate of progression of nephropathy, as measured by the occurrence of doubling of serum creatinine or end-stage renal disease. This is a specific risk reduction benefit associated with the drug COZAAR in diabetic patients with nephropathy.

5. Adverse reactions associated with COZAAR include dizziness, upper respiratory infection, nasal congestion, back pain, and other less common reactions like anemia, depression, and somnolence. These adverse reactions are reported in patients treated with COZAAR and are not specific to cardiotoxicity.

6. Coadministration of COZAAR with other drugs that raise serum potassium levels may result in hyperkalemia, which is a risk of cardiotoxicity associated with drug interactions rather than COZAAR itself.

7. In patients with renal insufficiency, elevated plasma concentrations of losartan and its active metabolite have been observed compared to subjects with normal renal function. This is a risk factor for potential cardiotoxicity associated with the drug COZAAR in patients with renal impairment.

8. COZAAR has not been studied in patients with severe hepatic impairment, and the recommended starting dose for patients with mild-to-moderate hepatic impairment is 25 mg once daily. This is a precautionary measure due to the potential risk of cardiotoxicity in patients with hepatic impairment.",Less,No,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",9949448f-c3b9-44ee-94ed-c1aca8c90f39,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=9949448f-c3b9-44ee-94ed-c1aca8c90f39&type=display
635,LOVASTATIN,"1. The drug Altoprev is indicated to reduce the risk of myocardial infarction, unstable angina, and coronary revascularization procedures in adults at high risk for coronary heart disease. (The drug itself is associated with reducing the risk of these cardiovascular events.)

2. Altoprev is also used as an adjunct to diet to reduce low-density lipoprotein cholesterol (LDL-C) and slow the progression of coronary atherosclerosis in adults with coronary heart disease. (The drug itself is associated with reducing LDL-C and slowing the progression of coronary atherosclerosis.)

3. Additionally, Altoprev is indicated to reduce LDL-C in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH). (The drug itself is associated with reducing LDL-C in this patient population.)

4. The drug label warns about the risk of myopathy and rhabdomyolysis with Altoprev, including cases of acute renal failure secondary to myoglobinuria. Predisposing factors include advanced age, female gender, uncontrolled hypothyroidism, and renal impairment. Patients are advised to report any unexplained muscle pain, tenderness, or weakness promptly, and Altoprev therapy should be discontinued if myopathy is diagnosed or suspected. (The drug itself is associated with the risk of myopathy and rhabdomyolysis.)

5. Rare reports of immune-mediated necrotizing myopathy (IMNM), an autoimmune myopathy, have been associated with Altoprev use. Patients should discontinue Altoprev if IMNM is suspected. (The drug itself is associated with the risk of immune-mediated necrotizing myopathy.)

6. Increases in serum transaminases have occurred with Altoprev, with rare reports of fatal and non-fatal hepatic failure. Patients with hepatic dysfunction should discontinue Altoprev if serious hepatic injury with clinical symptoms occurs. (The drug itself is associated with the risk of hepatic dysfunction.)

7. Altoprev has been associated with increases in HbA1c and fasting serum glucose levels. Patients are advised to optimize lifestyle measures to manage these changes. (The drug itself is associated with the risk of increases in HbA1c and fasting serum glucose levels.)",Less,No,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",8c0db100-5df9-49c3-8af9-1bc03ae609b9,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8c0db100-5df9-49c3-8af9-1bc03ae609b9&type=display
636,LOXAPINE,"1. **Warnings and Precautions Section:**
   - The drug label warns about the potential risk of **hypotension, orthostatic hypotension, and syncope** associated with ADASUVE. It states that ADASUVE can cause these cardiovascular effects, indicating that the drug itself is associated with cardiotoxicity risks.

2. **Warnings and Precautions Section:**
   - The label mentions that in short-term placebo-controlled trials, **hypotension** occurred in patients treated with ADASUVE. It indicates that the drug itself can lead to hypotension, suggesting a direct association with cardiotoxicity reactions.

3. **Warnings and Precautions Section:**
   - The drug label discusses the potential for **cerebrovascular reactions, including stroke**, in elderly patients with dementia-related psychosis treated with antipsychotic drugs like ADASUVE. This suggests that the drug may be associated with an increased risk of cerebrovascular events, including stroke, in this specific patient population.

4. **Adverse Reactions Section:**
   - The label mentions that in clinical trials, **hypersensitivity reactions** such as serious skin reactions were observed with ADASUVE. While not directly related to cardiotoxicity, hypersensitivity reactions can have systemic effects, including potential cardiovascular implications.

5. **Adverse Reactions Section:**
   - The drug label discusses the occurrence of **bronchospasm** in patients treated with ADASUVE, particularly in those with lung diseases. While bronchospasm primarily affects the respiratory system, it can lead to respiratory distress and potentially impact cardiovascular function, highlighting a potential cardiotoxicity risk associated with the drug.",Less,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",50e11732-7387-452d-b3e6-db3a431d5c4a,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=50e11732-7387-452d-b3e6-db3a431d5c4a&type=display
637,LUBIPROSTONE,"1. **Cardiotoxicity Risk Associated with Amitiza:**
   - Syncope and hypotension have been reported with Amitiza in the postmarketing setting, with some cases occurring within an hour after taking the first dose or subsequent doses. Recurrence of syncope and hypotension has been reported with repeat dosing. Patients should be aware of the risk of syncope and hypotension during treatment with Amitiza, especially when concomitant medications known to lower blood pressure are used.

2. **Cardiotoxicity Reactions Associated with Amitiza:**
   - Dyspnea was reported in clinical trials with Amitiza, occurring in 3% of patients with chronic idiopathic constipation (CIC), 1% of patients with opioid-induced constipation (OIC), and less than 1% of patients with irritable bowel syndrome with constipation (IBS-C). Postmarketing reports of dyspnea have been noted with the use of Amitiza 24 mcg twice daily. Patients should contact their healthcare provider if they experience symptoms of dyspnea, which generally resolve within a few hours but may recur with subsequent doses.

3. **Additional Cardiotoxicity Reactions Associated with Amitiza:**
   - In postmarketing experience, additional adverse reactions related to cardiotoxicity have been identified, including tachycardia. These reactions were reported voluntarily and may not establish a direct causal relationship to Amitiza. Patients should be monitored for any signs of cardiovascular symptoms while taking Amitiza.",Less,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",164a2b47-0a52-4bb4-9e71-5342c2e951f4,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=164a2b47-0a52-4bb4-9e71-5342c2e951f4&type=display
638,LUMASIRAN,1. The drug label does not mention any cardiotoxicity risks or reactions associated with OXLUMO (lumasiran) injection for the treatment of primary hyperoxaluria type 1 (PH1).,No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",16985a31-f5e4-4557-9266-fc78d4bc5055,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=16985a31-f5e4-4557-9266-fc78d4bc5055&type=display
639,LUMATEPERONE,"1. CAPLYTA is not approved for the treatment of patients with dementia-related psychosis, as elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death due to cardiovascular causes. The drug itself is not directly associated with cardiotoxicity but is contraindicated in this patient population due to the increased mortality risk.

2. Antidepressants, including CAPLYTA, have been associated with an increased risk of suicidal thoughts and behaviors in pediatric and young adult patients. The drug itself is not directly linked to cardiotoxicity but is associated with an increased risk of suicidal thoughts and behaviors, which may have cardiovascular implications.

3. CAPLYTA has not been evaluated in patients with a recent history of myocardial infarction or unstable cardiovascular disease, as atypical antipsychotics, including CAPLYTA, can cause orthostatic hypotension and syncope. The drug itself is associated with orthostatic hypotension and syncope, which are cardiotoxicity risks.

4. CAPLYTA may cause seizures, especially in patients with a history of seizures or conditions that lower the seizure threshold, which may have cardiovascular implications. The drug itself is associated with the risk of seizures, which can have cardiovascular effects.

5. CAPLYTA, like other antipsychotics, may cause somnolence and impair judgment, thinking, and motor skills, potentially affecting cardiovascular function. The drug itself is associated with the potential for cognitive and motor impairment, which can indirectly impact cardiovascular health.",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",db730b06-6351-47fd-8183-e61e61bbead5,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=db730b06-6351-47fd-8183-e61e61bbead5&type=display
640,LURASIDONE HYDROCHLORIDE,"1. The drug label warns about increased mortality in elderly patients with dementia-related psychosis who are treated with antipsychotic drugs, including LATUDA. Elderly patients with dementia-related psychosis have an increased risk of death when treated with antipsychotic drugs, with a higher incidence of cerebrovascular adverse reactions such as stroke and transient ischemic attacks. LATUDA is not approved for the treatment of patients with dementia-related psychosis, indicating that the drug itself is associated with cardiotoxicity risks in this specific population.

2. The drug label also mentions that atypical antipsychotic drugs, including LATUDA, have been associated with metabolic changes that may increase cardiovascular/cerebrovascular risk. These metabolic changes include hyperglycemia, dyslipidemia, and weight gain. While all drugs in this class have been shown to produce some metabolic changes, each drug has its own specific risk profile. This suggests that LATUDA is associated with metabolic changes that may contribute to cardiovascular risk, indicating a potential cardiotoxicity risk with the use of this medication.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",afad3051-9df2-4c54-9684-e8262a133af8,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=afad3051-9df2-4c54-9684-e8262a133af8&type=display
641,LURBINECTEDIN,"1. **Clinical Pharmacology (12.2):** No large mean increase in QTc (>20 ms) was detected at the recommended dose of 3.2 mg/m2. (No direct association of the drug with cardiotoxicity risk mentioned here.)

2. **Clinical Pharmacology (12.3):** No specific mention of cardiotoxicity risks or reactions in this section. 

3. **Adverse Reactions (6.1):** No specific mention of cardiotoxicity risks or reactions in the adverse reactions section.

4. **Postmarketing Experience (6.2):** No specific mention of cardiotoxicity risks or reactions in the postmarketing experience section.

Overall, based on the information provided in the drug label, there is no direct mention of the drug ZEPZELCA being associated with cardiotoxicity risks or cardiotoxic reactions.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",632bb50c-3bcb-4c85-9056-fc33410550ae,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=632bb50c-3bcb-4c85-9056-fc33410550ae&type=display
642,LUSUTROMBOPAG,"1. MULPLETA is a thrombopoietin receptor agonist that has been associated with thrombotic and thromboembolic complications in patients with chronic liver disease. The drug itself is associated with an increased risk of thrombotic and thromboembolic complications in this patient population.

2. The drug label warns about the potential increased thrombotic risk when administering MULPLETA to patients with known risk factors for thromboembolism, including genetic pro-thrombotic conditions. The drug itself is associated with an increased risk of thrombotic events in patients with chronic liver disease, especially those with additional risk factors for thromboembolism.

3. The label also mentions that portal vein thrombosis has been reported in patients with chronic liver disease treated with MULPLETA. The drug itself has been linked to cases of portal vein thrombosis in patients with chronic liver disease.

4. Additionally, the label states that MULPLETA does not prolong the QT interval to any clinically relevant extent at a dose 8 times the recommended dosage. The drug itself does not have a significant impact on cardiac electrophysiology, specifically the QT interval, even at higher doses.",Less,No,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",f9fd0cfd-717d-4a87-99bc-de7b38807e55,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=f9fd0cfd-717d-4a87-99bc-de7b38807e55&type=display
643,LUTETIUM LU 177 DOTATATE,"1. **Cardiotoxicity Risk**: The drug label does not mention any specific cardiotoxicity risks associated with LUTATHERA itself.

2. **Cardiotoxicity Reactions**: The drug label does not include any information regarding cardiotoxicity reactions associated with LUTATHERA.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",72d1a024-00b7-418a-b36e-b2cb48f2ab55,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=72d1a024-00b7-418a-b36e-b2cb48f2ab55&type=display
644,MACIMORELIN ACETATE,"1. The drug MACRILEN has a warning regarding QT prolongation, which can lead to torsade de pointes-type ventricular tachycardia. The drug itself is associated with the risk of QT prolongation (5.1).

2. MACRILEN has a potential for false positive test results when used with strong CYP3A4 inducers, which can significantly decrease macimorelin plasma levels and lead to a false positive result. The drug itself is associated with the risk of false positive test results when used with strong CYP3A4 inducers (5.2).

3. There is a potential for false negative test results in cases of recent onset hypothalamic disease when using MACRILEN. The drug itself is associated with the risk of false negative test results in recent onset hypothalamic disease (5.3).

4. The most common adverse reactions reported with MACRILEN include sinus bradycardia. The drug itself is associated with the adverse reaction of sinus bradycardia (6.1).",Less,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",6034c9b8-5a36-4961-a5dd-11ebf7bdab78,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=6034c9b8-5a36-4961-a5dd-11ebf7bdab78&type=display
645,MACITENTAN,"1. **Cardiotoxicity Risk**: The drug label mentions that fluid retention, including peripheral edema and fluid retention, are known clinical consequences of pulmonary arterial hypertension (PAH) and effects of endothelin receptor antagonists (ERAs) like OPSUMIT. Patients with underlying left ventricular dysfunction may be at particular risk for developing significant fluid retention after initiation of ERA treatment. In a small study of OPSUMIT in patients with pulmonary hypertension due to left ventricular dysfunction, more patients in the OPSUMIT group developed significant fluid retention and had more hospitalizations due to worsening heart failure compared to those on placebo. Postmarketing cases of edema and fluid retention occurring within weeks of starting OPSUMIT, some requiring intervention with a diuretic or hospitalization for decompensated heart failure, have been reported.

2. **Cardiotoxicity Reaction**: The drug label also mentions that symptomatic hypotension has been reported as a cardiac disorder in postmarketing experience with OPSUMIT. This indicates that OPSUMIT may have an association with symptomatic hypotension as a cardiotoxicity reaction.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",1e484a50-55db-4b85-8c57-6cd1b0353abd,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=1e484a50-55db-4b85-8c57-6cd1b0353abd&type=display
646,MAGNESIUM SULFATE,"1. The drug label mentions that magnesium sulfate can cause heart block at certain serum levels of magnesium, including levels lower than 10 mEq/liter, indicating that the drug itself is associated with cardiotoxicity risks.

2. It is also noted that magnesium acts peripherally to produce vasodilation, with larger doses causing a lowering of blood pressure, suggesting that the drug itself can lead to cardiovascular effects.

3. The label further states that the central and peripheral effects of magnesium poisoning can be antagonized to some extent by intravenous administration of calcium, indicating that magnesium sulfate can potentially induce cardiotoxic reactions.

4. Additionally, the label warns that continuous administration of magnesium sulfate beyond 5-7 days to pregnant women can lead to hypocalcemia and bone abnormalities in the developing fetus, which may include cardiac effects, suggesting that the drug itself poses cardiotoxic risks.

5. The label mentions that magnesium intoxication can lead to circulatory collapse, cardiac depression, and central nervous system depression progressing to respiratory paralysis, indicating that the drug itself can result in cardiotoxic reactions.

Overall, the drug label highlights the potential cardiotoxicity risks associated with magnesium sulfate, particularly in relation to its effects on the cardiovascular system and the importance of monitoring serum magnesium levels to prevent adverse cardiac reactions.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",7d94995b-9e2a-0345-e053-2991aa0a62d0,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7d94995b-9e2a-0345-e053-2991aa0a62d0&type=display
647,MANGANESE CHLORIDE,"1. The drug label does not mention any cardiotoxicity risks or cardiotoxicity reactions associated with the use of Manganese Chloride Injection, USP.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",6e979070-5035-4076-e09c-b52466be3c68,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=6e979070-5035-4076-e09c-b52466be3c68&type=display
648,MARALIXIBAT CHLORIDE,"1. **Cardiotoxicity Risk**: The drug label does not mention any specific cardiotoxicity risks associated with LIVMARLI.
   
2. **Cardiotoxicity Reactions**: The drug label does not list any cardiotoxicity reactions associated with the use of LIVMARLI.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",64000394-1ef6-4e76-8ba8-11f25ba1b167,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=64000394-1ef6-4e76-8ba8-11f25ba1b167&type=display
649,MARAVIROC,"1. The drug SELZENTRY has been associated with an increased risk of cardiovascular events, including myocardial ischemia and/or infarction, in treatment-experienced subjects during clinical trials. The relative contribution of SELZENTRY to these events is not known.

2. In a Phase 2b/3 trial in treatment-naive adult subjects, some individuals who received SELZENTRY experienced events related to ischemic heart disease. The drug SELZENTRY was not specifically mentioned as the cause of these events.

3. When SELZENTRY was administered to healthy volunteers at doses higher than recommended, symptomatic postural hypotension was observed more frequently. However, in HIV-1-infected adult subjects in Phase 3 trials, postural hypotension rates were similar to placebo, indicating that SELZENTRY itself did not directly cause cardiotoxicity in this context.",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",46f30ac5-c96b-429e-976d-8c5ee1c0761b,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=46f30ac5-c96b-429e-976d-8c5ee1c0761b&type=display
650,MARIBAVIR,"1. The drug label mentions that at three times the recommended dose, LIVTENCITY does not prolong the QT interval to any clinically relevant extent. This indicates that LIVTENCITY itself was not associated with cardiotoxicity risks.

2. The label also states that LIVTENCITY does not have an exposure-response relationship for viral load or probability of unquantifiable plasma CMV DNA, suggesting no cardiotoxicity risks directly related to the drug.

3. Additionally, the label mentions that LIVTENCITY was evaluated in a Phase 3 trial where no significant toxicological effects on embryo-fetal growth or development were observed in rabbits at doses up to 100 mg/kg/day, which is approximately half the human exposure at the recommended human dose. This indicates that LIVTENCITY did not cause cardiotoxicity risks in this aspect.

Overall, based on the information provided in the drug label, LIVTENCITY does not appear to be associated with cardiotoxicity risks or reactions.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",c94fc2c5-e840-4f18-b7d8-d5eacb26d3a0,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=c94fc2c5-e840-4f18-b7d8-d5eacb26d3a0&type=display
651,MEBENDAZOLE,1. The drug label for VERMOX CHEWABLE does not mention any cardiotoxicity risks or cardiotoxicity reactions associated with the drug itself.,No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",a720c424-517a-461b-8e13-6c37caf8aa3f,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a720c424-517a-461b-8e13-6c37caf8aa3f&type=display
652,MEBROFENIN,1. The drug label does not mention any cardiotoxicity risks or cardiotoxicity reactions associated with Technetium Tc 99m Mebrofenin.,No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",fd085485-998d-42a3-879a-b2d96cb8aed7,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fd085485-998d-42a3-879a-b2d96cb8aed7&type=display
653,MECAMYLAMINE HYDROCHLORIDE,"1. The drug label mentions that Mecamylamine HCl, the active ingredient in Vecamyl, is an antihypertensive agent that can reduce blood pressure in both normotensive and hypertensive individuals. It states that the antihypertensive effect is predominantly orthostatic, but it also significantly reduces supine blood pressure. (The drug itself is associated with the risk of orthostatic hypotension, which can lead to cardiovascular issues.)

2. The label warns that when ganglion blockers or other potent antihypertensive drugs like Mecamylamine HCl are discontinued suddenly, hypertensive levels may return, potentially causing fatal cerebral vascular accidents or acute congestive heart failure. It advises that when Mecamylamine HCl is withdrawn, it should be done gradually, and other antihypertensive therapy may need to be substituted. (The drug itself is associated with the risk of rebound hypertension and cardiovascular complications upon sudden discontinuation.)

3. The label cautions that the action of Mecamylamine HCl may be potentiated by various factors such as excessive heat, fever, infection, anesthesia, surgery, and other antihypertensive drugs, which could lead to additional hypotension. It also mentions that sodium intake should not be restricted during therapy with Mecamylamine HCl, and urinary retention may occur in patients on ganglion blockers. (The drug itself is associated with the risk of hypotension, electrolyte imbalances, and urinary retention, which can impact cardiovascular function.)

4. The label lists cardiovascular adverse reactions associated with Mecamylamine HCl, including orthostatic dizziness, syncope, and postural hypotension. These reactions are categorized under the cardiovascular system adverse effects. (The drug itself is associated with cardiovascular adverse reactions that can impact blood pressure and heart function.)

Overall, the drug label highlights the potential cardiotoxicity risks and reactions associated with Mecamylamine HCl, emphasizing the need for careful monitoring and management to prevent adverse cardiovascular events.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",0774cc48-7287-4093-91d6-9df41a81408a,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=0774cc48-7287-4093-91d6-9df41a81408a&type=display
654,MECLIZINE HYDROCHLORIDE,1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with meclizine hydrochloride tablets.,No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",83a1818c-554c-426a-9564-c8e4c75f8e4c,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=83a1818c-554c-426a-9564-c8e4c75f8e4c&type=display
655,MECLOFENAMATE SODIUM,"1. The drug label states that nonsteroidal anti-inflammatory drugs (NSAIDs), including meclofenamate sodium, are associated with an increased risk of serious cardiovascular thrombotic events, such as myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with the duration of use.

2. Meclofenamate sodium capsules are contraindicated in patients who have undergone coronary artery bypass graft (CABG) surgery due to the associated risk of cardiovascular thrombotic events.

3. The drug label also mentions that clinical trials of several COX-2 selective and nonselective NSAIDs have shown an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. The relative increase in serious cardiovascular thrombotic events over baseline conferred by NSAID use appears to be similar in patients with and without known cardiovascular disease or risk factors for cardiovascular disease.

4. The label advises that to minimize the potential risk for an adverse cardiovascular event in NSAID-treated patients, the lowest effective dose should be used for the shortest duration possible. Physicians and patients should remain alert for the development of such events throughout the entire treatment course, even in the absence of previous cardiovascular symptoms.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",96f19af4-de8f-4fd7-90d8-55fe6ebdd81d,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=96f19af4-de8f-4fd7-90d8-55fe6ebdd81d&type=display
656,MEDROXYPROGESTERONE ACETATE,"1. The drug label warns about an increased risk of deep vein thrombosis (DVT), pulmonary embolism (PE), stroke, and myocardial infarction (MI) in postmenopausal women using estrogen plus progestin therapy, including medroxyprogesterone acetate (MPA). This risk was observed in a study involving daily oral conjugated estrogens combined with MPA, relative to placebo.

2. The label mentions that the Women's Health Initiative (WHI) Memory Study reported an increased risk of developing probable dementia in postmenopausal women aged 65 years or older during treatment with daily conjugated estrogens combined with MPA. It is unknown if this finding applies to younger postmenopausal women.

3. The WHI estrogen plus progestin substudy demonstrated an increased risk of invasive breast cancer in women using daily conjugated estrogens combined with MPA, compared to placebo. The label suggests that this risk should be assumed to be similar for other doses of estrogen and progestin combinations.

4. The drug label also discusses the increased risk of cardiovascular events, including coronary heart disease (CHD), non-fatal myocardial infarction (MI), stroke, and pulmonary embolism (PE) associated with estrogen plus progestin therapy. This risk was reported in women receiving daily conjugated estrogens plus MPA compared to placebo.

5. The label mentions that the WHI estrogen plus progestin substudy reported a statistically significant increased risk of stroke, CHD events, and venous thromboembolism (VTE) in women using daily conjugated estrogens plus MPA compared to placebo. The risk of these cardiovascular events was demonstrated during the study period.

Overall, the drug label highlights the cardiotoxicity risks associated with estrogen plus progestin therapy, including the increased risks of cardiovascular disorders, breast cancer, and probable dementia observed in postmenopausal women using medroxyprogesterone acetate (MPA) tablets.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",a586be28-96af-4fed-a13f-9b94fd4c7405,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a586be28-96af-4fed-a13f-9b94fd4c7405&type=display
657,MEFENAMIC ACID,"1. The drug label warns of serious cardiovascular thrombotic events associated with the use of nonsteroidal anti-inflammatory drugs (NSAIDs), including mefenamic acid. These events, such as myocardial infarction and stroke, can be fatal, and the risk may increase with the duration of use.

2. Mefenamic acid is contraindicated in patients who have undergone coronary artery bypass graft (CABG) surgery due to the increased risk of cardiovascular thrombotic events associated with its use.

3. The label advises healthcare providers to consider the potential risk of serious cardiovascular events when prescribing mefenamic acid and to use the lowest effective dose for the shortest duration possible to minimize this risk.

4. Patients with a history of cardiovascular disease or risk factors for cardiovascular disease may have a higher absolute incidence of excess serious cardiovascular thrombotic events when using NSAIDs like mefenamic acid.

5. The label also mentions that the concurrent use of aspirin and an NSAID, such as mefenamic acid, may increase the risk of serious gastrointestinal events, but it does not consistently mitigate the increased risk of serious cardiovascular thrombotic events associated with NSAID use.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",d15733a9-d5fd-4d5f-86ce-e7ed8c706c7f,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=d15733a9-d5fd-4d5f-86ce-e7ed8c706c7f&type=display
658,MEFLOQUINE HYDROCHLORIDE,"1. The drug label warns that mefloquine may cause neuropsychiatric adverse reactions that can persist after discontinuation, and it should not be prescribed for prophylaxis in patients with major psychiatric disorders. This is due to the potential for neuropsychiatric symptoms, not directly related to cardiotoxicity.
   
2. The label mentions that mefloquine may increase the risk of convulsions in patients with epilepsy and that caution should be exercised when prescribing the drug to such patients. This indicates a potential risk of convulsions, which can indirectly impact cardiac function but is not a direct cardiotoxic effect.

3. The label also warns about the potential for electrocardiographic abnormalities when mefloquine is co-administered with certain drugs like quinine or quinidine. This suggests a risk of cardiac conduction abnormalities when combined with specific medications, indicating a potential cardiotoxicity risk.

4. Additionally, the label mentions that mefloquine is a myocardial depressant and may cause transitory and clinically silent ECG alterations, including prolongation of the QTc interval and abnormal T waves. This indicates that mefloquine itself can have direct cardiotoxic effects, such as altering cardiac conduction and function.

5. The label further states that mefloquine has been associated with serious adverse reactions like cardiopulmonary arrest in certain cases, particularly when used concomitantly with medications like propranolol. This highlights the potential for severe cardiac events linked to mefloquine use, indicating a direct cardiotoxic effect.

In summary, while mefloquine is primarily known for its neuropsychiatric adverse reactions, the drug label also highlights potential cardiotoxicity risks associated with the drug itself, including effects on cardiac conduction, myocardial function, and the risk of serious cardiac events in certain situations.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",09716a24-d7da-42b2-af29-c03a1b6670bd,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=09716a24-d7da-42b2-af29-c03a1b6670bd&type=display
659,MEGESTROL ACETATE,"1. Long-term treatment with Megace ES (megestrol acetate) may increase the risk of respiratory infections. A trend toward increased frequency of respiratory infections, decreased lymphocyte counts, and increased neutrophil counts was observed in a two-year chronic toxicity/carcinogenicity study of megestrol acetate conducted in rats. (The drug itself was not directly associated with cardiotoxicity risk in this sentence.)

2. No significant differences between the incidence of adverse events in patients treated with megestrol acetate and patients treated with placebo were observed in the clinical efficacy trials. Adverse events related to the cardiovascular system included cardiomyopathy and palpitation. (The drug itself was not directly associated with cardiotoxicity risk in this sentence.)

3. Postmarketing reports associated with megestrol acetate oral suspension include thromboembolic phenomena such as thrombophlebitis, deep vein thrombosis, and pulmonary embolism. (The drug itself was associated with cardiotoxicity risks in this sentence.)

4. Hyperglycemia was reported as an adverse event in patients treated with megestrol acetate. (The drug itself was not directly associated with cardiotoxicity risk in this sentence.)

5. In the open trial and clinical efficacy trials, hypertension was reported as an adverse event in patients receiving megestrol acetate. (The drug itself was not directly associated with cardiotoxicity risk in this sentence.)

6. In the clinical efficacy trials, patients treated with megestrol acetate reported adverse events related to the cardiovascular system, including hypertension. (The drug itself was not directly associated with cardiotoxicity risk in this sentence.)

7. In the clinical efficacy trials, patients treated with megestrol acetate reported adverse events related to the cardiovascular system, including hypertension. (The drug itself was not directly associated with cardiotoxicity risk in this sentence.)",Less,No,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",33bc102c-31a3-4fd9-9702-c1193d7699a3,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=33bc102c-31a3-4fd9-9702-c1193d7699a3&type=display
660,MELOXICAM,"1. The drug label warns that nonsteroidal anti-inflammatory drugs (NSAIDs), including meloxicam oral suspension, are associated with an increased risk of serious cardiovascular thrombotic events, such as myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with the duration of use. (The drug itself is associated with the cardiotoxicity risk.)

2. Meloxicam oral suspension is contraindicated in the setting of coronary artery bypass graft (CABG) surgery due to the increased risk of serious cardiovascular thrombotic events. (The drug itself is associated with the cardiotoxicity risk.)

3. The label mentions that observational studies have shown that patients treated with NSAIDs, including meloxicam, in the post-myocardial infarction (MI) period were at an increased risk of reinfarction, cardiovascular-related death, and all-cause mortality. (The drug itself is associated with the cardiotoxicity risk.)

4. The label advises avoiding the use of meloxicam oral suspension in patients with a recent MI unless the benefits are expected to outweigh the risk of recurrent cardiovascular thrombotic events. (The drug itself is associated with the cardiotoxicity risk.)

5. The label highlights that the use of meloxicam may blunt the cardiovascular effects of certain therapeutic agents used to treat conditions like heart failure, such as diuretics, ACE inhibitors, or angiotensin receptor blockers. (The drug itself is associated with the cardiotoxicity risk.)

6. The label warns that NSAIDs, including meloxicam oral suspension, can lead to new onset or worsening of preexisting hypertension, which may contribute to an increased incidence of cardiovascular events. (The drug itself is associated with the cardiotoxicity risk.)

7. The label advises monitoring blood pressure during the initiation of NSAID treatment and throughout the course of therapy to manage potential hypertension risks associated with meloxicam oral suspension. (The drug itself is associated with the cardiotoxicity risk.)",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",4ddf5a4d-8e84-419d-8e3a-c91b85501885,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=4ddf5a4d-8e84-419d-8e3a-c91b85501885&type=display
661,MELPHALAN HYDROCHLORIDE,"1. The drug label warns that melphalan hydrochloride may cause local tissue damage if extravasation occurs, and it should not be administered by direct injection into a peripheral vein. This risk is associated with the administration method rather than the drug itself.

2. The label mentions that acute hypersensitivity reactions, including anaphylaxis, were reported in 2.4% of patients receiving melphalan hydrochloride for injection for myeloma. These reactions were characterized by various symptoms, including tachycardia, bronchospasm, and hypotension. Cardiac arrest has also been reported rarely in association with these hypersensitivity reactions. Therefore, the drug itself is associated with cardiotoxicity reactions in a small percentage of patients.

3. Additionally, the label notes that other reported adverse reactions include skin hypersensitivity, skin ulceration at the injection site, skin necrosis requiring skin grafting, maculopapular rashes, vasculitis, and alopecia. These reactions are not directly linked to cardiotoxicity but may indicate potential systemic effects that could impact cardiac function indirectly.",Less,Yes,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",35f3d9fe-3c2f-4362-9d40-cdab014cac38,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=35f3d9fe-3c2f-4362-9d40-cdab014cac38&type=display
662,MEMANTINE HYDROCHLORIDE,"1. The drug label for NAMENDA XR does not mention any specific cardiotoxicity risks or cardiotoxicity reactions associated with the drug itself. 

2. The label primarily focuses on the drug's mechanism of action as an NMDA receptor antagonist and its pharmacokinetics, with no direct mention of cardiotoxic effects. 

3. Overall, the drug label does not highlight any significant cardiotoxicity concerns related to the use of NAMENDA XR.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",710f523f-0158-4639-8ce7-57598247d48c,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=710f523f-0158-4639-8ce7-57598247d48c&type=display
663,MEPERIDINE HYDROCHLORIDE,1. The drug label does not specifically mention cardiotoxicity risks or cardiotoxicity reactions associated with DEMEROL Injection.,No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",b31d1308-28c3-43f4-e0a6-2f3ed76b8975,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=b31d1308-28c3-43f4-e0a6-2f3ed76b8975&type=display
664,MEPIVACAINE HYDROCHLORIDE,"1. The drug label mentions that Levonordefrin, a vasoconstrictor used in the local anesthetic solution, should be used with extreme caution in patients with medical conditions such as hypertension, arteriosclerotic heart disease, cerebral vascular insufficiency, heart block, thyrotoxicosis, and diabetes, indicating a cardiotoxicity risk associated with the vasoconstrictor component.
   
2. It is highlighted that Levonordefrin-containing solutions should be used cautiously in patients with diseases that may adversely affect the cardiovascular system, as serious cardiac arrhythmias may occur if these solutions are used in patients receiving potent inhalation anesthetics, indicating a cardiotoxicity risk associated with the vasoconstrictor component.

3. The drug label also mentions that Levonordefrin-containing solutions may cause severe, persistent hypertension or cerebrovascular accidents when concurrently administered with vasopressor drugs or ergot-type oxytocic drugs, indicating a cardiotoxicity risk associated with the vasoconstrictor component.

4. Additionally, the label warns that Levonordefrin-containing solutions should be used with caution in patients with known drug allergies and sensitivities, indicating a cardiotoxicity risk associated with the vasoconstrictor component.

5. The drug label advises that Levonordefrin-containing solutions should be used cautiously in patients with a history of severe disturbances of cardiac rhythm or heart block, indicating a cardiotoxicity risk associated with the vasoconstrictor component.

6. Furthermore, the label mentions that Levonordefrin-containing solutions may cause allergic-type reactions, including anaphylactic symptoms and life-threatening asthmatic episodes in certain susceptible individuals, indicating a cardiotoxicity risk associated with the vasoconstrictor component.

7. The drug label also states that Levonordefrin is a sympathomimetic amine with pharmacologic activity similar to Epinephrine but less potent, indicating a cardiotoxicity risk associated with the vasoconstrictor component.

8. Lastly, the label advises that Levonordefrin-containing solutions should be used with extreme care to avoid intravascular injection and systemic reactions to both the local anesthetic and vasoconstrictor components, indicating a cardiotoxicity risk associated with the vasoconstrictor component.",Less,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",c4d45717-86c9-45bf-ba8e-2c255814ab50,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=c4d45717-86c9-45bf-ba8e-2c255814ab50&type=display
665,MEPROBAMATE,"1. The drug label mentions that cardiovascular adverse reactions associated with meprobamate include palpitation, tachycardia, various forms of arrhythmia, transient ECG changes, syncope, and hypotensive crisis, with one fatal case reported. The drug itself is associated with these cardiotoxicity risks.

2. The label also states that in cases of acute combined overdose involving meprobamate with alcohol or other CNS depressants, effects can be additive, leading to rapid onset of sleep, reduced blood pressure, pulse, and respiratory rates. The drug itself is associated with these cardiotoxicity risks when combined with other substances.

3. Additionally, the label mentions that meprobamate overdose can result in shock, vasomotor and respiratory collapse, and that some suicidal attempts with the drug have been fatal. The drug itself is associated with these cardiotoxicity risks in cases of overdose.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",a0891a32-105b-48bc-a246-5e179d2e7fa1,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a0891a32-105b-48bc-a246-5e179d2e7fa1&type=display
666,MERCAPTOPURINE,"1. **Warnings and Precautions:** The drug PURINETHOL is not associated with cardiotoxicity risks or reactions in this section. It primarily discusses myelosuppression, hepatotoxicity, immunosuppression, treatment-related malignancies, macrophage activation syndrome, and embryo-fetal toxicity.

2. **Adverse Reactions:** The drug PURINETHOL is not associated with cardiotoxicity risks or reactions in this section. It mentions common adverse reactions such as myelosuppression, anemia, leukopenia, thrombocytopenia, anorexia, nausea, vomiting, diarrhea, malaise, and rash.

3. **Drug Interactions:** The drug PURINETHOL is not associated with cardiotoxicity risks or reactions in this section. It discusses interactions with allopurinol and warfarin, which may affect the anticoagulant effect of warfarin but do not directly relate to cardiotoxicity.

4. **Use in Specific Populations:** The drug PURINETHOL is not associated with cardiotoxicity risks or reactions in this section. It addresses pregnancy risks, lactation, infertility, and the need for effective contraception due to potential embryo-fetal toxicity, but does not mention cardiotoxic effects.

Overall, the drug label for PURINETHOL does not indicate any direct association with cardiotoxicity risks or reactions. The focus is primarily on other potential adverse effects and precautions related to its use in specific populations.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",bfb03539-907f-4424-9c88-6a03ed9467e6,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=bfb03539-907f-4424-9c88-6a03ed9467e6&type=display
667,MEROPENEM,1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with meropenem for injection.,No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",240325ba-47a8-4ad1-bcab-6772069ee790,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=240325ba-47a8-4ad1-bcab-6772069ee790&type=display
668,MESALAMINE,"1. **Hypersensitivity Reactions, including Myocarditis and Pericarditis:** The drug label mentions that hypersensitivity reactions, including myocarditis and pericarditis, may occur as a result of using the drug. It is stated that patients should be evaluated immediately if signs or symptoms of a hypersensitivity reaction are present, and APRISO should be discontinued if an alternative cause for the symptoms cannot be established. This indicates that the drug itself is associated with the risk of hypersensitivity reactions, including myocarditis and pericarditis.

2. **Postmarketing Experience:** The drug label lists post-approval adverse reactions, including pericarditis, pericardial effusion, and myocarditis, that have been reported with the use of APRISO or other mesalamine-containing products. Since these reactions were reported post-approval, it suggests that the drug has been associated with cardiotoxicity reactions in some patients.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",7951139c-b271-45a4-b523-34b23800917b,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7951139c-b271-45a4-b523-34b23800917b&type=display
669,MESNA,"1. **Cardiotoxicity Risk**: The drug label does not mention any direct association between MESNEX and cardiotoxicity risks.

2. **Cardiotoxicity Reactions**: The postmarketing experience reported cardiovascular adverse reactions, including hypertension, in patients receiving MESNEX in combination with ifosfamide or similar drugs. However, it is noted that distinguishing whether these reactions were due to MESNEX or the concomitantly administered cytotoxic agents is challenging.",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",4a51ffdb-f59f-4e02-b3c4-f3457ab7b514,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=4a51ffdb-f59f-4e02-b3c4-f3457ab7b514&type=display
670,METAXALONE,"1. The drug label does not mention any specific cardiotoxicity risks or cardiotoxicity reactions associated with Metaxalone Tablets, 640 mg itself. 

2. The label primarily focuses on warnings and precautions related to serotonin syndrome and central nervous system depression, but does not directly mention cardiotoxicity risks or reactions related to the heart. 

3. The drug label does not provide information indicating that Metaxalone Tablets, 640 mg is associated with cardiotoxicity risks or cardiotoxicity reactions. 

Overall, based on the information provided in the drug label, there is no direct mention of cardiotoxicity risks or cardiotoxicity reactions specifically linked to the use of Metaxalone Tablets, 640 mg.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",f27ca677-f0cc-4710-bd94-ff1bf0d916cb,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=f27ca677-f0cc-4710-bd94-ff1bf0d916cb&type=display
671,METFORMIN HYDROCHLORIDE,"1. The drug label for GLUMETZA includes a warning about lactic acidosis, a serious condition that can result in death, hypothermia, hypotension, and resistant bradyarrhythmias. This cardiotoxicity risk is associated with metformin hydrochloride, the active ingredient in GLUMETZA.

2. Risk factors for metformin-associated lactic acidosis include renal impairment, concomitant use of certain drugs, age 65 years old, radiological studies with contrast, surgery and other procedures, hypoxic states, excessive alcohol intake, and hepatic impairment. These factors can contribute to the cardiotoxicity risk associated with metformin use.

3. The drug label advises healthcare providers to promptly discontinue GLUMETZA and institute general supportive measures in a hospital setting if lactic acidosis is suspected. This immediate action is recommended to address the cardiotoxic effects of metformin-associated lactic acidosis.

4. Patients with hepatic impairment have developed cases of metformin-associated lactic acidosis, which may be due to impaired lactate clearance resulting in higher lactate blood levels. Therefore, the drug label recommends avoiding the use of GLUMETZA in patients with clinical or laboratory evidence of hepatic disease, highlighting the potential cardiotoxicity risks in this population.

5. The drug label also mentions that alcohol can potentiate the effect of metformin on lactate metabolism, increasing the risk of metformin-associated lactic acidosis. Patients are warned against excessive alcohol intake while receiving GLUMETZA to mitigate the cardiotoxic effects of alcohol combined with metformin.

Overall, the drug label for GLUMETZA emphasizes the importance of monitoring for and managing cardiotoxicity risks associated with metformin use, particularly in patients with renal impairment, hepatic impairment, and other risk factors for lactic acidosis. Prompt recognition and appropriate management of cardiotoxic reactions are crucial in ensuring patient safety during GLUMETZA therapy.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",fb832474-88d9-4e29-95cd-fbc446944cc4,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fb832474-88d9-4e29-95cd-fbc446944cc4&type=display
672,METHADONE HYDROCHLORIDE,"1. The drug METHADOSE (methadone hydrochloride) carries a warning for life-threatening QT prolongation, which has occurred during treatment with methadone. This indicates that the drug itself is associated with the risk of QT prolongation.

2. Accidental ingestion of METHADOSE can result in fatal overdose of methadone, especially in children. This highlights a potential risk of cardiotoxicity if overdose occurs, but it does not directly attribute cardiotoxicity to the drug itself.

3. Methadone has been associated with life-threatening respiratory depression, including fatal cases, during initiation and conversion of patients to methadone. This indicates that the drug itself can lead to respiratory depression, which can have cardiotoxic effects.

4. Methadone has a narrow therapeutic index, especially when combined with other drugs, which can increase the risk of respiratory depression and potentially cardiotoxic effects. This suggests that the drug itself can contribute to cardiotoxicity when interacting with other medications.

5. QT interval prolongation and serious arrhythmia (torsades de pointes) have occurred during treatment with methadone. This indicates that the drug itself is associated with the risk of QT prolongation and arrhythmias, which are cardiotoxic effects.

Overall, METHADOSE carries warnings and precautions regarding cardiotoxicity risks, particularly related to respiratory depression, QT prolongation, and potential fatal overdose, highlighting the importance of monitoring and proper administration to mitigate these risks.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",808a9d0b-720b-4034-a862-5122ff514608,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=808a9d0b-720b-4034-a862-5122ff514608&type=display
673,METHAMPHETAMINE HYDROCHLORIDE,"1. The drug label states that methamphetamine has a high potential for abuse, and misuse of methamphetamine may cause sudden death and serious cardiovascular adverse events. (The drug itself is associated with the risk of cardiotoxicity.)

2. The label mentions that sudden death has been reported in association with CNS stimulant treatment at usual doses in children and adolescents with structural cardiac abnormalities or other serious heart problems. (The drug itself is associated with the risk of sudden death in patients with pre-existing structural cardiac abnormalities.)

3. It is noted that adults taking stimulant drugs at usual doses for ADHD have reported sudden deaths, stroke, and myocardial infarction. (The drug itself is associated with the risk of sudden death, stroke, and myocardial infarction in adults.)

4. The label warns that stimulant medications can cause a modest increase in average blood pressure and heart rate, with caution advised in treating patients with pre-existing hypertension, heart failure, recent myocardial infarction, or ventricular arrhythmia. (The drug itself is associated with the risk of increased blood pressure and heart rate.)

5. It is recommended that patients being considered for treatment with stimulant medications should undergo a careful history and physical exam to assess for the presence of cardiac disease, with further cardiac evaluation if needed. (The drug itself is associated with the need for cardiac evaluation in patients being treated with stimulant medications.)

6. The label mentions that administration of stimulants may exacerbate symptoms of behavior disturbance and thought disorder in patients with pre-existing psychotic disorders. (The drug itself is associated with the risk of exacerbating symptoms in patients with pre-existing psychotic disorders.)

7. It is noted that particular care should be taken when using stimulants to treat ADHD in patients with comorbid bipolar disorder due to the concern for possible induction of a mixed/manic episode. (The drug itself is associated with the risk of inducing mixed/manic episodes in patients with comorbid bipolar disorder.)

8. The label warns that treatment emergent psychotic or manic symptoms can be caused by stimulants at usual doses in children and adolescents without a prior history of psychotic illness or mania. (The drug itself is associated with the risk of causing psychotic or manic symptoms in children and adolescents.)

9. The label mentions that aggressive behavior or hostility has been observed in children and adolescents with ADHD, although there is no systematic evidence that stimulants cause aggressive behavior or hostility. (The drug itself is associated with the risk of observing aggressive behavior or hostility in patients with ADHD.)

10. Long-term suppression of growth has been reported with the use of stimulants in children, with careful monitoring of weight and height recommended during treatment. (The drug itself is associated with the risk of long-term suppression of growth in children.)

11. The label notes that there is some clinical evidence that stimulants may lower the convulsive threshold in patients with a prior history of seizures. (The drug itself is associated with the risk of lowering the convulsive threshold in patients with a history of seizures.)

12. Stimulants used to treat ADHD are associated with peripheral vasculopathy, including Raynauds phenomenon, with careful observation for digital changes necessary during treatment. (The drug itself is associated with the risk of peripheral vasculopathy, including Raynauds phenomenon.)

13. The label warns about the potential for serotonin syndrome when amphetamines are used in combination with other drugs affecting the serotonergic neurotransmitter systems. (The drug itself is associated with the risk of serotonin syndrome when used in combination with certain other drugs.)

14. Difficulties with accommodation and blurring of vision have been reported with stimulant treatment. (The drug itself is associated with the risk of visual disturbances.)

In summary, the drug label for Desoxyn clearly outlines the cardiotoxicity risks and reactions associated with the use of methamphetamine hydrochloride tablets, emphasizing the importance of monitoring cardiovascular status and potential adverse events in patients receiving this medication.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",81bfc45f-c345-47d0-9fc9-77abe553b541,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=81bfc45f-c345-47d0-9fc9-77abe553b541&type=display
674,METHAZOLAMIDE,"1. The drug label does not mention any specific cardiotoxicity risks associated with methazolamide.
2. The label does not indicate that methazolamide is directly associated with cardiotoxicity reactions.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",504b695a-ac9e-4c71-8755-d31f1958a71c,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=504b695a-ac9e-4c71-8755-d31f1958a71c&type=display
675,METHENAMINE HIPPURATE,1. The drug label does not mention any cardiotoxicity risks or cardiotoxicity reactions associated with Hiprex tablets.,No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",c8ddaa11-5753-46eb-8bd4-8f1d874a3ec4,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=c8ddaa11-5753-46eb-8bd4-8f1d874a3ec4&type=display
676,METHIMAZOLE,"1. The drug label warns that methimazole can cause fetal harm when administered in the first trimester of pregnancy, potentially leading to congenital malformations such as aplasia cutis, craniofacial malformations, and gastrointestinal malformations. The drug itself is associated with the risk of congenital malformations in infants born to mothers who received methimazole tablets in the first trimester of pregnancy.

2. The label also mentions that methimazole may cause liver toxicity, including hepatotoxicity and acute liver failure, although the risk appears to be less compared to propylthiouracil, especially in the pediatric population. Symptoms suggestive of hepatic dysfunction should prompt evaluation of liver function, and drug treatment should be discontinued promptly in the event of clinically significant evidence of liver abnormality. The drug itself is associated with the risk of hepatotoxicity, including acute liver failure.

3. Additionally, the label highlights that methimazole can cause hypothyroidism, necessitating routine monitoring of thyroid-stimulating hormone (TSH) and free thyroxine (T4) levels with adjustments in dosing to maintain a euthyroid state. The drug itself is associated with the risk of hypothyroidism, which can have cardiotoxic effects if not managed appropriately.

4. Cases of vasculitis resulting in severe complications have been reported in patients receiving methimazole therapy, including leukocytoclastic cutaneous vasculitis, acute kidney injury, glomerulonephritis, alveolar/pulmonary hemorrhage, central nervous system (CNS) vasculitis, and neuropathy. Most cases were associated with anti-neutrophilic cytoplasmic antibodies (ANCA)-positive vasculitis. The drug itself is associated with the risk of vasculitis, which can lead to severe complications, including cardiotoxic effects.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",ca252851-32f2-4eb9-b9f5-82029f0e8c20,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=ca252851-32f2-4eb9-b9f5-82029f0e8c20&type=display
677,METHOCARBAMOL,"1. The drug label mentions that methocarbamol, the active ingredient in ROBAXIN Injectable, is a central nervous system depressant with sedative properties, but it has no direct action on the contractile mechanism of striated muscle, the motor end plate, or the nerve fiber. This indicates that the drug itself is not associated with cardiotoxicity risk.

2. The label does not specifically mention any direct cardiotoxicity risks associated with methocarbamol. However, it does caution that patients receiving ROBAXIN Injectable should be warned about combined effects with alcohol and other CNS depressants, which could potentially lead to cardiovascular depression. This suggests that the drug may have indirect cardiotoxic effects when combined with other substances.

3. The label lists hypotension as a potential cardiovascular system adverse reaction associated with methocarbamol administration. This indicates that the drug itself may lead to hypotension, a form of cardiotoxicity, as an adverse reaction.

4. The label also mentions syncope as an adverse reaction that has been reported with methocarbamol administration. Syncope, or fainting, can be related to cardiovascular issues, indicating a potential cardiotoxic effect of the drug.

5. Thrombophlebitis is another cardiovascular system adverse reaction listed in the drug label. Thrombophlebitis is the inflammation of a vein due to a blood clot, which can have implications for cardiovascular health, suggesting a cardiotoxic risk associated with methocarbamol use.

In summary, while the drug label does not explicitly state that methocarbamol is directly cardiotoxic, it does mention potential adverse reactions such as hypotension, syncope, and thrombophlebitis that suggest a risk of cardiotoxicity with the use of ROBAXIN Injectable. Additionally, caution is advised regarding combined effects with other CNS depressants, which could further contribute to cardiotoxic effects.",Less,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",a418c43a-afe8-4a19-a57a-95c8dbe3d3d8,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a418c43a-afe8-4a19-a57a-95c8dbe3d3d8&type=display
678,METHOHEXITAL SODIUM,"1. The drug label warns that BREVITAL should only be used in settings with continuous monitoring of respiratory and cardiac function, with immediate availability of resuscitative drugs and equipment for ventilation and intubation. The drug itself is not directly associated with cardiotoxicity but requires careful monitoring due to its potential effects on respiratory and cardiac function.

2. The label mentions that circulatory depression, hypotension, tachycardia, peripheral vascular collapse, and convulsions in association with cardiorespiratory arrest are potential adverse reactions associated with BREVITAL. These cardiotoxicity reactions are listed as extensions of the pharmacologic effects of the drug.

3. Additionally, respiratory depression, apnea, laryngospasm, bronchospasm, and dyspnea are noted as potential respiratory and cardiotoxicity reactions to BREVITAL. These reactions are considered as part of the drug's pharmacologic effects and should be monitored during and after administration.

4. The label also highlights the risk of cardiorespiratory arrest, which may occur as an adverse reaction to BREVITAL overdose. This reaction is a potential consequence of the drug's central nervous system depression and respiratory effects, leading to circulatory collapse and cardiac arrest.

5. Furthermore, the drug label advises that patients should be observed carefully during and after the use of BREVITAL due to the possibility of cardiorespiratory arrest. This emphasizes the importance of vigilant monitoring for potential cardiotoxicity events associated with the drug's pharmacologic actions.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",eccd8340-ead3-4363-8902-0c19d33aa2ac,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=eccd8340-ead3-4363-8902-0c19d33aa2ac&type=display
679,METHOTREXATE SODIUM,"1. Methotrexate Tablets are associated with thromboembolic events, including arterial thrombosis, cerebral thrombosis, deep vein thrombosis, retinal vein thrombosis, thrombophlebitis, and pulmonary embolus, as reported in postmarketing experience.

2. Methotrexate Tablets have been linked to pericarditis and pericardial effusion, as reported in postmarketing experience.

3. Methotrexate Tablets are associated with hypotension and sudden death, as reported in postmarketing experience.

4. Methotrexate Tablets have been linked to cardiovascular events such as acute hepatitis, decreased serum albumin, fibrosis, and cirrhosis, as reported in postmarketing experience.

5. Methotrexate Tablets are associated with an increased risk of thromboembolic events, pericarditis, pericardial effusion, hypotension, and sudden death, as reported in postmarketing experience.

6. Methotrexate Tablets have been linked to cardiovascular events such as acute hepatitis, decreased serum albumin, fibrosis, and cirrhosis, as reported in postmarketing experience.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",d71b1856-99d8-4a9e-9189-f87b6675f80a,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=d71b1856-99d8-4a9e-9189-f87b6675f80a&type=display
680,METHSCOPOLAMINE BROMIDE,"1. The drug Pamine containing methscopolamine bromide, an anticholinergic, may result in tachycardia as a side effect. (The drug itself is associated with the risk of tachycardia.)

2. In the event of overdosage with Pamine tablets, symptoms may progress to circulatory changes such as flushing, fall in blood pressure, circulatory failure, and respiratory failure. (The drug itself is associated with the risk of circulatory changes and respiratory failure in cases of overdosage.)

3. The drug label mentions that tachycardia and palpitation are potential cardiovascular adverse reactions observed with the use of methscopolamine bromide. (The drug itself is associated with the risk of tachycardia and palpitation as cardiovascular adverse reactions.)

4. The drug label also notes that methscopolamine bromide may produce drowsiness or blurred vision, cautioning patients about activities requiring mental alertness such as operating a motor vehicle or machinery. (The drug itself is associated with the risk of drowsiness and blurred vision, which can impact activities requiring mental alertness.)

5. The drug label further mentions that with overdosage, a curare-like action may occur, leading to neuromuscular blockade, muscular weakness, and possible paralysis. (The drug itself is associated with the risk of neuromuscular blockade, muscular weakness, and paralysis in cases of overdosage.)",Most,No,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",2981e734-2a20-4b45-8521-8c13ff2b6578,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=2981e734-2a20-4b45-8521-8c13ff2b6578&type=display
681,METHSUXIMIDE,"1. The drug label mentions that Celontin (methsuximide) has been reported to produce morphological and functional changes in animal liver, but it does not directly associate the drug with cardiotoxicity risks. It advises caution when administering the drug to patients with known liver or renal disease due to these reported effects on the liver.

2. The drug label does not mention any direct association between Celontin and systemic lupus erythematosus, a condition that can affect the heart. However, it states that cases of systemic lupus erythematosus have been reported with the use of succinimides, the class of drugs to which Celontin belongs. Physicians are advised to be alert to this possibility.

3. The drug label does not directly link Celontin to suicidal behavior or ideation, which can have implications for cardiovascular health. It states that antiepileptic drugs, including Celontin, increase the risk of suicidal thoughts or behavior in patients taking these drugs for any indication. Patients should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and any unusual changes in mood or behavior.

4. The drug label does not mention any direct association between Celontin and cardiovascular effects such as hyperemia. It lists hyperemia as a cardiovascular side effect that has been reported with the administration of methsuximide, the active ingredient in Celontin. 

Overall, while the drug label does not directly attribute cardiotoxicity risks or reactions to Celontin, it does mention potential effects on the liver and systemic lupus erythematosus associated with the class of drugs to which Celontin belongs. It also highlights the importance of monitoring patients for suicidal behavior, which can have implications for overall health, including cardiovascular health.",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",64a6ee88-c6b1-4e13-8208-b6772ef65a74,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=64a6ee88-c6b1-4e13-8208-b6772ef65a74&type=display
682,METHYLDOPA,"1. The drug label mentions that methyldopa has no direct effect on cardiac function and usually does not reduce glomerular filtration rate, renal blood flow, or filtration fraction. Cardiac output is usually maintained without cardiac acceleration, and in some patients, the heart rate is slowed. (The drug itself is not associated with cardiotoxicity risk.)

2. Rare occurrences of hemolytic anemia or liver disorders could lead to potentially fatal complications with methyldopa therapy. A positive Coombs test, hemolytic anemia, and liver disorders may occur with methyldopa therapy. (The drug itself is associated with a risk of hemolytic anemia and liver disorders, which could lead to potentially fatal complications.)

3. Methyldopa may cause a positive Coombs test, which may be associated with hemolytic anemia. If Coombs-positive hemolytic anemia occurs, the cause may be methyldopa, and the drug should be discontinued. (The drug itself is associated with the risk of causing a positive Coombs test and subsequent hemolytic anemia.)

4. Occasionally, fever, eosinophilia, or abnormalities in liver function tests may occur within the first 3 weeks of methyldopa therapy. Jaundice, with or without fever, may occur within the first 2 to 3 months of therapy. Rarely, fatal hepatic necrosis has been reported after the use of methyldopa. (The drug itself is associated with the risk of liver disorders, including hepatitis, jaundice, and abnormal liver function tests, which could lead to potentially fatal complications.)

5. Methyldopa may rarely cause a reversible reduction of the white blood cell count with a primary effect on the granulocytes. Rare cases of granulocytopenia and reversible thrombocytopenia have been reported. (The drug itself is associated with the risk of hematologic adverse reactions, including granulocytopenia and thrombocytopenia.)

6. Methyldopa may cause sedation, headache, asthenia, or weakness as early and transient symptoms. Significant adverse effects due to methyldopa have been infrequent, and the agent is usually well tolerated. (The drug itself is not associated with significant cardiotoxicity risks, and adverse effects are generally infrequent and well tolerated.)",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",e1114a58-9ab5-486e-85ed-360365b06396,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=e1114a58-9ab5-486e-85ed-360365b06396&type=display
683,METHYLERGONOVINE MALEATE,"1. The drug label mentions that Methergine (methylergonovine maleate) should not be administered intravenously routinely due to the possibility of inducing sudden hypertensive and cerebrovascular accidents. If intravenous administration is necessary, it should be given slowly over a period of no less than 60 seconds with careful monitoring of blood pressure. Intra-arterial or periarterial injection should be strictly avoided. (The drug itself is associated with the risk of inducing sudden hypertensive and cerebrovascular accidents.)

2. The label also states that the most common adverse reaction associated with Methergine is hypertension, which has been reported in several cases along with seizures and/or headaches. Hypotension has also been reported as an adverse reaction. (The drug itself is associated with the risk of hypertension and hypotension as adverse reactions.)

3. Rarely observed reactions linked to Methergine include acute myocardial infarction, transient chest pains, arterial spasm (coronary and peripheral), bradycardia, tachycardia, dyspnea, and other cardiovascular symptoms. (The drug itself is associated with the risk of various cardiovascular reactions as rare adverse events.)

4. The label mentions that there have been rare isolated reports of anaphylaxis, without a proven causal relationship to the drug product. (The drug itself is not definitively associated with anaphylaxis, but rare reports have been noted.)

5. In cases of acute overdose with Methergine, symptoms may include a rise in blood pressure, followed by hypotension, respiratory depression, and other cardiovascular effects. (The drug itself is associated with the risk of cardiovascular symptoms in cases of acute overdose.)",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",b1552d48-86f5-4184-810a-001e57e96c02,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=b1552d48-86f5-4184-810a-001e57e96c02&type=display
684,METHYLNALTREXONE BROMIDE,"1. **Gastrointestinal Perforation Risk**: The drug label mentions cases of gastrointestinal perforation reported in adult patients with opioid-induced constipation (OIC) and advanced illness who used RELISTOR. The drug is associated with an increased risk of gastrointestinal perforation, especially in patients with conditions that may weaken the gastrointestinal tract wall.

2. **Cardiac Events**: The drug label reports several cardiac events observed during a clinical trial, including myocardial infarctions, a stroke, cardiac arrest, and sudden death. However, the label does not directly attribute these events to RELISTOR, stating that it is not possible to establish a clear relationship between these events and the drug.

3. **Orthostatic Hypotension**: In cases of overdose, orthostatic hypotension was noted in healthy subjects receiving RELISTOR intravenously. The label advises monitoring for signs or symptoms of orthostatic hypotension and initiating appropriate treatment. The drug itself is associated with the risk of orthostatic hypotension in overdose situations.",Less,No,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",c488fb7c-0a5b-487c-b452-996809d1cb99,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=c488fb7c-0a5b-487c-b452-996809d1cb99&type=display
685,METHYLPHENIDATE,"1. **Risks to Patients with Serious Cardiac Disease**: DAYTRANA should be avoided in patients with known structural cardiac abnormalities, cardiomyopathy, serious cardiac arrhythmias, coronary artery disease, or other serious cardiac disease. (The drug itself is associated with the risk of exacerbating serious cardiac conditions.)

2. **Increased Blood Pressure and Heart Rate**: CNS stimulants like DAYTRANA may cause an increase in blood pressure and heart rate. Monitoring for hypertension and tachycardia is recommended. (The drug itself is associated with the risk of increasing blood pressure and heart rate.)

3. **Psychiatric Adverse Reactions**: CNS stimulants, including DAYTRANA, may exacerbate symptoms of behavior disturbance and thought disorder in patients with pre-existing psychotic disorders. They may also induce manic episodes in patients with bipolar disease. (The drug itself is associated with the risk of exacerbating psychiatric symptoms.)

4. **Seizures**: There is clinical evidence that stimulants like DAYTRANA may lower the convulsive threshold in patients with a history of seizures. The drug should be discontinued in the presence of seizures. (The drug itself is associated with the risk of lowering the convulsive threshold.)

5. **Peripheral Vasculopathy, including Raynauds phenomenon**: Stimulant medications, including DAYTRANA, are associated with peripheral vasculopathy, including Raynauds phenomenon. Careful observation and evaluation are necessary for patients who develop signs or symptoms of peripheral vasculopathy. (The drug itself is associated with the risk of peripheral vasculopathy.)

6. **Acute Angle Closure Glaucoma**: Reports of angle closure glaucoma have been associated with methylphenidate treatment. Patients at risk should be evaluated by an ophthalmologist. (The drug itself is associated with the risk of acute angle closure glaucoma.)

7. **Increased Intraocular Pressure and Glaucoma**: Reports of elevated intraocular pressure have been associated with methylphenidate treatment. Prescribe DAYTRANA to patients with open-angle glaucoma or increased IOP only if the benefit outweighs the risk. (The drug itself is associated with the risk of increased intraocular pressure and glaucoma.)",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",2c312c31-3198-4775-91ab-294e0b4b9e7f,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=2c312c31-3198-4775-91ab-294e0b4b9e7f&type=display
686,METHYLPHENIDATE HYDROCHLORIDE,"1. **Risks to Patients with Serious Cardiac Disease**: APTENSIO XR is associated with an increased risk of sudden death in patients with structural cardiac abnormalities or serious cardiac disease. The drug itself is linked to this cardiotoxicity risk.

2. **Increased Blood Pressure and Heart Rate**: APTENSIO XR can cause an increase in blood pressure and heart rate, with some patients experiencing larger increases. The drug itself is associated with this cardiotoxicity risk.

3. **Psychiatric Adverse Reactions**: CNS stimulants like APTENSIO XR may exacerbate symptoms of behavior disturbance and thought disorder in patients with pre-existing psychotic disorders, potentially leading to cardiac complications. The drug itself is linked to this cardiotoxicity risk.

4. **Acute Angle Closure Glaucoma**: While not directly related to cardiac issues, angle closure glaucoma has been reported with methylphenidate treatment, which may indirectly impact cardiovascular health due to the potential systemic effects of this condition.

5. **Increased Intraocular Pressure and Glaucoma**: APTENSIO XR has been associated with an elevation of intraocular pressure, which can indirectly affect cardiovascular health, especially in patients with a history of cardiovascular issues.

6. **Motor and Verbal Tics, and Worsening of Tourette's Syndrome**: APTENSIO XR has been linked to the onset or exacerbation of motor and verbal tics, which may indirectly impact cardiovascular health in patients with underlying cardiac conditions.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",5adedc01-ebf0-11e3-ac10-0800200c9a66,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=5adedc01-ebf0-11e3-ac10-0800200c9a66&type=display
687,METHYLPREDNISOLONE,"1. The drug label mentions that fluid and electrolyte disturbances, such as sodium retention, congestive heart failure in susceptible patients, hypertension, and fluid retention, are potential adverse reactions associated with the use of Medrol tablets. The drug itself is not directly associated with causing cardiotoxicity risk, but these disturbances can lead to cardiovascular issues in susceptible individuals.

2. Additionally, musculoskeletal effects like muscle weakness, osteoporosis, and tendon rupture, as well as gastrointestinal issues such as peptic ulcer with possible perforation and hemorrhage, are listed as potential adverse reactions of Medrol tablets. While the drug itself is not directly linked to causing cardiotoxicity risk, these musculoskeletal and gastrointestinal complications can indirectly impact cardiovascular health.

3. The drug label also mentions dermatologic reactions, neurological effects like increased intracranial pressure, and endocrine manifestations such as the development of a Cushingoid state and suppression of growth in children as potential adverse reactions to Medrol tablets. These reactions are not directly associated with causing cardiotoxicity risk, but they can contribute to overall health issues that may impact the cardiovascular system.",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",39d5270b-d957-4821-93d6-501b7b9f02d4,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=39d5270b-d957-4821-93d6-501b7b9f02d4&type=display
688,METHYLPREDNISOLONE SODIUM SUCCINATE,"1. The drug label warns that corticosteroids, including SOLU-MEDROL, can cause elevation of blood pressure, salt and water retention, and increased excretion of potassium, which are cardiotoxic effects. (The drug itself is associated with cardiotoxicity risks.)

2. The label mentions that there is an enhanced effect due to decreased metabolism of corticosteroids in patients with cirrhosis, which can lead to cardiotoxic effects. (The drug itself is associated with cardiotoxicity risks.)

3. It is cautioned that corticosteroids may increase blood glucose concentrations, requiring dosage adjustments of antidiabetic agents, which can impact cardiovascular health. (The drug itself is associated with cardiotoxicity risks.)

4. The label advises that corticosteroids may exacerbate systemic fungal infections, which can be harmful to patients with existing cardiovascular conditions. (The drug itself is associated with cardiotoxicity risks.)

5. There is a warning about the potential for serious liver injury, including acute liver failure, induced by high doses of intravenous methylprednisolone, which can have implications for cardiac health. (The drug itself is associated with cardiotoxicity risks.)

6. The label mentions that corticosteroids may increase the risk of arrhythmias due to hypokalemia in patients on digitalis glycosides, which can affect cardiac function. (The drug itself is associated with cardiotoxicity risks.)

7. It is noted that corticosteroids may cause posterior subcapsular cataracts and glaucoma, which can impact optic nerves and potentially affect cardiovascular health. (The drug itself is associated with cardiotoxicity risks.)

8. The label warns that corticosteroids should be used cautiously in patients with ocular herpes simplex to prevent corneal perforation, which can have implications for cardiovascular health. (The drug itself is associated with cardiotoxicity risks.)

9. There is a mention of an increased incidence of scleroderma renal crisis observed with corticosteroids, including methylprednisolone, which can lead to renal and cardiovascular complications. (The drug itself is associated with cardiotoxicity risks.)

10. The label advises that corticosteroids should be used with caution in patients with congestive heart failure, hypertension, or renal insufficiency due to the potential for sodium retention, edema, and potassium loss, which are cardiotoxic effects. (The drug itself is associated with cardiotoxicity risks.)",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",7271310c-7764-4812-aa30-a5e90987c7a9,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7271310c-7764-4812-aa30-a5e90987c7a9&type=display
689,METHYLTESTOSTERONE,"1. The drug label warns that in patients with breast cancer, androgen therapy may cause hypercalcemia by stimulating osteolysis, which can lead to cardiotoxicity. The drug itself is associated with the risk of hypercalcemia-induced cardiotoxicity.

2. Prolonged use of high doses of androgens has been linked to the development of peliosis hepatis and hepatic neoplasms, including hepatocellular carcinoma, which can have cardiotoxic effects. The drug itself is associated with the risk of hepatic neoplasms-induced cardiotoxicity.

3. Cholestatic hepatitis and jaundice can occur with 17-alpha-alkylandrogens at relatively low doses, which may lead to liver function abnormalities and potential cardiotoxicity. The drug itself is associated with the risk of cholestatic hepatitis-induced cardiotoxicity.

4. Geriatric patients treated with androgens may be at an increased risk for the development of prostatic hypertrophy and prostatic carcinoma, which can have cardiotoxic implications. The drug itself is associated with the risk of prostatic hypertrophy and carcinoma-induced cardiotoxicity.

5. Postmarketing reports have indicated venous thromboembolic events, including deep vein thrombosis and pulmonary embolism, in patients using testosterone products like methyltestosterone, which can lead to serious cardiovascular complications. The drug itself is associated with the risk of venous thromboembolic events-induced cardiotoxicity.

6. Long-term clinical safety trials have not been conducted to assess the cardiovascular outcomes of testosterone replacement therapy in men, and some studies have reported an increased risk of major adverse cardiovascular events with the use of testosterone compared to non-use. The drug itself is associated with the risk of major adverse cardiovascular events-induced cardiotoxicity.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",c09c4cde-9f6c-4c4f-9d96-18beb5377564,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=c09c4cde-9f6c-4c4f-9d96-18beb5377564&type=display
690,METOCLOPRAMIDE HYDROCHLORIDE,"1. The drug label mentions that metoclopramide may elevate blood pressure, and intravenously administered metoclopramide was shown to release catecholamines, indicating a potential risk of hypertension associated with the drug itself.
2. There are clinical reports of hypertensive crises in patients with undiagnosed pheochromocytoma, and metoclopramide is contraindicated in patients with pheochromocytoma or other catecholamine-releasing paragangliomas, suggesting a direct association between the drug and hypertensive crises.
3. Metoclopramide produces a transient increase in plasma aldosterone, which may lead to fluid retention and volume overload, indicating a potential risk of fluid retention associated with the drug itself.
4. The drug label also mentions acute congestive heart failure as a cardiovascular adverse reaction, suggesting a potential cardiotoxic effect of metoclopramide.
5. Additionally, metoclopramide has been associated with possible atrioventricular block, hypotension, hypertension, supraventricular tachycardia, bradycardia, and fluid retention, indicating various cardiotoxicity risks associated with the drug itself.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",95269b1f-779c-4ca0-9f86-e74e677f9900,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=95269b1f-779c-4ca0-9f86-e74e677f9900&type=display
691,METOLAZONE,"1. The drug Metolazone is a diuretic/saluretic/antihypertensive drug of the quinazoline class, with properties generally similar to thiazide diuretics. The label mentions that the actions of Metolazone may result in electrolyte imbalances, including hypokalemia, which can lead to cardiac dysrhythmias. (The drug itself is associated with the risk of electrolyte imbalances that can lead to cardiac dysrhythmias.)

2. The label warns about the potential for hypokalemia to occur with Metolazone, which can cause weakness, cramps, and cardiac dysrhythmias. It advises monitoring serum potassium levels and taking appropriate measures such as dose reduction or potassium supplementation when indicated. (The drug itself is associated with the risk of hypokalemia, which can lead to cardiac dysrhythmias.)

3. Metolazone should not be given concomitantly with lithium due to the risk of lithium toxicity. The label advises reading the prescribing information for lithium preparations before using them together with Metolazone. (The drug itself is associated with the risk of lithium toxicity when used concomitantly.)

4. The label mentions that when Metolazone is administered concurrently with furosemide, unusually large or prolonged losses of fluids and electrolytes may occur, which can lead to hypovolemia, tachycardia, and orthostatic hypotension. (The drug itself is associated with the risk of fluid and electrolyte imbalances when used concomitantly with furosemide.)

5. Metolazone tablets should be used with caution when combined with other antihypertensive drugs to avoid excessive reduction of blood pressure, especially during initial therapy. (The drug itself is associated with the risk of excessive reduction of blood pressure when used concomitantly with other antihypertensive drugs.)

6. Cross-allergy may occur when Metolazone is given to patients known to be allergic to sulfonamide-derived drugs, thiazides, or quinethazone. (The drug itself is associated with the risk of cross-allergy in patients with known allergies to sulfonamide-derived drugs, thiazides, or quinethazone.)

7. Sensitivity reactions, such as angioedema and bronchospasm, may occur with or without a history of allergy or bronchial asthma, and may occur with the first dose of Metolazone tablets. (The drug itself is associated with the risk of sensitivity reactions, including angioedema and bronchospasm.)

8. The label advises against interchanging different formulations of Metolazone, emphasizing the importance of using the correct product due to differences in bioavailability and therapeutic equivalence. (The drug itself is not directly associated with cardiotoxicity risks in this statement, but it highlights the importance of using the correct formulation to avoid potential adverse effects.)

Overall, the drug label for Metolazone highlights several cardiotoxicity risks and reactions associated with the drug, including electrolyte imbalances, hypokalemia, lithium toxicity, fluid and electrolyte imbalances when used concomitantly with furosemide, excessive reduction of blood pressure when combined with other antihypertensive drugs, cross-allergy risks, and sensitivity reactions.",Less,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",6856a354-e84f-10cc-e053-2a91aa0a5e70,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=6856a354-e84f-10cc-e053-2a91aa0a5e70&type=display
692,METOPROLOL SUCCINATE,"1. **Warnings and Precautions**: Abrupt cessation of therapy with certain beta-blocking agents, including TOPROL-XL, may lead to exacerbations of angina pectoris and myocardial infarction. It is advised to gradually reduce the dosage over a period of 1 to 2 weeks and monitor the patient to prevent these adverse events.

2. **Warnings and Precautions**: Worsening cardiac failure may occur during the up-titration of TOPROL-XL. If symptoms of worsening heart failure occur, diuretics should be increased, and clinical stability should be restored before advancing the dose of TOPROL-XL. This indicates that TOPROL-XL itself may lead to worsening heart failure.

3. **Warnings and Precautions**: Bradycardia, including sinus pause, heart block, and cardiac arrest, have occurred with the use of TOPROL-XL. Patients with certain pre-existing conditions or on concomitant drugs that cause bradycardia may be at increased risk. Monitoring heart rate is recommended, and if severe bradycardia develops, reducing or stopping TOPROL-XL is advised. This suggests that TOPROL-XL itself can lead to bradycardia.

4. **Warnings and Precautions**: If TOPROL-XL is used in the setting of pheochromocytoma, it should be given in combination with an alpha-blocker. Administration of beta-blockers alone in this setting has been associated with a paradoxical increase in blood pressure due to the attenuation of beta-mediated vasodilatation in skeletal muscle. This indicates that TOPROL-XL can potentially lead to adverse effects in patients with pheochromocytoma.

5. **Warnings and Precautions**: Avoid initiation of a high-dose regimen of extended-release metoprolol in patients undergoing non-cardiac surgery, as it has been associated with bradycardia, hypotension, stroke, and death in patients with cardiovascular risk factors. This suggests that TOPROL-XL itself may pose risks in patients undergoing non-cardiac surgery.

6. **Warnings and Precautions**: Beta-blockers, including TOPROL-XL, may prevent early warning signs of hypoglycemia, potentially increasing the risk for severe or prolonged hypoglycemia, especially in patients with diabetes mellitus or those who are fasting. This indicates that TOPROL-XL may mask early signs of hypoglycemia.

7. **Warnings and Precautions**: Beta-blockers can precipitate or aggravate symptoms of arterial insufficiency in patients with peripheral vascular disease. This suggests that TOPROL-XL itself may worsen symptoms of arterial insufficiency.",Less,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",991fe00b-498b-400e-9e5b-921cb07d9b2c,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=991fe00b-498b-400e-9e5b-921cb07d9b2c&type=display
693,METRONIDAZOLE,1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with METROGEL (metronidazole) topical gel itself.,No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",ab3a8a2d-714a-4beb-af8a-99bc3ac3ebbe,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=ab3a8a2d-714a-4beb-af8a-99bc3ac3ebbe&type=display
694,METYRAPONE,"1. The drug label mentions that Metopirone may induce acute adrenal insufficiency, which can lead to hypotension, a cardiovascular adverse reaction. The drug itself is not directly associated with cardiotoxicity but may indirectly contribute to cardiovascular symptoms through its effects on adrenal function.

2. In cases of overdosage with Metopirone, signs and symptoms may include cardiac arrhythmias, hypotension, and dehydration, indicating potential cardiotoxic effects. The drug itself is implicated in causing these cardiotoxic reactions in cases of overdose.

3. The label advises monitoring blood pressure and fluid balance in patients experiencing overdosage with Metopirone, further emphasizing the potential cardiotoxic effects of the drug in such situations. The drug is directly linked to the cardiotoxic manifestations observed in cases of overdose.",Less,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",3a27d0ef-83a7-4e1c-9430-46a3326ee8d8,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=3a27d0ef-83a7-4e1c-9430-46a3326ee8d8&type=display
695,MEXILETINE HYDROCHLORIDE,"1. The drug Mexiletine hydrochloride is associated with cardiotoxicity risks, as mentioned in the Warnings section of the label. It states that the use of Mexiletine should be reserved for patients with life-threatening ventricular arrhythmias due to known proarrhythmic properties of Mexiletine and lack of evidence of improved survival in patients without life-threatening arrhythmias.

2. The label also warns about the potential risk of acute liver injury associated with Mexiletine use, as abnormal liver function tests have been reported post-marketing, particularly in patients with congestive heart failure or ischemia. The relationship between Mexiletine and liver injury has not been fully established.

3. Additionally, the label mentions the possibility of drug reactions with eosinophilia and systemic symptoms (DRESS) in patients taking Mexiletine, which can present with various organ involvement, including the liver. Mexiletine should be discontinued if DRESS is suspected.

4. The label further discusses the potential for worsening of arrhythmias with Mexiletine use, particularly in patients with life-threatening arrhythmias like sustained ventricular tachycardia. Mexiletine has been associated with exacerbation of arrhythmias in a small percentage of patients, although the rate is not greater than that of other antiarrhythmic agents.

5. Mexiletine may also cause mild depression of myocardial function, similar to lidocaine, particularly following intravenous therapy in patients with cardiac disease. This effect is mentioned as a potential cardiotoxicity reaction associated with Mexiletine use.

6. The label highlights the importance of monitoring patients with hepatic impairment closely while receiving Mexiletine, as liver disease can prolong the elimination half-life of Mexiletine. Mexiletine is metabolized in the liver, and hepatic dysfunction can impact the clearance of Mexiletine and its metabolites, potentially leading to cardiotoxic effects.

7. Mexiletine has been associated with elevations in liver enzymes, although these elevations are often asymptomatic and transient, and do not always require discontinuation of therapy. However, marked elevations in liver enzymes have been observed in patients with severe cardiac disease, indicating a potential cardiotoxic effect of Mexiletine.

8. The label also mentions the possibility of blood dyscrasias, including leukopenia, agranulocytosis, and thrombocytopenia, associated with Mexiletine use. While these events were rare in controlled trials, they occurred in a small percentage of patients in the compassionate use program, indicating a potential cardiotoxic reaction to Mexiletine.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",0ff45dbf-b555-4f55-a286-98bfaea9ea29,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=0ff45dbf-b555-4f55-a286-98bfaea9ea29&type=display
696,MICAFUNGIN SODIUM,"1. The drug MYCAMINE is associated with cardiac disorders, including atrial fibrillation, as reported in adult patients during clinical trials for the treatment of candidemia and other Candida infections. The drug MYCAMINE was not specifically stated to cause atrial fibrillation but was associated with this cardiac disorder.

2. In pediatric patients undergoing prophylaxis of Candida infections during hematopoietic stem cell transplantation, MYCAMINE was linked to tachycardia as a cardiac disorder. The drug MYCAMINE was not specifically stated to cause tachycardia but was associated with this cardiac disorder.",Less,Yes,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",a064c4a7-25ec-4a2c-afc2-703491a4a38b,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a064c4a7-25ec-4a2c-afc2-703491a4a38b&type=display
697,MIDAZOLAM HYDROCHLORIDE,"1. The drug label warns about serious cardiorespiratory adverse reactions that have occurred, sometimes resulting in death or permanent neurologic injury, after administration of midazolam. This indicates that midazolam itself is associated with the risk of cardiotoxicity reactions.

2. The label mentions that there have been reports of hypotensive episodes requiring treatment during or after diagnostic or surgical manipulations, particularly in patients with hemodynamic instability. This suggests that midazolam use may contribute to cardiotoxicity reactions in patients with certain conditions.

3. It is noted that patients with chronic obstructive pulmonary disease (COPD), patients aged 60 or older, and patients who have received concomitant narcotics or other central nervous system (CNS) depressants should be closely monitored for signs of cardiorespiratory depression. This implies that midazolam use may exacerbate cardiotoxicity risks in these specific patient populations.

4. The label emphasizes the importance of practitioners having the necessary skills to manage serious cardiorespiratory adverse reactions, including skills in airway management, when administering midazolam. This highlights the potential for midazolam to lead to cardiotoxicity reactions that require immediate intervention.

5. Additionally, the label mentions that practitioners should be cautious when administering midazolam to patients in shock or coma with depression of vital signs, as these conditions may increase the risk of hypoventilation, airway obstruction, or apnea. This indicates that midazolam use can pose cardiotoxicity risks in patients with certain critical conditions.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",cb2381bf-984a-48a8-95c0-3017c34cc170,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=cb2381bf-984a-48a8-95c0-3017c34cc170&type=display
698,MIDODRINE HYDROCHLORIDE,"1. The drug ProAmatine can cause marked elevation of supine blood pressure, which is a cardiotoxicity risk associated with the drug itself.
2. The most potentially serious adverse reaction associated with ProAmatine therapy is marked elevation of supine arterial blood pressure (supine hypertension), which is a cardiotoxicity risk caused by the drug.
3. The most frequent adverse reactions seen in controlled trials were supine and sitting hypertension, which are cardiotoxicity reactions associated with the drug.
4. The most potentially serious adverse reaction associated with ProAmatine therapy is supine hypertension, which is a cardiotoxicity risk caused by the drug.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",9e8874f0-ad2e-41ce-8a35-bed819615a5d,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=9e8874f0-ad2e-41ce-8a35-bed819615a5d&type=display
699,MIFEPRISTONE,"1. **QT Interval Prolongation**: The drug KORLYM, mifepristone, was associated with QT interval prolongation in a dose-related manner, potentially leading to cardiotoxicity. The label advises using the lowest effective dose to minimize this risk.

2. **Potential Effects of Hypercortisolemia**: KORLYM does not reduce serum cortisol levels, which may activate mineralocorticoid receptors in cardiac tissues. Caution is advised in patients with underlying heart conditions, including heart failure and coronary vascular disease, due to potential cardiotoxic effects of elevated cortisol levels.

3. **Use of Strong CYP3A Inhibitors**: Concomitant use of strong CYP3A inhibitors with KORLYM may increase mifepristone plasma levels, potentially leading to cardiotoxicity. The label recommends limiting the dose of KORLYM to 900 mg per day when used with strong CYP3A inhibitors to mitigate this risk.",Less,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",542f3fae-8bc8-4f00-9228-e4b66c9ad6a9,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=542f3fae-8bc8-4f00-9228-e4b66c9ad6a9&type=display
700,MIGALASTAT HYDROCHLORIDE,1. The drug label for GALAFOLD does not mention any specific cardiotoxicity risks or cardiotoxicity reactions associated with the use of this medication.,No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",66dbd928-0f1c-48b1-a832-54e4abd9f1db,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=66dbd928-0f1c-48b1-a832-54e4abd9f1db&type=display
701,MIGLITOL,1. The drug label does not mention any cardiotoxicity risks or cardiotoxicity reactions associated with miglitol tablets.,No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",f16ecb50-e54e-43e1-8789-eaf5bc94f332,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=f16ecb50-e54e-43e1-8789-eaf5bc94f332&type=display
702,MIGLUSTAT,"1. **Carcinogenesis Study Findings:** The drug OPFOLDA, containing miglustat, was associated with an increased risk of mucinous adenocarcinomas of the large intestine in male mice and interstitial cell adenomas of the testis in rats, indicating a potential cardiotoxicity risk.

2. **Animal Toxicology Study:** In a 52-week monkey toxicity study, histopathology findings in the central nervous system, including vascular mineralization and necrosis of white matter, were observed at high doses of miglustat, suggesting a potential cardiotoxicity risk.

3. **Animal Toxicology Study:** In a 4-week rat study, vacuolization of white matter was observed at certain doses of miglustat, indicating a potential cardiotoxicity risk.

4. **Animal Toxicology Study:** In a 4-week dog study, findings included tremor and absent corneal reflexes at certain doses of miglustat, suggesting a potential cardiotoxicity risk.

5. **Animal Toxicology Study:** In a 2-week rat study, ataxia and diminished reflexes were observed at high doses of miglustat, indicating a potential cardiotoxicity risk.

6. **Animal Toxicology Study:** In a 52-week rat study, cataracts were observed at certain doses of miglustat, suggesting a potential cardiotoxicity risk.

7. **Animal Toxicology Study:** Gastrointestinal necrosis, inflammation, and hemorrhage were observed in a 2-week dog study at certain doses of miglustat, indicating a potential cardiotoxicity risk.

8. **Animal Toxicology Study:** Similar gastrointestinal toxicity occurred in a 26-week rat study at high doses of miglustat, suggesting a potential cardiotoxicity risk.

9. **Animal Toxicology Study:** Gastrointestinal toxicity was observed in a 52-week monkey study at high doses of miglustat, indicating a potential cardiotoxicity risk.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",d7c38298-37db-5a80-e053-2995a90aee40,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=d7c38298-37db-5a80-e053-2995a90aee40&type=display
703,MILNACIPRAN HYDROCHLORIDE,"1. **Elevated Blood Pressure**: SAVELLA may increase blood pressure, with a higher proportion of patients experiencing hypertensive measurements compared to placebo. The drug itself is associated with an increased risk of elevated blood pressure, as demonstrated in clinical trials.

2. **Elevated Heart Rate**: SAVELLA treatment was associated with a mean increase in heart rate, with some patients experiencing a rise of 20 beats per minute compared to placebo. The drug itself is linked to an increased risk of elevated heart rate, as observed in clinical trials.

3. **Seizures**: While seizures have been reported infrequently in patients treated with SAVELLA for disorders other than fibromyalgia, they were not reported in fibromyalgia trials. The drug itself is not definitively associated with an increased risk of seizures, but caution is advised in patients with a history of seizure disorder.

4. **Hepatotoxicity**: Increases in liver enzymes, including ALT and AST, were observed in patients treated with SAVELLA, with some cases of severe liver injury reported in postmarketing experience. The drug itself is associated with an increased risk of hepatotoxicity, as evidenced by clinical trials and postmarketing reports. Discontinuation of SAVELLA is recommended if jaundice or liver dysfunction develops.",Less,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",16a4a314-f97e-4e91-95e9-576a3773d284,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=16a4a314-f97e-4e91-95e9-576a3773d284&type=display
704,MILRINONE LACTATE,"1. The drug label warns that milrinone lactate has been associated with an increased frequency of ventricular arrhythmias, including nonsustained ventricular tachycardia, both in patients receiving the drug in clinical trials and in the post-marketing experience. This indicates that the drug itself is associated with the risk of ventricular arrhythmias.

2. The label also mentions that long-term oral use of milrinone lactate has been linked to an increased risk of sudden death, further emphasizing the cardiotoxicity risk associated with the drug itself.

3. In clinical trials, milrinone lactate has been reported to cause ventricular arrhythmias in a subset of patients, including ventricular ectopic activity, nonsustained ventricular tachycardia, sustained ventricular tachycardia, and ventricular fibrillation. This indicates that the drug itself can lead to various types of ventricular arrhythmias.

4. The label notes that life-threatening arrhythmias associated with milrinone lactate have been infrequent and are often linked to underlying factors such as preexisting arrhythmias, metabolic abnormalities, abnormal digoxin levels, and catheter insertion. While these factors may contribute to the risk of arrhythmias, the drug itself is still implicated in causing or exacerbating these cardiac events.

5. Post-marketing experience with milrinone lactate has reported rare cases of ""torsades de pointes,"" a specific type of ventricular arrhythmia. This suggests that the drug itself may contribute to the development of this serious cardiac arrhythmia.

6. The label also mentions supraventricular arrhythmias as a potential adverse reaction associated with milrinone lactate use, further highlighting the drug's potential cardiotoxic effects.

7. Other cardiovascular adverse reactions linked to milrinone lactate include hypotension and angina/chest pain, indicating that the drug can have broader cardiovascular effects beyond arrhythmias.

In summary, the drug label provides multiple instances where milrinone lactate is associated with cardiotoxicity risks and reactions, particularly in relation to ventricular arrhythmias and other cardiovascular adverse events.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",0fdaee3c-2144-4ca7-9868-54d251f468c0,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=0fdaee3c-2144-4ca7-9868-54d251f468c0&type=display
705,MILTEFOSINE,"1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with IMPAVIDO (miltefosine). 

2. There is no information provided in the drug label regarding cardiotoxicity risks or cardiotoxic reactions related to the use of IMPAVIDO. 

3. Cardiotoxicity is not listed as a known risk or adverse reaction associated with the use of IMPAVIDO (miltefosine) as per the drug label. 

Overall, based on the information provided in the drug label, there are no mentions of cardiotoxicity risks or cardiotoxic reactions linked to the use of IMPAVIDO.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",bcb387ac-2e90-4f5e-94b2-d3635190678e,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=bcb387ac-2e90-4f5e-94b2-d3635190678e&type=display
706,MINOCYCLINE HYDROCHLORIDE,"1. The drug label mentions that MINOCIN (minocycline) for Injection contains magnesium sulfate heptahydrate, and because magnesium is excreted primarily by the kidney, serum levels of magnesium should be monitored in patients with renal impairment. This indicates that the drug itself is not directly associated with cardiotoxicity but may require monitoring in patients with renal impairment due to potential effects on magnesium levels.

2. The label also states that because MINOCIN (minocycline) for Injection contains magnesium, close monitoring is recommended in patients with heart block or myocardial damage. This suggests that the drug itself is not directly linked to cardiotoxicity but may require monitoring in patients with specific heart conditions.

3. Additionally, the label mentions that hepatotoxicity has been reported with minocycline, so caution should be exercised when using the drug in patients with hepatic dysfunction and in conjunction with other hepatotoxic drugs. While this does not directly relate to cardiotoxicity, it highlights the need for caution in patients with liver issues who may also have cardiac concerns.

4. The drug label warns about the potential for central nervous system side effects, including light-headedness, dizziness, or vertigo, which have been reported. Patients experiencing these symptoms should be cautioned about driving or using machinery while on minocycline therapy. While not directly related to cardiotoxicity, these central nervous system effects could impact cardiovascular function indirectly.

5. The label also mentions that intracranial hypertension (pseudotumor cerebri) has been associated with the use of tetracyclines, including Minocin. Clinical manifestations of intracranial hypertension include headache, blurred vision, diplopia, and vision loss. This indicates a potential risk of intracranial hypertension with the drug, which could indirectly affect cardiovascular health.

Overall, while the drug label does not directly associate MINOCIN (minocycline) for Injection with cardiotoxicity, it highlights the importance of monitoring magnesium levels in patients with renal impairment, exercising caution in patients with heart block or myocardial damage, and being aware of potential central nervous system effects that could impact cardiovascular function.",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",e415c323-8219-464b-9e3e-72c5a796cdaa,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=e415c323-8219-464b-9e3e-72c5a796cdaa&type=display
707,MINOXIDIL,"1. The drug label warns that minoxidil tablets contain the antihypertensive agent minoxidil, which may lead to serious adverse effects such as pericardial effusion and angina pectoris exacerbation. Minoxidil itself is associated with the risk of cardiotoxicity.

2. Experimental animal studies showed that minoxidil caused various myocardial lesions and adverse cardiac effects. These effects were observed in animals treated with minoxidil, indicating a direct association between the drug and cardiotoxicity risks.

3. Minoxidil must be administered under close supervision, often in combination with a beta-adrenergic blocking agent and a diuretic, to prevent tachycardia and fluid accumulation. The drug label emphasizes the importance of monitoring and concomitant use of other medications to mitigate the cardiotoxicity risks associated with minoxidil.

4. Cardiac lesions, including papillary muscle/subendocardial necrosis, hemorrhagic lesions, epicarditis, and hypertrophy/dilation, have been observed in animals treated with minoxidil. These cardiotoxic effects are directly linked to the administration of minoxidil in animal studies.

5. Autopsies of patients who received minoxidil for hypertension did not show the characteristic cardiac lesions seen in animals. However, some patients exhibited papillary muscle and subendocardial necrosis, which were attributed to pre-existing coronary artery disease. The association between minoxidil and cardiotoxicity in humans remains unclear based on autopsy findings.

6. The drug label highlights the importance of close monitoring for pericardial effusion, tamponade, and other cardiac disorders in patients taking minoxidil. These cardiotoxic reactions may occur in a small percentage of patients, necessitating vigilant observation and potential intervention.

7. Minoxidil is contraindicated in patients with pheochromocytoma due to its potential to stimulate catecholamine secretion, which can lead to adverse cardiovascular effects. The drug label explicitly states the risk of cardiotoxicity in patients with specific conditions, emphasizing the need for caution in such populations.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",7aa8d272-0e44-43df-9263-9d84b2aa8946,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7aa8d272-0e44-43df-9263-9d84b2aa8946&type=display
708,MIPOMERSEN SODIUM,"1. The drug label for KYNAMRO (mipomersen sodium injection) does not explicitly mention any cardiotoxicity risks associated with the drug itself.

2. There is no specific information provided in the drug label regarding cardiotoxicity reactions linked directly to the use of mipomersen sodium injection. 

Overall, based on the information provided in the drug label, there are no direct references to cardiotoxicity risks or reactions associated with the use of KYNAMRO (mipomersen sodium injection).",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",774c7847-490b-41d5-9e0e-2baedbc94f62,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=774c7847-490b-41d5-9e0e-2baedbc94f62&type=display
709,MIRABEGRON,"1. **Increases in Blood Pressure**: MYRBETRIQ/MYRBETRIQ Granules can increase blood pressure in adult or pediatric patients. Periodic monitoring of blood pressure is recommended, especially in hypertensive patients. The drug itself is associated with the risk of increasing blood pressure, particularly in patients with hypertension.

2. **Urinary Retention in Patients with Bladder Outlet Obstruction**: MYRBETRIQ should be administered with caution in patients with bladder outlet obstruction due to the risk of urinary retention. While a controlled clinical study did not show increased urinary retention in patients with bladder outlet obstruction, caution is still advised. The drug itself is associated with the risk of urinary retention in these patients.

3. **Angioedema**: Angioedema of the face, lips, tongue, and larynx has been reported with MYRBETRIQ/MYRBETRIQ Granules. This reaction may be life-threatening, and prompt discontinuation of the drug is necessary if angioedema occurs. The drug itself is associated with the risk of angioedema, which can occur after the first dose or after multiple doses.",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",ba9e9e15-e666-4c56-9271-2e24739cfa2d,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=ba9e9e15-e666-4c56-9271-2e24739cfa2d&type=display
710,MIRTAZAPINE,"1. REMERON (mirtazapine) has been associated with a mean increase in heart rate of 3.4 bpm compared to 0.8 bpm for placebo in clinical trials, although the clinical significance of these changes is unknown. (The drug itself was associated with an increase in heart rate.)

2. Cases of QT prolongation, Torsades de Pointes, ventricular tachycardia, and sudden death have been reported during postmarketing use of mirtazapine. The majority of these reports occurred in association with overdose or in patients with other risk factors for QT prolongation. (The drug itself was associated with QT prolongation and related cardiac events.)

3. REMERON was associated with significant orthostatic hypotension in early clinical pharmacology trials with normal volunteers, although orthostatic hypotension was infrequently observed in clinical trials with depressed patients. (The drug itself was associated with orthostatic hypotension.)

4. Electrocardiograms of patients who received REMERON showed a mean increase in heart rate of 3.4 bpm, compared to 0.8 bpm for placebo. The clinical significance of these changes is unknown. (The drug itself was associated with an increase in heart rate.)

5. The pupillary dilation following the use of REMERON may trigger an angle-closure attack in patients with anatomically narrow angles who do not have a patent iridectomy. (The drug itself was associated with the potential risk of triggering angle-closure glaucoma.)

6. REMERON should be used with caution in patients with known cardiovascular disease or a family history of QT prolongation, and in concomitant use with other drugs that may prolong the QTc interval. (The drug itself was associated with the need for caution in patients with cardiovascular risks.)

7. The effect of REMERON on QTc interval was assessed in a clinical trial involving healthy volunteers, showing a positive relationship between mirtazapine concentrations and QTc interval prolongation. (The drug itself was associated with QTc interval prolongation.)

8. REMERON was associated with a mean increase in heart rate of 3.4 bpm in clinical trials, compared to 0.8 bpm for placebo. The clinical significance of these changes is unknown. (The drug itself was associated with an increase in heart rate.)

Overall, REMERON (mirtazapine) has been associated with various cardiotoxicity risks and reactions, including QT prolongation, orthostatic hypotension, and potential effects on heart rate, which should be considered when prescribing the medication to patients with cardiovascular concerns.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",98ad1917-a094-44f5-a28f-a64a8cfcd887,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=98ad1917-a094-44f5-a28f-a64a8cfcd887&type=display
711,MISOPROSTOL,"1. The drug label warns that Cytotec (misoprostol) administration to pregnant women can lead to uterine rupture, which has been reported when the drug was used to induce labor or abortion. The risk of uterine rupture increases with advancing gestational ages and with prior uterine surgery, including Cesarean delivery. (The drug itself is not directly associated with cardiotoxicity in this context.)

2. The label mentions that Cytotec does not produce clinically significant effects on the cardiovascular system at recommended doses. (The drug is not associated with cardiotoxicity in this context.)

3. In the section on adverse reactions, the label reports that cardiovascular adverse events such as chest pain, edema, hypotension, hypertension, arrhythmia, and myocardial infarction have been reported in subjects receiving Cytotec. Some of these events were fatal. (The drug is associated with cardiovascular adverse events, including myocardial infarction, which can be considered as cardiotoxicity reactions.)

4. The label also notes that Cytotec has been associated with thromboembolic events such as pulmonary embolism, arterial thrombosis, and cerebrovascular accidents (CVA). (The drug is associated with thromboembolic events, which can be considered as cardiotoxicity reactions.)

5. Additionally, the label mentions that Cytotec has been associated with high fevers, autonomic and central nervous system effects, tachycardia, disorientation, agitation, and convulsions when used for postpartum hemorrhage management. (The drug is associated with adverse effects on the central nervous system and cardiovascular system, including tachycardia and convulsions, which can be considered as cardiotoxicity reactions.)",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",4ab12da7-5731-4e06-bf1c-bc3f2e711f12,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=4ab12da7-5731-4e06-bf1c-bc3f2e711f12&type=display
712,MITOTANE,"1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with LYSODREN (mitotane). 

2. Cardiotoxicity is not listed as a known adverse reaction or risk factor for LYSODREN in the provided drug label information. 

3. There is no mention of LYSODREN causing or being associated with cardiotoxicity in the drug label. 

Overall, based on the information provided in the drug label, LYSODREN does not appear to have any documented cardiotoxicity risks or reactions.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",f0cd76e9-460c-450e-b094-172e636f340a,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=f0cd76e9-460c-450e-b094-172e636f340a&type=display
713,MITOXANTRONE,"1. The drug label warns that congestive heart failure (CHF), potentially fatal, may occur during therapy with mitoxantrone or months to years after termination of therapy. The risk of cardiotoxicity increases with cumulative mitoxantrone dose and may occur whether or not cardiac risk factors are present. (The drug itself is associated with the risk of CHF.)

2. Presence or history of cardiovascular disease, radiotherapy to the mediastinal/pericardial area, previous therapy with other anthracyclines or anthracenediones, or use of other cardiotoxic drugs may increase the risk of cardiotoxicity with mitoxantrone. (The drug itself is associated with an increased risk of cardiotoxicity in patients with certain conditions or treatments.)

3. In cancer patients, the risk of symptomatic CHF was estimated to be 2.6% for patients receiving up to a cumulative dose of 140 mg/m^2. Mitoxantrone therapy should be carefully considered to mitigate the cardiotoxicity risk. (The drug itself is associated with an increased risk of symptomatic CHF in cancer patients.)

4. Changes in cardiac function may occur in patients with multiple sclerosis treated with mitoxantrone. Cardiac monitoring, including assessment of left ventricular ejection fraction (LVEF), is recommended before and during mitoxantrone therapy in multiple sclerosis patients. (The drug itself is associated with potential changes in cardiac function in multiple sclerosis patients.)",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",accf9569-4b57-4e83-a7db-4e890a75d1ba,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=accf9569-4b57-4e83-a7db-4e890a75d1ba&type=display
714,MOBOCERTINIB,"1. **Cardiotoxicity Risk**: The drug label warns that EXKIVITY can cause life-threatening heart rate-corrected QT (QTc) prolongation, including Torsades de Pointes, which can be fatal, and requires monitoring of QTc and electrolytes at baseline and periodically during treatment. The drug itself is associated with the risk of QTc prolongation and Torsades de Pointes.

2. **Cardiac Toxicity**: EXKIVITY can cause cardiac toxicity, including decreased ejection fraction, cardiomyopathy, and congestive heart failure, which can be fatal. The label advises monitoring cardiac function, including left ventricular ejection fraction, at baseline and during treatment. The drug itself is associated with the risk of cardiac toxicity leading to heart failure.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",f1a91500-a944-4cb8-b4a8-ae278bcf728d,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=f1a91500-a944-4cb8-b4a8-ae278bcf728d&type=display
715,MODAFINIL,"1. Cardiovascular Events: The drug label mentions that in clinical studies of modafinil, cardiovascular adverse reactions such as chest pain, palpitations, dyspnea, and transient ischemic T-wave changes on ECG occurred in some subjects. The label indicates that these events were associated with underlying conditions like mitral valve prolapse or left ventricular hypertrophy, and not directly caused by modafinil itself.

2. Blood Pressure Monitoring: The label states that while short-term controlled trials did not show significant changes in blood pressure with modafinil use, a retrospective analysis revealed that a greater proportion of patients on modafinil required new or increased use of antihypertensive medications compared to placebo. This suggests a potential association between modafinil use and alterations in blood pressure that may necessitate monitoring.

3. Increased Monitoring: The label advises increased monitoring of heart rate and blood pressure in patients on modafinil, especially those with known cardiovascular disease. This recommendation implies that modafinil may have an impact on cardiovascular parameters that warrants closer observation to ensure patient safety.",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",e16c26ad-7bc2-d155-3a5d-da83ad6492c8,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=e16c26ad-7bc2-d155-3a5d-da83ad6492c8&type=display
716,MOEXIPRIL HYDROCHLORIDE,"1. The drug label warns about fetal toxicity associated with drugs that act directly on the renin-angiotensin system, which can cause injury and death to the developing fetus. The warning advises discontinuing the drug as soon as pregnancy is detected, indicating that the drug itself is associated with fetal toxicity risks.

2. The label mentions that symptomatic hypotension, although unusual in uncomplicated hypertensive patients treated with the drug alone, can occur. It states that symptomatic hypotension was seen in a small percentage of patients and led to discontinuation of therapy in some cases, suggesting that the drug itself can cause symptomatic hypotension reactions.

3. The drug label discusses the potential risk of angioedema, including head and neck angioedema, associated with ACE inhibitors like the drug in question. It reports that symptoms suggestive of angioedema occurred in a small percentage of patients, indicating that the drug itself is associated with the risk of angioedema reactions.

4. The label mentions that intestinal angioedema has been reported in patients treated with ACE inhibitors, including the drug, and advises including it in the differential diagnosis of patients presenting with abdominal pain. This suggests that the drug itself is associated with the risk of intestinal angioedema reactions.

5. Anaphylactoid reactions have been reported in patients receiving ACE inhibitors, including the drug, during desensitization or membrane exposure. This indicates that the drug itself is associated with the risk of anaphylactoid reactions in certain clinical settings.

6. The drug label warns about the potential for hypotension in patients with congestive heart failure, where ACE inhibitor therapy may cause excessive hypotension, renal insufficiency, and acute renal failure. This suggests that the drug itself is associated with the risk of hypotension and renal complications in patients with congestive heart failure.

7. The label discusses the potential for neutropenia and agranulocytosis associated with ACE inhibitors, although no severe neutropenia cases were reported with the drug in question. Monitoring of white blood cell counts is recommended, indicating that the drug itself is associated with the risk of neutropenia and agranulocytosis, similar to other ACE inhibitors.

8. The drug label warns about the potential for hepatic failure associated with ACE inhibitors, including the drug, which can progress to fulminant hepatic necrosis and death. This suggests that the drug itself is associated with the risk of hepatic failure reactions in rare cases.",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",e16c2ad3-1ce5-48fc-96b2-5d63dc6b68d5,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=e16c2ad3-1ce5-48fc-96b2-5d63dc6b68d5&type=display
717,MOLINDONE HYDROCHLORIDE,"1. The drug label warns about an increased risk of mortality in elderly patients with dementia-related psychosis who are treated with antipsychotic drugs, including Molindone Hydrochloride Tablets. The risk of death in drug-treated patients was found to be higher compared to placebo-treated patients, with most deaths attributed to cardiovascular causes like heart failure and sudden death.

2. The drug label mentions that rare, transient, non-specific T wave changes have been reported on E.K.G., but the association with a clinical syndrome has not been established. Additionally, significant hypotension has been rarely reported with Molindone Hydrochloride, suggesting a potential cardiotoxicity risk associated with the drug.

3. The drug label also notes that one patient experienced priapism while being treated with Molindone Hydrochloride, which required surgical intervention and resulted in residual impairment of erectile function. This indicates a potential cardiotoxicity reaction associated with the drug.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",1275e92f-9573-4d0c-8e77-1c9ac47696d2,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=1275e92f-9573-4d0c-8e77-1c9ac47696d2&type=display
718,MONOMETHYL FUMARATE,"1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with BAFIERTAM itself. 

2. The drug label does not indicate any direct association between BAFIERTAM and cardiotoxicity risks or reactions. 

3. BAFIERTAM is not linked to any cardiotoxicity risks or reactions based on the information provided in the drug label. 

4. There are no mentions of cardiotoxicity risks or reactions attributed to BAFIERTAM in the drug label. 

5. The drug label does not discuss any cardiotoxicity risks or reactions related to BAFIERTAM.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",a161f9d4-70f1-4097-957a-eafb35d3274f,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a161f9d4-70f1-4097-957a-eafb35d3274f&type=display
719,MONTELUKAST SODIUM,"1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with the use of SINGULAIR itself.

2. However, the drug label does mention that cases of cholestatic hepatitis, hepatocellular liver injury, and mixed-pattern liver injury have been reported in patients treated with SINGULAIR. Most of these cases occurred in combination with other confounding factors, such as the use of other medications or when SINGULAIR was administered to patients with underlying potential for liver disease, such as alcohol use or other forms of hepatitis. This suggests that SINGULAIR may have an indirect association with liver-related adverse events, which could potentially impact cardiac function indirectly through liver dysfunction.",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",482dcc92-b47f-4ea6-854a-f5ac2aea7842,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=482dcc92-b47f-4ea6-854a-f5ac2aea7842&type=display
720,MORPHINE SULFATE,"1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with morphine sulfate oral solution itself.

2. However, the label does highlight the risk of severe hypotension, which can be a concern for patients with cardiovascular issues. This risk is associated with the use of morphine sulfate oral solution, particularly during dosage initiation and titration.

3. Additionally, the label mentions the importance of evaluating patients closely, especially those with chronic pulmonary disease or elderly, cachectic, or debilitated patients, for life-threatening respiratory depression. While not directly stating cardiotoxicity, respiratory depression can impact cardiovascular function in vulnerable patients.

4. The label also advises monitoring patients for sedation and respiratory depression in those with increased intracranial pressure, brain tumors, head injury, or impaired consciousness. While not explicitly cardiotoxicity, these conditions can have implications for cardiovascular health.

5. Overall, while the drug label does not directly link morphine sulfate oral solution to cardiotoxicity risks or reactions, it does emphasize the need for careful monitoring and consideration of potential adverse effects on various body systems, including the cardiovascular system, in certain patient populations.",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",ca359246-4674-4b32-b8b2-673d32b7112f,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=ca359246-4674-4b32-b8b2-673d32b7112f&type=display
721,MOXIDECTIN,"1. The drug label mentions that Moxidectin Tablets do not prolong the QT interval to any clinically relevant extent at a dose 4.5 times the approved recommended dose, indicating that the drug itself is not associated with QT prolongation. (Source: Clinical Pharmacology, Mechanism of Action)

2. The label also highlights that patients who received Moxidectin Tablets may develop symptomatic orthostatic hypotension, with an increased incidence compared to those who received ivermectin. This reaction is associated with the drug and should be monitored post-treatment. (Source: Warnings and Precautions, Symptomatic Orthostatic Hypotension)

3. Additionally, the drug label warns that patients co-infected with Loa loa may experience serious or fatal encephalopathy following treatment with Moxidectin Tablets. This reaction is associated with the drug and requires assessment for loiasis prior to treatment. (Source: Warnings and Precautions, Encephalopathy in Loa loa Co-infected Patients)

4. Patients with hyper-reactive onchodermatitis may be more likely to experience severe edema and worsening of onchodermatitis following the use of Moxidectin Tablets. This reaction is associated with the drug and may require symptomatic treatment. (Source: Warnings and Precautions, Edema and Worsening of Onchodermatitis)",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",6eb02ae9-9065-176f-e053-2991aa0ac891,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=6eb02ae9-9065-176f-e053-2991aa0ac891&type=display
722,MOXIFLOXACIN HYDROCHLORIDE,"1. The drug Moxifloxacin has been shown to prolong the QT interval of the electrocardiogram in some patients, with a mean change in QTc from the pre-dose value at the time of maximum drug concentration. This indicates that the drug itself is associated with QT prolongation.

2. Moxifloxacin should be avoided in patients with known prolongation of the QT interval, uncorrected hypokalemia, and those receiving certain antiarrhythmic agents due to the lack of clinical experience with the drug in these patient populations. This suggests that the drug itself may exacerbate existing QT prolongation risks.

3. The drug should be used with caution in patients with ongoing proarrhythmic conditions, such as clinically significant bradycardia or acute myocardial ischemia. This indicates that the drug itself may pose risks in patients with specific cardiac conditions.

4. Moxifloxacin has been associated with an increased risk of seizures, increased intracranial pressure, dizziness, and tremors, which are central nervous system effects that may impact cardiac function. This suggests that the drug itself may lead to adverse cardiac effects through its impact on the central nervous system.

5. The drug has been linked to an increased rate of aortic aneurysm and dissection within two months of use, particularly in elderly patients. This indicates that the drug itself may contribute to the risk of aortic complications.

6. Moxifloxacin has been shown to cause lameness and permanent cartilage lesions in weight-bearing joints of immature dogs, suggesting potential arthropathic effects that could indirectly impact cardiac function. This implies that the drug itself may lead to musculoskeletal issues that could indirectly affect the heart.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",a4e28b09-714b-46e7-b4e6-0163cad78fc5,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a4e28b09-714b-46e7-b4e6-0163cad78fc5&type=display
723,MYCOPHENILIC ACID,1. The drug label does not specifically mention cardiotoxicity risks or cardiotoxicity reactions associated with mycophenolic acid delayed-release tablets.,No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",30cb1078-929b-4c0f-be1d-49ef352dfab9,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=30cb1078-929b-4c0f-be1d-49ef352dfab9&type=display
724,MYCOPHENOLATE MOFETIL,"1. The drug label mentions that CellCept, when used in combination with corticosteroids and cyclosporine for the prevention of organ rejection in cardiac transplant patients, was compared to azathioprine in a study. The study did not establish any difference between CellCept and azathioprine in terms of biopsy-proven rejection with hemodynamic compromise, indicating that CellCept was not associated with cardiotoxicity risk in this context.

2. In a cardiac transplant study, CellCept was shown to be at least as effective as azathioprine in preventing death or retransplantation at 1 year, suggesting that CellCept did not lead to increased cardiotoxicity reactions compared to azathioprine.

Overall, the drug label does not indicate any direct association between CellCept and cardiotoxicity risks or cardiotoxicity reactions in cardiac transplant patients.",Less,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",23d74606-134c-464c-8323-9cf52bb3c5fa,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=23d74606-134c-464c-8323-9cf52bb3c5fa&type=display
725,MYCOPHENOLIC ACID,"1. The drug label does not specifically mention cardiotoxicity risks or cardiotoxicity reactions associated with Myfortic itself.

2. However, the label does caution about serious infections, including bacterial, viral, fungal, and protozoal infections, which could potentially impact the cardiovascular system indirectly through systemic effects of severe infections.

3. Additionally, the label mentions gastrointestinal complications such as gastrointestinal bleeding, intestinal perforations, and ulcers, which could lead to complications affecting the cardiovascular system if severe.

4. It is important to note that while the drug label does not directly associate Myfortic with cardiotoxicity risks or reactions, patients should be monitored for any signs of cardiovascular issues during treatment, especially in the context of the drug's impact on the immune system and potential for serious infections.",No,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",eed26501-890d-4ff6-88e7-6dbea4726e53,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=eed26501-890d-4ff6-88e7-6dbea4726e53&type=display
726,NABILONE,"1. Cesamet has been observed to elevate supine and standing heart rates and to cause supine and orthostatic hypotension. (The drug itself is associated with cardiotoxicity risks.)

2. Cardiovascular adverse reactions reported in patients treated with Cesamet include orthostatic hypotension, hypotension, tachycardia, syncope, palpitation, flushing, hypertension, arrhythmia, and cerebral vascular accident. (The drug itself is associated with cardiotoxicity reactions.)

3. Overdosage of Cesamet may lead to hypertension and hypotension, with tachycardia and orthostatic hypotension being commonly reported symptoms. (The drug itself is associated with cardiotoxicity risks and reactions.)",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",83c7ac15-ece9-47de-b83c-d575544fa449,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=83c7ac15-ece9-47de-b83c-d575544fa449&type=display
727,NABUMETONE,"1. The drug label states that nonsteroidal anti-inflammatory drugs (NSAIDs), including nabumetone tablets, are associated with an increased risk of serious cardiovascular thrombotic events, such as myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use. (The drug itself is associated with the cardiotoxicity risk.)

2. Nabumetone tablets are contraindicated in the setting of coronary artery bypass graft (CABG) surgery. (The drug itself is associated with the cardiotoxicity risk.)

3. The drug label warns about the potential risk of cardiovascular thrombotic events with NSAID use, advising physicians and patients to use the lowest effective dose for the shortest duration possible to minimize this risk. (The drug itself is associated with the cardiotoxicity risk.)

4. The label also mentions that observational studies have shown an increased risk of reinfarction, cardiovascular-related death, and all-cause mortality in post-myocardial infarction (MI) patients treated with NSAIDs, including nabumetone tablets. (The drug itself is associated with the cardiotoxicity risk.)

5. The drug label advises avoiding the use of nabumetone tablets in patients with a recent MI unless the benefits outweigh the risk of recurrent cardiovascular thrombotic events. (The drug itself is associated with the cardiotoxicity risk.)

6. NSAIDs, including nabumetone tablets, can lead to the onset of new hypertension or worsening of preexisting hypertension, contributing to an increased incidence of cardiovascular events. (The drug itself is associated with the cardiotoxicity risk.)

7. The label mentions that NSAIDs, including nabumetone tablets, should be used with caution in patients with hypertension, and blood pressure should be monitored closely during treatment. (The drug itself is associated with the cardiotoxicity risk.)

8. Nabumetone tablets should be avoided in patients with severe heart failure unless the benefits outweigh the risk of worsening heart failure, and patients should be monitored for signs of worsening heart failure if the drug is used in such patients. (The drug itself is associated with the cardiotoxicity risk.)

In summary, the drug label clearly outlines the association between nabumetone tablets and the increased risk of cardiovascular thrombotic events, emphasizing the importance of using the lowest effective dose for the shortest duration possible to minimize these risks.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",6106afa3-e138-4b4d-8c13-992bf5062097,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=6106afa3-e138-4b4d-8c13-992bf5062097&type=display
728,NADOLOL,"1. The drug CORGARD (nadolol) is a nonselective beta-adrenergic receptor blocking agent that has been associated with risks of cardiac failure, hypotension, and rhythm/conduction disturbances in about 1 out of 100 patients.
   
2. Nadolol, the active ingredient in CORGARD, has been linked to bradycardia, with heart rates below 40 beats per minute and/or symptomatic bradycardia seen in about 2 out of 100 patients.

3. The drug has been associated with symptoms of peripheral vascular insufficiency, usually of the Raynaud type, occurring in approximately 2 out of 100 patients.

4. Cardiac failure, hypotension, and rhythm/conduction disturbances have each occurred in about 1 out of 100 patients taking nadolol.

5. Single instances of first degree and third degree heart block have been reported with nadolol, and intensification of AV block is a known effect of beta-blockers.

6. Nadolol has been linked to dizziness or fatigue in approximately 2 out of 100 patients, with paresthesias, sedation, and changes in behavior reported in about 6 out of 1000 patients.

7. Bronchospasm has been reported in approximately 1 out of 1000 patients taking nadolol, indicating a potential risk of respiratory complications associated with the drug.

8. Nadolol has been associated with gastrointestinal adverse effects, such as nausea, diarrhea, abdominal discomfort, constipation, vomiting, indigestion, anorexia, bloating, and flatulence, occurring in 1 to 5 out of 1000 patients.

9. The drug has been linked to reversible alopecia, rash, pruritus, headache, dry mouth, eyes, or skin, impotence or decreased libido, facial swelling, weight gain, slurred speech, cough, nasal stuffiness, sweating, tinnitus, and blurred vision, each reported in 1 to 5 out of 1000 patients.

10. Reversible mental depression progressing to catatonia, visual disturbances, hallucinations, and an acute reversible syndrome characterized by disorientation, short-term memory loss, emotional lability, and decreased performance on neuropsychometrics have been reported with nadolol and other beta-blockers, although no causal relationship to nadolol has been established.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",c3c0fc03-7cca-4ac9-94b1-e3666470fe16,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=c3c0fc03-7cca-4ac9-94b1-e3666470fe16&type=display
729,NAFCILLIN,"1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with Nafcillin itself.

2. The label does not indicate any direct association between Nafcillin and cardiotoxicity risks or reactions.

3. There is no mention of Nafcillin being linked to cardiotoxicity risks or reactions in the drug label.

4. The drug label does not provide information on Nafcillin causing cardiotoxicity risks or reactions.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",cd2d18c5-95a2-4fb4-bd8b-b5d39e2da416,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=cd2d18c5-95a2-4fb4-bd8b-b5d39e2da416&type=display
730,NALBUPHINE HYDROCHLORIDE,"1. The drug label mentions that during the evaluation of Nalbuphine Hydrochloride Injection in anesthesia, a higher incidence of bradycardia has been reported in patients who did not receive atropine pre-operatively. (The drug itself was not associated with causing cardiotoxicity but was mentioned in the context of anesthesia evaluation.)

2. Nalbuphine Hydrochloride Injection may cause severe hypotension including orthostatic hypotension and syncope in ambulatory patients. There is an increased risk in patients whose ability to maintain blood pressure has already been compromised by a reduced blood volume or concurrent administration of certain CNS depressant drugs. (The drug itself was associated with causing severe hypotension and syncope.)

3. In patients with circulatory shock, Nalbuphine Hydrochloride Injection may cause vasodilation that can further reduce cardiac output and blood pressure. Avoid the use of Nalbuphine Hydrochloride Injection in patients with circulatory shock. (The drug itself was associated with causing vasodilation and reducing cardiac output in patients with circulatory shock.)

4. The drug label also mentions that during use of nalbuphine during anesthesia, a higher incidence of bradycardia has been reported in patients who did not receive atropine pre-operatively. Opioids produce peripheral vasodilation, which may result in orthostatic hypotension or syncope. (The drug itself was associated with causing bradycardia and peripheral vasodilation leading to orthostatic hypotension or syncope.)

Overall, Nalbuphine Hydrochloride Injection is associated with cardiotoxicity risks such as bradycardia, hypotension, and vasodilation, which can lead to adverse cardiovascular effects in certain patient populations.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",a99fe500-f52b-483c-807c-178f1a78a02b,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a99fe500-f52b-483c-807c-178f1a78a02b&type=display
731,NALDEMEDINE,"1. The drug SYMPROIC, containing naldemedine, is an opioid antagonist primarily acting on mu-opioid receptors in the gastrointestinal tract, reducing constipating effects of opioids. The drug is not associated with prolongation of the QT interval to any clinically relevant extent, indicating no direct cardiotoxicity risk.

2. Naldemedine, the active ingredient in SYMPROIC, is a peripherally-acting mu-opioid receptor antagonist, with minimal CNS penetration expected at recommended doses, reducing the potential for interference with centrally-mediated opioid analgesia. This mechanism of action does not suggest any direct cardiotoxicity risk.

3. In clinical studies, SYMPROIC did not show any significant effects on cardiac repolarization even at doses up to 5 times the recommended dose, indicating no direct association with cardiotoxicity risks.

Overall, the drug label does not indicate any direct cardiotoxicity risks or reactions associated with the use of SYMPROIC containing naldemedine.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",b1a1256c-a1eb-4abe-ab1e-30e4711afd16,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=b1a1256c-a1eb-4abe-ab1e-30e4711afd16&type=display
732,NALMEFENE HYDROCHLORIDE,"1. **Warnings and Precautions - Risk of Cardiovascular (CV) Effects**: The drug, OPVEE, is associated with a risk of cardiovascular effects, particularly in patients with preexisting cardiovascular disorders or those who have received other drugs with similar adverse cardiovascular effects. The drug may lead to adverse cardiovascular events such as hypotension, ventricular tachycardia or fibrillation, and pulmonary edema. Monitoring in an appropriate healthcare setting is recommended after the use of OPVEE.

2. **Warnings and Precautions - Precipitation of Severe Opioid Withdrawal**: The drug, OPVEE, may precipitate severe opioid withdrawal, which can include cardiovascular effects such as tachycardia, hypertension, and ventricular tachycardia. These effects can be particularly severe in patients with preexisting cardiovascular disorders or those receiving medications with similar adverse cardiovascular effects.

3. **Warnings and Precautions - Risk of Opioid Overdose from Attempts to Overcome the Blockade**: OPVEE is unlikely to produce acute withdrawal symptoms in non-opioid dependent patients. However, in opioid-dependent patients, the use of OPVEE may precipitate opioid withdrawal, leading to potential cardiotoxicity risks. Attempts to overcome the opioid blockade with high or repeated doses of opioids may result in opioid intoxication and cardiovascular complications.

4. **Adverse Reactions**: The drug label mentions that abrupt reversal of opioid depression using OPVEE has resulted in cardiovascular instability, including tachycardia, hypotension, hypertension, ventricular tachycardia and fibrillation, pulmonary edema, and cardiac arrest. These cardiotoxic reactions have been reported primarily in patients with preexisting cardiovascular disorders or those receiving medications with similar adverse cardiovascular effects.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",999a4269-9e54-4801-b2ac-2a7276f0b94f,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=999a4269-9e54-4801-b2ac-2a7276f0b94f&type=display
733,NALOXEGOL OXALATE,"1. The drug MOVANTIK (naloxegol) is an opioid antagonist that functions as a peripherally-acting mu-opioid receptor antagonist in tissues like the gastrointestinal tract, decreasing the constipating effects of opioids. The drug itself is not associated with cardiotoxicity risks.

2. In a thorough QTc prolongation study, a single therapeutic dose or a higher dose of naloxegol did not have an effect on the QTc interval compared to placebo. The drug itself is not associated with cardiotoxicity risks.

3. The exposure-response analysis for adverse events showed that the probability of experiencing abdominal pain increased with increasing naloxegol exposure, but the drug itself is not associated with cardiotoxicity risks.

4. No antidote is known for naloxegol overdose, and dialysis was noted to be ineffective in a clinical study in patients with renal failure. If a patient receives an overdose, they should be monitored for potential evidence of opioid withdrawal symptoms, but the drug itself is not associated with cardiotoxicity risks.",Less,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",300a6474-ebcd-4404-8040-48fdcfcc1635,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=300a6474-ebcd-4404-8040-48fdcfcc1635&type=display
734,NALOXONE HYDROCHLORIDE,"1. **Warnings and Precautions - Risk of Cardiovascular (CV) Effects:** The drug label mentions that abrupt postoperative reversal of opioid depression with REXTOVY Nasal Spray may result in adverse cardiovascular effects. It states that these events have primarily occurred in patients who had preexisting CV disorders or received other drugs that may have similar adverse CV effects. This indicates that the drug itself is associated with the risk of cardiotoxicity in certain patient populations.

2. **Warnings and Precautions - Precipitation of Severe Opioid Withdrawal:** The label also warns about the risk of precipitating severe opioid withdrawal with the use of REXTOVY Nasal Spray in patients who are opioid dependent. It mentions that abrupt postoperative reversal of opioid depression may result in adverse CV effects, including hypotension, hypertension, seizures, ventricular tachycardia and fibrillation, pulmonary edema, and cardiac arrest. This suggests that the drug can lead to cardiotoxic reactions in patients with preexisting cardiovascular disorders or those receiving medications with potential adverse cardiovascular effects.",Less,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",fe9735db-c57e-44a8-bffb-b87a84c2a6f3,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fe9735db-c57e-44a8-bffb-b87a84c2a6f3&type=display
735,NALTREXONE,"1. **Vulnerability to Opioid Overdose**: The drug VIVITROL itself is not directly associated with cardiotoxicity risks, but it mentions that patients may be vulnerable to potentially fatal overdose due to reduced opioid tolerance after treatment with VIVITROL, especially at the end of a dosing interval or after missing a dose.

2. **Injection Site Reactions**: While not directly related to cardiotoxicity, severe injection site reactions have been reported with VIVITROL, including cases requiring surgical intervention. These reactions, although not cardiac in nature, indicate potential severe adverse reactions associated with the drug.

3. **Precipitation of Opioid Withdrawal**: VIVITROL is not directly linked to cardiotoxicity risks, but it mentions that precipitated opioid withdrawal, which can be severe enough to require hospitalization, may occur in opioid-dependent patients transitioning to VIVITROL treatment. This severe withdrawal reaction is not cardiac-related but highlights potential risks associated with abrupt opioid antagonist therapy.

4. **Hepatotoxicity**: While not directly related to cardiotoxicity, cases of hepatitis and liver dysfunction have been observed with VIVITROL treatment. Although not cardiac-specific, hepatotoxicity can indicate potential systemic adverse effects associated with the drug.

5. **Depression and Suicidality**: VIVITROL itself is not directly associated with cardiotoxicity risks, but it mentions monitoring patients for the development of depression or suicidal thinking. While not cardiac-related, these mental health effects can impact overall patient well-being and may indirectly affect cardiovascular health.",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",cd11c435-b0f0-4bb9-ae78-60f101f3703f,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=cd11c435-b0f0-4bb9-ae78-60f101f3703f&type=display
736,NALTREXONE HYDROCHLORIDE,"1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with naltrexone hydrochloride itself. 

2. The label does not indicate any direct association between naltrexone hydrochloride and cardiotoxicity risks or reactions. 

3. There is no mention of naltrexone hydrochloride causing cardiotoxicity risks or reactions in the drug label. 

4. The drug label does not attribute any cardiotoxicity risks or reactions to naltrexone hydrochloride. 

5. Naltrexone hydrochloride is not linked to any cardiotoxicity risks or reactions based on the information provided in the drug label.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",7e126353-8d94-4163-b7f5-dc7c47e685b2,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7e126353-8d94-4163-b7f5-dc7c47e685b2&type=display
737,NAPROXEN,"1. The drug label warns that nonsteroidal anti-inflammatory drugs (NSAIDs), including NAPROSYN Suspension, are associated with an increased risk of serious cardiovascular thrombotic events, such as myocardial infarction and stroke, which can be fatal. The risk may occur early in treatment and may increase with the duration of use. (The drug itself is associated with the cardiotoxicity risk.)

2. NAPROSYN Suspension is contraindicated in the setting of coronary artery bypass graft (CABG) surgery due to the increased risk of serious cardiovascular thrombotic events. (The drug itself is associated with the cardiotoxicity risk.)

3. The label advises that patients with a recent myocardial infarction (MI) should avoid using NAPROSYN Suspension unless the benefits are expected to outweigh the risk of recurrent cardiovascular thrombotic events. Monitoring for signs of cardiac ischemia is recommended if the drug is used in these patients. (The drug itself is associated with the cardiotoxicity risk.)

4. The label also mentions that observational studies have shown an increased risk of reinfarction, cardiovascular-related death, and all-cause mortality in post-MI patients treated with NSAIDs, including NAPROSYN Suspension. (The drug itself is associated with the cardiotoxicity risk.)

5. The drug label emphasizes the importance of using the lowest effective dose of NAPROSYN Suspension for the shortest duration possible to minimize the potential risk of adverse cardiovascular events. Patients and physicians are advised to remain vigilant for symptoms of serious cardiovascular events throughout the treatment course. (The drug itself is associated with the cardiotoxicity risk.)",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",f9b4173d-7836-4d7d-b149-1d96f9377ad0,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=f9b4173d-7836-4d7d-b149-1d96f9377ad0&type=display
738,NAPROXEN SODIUM,"1. The drug label warns that nonsteroidal anti-inflammatory drugs (NSAIDs), including NAPRELAN, are associated with an increased risk of serious cardiovascular thrombotic events, such as myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with the duration of use.

2. NAPRELAN is contraindicated in patients who have undergone coronary artery bypass graft (CABG) surgery due to the risk of serious cardiovascular events associated with NSAID use.

3. Clinical trials have shown that several COX-2 selective and nonselective NSAIDs, including NAPRELAN, may increase the risk of serious cardiovascular thrombotic events, such as myocardial infarction and stroke. The risk appears to be similar in patients with and without known cardiovascular disease or risk factors, but patients with existing cardiovascular conditions may have a higher absolute incidence of these events.

4. The drug label advises using the lowest effective dose of NAPRELAN for the shortest duration possible to minimize the potential risk of adverse cardiovascular events. Patients and physicians should remain vigilant for symptoms of serious cardiovascular events throughout the treatment course.

5. The drug label also highlights that there is no consistent evidence that concurrent use of aspirin mitigates the increased risk of serious cardiovascular thrombotic events associated with NSAID use. The use of aspirin and NSAIDs together may increase the risk of serious gastrointestinal events.

6. NAPRELAN is contraindicated in patients with a recent myocardial infarction (MI) unless the benefits outweigh the risk of recurrent cardiovascular thrombotic events. Patients with a recent MI who are prescribed NAPRELAN should be closely monitored for signs of cardiac ischemia.

7. The drug label emphasizes that NSAIDs, including NAPRELAN, should be avoided in patients with severe heart failure unless the benefits are expected to outweigh the risk of worsening heart failure. Monitoring for signs of worsening heart failure is recommended if NAPRELAN is used in patients with severe heart failure.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",e633ff0b-eab7-f167-8d08-e9236e54042b,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=e633ff0b-eab7-f167-8d08-e9236e54042b&type=display
739,NARATRIPTAN,"1. Naratriptan tablets are contraindicated in patients with ischemic or vasospastic coronary artery disease (CAD) due to rare reports of serious cardiac adverse reactions, including acute myocardial infarction, occurring within a few hours following administration of the drug. The drug itself is associated with the cardiotoxicity risk.

2. Life-threatening disturbances of cardiac rhythm, including ventricular tachycardia and ventricular fibrillation leading to death, have been reported within a few hours following the administration of 5-HT1 agonists like naratriptan tablets. Discontinue naratriptan tablets if these disturbances occur. The drug itself is associated with the cardiotoxicity risk.

3. Sensations of tightness, pain, and pressure in the chest, throat, neck, and jaw may occur after treatment with naratriptan tablets and are usually non-cardiac in origin. However, a cardiac evaluation is recommended if patients are at high cardiac risk. The drug itself is not directly associated with the cardiotoxicity risk but may lead to symptoms that require cardiac evaluation.

4. Naratriptan tablets may cause non-coronary vasospastic reactions, such as peripheral vascular ischemia and gastrointestinal vascular ischemia. Reports of transient and permanent blindness and significant partial vision loss have been reported with the use of 5-HT1 agonists like naratriptan tablets. The drug itself is associated with the risk of non-coronary vasospasm reactions that may lead to serious cardiovascular events.

5. Naratriptan tablets are contraindicated in patients with a history of stroke, transient ischemic attack (TIA), or hemiplegic or basilar migraine due to the increased risk of cerebrovascular events. Discontinue naratriptan tablets if a cerebrovascular event occurs. The drug itself is associated with the risk of cerebrovascular events in patients with specific medical histories.

6. Naratriptan tablets are contraindicated in patients with uncontrolled hypertension due to the risk of significant elevation in blood pressure, including hypertensive crisis with acute impairment of organ systems. Monitor blood pressure in patients treated with naratriptan tablets. The drug itself is associated with the risk of increased blood pressure and hypertensive crisis in patients with uncontrolled hypertension.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",93b7e6c2-e6a7-4f6b-9ecd-62d6bb0a6dda,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=93b7e6c2-e6a7-4f6b-9ecd-62d6bb0a6dda&type=display
740,NATEGLINIDE,"1. The drug label does not mention any specific cardiotoxicity risks or cardiotoxicity reactions associated with Nateglinide tablets.
2. Nateglinide has no established clinical studies showing conclusive evidence of macrovascular risk reduction.
3. No clinical trials have reported cardiotoxicity reactions related to Nateglinide use.
4. The drug label does not list cardiotoxicity as a known adverse reaction associated with Nateglinide tablets.
5. Overall, there is no indication in the drug label that Nateglinide is linked to cardiotoxicity risks or reactions.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",88698921-cd8f-4d41-96e6-ff671913c5c3,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=88698921-cd8f-4d41-96e6-ff671913c5c3&type=display
741,NEBIVOLOL,"1. **Warnings and Precautions**: The drug label warns against the abrupt cessation of therapy with nebivolol tablets in patients with coronary artery disease, as it may lead to severe exacerbation of angina, myocardial infarction, and ventricular arrhythmias. The drug itself is associated with the risk of acute exacerbation of coronary artery disease upon cessation of therapy.

2. **Warnings and Precautions**: Nebivolol tablets were not studied in patients with angina pectoris or recent myocardial infarction. The drug label does not directly associate nebivolol tablets with the risk of angina or acute myocardial infarction.

3. **Warnings and Precautions**: Patients with bronchospastic diseases are generally advised not to receive -blockers, which includes nebivolol tablets. The drug label does not directly associate nebivolol tablets with the risk of bronchospasm.

4. **Warnings and Precautions**: The drug label advises caution in patients already on beta-blockers to continue treatment throughout the perioperative period to avoid an increased risk of myocardial infarction and chest pain upon withdrawal. The drug itself is associated with the risk of increased myocardial infarction and chest pain upon withdrawal.

5. **Warnings and Precautions**: Nebivolol tablets can exacerbate the effects of myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists, which may lead to negative inotropic and chronotropic effects. The drug itself is associated with the risk of exacerbating the effects of myocardial depressants or AV conduction inhibitors.

6. **Adverse Reactions**: In clinical trials, nebivolol tablets were associated with adverse reactions such as bradycardia, fatigue, and chest pain. The drug itself is associated with the risk of bradycardia and chest pain as adverse reactions.

7. **Overdosage**: In cases of overdose, nebivolol tablets may lead to signs and symptoms such as bradycardia, hypotension, cardiac failure, and dizziness. The drug itself is associated with the risk of cardiotoxicity reactions in cases of overdose.",Less,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",a9bad35e-cd48-48f1-93ca-46490dbf70a8,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a9bad35e-cd48-48f1-93ca-46490dbf70a8&type=display
742,NEFAZODONE HYDROCHLORIDE,"1. The drug label warns that nefazodone hydrochloride tablets are contraindicated in patients who were withdrawn from nefazodone due to evidence of liver injury, indicating that the drug itself is associated with a risk of hepatotoxicity.
   
2. The label also mentions that nefazodone has been associated with cases of life-threatening hepatic failure, with a reported rate of about 1 case of liver failure resulting in death or transplant per 250,000 to 300,000 patient-years of nefazodone treatment, suggesting a potential risk of hepatotoxicity with the drug.

3. Additionally, the label advises that patients should be monitored for signs and symptoms of liver dysfunction, such as jaundice, anorexia, gastrointestinal complaints, and malaise, and to report them to their doctor immediately if they occur, indicating a potential risk of hepatotoxicity with nefazodone.

4. The label further states that nefazodone should be discontinued if clinical signs or symptoms suggest liver failure, and patients who develop evidence of hepatocellular injury while on nefazodone should be withdrawn from the drug, suggesting a potential risk of hepatotoxicity with the medication.",Most,No,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",0bd4c34a-4f43-4c84-8b98-1d074cba97d5,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=0bd4c34a-4f43-4c84-8b98-1d074cba97d5&type=display
743,NELARABINE,"1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with ARRANON (nelarabine). 

2. No information is provided regarding cardiotoxicity risks or reactions related to the use of ARRANON in the highlighted sections of the drug label. 

3. Cardiotoxicity is not listed as a known risk or adverse reaction associated with the use of ARRANON based on the provided drug label information. 

In summary, the drug label for ARRANON does not mention any cardiotoxicity risks or reactions associated with the use of this medication.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",fffa5d75-0dba-4ad7-a252-5f60fa28489a,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fffa5d75-0dba-4ad7-a252-5f60fa28489a&type=display
744,NELFINAVIR MESYLATE,"1. The drug label mentions that coadministration of VIRACEPT with certain drugs, such as antiarrhythmics like amiodarone and quinidine, can potentially lead to serious and/or life-threatening cardiac arrhythmias. This indicates that VIRACEPT itself is associated with a cardiotoxicity risk.

2. Additionally, the label warns about the potential for QTc prolongation and torsades de pointes as cardiovascular adverse events associated with VIRACEPT use. This suggests that VIRACEPT itself may cause cardiotoxicity reactions.

3. The drug label also highlights the interaction between VIRACEPT and salmeterol, an inhaled beta agonist, which is not recommended due to an increased risk of cardiovascular adverse events associated with salmeterol, including QT prolongation, palpitations, and sinus tachycardia. This indicates that VIRACEPT may contribute to cardiotoxicity reactions when used in combination with salmeterol.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",e72c2bc6-9462-4a2e-8e1d-b97592376cbd,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=e72c2bc6-9462-4a2e-8e1d-b97592376cbd&type=display
745,NEOMYCIN SULFATE,"1. The drug label warns that systemic absorption of neomycin occurs following oral administration and toxic reactions may occur, including neurotoxicity and nephrotoxicity. Neomycin itself is associated with the risk of nephrotoxicity and ototoxicity.
   
2. The label mentions that neuromuscular blockage and respiratory paralysis have been reported following the oral use of neomycin. Neomycin itself is associated with the risk of neuromuscular blockage and respiratory paralysis.

3. The label advises that concurrent or sequential use of other potentially nephrotoxic and/or neurotoxic drugs with neomycin should be avoided due to potential additive toxicity. Neomycin itself is associated with the risk of nephrotoxicity and ototoxicity.

4. It is noted that the risk of nephrotoxicity and ototoxicity is greater in patients with impaired renal function. Neomycin itself is associated with the risk of nephrotoxicity and ototoxicity.

5. The label cautions that advanced age and dehydration are factors that increase the risk of toxicity associated with neomycin use. Neomycin itself is associated with the risk of toxicity in elderly patients and dehydrated individuals.

6. The label mentions that oral neomycin inhibits the gastrointestinal absorption of certain substances, which may lead to a malabsorption syndrome. Neomycin itself is associated with the risk of malabsorption syndrome and potential cardiotoxicity reactions.

7. It is advised that neomycin should be used with caution in patients with muscular disorders such as myasthenia gravis or parkinsonism due to potential aggravation of muscle weakness. Neomycin itself is associated with the risk of exacerbating muscle weakness in patients with muscular disorders.

8. The label states that neomycin may enhance the effect of coumarin in anticoagulants by decreasing vitamin K availability. Neomycin itself is associated with the risk of altering the effects of anticoagulants, potentially leading to cardiotoxicity reactions.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",0aa6947b-4739-4b00-be93-7303a5fc687d,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=0aa6947b-4739-4b00-be93-7303a5fc687d&type=display
746,NEOSTIGMINE METHYLSULFATE,"1. Neostigmine Methylsulfate injection is associated with bradycardia risk, and it is recommended to administer an anticholinergic agent (e.g., atropine or glycopyrrolate) prior to its administration to lessen the risk of bradycardia.

2. Cardiovascular complications such as cardiac arrhythmias, nonspecific electrocardiogram changes, cardiac arrest, syncope, and hypotension have been reported with neostigmine methylsulfate. Patients with certain cardiovascular conditions may be at an increased risk of blood pressure and heart rate complications when using neostigmine methylsulfate. Standard antagonism with anticholinergics (e.g., atropine) is generally successful in mitigating the risk of cardiovascular complications.",Less,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",088f96eb-20b8-48f8-ac83-329f75a44ce1,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=088f96eb-20b8-48f8-ac83-329f75a44ce1&type=display
747,NERATINIB,"1. **Warnings and Precautions - Hepatotoxicity:** The drug label mentions that NERLYNX has been associated with hepatotoxicity characterized by increased liver enzymes. This indicates that NERLYNX itself is associated with the risk of hepatotoxicity.

2. **Adverse Reactions - Clinical Trials Experience - Extended Adjuvant Treatment of Early-Stage Breast Cancer:** In the ExteNET trial, the label reports that NERLYNX as a single agent was associated with serious adverse reactions, including ALT increased, AST increased, and hepatotoxicity. This suggests that NERLYNX itself was associated with these hepatotoxicity reactions.

3. **Adverse Reactions - Clinical Trials Experience - Advanced or Metastatic Breast Cancer:** In the NALA trial, the label states that NERLYNX in combination with capecitabine was associated with serious adverse reactions, including hepatotoxicity. This indicates that NERLYNX itself, when used in combination with capecitabine, was associated with hepatotoxicity reactions.",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",d1e41dcf-e82a-47c2-a0ad-6c6eef621834,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=d1e41dcf-e82a-47c2-a0ad-6c6eef621834&type=display
748,NEVIRAPINE,1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with VIRAMUNE (nevirapine).,No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",5ec05500-6333-4bd0-ac83-464fad0d5162,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=5ec05500-6333-4bd0-ac83-464fad0d5162&type=display
749,NIACIN,"1. The drug label mentions that NIASPAN, when coadministered with simvastatin, did not reduce the incidence of cardiovascular events more than simvastatin alone in a randomized controlled trial. This suggests that NIASPAN did not provide incremental benefit in reducing cardiovascular events over simvastatin alone.

2. The AIM-HIGH trial, involving patients with stable cardiovascular disease, showed that the addition of NIASPAN to simvastatin did not demonstrate efficacy in reducing the risk of coronary heart disease events compared to simvastatin alone. This indicates that the combination of NIASPAN and simvastatin did not show a significant benefit in reducing cardiovascular events.

3. The drug label also mentions that cases of rhabdomyolysis have been associated with the concomitant administration of niacin and statins, particularly lovastatin or simvastatin. This suggests that the combination of NIASPAN with these statins may increase the risk of rhabdomyolysis.

4. Severe hepatic toxicity, including fulminant hepatic necrosis, has occurred in patients who substituted sustained-release niacin products for immediate-release niacin at equivalent doses. This indicates that the substitution of niacin formulations can lead to severe hepatic toxicity.

5. The label warns that NIASPAN should be used with caution in patients with unstable angina or in the acute phase of a myocardial infarction, especially when vasoactive drugs are also being administered. This suggests that NIASPAN may pose risks in patients with certain cardiovascular conditions.

6. NIASPAN is contraindicated in patients with active liver disease or unexplained elevations in hepatic transaminases. This indicates that NIASPAN may exacerbate liver conditions or cause liver enzyme abnormalities.

7. The drug label advises monitoring liver enzymes before and during treatment with NIASPAN due to the risk of persistent elevations in hepatic transaminase levels. This suggests that NIASPAN may lead to liver enzyme abnormalities.

8. NIASPAN has been associated with small but statistically significant dose-related reductions in platelet count and increases in prothrombin time. This indicates that NIASPAN may affect blood clotting parameters, potentially leading to cardiotoxicity risks.

Overall, the drug label highlights several cardiotoxicity risks and reactions associated with NIASPAN, including its potential impact on cardiovascular events, rhabdomyolysis when combined with certain statins, hepatic toxicity, and effects on blood clotting parameters.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",fc312806-1441-478d-95a2-68ce9a7a796d,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fc312806-1441-478d-95a2-68ce9a7a796d&type=display
750,NICARDIPINE HYDROCHLORIDE,"1. The drug CARDENE IV (nicardipine hydrochloride) is a calcium channel blocker indicated for the short-term treatment of hypertension when oral therapy is not feasible. It is not directly associated with causing cardiotoxicity risks.

2. In patients with coronary artery disease, CARDENE IV has been shown to improve left ventricular diastolic distensibility during the early filling phase, probably due to a faster rate of myocardial relaxation in previously underperfused areas. There is little or no effect on normal myocardium, suggesting the improvement is mainly by indirect mechanisms such as afterload reduction and reduced ischemia. The drug itself is not directly linked to causing cardiotoxicity risks.

3. CARDENE IV has no negative effect on myocardial relaxation at therapeutic doses. The clinical benefits of these properties have not yet been demonstrated. The drug does not pose a direct cardiotoxicity risk based on this information.

4. During acute electrophysiologic studies, CARDENE IV increased heart rate and prolonged the corrected QT interval to a minor degree. It did not affect sinus node recovery or SA conduction times. The PA, AH, and HV intervals or the functional and effective refractory periods of the atrium were not prolonged. The relative and effective refractory periods of the His-Purkinje system were slightly shortened. While there are some effects on cardiac electrophysiology, the drug itself is not directly associated with causing significant cardiotoxicity risks.

Overall, based on the information provided in the drug label, CARDENE IV does not appear to be directly linked to causing significant cardiotoxicity risks or reactions. It primarily functions as a calcium channel blocker for the treatment of hypertension, with some effects on cardiac function and electrophysiology noted in the clinical studies.",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",a3e33add-0d09-423a-9109-42e5ba7148d5,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a3e33add-0d09-423a-9109-42e5ba7148d5&type=display
751,NIFEDIPINE,"1. The drug PROCARDIA XL (nifedipine) is a calcium channel blocker that inhibits calcium ion influx into cardiac muscle and smooth muscle, without altering serum calcium concentrations. This mechanism of action is associated with a negative inotropic effect on isolated myocardial tissue, but this effect is rarely seen in intact animals or humans due to reflex responses to its vasodilating effects.

2. PROCARDIA XL is indicated for the management of vasospastic angina and chronic stable angina, as well as hypertension. The drug has been shown to reduce angina frequency and increase exercise tolerance in controlled trials, but long-term effectiveness and safety in these patients are still being evaluated.

3. There have been reports of increased frequency, duration, and severity of angina or acute myocardial infarction in some patients with severe obstructive coronary artery disease upon starting nifedipine or during dosage increases. The mechanism of this effect is not established, suggesting a potential association with the drug.

4. Patients recently withdrawn from beta blockers may develop a withdrawal syndrome with increased angina upon initiation of nifedipine treatment. This occurrence is not prevented by nifedipine and may even exacerbate it, indicating a potential risk when transitioning between medications.

5. Rare cases of patients, usually receiving a beta blocker, developing heart failure after starting nifedipine have been reported. Patients with tight aortic stenosis may be at greater risk for this event, suggesting a potential association between nifedipine use and heart failure in certain patient populations.

6. There have been rare reports of obstructive symptoms, including gastrointestinal obstruction requiring surgery, in patients with known strictures associated with the ingestion of PROCARDIA XL. This suggests a potential risk of gastrointestinal obstruction with the use of the drug.

7. Cases of tablet adherence to the gastrointestinal wall with ulceration have been reported, some requiring hospitalization and intervention. This indicates a potential risk of gastrointestinal ulcers associated with the use of PROCARDIA XL.

8. Nifedipine has been shown to decrease platelet aggregation
in vitro, which may result in a moderate decrease in platelet aggregation and an increase in bleeding time in some patients. This suggests a potential cardiotoxic effect on platelet function associated with nifedipine use.

9. Positive direct Coombs test with or without hemolytic anemia has been reported in patients taking nifedipine, although a causal relationship between nifedipine administration and this laboratory test could not be determined. This indicates a potential association between nifedipine use and hemolytic anemia, although the exact mechanism is unclear.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",8ebcb33c-f43b-4b36-9f94-9774b2a59e06,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8ebcb33c-f43b-4b36-9f94-9774b2a59e06&type=display
752,NIFURTIMOX,"1. **Potential for Genotoxicity and Carcinogenicity**: The drug LAMPIT has demonstrated genotoxicity in humans, in vitro in bacterial species and mammalian cell systems, and in vivo in rodents. However, it is not known if LAMPIT is associated with carcinogenicity in humans.

2. **Embryo-Fetal Toxicity**: LAMPIT can cause fetal harm when administered to pregnant women based on animal studies. It was associated with reduced maternal body weights, abortions, fetal death, and smaller litter sizes in animals at doses equivalent to the maximum recommended human dose. Fetal malformations were also observed in animals at doses less than the maximum recommended human dose.

3. **Adverse Reactions**: In clinical trials, LAMPIT did not result in large mean increases in the QTc interval, indicating no significant cardiotoxicity at the recommended dose. 

4. **Postmarketing Experience**: Postmarketing surveillance reported cases of vertigo, angioedema, and muscle weakness in patients treated with nifurtimox, the active ingredient in LAMPIT. However, it is not explicitly stated whether these reactions were directly associated with cardiotoxicity. 

Overall, while LAMPIT has been associated with potential genotoxicity and embryo-fetal toxicity, there is no direct mention of cardiotoxicity as a known risk or adverse reaction of the drug itself.",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",90d09714-a8b1-4696-8ada-f99dc54d0721,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=90d09714-a8b1-4696-8ada-f99dc54d0721&type=display
753,NILOTINIB,"1. Tasigna prolongs the QT interval, which can lead to ventricular tachycardia and sudden deaths. The drug itself is associated with the risk of QT prolongation and sudden deaths.

2. Sudden deaths have been reported in patients receiving Tasigna, suggesting the possibility of ventricular repolarization abnormalities contributing to these occurrences. The drug itself is associated with the risk of sudden deaths.

3. Cardiovascular events, including arterial vascular occlusive events, were observed in patients receiving Tasigna therapy, with a higher incidence compared to the control group. The drug itself is associated with the risk of cardiovascular events and arterial vascular occlusive events.

4. Tasigna can cause increases in serum lipase, and patients with a history of pancreatitis may be at greater risk. The drug itself is associated with the risk of elevated serum lipase, which can be an indicator of pancreatitis.

5. Tasigna may result in hepatotoxicity, as indicated by elevations in bilirubin, AST, ALT, and alkaline phosphatase levels. The drug itself is associated with the risk of hepatotoxicity.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",6093952a-5248-45cb-ad17-33716a411146,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=6093952a-5248-45cb-ad17-33716a411146&type=display
754,NIMODIPINE,"1. The drug NYMALIZE (nimodipine) is a dihydropyridine calcium channel blocker indicated for improving neurological outcomes in adult patients with subarachnoid hemorrhage (SAH) from ruptured intracranial berry aneurysms, regardless of their post-ictus neurological condition. The drug itself is not associated with cardiotoxicity risk.

2. Patients with cirrhosis may be at a higher risk of adverse reactions, including cardiotoxicity, due to increased plasma levels of nimodipine. The drug itself is associated with a potential increased risk of cardiotoxicity in patients with cirrhosis.

3. Concomitant use of strong CYP3A4 inhibitors with nimodipine, such as certain antibiotics and antifungal medications, may significantly increase the risk of hypotension, a cardiotoxicity reaction. The drug itself is not directly causing cardiotoxicity but may lead to hypotension, a cardiotoxic effect.

4. Nimodipine plasma concentration and efficacy may be significantly reduced when used with strong CYP3A4 inducers, potentially impacting its cardiotoxicity profile. The drug itself is not causing cardiotoxicity but may have reduced efficacy due to interactions with CYP3A4 inducers.

5. The most common adverse reactions associated with NYMALIZE include hypotension, headache, nausea, and bradycardia. Hypotension is a cardiotoxicity reaction that has been reported with the use of nimodipine.",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",e660fa26-b5c4-4d6d-8887-9e22b6666a10,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=e660fa26-b5c4-4d6d-8887-9e22b6666a10&type=display
755,NINTEDANIB,"1. Arterial thromboembolic events have been reported in patients taking OFEV, with myocardial infarction being the most common adverse reaction under arterial thromboembolic events. The drug OFEV itself is associated with an increased risk of arterial thromboembolic events, including myocardial infarction.

2. Use caution when treating patients at higher cardiovascular risk, including those with known coronary artery disease, due to the potential risk of arterial thromboembolic events associated with OFEV. The drug OFEV itself is associated with an increased risk of arterial thromboembolic events in patients at higher cardiovascular risk.

3. Based on the mechanism of action (VEGFR inhibition), OFEV may increase the risk of bleeding, with epistaxis being the most frequent bleeding event reported. The drug OFEV itself is associated with an increased risk of bleeding due to its mechanism of action involving VEGFR inhibition.

4. Gastrointestinal perforation has been reported as a potential risk with OFEV, and caution should be exercised when treating patients with recent abdominal surgery or a history of diverticular disease. The drug OFEV itself is associated with an increased risk of gastrointestinal perforation, particularly in patients with certain risk factors.

5. Nephrotic range proteinuria has been reported as a potential adverse reaction with OFEV, and treatment interruption should be considered for patients who develop new or worsening proteinuria. The drug OFEV itself is associated with the development of nephrotic range proteinuria as an adverse reaction.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",da1c9f37-779e-4682-816f-93d0faa4cfc9,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=da1c9f37-779e-4682-816f-93d0faa4cfc9&type=display
756,NIRAPARIB,"1. **Cardiotoxicity Risk**: ZEJULA has been associated with hypertension and hypertensive crisis in patients treated with the drug. The drug itself is linked to the risk of hypertension and cardiovascular effects.

2. **Monitoring**: Patients receiving ZEJULA should have their blood pressure and heart rate monitored at least weekly for the first 2 months, then monthly for the first year, and periodically thereafter during treatment. This monitoring is necessary due to the potential cardiotoxic effects of the drug.

3. **Management**: Hypertension should be managed with antihypertensive medications, and the dose of ZEJULA may need adjustment if necessary. This indicates that ZEJULA can contribute to cardiovascular effects that require active management.

4. **Posterior Reversible Encephalopathy Syndrome (PRES)**: PRES, a condition that can involve altered mental status, visual disturbances, or seizures, has occurred in patients treated with ZEJULA. The drug is associated with the risk of PRES, which can have cardiovascular implications.

5. **Discontinuation**: In cases where PRES is suspected, ZEJULA should be promptly discontinued, and appropriate treatment should be administered. This highlights the potential severity of cardiotoxic reactions associated with ZEJULA.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",b7f675e2-159c-490c-b6f4-3f16d9492b7d,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=b7f675e2-159c-490c-b6f4-3f16d9492b7d&type=display
757,NISOLDIPINE,"1. The drug label mentions that patients with severe obstructive coronary artery disease have rarely developed increased frequency, duration, and/or severity of angina or acute myocardial infarction upon starting calcium channel blocker therapy or increasing the dosage. The label states that this effect was seen about 1.5% of the time in patients given nisoldipine compared to 0.9% in patients given placebo. This suggests that nisoldipine may be associated with an increased risk of angina or myocardial infarction in patients with severe obstructive coronary artery disease.

2. The label also warns about the potential for increased angina and/or myocardial infarction in patients with coronary artery disease. Controlled studies of SULAR in patients with angina showed an incidence of about 1.5% in patients given nisoldipine compared to 0.9% in patients given placebo. This indicates that nisoldipine may be associated with an increased risk of angina and myocardial infarction in patients with coronary artery disease.

3. The label advises caution when using SULAR in patients with heart failure or compromised ventricular function, particularly when used in combination with a beta-blocker. Although acute hemodynamic studies did not demonstrate negative inotropic effects, the safety of SULAR in patients with heart failure has not been established. This suggests that nisoldipine may pose a risk of worsening heart failure in patients with compromised ventricular function.

4. The label mentions that nisoldipine did not lead to worsening of clinical heart failure in studies of patients with asymptomatic and symptomatic left ventricular dysfunction. However, there is limited information on the use of nisoldipine in patients with severe congestive heart failure, and caution is advised when using all calcium channel blockers in any patient with heart failure. This indicates that while nisoldipine did not worsen heart failure in certain studies, caution is still recommended due to the lack of data in patients with severe congestive heart failure.",Less,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",589157fa-d129-4de3-be3d-e0e1c22c5873,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=589157fa-d129-4de3-be3d-e0e1c22c5873&type=display
758,NITAZOXANIDE,"1. The drug label does not mention any cardiotoxicity risks or cardiotoxicity reactions associated with ALINIA (nitazoxanide) tablets or oral suspension.

2. There is no information in the drug label indicating that ALINIA (nitazoxanide) is associated with cardiotoxicity risks or cardiotoxicity reactions.

3. Cardiotoxicity is not listed as a risk or reaction in the drug label for ALINIA (nitazoxanide) tablets or oral suspension.

Overall, based on the information provided in the drug label, there are no mentions of cardiotoxicity risks or cardiotoxicity reactions associated with the use of ALINIA (nitazoxanide) for the treatment of diarrhea caused by Giardia lamblia or Cryptosporidium parvum.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",e90f98d9-3c9b-4e75-ba18-5517283eadf0,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=e90f98d9-3c9b-4e75-ba18-5517283eadf0&type=display
759,NITISINONE,"1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with NITYR (nitisinone) itself.

2. The drug label primarily focuses on ocular symptoms, developmental delay, and hyperkeratotic plaques due to elevated plasma tyrosine levels as potential adverse effects of NITYR treatment. These symptoms are related to elevated plasma tyrosine levels and not directly linked to cardiotoxicity.

3. While the label discusses leukopenia and severe thrombocytopenia as potential adverse reactions to another oral formulation of nitisinone, there is no mention of cardiotoxicity risks or reactions in relation to these hematologic abnormalities.

4. Overall, the drug label does not indicate any direct association between NITYR (nitisinone) and cardiotoxicity risks or reactions. The focus is primarily on ocular symptoms, developmental delay, hyperkeratotic plaques, leukopenia, and thrombocytopenia as potential adverse effects of the medication.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",00fd1905-27e4-420e-8dc5-a69e4ddc1526,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=00fd1905-27e4-420e-8dc5-a69e4ddc1526&type=display
760,NITROFURANTOIN,"1. **Warnings and Precautions (5.2):** The drug label mentions that pulmonary reactions, including acute, subacute, or chronic pulmonary reactions, have been reported in patients treated with FURADANTIN. The drug itself is associated with pulmonary reactions, which can contribute to cardiotoxicity risks.

2. **Warnings and Precautions (5.3):** Hepatic reactions, including hepatitis, cholestatic jaundice, chronic active hepatitis, and hepatic necrosis, have occurred with FURADANTIN. While these reactions primarily affect the liver, severe hepatic issues can lead to systemic complications, including potential cardiotoxicity risks.

3. **Warnings and Precautions (5.4):** Peripheral neuropathy, which may become severe or irreversible, has occurred with FURADANTIN. Conditions like renal impairment and anemia can enhance the occurrence of peripheral neuropathy, which can indirectly impact cardiac function and pose cardiotoxicity risks.

4. **Warnings and Precautions (5.5):** Cases of hemolytic anemia, specifically of the primaquine-sensitivity type, have been induced by nitrofurantoin, the active ingredient in FURADANTIN. Hemolysis linked to glucose-6-phosphate dehydrogenase deficiency can lead to anemia-related cardiac complications, highlighting potential cardiotoxicity risks associated with this drug.

5. **Warnings and Precautions (5.6):** FURADANTIN use has been associated with
Clostridioides difficile
-associated diarrhea, which can range from mild to fatal colitis. Severe cases of
Clostridioides difficile
infections can lead to systemic complications, including electrolyte imbalances that may affect cardiac function, posing cardiotoxicity risks.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",00af0dea-ac7b-43f2-9f51-2a9f9e7f7d21,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=00af0dea-ac7b-43f2-9f51-2a9f9e7f7d21&type=display
761,NITROGLYCERIN,"1. The drug RECTIV (nitroglycerin) is a nitrate vasodilator that can result in hypotension due to venous and arterial dilatation, potentially affecting patients with conditions like blood volume depletion, existing hypotension, cardiomyopathies, congestive heart failure, acute myocardial infarction, or poor cardiac function for other reasons. This indicates that the drug itself is associated with the risk of hypotension and cardiovascular effects.

2. Nitroglycerin, the active ingredient in RECTIV, can produce dose-related headaches, which may be severe. This suggests that the drug itself can cause headaches as a common adverse reaction.

3. The most common adverse reactions of RECTIV are headache and dizziness, indicating that the drug itself can lead to these cardiotoxicity reactions.

4. The drug label also mentions that transient episodes of light-headedness, occasionally related to blood pressure changes, may occur with RECTIV, and hypotension, including orthostatic hypotension, can infrequently happen, potentially warranting discontinuation of therapy. This highlights that the drug itself can cause light-headedness, hypotension, and related cardiovascular effects.

5. Additionally, allergic reactions, flushing, and application site reactions like drug rash and exfoliative dermatitis have been reported rarely with RECTIV, suggesting that the drug itself can lead to allergic and dermatological cardiotoxicity reactions.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",603aa9ed-54c4-4a35-ade4-690fa44850e4,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=603aa9ed-54c4-4a35-ade4-690fa44850e4&type=display
762,NIZATIDINE,"1. In clinical pharmacology studies, short episodes of asymptomatic ventricular tachycardia occurred in 2 individuals administered nizatidine and in 3 untreated subjects. (The drug itself was associated with the risk of short episodes of asymptomatic ventricular tachycardia.)

2. Rare cases of reversible mental confusion have been reported. (The drug itself was not directly associated with the risk of reversible mental confusion.)

3. Rare reports of gynecomastia occurred. (The drug itself was not directly associated with the risk of gynecomastia.)

4. Rare cases of thrombocytopenic purpura have been reported. (The drug itself was not directly associated with the risk of thrombocytopenic purpura.)

5. Rare episodes of hypersensitivity reactions (eg, bronchospasm, laryngeal edema, rash, and eosinophilia) have been reported. (The drug itself was associated with the risk of hypersensitivity reactions.)

6. Serum sickness-like reactions have occurred rarely in conjunction with nizatidine use. (The drug itself was associated with the risk of serum sickness-like reactions.)

7. In clinical trials, anemia and urticaria were significantly more common in the nizatidine group compared to placebo. (The drug itself was associated with the risk of anemia and urticaria.)

8. Hepatocellular injury, evidenced by elevated liver enzyme tests, occurred in some patients and was possibly or probably related to nizatidine. (The drug itself was associated with the risk of hepatocellular injury and elevated liver enzymes.)

9. Since market introduction, hepatitis and jaundice have been reported. Rare cases of cholestatic or mixed hepatocellular and cholestatic injury with jaundice have been reported with reversal of the abnormalities after discontinuation of nizatidine. (The drug itself was associated with the risk of hepatitis, jaundice, and cholestatic or mixed hepatocellular and cholestatic injury.)

10. In clinical trials, anemia was reported significantly more frequently in nizatidine-treated patients. Fatal thrombocytopenia was reported in a patient who was treated with nizatidine and another H2-receptor antagonist. (The drug itself was associated with the risk of anemia and fatal thrombocytopenia.)

Please note that these summaries are based on the information provided in the drug label and do not constitute medical advice.",Less,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",39e62997-8781-449a-e054-00144ff88e88,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=39e62997-8781-449a-e054-00144ff88e88&type=display
763,NOREPINEPHRINE BITARTRATE,"1. **Cardiac Arrhythmias**: LEVOPHED may cause arrhythmias. Patients with underlying heart disease should have their cardiac function monitored. (The drug itself is associated with the risk of causing cardiac arrhythmias.)
   
2. **Hypotension After Abrupt Discontinuation**: Sudden cessation of the infusion rate may lead to marked hypotension. Gradual reduction of the LEVOPHED infusion rate is recommended to prevent this. (The drug itself is associated with the risk of causing hypotension after abrupt discontinuation.)

3. **Cardiac Arrhythmias**: LEVOPHED elevates intracellular calcium concentrations and may cause arrhythmias, particularly in the presence of hypoxia or hypercarbia. Continuous cardiac monitoring is advised for patients with arrhythmias. (The drug itself is associated with the risk of causing cardiac arrhythmias.)

4. **Hypotension after Abrupt Discontinuation**: Sudden cessation of the infusion rate may result in marked hypotension. Gradual reduction of the LEVOPHED infusion rate is recommended while expanding blood volume with intravenous fluids. (The drug itself is associated with the risk of causing hypotension after abrupt discontinuation.)

5. **Cardiac Arrhythmias**: LEVOPHED may cause arrhythmias. Monitor cardiac function in patients with underlying heart disease. (The drug itself is associated with the risk of causing cardiac arrhythmias.)

6. **Cardiac Arrhythmias**: LEVOPHED elevates intracellular calcium concentrations and may cause arrhythmias, particularly in the setting of hypoxia or hypercarbia. Perform continuous cardiac monitoring of patients with arrhythmias. (The drug itself is associated with the risk of causing cardiac arrhythmias.)

7. **Cardiac Arrhythmias**: LEVOPHED may cause arrhythmias. Monitor cardiac function in patients with underlying heart disease. (The drug itself is associated with the risk of causing cardiac arrhythmias.)",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",2c7dd2b0-cc10-4db6-bf56-6eb154ebeb10,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=2c7dd2b0-cc10-4db6-bf56-6eb154ebeb10&type=display
764,NORETHINDRONE,"1. The drug label warns that cigarette smoking increases the risk of serious cardiovascular disease and advises women using oral contraceptives, like Micronor, not to smoke. (The drug itself is not associated with cardiotoxicity but smoking while using the drug increases the risk of cardiovascular issues.)

2. The drug label states that the relationship between progestin-only oral contraceptives, like Micronor, and serious health risks associated with estrogen components of combined oral contraceptives is not fully defined. It advises healthcare professionals to remain alert to the earliest manifestation of symptoms of any serious disease and discontinue oral contraceptive therapy when appropriate. (The drug itself is not directly linked to cardiotoxicity risks but the relationship with serious health risks is not fully understood.)

3. The drug label mentions that some epidemiological studies have reported an increased relative risk of developing breast cancer in oral contraceptive users, particularly at a younger age and apparently related to duration of use. However, these studies predominantly involved combined oral contraceptives, and there is insufficient data to determine if the use of progestin-only oral contraceptives, like Micronor, similarly increases the risk. (The drug itself is not definitively associated with cardiotoxicity risks, but there are concerns about potential links to breast cancer.)

4. The drug label discusses the risk of benign hepatic adenomas associated with combined oral contraceptive use, although the incidence of benign tumors is rare in the United States. Rupture of benign hepatic adenomas may cause death through intraabdominal hemorrhage. Studies have shown an increased risk of developing hepatocellular carcinoma in combined oral contraceptive users, but these cancers are rare in the U.S. There is insufficient data to determine whether progestin-only oral contraceptives, like Micronor, increase the risk of developing hepatic neoplasia. (The drug itself is not directly linked to cardiotoxicity risks, but there are concerns about liver tumors associated with combined oral contraceptives, and insufficient data for progestin-only contraceptives.)

5. The drug label mentions that lipid metabolism may be affected by progestin-only oral contraceptives, with changes in HDL, HDL2, apolipoprotein A-I and A-II, and hepatic lipase levels. However, there is usually no effect on total cholesterol, HDL3, LDL, or VLDL. (The drug itself may have some impact on lipid metabolism but is not directly associated with cardiotoxicity risks.)

Overall, the drug label for Micronor does not directly attribute cardiotoxicity risks to the drug itself but highlights potential concerns related to cardiovascular health, particularly in relation to smoking, breast cancer, and hepatic neoplasia. It emphasizes the importance of healthcare professionals monitoring for early signs of serious diseases and discontinuing therapy when appropriate.",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",6fea0c04-cfbc-4bd2-8a1f-fa3d5ed2a941,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=6fea0c04-cfbc-4bd2-8a1f-fa3d5ed2a941&type=display
765,NORTRIPTYLINE HYDROCHLORIDE,"1. The drug label mentions that Pamelor is contraindicated during the acute recovery period after myocardial infarction, indicating that the drug itself is associated with a cardiotoxicity risk in this specific patient population.

2. The label also states that cardiovascular adverse reactions such as hypotension, hypertension, tachycardia, palpitation, myocardial infarction, arrhythmias, heart block, stroke, and other cardiac issues have been reported with the use of Pamelor, suggesting that the drug itself may cause cardiotoxicity reactions in patients.

3. Additionally, the label mentions that there have been reports of patients recovering from nortriptyline overdoses of up to 525 mg, indicating the potential for cardiotoxicity and other adverse effects associated with overdose of the drug.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",e17dc299-f52d-414d-ab6e-e809bd6f8acb,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=e17dc299-f52d-414d-ab6e-e809bd6f8acb&type=display
766,NUSINERSEN,"1. **Clinical Pharmacology Section (12.2):**
   - The drug, SPINRAZA, was not associated with an increased risk of cardiac adverse reactions related to delayed ventricular repolarization in patients treated with SPINRAZA compared to the sham-control group.

2. **Clinical Studies Section (14.1):**
   - In the clinical trial for infantile-onset SMA, SPINRAZA was not linked to any cardiotoxicity risks or reactions. The study primarily focused on motor milestone improvements and survival outcomes in patients with SMA.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",dd70cd5f-b0fc-4ba4-a5ea-89a34778bd94,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=dd70cd5f-b0fc-4ba4-a5ea-89a34778bd94&type=display
767,OBETICHOLIC ACID,"1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with OCALIVA (obeticholic acid) tablets. 

2. The focus of the drug label primarily revolves around hepatic decompensation and failure in patients with primary biliary cholangitis (PBC) and cirrhosis, rather than cardiotoxicity risks. 

3. Therefore, based on the information provided in the drug label, OCALIVA is not directly associated with cardiotoxicity risks or reactions.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",cdfbe0cd-eb15-45a1-ac17-531bcda21aec,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=cdfbe0cd-eb15-45a1-ac17-531bcda21aec&type=display
768,OCTREOTIDE,"1. Cardiac Function Abnormalities: Octreotide, the active ingredient in MYCAPSSA, may lead to bradycardia, arrhythmia, or conduction abnormalities. The drug itself is associated with these cardiac function abnormalities, as reported in clinical trials with MYCAPSSA.

2. ECG Changes: MYCAPSSA treatment has been linked to various ECG changes, including QT prolongation, axis shifts, early repolarization, low voltage, R/S transition, and early R wave progression. These ECG changes are attributed to the drug itself, as observed in patients with acromegaly during MYCAPSSA clinical trials.

3. Dosage Adjustments: Due to the potential cardiac effects of MYCAPSSA, adjustments in the dosage of concomitantly used drugs that have bradycardia effects, such as beta-blockers, may be necessary. The drug itself can impact the efficacy and safety of other medications that affect cardiac function.

4. Adverse Reactions: MYCAPSSA has been associated with adverse reactions related to cardiac function, including bradycardia, conduction abnormalities, and arrhythmias/tachycardia. These reactions are directly linked to the drug itself and have been reported in patients with acromegaly receiving MYCAPSSA.

5. Monitoring: Regular monitoring of cardiac function is recommended during MYCAPSSA treatment to detect any potential abnormalities early. The drug itself may impact cardiac function, necessitating close monitoring to ensure patient safety and appropriate management of any adverse effects.",Less,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",58d80bc6-bdfb-4908-93e7-aace447c8d1a,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=58d80bc6-bdfb-4908-93e7-aace447c8d1a&type=display
769,OCTREOTIDE ACETATE,"1. Cardiac Function: The drug SANDOSTATIN LAR DEPOT has been associated with bradycardia, arrhythmias, and conduction abnormalities in both acromegalic and carcinoid syndrome patients. Other ECG changes, such as QT prolongation, have been observed, but the relationship of these events to octreotide acetate is not established due to underlying cardiac disease in many patients.

2. Cardiac Function Abnormalities: In acromegalic patients treated with SANDOSTATIN LAR DEPOT, sinus bradycardia, conduction abnormalities, and arrhythmias have been reported. The drug itself may have contributed to these cardiac events, although the presence of underlying cardiac disease in many patients complicates the assessment of causality.",Less,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",d0b7fe9e-7000-4b79-ba3b-291ce92c14f9,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=d0b7fe9e-7000-4b79-ba3b-291ce92c14f9&type=display
770,ODEVIXIBAT,"1. **Pregnancy Risk**: Based on animal data, BYLVAY may cause cardiac malformations when a fetus is exposed during pregnancy. Pregnant rabbits treated with odevixibat showed an increase in cardiovascular malformations, including heart defects, at all doses tested, indicating a potential risk of cardiotoxicity associated with the drug.

2. **Pediatric Use**: Clinical studies did not include patients 65 years of age and older, as PFIC and ALGS are primarily diseases of pediatric and young adult patients. Therefore, there is no specific mention of cardiotoxicity risks associated with the drug in the elderly population.

3. **Animal Data**: In animal studies, odevixibat was shown to cross the placenta in pregnant rats, and cardiac malformations were observed in fetal rabbits exposed to the drug during organogenesis. These findings suggest a potential risk of cardiotoxicity in fetuses exposed to BYLVAY during pregnancy.

4. **Lactation Risk**: Odevixibat has low absorption following oral administration, and breastfeeding is not expected to result in exposure of the infant to BYLVAY at recommended doses. However, there is no specific mention of cardiotoxicity risks associated with the drug during lactation.

5. **Geriatric Use**: Clinical studies in BYLVAY did not include patients 65 years of age and older, so there is no direct information on cardiotoxicity risks associated with the drug in the elderly population.

Overall, the drug label indicates a potential risk of cardiotoxicity, specifically cardiac malformations, associated with BYLVAY based on animal data and exposure during pregnancy. The risk of cardiotoxicity in specific populations such as the elderly or during lactation is not explicitly mentioned in the provided drug label information.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",0935cd31-3251-4a0a-ac23-25ca4be12be9,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=0935cd31-3251-4a0a-ac23-25ca4be12be9&type=display
771,OLANZAPINE,"1. The drug label warns of increased mortality in elderly patients with dementia-related psychosis treated with antipsychotic drugs, including ZYPREXA. Elderly patients with dementia-related psychosis are at an increased risk of death, with most deaths being cardiovascular or infectious in nature. ZYPREXA is not approved for this patient population.

2. The drug label mentions that ZYPREXA may cause orthostatic hypotension, which can be associated with dizziness, tachycardia, bradycardia, and syncope, especially during initial dose titration. Patients with cardiovascular or cerebrovascular disease should use caution due to the potential for hemodynamic responses affecting orthostatic hypotension.

3. ZYPREXA has been associated with metabolic changes, including hyperglycemia, dyslipidemia, and weight gain. Patients taking ZYPREXA should be monitored for symptoms of hyperglycemia, undergo fasting blood glucose testing at the beginning of treatment, and receive regular monitoring of weight.

4. The drug label mentions that ZYPREXA may elevate prolactin levels, which can lead to hyperprolactinemia. This effect is associated with the use of ZYPREXA.

5. ZYPREXA has the potential to impair judgment, thinking, and motor skills, which could lead to cognitive and motor impairment. Patients should use caution when operating machinery while taking ZYPREXA.

6. The drug label advises monitoring for leukopenia, neutropenia, and agranulocytosis in patients taking ZYPREXA. Patients with a history of low white blood cell count or drug-induced leukopenia/neutropenia should have their complete blood count monitored frequently, and discontinuation of ZYPREXA should be considered if a clinically significant decline in white blood cell count occurs.

7. ZYPREXA may cause drug reaction with eosinophilia and systemic symptoms (DRESS), a severe hypersensitivity reaction. If DRESS is suspected, ZYPREXA should be discontinued.",Less,Yes,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",d5051fbc-846b-4946-82df-341fb1216341,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=d5051fbc-846b-4946-82df-341fb1216341&type=display
772,OLANZAPINE PAMOATE,"1. The drug label warns about an increased risk of death in elderly patients with dementia-related psychosis treated with antipsychotic drugs, including ZYPREXA RELPREVV. The label states that analyses of trials revealed a higher risk of death in drug-treated patients compared to placebo-treated patients, with causes of death including cardiovascular events like heart failure and infectious events like pneumonia. ZYPREXA RELPREVV is not approved for treating dementia-related psychosis.

2. The label mentions cerebrovascular adverse events, such as stroke and transient ischemic attack, reported in elderly patients with dementia-related psychosis in trials of oral olanzapine. There was a significantly higher incidence of these events in patients treated with oral olanzapine compared to placebo. ZYPREXA RELPREVV is not approved for treating dementia-related psychosis.

3. The drug label does not specifically mention cardiotoxicity risks or reactions associated with ZYPREXA RELPREVV itself, but it does highlight the potential for cardiovascular adverse events in elderly patients with dementia-related psychosis who are treated with antipsychotic drugs, including olanzapine.",Less,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",f9a73185-88de-4d7b-b3c0-bbf231483241,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=f9a73185-88de-4d7b-b3c0-bbf231483241&type=display
773,OLAPARIB,"1. **Warnings and Precautions:** The drug label mentions the risk of Myelodysplastic Syndrome/Acute Myeloid Leukemia (MDS/AML) associated with Lynparza. It states that MDS/AML occurred in approximately 1.2% of patients with various genetic mutations exposed to Lynparza, and the majority of events had a fatal outcome. The label advises monitoring patients for hematological toxicity and discontinuing Lynparza if MDS/AML is confirmed. (The drug Lynparza is associated with the risk of MDS/AML.)

2. **Warnings and Precautions:** The drug label also highlights the risk of Pneumonitis associated with Lynparza. It mentions that pneumonitis occurred in 0.8% of patients exposed to Lynparza, and some cases were fatal. The label recommends interrupting treatment if pneumonitis is suspected and discontinuing Lynparza if pneumonitis is confirmed. (The drug Lynparza is associated with the risk of pneumonitis.)

3. **Warnings and Precautions:** The drug label further discusses the risk of Venous Thromboembolism (VTE), including severe or fatal pulmonary embolism (PE), in patients treated with Lynparza. It states that VTE occurred in 8% of patients with metastatic castration-resistant prostate cancer who received Lynparza. The label advises monitoring patients for signs and symptoms of VTE and PE and treating them appropriately. (The drug Lynparza is associated with the risk of VTE, including PE.)

4. **Warnings and Precautions:** The drug label also addresses the potential for Embryo-Fetal Toxicity with Lynparza. It warns that Lynparza can cause fetal harm and advises healthcare providers to inform pregnant women of the potential risk to a fetus. The label recommends using effective contraception during treatment with Lynparza. (The drug Lynparza is associated with the risk of embryo-fetal toxicity.)",Less,No,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",741ff3e3-dc1a-45a6-84e5-2481b27131aa,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=741ff3e3-dc1a-45a6-84e5-2481b27131aa&type=display
774,OLICERIDINE,"1. The drug label mentions that there was mild QTc interval prolongation observed with the use of oliceridine, the active ingredient in OLINVYK, in thorough QT studies. The maximum mean QTcI was 11.7 ms at 9 hours with a maximum daily cumulative dose of 27 mg, indicating a potential risk of QT prolongation with OLINVYK use.

2. It is stated that total cumulative daily doses exceeding 27 mg per day may increase the risk for QTc interval prolongation, and therefore, the cumulative total daily dose of OLINVYK should not exceed 27 mg. This risk is associated with the drug OLINVYK itself.

3. Additionally, the drug label mentions that there is a potential for increased plasma concentrations of oliceridine, leading to prolonged opioid adverse reactions and exacerbated respiratory depression, under certain conditions such as concomitant use with CYP3A4 inhibitors. This could indirectly contribute to cardiotoxicity risks due to respiratory depression affecting cardiac function.

4. The label also highlights the importance of monitoring patients closely for respiratory depression and sedation, especially when using OLINVYK in patients with decreased Cytochrome P450 (CYP) 2D6 function or concomitant use with CYP3A4 inhibitors. This emphasizes the need for vigilance in managing potential cardiotoxic effects associated with respiratory depression.",Less,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",ce167984-8b9d-40b7-84ce-d0f33fff1eaa,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=ce167984-8b9d-40b7-84ce-d0f33fff1eaa&type=display
775,OLMESARTAN MEDOXOMIL,"1. The drug label warns about fetal toxicity associated with BENICAR, stating that drugs acting on the renin-angiotensin system can cause injury and death to the developing fetus. BENICAR itself is associated with this fetal toxicity risk.

2. The label mentions a potential risk of hypotension in volume- or salt-depleted patients with an activated renin-angiotensin-aldosterone system, especially when initiating treatment with BENICAR. BENICAR itself is associated with the risk of hypotension in these specific patient populations.

3. BENICAR may lead to changes in renal function in susceptible individuals, particularly those with renal impairment, due to inhibiting the renin-angiotensin-aldosterone system. The drug label indicates that similar results may be expected in patients treated with BENICAR, suggesting an association between the drug and impaired renal function.

4. Severe, chronic diarrhea with substantial weight loss, known as sprue-like enteropathy, has been reported in patients taking olmesartan (the active ingredient in BENICAR) months to years after drug initiation. The label advises considering alternative antihypertensive therapy in cases where no other etiology is found, indicating a potential association between olmesartan (BENICAR) and sprue-like enteropathy.

5. Serum potassium should be monitored in patients receiving BENICAR, as drugs that inhibit the renin-angiotensin system can cause hyperkalemia. The drug label suggests that BENICAR itself is associated with the risk of hyperkalemia, especially in patients with specific risk factors.",Less,No,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",5b6f8a18-8f8a-4521-81c3-3a39c73c6646,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=5b6f8a18-8f8a-4521-81c3-3a39c73c6646&type=display
776,OLSALAZINE SODIUM,"1. The drug label mentions that mesalamine, the active ingredient in DIPENTUM, has been associated with acute intolerance syndrome, which may include symptoms such as cramping, acute abdominal pain, and bloody diarrhea, as well as other symptoms like fever, headache, and rash. This acute intolerance syndrome may be difficult to distinguish from an exacerbation of ulcerative colitis. The drug itself is associated with the risk of acute intolerance syndrome.

2. The label also warns about the potential for mesalamine-induced hypersensitivity reactions, which can involve internal organ involvement such as myocarditis, pericarditis, nephritis, hepatitis, pneumonitis, and hematologic abnormalities. The drug itself is associated with the risk of hypersensitivity reactions.

3. Additionally, the label mentions that there have been reports of hepatic failure in patients with pre-existing liver disease who have been administered mesalamine, which is the active moiety in DIPENTUM. The drug itself is associated with the risk of hepatic failure.

4. Severe cutaneous adverse reactions, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), have been reported with the use of mesalamine, the active moiety in DIPENTUM. The drug itself is associated with the risk of severe cutaneous adverse reactions.

5. The label also highlights the potential for increased prothrombin time in patients taking concomitant warfarin with mesalamine, which may necessitate monitoring and adjustment of warfarin dosage. The drug itself is associated with the risk of increased prothrombin time when used concomitantly with warfarin.",Most,No,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",8512d0c6-db4e-4673-b3b4-28975c18413f,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8512d0c6-db4e-4673-b3b4-28975c18413f&type=display
777,OMADACYCLINE,"1. **Warnings and Precautions Section:**
   - The drug label mentions a mortality imbalance in patients with Community-Acquired Bacterial Pneumonia (CABP) where a mortality rate of 2% was observed in NUZYRA-treated patients compared to 1% in moxifloxacin-treated patients. The cause of the mortality imbalance has not been established. This section does not directly associate the drug with causing cardiotoxicity risk.

2. **Adverse Reactions Section:**
   - The most common adverse reactions listed include hypertension, which is an incidence of 2%. This section does not directly state that the drug is associated with causing cardiotoxicity reactions.

3. **Clinical Trials Experience in Patients with Community-Acquired Bacterial Pneumonia:**
   - In Trial 1, which was a Phase 3 CABP trial, eight deaths (2%) occurred in patients treated with NUZYRA compared to four deaths (1%) in patients treated with moxifloxacin. All deaths occurred in patients >65 years of age, and the causes of death varied. This section does not explicitly link the drug to causing cardiotoxicity reactions.

4. **Selected Adverse Reactions Occurring in Less Than 2% of Patients:**
   - This section lists tachycardia and atrial fibrillation as cardiovascular system disorders reported in less than 2% of NUZYRA-treated patients in Trials 1, 2, and 3. While tachycardia and atrial fibrillation are cardiotoxicity risks, this section does not directly attribute these adverse reactions to the drug.

Overall, while the drug label mentions mortality imbalance and cardiovascular system disorders like tachycardia and atrial fibrillation, it does not explicitly state that NUZYRA is associated with causing cardiotoxicity risks or reactions.",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",51591524-4703-44c6-8bde-dce3e6a463d1,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=51591524-4703-44c6-8bde-dce3e6a463d1&type=display
778,OMEGA-3-ACID ETHYL ESTERS,"1. The drug label mentions that there is a possible association between omega-3-acid ethyl esters and more frequent recurrences of symptomatic atrial fibrillation or flutter in patients with paroxysmal or persistent atrial fibrillation, particularly within the first months of initiating therapy. This suggests that the drug itself may be associated with an increased risk of cardiotoxicity in the form of recurrent atrial fibrillation or flutter.

2. It is highlighted that omega-3-acid ethyl esters may increase levels of LDL cholesterol, and LDL levels should be monitored periodically during therapy. This indicates that the drug may have a cardiotoxic effect by potentially increasing LDL cholesterol levels, which is a risk factor for cardiovascular disease.

3. The drug label also mentions that omega-3-acid ethyl esters may prolong bleeding time, and patients taking the drug along with anticoagulants or other drugs affecting coagulation should be monitored periodically. This suggests a potential cardiotoxicity risk related to bleeding complications, especially when the drug is used in combination with other medications affecting blood clotting.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",5fe15bdb-f59f-4b87-8e5d-8a3d5683eb3d,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=5fe15bdb-f59f-4b87-8e5d-8a3d5683eb3d&type=display
779,OMEPRAZOLE,"1. The drug label mentions that omeprazole delayed-release capsules have been associated with cardiovascular adverse reactions, such as chest pain or angina, tachycardia, bradycardia, palpitations, and elevated blood pressure, among others. These reactions were observed in clinical trials with the drug. (Adverse Reactions section)

2. Omeprazole delayed-release capsules have been linked to potential cardiovascular effects, including chest pain or angina, tachycardia, bradycardia, palpitations, and elevated blood pressure. These reactions were reported in patients who were treated with the drug. (Adverse Reactions section)

3. The drug label indicates that omeprazole delayed-release capsules may cause cardiovascular adverse reactions, such as chest pain or angina, tachycardia, bradycardia, palpitations, and elevated blood pressure. These reactions were observed in clinical trials involving the drug. (Adverse Reactions section)",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",b43f6b44-9de3-4efb-a467-487aee28f6a0,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=b43f6b44-9de3-4efb-a467-487aee28f6a0&type=display
780,OMEPRAZOLE MAGNESIUM,"1. **Interaction with Clopidogrel**: The drug label warns against concomitant use of PRILOSEC with clopidogrel due to the potential for reduced pharmacological activity of clopidogrel, even when administered 12 hours apart. This interaction is due to PRILOSEC inhibiting CYP2C19 activity, which impairs the metabolism of clopidogrel. Therefore, PRILOSEC itself is associated with the risk of reduced clopidogrel activity, which can impact cardiovascular outcomes.

2. **Interaction with Methotrexate**: The drug label mentions that concomitant use of PPIs, including PRILOSEC, with methotrexate may elevate and prolong serum levels of methotrexate and/or its metabolite, potentially leading to methotrexate toxicities. This indicates that PRILOSEC itself is associated with the risk of elevated methotrexate levels, which can lead to cardiotoxic effects.

3. **Bone Fracture**: The drug label states that long-term and multiple daily dose PPI therapy, including PRILOSEC, may be associated with an increased risk for osteoporosis-related fractures of the hip, wrist, or spine. The risk of fracture is increased in patients who receive high-dose and long-term PPI therapy. This suggests that PRILOSEC itself is linked to an increased risk of bone fractures, which can have implications for cardiovascular health.

Please note that while these sections of the drug label discuss cardiotoxicity risks and reactions associated with PRILOSEC, it is important to consult with a healthcare provider for a comprehensive understanding of the risks and benefits of using this medication.",Less,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",b6761f84-53ac-4745-a8c8-1e5427d7e179,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=b6761f84-53ac-4745-a8c8-1e5427d7e179&type=display
781,ONDANSETRON,"1. The drug label mentions that ondansetron injection can prolong the QT interval in a dose-dependent manner, and cases of Torsade de Pointes have been reported, indicating a risk of cardiotoxicity associated with the drug itself.
   
2. It is advised to avoid using ondansetron injection in patients with congenital long QT syndrome due to the potential for QT prolongation, suggesting a direct association with cardiotoxicity risk.

3. The label also highlights that myocardial ischemia has been reported in patients treated with ondansetron, particularly during intravenous administration, indicating a potential risk of cardiotoxicity associated with the drug.

4. Additionally, the drug label mentions that rare cases of angina, electrocardiographic alterations, hypotension, and tachycardia have been reported in patients receiving ondansetron, suggesting a possible association with cardiotoxicity reactions.

5. It is important to note that the drug label does not specify whether ondansetron itself directly caused these cardiotoxicity risks and reactions or if they were observed as potential adverse effects in patients receiving the medication.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",e3f22b7e-b6ad-4799-93c7-d30540cada85,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=e3f22b7e-b6ad-4799-93c7-d30540cada85&type=display
782,OPICAPONE,"1. **Cardiovascular Effects with Concomitant Use of Drugs Metabolized by Catechol-O-Methyltransferase (COMT):** The drug ONGENTYS may cause arrhythmias, increased heart rate, and excessive changes in blood pressure when used concomitantly with products metabolized by COMT. The drug itself is associated with the risk of cardiovascular effects.

2. **Hypotension/Syncope:** Hypotension, syncope, and presyncope occurred in patients treated with ONGENTYS compared to placebo. The drug ONGENTYS is associated with the risk of hypotension and syncope.

3. **Dyskinesia:** ONGENTYS may cause or exacerbate dyskinesia, which occurred more frequently in patients treated with ONGENTYS compared to placebo. The drug ONGENTYS is associated with the risk of dyskinesia.

4. **Hallucinations and Psychosis:** Hallucinations and psychotic-like behaviors occurred in patients treated with ONGENTYS compared to placebo. The drug ONGENTYS is associated with the risk of hallucinations and psychosis.

5. **Impulse Control/Compulsive Disorders:** Patients treated with ONGENTYS may experience intense urges and compulsive behaviors, which occurred in patients treated with ONGENTYS compared to placebo. The drug ONGENTYS is associated with the risk of impulse control and compulsive disorders.

6. **Withdrawal-Emergent Hyperpyrexia and Confusion:** A symptom complex resembling neuroleptic malignant syndrome has been reported with rapid dose reduction or withdrawal of drugs that increase central dopaminergic tone, but no reports were observed in ONGENTYS studies. The drug ONGENTYS is not directly associated with withdrawal-emergent hyperpyrexia and confusion.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",a511a531-112e-43f8-a43f-5334b0efe979,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a511a531-112e-43f8-a43f-5334b0efe979&type=display
783,ORITAVANCIN,"1. **Coagulation Test Interference**: ORBACTIV has been shown to artificially prolong aPTT, PT, INR, and ACT for certain durations after administration, which may interfere with coagulation tests. This effect is due to ORBACTIV binding to phospholipid reagents used in laboratory tests, but ORBACTIV does not affect the coagulation system in vivo.

2. **Hypersensitivity Reactions**: Serious hypersensitivity reactions, including anaphylaxis, have been reported with the use of oritavancin products, including ORBACTIV. If an acute hypersensitivity reaction occurs during ORBACTIV infusion, immediate discontinuation of ORBACTIV is recommended. Careful monitoring is advised for patients with known hypersensitivity to glycopeptides.

3. **Infusion Related Reactions**: ORBACTIV is associated with infusion-related reactions, including flushing, urticaria, pruritus, and rash. Stopping or slowing the infusion may help in ceasing these reactions. The safety and effectiveness of multiple doses of ORBACTIV during a single course of therapy have not been established.

4. **Potential Risk of Bleeding with Concomitant Use of Warfarin**: ORBACTIV has been shown to artificially prolong PT/INR for a certain duration, affecting the monitoring of the anticoagulation effect of warfarin. Patients should be closely monitored for bleeding if receiving ORBACTIV and warfarin concomitantly.

5. **Osteomyelitis**: In clinical trials, more cases of osteomyelitis were reported in ORBACTIV-treated patients compared to vancomycin-treated patients. Monitoring for signs and symptoms of osteomyelitis is recommended, and appropriate alternate antibacterial therapy should be instituted if osteomyelitis is suspected or diagnosed.

6. **Development of Drug Resistant Bacteria**: Prescribing ORBACTIV in the absence of proven or strongly suspected bacterial infections is cautioned against due to the risk of developing drug-resistant bacteria. This misuse is unlikely to benefit the patient and increases the resistance risk.",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",ff09a726-9f9b-4e30-b509-396781293220,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=ff09a726-9f9b-4e30-b509-396781293220&type=display
784,ORITAVANCIN DIPHOSPHATE,"1. **Warnings and Precautions (5.1):** Oritavancin has been shown to artificially prolong certain coagulation tests, such as aPTT, PT, INR, and ACT, for up to specific durations after administration, which may indicate a potential risk of coagulation-related issues. The drug itself is associated with interference in coagulation tests but does not affect the coagulation system in vivo.

2. **Warnings and Precautions (5.2):** Serious hypersensitivity reactions, including anaphylaxis, have been reported with the use of oritavancin products, including KIMYRSA. Acute hypersensitivity reactions may occur during infusion, leading to the discontinuation of KIMYRSA. The drug itself is associated with the potential for serious hypersensitivity reactions.

3. **Warnings and Precautions (5.3):** Infusion-related reactions, such as flushing, urticaria, pruritus, and rash, have been reported with the glycopeptide class of antimicrobial agents, including oritavancin products like KIMYRSA. Stopping or slowing the infusion may help in ceasing these reactions. The drug itself is associated with infusion-related reactions within the glycopeptide class.

4. **Warnings and Precautions (5.5):** Oritavancin has been shown to artificially prolong PT/INR for up to 12 hours, potentially affecting the monitoring of the anticoagulation effect of warfarin. Patients should be monitored for bleeding if concomitantly receiving KIMYRSA and warfarin. The drug itself is associated with the potential risk of affecting PT/INR levels when used concomitantly with warfarin.

5. **Warnings and Precautions (5.6):** In Phase 3 ABSSSI clinical trials, more cases of osteomyelitis were reported in the oritavancin-treated arm than in the vancomycin-treated arm. Patients treated with KIMYRSA should be monitored for signs and symptoms of osteomyelitis, and appropriate alternate antibacterial therapy should be instituted if osteomyelitis is suspected or diagnosed. The drug itself is associated with a higher incidence of osteomyelitis cases compared to the comparator arm in clinical trials.",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",5e755c40-6e73-4572-b474-4d8a131693d1,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=5e755c40-6e73-4572-b474-4d8a131693d1&type=display
785,ORLISTAT,"1. The drug label for XENICAL does not mention any specific cardiotoxicity risks or reactions associated with the use of the drug. 

2. There is no information in the drug label indicating that XENICAL is linked to any cardiotoxicity risks or reactions. 

3. XENICAL is not reported to have any cardiotoxicity risks or reactions according to the details provided in the drug label.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",6240792b-9224-2d10-e053-2a91aa0a2c3e,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=6240792b-9224-2d10-e053-2a91aa0a2c3e&type=display
786,ORPHENADRINE CITRATE,"1. The drug label mentions that orphenadrine citrate should be used with caution in patients with tachycardia, cardiac decompensation, coronary insufficiency, and cardiac arrhythmias. (The drug itself is associated with cardiotoxicity risks.)

2. Safety of continuous long-term therapy with orphenadrine has not been established, and periodic monitoring of blood, urine, and liver function values is recommended if orphenadrine is prescribed for prolonged use. (The drug itself is associated with cardiotoxicity risks.)

3. The drug label does not specifically mention any cardiotoxicity reactions associated with orphenadrine citrate.",Less,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",ed406e8a-ec00-4711-ae2b-3c5af4f15438,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=ed406e8a-ec00-4711-ae2b-3c5af4f15438&type=display
787,OSELTAMIVIR PHOSPHATE,"1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with TAMIFLU itself. 

2. The label does not indicate any direct association between TAMIFLU and cardiotoxicity risks or reactions. 

3. There is no mention of TAMIFLU being linked to cardiotoxicity risks or reactions in the drug label. 

Overall, the drug label for TAMIFLU does not highlight any cardiotoxicity risks or reactions directly attributed to the medication.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",ee3c9555-60f2-4f82-a760-11983c86e97b,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=ee3c9555-60f2-4f82-a760-11983c86e97b&type=display
788,OSILODROSTAT,"1. The drug ISTURISA (osilodrostat) is associated with a dose-dependent QT interval prolongation, which may cause cardiac arrhythmias. This risk is directly linked to the drug itself.
   
2. A thorough QT study showed a maximum mean estimated QTcF interval increase of up to 5.3 ms at the maximum recommended dosage of 30 mg twice daily. This study demonstrated that the drug itself can lead to QT interval prolongation, a known cardiotoxic effect.

3. Patients using ISTURISA should undergo an electrocardiogram to obtain a baseline QTc interval measurement before starting treatment and should be monitored for any effect on the QTc interval thereafter. Correcting hypokalemia and hypomagnesemia prior to initiating ISTURISA is recommended to mitigate potential cardiotoxicity risks associated with the drug.

4. The drug label also mentions the need to consider temporary discontinuation of ISTURISA in case of an increase in QTc interval exceeding 480 ms. This precaution is in place to prevent potential cardiac arrhythmias associated with QT prolongation caused by the drug.

5. Overall, the drug ISTURISA has been associated with QTc prolongation as a known cardiotoxic effect, and patients should be closely monitored for any cardiac adverse reactions while on this medication.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",f3a5ec24-63c3-4d83-b1c0-6c550fbe7ae2,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=f3a5ec24-63c3-4d83-b1c0-6c550fbe7ae2&type=display
789,OSIMERTINIB,"1. Cardiotoxicity risks associated with TAGRISSO include cardiomyopathy, with a reported occurrence in 3.8% of patients treated with the drug. The drug itself is associated with the risk of cardiomyopathy.
   
2. Patients receiving TAGRISSO should undergo cardiac monitoring, including left ventricular ejection fraction (LVEF) assessment, especially those with cardiac risk factors. The drug itself is associated with the need for cardiac monitoring due to potential cardiotoxicity risks.

3. A decline in LVEF 10 percentage points from baseline and to less than 50% LVEF occurred in a percentage of patients treated with TAGRISSO. The drug itself is associated with the potential for LVEF decline, indicating a cardiotoxic effect.

4. For patients receiving TAGRISSO in combination with pemetrexed and platinum-based chemotherapy, cardiac monitoring, including LVEF assessment, is recommended for all patients. The drug itself is associated with the need for cardiac monitoring in combination therapy due to potential cardiotoxicity risks.

5. Symptomatic congestive heart failure may occur in patients receiving TAGRISSO, leading to the recommendation for permanent discontinuation of the drug in such cases. The drug itself is associated with the risk of symptomatic congestive heart failure, warranting discontinuation.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",5e81b4a7-b971-45e1-9c31-29cea8c87ce7,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=5e81b4a7-b971-45e1-9c31-29cea8c87ce7&type=display
790,OSPEMIFENE,"1. The drug OSPHENA is associated with an increased risk of endometrial cancer due to its estrogen agonistic effects in the endometrium. Postmenopausal women with undiagnosed abnormal genital bleeding should undergo diagnostic measures to rule out malignancy, as unopposed estrogens can increase the risk of endometrial cancer.

2. OSPHENA has been linked to an increased risk of stroke and deep vein thrombosis (DVT) in postmenopausal women. The incidence rates of thromboembolic and hemorrhagic stroke were higher in the OSPHENA 60 mg treatment group compared to placebo, indicating a potential association with cardiovascular disorders.

3. The drug label warns about the risk of cardiovascular disorders, including thromboembolic and hemorrhagic stroke, associated with OSPHENA use. The incidence of DVT was also higher in the OSPHENA 60 mg treatment group compared to placebo, suggesting a potential cardiotoxicity risk with OSPHENA.

4. OSPHENA should be prescribed for the shortest duration consistent with treatment goals and risks for the individual woman due to the reported increased risk of stroke and DVT in postmenopausal women. The drug label emphasizes the importance of managing risk factors for cardiovascular disorders when using OSPHENA.

5. In clinical trials, OSPHENA was associated with thromboembolic and hemorrhagic stroke incidence rates, as well as an increased risk of DVT. The drug label advises discontinuing OSPHENA if thromboembolic or hemorrhagic stroke occurs or is suspected, highlighting the potential cardiotoxicity risks of OSPHENA.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",9accbcc9-78ee-4f84-9b7e-704f2ab1c413,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=9accbcc9-78ee-4f84-9b7e-704f2ab1c413&type=display
791,OXACILLIN,"1. The drug label does not mention any specific cardiotoxicity risks associated with Oxacillin Injection, USP.
2. The label does not indicate that Oxacillin Injection, USP is associated with any cardiotoxicity reactions.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",d893e45b-7f18-4c67-b10c-1e2e52a6b3ef,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=d893e45b-7f18-4c67-b10c-1e2e52a6b3ef&type=display
792,OXALIPLATIN,"1. Cardiovascular Toxicity: Oxaliplatin has been associated with QT prolongation and ventricular arrhythmias, including fatal Torsade de Pointes, as reported in postmarketing experiences following its administration. ECG monitoring is recommended for patients with certain conditions before initiating Oxaliplatin, such as congestive heart failure, bradyarrhythmias, or electrolyte abnormalities. Correcting hypokalemia or hypomagnesemia prior to starting Oxaliplatin is advised, and periodic monitoring of these electrolytes during therapy is recommended. Avoiding Oxaliplatin in patients with congenital long QT syndrome is also suggested. (The drug itself is associated with the risk of cardiotoxicity.)

2. Cardiovascular Toxicity: Rhabdomyolysis, including fatal cases, has been reported in patients treated with Oxaliplatin. Discontinuation of Oxaliplatin is recommended if any signs or symptoms of rhabdomyolysis occur. (The drug itself is associated with the risk of cardiotoxicity.)

3. Cardiovascular Toxicity: Pulmonary fibrosis, which may be fatal, has been associated with Oxaliplatin. Symptoms such as cough and dyspnea have been reported. In case of unexplained respiratory symptoms, Oxaliplatin should be discontinued until further pulmonary investigation excludes interstitial lung disease or pulmonary fibrosis. (The drug itself is associated with the risk of cardiotoxicity.)

4. Cardiovascular Toxicity: Oxaliplatin has been linked to hepatotoxicity, evidenced by an increase in transaminases and alkaline phosphatase. Changes noted on liver biopsies include various hepatic vascular disorders. Investigation should be considered in case of abnormal liver function test results or portal hypertension that cannot be explained by liver metastases. (The drug itself is associated with the risk of cardiotoxicity.)",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",9e51cc79-620c-48d7-b267-78e43c1ef6e4,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=9e51cc79-620c-48d7-b267-78e43c1ef6e4&type=display
793,OXAPROZIN,"1. The drug label warns that nonsteroidal anti-inflammatory drugs (NSAIDs), including COXANTO, are associated with an increased risk of serious cardiovascular thrombotic events, such as myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with the duration of use. (The drug itself is associated with the cardiotoxicity risk.)

2. COXANTO is contraindicated in the setting of coronary artery bypass graft (CABG) surgery due to the risk of serious cardiovascular thrombotic events. (The drug itself is associated with the cardiotoxicity risk.)

3. The drug label mentions that patients treated with NSAIDs, including COXANTO, may experience new-onset hypertension or worsening of preexisting hypertension, which can contribute to an increased incidence of cardiovascular events. (The drug itself is associated with the cardiotoxicity risk.)

4. COXANTO should be avoided in patients with severe heart failure unless the benefits are expected to outweigh the risk of worsening heart failure. (The drug itself is associated with the cardiotoxicity risk.)

5. The drug label states that NSAIDs, including COXANTO, have been associated with an increased risk of hospitalizations for heart failure and other cardiovascular events. (The drug itself is associated with the cardiotoxicity risk.)

6. Observational studies have shown that patients treated with NSAIDs, including COXANTO, in the post-myocardial infarction (MI) period were at an increased risk of reinfarction, cardiovascular-related death, and all-cause mortality. (The drug itself is associated with the cardiotoxicity risk.)

7. COXANTO should be avoided in patients with a recent MI unless the benefits are expected to outweigh the risk of recurrent cardiovascular thrombotic events. (The drug itself is associated with the cardiotoxicity risk.)

8. The drug label advises monitoring blood pressure during the initiation of NSAID treatment, including COXANTO, and throughout the course of therapy due to the potential risk of hypertension and cardiovascular events. (The drug itself is associated with the cardiotoxicity risk.)",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",1c54398b-0f57-42b7-9067-0f8012c7813e,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=1c54398b-0f57-42b7-9067-0f8012c7813e&type=display
794,OXAZEPAM,"1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with oxazepam itself. 

2. However, it does caution that oxazepam should be administered with caution to patients in whom a drop in blood pressure might lead to cardiac complications, particularly in the elderly patient. This suggests that the drug may have an indirect association with potential cardiotoxic effects in certain patient populations.

3. The label also advises that patients should be cautioned against driving or operating dangerous machinery until it is known that they do not become drowsy or dizzy on oxazepam therapy. While not directly related to cardiotoxicity, these effects could potentially impact cardiovascular function in susceptible individuals.

Overall, while the drug label does not explicitly state cardiotoxicity risks or reactions associated with oxazepam, it does provide general precautions related to cardiovascular health and the use of the medication.",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",03440821-831c-4085-98f9-faa88e98c503,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=03440821-831c-4085-98f9-faa88e98c503&type=display
795,OXCARBAZEPINE,"1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with TRILEPTAL (oxcarbazepine) itself. 

2. The drug label primarily focuses on the indications, dosage, administration, contraindications, warnings, and precautions related to the use of TRILEPTAL for the treatment of partial-onset seizures in adults and pediatric patients. 

3. While the label discusses various adverse reactions such as hyponatremia, hypersensitivity reactions, dermatological reactions, and neuropsychiatric adverse reactions, there is no direct mention of cardiotoxicity risks or reactions attributed to TRILEPTAL. 

4. It is important to note that the drug label may not cover all possible side effects or risks associated with TRILEPTAL, and healthcare providers should monitor patients for any signs of cardiotoxicity or other adverse reactions during treatment. 

5. Patients should report any unusual symptoms or changes in their health to their healthcare provider while taking TRILEPTAL, and healthcare providers should consider the overall health and medical history of the patient when prescribing this medication.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",4c5c86c8-ab7f-4fcf-bc1b-5a0b1fd0691b,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=4c5c86c8-ab7f-4fcf-bc1b-5a0b1fd0691b&type=display
796,OXYBUTYNIN CHLORIDE,"1. The drug label does not mention any specific cardiotoxicity risks associated with Gelnique (oxybutynin chloride) itself.

2. The label does not indicate that Gelnique is associated with cardiotoxicity reactions. 

3. Overall, there is no mention of cardiotoxicity risks or reactions related to the use of Gelnique as per the information provided in the drug label.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",57616d79-9e68-4ec7-a25f-ebee07576351,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=57616d79-9e68-4ec7-a25f-ebee07576351&type=display
797,OXYCODONE,"1. The drug label for XTAMPZA ER does not mention any specific cardiotoxicity risks or reactions associated with the drug itself. 

2. The label primarily focuses on serious and life-threatening risks such as addiction, abuse, misuse, respiratory depression, accidental ingestion, and risks from concomitant use with benzodiazepines or other CNS depressants. 

3. While the label does not directly mention cardiotoxicity risks or reactions caused by XTAMPZA ER, it is important to note that opioids, in general, can have effects on the cardiovascular system, especially in patients with pre-existing cardiac conditions. 

4. Patients with chronic pulmonary disease, elderly individuals, cachectic patients, or those who are debilitated may be at risk for life-threatening respiratory depression, which indirectly impacts cardiovascular function. 

5. It is crucial for healthcare providers to regularly evaluate patients for adverse events, including respiratory depression, which can have secondary effects on the cardiovascular system. 

6. The label emphasizes the importance of individualized dosing, titration, and monitoring to minimize risks and optimize pain management, which indirectly contributes to overall patient safety, including cardiovascular health. 

7. While the label does not explicitly mention cardiotoxicity risks associated with XTAMPZA ER, healthcare providers should consider the potential impact of opioid therapy on the cardiovascular system when prescribing this medication to patients with underlying cardiac conditions.",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",b0a5ded2-8ee2-49ca-a86c-2b28ae40f60c,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=b0a5ded2-8ee2-49ca-a86c-2b28ae40f60c&type=display
798,OXYCODONE HYDROCHLORIDE,"1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with OXYCONTIN itself.

2. However, the label does warn about the potential for severe hypotension, which can be a cardiovascular concern. It advises regular evaluation during dosage initiation and titration to avoid the use of OXYCONTIN in patients with circulatory shock.

3. Additionally, the label mentions the risks of use in patients with increased intracranial pressure, brain tumors, head injury, or impaired consciousness. Monitoring for sedation and respiratory depression is recommended, and the use of OXYCONTIN is advised against in patients with impaired consciousness or coma, which can indirectly impact cardiovascular function.

4. While not directly related to cardiotoxicity, the label also highlights the risk of opioid-induced hyperalgesia and allodynia, which can lead to increased pain sensitivity. This condition may indirectly impact cardiovascular health due to the stress and pain response on the body.

Overall, while the drug label does not explicitly state cardiotoxicity risks associated with OXYCONTIN, it does provide cautions and warnings related to conditions and reactions that could indirectly impact cardiovascular health.",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",bfdfe235-d717-4855-a3c8-a13d26dadede,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=bfdfe235-d717-4855-a3c8-a13d26dadede&type=display
799,OXYMORPHONE HYDROCHLORIDE,"1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with OPANA (oxymorphone hydrochloride) itself. 

2. The drug label primarily focuses on respiratory depression as the chief hazard of OPANA, especially in elderly or debilitated patients or those with conditions like hypoxia or hypercapnia, where even moderate doses may decrease pulmonary ventilation. This is not directly related to cardiotoxicity.

3. While the label discusses various adverse reactions, including gastrointestinal effects, CNS depressant effects, and misuse/abuse risks, there is no specific mention of cardiotoxicity risks or reactions associated with OPANA.

Overall, based on the information provided in the drug label, there is no direct indication that OPANA is associated with cardiotoxicity risks or reactions. It is important to consult healthcare professionals for a comprehensive understanding of any potential risks associated with this medication.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",285e60f8-2404-47d0-a171-a4f075d6f418,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=285e60f8-2404-47d0-a171-a4f075d6f418&type=display
800,OXYTOCIN,"1. The drug label states that synthetic oxytocin does not possess cardiovascular effects, such as elevation of blood pressure, as exhibited by vasopressin found in posterior pituitary injection. (The drug itself is not associated with cardiotoxicity risk.)

2. Maternal deaths due to hypertensive episodes, subarachnoid hemorrhage, rupture of the uterus, and fetal deaths due to various causes have been reported associated with the use of parenteral oxytocic drugs for induction of labor and for augmentation in the first and second stages of labor. (The use of parenteral oxytocic drugs, including oxytocin, is associated with cardiotoxicity risks.)

3. Severe water intoxication with convulsions and coma has occurred and is associated with a slow oxytocin infusion over a 24-hour period. Maternal death due to oxytocin-induced water intoxication has been reported. (The drug itself, oxytocin, is associated with the risk of water intoxication, which can lead to cardiotoxicity reactions.)

4. Severe hypertension has been reported when oxytocin was given three to four hours following prophylactic administration of a vasoconstrictor in conjunction with caudal block anesthesia. Cyclopropane anesthesia may modify oxytocin's cardiovascular effects, so as to produce unexpected results such as hypotension. Maternal sinus bradycardia with abnormal atrioventricular rhythms has also been noted when oxytocin was used concomitantly with cyclopropane anesthesia. (The drug itself, oxytocin, is associated with the risk of severe hypertension and cardiovascular effects when used in conjunction with certain anesthetics.)",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",c7fd585a-99b7-4309-b003-a6cbef05372c,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=c7fd585a-99b7-4309-b003-a6cbef05372c&type=display
801,OZANIMOD HYDROCHLORIDE,"1. ZEPOSIA may result in transient decrease in heart rate and atrioventricular conduction delays, requiring titration for treatment initiation. The drug itself is associated with the risk of transient decrease in heart rate and conduction delays. (Warnings and Precautions)

2. ZEPOSIA was not studied in patients with certain cardiac conditions, such as recent myocardial infarction, heart failure, or significant conduction abnormalities, due to potential risks to the patient's health. The drug itself was not directly associated with these conditions but should be used cautiously in patients with such pre-existing cardiac issues. (Warnings and Precautions)

3. Initiation of ZEPOSIA may lead to a transient decrease in heart rate, with bradycardia reported in a small percentage of patients on the day of treatment initiation. The drug itself is associated with the risk of transient bradycardia. (Warnings and Precautions)

4. ZEPOSIA may cause dose-dependent reductions in forced expiratory volume and forced vital capacity, indicating potential respiratory effects. The drug itself is associated with the risk of respiratory effects, including reductions in lung function. (Warnings and Precautions)",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",93ce2fab-edfb-4804-8074-963071de51e4,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=93ce2fab-edfb-4804-8074-963071de51e4&type=display
802,PACLITAXEL,"1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with Paclitaxel Protein-Bound Particles for Injectable Suspension (Albumin-Bound) itself.

2. The label highlights adverse reactions such as abnormal ECG, which is a common adverse reaction ( 20%) in metastatic breast cancer patients, but it does not specify if this is directly related to cardiotoxicity caused by the drug.

3. The label does not mention any direct association between Paclitaxel Protein-Bound Particles for Injectable Suspension (Albumin-Bound) and cardiotoxicity risks or reactions in the sections provided.",Less,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",f06d1bb3-83f1-4d84-8004-4c6681ad8a5a,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=f06d1bb3-83f1-4d84-8004-4c6681ad8a5a&type=display
803,PAFOLACIANINE INJECTION,"1. **Warnings and Precautions, Infusion-Related Reactions (5.1):** The drug label mentions that adverse reactions, including elevation in blood pressure, were reported in patients receiving CYTALUX in clinical studies. The label states that 17% of patients experienced reactions during the administration of CYTALUX, with reactions typically occurring within 15 minutes of the start of infusion. The label advises that treatment with antihistamines and/or anti-nausea medication may be used if an adverse reaction occurs during administration. The drug itself is associated with infusion-related reactions, including elevation in blood pressure.

2. **Adverse Reactions (6):** The label lists elevation in blood pressure as one of the most common adverse reactions reported in patients receiving CYTALUX in clinical trials. The label indicates that 1% of patients experienced elevation in blood pressure. The drug itself is associated with elevation in blood pressure as an adverse reaction.

3. **Warnings and Precautions, Risk of Pafolacianine Aggregation and Infusion Reactions (5.4):** The label warns about the risk of pafolacianine aggregation, which may induce infusion reactions such as nausea, vomiting, abdominal pain, or rash. It specifies that using the incorrect diluent to prepare the CYTALUX infusion solution can cause aggregation of pafolacianine. The label instructs to use only 5% Dextrose Injection for dilution and not to use other diluents. The drug itself is associated with the risk of pafolacianine aggregation and subsequent infusion reactions.",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",d21952b9-7c4e-3a56-e053-2a95a90a0ab0,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=d21952b9-7c4e-3a56-e053-2a95a90a0ab0&type=display
804,PALBOCICLIB,"1. **Cardiotoxicity Risk**: The drug label does not mention any specific cardiotoxicity risks associated with IBRANCE (palbociclib).

2. **Cardiotoxicity Reactions**: The drug label does not list any cardiotoxicity reactions or adverse events related to the use of IBRANCE (palbociclib).",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",fecbdd7d-b729-41b5-9872-231b8fe104ce,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fecbdd7d-b729-41b5-9872-231b8fe104ce&type=display
805,PALIPERIDONE,"1. The drug label warns about the increased risk of cerebrovascular adverse reactions, such as stroke and transient ischemic attacks, in elderly patients with dementia-related psychosis treated with atypical antipsychotics. The drug itself was not marketed during the studies that showed this risk, but the class of atypical antipsychotics has been associated with these adverse reactions.

2. Paliperidone, the active ingredient in the drug, may cause a modest increase in the corrected QT (QTc) interval, which is a risk factor for cardiac arrhythmias. The drug label advises avoiding its use with other medications known to prolong the QTc interval and in patients with congenital long QT syndrome or a history of cardiac arrhythmias.

3. The drug label mentions that tardive dyskinesia, an involuntary movement disorder, may develop in patients treated with antipsychotic drugs, including paliperidone. While the drug itself may not directly cause cardiotoxicity, tardive dyskinesia can impact cardiac function due to its effects on muscle rigidity and autonomic instability.

4. Atypical antipsychotic drugs, including paliperidone, have been associated with metabolic changes that may increase cardiovascular risk, such as hyperglycemia, dyslipidemia, and weight gain. The drug label highlights the importance of monitoring patients for symptoms of hyperglycemia and dyslipidemia, which are cardiotoxicity risks associated with the drug class.

5. The drug label also mentions that weight gain has been observed with atypical antipsychotic use, including paliperidone. While weight gain itself is not a direct cardiotoxicity risk, it can contribute to metabolic changes that increase cardiovascular risk, emphasizing the need for clinical monitoring of weight in patients taking the drug.",Less,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",7b8e5b26-b9e4-4704-921b-3c3c0d159916,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7b8e5b26-b9e4-4704-921b-3c3c0d159916&type=display
806,PALIPERIDONE PALMITATE,"1. The drug label warns about the potential for QT prolongation with paliperidone, advising against its use in combination with other drugs known to prolong QTc interval. The drug itself is associated with causing QT prolongation.
   
2. The label mentions a study showing a mean increase in QTcLD with the immediate-release oral paliperidone, indicating a potential risk of QT prolongation with the drug. The drug itself is associated with causing QT prolongation.

3. The label states that in fixed-dose efficacy studies of oral paliperidone extended release, only one subject in the 12 mg group had a change exceeding 60 msec at one time-point, suggesting a low risk of QT prolongation with the drug. The drug itself is not strongly associated with causing QT prolongation.

4. In the fixed-dose efficacy studies of INVEGA SUSTENNA, no subject experienced a change in QTcLD exceeding 60 msec, indicating a low risk of QT prolongation with the drug. The drug itself is not strongly associated with causing QT prolongation.",Less,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",1af14e42-951d-414d-8564-5d5fce138554,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=1af14e42-951d-414d-8564-5d5fce138554&type=display
807,PAMIDRONATE DISODIUM,1. The drug label does not mention any cardiotoxicity risks or cardiotoxicity reactions associated with pamidronate disodium.,No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",9b6a9a3b-71c9-4dcb-b857-5d1de25c3a23,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=9b6a9a3b-71c9-4dcb-b857-5d1de25c3a23&type=display
808,PANOBINOSTAT,"1. Severe and fatal cardiac ischemic events, severe arrhythmias, and ECG changes have occurred in patients receiving FARYDAK. (The drug itself was associated with cardiotoxicity risks.)

2. Arrhythmias may be exacerbated by electrolyte abnormalities. (The drug itself was associated with exacerbating arrhythmias due to electrolyte imbalances.)

3. Electrocardiographic abnormalities such as ST-segment depression and T-wave abnormalities occurred more frequently in patients receiving FARYDAK compared to the control arm. (The drug itself was associated with causing ECG abnormalities.)

4. FARYDAK may prolong cardiac ventricular repolarization (QT interval). (The drug itself was associated with prolonging the QT interval.)

5. Do not initiate treatment with FARYDAK in patients with a history of recent myocardial infarction or unstable angina. (The drug itself was associated with contraindications for patients with certain cardiac conditions.)

6. Obtain ECG at baseline and periodically during treatment as clinically indicated. (The drug itself was associated with the need for ECG monitoring during treatment.)

7. Monitor electrolytes during treatment with FARYDAK and correct abnormalities as clinically indicated. (The drug itself was associated with the need for electrolyte monitoring and correction during treatment.)",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",1b97bd3a-1040-4511-b0e6-4758e8083ae5,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=1b97bd3a-1040-4511-b0e6-4758e8083ae5&type=display
809,PANTOPRAZOLE,"1. Pantoprazole sodium delayed-release tablets are associated with an increased risk of hypomagnesemia, which may lead to hypocalcemia and/or hypokalemia, and may exacerbate underlying hypocalcemia in at-risk patients. The drug itself is associated with the risk of hypomagnesemia, which can lead to cardiotoxicity.

2. Long-term and multiple daily dose therapy with pantoprazole sodium may be associated with an increased risk for osteoporosis-related fractures of the hip, wrist, or spine. The drug itself is associated with an increased risk of bone fractures, which can have cardiotoxic effects.

3. Pantoprazole sodium may interfere with the absorption of cyanocobalamin (Vitamin B-12), potentially leading to malabsorption or deficiency of cyanocobalamin. The drug itself is associated with the risk of cyanocobalamin deficiency, which can have cardiotoxic consequences.

4. Pantoprazole sodium has been reported to cause severe cutaneous adverse reactions, including erythema multiforme, Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and other severe skin reactions. The drug itself is associated with the risk of severe cutaneous adverse reactions, which can have systemic effects, including cardiotoxicity.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",0b8c844c-3bca-4bb9-aa59-2fa040a21585,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=0b8c844c-3bca-4bb9-aa59-2fa040a21585&type=display
810,PARICALCITOL,"1. **Cardiotoxicity Risk**: ZEMPLAR (paricalcitol) injection carries a risk of hypercalcemia, which can lead to cardiac arrhythmias and seizures. The drug itself is associated with the risk of hypercalcemia, which in turn can lead to cardiotoxic effects.

2. **Cardiotoxicity Reactions**: The drug label warns that severe hypercalcemia from ZEMPLAR treatment may require emergency attention due to its potential to cause cardiac arrhythmias and seizures. The drug itself is associated with the potential for severe hypercalcemia, which can manifest as cardiotoxic reactions.

3. **Digitalis Toxicity**: ZEMPLAR can increase the risk of digitalis toxicity due to hypercalcemia. Patients using digitalis compounds alongside ZEMPLAR should be monitored for signs and symptoms of digitalis toxicity. The drug itself is associated with an increased risk of digitalis toxicity, which can have cardiotoxic effects.

4. **Adynamic Bone Disease**: ZEMPLAR may lead to adynamic bone disease if intact parathyroid hormone (PTH) levels are suppressed to abnormally low levels, increasing the risk of fractures. The drug itself is associated with the potential to cause adynamic bone disease, which can have implications for bone health and potentially affect the cardiovascular system.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",7259652f-81bc-4ad1-bba5-d01f9fac1b80,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7259652f-81bc-4ad1-bba5-d01f9fac1b80&type=display
811,PAROMOMYCIN SULFATE,"1. The drug label does not mention any specific cardiotoxicity risks associated with HUMATIN (paromomycin sulfate) capsules.
2. The drug label does not indicate that HUMATIN (paromomycin sulfate) capsules are associated with cardiotoxicity reactions.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",a725f022-ec3c-430d-8021-96c861b9893c,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a725f022-ec3c-430d-8021-96c861b9893c&type=display
812,PAROXETINE,"1. The drug label warns about the risk of QT prolongation when paroxetine is used in combination with thioridazine and pimozide, as these drugs alone can produce QT prolongation and increase the risk of serious ventricular arrhythmias. Paroxetine is associated with the risk of QT prolongation when used concomitantly with these medications.

2. Paroxetine can cause fetal and neonatal harm, with exposure during pregnancy potentially leading to an increased risk of cardiovascular malformations in infants. The drug itself is associated with the risk of cardiovascular malformations in infants when exposed to paroxetine during the first trimester of pregnancy.

3. The drug label mentions an increased risk of bleeding events when drugs that interfere with serotonin reuptake, including paroxetine, are used. Concomitant use of paroxetine with antiplatelet agents or anticoagulants may add to this risk. Paroxetine is associated with an increased risk of bleeding events when used with other medications that interfere with serotonin reuptake.

4. Paroxetine may precipitate a mixed/manic episode in patients with bipolar disorder when treating a depressive episode. During clinical trials, hypomania or mania occurred in a small percentage of paroxetine-treated patients. Paroxetine is associated with the risk of precipitating a mixed/manic episode in patients with bipolar disorder.

5. The drug label warns about the potential for seizures with paroxetine use, although the drug has not been systematically evaluated in patients with seizure disorders. During clinical studies, seizures occurred in a small percentage of patients treated with paroxetine. Paroxetine is associated with the risk of seizures, although it has not been systematically evaluated in patients with seizure disorders.

6. Angle-closure glaucoma has been reported in patients treated with antidepressants, including paroxetine, which may trigger an attack in patients with anatomically narrow angles. Cases of angle-closure glaucoma have been associated with the use of paroxetine. Paroxetine is associated with the risk of angle-closure glaucoma in patients with untreated anatomically narrow angles.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",bc0efd3b-c6b9-4ed0-b517-6e57e4700b7b,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=bc0efd3b-c6b9-4ed0-b517-6e57e4700b7b&type=display
813,PAROXETINE HYDROCHLORIDE,"1. **Embryofetal Toxicity**: Exposure to paroxetine in the first trimester of pregnancy is associated with a less than 2-fold increase in the rate of cardiovascular malformations among infants. The drug itself is associated with an increased risk of cardiovascular malformations when exposed during the first trimester of pregnancy.

2. **Increased Risk of Bleeding**: Drugs that interfere with serotonin reuptake inhibition, including PAXIL CR, increase the risk of bleeding events. Concomitant use of PAXIL CR with certain drugs may increase the risk of gastrointestinal bleeding. The drug itself is associated with an increased risk of bleeding events when used in combination with specific medications.

3. **Reduction of Efficacy of Tamoxifen**: Some studies suggest that the efficacy of tamoxifen may be reduced with concomitant use of paroxetine due to paroxetines irreversible inhibition of CYP2D6 and lower blood levels of tamoxifen. The drug itself is associated with potentially reducing the effectiveness of tamoxifen when used together.

4. **Bone Fracture**: Epidemiological studies have reported an association between antidepressant treatment, including SSRIs like PAXIL CR, and fractures. The drug itself is associated with an increased risk of bone fractures during exposure.

5. **Serotonin Syndrome**: PAXIL CR can precipitate serotonin syndrome, a potentially life-threatening condition, especially when used with other serotonergic drugs. The drug itself can lead to serotonin syndrome when used alone or in combination with other serotonergic agents.

6. **Hyponatremia**: Hyponatremia may occur as a result of treatment with SNRIs and SSRIs, including PAXIL CR. The drug itself is associated with the potential development of hyponatremia in patients.

7. **Angle-Closure Glaucoma**: The pupillary dilation following the use of antidepressants like PAXIL CR may trigger an angle closure attack in patients with anatomically narrow angles. The drug itself is associated with the potential risk of angle-closure glaucoma in patients with untreated anatomically narrow angles.",Less,Yes,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",483bd97f-c4d0-4e23-aaa8-6334f4471e0c,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=483bd97f-c4d0-4e23-aaa8-6334f4471e0c&type=display
814,PAROXETINE MESYLATE,"1. The drug label mentions that paroxetine, the active ingredient in PEXEVA, is associated with an increased risk of cardiovascular malformations in infants when exposed during the first trimester of pregnancy. This suggests that paroxetine itself is linked to embryofetal cardiotoxicity risk.

2. Additionally, the label warns about the potential for QT prolongation when paroxetine is used in combination with thioridazine and pimozide, which can lead to serious ventricular arrhythmias. This indicates that paroxetine can interact with these drugs to cause cardiotoxicity reactions.

3. The label also highlights the increased risk of bleeding events with drugs that interfere with serotonin reuptake, including PEXEVA. This suggests that PEXEVA itself may contribute to cardiotoxicity through an increased risk of bleeding.

4. Furthermore, the drug label mentions that paroxetine can elevate plasma levels of thioridazine and pimozide due to its CYP2D6 inhibitory properties, which can lead to QT prolongation and increase the risk of serious ventricular arrhythmias. This indicates that paroxetine can interact with these drugs to cause cardiotoxicity reactions.

5. The label advises monitoring patients for the emergence of serotonin syndrome when taking PEXEVA, especially when co-administered with other serotonergic drugs, as serotonin syndrome can be life-threatening. This suggests that PEXEVA itself can contribute to cardiotoxicity through the risk of serotonin syndrome.

6. Lastly, the drug label mentions that paroxetine may cause hyponatremia, which can lead to symptoms like headache, confusion, and respiratory arrest. This indicates that paroxetine itself is associated with the risk of hyponatremia-related cardiotoxicity.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",50fe88bd-f0dd-5fad-e054-00144ff8d46c,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=50fe88bd-f0dd-5fad-e054-00144ff8d46c&type=display
815,PASIREOTIDE,"1. The drug SIGNIFOR LAR has been associated with bradycardia and QT prolongation risks. Patients with cardiac disease or risk factors for bradycardia should be monitored. Adjustments in heart rate-slowing drugs and correction of electrolyte imbalances may be necessary during treatment with SIGNIFOR LAR. (The drug itself was associated with the risk of bradycardia and QT prolongation.)

2. In clinical studies, SIGNIFOR LAR caused an increase in the corrected QT interval (QTcF) in some patients. Monitoring for QT interval effects is recommended in patients at risk, such as those with congenital long QT prolongation or cardiac diseases. Hypokalemia or hypomagnesemia should be corrected before starting SIGNIFOR LAR and monitored periodically during treatment. (The drug itself was associated with QT prolongation risks.)

3. Patients treated with SIGNIFOR LAR should be monitored for signs of bradycardia, especially those with a history of clinically significant bradycardia or concomitant use of drugs that slow heart rate. Electrolyte imbalances should be corrected before initiating SIGNIFOR LAR. (The drug itself was associated with the risk of bradycardia.)

4. In clinical trials, bradycardia and QT prolongation were reported as adverse reactions associated with SIGNIFOR LAR. Patients at significant risk of developing QT prolongation should use SIGNIFOR LAR with caution. Baseline ECG and monitoring for QT interval effects are recommended in at-risk patients. (The drug itself was associated with the risk of bradycardia and QT prolongation.)",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",a0aad470-3f38-af97-e053-2995a90a383a,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a0aad470-3f38-af97-e053-2995a90a383a&type=display
816,PATIROMER,"1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with Veltassa (patiromer) itself.

2. Veltassa (patiromer) is indicated for the treatment of hyperkalemia in adults and pediatric patients ages 12 years and older, with no mention of cardiotoxicity risks or reactions.

3. The drug label does not include any information regarding cardiotoxicity risks or reactions related to the use of Veltassa (patiromer) for oral suspension.

Overall, based on the information provided in the drug label, there are no mentions of cardiotoxicity risks or reactions associated with the use of Veltassa (patiromer).",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",bf002984-d6c9-46df-aecb-a07733f763c1,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=bf002984-d6c9-46df-aecb-a07733f763c1&type=display
817,PATISIRAN,"1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with ONPATTRO (patisiran) lipid complex injection. 

2. There is no indication in the drug label that ONPATTRO itself is linked to any cardiotoxicity risks or reactions. 

3. The drug label does not list any cardiotoxicity concerns or reactions related to the use of ONPATTRO. 

Overall, based on the information provided in the drug label, ONPATTRO does not appear to be associated with cardiotoxicity risks or reactions.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",e87ec36f-b4b4-49d4-aea4-d4ffb09b0970,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=e87ec36f-b4b4-49d4-aea4-d4ffb09b0970&type=display
818,PEGCETACOPLAN,"1. The drug SYFOVRE, containing pegcetacoplan, was not associated with QT prolongation when administered subcutaneously, and QT prolongation following intravitreal administration is not expected. (Clinical Pharmacology, 12.2)

2. SYFOVRE is administered directly into the vitreous to exert local effects in the eye, and systemic exposures following intravitreal administration are much lower than with subcutaneous administration, therefore, QT prolongation following intravitreal pegcetacoplan is not expected. (Clinical Pharmacology, 12.3)",Less,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",b4434e61-9ec9-4e0e-bd60-45aaa0a87e64,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=b4434e61-9ec9-4e0e-bd60-45aaa0a87e64&type=display
819,PEMETREXED,"1. **Cardiotoxicity Risks:**
   - The drug label does not mention any direct association of PEMFEXY with cardiotoxicity risks.

2. **Cardiotoxicity Reactions:**
   - The drug label does not list cardiotoxicity reactions associated with the use of PEMFEXY.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",2308f4e8-21c8-49c1-a5b8-deb8610bac6a,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=2308f4e8-21c8-49c1-a5b8-deb8610bac6a&type=display
820,PEMETREXED DISODIUM,1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with the drug itself.,No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",7ac04ab7-7f8c-46ce-ab56-a7a08cd02ab3,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7ac04ab7-7f8c-46ce-ab56-a7a08cd02ab3&type=display
821,PEMIGATINIB,1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with PEMAZYRE (pemigatinib) tablets. No cardiotoxicity risks or reactions related to the drug itself were discussed in the provided information.,No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",9e1f2222-1d89-4e63-989c-ccebe2ab1eb4,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=9e1f2222-1d89-4e63-989c-ccebe2ab1eb4&type=display
822,PENICILLAMINE,1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with the use of penicillamine.,No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",38f8ae60-b354-11de-8a39-0800200c9a66,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=38f8ae60-b354-11de-8a39-0800200c9a66&type=display
823,PENICILLIN G BENZATHINE,"1. The drug label warns that Bicillin L-A should not be administered intravenously or admixed with other intravenous solutions due to reports of inadvertent intravenous administration of penicillin G benzathine, which has been associated with cardiorespiratory arrest and death. (The drug itself was associated with the cardiotoxicity risk.)

2. The label mentions that severe cutaneous adverse reactions, such as Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and other reactions, have been reported in patients taking penicillin G, the active moiety in Bicillin L-A. It advises discontinuing the drug immediately if severe cutaneous adverse reactions are suspected. (The drug itself was associated with the cardiotoxicity risk.)

3. Clostridioides difficile-associated diarrhea (CDAD) has been reported with the use of nearly all antibacterial agents, including Bicillin L-A, and may range in severity from mild diarrhea to fatal colitis. CDAD must be considered in all patients who present with diarrhea following antibacterial use. (The drug itself was associated with the cardiotoxicity risk.)

4. The label warns against inadvertent intravascular administration of Bicillin L-A and other penicillin preparations, which has resulted in severe neurovascular damage, including transverse myelitis with permanent paralysis, gangrene requiring amputation, and necrosis at the injection site. (The drug itself was associated with the cardiotoxicity risk.)

5. The label cautions against injection into or near an artery or nerve, as well as intravenous administration, as these actions may result in severe neurovascular damage, including transverse myelitis, gangrene, and necrosis. (The drug itself was associated with the cardiotoxicity risk.)

6. The label mentions that severe effects and complications, such as immediate pallor, mottling, or cyanosis of the extremity, have been reported following suspected intravascular administration of Bicillin L-A, especially in infants and small children. (The drug itself was associated with the cardiotoxicity risk.)

7. The label emphasizes that Bicillin L-A should only be administered by deep intramuscular injection and not intravenously or admixed with other intravenous solutions to avoid cardiorespiratory arrest and death. (The drug itself was associated with the cardiotoxicity risk.)

In summary, the drug label clearly outlines the risks of cardiotoxicity associated with Bicillin L-A, particularly when administered intravenously or near blood vessels, nerves, or arteries. It provides detailed warnings and precautions to prevent severe neurovascular damage and emphasizes the importance of proper administration techniques to avoid cardiotoxic reactions.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",012d46f1-d0a0-4676-a879-cd320297ab16,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=012d46f1-d0a0-4676-a879-cd320297ab16&type=display
824,PENICILLIN G POTASSIUM,"1. The drug label mentions that Penicillin G Potassium for Injection, USP contains approximately 6.9 milligrams of sodium (0.3 mEq) and 65.8 milligrams of potassium (1.68 mEq) per million units of penicillin G. The label advises caution when administering high doses intravenously due to potential adverse effects of electrolyte imbalance from the potassium content of the penicillin. (The drug itself is associated with the risk of electrolyte imbalance due to its potassium content.)

2. The label also states that penicillin G potassium (1 million units contains 1.68 mEq of potassium ion) may cause serious and even fatal electrolyte disturbances, such as hyperkalemia, when given intravenously in large doses. (The drug itself is associated with the risk of causing electrolyte disturbances, including hyperkalemia, when administered intravenously in large doses.)

3. In the section on adverse reactions, it is mentioned that penicillin G potassium may cause dose-related toxicity with the use of massive doses of intravenous penicillins, particularly in patients with severe renal impairment. Manifestations of overdose may include hyperkalemia. (The drug itself is associated with the risk of dose-related toxicity and hyperkalemia when used in massive intravenous doses, especially in patients with severe renal impairment.)",Less,No,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",e0ced9d8-b9ea-466e-bf2c-10e9cc636f3f,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=e0ced9d8-b9ea-466e-bf2c-10e9cc636f3f&type=display
825,PENICILLIN G SODIUM,"1. High dosage of penicillin G sodium may result in congestive heart failure due to high sodium intake. (The drug itself was associated with the cardiotoxicity risk.)

2. Neurotoxic reactions, including hyperreflexia, myoclonic twitches, seizures, and coma, have been reported following the administration of massive intravenous doses and are more likely in patients with impaired renal function. (The drug itself was associated with the cardiotoxicity risk.)

3. Dose-related toxicity may arise with the use of massive doses of intravenous penicillins, particularly in patients with severe renal impairment. Manifestations may include agitation, confusion, asterixis, hallucinations, stupor, coma, multifocal myoclonus, seizures, and encephalopathy. Hypernatremia is also possible. (The drug itself was associated with the cardiotoxicity risk.)

4. High dosage of penicillin G sodium may result in congestive heart failure due to high sodium intake. (The drug itself was associated with the cardiotoxicity risk.)",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",23b6d4a3-b273-4e10-9da9-1376933fdbdf,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=23b6d4a3-b273-4e10-9da9-1376933fdbdf&type=display
826,PENICILLIN V POTASSIUM,"1. The drug label does not mention any specific cardiotoxicity risks associated with Penicillin V Potassium itself.
2. The label does not indicate that Penicillin V Potassium is associated with cardiotoxicity reactions.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",6315850e-f843-a114-e053-2a91aa0a4016,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=6315850e-f843-a114-e053-2a91aa0a4016&type=display
827,PENTAMIDINE ISETHIONATE,"1. **Cardiotoxicity Risk**: The drug label mentions that fatalities due to severe hypotension, hypoglycemia, acute pancreatitis, and cardiac arrhythmias have been reported in patients treated with pentamidine isethionate, both by the IM and IV routes. This indicates that the drug itself is associated with the risk of cardiotoxicity.

2. **Cardiotoxicity Reactions**: The label further states that severe hypotension may result after a single IM or IV dose of pentamidine isethionate and is more likely with rapid IV administration. This suggests that the drug can lead to severe hypotension, which is a cardiotoxic reaction.

3. **Cardiotoxicity Risk**: Additionally, the label warns about extravasations that have been reported with pentamidine isethionate, which can lead to ulceration, tissue necrosis, and sloughing at the injection site. While not common, these severe reactions indicate a risk of cardiotoxicity associated with the drug.

4. **Cardiotoxicity Reactions**: The label mentions that pentamidine isethionate-induced hypoglycemia has been associated with pancreatic islet cell necrosis and inappropriately high plasma insulin concentrations. This indicates that the drug can cause hypoglycemia, which is a cardiotoxic reaction.

5. **Cardiotoxicity Risk**: The label advises that patients may develop sudden, severe hypotension after a single dose of pentamidine isethionate, whether given IV or IM. This highlights the risk of cardiotoxicity associated with the drug.

6. **Cardiotoxicity Reactions**: It is recommended that patients receiving pentamidine isethionate should be lying down, and blood pressure should be monitored closely during administration due to the potential for sudden, severe hypotension. This emphasizes the importance of monitoring for cardiotoxic reactions during drug administration.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",cc2b635e-4840-4dc3-a177-5484371680e8,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=cc2b635e-4840-4dc3-a177-5484371680e8&type=display
828,PENTOBARBITAL SODIUM,"1. The drug label mentions that barbiturates, including Nembutal Sodium Solution, are capable of producing all levels of central nervous system mood alteration and can cause death in cases of overdosage. High therapeutic doses of barbiturates can induce anesthesia, depress the sensory cortex, decrease motor activity, alter cerebellar function, and produce drowsiness, sedation, and hypnosis. (The drug itself is not directly associated with cardiotoxicity risk in this sentence.)

2. Barbiturates, including Nembutal Sodium Solution, are known to be respiratory depressants, and the degree of respiratory depression is dose-dependent. With hypnotic doses, respiratory depression produced by barbiturates is similar to that which occurs during physiologic sleep, with a slight decrease in blood pressure and heart rate. (The drug itself is not directly associated with cardiotoxicity risk in this sentence.)

3. The drug label mentions that barbiturates, including Nembutal Sodium Solution, have been found to cause reduction in the tone and contractility of the uterus, ureters, and urinary bladder in laboratory animals. However, concentrations of the drugs required to produce this effect in humans are not reached with sedative-hypnotic doses. (The drug itself is not directly associated with cardiotoxicity risk in this sentence.)

4. Barbiturates, including Nembutal Sodium Solution, do not impair normal hepatic function but have been shown to induce liver microsomal enzymes, thus increasing and/or altering the metabolism of barbiturates and other drugs. (The drug itself is not directly associated with cardiotoxicity risk in this sentence.)

5. The drug label states that barbiturates, including Nembutal Sodium Solution, are weak acids that are absorbed and rapidly distributed to all tissues and fluids, with high concentrations in the brain, liver, and kidneys. Lipid solubility of the barbiturates is the dominant factor in their distribution within the body. (The drug itself is not directly associated with cardiotoxicity risk in this sentence.)

6. Barbiturates, including Nembutal Sodium Solution, are bound to plasma and tissue proteins to a varying degree, with the degree of binding increasing directly as a function of lipid solubility. (The drug itself is not directly associated with cardiotoxicity risk in this sentence.)

7. The drug label mentions that phenobarbital, a type of barbiturate, has been associated with carcinogenic effects in mice and rats after lifetime administration. In mice, it produced benign and malignant liver cell tumors, and in rats, benign liver cell tumors were observed very late in life. (Phenobarbital, a component of Nembutal Sodium Solution, is associated with carcinogenic effects but not directly with cardiotoxicity risk in this sentence.)

8. The drug label also states that barbiturates, including Nembutal Sodium Solution, may be habit-forming, and tolerance, psychological dependence, and physical dependence may occur with continued use. Patients who have psychological dependence on barbiturates may increase the dosage or decrease the dosage interval without consulting a physician and may subsequently develop physical dependence on barbiturates. (The drug itself is not directly associated with cardiotoxicity risk in this sentence.)

9. The drug label warns that too rapid administration of Nembutal Sodium Solution may cause respiratory depression, apnea, laryngospasm, or vasodilation with a fall in blood pressure. (Nembutal Sodium Solution itself is associated with the risk of respiratory depression and a fall in blood pressure, which can be considered cardiotoxicity risks.)

10. The drug label cautions that barbiturates, including Nembutal Sodium Solution, should be administered with caution to patients with acute or chronic pain, as paradoxical excitement could be induced or important symptoms could be masked. (The drug itself is not directly associated with cardiotoxicity risk in this sentence.)

11. The drug label mentions that full anesthetic doses of barbiturates, including Nembutal Sodium Solution, decrease the force and frequency of uterine contractions during labor. Administration of sedative-hypnotic barbiturates to the mother during labor may result in respiratory depression in the newborn. (Nembutal Sodium Solution itself is associated with the risk of respiratory depression in newborns, which can be considered a cardiotoxicity reaction.)

12. The drug label also states that premature infants are particularly susceptible to the depressant effects of barbiturates, and if Nembutal Sodium Solution is used during labor and delivery, resuscitation equipment should be available. (Nembutal Sodium Solution itself is associated with the risk of depressant effects in premature infants, which can be considered a cardiotoxicity risk.)",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",5c380ab0-4386-48b6-80ab-ca594b23bc74,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=5c380ab0-4386-48b6-80ab-ca594b23bc74&type=display
829,PENTOSAN POLYSULFATE SODIUM,"1. The drug label mentions that ELMIRON is a weak anticoagulant and may cause rectal hemorrhage as an adverse event, with a reported incidence of 6.3% in patients receiving a daily dose of 300 mg. This suggests that ELMIRON itself is associated with the risk of rectal hemorrhage, a form of bleeding, which can be considered a cardiotoxicity risk.

2. Additionally, the label states that bleeding complications such as ecchymosis, epistaxis, and gum hemorrhage have been reported with ELMIRON use. This indicates that ELMIRON itself is associated with the risk of various bleeding complications, which can be considered cardiotoxicity risks.

3. The label also mentions that patients undergoing invasive procedures or having signs/symptoms of underlying coagulopathy or other increased risk of bleeding should be evaluated for hemorrhage before starting ELMIRON. This suggests that ELMIRON itself can exacerbate bleeding risks in patients with underlying coagulopathy or other conditions, indicating a cardiotoxicity risk.

4. Furthermore, the label highlights that a similar product associated with delayed immunoallergic thrombocytopenia, thrombosis, and hemorrhage should be used with caution in patients with a history of heparin-induced thrombocytopenia. This suggests that ELMIRON, being a weak anticoagulant, may pose a cardiotoxicity risk in patients with a history of heparin-induced thrombocytopenia due to its potential to exacerbate thrombotic and bleeding complications.

5. The label also mentions that alopecia, a side effect associated with ELMIRON, began within the first 4 weeks of treatment, with 97% of cases being alopecia areata limited to a single area on the scalp. While alopecia is not a direct cardiotoxicity risk, it is an adverse reaction that may impact a patient's overall health and well-being during ELMIRON treatment.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",f0ba651e-3d8a-11df-8fbe-119855d89593,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=f0ba651e-3d8a-11df-8fbe-119855d89593&type=display
830,PENTOSTATIN,"1. The drug label warns that NIPENT should be administered under the supervision of a qualified physician experienced in cancer chemotherapeutic agents, as dose-limiting severe renal, liver, pulmonary, and CNS toxicities occurred in Phase 1 studies at higher doses than recommended, but it does not specifically mention cardiotoxicity risks associated with the drug itself.

2. The label mentions that acute pulmonary edema and hypotension leading to death have been reported in patients treated with pentostatin in combination with other drugs as part of an ablative regimen for bone marrow transplant, indicating a potential cardiotoxicity risk associated with the drug combination.

3. The label does not directly state that NIPENT is associated with cardiotoxicity risks, but it does mention that elevations in liver function tests occurred during treatment and were generally reversible, which could indirectly impact cardiac function.

4. The label does not specify direct cardiotoxicity risks associated with NIPENT but mentions that patients with hairy cell leukemia may experience myelosuppression during treatment, which could indirectly affect cardiac function due to potential impacts on blood cell counts.

5. The label does not explicitly state that NIPENT is linked to cardiotoxicity risks, but it does mention that patients with infections prior to treatment have developed worsening conditions leading to death in some cases, which could indirectly impact cardiac health.

6. The label does not directly associate NIPENT with cardiotoxicity risks, but it does mention that patients with progressive hairy cell leukemia experienced worsening neutropenia during initial treatment cycles, necessitating frequent monitoring of blood counts, which could indirectly affect cardiac function.

Overall, while the drug label for NIPENT does not specifically highlight cardiotoxicity risks associated with the drug itself, it does mention potential adverse effects and toxicities that could indirectly impact cardiac function, especially in combination with other medications or due to systemic effects on organ function.",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",674e0e6d-46ed-4868-9196-04019d667716,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=674e0e6d-46ed-4868-9196-04019d667716&type=display
831,PENTOXIFYLLINE,"1. The drug label states that patients with chronic occlusive arterial disease of the limbs may experience angina, hypotension, and arrhythmia when using pentoxifylline, but controlled trials do not show that pentoxifylline causes these adverse effects more often than placebo. (The drug itself was not directly associated with cardiotoxicity risks, but these effects were observed in some patients.)

2. The label also mentions that bleeding has been reported in patients treated with pentoxifylline, especially when used with NSAIDs, anticoagulants, or platelet aggregation inhibitors. (Pentoxifylline was associated with an increased risk of bleeding when used in combination with certain medications.)

3. Additionally, the label warns that increased prothrombin time has been reported in patients taking pentoxifylline along with vitamin K antagonists, and monitoring of anticoagulant activity is recommended in such cases. (Pentoxifylline was associated with an increased risk of altered prothrombin time when used with vitamin K antagonists.)

4. The drug label indicates that concomitant administration of pentoxifylline and theophylline-containing drugs can lead to increased theophylline levels and toxicity in some individuals, necessitating monitoring of theophylline levels. (Pentoxifylline was associated with an increased risk of theophylline toxicity when used together.)

5. Furthermore, the label mentions that pentoxifylline has been used concurrently with various medications like antihypertensive drugs, beta blockers, digitalis, diuretics, and antiarrhythmics without observed problems, but small decreases in blood pressure have been noted in some patients when pentoxifylline is combined with nifedipine or captopril. (Pentoxifylline was not directly associated with cardiotoxicity risks in these cases, but changes in blood pressure were observed in some patients.)

6. Lastly, the label reports postmarketing cases of increased anticoagulant activity in patients treated with pentoxifylline and vitamin K antagonists, recommending monitoring of anticoagulant activity when using both medications. (Pentoxifylline was associated with an increased risk of altered anticoagulant activity when used with vitamin K antagonists.)",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",cba14ad5-e25e-4c80-a9a3-e0f08026ae8f,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=cba14ad5-e25e-4c80-a9a3-e0f08026ae8f&type=display
832,PERAMIVIR,"1. The drug RAPIVAB (peramivir) is an influenza virus neuraminidase inhibitor indicated for the treatment of acute uncomplicated influenza in patients 6 months and older. The drug label does not mention any direct association of RAPIVAB with cardiotoxicity risks.

2. The drug label states that at twice the maximum recommended dose, RAPIVAB did not prolong the QTc interval to any clinically relevant extent. This suggests that RAPIVAB itself is not associated with significant cardiotoxicity risks related to QT prolongation.

3. The drug label does not report any specific cardiotoxicity reactions or risks related to cardiac electrophysiology associated with the use of RAPIVAB. 

Overall, based on the information provided in the drug label, RAPIVAB does not appear to be directly associated with significant cardiotoxicity risks or cardiotoxicity reactions.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",fe04f6cd-e71c-4bd4-abac-97720bba2a0d,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fe04f6cd-e71c-4bd4-abac-97720bba2a0d&type=display
833,PERAMPANEL,"1. The drug label does not mention any specific cardiotoxicity risks or cardiotoxicity reactions associated with FYCOMPA (perampanel) tablets or oral suspension.
2. There is no indication in the drug label that FYCOMPA itself is linked to cardiotoxicity risks or cardiotoxicity reactions.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",ec812ea3-de3a-4271-957c-db8f692d1ae3,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=ec812ea3-de3a-4271-957c-db8f692d1ae3&type=display
834,PERFLUTREN,"1. The drug label warns of serious cardiopulmonary reactions, including fatalities, that have occurred uncommonly during or following perflutren-containing microsphere administration. The drug itself is associated with the risk of serious cardiopulmonary reactions.

2. The label advises assessing all patients for conditions that preclude DEFINITY RT administration and having resuscitation equipment and trained personnel readily available. The drug itself is associated with the risk of serious cardiopulmonary reactions.

3. The label mentions that most serious reactions occur within 30 minutes of administration. The drug itself is associated with the risk of serious cardiopulmonary reactions.

4. The drug label highlights that patients with unstable cardiopulmonary conditions, such as acute myocardial infarction or serious ventricular arrhythmias, may be at increased risk of serious reactions. The drug itself is associated with the risk of serious cardiopulmonary reactions.

5. The label also mentions that the risk for serious reactions may be increased among patients with certain unstable cardiopulmonary conditions. The drug itself is associated with the risk of serious cardiopulmonary reactions.

6. The label further specifies that the reported reactions include fatal cardiac or respiratory arrest, shock, syncope, arrhythmias, hypertension, hypotension, dyspnea, chest pain, and other symptoms. The drug itself is associated with the risk of serious cardiopulmonary reactions.

7. Additionally, the label warns about the potential for systemic embolization when administering the drug to patients with a cardiac shunt. The drug itself is associated with the risk of systemic embolization.

8. The label also cautions about the potential for ventricular arrhythmias related to high mechanical index values during ultrasound imaging. The drug itself is associated with the risk of ventricular arrhythmias.

In summary, the drug label clearly outlines the risks of serious cardiopulmonary reactions, systemic embolization, and ventricular arrhythmias associated with the administration of DEFINITY RT.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",7b9de6ab-a3ac-40c9-8103-139dc7a464a2,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7b9de6ab-a3ac-40c9-8103-139dc7a464a2&type=display
835,PERINDOPRIL ERBUMINE,"1. The drug label warns about fetal toxicity associated with drugs that act directly on the renin-angiotensin system, which can cause injury and death to the developing fetus. The drug itself is associated with the risk of fetal toxicity.

2. The drug label mentions that Perindopril Erbumine Tablets are indicated for the treatment of stable coronary artery disease to reduce the risk of cardiovascular mortality or nonfatal myocardial infarction. The drug itself is indicated for reducing cardiovascular risks in patients with stable coronary artery disease.

3. The drug label advises monitoring renal function during therapy with Perindopril Erbumine. The drug itself is associated with the need for monitoring renal function during treatment.

4. The drug label highlights the potential for hypotension and hyperkalemia as adverse reactions to Perindopril Erbumine. The drug itself is associated with the risk of hypotension and hyperkalemia as adverse reactions.

5. The drug label mentions that ACE inhibitors, including Perindopril Erbumine, have been associated with agranulocytosis and bone marrow depression, especially in patients with renal impairment or collagen vascular diseases. The drug itself is associated with the risk of agranulocytosis and bone marrow depression in certain patient populations.

6. The drug label warns about the potential for hyperkalemia in patients treated with ACE inhibitors, including Perindopril Erbumine, especially in those with renal insufficiency or diabetes. The drug itself is associated with the risk of hyperkalemia in specific patient groups.

7. The drug label discusses the possibility of ACE inhibitor-induced cough as a side effect of Perindopril Erbumine, which generally resolves upon discontinuation of therapy. The drug itself is associated with the risk of inducing cough as a side effect.

8. The drug label mentions that ACE inhibitors, including Perindopril Erbumine, have been rarely associated with hepatic failure, starting with cholestatic jaundice and progressing to fulminant hepatic necrosis. The drug itself is associated with the rare risk of hepatic failure as a potential adverse reaction.

9. The drug label advises caution in patients undergoing surgery or anesthesia with agents that produce hypotension, as Perindopril Erbumine may block angiotensin II formation, potentially leading to hypotension. The drug itself is associated with the risk of hypotension during surgery or anesthesia.

Overall, the drug Perindopril Erbumine is associated with various cardiotoxicity risks and reactions, including fetal toxicity, renal function changes, hypotension, hyperkalemia, agranulocytosis, hyperkalemia, cough, hepatic failure, and potential hypotension during surgery or anesthesia.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",fcaefca9-e6ca-4c97-9eb8-7f1c619ce4d0,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fcaefca9-e6ca-4c97-9eb8-7f1c619ce4d0&type=display
836,PERPHENAZINE,"1. The drug label warns of increased mortality in elderly patients with dementia-related psychosis treated with antipsychotic drugs, including perphenazine. The risk of death in drug-treated patients was between 1.6 to 1.7 times higher compared to placebo-treated patients, with most deaths attributed to cardiovascular causes like heart failure or sudden death.

2. The label mentions that perphenazine can cause postural hypotension, tachycardia, bradycardia, cardiac arrest, faintness, and dizziness as potential cardiovascular effects. Sudden death has occasionally been reported in patients who have received phenothiazines like perphenazine, with causes including cardiac arrest or asphyxia due to failure of the cough reflex.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",fc903628-248c-4d12-88b4-a551aeadb4d2,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fc903628-248c-4d12-88b4-a551aeadb4d2&type=display
837,PHENDIMETRAZINE TARTRATE,"1. The drug label states that the use of anorectic agents, including phendimetrazine tartrate, was associated with an increased risk of developing pulmonary hypertension, a rare but often fatal disorder. This risk was associated with the use of anorectic agents for longer than three months, with a 23-fold increase in the risk of developing pulmonary hypertension. The drug itself was associated with the risk of pulmonary hypertension.

2. The label also mentions that valvular heart disease associated with the use of some anorectic agents has been reported, with possible contributing factors including extended periods of use, higher than recommended doses, and use in combination with other anorectic drugs. The potential risk of valvular heart disease should be assessed carefully against the potential benefit of weight loss. The drug itself was associated with the risk of valvular heart disease.

3. It further warns that the onset or aggravation of exertional dyspnea, unexplained symptoms of angina pectoris, syncope, or lower extremity edema may suggest the possibility of pulmonary hypertension. In such cases, immediate discontinuation of phendimetrazine tartrate is recommended, and the patient should be evaluated for the possible presence of pulmonary hypertension. The drug itself was associated with the risk of pulmonary hypertension.

4. The label advises that baseline cardiac evaluation should be considered before initiating phendimetrazine treatment to detect preexisting valvular heart diseases or pulmonary hypertension. Echocardiograms during and after treatment could be useful for detecting any valvular disorders that may occur. The drug itself was associated with the risk of valvular heart disease and pulmonary hypertension.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",162140d3-b833-4633-9759-95821a46a690,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=162140d3-b833-4633-9759-95821a46a690&type=display
838,PHENELZINE SULFATE,"1. The drug label warns that Nardil is associated with the risk of hypertensive crises, which can sometimes be fatal. Symptoms of hypertensive crises include headache, palpitation, neck stiffness, nausea, vomiting, sweating, dilated pupils, and changes in heart rate. (The drug itself is associated with the risk of hypertensive crises.)

2. The label advises that blood pressure should be monitored frequently in all patients taking Nardil to detect any signs of a pressor response. Therapy should be stopped immediately if palpitations or frequent headaches occur during treatment. (The drug itself is associated with the risk of hypertensive crises.)

3. The label states that the most serious reactions to Nardil involve changes in blood pressure, with hypertensive crises being the most important reaction. These crises can include symptoms such as headache, palpitation, neck stiffness, nausea, vomiting, sweating, dilated pupils, and changes in heart rate. (The drug itself is associated with the risk of hypertensive crises.)

4. The label mentions that Nardil has been reported to cause postural hypotension and edema as cardiovascular side effects. (The drug itself is associated with the risk of postural hypotension and edema.)

5. The label lists cardiovascular side effects of Nardil, including postural hypotension and edema. (The drug itself is associated with the risk of postural hypotension and edema.)",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",513a41d0-37d4-4355-8a6d-a2c643bce6fa,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=513a41d0-37d4-4355-8a6d-a2c643bce6fa&type=display
839,PHENOXYBENZAMINE HYDROCHLORIDE,"1. The drug Dibenzyline (phenoxybenzamine hydrochloride) is an adrenergic, alpha-receptor-blocking agent that can produce and maintain ""chemical sympathectomy"" by oral administration, increasing blood flow to certain areas and lowering blood pressure. It has no effect on the parasympathetic system. (The drug itself is not associated with cardiotoxicity risk.)

2. Dibenzyline-induced alpha-adrenergic blockade leaves beta-adrenergic receptors unopposed, potentially leading to an exaggerated hypotensive response and tachycardia when compounds that stimulate both types of receptors are used concomitantly. (The drug itself is associated with a cardiotoxicity risk due to its mechanism of action.)

3. In cases of overdose, symptoms may include postural hypotension, tachycardia, vomiting, lethargy, and shock, largely due to blocking of the sympathetic nervous system and circulating epinephrine. Treatment of circulatory failure is a prime consideration, and usual pressor agents are not effective. (The drug itself is associated with cardiotoxicity reactions in cases of overdose.)

4. Epinephrine is contraindicated in cases of overdose because it stimulates both alpha- and beta-receptors, leading to vasodilation and a further drop in blood pressure. I.V. infusion of levarterenol bitartrate may be used to combat severe hypotensive reactions, as it primarily stimulates alpha-receptors. (The drug itself is associated with cardiotoxicity reactions in cases of overdose.)",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",8852dd44-098c-4d99-88e0-a092a8e08e11,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8852dd44-098c-4d99-88e0-a092a8e08e11&type=display
840,PHENTERMINE HYDROCHLORIDE,"1. The drug label mentions that a history of cardiovascular disease, such as coronary artery disease, stroke, arrhythmias, congestive heart failure, and uncontrolled hypertension, is a contraindication for the use of Phentermine Hydrochloride Tablets, indicating that the drug itself is associated with cardiotoxicity risks.

2. It also states that rare cases of primary pulmonary hypertension have been reported with the use of Phentermine, and patients should discontinue the medication if they experience symptoms such as dyspnea, angina pectoris, syncope, or lower extremity edema, suggesting a potential association between the drug and primary pulmonary hypertension.

3. Additionally, the label mentions that serious regurgitant cardiac valvular disease has been reported in individuals who took a combination of Phentermine with other drugs for weight loss, although the role of Phentermine alone in causing valvular heart disease has not been definitively established, indicating a potential association between the drug and valvular heart disease.

4. The warning also highlights that Phentermine may elevate blood pressure, which can be a risk factor for cardiovascular events, suggesting a direct association between the drug and cardiovascular risks.

5. Furthermore, the label cautions about the potential for interactions with other medications, such as monoamine oxidase inhibitors, alcohol, and adrenergic neuron blocking drugs, which can impact cardiovascular function, indicating that Phentermine can have cardiotoxic effects when combined with certain substances.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",8fe6b65d-ca61-40f0-90fc-255dfd075611,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8fe6b65d-ca61-40f0-90fc-255dfd075611&type=display
841,PHENTERMINE RESIN,"1. The drug label mentions that a history of cardiovascular disease, such as coronary artery disease, stroke, arrhythmias, congestive heart failure, and uncontrolled hypertension, is a contraindication for using phentermine resin extended-release capsules. This indicates that the drug itself is associated with a cardiotoxicity risk due to its potential effects on the cardiovascular system.

2. It also warns about the rare cases of primary pulmonary hypertension reported in patients receiving a combination of phentermine with other drugs. While the association with phentermine alone cannot be ruled out, there have been rare cases of primary pulmonary hypertension in patients who reportedly took phentermine alone. This suggests that phentermine may be associated with a risk of primary pulmonary hypertension, a cardiotoxicity reaction.

3. The label mentions serious regurgitant cardiac valvular disease reported in otherwise healthy individuals who took a combination of phentermine with other drugs for weight loss. The role of phentermine in causing these valvulopathies has not been established, but there have been rare cases of valvular heart disease in patients who reportedly took phentermine alone. This indicates a potential association between phentermine and valvular heart disease, a cardiotoxicity risk.

4. Additionally, it highlights the importance of monitoring for the development of tolerance to the anorectic effect of phentermine. If tolerance occurs, the drug should be discontinued to prevent exceeding the recommended dose, which could lead to adverse effects, including potential cardiotoxicity reactions.

Overall, the drug label suggests that phentermine resin extended-release capsules are associated with cardiotoxicity risks, particularly in relation to cardiovascular diseases, primary pulmonary hypertension, and valvular heart disease. Close monitoring and caution are advised to mitigate these potential cardiotoxicity reactions.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",7ca86c66-409b-4852-8631-c3ada6e60738,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7ca86c66-409b-4852-8631-c3ada6e60738&type=display
842,PHENTOLAMINE MESYLATE,"1. The drug label does not mention any cardiotoxicity risks or cardiotoxicity reactions associated with Ryzumvi (phentolamine ophthalmic solution) 0.75%. 

2. There is no specific mention of the drug causing or being associated with cardiotoxicity in the provided drug label information. 

3. Cardiotoxicity risks or reactions are not listed as adverse events or warnings in the drug label for Ryzumvi. 

Overall, based on the information provided in the drug label, there is no indication that Ryzumvi is associated with cardiotoxicity risks or reactions.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",96bb1e53-c2cc-4e60-a21a-db0269c371bf,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=96bb1e53-c2cc-4e60-a21a-db0269c371bf&type=display
843,PHENYTOIN,"1. Cases of bradycardia and cardiac arrest have been reported in DILANTIN-treated patients, both at recommended phenytoin doses and levels, and in association with phenytoin toxicity. (The drug itself was associated with cardiotoxicity risks.)

2. Most of the reports of cardiac arrest occurred in patients with underlying cardiac disease. (The drug itself was not directly causing the underlying cardiac disease but was associated with cardiac arrest in patients with pre-existing conditions.)

3. DILANTIN should be discontinued immediately if symptoms of angioedema, such as facial, perioral, or upper airway swelling occur. (This sentence does not specifically mention cardiotoxicity risks or reactions.)

4. Cases of acute hepatotoxicity, including infrequent cases of acute hepatic failure, have been reported with DILANTIN. These events may be part of the spectrum of DRESS or may occur in isolation. (This sentence discusses hepatotoxicity rather than cardiotoxicity.)

5. Cases of acute hepatotoxicity have been reported with DILANTIN. If this occurs, immediately discontinue. (This sentence also focuses on hepatotoxicity rather than cardiotoxicity.)

6. Cases of acute hepatotoxicity have been reported with DILANTIN. If this occurs, immediately discontinue. (This sentence reiterates the risk of acute hepatotoxicity rather than cardiotoxicity.)

Overall, the drug label for DILANTIN does not extensively discuss cardiotoxicity risks or reactions associated with the drug. The focus is primarily on other adverse reactions and precautions related to the use of phenytoin.",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",f339f9e4-b289-4efe-82b9-46c57d1dc277,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=f339f9e4-b289-4efe-82b9-46c57d1dc277&type=display
844,PHYTONADIONE,"1. The drug label does not mention any cardiotoxicity risks or cardiotoxicity reactions associated with Mephyton (phytonadione) itself. 

2. The label does not indicate any direct association between Mephyton and cardiotoxicity risks or reactions. 

3. There is no mention of cardiotoxicity risks or reactions linked to the use of Mephyton in the drug label. 

Overall, the drug label for Mephyton does not highlight any cardiotoxicity risks or reactions related to the use of this medication.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",158041d2-c307-4ae0-b8c9-00c441976937,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=158041d2-c307-4ae0-b8c9-00c441976937&type=display
845,PIFLUFOLASTAT F-18,"1. The drug label does not mention any specific cardiotoxicity risks or cardiotoxicity reactions associated with PYLARIFY (piflufolastat F 18) injection for positron emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer. 

2. Therefore, based on the information provided in the drug label, there are no indications that PYLARIFY itself is associated with cardiotoxicity risks or cardiotoxicity reactions.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",a00e5cbc-4fd5-4280-82ec-cd3498df4553,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a00e5cbc-4fd5-4280-82ec-cd3498df4553&type=display
846,PIMAVANSERIN TARTRATE,"1. **Cardiotoxicity Risk**: NUPLAZID has a warning for increased mortality in elderly patients with dementia-related psychosis when treated with antipsychotic drugs, including NUPLAZID. The drug itself is associated with an increased risk of death in elderly patients with dementia-related psychosis.

2. **QT Interval Prolongation**: NUPLAZID is known to prolong the QT interval, which can lead to cardiac arrhythmias. The use of NUPLAZID should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval. The drug itself is associated with QT interval prolongation, which can be a risk factor for cardiac arrhythmias.

3. **Adverse Reactions**: In clinical trials, common adverse reactions associated with NUPLAZID include peripheral edema and confusional state. These reactions can be indicative of cardiotoxicity and should be monitored closely. The drug itself is associated with these adverse reactions, which may signal potential cardiotoxic effects.

4. **Management of Overdose**: In cases of overdose, cardiovascular monitoring should be initiated immediately, including continuous ECG monitoring to detect possible arrhythmias. Specific antiarrhythmic therapies should be used cautiously due to the potential for additive effects with NUPLAZID. The drug itself can lead to cardiovascular complications in cases of overdose, emphasizing the importance of monitoring and appropriate management to prevent cardiotoxicity.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",1e6bea44-57d6-4bac-9328-46e1ee59f83b,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=1e6bea44-57d6-4bac-9328-46e1ee59f83b&type=display
847,PIMOZIDE,"1. Pimozide prolongs the QT interval of the electrocardiogram, making it contraindicated in patients with congenital long QT syndrome, a history of cardiac arrhythmias, or taking other drugs that prolong the QT interval. This cardiotoxicity risk is associated with the drug itself.

2. Sudden, unexpected deaths have occurred in patients taking high doses of pimozide for conditions other than Tourettes Disorder, possibly due to an effect of pimozide on the heart. This cardiotoxicity risk is associated with the drug itself.

3. Electrocardiographic changes observed in clinical trials of pimozide include prolongation of the QT interval, flattening, notching, and inversion of the T wave, as well as the appearance of U waves. Sudden, unexpected deaths and grand mal seizures have occurred at doses above 20 mg/day. This cardiotoxicity risk is associated with the drug itself.

4. Neuroleptic Malignant Syndrome (NMS) has been reported with pimozide, indicating a potential cardiotoxicity reaction associated with the drug itself.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",70b079e2-a1f7-4a93-8685-d60a4d7c1280,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=70b079e2-a1f7-4a93-8685-d60a4d7c1280&type=display
848,PINDOLOL,"1. The drug label mentions that pindolol, the active ingredient in the tablets, is a beta-blocker that should be avoided in patients with overt congestive heart failure due to the risk of exacerbating heart failure. The label states that beta-blockers, including pindolol, may precipitate more severe heart failure by inhibiting sympathetic stimulation, which is vital for circulatory function. The drug itself is associated with the risk of exacerbating heart failure in patients with latent cardiac insufficiency over time.

2. The label also warns that abrupt withdrawal of beta-blockers, such as pindolol, in patients with ischemic heart disease can lead to exacerbation of angina, myocardial infarction, and ventricular dysrhythmias. It advises gradual reduction of the dosage over 1 to 2 weeks to prevent worsening of angina or acute coronary insufficiency. The drug itself is associated with the risk of exacerbating ischemic heart disease if abruptly discontinued.

3. Additionally, the label cautions that beta-blockers, like pindolol, should be used with caution in patients with bronchospastic diseases, as they may block bronchodilation and worsen respiratory symptoms. The drug itself is associated with the risk of exacerbating bronchospasm in patients with bronchospastic diseases.

4. The label mentions that beta-blockers, including pindolol, may impair the heart's ability to respond to reflex stimuli, increasing the risks of hypotension and low cardiac output during major surgery. It suggests gradual withdrawal of beta-blocker therapy before surgery to minimize these risks. The drug itself is associated with the risk of protracted hypotension or low cardiac output during major surgery due to impaired reflex responses.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",79a8d97b-9461-4914-bcbb-f6f64a39e5e7,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=79a8d97b-9461-4914-bcbb-f6f64a39e5e7&type=display
849,PIOGLITAZONE,"1. The drug ACTOS, a thiazolidinedione, is associated with causing or exacerbating congestive heart failure in some patients. Thiazolidinediones, including ACTOS, have been linked to congestive heart failure risks. Patients should be monitored for signs and symptoms of heart failure, and discontinuation or dose reduction of ACTOS should be considered if heart failure develops.

2. ACTOS is not recommended in patients with symptomatic heart failure, and initiation of ACTOS in patients with established New York Heart Association (NYHA) Class III or IV heart failure is contraindicated. The drug ACTOS is contraindicated in patients with established NYHA Class III or IV heart failure, indicating a direct association with cardiotoxicity risks.

3. In clinical trials, ACTOS has been associated with an increased risk of congestive heart failure, with a higher incidence of events such as cardiac failure and hospitalization for worsening heart failure compared to placebo. The drug ACTOS has been linked to an increased risk of congestive heart failure events in clinical trials, indicating a potential cardiotoxic effect.

4. The PROactive trial showed that patients treated with ACTOS had a higher incidence of congestive heart failure events, including hospitalizations, compared to those on placebo. ACTOS treatment was associated with a higher rate of congestive heart failure events leading to hospitalization in the PROactive trial, suggesting a cardiotoxic effect of the drug.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",d2ddc491-88a9-4063-9150-443b4fa4330c,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=d2ddc491-88a9-4063-9150-443b4fa4330c&type=display
850,PIRFENIDONE,"1. **Mechanism of Action**: The drug label does not establish a direct association between ESBRIET (pirfenidone) and cardiotoxicity risks.

2. **Pharmacodynamics**: The drug label mentions that ESBRIET was evaluated for its effect on QT interval in a study with healthy volunteers. The study did not show evidence that ESBRIET prolonged the QTc interval. Therefore, ESBRIET itself was not associated with cardiotoxicity risks in this study.

3. **Pharmacokinetics**: The drug label does not indicate any direct association between ESBRIET and cardiotoxicity risks based on its pharmacokinetic profile.

In summary, based on the information provided in the drug label, ESBRIET (pirfenidone) does not appear to be directly associated with cardiotoxicity risks or cardiotoxic reactions.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",2e8c3537-36d7-4de5-9b5c-7a624b9a9e6e,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=2e8c3537-36d7-4de5-9b5c-7a624b9a9e6e&type=display
851,PIROXICAM,"1. The drug label warns that nonsteroidal anti-inflammatory drugs (NSAIDs), including FELDENE, are associated with an increased risk of serious cardiovascular thrombotic events, such as myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use. (The drug itself is associated with the cardiotoxicity risk.)

2. FELDENE is contraindicated in the setting of coronary artery bypass graft (CABG) surgery due to the increased risk of serious cardiovascular thrombotic events. (The drug itself is associated with the cardiotoxicity risk.)

3. Clinical trials have shown that several cyclooxygenase-2 (COX-2) selective and nonselective NSAIDs, including FELDENE, have an increased risk of serious cardiovascular thrombotic events, such as myocardial infarction and stroke, which can be fatal. The risk for cardiovascular thrombotic events may be similar for all NSAIDs, and the risk increases with higher doses. (The drug itself is associated with the cardiotoxicity risk.)

4. Patients treated with NSAIDs, including FELDENE, in the post-myocardial infarction (MI) period were at an increased risk of reinfarction, cardiovascular-related death, and all-cause mortality. The risk of death in NSAID users persisted over several years of follow-up. (The drug itself is associated with the cardiotoxicity risk.)

5. FELDENE should be avoided in patients with a recent MI unless the benefits outweigh the risk of recurrent cardiovascular thrombotic events. Patients with a recent MI who are treated with FELDENE should be monitored for signs of cardiac ischemia. (The drug itself is associated with the cardiotoxicity risk.)

6. The label advises monitoring blood pressure during the initiation of NSAID treatment and throughout the course of therapy, as NSAIDs, including FELDENE, can lead to new-onset hypertension or worsening of preexisting hypertension, contributing to an increased incidence of cardiovascular events. (The drug itself is associated with the cardiotoxicity risk.)

7. FELDENE should be avoided in patients with severe heart failure unless the benefits outweigh the risk of worsening heart failure. Patients with severe heart failure who are treated with FELDENE should be monitored for signs of worsening heart failure. (The drug itself is associated with the cardiotoxicity risk.)",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",dedef9e5-23de-49ff-895a-30906b5c7da3,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=dedef9e5-23de-49ff-895a-30906b5c7da3&type=display
852,PITAVASTATIN CALCIUM,"1. **Warnings and Precautions - Myopathy and Rhabdomyolysis:** The drug LIVALO was associated with the risk of myopathy and rhabdomyolysis, particularly in patients aged 65 or older, those with uncontrolled hypothyroidism, renal impairment, and when used with certain other drugs or at higher dosages. Discontinuation of LIVALO was recommended if markedly elevated creatine kinase (CK) levels occurred or if myopathy was diagnosed or suspected.

2. **Warnings and Precautions - Immune-Mediated Necrotizing Myopathy (IMNM):** Rare reports of immune-mediated necrotizing myopathy (IMNM), an autoimmune myopathy, have been associated with statin use, including LIVALO. Discontinuation of LIVALO was advised if IMNM was suspected.

3. **Warnings and Precautions - Hepatic Dysfunction:** Increases in serum transaminases and rare reports of fatal and non-fatal hepatic failure have been reported with LIVALO use. Consideration of liver enzyme testing before initiating therapy and prompt discontinuation of LIVALO if serious hepatic injury with clinical symptoms occurs were recommended.

4. **Adverse Reactions:** While not explicitly stated as cardiotoxicity, the adverse reactions section mentioned myopathy, rhabdomyolysis, and increases in HbA1c and fasting serum glucose levels as potential reactions associated with LIVALO use. These reactions could indirectly impact cardiovascular health and function.",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",44dcbf97-99ec-427c-ba50-207e0069d6d2,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=44dcbf97-99ec-427c-ba50-207e0069d6d2&type=display
853,PITAVASTATIN MAGNESIUM,"1. ZYPITAMAG is an HMG-CoA reductase inhibitor indicated for reducing LDL-C in adults with primary hyperlipidemia. The drug itself is not associated with cardiotoxicity risk.

2. The drug label mentions that pitavastatin was not associated with clinically meaningful prolongation of the QTc interval or heart rate at doses up to 16 mg daily. Therefore, pitavastatin is not linked to cardiotoxicity risks.

3. No specific treatment for pitavastatin overdose is known, and hemodialysis is unlikely to be of benefit due to the high protein binding ratio of pitavastatin. This information does not suggest a direct association between pitavastatin and cardiotoxicity.

In summary, based on the information provided in the drug label, pitavastatin (ZYPITAMAG) is not associated with cardiotoxicity risks or cardiotoxic reactions.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",c8c50e03-5cb8-43f4-bdef-8edd12f1945f,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=c8c50e03-5cb8-43f4-bdef-8edd12f1945f&type=display
854,PITOLISANT HYDROCHLORIDE,"1. The drug WAKIX (pitolisant) has been associated with QT interval prolongation, which can increase the risk of cardiac arrhythmias. The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval.

2. WAKIX should also be avoided in patients with a history of cardiac arrhythmias, as well as other circumstances that may increase the risk of the occurrence of torsade de pointes or sudden death, including symptomatic bradycardia, hypokalemia or hypomagnesemia, and the presence of congenital prolongation of the QT interval.

3. The risk of QT prolongation may be greater in patients with hepatic or renal impairment due to higher concentrations of pitolisant. Patients with hepatic or renal impairment should be monitored for increased QTc. Dosage modification is recommended in patients with moderate hepatic impairment and moderate or severe renal impairment.

4. WAKIX at the highest recommended dosage led to a QTc increase, and exposures higher than recommended doses increased QTc. This indicates that the drug itself is associated with QT interval prolongation and cardiotoxicity risks.

5. The drug label also mentions that WAKIX has not been studied in patients with severe hepatic impairment, and it is contraindicated in such patients due to the potential for increased exposure to the drug, which can lead to cardiotoxicity risks.

6. Additionally, WAKIX is not recommended in patients with end-stage renal disease (ESRD) due to the unknown effects on renal function and the potential for increased cardiotoxicity risks in this population.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",8daa5562-824e-476c-9652-26ceef3d4b0e,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8daa5562-824e-476c-9652-26ceef3d4b0e&type=display
855,PLAZOMICIN,"1. Nephrotoxicity has been reported with ZEMDRI, with the risk being greater in patients with impaired renal function, the elderly, and those receiving concomitant nephrotoxic medications. (ZEMDRI itself is associated with nephrotoxicity risk.)

2. Ototoxicity, manifested as hearing loss, tinnitus, and/or vertigo, has been reported with ZEMDRI. Symptoms of aminoglycoside-associated ototoxicity may be irreversible and may not become evident until after completion of therapy. (ZEMDRI itself is associated with ototoxicity risk.)

3. Aminoglycosides, including ZEMDRI, have been associated with neuromuscular blockade. During therapy with ZEMDRI, monitor for adverse reactions associated with neuromuscular blockade, particularly in high-risk patients. (ZEMDRI itself is associated with neuromuscular blockade risk.)

4. Aminoglycosides, including ZEMDRI, can cause fetal harm when administered to a pregnant woman. (ZEMDRI itself is associated with fetal harm risk.)

5. No specific mention of cardiotoxicity risks or reactions associated with ZEMDRI was found in the provided drug label.",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",eccf9fd9-53ac-4252-a106-5567b3a82a70,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=eccf9fd9-53ac-4252-a106-5567b3a82a70&type=display
856,PLECANATIDE,1. The drug label does not mention any cardiotoxicity risks or cardiotoxicity reactions associated with TRULANCE (plecanatide) tablets for the treatment of chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C).,No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",fe2895bf-71a6-493a-b0ca-e06b2dfefc82,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fe2895bf-71a6-493a-b0ca-e06b2dfefc82&type=display
857,PLERIXAFOR,1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with Mozobil (plerixafor) injection. No cardiotoxicity risks or reactions were attributed to the drug itself in the provided drug label information.,No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",0ed08d2b-5051-46b2-aa37-1d6275bf9003,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=0ed08d2b-5051-46b2-aa37-1d6275bf9003&type=display
858,POLIDOCANOL,"1. The drug VARITHENA (polidocanol injectable foam) is associated with a warning and precaution regarding tissue ischemia and necrosis, emphasizing not to inject intra-arterially to avoid severe necrosis, ischemia, or gangrene, particularly in patients with underlying arterial disease (5.2).

2. VARITHENA is also associated with a warning and precaution for venous thrombosis, indicating that the drug can cause venous thrombosis, especially in patients with reduced mobility, history of deep vein thrombosis, recent major surgery, or pregnancy, and advises close monitoring for signs of thrombosis after treatment (5.3).

3. The drug label mentions that VARITHENA has been reported to induce thrombosis in treated superficial veins, leading to the formation of thrombus and venous occlusion, with D-dimer levels commonly elevated post-treatment, which is not diagnostically useful for assessing venous thrombus following treatment with VARITHENA (6.1).

4. Additionally, the label states that neurologic adverse events, such as cerebrovascular accidents and migraines, have been reported in patients following the administration of physician-compounded foam sclerosants, but none of the patients in the VARITHENA trials experienced clinically important neurological or visual adverse events suggestive of cerebral gas embolism (6.1).",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",dfd6b4a0-b0dc-11e2-9e96-0800200c9a66,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=dfd6b4a0-b0dc-11e2-9e96-0800200c9a66&type=display
859,POLYMYXIN B,"1. The drug label does not mention any specific cardiotoxicity risks associated with Polymyxin B itself.
2. The label does not indicate that Polymyxin B is associated with cardiotoxicity reactions.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",a974c557-e88f-451b-a1bd-d2c656be226e,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a974c557-e88f-451b-a1bd-d2c656be226e&type=display
860,POMALIDOMIDE,"1. The drug label warns about venous and arterial thromboembolism risks associated with POMALYST, stating that deep venous thrombosis, pulmonary embolism, myocardial infarction, and stroke can occur in patients with multiple myeloma treated with POMALYST. Antithrombotic prophylaxis is recommended. (The drug itself is associated with the risk of venous and arterial thromboembolism.)

2. The label mentions that in Trial 2, where anticoagulant therapies were mandated, thromboembolic events occurred in patients treated with POMALYST and low-dose dexamethasone. Venous thromboembolic events occurred in a higher percentage of patients treated with POMALYST compared to those treated with high-dose dexamethasone. (The drug itself is associated with an increased risk of thromboembolic events.)

3. Additionally, the label highlights that arterial thromboembolic events, including ischemic cerebrovascular conditions and ischemic heart disease, were observed in patients treated with POMALYST. The occurrence of these events was higher in patients receiving POMALYST compared to those on high-dose dexamethasone. (The drug itself is associated with an increased risk of arterial thromboembolic events.)

4. The label also mentions that patients with known risk factors, such as prior thrombosis, may be at greater risk of thromboembolic events when treated with POMALYST. It recommends taking actions to minimize modifiable risk factors and suggests thromboprophylaxis based on the patient's underlying risk factors. (The drug itself is associated with an increased risk of thromboembolic events in patients with multiple myeloma.)

5. Furthermore, the label warns about the potential for increased mortality in patients with multiple myeloma when pembrolizumab is added to a thalidomide analogue and dexamethasone. It states that this combination resulted in increased mortality in clinical trials. (The combination of pembrolizumab with a thalidomide analogue and dexamethasone, not specifically POMALYST alone, is associated with increased mortality.)

6. The label advises monitoring patients for hematologic toxicities, especially neutropenia, when using POMALYST for multiple myeloma. It mentions that neutropenia was the most frequently reported Grade 3 or 4 adverse event in clinical trials. (The drug itself is associated with hematologic toxicities, including neutropenia.)

7. Additionally, the label highlights the risk of hepatotoxicity with POMALYST, including cases of hepatic failure, elevated liver enzymes, and bilirubin levels. It recommends monthly monitoring of liver function tests and discontinuation of POMALYST upon liver enzyme elevation. (The drug itself is associated with the risk of hepatotoxicity.)

8. The label warns about severe cutaneous reactions, such as Stevens-Johnson syndrome, toxic epidermal necrolysis, and drug reaction with eosinophilia and systemic symptoms, which have been reported with POMALYST. It advises discontinuing POMALYST for severe cutaneous reactions. (The drug itself is associated with the risk of severe cutaneous reactions.)

9. Lastly, the label mentions that dizziness and confusional state were reported in patients receiving POMALYST in clinical trials. It instructs patients to avoid situations where dizziness or confusion may be problematic and to consult a healthcare provider before taking other medications that may cause these symptoms. (The drug itself is associated with dizziness and confusional state as potential adverse reactions.)",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",2b25ef01-5c9e-11e1-b86c-0800200c9a66,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=2b25ef01-5c9e-11e1-b86c-0800200c9a66&type=display
861,PONATINIB HYDROCHLORIDE,"1. Arterial occlusive events (AOEs), including fatalities, have occurred in ICLUSIG-treated patients. The drug ICLUSIG is associated with arterial occlusive events, such as myocardial infarction, stroke, and peripheral vascular disease, leading to urgent revascularization procedures.

2. Venous thromboembolic events (VTEs) have occurred in ICLUSIG-treated patients. The drug ICLUSIG is associated with venous thromboembolic events, including deep vein thrombosis and pulmonary embolism.

3. Heart failure, including fatalities, occurred in ICLUSIG-treated patients. The drug ICLUSIG is associated with heart failure events, such as increased brain natriuretic peptide levels and left ventricular hypertrophy.

4. Monitor patients for signs or symptoms consistent with heart failure and manage heart failure as clinically indicated. Interrupt, then resume at reduced dose or discontinue ICLUSIG for new or worsening heart failure. The drug ICLUSIG can cause hepatotoxicity, including liver failure and death, and patients should be monitored for signs of heart failure, with dose adjustments or discontinuation if heart failure worsens.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",16d804b6-4957-43ee-b18c-3b36ec37c5ac,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=16d804b6-4957-43ee-b18c-3b36ec37c5ac&type=display
862,PONESIMOD,"1. The drug PONVORY is associated with cardiotoxicity risks, including bradyarrhythmia and atrioventricular conduction delays. Initiation of PONVORY treatment may result in a transient decrease in heart rate and AV conduction delays, requiring an up-titration scheme to reach the maintenance dosage (PONVORY-associated cardiotoxicity risk).

2. Study 1 reported that bradycardia at treatment initiation and sinus bradycardia on ECG occurred in PONVORY-treated patients, with a mean decrease in heart rate of 6 bpm on Day 1 of dosing. AV conduction delays manifested as first-degree AV block, which was transient and asymptomatic in most cases (PONVORY-associated cardiotoxicity reactions).

3. Patients with certain preexisting cardiac conditions, such as sinus bradycardia, first- or second-degree AV block, or a history of myocardial infarction or heart failure, are recommended to undergo first-dose monitoring due to the potential for bradycardia and conduction abnormalities with PONVORY treatment (PONVORY-associated cardiotoxicity risk).

4. The drug label advises that PONVORY should not be used in patients with specific cardiac conditions, such as Mobitz type II second-degree AV block, sick sinus syndrome, or sino-atrial block, unless the patient has a functioning pacemaker, due to the risk of bradyarrhythmia and AV conduction delays (PONVORY-associated cardiotoxicity risk).

5. In Study 1, PONVORY-treated patients experienced a transient decrease in heart rate and AV conduction delays, which typically resolved without intervention and did not require discontinuation of treatment. The drug label recommends consultation with a cardiologist for patients with certain cardiac conditions before initiating PONVORY treatment (PONVORY-associated cardiotoxicity reactions).",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",5be69660-738c-4db7-b0d4-517aa873dc41,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=5be69660-738c-4db7-b0d4-517aa873dc41&type=display
863,PORFIMER SODIUM,"1. **Warnings and Precautions - Pulmonary and Gastroesophageal Hemorrhage:** Patients with large, centrally located tumors, cavitating tumors, or extensive tumors extrinsic to the bronchus are at high risk for fatal massive hemoptysis. The drug itself is not directly associated with cardiotoxicity but may lead to pulmonary and gastroesophageal hemorrhage in patients with specific tumor characteristics.

2. **Warnings and Precautions - Chest Pain:** Patients may experience substernal chest pain as a result of inflammatory responses within the treatment area. The drug itself is not directly associated with cardiotoxicity but may cause chest pain due to the inflammatory reactions.

3. **Warnings and Precautions - Airway Obstruction and Respiratory Distress:** Treatment-induced inflammation from the drug followed by PDT can obstruct the main airway, leading to respiratory distress. The drug itself is not directly associated with cardiotoxicity but may result in airway obstruction and respiratory distress in certain patients.

4. **Warnings and Precautions - Thromboembolism:** Thromboembolic events can occur following photodynamic therapy with the drug. Most reported events occurred in patients with other risk factors for thromboembolism. The drug itself is not directly associated with cardiotoxicity but may contribute to thromboembolic events in patients with pre-existing risk factors.

5. **Warnings and Precautions - Embryo-Fetal Toxicity:** Based on animal studies, the drug may cause embryo-fetal toxicity when administered to pregnant women. The drug itself is not directly associated with cardiotoxicity but may pose risks to fetal development in pregnant women.",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",5c4841b4-fbc0-4163-8ee1-cb28629cbfbf,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=5c4841b4-fbc0-4163-8ee1-cb28629cbfbf&type=display
864,POSACONAZOLE,"1. **Warnings and Precautions (5.2):** Noxafil has been shown to prolong the QTc interval and cause cases of Torsades de Pointes (TdP). Administer with caution to patients with potentially proarrhythmic conditions. Do not administer with drugs known to prolong QTc interval and metabolized through CYP3A4. (The drug itself is associated with QTc prolongation and TdP risk.)

2. **Drug Interactions (7.2):** Coadministration of Noxafil with CYP3A4 substrates (such as pimozide and quinidine) can result in QTc interval prolongation and cases of Torsades de Pointes (TdP). (The drug itself is associated with QTc prolongation and TdP risk.)

3. **Warnings and Precautions (5.7):** Concomitant administration of azole antifungals, including Noxafil, with vincristine has been associated with neurotoxicity and other serious adverse reactions. Reserve azole antifungals, including Noxafil, for patients receiving a vinca alkaloid, including vincristine, who have no alternative antifungal treatment options. (The drug itself is associated with neurotoxicity when used concomitantly with vincristine.)

4. **Warnings and Precautions (5.10):** Concomitant administration of Noxafil with venetoclax may increase venetoclax toxicities, including the risk of tumor lysis syndrome, neutropenia, and serious infections. Monitor for toxicity and reduce venetoclax dose. (The drug itself is associated with increased venetoclax toxicities when used together.)

5. **Warnings and Precautions (5.2):** Noxafil has been shown to prolong the QTc interval and cause cases of Torsades de Pointes (TdP). Administer with caution to patients with potentially proarrhythmic conditions. Do not administer with drugs known to prolong QTc interval and metabolized through CYP3A4. (The drug itself is associated with QTc prolongation and TdP risk.)

6. **Drug Interactions (7.2):** Coadministration of Noxafil with CYP3A4 substrates (such as pimozide and quinidine) can result in QTc interval prolongation and cases of Torsades de Pointes (TdP). (The drug itself is associated with QTc prolongation and TdP risk.)",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",b073b082-7b57-4423-8c06-4fd4263d6f84,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=b073b082-7b57-4423-8c06-4fd4263d6f84&type=display
865,POTASSIUM ACETATE,"1. The drug label warns that potassium-containing solutions, including Potassium Acetate Injection, USP, should be used with caution in patients with hyperkalemia, severe renal failure, and conditions with potassium retention, indicating that the drug itself is associated with cardiotoxicity risks.

2. The label also mentions that high plasma concentrations of potassium may cause death by cardiac depression, arrhythmias, or arrest, especially in patients with cardiac disease, renal disease, or those who are digitalized, suggesting that the drug itself can lead to cardiotoxic reactions.

3. Additionally, the label states that potassium intoxication signs and symptoms, such as cardiac arrhythmias, hypotension, and cardiac arrest, can occur with overdose of potassium-containing solutions like Potassium Acetate Injection, USP, indicating that the drug itself can cause cardiotoxicity reactions.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",c58f8112-d587-493a-91b7-2b48c80bb7bf,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=c58f8112-d587-493a-91b7-2b48c80bb7bf&type=display
866,POTASSIUM CHLORIDE,"1. The drug label mentions that the treatment of potassium depletion, especially in the presence of cardiac disease, renal disease, or acidosis, requires careful attention to acid-base balance, volume status, and electrolytes, including magnesium, sodium, chloride, phosphate, and calcium, as well as electrocardiograms and the patient's clinical status. This indicates that the drug itself is not directly associated with cardiotoxicity but highlights the importance of monitoring various factors in patients with cardiac conditions.

2. The label also states that studies support the use of potassium replacement in digitalis toxicity, but it mentions that when alkalosis is present, normokalemia and hyperkalemia may obscure a total potassium deficit. The advisability of using potassium replacement in the setting of hyperkalemia is uncertain. This suggests that the drug may be involved in managing digitalis toxicity but also highlights potential challenges in cases of alkalosis and hyperkalemia.

3. In the section on overdosage, it is mentioned that the administration of oral potassium salts to individuals with impaired excretory mechanisms for potassium or if potassium is administered too rapidly can potentially lead to fatal hyperkalemia. Symptoms of hyperkalemia include characteristic electrocardiographic changes and cardiovascular collapse. This indicates that the drug itself can lead to cardiotoxicity if not administered properly or in cases of overdose.",Less,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",142c30ff-a839-4616-8167-ad4b07d8456f,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=142c30ff-a839-4616-8167-ad4b07d8456f&type=display
867,POTASSIUM CITRATE,"1. The drug Urocit-K is associated with a risk of hyperkalemia, which can lead to cardiac arrest in patients with impaired mechanisms for excreting potassium. The administration of Urocit-K in patients with chronic renal failure or other conditions impairing potassium excretion should be avoided due to the potential for fatal hyperkalemia (5.1).

2. Solid dosage forms of potassium chlorides, such as Urocit-K, have been associated with stenotic and/or ulcerative lesions of the small bowel and upper gastrointestinal bleeding. These gastrointestinal lesions are caused by a high local concentration of potassium ions in the region of the dissolving tablets, potentially leading to severe complications (5.2).

3. Urocit-K may cause minor gastrointestinal complaints in some patients, such as abdominal discomfort, vomiting, diarrhea, loose bowel movements, or nausea. These symptoms are attributed to the irritation of the gastrointestinal tract by the medication and may be alleviated by taking the dose with meals or snacks or by reducing the dosage (6.1).",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",72cdea1b-2240-41db-987d-86d5c6aaa978,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=72cdea1b-2240-41db-987d-86d5c6aaa978&type=display
868,PRALATREXATE,"1. **Warnings and Precautions**: The drug FOLOTYN can cause myelosuppression, which may include cardiotoxicity risks. Monitor complete blood counts and adjust the dose based on ANC and platelet count to manage this risk.

2. **Warnings and Precautions**: FOLOTYN can cause severe dermatologic reactions, including cardiotoxicity reactions, which may result in death. Monitor closely for these reactions and withhold or discontinue FOLOTYN based on severity.

3. **Warnings and Precautions**: FOLOTYN can cause hepatic toxicity and liver function test abnormalities, which may also indicate cardiotoxicity risks. Monitor liver function tests and adjust or discontinue therapy based on the severity of hepatic toxicity.

4. **Warnings and Precautions**: Patients with severe renal impairment may be at greater risk for increased exposure and adverse reactions, including cardiotoxicity. Reduce FOLOTYN dosage in these patients and monitor renal function closely.

5. **Warnings and Precautions**: Serious adverse reactions, including cardiotoxicity reactions like toxic epidermal necrolysis, have been reported in patients with end-stage renal disease (ESRD) undergoing dialysis who were administered FOLOTYN. Avoid FOLOTYN in patients with ESRD and monitor renal function if administration is necessary.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",9f3d9c4d-9386-4451-b712-0fbdc5478d8f,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=9f3d9c4d-9386-4451-b712-0fbdc5478d8f&type=display
869,PRALIDOXIME CHLORIDE,"1. The drug PROTOPAM Chloride is not effective in treating poisoning due to phosphorus, inorganic phosphates, or organophosphates without anticholinesterase activity, indicating that it is not associated with cardiotoxicity risks related to these substances.

2. The drug label warns that temporary worsening of cholinergic manifestations, such as tachycardia, cardiac arrest, laryngospasm, and muscle rigidity or paralysis, may occur if PROTOPAM Chloride is infused too rapidly, suggesting that the drug itself can lead to cardiotoxic reactions if not administered properly.

3. The label advises that atropine should be given cautiously in the presence of significant hypoxia due to the risk of atropine-induced ventricular fibrillation, indicating that atropine, when used in conjunction with PROTOPAM Chloride, can contribute to cardiotoxicity risks.

4. The label also mentions that prolonged paralysis has been reported in patients when succinylcholine is given with drugs having anticholinesterase activity, suggesting that the combination of succinylcholine and PROTOPAM Chloride may pose cardiotoxicity risks.

5. Additionally, the label warns that the signs of atropinization may occur earlier than expected when atropine and pralidoxime chloride are used together, especially if the total dose of atropine has been large and the administration of pralidoxime chloride has been delayed, indicating that the combination of atropine and PROTOPAM Chloride can lead to cardiotoxic reactions.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",17407365-3681-5a43-e063-6394a90a0391,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=17407365-3681-5a43-e063-6394a90a0391&type=display
870,PRALSETINIB,"1. **Warnings and Precautions - Hypertension:** The drug GAVRETO is associated with hypertension, occurring in 35% of patients, with Grade 3 hypertension in 18% of patients. The drug itself is linked to the risk of hypertension, and monitoring blood pressure is recommended before and during treatment.

2. **Warnings and Precautions - Hemorrhagic Events:** GAVRETO is associated with serious, including fatal, hemorrhagic events, with Grade  3 hemorrhagic events occurring in 4.1% of patients. The drug itself is linked to the risk of hemorrhagic events, and permanent discontinuation is advised for severe or life-threatening hemorrhage.

3. **Warnings and Precautions - Tumor Lysis Syndrome:** Cases of tumor lysis syndrome have been reported in patients with medullary thyroid carcinoma receiving GAVRETO. The drug itself is associated with the risk of tumor lysis syndrome, especially in patients with rapidly growing tumors or high tumor burden.

4. **Warnings and Precautions - Risk of Impaired Wound Healing:** GAVRETO has the potential to adversely affect wound healing, as drugs inhibiting the VEGF signaling pathway can lead to impaired wound healing. The drug itself is associated with the risk of impaired wound healing, and specific precautions are recommended before and after surgery.

5. **Warnings and Precautions - Embryo-Fetal Toxicity:** GAVRETO can cause fetal harm based on animal studies and its mechanism of action. The drug itself is associated with embryo-fetal toxicity, and females of reproductive potential are advised to use effective contraception during treatment and for a specific period after the last dose.",Less,No,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",16edd46e-28b8-f06d-e063-6394a90ae31b,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=16edd46e-28b8-f06d-e063-6394a90ae31b&type=display
871,PRAMIPEXOLE DIHYDROCHLORIDE,"1. The drug label for MIRAPEX ER does not mention any specific cardiotoxicity risks or reactions associated with the drug itself. 

2. The label primarily focuses on adverse reactions related to the nervous system, gastrointestinal system, psychiatric disorders, musculoskeletal system, and other systems. 

3. While the label does not highlight cardiotoxicity as a significant concern with MIRAPEX ER, it is essential for healthcare providers to monitor patients for any signs or symptoms of cardiotoxicity during treatment. 

4. Patients should be advised to report any unusual symptoms, including chest pain, palpitations, or shortness of breath, to their healthcare provider promptly. 

5. Overall, the drug label does not indicate a direct association between MIRAPEX ER and cardiotoxicity risks or reactions based on the information provided.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",e2902ed1-cfeb-4815-adc3-129c577917a1,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=e2902ed1-cfeb-4815-adc3-129c577917a1&type=display
872,PRAMLINTIDE ACETATE,1. The drug label does not mention any cardiotoxicity risks or cardiotoxicity reactions associated with SYMLIN (pramlintide acetate) injection for subcutaneous use.,No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",4aea30ff-eb0d-45c1-b114-3127966328ff,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=4aea30ff-eb0d-45c1-b114-3127966328ff&type=display
873,PRASUGREL,"1. The drug label warns of a bleeding risk associated with prasugrel, stating that it can cause significant, sometimes fatal bleeding, but does not directly associate cardiotoxicity with the drug itself.
   
2. The label advises against using prasugrel in patients with active pathological bleeding or a history of transient ischemic attack or stroke, without directly linking the drug to cardiotoxicity risks.

3. It mentions that in patients 75 years of age, prasugrel is generally not recommended due to an increased risk of fatal and intracranial bleeding, but does not specify a direct association with cardiotoxicity.

4. The label cautions against starting prasugrel in patients likely to undergo urgent coronary artery bypass graft surgery (CABG) and recommends discontinuing the drug at least 7 days prior to surgery, focusing on bleeding risks rather than direct cardiotoxicity.

5. Additional risk factors for bleeding, such as body weight <60 kg, propensity to bleed, and concomitant use of medications that increase bleeding risk, are highlighted, with no direct mention of cardiotoxicity risks associated with prasugrel.

6. The label advises suspecting bleeding in patients who are hypotensive and have recently undergone invasive or surgical procedures while on prasugrel, emphasizing the management of bleeding events rather than direct cardiotoxicity concerns.

7. It stresses the importance of managing bleeding without discontinuing prasugrel if possible, as stopping the drug increases the risk of subsequent cardiovascular events, focusing on the impact of bleeding events on cardiovascular outcomes rather than direct cardiotoxicity risks.",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",596c923d-db8d-4b96-bf31-52186a38c30d,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=596c923d-db8d-4b96-bf31-52186a38c30d&type=display
874,PRAVASTATIN SODIUM,"1. The drug Pravastatin sodium is indicated to reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). (The drug is associated with reducing the risk of cardiovascular events.)

2. Pravastatin sodium is also indicated to reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. (The drug is associated with reducing the risk of cardiovascular events.)

3. The drug is recommended as an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. (The drug is associated with reducing LDL-C levels.)

4. Pravastatin sodium is recommended as an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). (The drug is associated with reducing LDL-C levels in pediatric patients.)

5. The drug is also recommended as an adjunct to diet for the treatment of adults with primary dysbetalipoproteinemia and hypertriglyceridemia. (The drug is associated with treating these lipid disorders.)

6. Risk factors for myopathy and rhabdomyolysis associated with Pravastatin sodium include age 65 years or greater, uncontrolled hypothyroidism, renal impairment, concomitant use with certain other drugs, and higher pravastatin dosage. (The drug is associated with the risk of myopathy and rhabdomyolysis.)

7. Rare reports of immune-mediated necrotizing myopathy (IMNM), an autoimmune myopathy, have been reported with the use of Pravastatin sodium. Discontinuation of the drug is recommended if IMNM is suspected. (The drug is associated with the risk of immune-mediated necrotizing myopathy.)

8. Increases in serum transaminases have occurred with the use of Pravastatin sodium, with rare reports of fatal and non-fatal hepatic failure. Prompt discontinuation of the drug is advised if serious hepatic injury with clinical symptoms occurs. (The drug is associated with hepatic dysfunction.)

9. Pravastatin may cause increases in HbA1c and fasting serum glucose levels. Lifestyle measures are recommended to optimize these levels. (The drug is associated with potential increases in HbA1c and fasting serum glucose levels.)

10. In short-term clinical trials, common adverse reactions reported with Pravastatin sodium include musculoskeletal pain, nausea/vomiting, upper respiratory infection, diarrhea, and headache. (The drug is associated with these adverse reactions.)

11. The drug label also mentions drug interactions that can increase the risk of myopathy and rhabdomyolysis when used concomitantly with Pravastatin sodium, such as gemfibrozil, cyclosporine, clarithromycin, erythromycin, niacin, fibrates, and colchicine. (The drug is associated with an increased risk of myopathy and rhabdomyolysis when used with these medications.)",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",e0b4b77d-e196-4d83-98ad-f4bc4b441dce,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=e0b4b77d-e196-4d83-98ad-f4bc4b441dce&type=display
875,PRAZIQUANTEL,"1. Cardiac arrhythmias, including bradycardia, ectopic rhythms, ventricular fibrillation, and AV blocks, have been observed with Biltricide administration. The drug itself is associated with the risk of cardiac arrhythmias, and patients with cardiac arrhythmias should be monitored during treatment.

2. Biltricide can exacerbate central nervous system pathology due to schistosomiasis, which may include cardiac involvement. Consideration should be given to administering Biltricide to individuals with a history of epilepsy or other signs of potential central nervous system involvement. The drug itself is associated with the risk of exacerbating central nervous system pathology, which may include cardiac effects.

3. Clinical deterioration, including potentially life-threatening events such as respiratory failure, encephalopathy, papilledema, and cerebral vasculitis, can occur in patients treated with Biltricide during the acute phase of schistosomiasis. The drug itself is associated with the risk of clinical deterioration, which may lead to serious cardiac and other complications.

4. The drug label mentions that Biltricide has been associated with paradoxical reactions, serum sickness, and Jarisch-Herxheimer-like reactions, which are sudden inflammatory immune responses that can lead to potentially life-threatening events. The drug itself is associated with the risk of these immune reactions, which may have cardiac manifestations.

5. The label advises monitoring patients with cardiac arrhythmias during Biltricide treatment, indicating the potential for cardiotoxicity reactions with this medication. The drug itself is associated with the risk of cardiac arrhythmias, and close monitoring is recommended during treatment.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",34ce1cdd-648e-4f1e-8512-bf3d4cc22eb9,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=34ce1cdd-648e-4f1e-8512-bf3d4cc22eb9&type=display
876,PRAZOSIN HYDROCHLORIDE,"1. The drug label mentions that MINIPRESS (prazosin hydrochloride) is indicated for the treatment of hypertension to lower blood pressure, reducing the risk of cardiovascular events such as strokes and myocardial infarctions. The label states that controlled trials have shown that antihypertensive drugs, including prazosin, have benefits in reducing cardiovascular morbidity and mortality, primarily through blood pressure reduction. (The drug itself is not directly associated with cardiotoxicity risk but aims to reduce cardiovascular events by lowering blood pressure.)

2. The label warns that MINIPRESS may cause syncope (fainting) due to excessive postural hypotensive effects, with syncopal episodes occurring within 30 to 90 minutes of the initial dose. It advises starting patients on the 1 mg capsules to minimize syncope risk and recommends caution when introducing additional antihypertensive drugs. (The drug itself is associated with the risk of syncope due to its hypotensive effects.)

3. Additionally, the label mentions that hypotension may develop in patients receiving MINIPRESS who are also taking a beta-blocker like propranolol. It advises placing the patient in a recumbent position if syncope occurs and states that this adverse effect is self-limiting and does not usually recur after the initial therapy period. (The drug itself is associated with the risk of hypotension, especially when used concomitantly with beta-blockers.)

4. The label also highlights the potential risk of priapism (prolonged erection) with alpha-1 blockers like prazosin, advising immediate medical assistance if an erection persists longer than 4 hours to prevent penile tissue damage. (The drug itself is associated with the risk of priapism, a potential cardiotoxic reaction.)

5. Furthermore, the label mentions that MINIPRESS has been associated with autonomic nervous system reactions like flushing, cardiovascular reactions such as angina pectoris and hypotension, and heart rate/rhythm effects like bradycardia in post-marketing experience. (The drug itself is associated with various cardiotoxic reactions based on post-marketing reports.)",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",36c4da56-502e-4da1-acf7-8e81ee453dcc,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=36c4da56-502e-4da1-acf7-8e81ee453dcc&type=display
877,PREDNISOLONE,"1. The drug label warns that average and large doses of hydrocortisone or cortisone, including the synthetic derivative prednisolone, can cause elevation of blood pressure, salt and water retention, and increased excretion of potassium. These effects are less likely to occur with the synthetic derivatives except when used in large doses. Dietary salt restriction and potassium supplementation may be necessary. (The drug itself is associated with cardiotoxicity risks.)

2. The label also mentions that prolonged use of corticosteroids, including prednisolone, may produce posterior subcapsular cataracts, glaucoma with possible damage to the optic nerves, and may enhance the establishment of secondary ocular infections due to fungi or viruses. (The drug itself is associated with cardiotoxicity risks.)

3. Additionally, the drug label states that corticosteroids, like prednisolone, may cause fluid and electrolyte disturbances, including sodium retention, fluid retention, congestive heart failure in susceptible patients, potassium loss, hypokalemic alkalosis, and hypertension. (The drug itself is associated with cardiotoxicity risks.)

4. The label warns that corticosteroids, such as prednisolone, can cause musculoskeletal issues like muscle weakness, steroid myopathy, loss of muscle mass, osteoporosis, vertebral compression fractures, aseptic necrosis of femoral and humeral heads, and pathologic fracture of long bones. (The drug itself is associated with cardiotoxicity risks.)

5. Furthermore, the drug label mentions that corticosteroids, including prednisolone, may lead to endocrine problems such as menstrual irregularities, development of a Cushingoid state, suppression of growth in pediatric patients, secondary adrenocortical and pituitary unresponsiveness, decreased carbohydrate tolerance, manifestations of latent diabetes mellitus, and increased requirements for insulin or oral hypoglycemic agents in diabetics. (The drug itself is associated with cardiotoxicity risks.)

6. Lastly, the label indicates that corticosteroids, like prednisolone, can have ophthalmic effects such as posterior subcapsular cataracts, increased intraocular pressure, glaucoma, and exophthalmos. (The drug itself is associated with cardiotoxicity risks.)",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",35f0b197-c3ae-445a-8da7-9ffcd4472e05,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=35f0b197-c3ae-445a-8da7-9ffcd4472e05&type=display
878,PREDNISOLONE SODIUM PHOSPHATE,"1. The drug label mentions that average and large doses of hydrocortisone or cortisone can cause elevation of blood pressure, salt and water retention, and increased excretion of potassium. These effects are less likely to occur with the synthetic derivatives except when used in large doses. Dietary salt restriction and potassium supplementation may be necessary. All corticosteroids increase calcium excretion. (The drug itself is associated with cardiotoxicity risks.)

2. It is noted that sodium retention with resultant edema and potassium loss may occur in patients receiving corticosteroids, and these agents should be used with caution in patients with hypertension, congestive heart failure, or renal insufficiency. (The drug itself is associated with cardiotoxicity risks.)

3. The drug label mentions that corticosteroids can produce reversible hypothalamic-pituitary adrenal (HPA) axis suppression with the potential for glucocorticosteroid insufficiency after withdrawal of treatment. (The drug itself is associated with cardiotoxicity risks.)

4. It is stated that corticosteroids may suppress reactions to skin tests, and other dermatologic reactions such as facial erythema, thin fragile skin, and urticaria may occur. (The drug itself is associated with cardiotoxicity risks.)

5. The label also mentions that corticosteroids may cause fluid retention, hypertension, hypokalemic alkalosis, and sodium retention, leading to cardiovascular effects. (The drug itself is associated with cardiotoxicity risks.)

6. Additionally, the drug label notes that corticosteroids can lead to congestive heart failure in susceptible patients, fluid retention, and electrolyte disturbances such as potassium loss. (The drug itself is associated with cardiotoxicity risks.)

7. It is mentioned that corticosteroids may cause hypertension, hypokalemic alkalosis, and potassium loss, which can impact cardiovascular health. (The drug itself is associated with cardiotoxicity risks.)

8. The label also states that corticosteroids can lead to increased intraocular pressure, which may have implications for ocular health and potentially affect cardiovascular function. (The drug itself is associated with cardiotoxicity risks.)

In summary, the drug label indicates that the use of corticosteroids, including the specific drug PEDIAPRED (prednisolone sodium phosphate), is associated with various cardiotoxicity risks and reactions, including effects on blood pressure, fluid retention, electrolyte disturbances, and cardiovascular health.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",1b996564-a777-4d37-ae00-b6a5ffc5e596,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=1b996564-a777-4d37-ae00-b6a5ffc5e596&type=display
879,PREDNISONE,"1. **Warnings and Precautions - Alterations in Cardiovascular/Renal Function**: The drug may cause elevation of blood pressure, salt and water retention, and increased excretion of potassium and calcium. These effects are less likely to occur with the synthetic derivatives except when used in large doses. Dietary salt restriction and potassium supplementation may be necessary. These agents should be used with caution in patients with congestive heart failure, hypertension, or renal insufficiency. (The drug itself is associated with cardiotoxicity risks.)

2. **Adverse Reactions - Cardiovascular**: The drug may lead to bradycardia, cardiac arrest, cardiac arrhythmias, cardiac enlargement, circulatory collapse, congestive heart failure, hypertension, hypertrophic cardiomyopathy in premature infants, myocardial rupture following recent myocardial infarction, pulmonary edema, syncope, tachycardia, thromboembolism, thrombophlebitis, and vasculitis. (The drug itself is associated with cardiotoxicity reactions.)

3. **Drug Interactions - Amphotericin B Injection**: There have been cases reported in which concomitant use of Amphotericin B and hydrocortisone (a corticosteroid) was followed by cardiac enlargement and congestive heart failure. (The drug itself is not directly associated with this cardiotoxicity risk, but a potential interaction with another drug may lead to cardiotoxicity reactions.)

4. **Warnings and Precautions - Kaposi's Sarcoma**: Kaposi's sarcoma has been reported to occur in patients receiving corticosteroid therapy, most often for chronic conditions. Discontinuation of corticosteroids may result in clinical improvement. (The drug itself is not directly associated with cardiotoxicity risks, but long-term corticosteroid therapy may lead to conditions like Kaposi's sarcoma, which can have cardiotoxic effects.)

Overall, the drug label highlights the potential for cardiotoxicity risks and reactions associated with the use of the drug, particularly in relation to alterations in cardiovascular function, adverse cardiovascular events, and potential interactions with other medications that may impact cardiac health.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",281ab967-7565-4bef-9c0c-a646589c671e,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=281ab967-7565-4bef-9c0c-a646589c671e&type=display
880,PREGABALIN,"1. **Cardiotoxicity Risk**: The drug label mentions that there were postmarketing reports of angioedema in patients receiving pregabalin therapy, which includes swelling of the face, mouth, and neck. The drug itself was associated with the risk of angioedema, which could lead to life-threatening respiratory compromise requiring emergency treatment.

2. **Cardiotoxicity Reactions**: The label also highlights that there were postmarketing reports of hypersensitivity reactions in patients shortly after initiation of treatment with pregabalin, including skin redness, blisters, hives, rash, dyspnea, and wheezing. The drug itself was associated with the risk of hypersensitivity reactions, which could be considered cardiotoxic.

3. **Cardiotoxicity Risk**: Additionally, the label warns about the potential for respiratory depression when pregabalin is co-administered with central nervous system depressants, particularly opioids, or in patients with underlying respiratory impairment. The drug itself was associated with the risk of respiratory depression, which could have cardiotoxic effects.

4. **Cardiotoxicity Reactions**: The label mentions that LYRICA CR may cause dizziness and somnolence, which could impair a patient's ability to perform tasks such as driving or operating machinery. The drug itself was associated with the risk of dizziness and somnolence, which could lead to adverse cardiovascular events.

5. **Cardiotoxicity Risk**: Furthermore, the label cautions that abrupt or rapid discontinuation of LYRICA CR may lead to symptoms such as insomnia, nausea, headache, anxiety, and diarrhea. Increased seizure frequency may occur in patients with seizure disorders if the drug is rapidly discontinued. The drug itself was associated with the risk of increased seizure frequency and other adverse reactions upon abrupt discontinuation, which could have cardiotoxic effects.

6. **Cardiotoxicity Reactions**: The label also mentions that LYRICA CR treatment may cause peripheral edema, particularly when co-administered with certain antidiabetic agents. The drug itself was associated with the risk of peripheral edema, which could be indicative of underlying cardiovascular issues.

Overall, the drug label for LYRICA CR highlights several cardiotoxicity risks and reactions associated with the use of pregabalin, the active ingredient in the medication. It is important for healthcare providers and patients to be aware of these potential cardiovascular effects when prescribing or taking LYRICA CR.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",f280bbd8-2af2-444a-bd96-e409337ca6dd,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=f280bbd8-2af2-444a-bd96-e409337ca6dd&type=display
881,PRETOMANID,"1. **QT Prolongation Risk**: The drug label mentions that QT prolongation was reported with the use of the combination regimen of Pretomanid Tablets, bedaquiline, and linezolid. The drug itself, Pretomanid, was associated with the risk of QT prolongation.

2. **QT Prolongation Monitoring**: The label advises monitoring ECGs due to the risk of QT prolongation with the combination regimen. The drug itself, Pretomanid, was associated with the need for ECG monitoring for QT prolongation.

3. **QT Prolongation Management**: It states to discontinue the combination regimen if significant ventricular arrhythmia or QTcF interval prolongation of greater than 500 ms develops. The drug itself, Pretomanid, was associated with the recommendation to discontinue treatment in case of significant QT prolongation.

4. **QT Prolongation Risk Factors**: The label mentions factors that may increase the risk of QT prolongation when using bedaquiline, a component of the combination regimen. The drug itself, Pretomanid, was indirectly associated with the risk factors for QT prolongation due to its combination with bedaquiline.

5. **QT Prolongation Risk Assessment**: It advises obtaining an ECG before treatment initiation and at specific intervals during treatment with the combination regimen. The drug itself, Pretomanid, was associated with the recommendation for ECG assessments to monitor for QT prolongation.

6. **QT Prolongation Electrolyte Monitoring**: The label recommends obtaining serum potassium, calcium, and magnesium levels and correcting abnormalities if QT prolongation is detected. The drug itself, Pretomanid, was associated with the need for electrolyte monitoring to manage QT prolongation risk.

7. **QT Prolongation Discontinuation**: It states to discontinue the combination regimen if clinically significant ventricular arrhythmia or QTcF interval prolongation occurs. The drug itself, Pretomanid, was associated with the recommendation to discontinue treatment in case of significant QT prolongation.",Less,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",f1906fc9-cb3c-4e13-8a4a-da76100c1bf3,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=f1906fc9-cb3c-4e13-8a4a-da76100c1bf3&type=display
882,PRILOCAINE HYDROCHLORIDE,"1. Excessive blood levels of the drug may cause changes in cardiac output, total peripheral resistance, and mean arterial pressure. These changes may be due to a direct depressant effect of the local anesthetic agent on various components of the cardiovascular system. (The drug itself is associated with cardiotoxicity risks.)

2. Signs and symptoms of depressed cardiovascular function may result from a vasovagal reaction, particularly if the patient is in an upright position. (The drug itself is not directly associated with cardiotoxicity risks in this context, but it may indirectly lead to cardiovascular symptoms.)

3. Patients with severe hepatic disease are at greater risk of developing toxic plasma concentrations due to their inability to metabolize local anesthetics normally. (The drug itself is associated with cardiotoxicity risks in patients with severe hepatic disease.)

4. Patients with impaired cardiovascular function may be less able to compensate for changes associated with the prolongation of A-V conduction produced by these drugs. (The drug itself is associated with cardiotoxicity risks in patients with impaired cardiovascular function.)

5. Many drugs used during anesthesia are considered potential triggering agents for familial malignant hyperthermia. It is suggested that a standard protocol for the management of malignant hyperthermia should be available when using amide-type local anesthetics. (The drug itself is not directly associated with cardiotoxicity risks in this context, but it may be a potential triggering agent for malignant hyperthermia.)

6. Early unexplained signs of tachycardia, tachypnea, labile blood pressure, and metabolic acidosis may precede temperature elevation in patients at risk of malignant hyperthermia. (The drug itself is not directly associated with cardiotoxicity risks in this context, but it may be a potential triggering agent for malignant hyperthermia.)

7. Successful outcome in cases of malignant hyperthermia is dependent on early diagnosis, prompt discontinuance of the suspect triggering agent(s), and appropriate treatment. (The drug itself is not directly associated with cardiotoxicity risks in this context, but it may be a potential triggering agent for malignant hyperthermia.)

8. Patients allergic to para-aminobenzoic acid derivatives have not shown cross-sensitivity to prilocaine. (The drug itself is not associated with cardiotoxicity risks in this context.)

9. Concurrent administration of vasopressor drugs and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents. (The drug itself is not directly associated with cardiotoxicity risks in this context, but it may interact with other drugs to cause cardiovascular complications.)

10. The drug itself is not associated with cardiotoxicity risks in the context of drug/laboratory test interactions.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",db23a56f-1e41-4843-9220-1b2e3059db41,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=db23a56f-1e41-4843-9220-1b2e3059db41&type=display
883,PRIMAQUINE PHOSPHATE,"1. **Cardiotoxicity Risk**: The drug primaquine phosphate is associated with a potential risk of prolonging the QT interval, necessitating ECG monitoring in patients with cardiac disease, long QT syndrome, history of ventricular arrhythmias, hypokalemia, hypomagnesemia, bradycardia, or when used concomitantly with other QT interval prolonging agents.

2. **Cardiotoxicity Reaction**: Overdosage of primaquine phosphate may lead to various cardiovascular disturbances, including cardiac arrhythmia and QT interval prolongation, as well as cyanosis and methemoglobinemia. These reactions are symptoms of an overdose and can occur in individuals who have taken excessive amounts of the drug.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",1bfbf4ae-81b8-4160-a00d-6322aadd4b59,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=1bfbf4ae-81b8-4160-a00d-6322aadd4b59&type=display
884,PRIMIDONE,"1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with Mysoline (primidone) itself. 

2. However, the label does mention that primidone may rarely cause blood problems, which could include symptoms such as fever, swollen glands, sore throat, frequent infections, tiredness, and shortness of breath. These symptoms may indicate potential hematologic toxicity but are not specifically labeled as cardiotoxic reactions. 

3. Additionally, the label states that Mysoline may rarely cause allergic reactions, which could manifest as skin rash, hives, sores in the mouth, or blistering or peeling skin. While these reactions are not directly related to cardiotoxicity, severe allergic reactions could potentially lead to cardiovascular complications in some cases. 

Overall, while the drug label does not explicitly mention cardiotoxicity risks or reactions associated with Mysoline, patients should be monitored for any signs of adverse effects, including potential hematologic or allergic reactions that may indirectly impact cardiovascular health.",Less,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",af593171-dabb-4ea3-b44c-89ed457b2c46,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=af593171-dabb-4ea3-b44c-89ed457b2c46&type=display
885,PROBENECID,1. The drug label does not mention any cardiotoxicity risks or cardiotoxicity reactions associated with Probenecid tablets.,No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",6aec72b5-a9f4-45a3-82a6-7d3de64ba5e5,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=6aec72b5-a9f4-45a3-82a6-7d3de64ba5e5&type=display
886,PROCAINAMIDE HYDROCHLORIDE,"1. The drug label mentions that procainamide hydrochloride, a Group 1A cardiac antiarrhythmic drug, can reduce impulse conduction velocity in the heart and has variable effects on the atrioventricular (A-V) node, potentially slowing A-V conduction slightly. This sentence indicates that the drug itself is associated with the risk of affecting impulse conduction in the heart.

2. It states that myocardial excitability is reduced in various parts of the heart by procainamide, leading to a decrease in automaticity, especially in ectopic sites. This sentence suggests that the drug itself can affect myocardial excitability and automaticity in the heart.

3. The label mentions that therapeutic levels of procainamide may exert vagolytic effects and produce slight acceleration of heart rate, while high or toxic concentrations may prolong A-V conduction time or induce abnormal automaticity. This sentence indicates that the drug itself can lead to changes in heart rate and A-V conduction, potentially causing cardiotoxicity.

4. It discusses the potential cardiotoxic effects of procainamide, such as widened QRS complexes, prolonged Q-T and P-R intervals, and decreased QRS and T wave amplitudes on the electrocardiogram. This sentence highlights that the drug itself can cause specific changes in the heart's electrical activity, indicating cardiotoxicity risks.

5. The label warns about the proarrhythmic effects of procainamide and its potential to produce serious hematological disorders, particularly leukopenia or agranulocytosis, which can be fatal. This sentence emphasizes that the drug itself is associated with the risk of serious hematological disorders, indicating potential cardiotoxicity reactions.

6. It cautions about the possibility of hypotension, serious disturbances of cardiorhythm, and ventricular asystole or fibrillation with intravenous administration of procainamide, indicating potential cardiotoxic reactions associated with the drug.

7. The label mentions that a lupus erythematosus-like syndrome, hematologic disorders, skin reactions, gastrointestinal symptoms, and nervous system effects can occur as adverse reactions to procainamide. These adverse reactions suggest potential cardiotoxic effects of the drug, impacting various systems in the body, including the cardiovascular system.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",fece65c0-fdbc-61d8-e053-6294a90a9a68,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fece65c0-fdbc-61d8-e053-6294a90a9a68&type=display
887,PROCARBAZINE HYDROCHLORIDE,"1. The drug label warns that Matulane may cause hypotension and tachycardia as cardiovascular adverse reactions. (The drug itself is associated with cardiotoxicity risk.)

2. Matulane has been reported to cause syncope as a cardiovascular adverse reaction. (The drug itself is associated with cardiotoxicity risk.)

3. The label mentions that patients with Hodgkins disease treated with procarbazine in combination with other chemotherapy and/or radiation have reported second nonlymphoid malignancies, including lung cancer and acute myelocytic leukemia. The risks of secondary lung cancer from treatment appear to be multiplied by tobacco use. (The combination treatment, including procarbazine, is associated with cardiotoxicity risk.)

4. The drug label also notes that Matulane has been associated with retinal hemorrhage, papilledema, photophobia, diplopia, and inability to focus as ophthalmic adverse reactions. (The drug itself is associated with cardiotoxicity risk.)

5. Matulane has been reported to cause hypotension, tachycardia, and syncope as cardiovascular adverse reactions. (The drug itself is associated with cardiotoxicity risk.)

6. The label mentions that patients with Hodgkins disease treated with procarbazine in combination with other chemotherapy and/or radiation have reported second nonlymphoid malignancies, including lung cancer and acute myelocytic leukemia. The risks of secondary lung cancer from treatment appear to be multiplied by tobacco use. (The combination treatment, including procarbazine, is associated with cardiotoxicity risk.)",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",1aa75a3a-18c9-49e1-91a6-293d0b7da756,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=1aa75a3a-18c9-49e1-91a6-293d0b7da756&type=display
888,PROCHLORPERAZINE,"1. The drug label warns about an increased risk of mortality in elderly patients with dementia-related psychosis who are treated with antipsychotic drugs, including prochlorperazine suppositories. The risk of death in drug-treated patients was found to be higher compared to placebo-treated patients, with most deaths attributed to cardiovascular causes such as heart failure and sudden death. The label states that the extent to which the increased mortality is directly caused by the antipsychotic drug is unclear.

2. The drug label mentions that prochlorperazine, as a phenothiazine derivative, may cause extrapyramidal symptoms that could be confused with signs of an undiagnosed primary disease responsible for vomiting, such as Reye's Syndrome. It is advised to avoid using prochlorperazine in children and adolescents with signs suggestive of Reye's Syndrome.

3. The label discusses the risk of tardive dyskinesia, an irreversible syndrome of involuntary movements, associated with neuroleptic (antipsychotic) drugs like prochlorperazine. The prevalence of tardive dyskinesia is higher in the elderly, but it can develop in patients of all ages. The label emphasizes the importance of minimizing the occurrence of tardive dyskinesia by prescribing neuroleptics judiciously and reassessing the need for continued treatment periodically.

4. Neuroleptic Malignant Syndrome (NMS), a potentially fatal symptom complex, has been reported in association with antipsychotic drugs like prochlorperazine. The label advises immediate discontinuation of antipsychotic drugs in patients with NMS and recommends intensive symptomatic treatment and medical monitoring. The management of NMS should include treatment of any concomitant serious medical problems and careful consideration before reintroducing antipsychotic drug therapy.

5. The drug label mentions that prochlorperazine may cause somnolence, postural hypotension, and motor instability, which could lead to falls and subsequent injuries. It advises conducting fall risk assessments for patients initiating antipsychotic treatment and periodically for those on long-term therapy, especially for patients with conditions that may exacerbate these effects.

6. Prochlorperazine, as a phenothiazine, may impair mental and physical abilities, especially during the initial days of therapy. Patients should be cautioned about activities requiring alertness, such as operating vehicles or machinery. Additionally, phenothiazines may intensify or prolong the effects of central nervous system depressants like alcohol, anesthetics, and narcotics.

7. The drug label mentions that phenothiazines like prochlorperazine may interfere with thermoregulatory mechanisms, cautioning against their use in individuals exposed to extreme heat. It also notes that phenothiazines can produce alpha-adrenergic blockade and may lower the convulsive threshold, necessitating dosage adjustments of anticonvulsants.

8. The label discusses the potential for cardiotoxicity reactions with phenothiazines, including prochlorperazine, such as hypotension, cardiac arrest, and EKG changes. It advises caution in patients with impaired cardiovascular systems and recommends careful monitoring and appropriate management if hypotension occurs after dosing.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",b23b67eb-78b7-48eb-84ff-c95d3ce8683c,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=b23b67eb-78b7-48eb-84ff-c95d3ce8683c&type=display
889,PROCHLORPERAZINE EDISYLATE,"1. The drug label warns about an increased risk of death in elderly patients with dementia-related psychosis treated with antipsychotic drugs, including prochlorperazine edisylate injection. The risk of death in drug-treated patients was higher compared to placebo-treated patients, with most deaths appearing to be cardiovascular or infectious in nature.

2. The drug label mentions that extrapyramidal symptoms from prochlorperazine may be confused with signs of an undiagnosed primary disease responsible for vomiting, such as Reyes syndrome. The use of prochlorperazine and other potential hepatotoxins should be avoided in children and adolescents with signs suggesting Reyes syndrome.

3. The drug label discusses the potential development of Tardive Dyskinesia, an irreversible syndrome of involuntary movements, in patients treated with antipsychotic drugs like prochlorperazine. The risk and irreversibility of Tardive Dyskinesia increase with the duration of treatment and cumulative dose of antipsychotic drugs.

4. Neuroleptic Malignant Syndrome (NMS), a potentially fatal symptom complex, has been reported in association with antipsychotic drugs like prochlorperazine. Clinical manifestations of NMS include hyperpyrexia, muscle rigidity, altered mental status, and autonomic instability.

5. The drug label mentions that falls may occur due to somnolence, postural hypotension, and motor instability caused by prochlorperazine edisylate injection. Patients with conditions that could exacerbate these effects should undergo fall risk assessments before initiating antipsychotic treatment.

6. An encephalopathic syndrome has occurred in some patients treated with lithium plus an antipsychotic, leading to irreversible brain damage. Close monitoring is recommended for patients receiving this combination therapy to detect early signs of neurologic toxicity.

7. The drug label advises caution in patients with bone marrow depression or hypersensitivity reactions to phenothiazines, as they should not receive prochlorperazine unless the benefits outweigh the risks. Prochlorperazine may impair mental and physical abilities, especially during initial therapy, requiring caution in activities requiring alertness.

8. Phenothiazines, including prochlorperazine, may intensify or prolong the effects of central nervous system depressants, such as alcohol and narcotics. They can also lower the convulsive threshold and interfere with the metabolism of other drugs like phenytoin, potentially leading to toxicity.

9. The drug label mentions that phenothiazines can produce alpha-adrenergic blockade, lower the convulsive threshold, and interfere with thermoregulatory mechanisms. Caution is advised when using phenothiazines in patients with glaucoma or those exposed to extreme heat.

10. Adverse reactions reported with prochlorperazine or other phenothiazine derivatives include cardiac arrest, blood dyscrasias, liver damage, and EKG changes. Some reactions may be dose-related or occur more frequently in patients with specific medical conditions, emphasizing the need for close monitoring and appropriate management.",Less,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",b3c5c1b7-310a-4658-bd01-b88b7334b591,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=b3c5c1b7-310a-4658-bd01-b88b7334b591&type=display
890,PROCHLORPERAZINE MALEATE,"1. The drug label warns of an increased risk of mortality in elderly patients with dementia-related psychosis treated with antipsychotic drugs, including prochlorperazine. The risk of death in drug-treated patients was higher compared to placebo-treated patients, with most deaths attributed to cardiovascular causes like heart failure or sudden death.

2. The drug label mentions that prochlorperazine may cause hypotension, which can be a cardiotoxic reaction. Large doses and parenteral administration should be used cautiously in patients with impaired cardiovascular systems to minimize the occurrence of hypotension.

3. The label advises that phenothiazines, including prochlorperazine, may interfere with thermoregulatory mechanisms, cautioning against their use in individuals exposed to extreme heat. This can lead to potential cardiotoxic effects in susceptible patients.

4. Adverse reactions reported with prochlorperazine or other phenothiazine derivatives include cardiac arrest, EKG changes, and cardiac arrhythmias, which are cardiotoxic reactions associated with the drug class. Some patients receiving phenothiazines have experienced sudden death, with causes such as cardiac arrest or asphyxia due to failure of the cough reflex.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",86102abe-0b72-4352-95ce-db88d2e14002,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=86102abe-0b72-4352-95ce-db88d2e14002&type=display
891,PROGESTERONE,"1. The drug label warns about cardiovascular disorders, including an increased risk of deep vein thrombosis, pulmonary embolism, stroke, and myocardial infarction associated with estrogen plus progestin therapy. The drug itself is associated with these cardiovascular risks.

2. The label mentions that the Women's Health Initiative (WHI) study reported an increased risk of cardiovascular events, such as stroke and myocardial infarction, in postmenopausal women receiving daily oral conjugated estrogens combined with medroxyprogesterone acetate, compared to placebo. The drug itself is associated with an increased risk of cardiovascular events.

3. The WHI Memory Study reported an increased risk of developing probable dementia in postmenopausal women aged 65 years or older during treatment with daily conjugated estrogens combined with medroxyprogesterone acetate, relative to placebo. The drug itself is associated with an increased risk of probable dementia.

4. The drug label also mentions an increased risk of invasive breast cancer associated with estrogen plus progestin therapy, as demonstrated in the WHI estrogen plus progestin substudy. The drug itself is associated with an increased risk of invasive breast cancer.

5. The label advises that estrogen plus progestin therapy should not be used for the prevention of cardiovascular disease or dementia due to the associated risks. The drug itself is associated with an increased risk of cardiovascular disorders, probable dementia, and breast cancer.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",1cf237ff-c4f8-4faa-a7aa-77599c856889,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=1cf237ff-c4f8-4faa-a7aa-77599c856889&type=display
892,PROMETHAZINE HYDROCHLORIDE,"1. The drug label mentions that promethazine hydrochloride may cause increased or decreased blood pressure, tachycardia, bradycardia, and faintness. (The drug itself is associated with cardiotoxicity risks.)

2. Additionally, the label warns about the potential for respiratory depression, which can be potentially fatal, as well as apnea, which can also be potentially fatal. (The drug itself is associated with cardiotoxicity reactions.)

3. The label also notes that promethazine hydrochloride may lead to potentially fatal neuroleptic malignant syndrome, which is characterized by hyperpyrexia, muscle rigidity, altered mental status, and evidence of autonomic instability. (The drug itself is associated with cardiotoxicity reactions.)",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",81fd29a9-c090-49ba-8b48-bd3656ca0c92,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=81fd29a9-c090-49ba-8b48-bd3656ca0c92&type=display
893,PROPAFENONE HYDROCHLORIDE,"1. The drug label warns about the increased rate of death or reversed cardiac arrest rate associated with Class IC antiarrhythmics like encainide or flecainide, indicating a significant risk of provoking proarrhythmic events in patients with structural heart disease. The drug itself is not directly associated with this cardiotoxicity risk but belongs to the same class of antiarrhythmics.

2. Propafenone, the active ingredient in RYTHMOL SR, may cause new or worsened arrhythmias, including sudden death and life-threatening ventricular arrhythmias such as ventricular fibrillation, ventricular tachycardia, asystole, and torsade de pointes. It may also worsen premature ventricular contractions or supraventricular arrhythmias, and it may prolong the QT interval, necessitating electrocardiographic evaluation prior to and during therapy to assess the response to treatment.

3. The drug label mentions that propafenone may provoke overt heart failure due to its negative inotropic activity on the myocardium and beta-blockade effects. The risk of proarrhythmic effects is higher when propafenone is administered to patients with heart failure or severe myocardial ischemia, indicating a potential cardiotoxicity risk associated with the drug itself.

4. Propafenone is known to slow atrioventricular conduction and may cause dose-related first-degree AV block, with average PR interval prolongation and increases in QRS duration also being dose-related. The drug label specifies that propafenone should not be given to patients with conduction defects in the absence of a pacemaker, highlighting a direct cardiotoxicity risk associated with propafenone's effects on cardiac conduction.

5. The drug label also mentions that propafenone may alter both pacing and sensing thresholds of implanted pacemakers and defibrillators, necessitating monitoring and potential re-programming of these devices during and after therapy. This indicates a direct cardiotoxicity risk associated with propafenone's potential effects on the function of implanted cardiac devices.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",8bb1bc4a-a019-49c8-af81-be899822428f,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8bb1bc4a-a019-49c8-af81-be899822428f&type=display
894,PROPOFOL,"1. The drug label warns that DIPRIVAN has been associated with arterial hypotension during induction of anesthesia, especially when ventilation is assisted or controlled, which can lead to a decrease in cardiac output. This effect is more pronounced compared to other intravenous induction agents, suggesting that DIPRIVAN itself is associated with cardiotoxicity risks.

2. Additionally, the label mentions that during maintenance of general anesthesia with DIPRIVAN, there may be a decrease in spontaneous minute ventilation and an increase in carbon dioxide tension, which can further impact cardiac function. This suggests that DIPRIVAN may contribute to cardiotoxicity reactions during the maintenance phase of anesthesia.

3. The label also highlights that during monitored anesthesia care (MAC) sedation with DIPRIVAN, attention should be given to cardiorespiratory effects such as hypotension, oxyhemoglobin desaturation, apnea, and airway obstruction, especially following rapid bolus administration. This indicates that DIPRIVAN itself can lead to cardiotoxicity reactions in patients undergoing MAC sedation.

4. Furthermore, the label warns about the potential for DIPRIVAN infusions to cause metabolic derangements and organ system failures, known as Propofol Infusion Syndrome, which can result in severe metabolic acidosis, hyperkalemia, rhabdomyolysis, and cardiac failure. This suggests that DIPRIVAN is associated with significant cardiotoxicity risks, especially in patients receiving prolonged, high-dose infusions.

5. Lastly, the label mentions that there have been reports of bradycardia, asystole, and cardiac arrest associated with DIPRIVAN administration, particularly in pediatric patients and when used concomitantly with other medications like fentanyl. This indicates that DIPRIVAN itself can lead to cardiotoxicity reactions, emphasizing the need for caution and monitoring during its use.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",5cec3b97-5183-4a9d-accd-21e76c99d3dd,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=5cec3b97-5183-4a9d-accd-21e76c99d3dd&type=display
895,PROPOXYPHENE HYDROCHLORIDE,"1. The drug label mentions that propoxyphene is a centrally acting opiate analgesic. (The drug itself is associated with the cardiotoxicity risk.)

2. The label states that propoxyphene and norpropoxyphene inhibit the voltage-gated potassium current carried by cardiac rapidly activating delayed rectifier (hERG) channels with approximately equal potency. (The drug itself is associated with the cardiotoxicity risk.)

3. It is mentioned that propoxyphene has been associated with cardiac disorders such as arrhythmia, bradycardia, cardiac/respiratory arrest, congestive heart failure (CHF), tachycardia, and myocardial infarction (MI). (The drug itself is associated with causing cardiotoxicity reactions.)

4. The label also notes that propoxyphene therapy has been linked to abnormal liver function tests and instances of reversible jaundice, including cholestatic jaundice. (The drug itself is associated with causing cardiotoxicity reactions.)

5. Additionally, the label mentions that liver dysfunction has been reported in association with propoxyphene use. (The drug itself is associated with causing cardiotoxicity reactions.)

6. The label further states that propoxyphene has been associated with respiratory depression, dyspnea, and respiratory arrest. (The drug itself is associated with causing cardiotoxicity reactions.)

7. It is noted that propoxyphene may cause spasm of the sphincter of Oddi and should be used with caution in patients with biliary tract disease, including acute pancreatitis. (The drug itself is associated with causing cardiotoxicity reactions.)

8. The label mentions that propoxyphene may cause orthostatic hypotension in ambulatory patients. (The drug itself is associated with causing cardiotoxicity reactions.)

9. Lastly, the label warns about the potential risk of hypotension with propoxyphene use, especially in individuals with compromised blood pressure maintenance or concurrent administration with certain drugs. (The drug itself is associated with causing cardiotoxicity reactions.)",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",f60e8f65-a12b-4073-ac0f-81e1186617d7,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=f60e8f65-a12b-4073-ac0f-81e1186617d7&type=display
896,PROPOXYPHENE NAPSYLATE,"1. The drug Darvon-N, containing propoxyphene napsylate, is associated with a risk of respiratory depression, which is the chief hazard from all opioid agonist preparations. This risk occurs most frequently in elderly or debilitated patients, especially following large initial doses in non-tolerant patients or when opioids are used with other agents that depress respiration. Darvon-N should be used cautiously in patients with significant chronic obstructive pulmonary disease or cor pulmonale, as well as in those with decreased respiratory reserve, hypoxia, hypercapnia, or pre-existing respiratory depression. (The drug Darvon-N is associated with the risk of respiratory depression.)

2. Darvon-N, like all opioid analgesics, may cause severe hypotension in individuals with compromised blood pressure maintenance due to depleted blood volume or concurrent administration with drugs that compromise vasomotor tone. This may lead to orthostatic hypotension in ambulatory patients. Darvon-N should be administered cautiously to patients in circulatory shock, as the drug's vasodilatory effects may further reduce cardiac output and blood pressure. (The drug Darvon-N is associated with the risk of causing severe hypotension.)

3. The drug Darvon-N has the potential to elevate cerebrospinal fluid pressure and exacerbate the respiratory depressant effects of narcotics in the presence of head injury, other intracranial lesions, or pre-existing increased intracranial pressure. Narcotics like Darvon-N can produce adverse reactions that may obscure the clinical course of patients with head injuries. (The drug Darvon-N is associated with the risk of exacerbating respiratory depressant effects and elevating intracranial pressure.)

4. Darvon-N, being an opioid analgesic, may interact with other CNS depressants, including alcohol, leading to potentially serious adverse events such as respiratory depression, hypotension, profound sedation, or coma. The drug should be prescribed cautiously for patients requiring concomitant administration of sedatives, tranquilizers, muscle relaxants, antidepressants, or other CNS depressants. (The drug Darvon-N is associated with the risk of interacting with other CNS depressants.)

5. Darvon-N may impair the mental and/or physical abilities necessary for performing potentially hazardous tasks, such as driving or operating machinery. Patients should be cautioned about the drug's potential to affect their abilities. (The drug Darvon-N is associated with the risk of impairing mental and physical abilities.)

6. Patients should be advised against combining Darvon-N with alcohol due to the potentially serious CNS-additive effects that can lead to adverse events, including death. The concomitant use of Darvon-N and alcohol should be avoided. (The drug Darvon-N is associated with the risk of interacting with alcohol.)

7. Darvon-N is a Schedule IV narcotic under the U.S. Controlled Substances Act and has the potential for drug dependence of the morphine type, leading to abuse. The drug may cause psychological and physical dependence, with symptoms of withdrawal upon abrupt discontinuation. Physicians should exercise caution in prescribing Darvon-N to prevent misuse, abuse, and addiction. (The drug Darvon-N is associated with the risk of causing drug dependence and abuse.)

8. Darvon-N is associated with adverse reactions such as cardiac arrest, respiratory arrest, and cardio-respiratory arrest, as reported in postmarketing surveillance. These reactions highlight the potential cardiotoxicity risks associated with the drug. (The drug Darvon-N is associated with the risk of causing adverse cardiac events.)",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",c6c48eee-240b-4425-8691-35462523652e,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=c6c48eee-240b-4425-8691-35462523652e&type=display
897,PROPRANOLOL HYDROCHLORIDE,"1. **Warnings and Precautions, Cardiac Ischemia after Abrupt Discontinuation:** The drug label warns that following abrupt discontinuation of therapy with beta-blockers like INNOPRAN XL, exacerbations of angina pectoris and myocardial infarction have occurred. The drug itself is associated with the risk of cardiac ischemia after abrupt discontinuation.

2. **Warnings and Precautions, Cardiac Failure:** Beta-blockers, including INNOPRAN XL, can cause depression of myocardial contractility and may precipitate heart failure and cardiogenic shock. The drug itself is associated with the risk of cardiac failure.

3. **Warnings and Precautions, Bradycardia:** Bradycardia, including sinus pause, heart block, and cardiac arrest have occurred with the use of INNOPRAN XL. The drug itself is associated with the risk of bradycardia.

4. **Warnings and Precautions, Reduced Effectiveness of Epinephrine in Treating Anaphylaxis:** Beta-adrenergic blocker-treated patients treated with epinephrine for a severe anaphylactic reaction may be less responsive to the typical doses of epinephrine. The drug itself is associated with the risk of reduced effectiveness of epinephrine in treating anaphylaxis.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",cd5601b3-4d87-4c3b-acac-b476e787609d,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=cd5601b3-4d87-4c3b-acac-b476e787609d&type=display
898,PROPYLTHIOURACIL,"1. The drug label warns of severe liver injury and acute liver failure, including cases requiring liver transplantation or resulting in death, associated with propylthiouracil therapy. This indicates that propylthiouracil itself is associated with the risk of liver toxicity.

2. The label mentions that liver injury, liver failure, and death have been reported in patients treated with propylthiouracil, particularly in pediatric patients. It also states that no cases of liver failure have been reported with the use of methimazole in pediatric patients. This suggests that propylthiouracil itself is associated with the risk of liver toxicity, especially in pediatric patients.

3. The drug label does not specifically mention cardiotoxicity risks or reactions associated with propylthiouracil. The focus is primarily on liver toxicity, agranulocytosis, vasculitis, hypothyroidism, and other adverse reactions.",No,No,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",b0c23a2c-b250-4c0d-9b2a-c1483faa2ca0,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=b0c23a2c-b250-4c0d-9b2a-c1483faa2ca0&type=display
899,PROTAMINE SULFATE,"1. The drug label warns that protamine sulfate can cause severe hypotension, cardiovascular collapse, noncardiogenic pulmonary edema, catastrophic pulmonary vasoconstriction, and pulmonary hypertension. The drug itself is associated with these cardiotoxicity risks.

2. Risk factors for these cardiotoxicity reactions include high dose or overdose, rapid administration, repeated doses, previous administration of protamine, and current or previous use of protamine-containing drugs. The drug itself is associated with these cardiotoxicity risks.

3. Allergy to fish, previous vasectomy, and severe left ventricular dysfunction are also mentioned as potential risk factors for cardiotoxicity reactions associated with protamine sulfate. The drug itself is associated with these cardiotoxicity risks.

4. The label advises that in patients with any of these risk factors, the risk to benefit of administration of protamine sulfate should be carefully considered. The drug itself is associated with these cardiotoxicity risks.

5. Vasopressors and resuscitation equipment should be immediately available in case of a severe reaction to protamine, indicating the potential for cardiotoxicity reactions. The drug itself is associated with these cardiotoxicity risks.

6. Protamine sulfate should not be given when bleeding occurs without prior heparin use, as it can lead to cardiotoxicity reactions. The drug itself is associated with these cardiotoxicity risks.

7. The label mentions that too-rapid administration of protamine sulfate can cause severe hypotensive and anaphylactoid reactions, indicating the potential for cardiotoxicity reactions. The drug itself is associated with these cardiotoxicity risks.

8. Severe adverse reactions reported include anaphylaxis resulting in severe respiratory distress, circulation collapse, and capillary leak, as well as anaphylactoid reactions with circulatory collapse and noncardiogenic pulmonary edema. The drug itself is associated with these cardiotoxicity risks.

9. Complement activation by the heparin-protamine complexes, release of lysosomal enzymes from neutrophils, and prostaglandin and thromboxane generation have been associated with the development of anaphylactoid reactions, indicating potential cardiotoxicity risks. The drug itself is associated with these cardiotoxicity risks.

10. Severe and potentially irreversible circulatory collapse associated with myocardial failure and reduced cardiac output can occur, suggesting cardiotoxicity risks. The drug itself is associated with these cardiotoxicity risks.

11. High-protein, noncardiogenic pulmonary edema associated with the use of protamine has been reported in patients on cardiopulmonary bypass undergoing cardiovascular surgery, indicating potential cardiotoxicity risks. The drug itself is associated with these cardiotoxicity risks.

12. Fatal anaphylactic and anaphylactoid reactions have been reported after the administration of protamine sulfate, emphasizing the importance of being prepared to manage cardiotoxicity reactions. The drug itself is associated with these cardiotoxicity risks.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",7a31fc4c-579f-45cc-9559-39cfad9a57b3,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7a31fc4c-579f-45cc-9559-39cfad9a57b3&type=display
900,PROTRIPTYLINE HYDROCHLORIDE,"1. The drug label includes a warning about the risk of cardiotoxicity, such as myocardial infarction, stroke, heart block, arrhythmias, hypotension, hypertension, tachycardia, and palpitations, associated with the use of Protriptyline Hydrochloride tablets. (The drug itself is associated with the risk of cardiotoxicity.)

2. The label also mentions that Protriptyline is more likely to aggravate agitation and anxiety and produce cardiovascular reactions such as tachycardia and hypotension. (The drug itself is associated with the risk of cardiovascular reactions.)

3. In cases of overdose, critical manifestations of cardiotoxicity may include cardiac dysrhythmias, severe hypotension, and changes in the electrocardiogram, which are clinically significant indicators of tricyclic antidepressant toxicity. (The drug itself is associated with the risk of cardiotoxicity in cases of overdose.)

4. The label advises that deaths may occur from overdosage with tricyclic antidepressants like Protriptyline, and that signs and symptoms of toxicity, including cardiac dysrhythmias, severe hypotension, and convulsions, develop rapidly after overdose. (The drug itself is associated with the risk of cardiotoxicity in cases of overdose.)

5. Management of overdose with Protriptyline includes obtaining an ECG, initiating cardiac monitoring, and protecting the patient's airway, as well as monitoring for signs of CNS or respiratory depression, hypotension, cardiac dysrhythmias, and seizures. (The drug itself is associated with the risk of cardiotoxicity in cases of overdose.)",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",c6c7c39e-e510-4f4a-bf7a-926f0e075d3a,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=c6c7c39e-e510-4f4a-bf7a-926f0e075d3a&type=display
901,PRUCALOPRIDE,"1. In the clinical trials, an evaluation by an independent adjudication committee found that the incidence rate for major adverse cardiovascular events (MACE) with MOTEGRITY was 3.5 per 1000 patient-years, compared to 5.2 per 1000 patient-years with placebo. The data did not establish a direct association between MOTEGRITY and an increased risk of MACE.

2. Postmarketing experience reported cases of suicidal ideation, behavior, and self-injurious ideation, including suicide attempts and completed suicides, within the first few weeks of starting MOTEGRITY. However, a causal association between MOTEGRITY and these events was not definitively established.

3. An observational cardiovascular cohort study using European healthcare databases assessed the overall cardiovascular safety of MOTEGRITY in adults with constipation. The study did not demonstrate an increased risk of MACE during prucalopride use relative to another medication, polyethylene glycol 3350.

4. The drug label also mentioned that in the double-blind trials, one patient reported a suicide attempt after treatment with MOTEGRITY, while no suicide attempts were reported in patients on placebo. Additionally, two patients in the open-label trials reported suicide attempts, and completed suicides were reported in two patients previously treated with MOTEGRITY.

Overall, while there were reports of suicidal ideation and behavior, as well as some cardiovascular events in patients taking MOTEGRITY, the drug label did not definitively establish a direct causal relationship between MOTEGRITY and these adverse events.",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",bca1e4c6-4b2b-4876-8ab3-654629c4ff1b,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=bca1e4c6-4b2b-4876-8ab3-654629c4ff1b&type=display
902,PRUSSIAN BLUE INSOLUBLE CAPSULES,"1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with Radiogardase itself.
2. Radiogardase is not known to cause any cardiotoxicity risks or reactions based on the information provided in the drug label.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",baa68c79-5f3d-468a-a510-58b9e978cd50,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=baa68c79-5f3d-468a-a510-58b9e978cd50&type=display
903,PYRAZINAMIDE,"1. The drug label does not mention any specific cardiotoxicity risks associated with pyrazinamide.
2. The label does not indicate that pyrazinamide is associated with cardiotoxicity reactions.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",beda4384-1314-4afc-a11f-22cd1dfb21b0,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=beda4384-1314-4afc-a11f-22cd1dfb21b0&type=display
904,PYRIDOSTIGMINE BROMIDE,"1. The drug label does not mention any specific cardiotoxicity risks associated with Mestinon (pyridostigmine bromide) itself.

2. The label does not indicate that Mestinon (pyridostigmine bromide) causes cardiotoxicity reactions. 

3. Overall, there is no mention in the drug label of Mestinon (pyridostigmine bromide) being linked to cardiotoxicity risks or reactions.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",a851795e-b7a8-40c3-9922-5e79d3eb4d92,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a851795e-b7a8-40c3-9922-5e79d3eb4d92&type=display
905,PYRIDOXINE HCI,"1. **Contraindications**: A history of sensitivity to pyridoxine or any of the ingredients in Pyridoxine Hydrochloride Injection, USP is a contraindication. (The drug itself is not associated with cardiotoxicity risk in this statement.)

2. **Warnings**: The product contains aluminum that may be toxic, especially with prolonged parenteral administration if kidney function is impaired. Premature neonates are particularly at risk due to their immature kidneys and the large amounts of calcium and phosphate solutions they require, which contain aluminum. Research indicates that patients with impaired kidney function who receive parenteral levels of aluminum may accumulate toxic levels associated with central nervous system and bone toxicity. (The aluminum content in the product is associated with potential cardiotoxicity risks.)

3. **Precautions**: Similar to the warnings, this section reiterates the risk of aluminum toxicity with prolonged parenteral administration, especially in patients with impaired kidney function. Premature neonates are highlighted as particularly vulnerable due to their immature kidneys. Research suggests that even lower rates of aluminum administration can lead to tissue loading and toxicity. (The aluminum content in the product is associated with potential cardiotoxicity risks.)

4. **Adverse Reactions**: Paresthesia, somnolence, and low serum folic acid levels have been reported. (No direct mention of cardiotoxicity reactions in this statement.)

5. **Overdosage**: In animals, pyridoxine given in high amounts can lead to convulsions and death. In humans, a high dose is generally well tolerated. (No direct mention of cardiotoxicity risks in this statement.)

In summary, the drug label does not directly associate pyridoxine hydrochloride with cardiotoxicity risks or reactions. The warnings and precautions primarily focus on the potential toxicity related to aluminum content in the product, especially in patients with impaired kidney function.",Less,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",946c8e50-08d0-755d-e053-2a95a90a84de,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=946c8e50-08d0-755d-e053-2a95a90a84de&type=display
906,PYRIMETHAMINE,"1. The drug label mentions that pyrimethamine has been reported to produce a significant increase in the number of lung tumors in mice when given intraperitoneally at certain doses, indicating a potential risk of cardiotoxicity associated with the drug itself.
   
2. Additionally, the label states that doses used in toxoplasmosis treatment may produce disorders of cardiac rhythm, suggesting a potential cardiotoxicity reaction associated with the use of pyrimethamine.

3. The label also warns that pyrimethamine has been associated with cases of megaloblastic anemia, leukopenia, thrombocytopenia, pancytopenia, and atrophic glossitis, which can be considered as potential cardiotoxicity reactions linked to the drug.

4. Furthermore, the label mentions that mild hepatotoxicity has been reported in some patients when lorazepam and pyrimethamine were administered concomitantly, indicating a potential risk of cardiotoxicity associated with the drug interaction between pyrimethamine and lorazepam.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",5368616d-6520-6f6e-2053-686b72656c69,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=5368616d-6520-6f6e-2053-686b72656c69&type=display
907,QUAZEPAM,"1. The drug label for DORAL does not mention any specific cardiotoxicity risks or reactions associated with the drug itself. 

2. The label primarily focuses on warnings related to concomitant use with opioids, abuse, misuse, addiction, dependence, withdrawal reactions, CNS depressant effects, and other adverse reactions. 

3. While the label does not directly link DORAL to cardiotoxicity risks, it does emphasize the importance of monitoring patients for various adverse effects, including CNS depressant effects and daytime impairment, which could indirectly impact cardiovascular function. 

4. Overall, the drug label does not highlight any direct cardiotoxicity risks or reactions specifically attributed to DORAL.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",9727e8b4-14f1-451d-9630-84eabc772e42,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=9727e8b4-14f1-451d-9630-84eabc772e42&type=display
908,QUETIAPINE FUMARATE,"1. The drug label warns about increased mortality in elderly patients with dementia-related psychosis who are treated with antipsychotic drugs, including SEROQUEL XR. The risk of death in drug-treated elderly patients was higher compared to placebo-treated patients, with most deaths being cardiovascular or infectious in nature. SEROQUEL XR is not approved for treating dementia-related psychosis, indicating a potential association with cardiotoxicity in this population.

2. The label also mentions the potential risk of cerebrovascular adverse reactions, such as stroke and transient ischemic attack, in elderly patients with dementia-related psychoses treated with atypical antipsychotic drugs, including SEROQUEL XR. This suggests a possible association between SEROQUEL XR and cerebrovascular adverse events in this specific patient population.

3. Additionally, the drug label highlights the occurrence of neuroleptic malignant syndrome (NMS) with antipsychotic drugs, including quetiapine (the active ingredient in SEROQUEL XR). NMS is a potentially fatal symptom complex associated with antipsychotic drug administration, and rare cases have been reported with quetiapine. This indicates a potential risk of NMS, a serious cardiotoxic reaction, with the use of SEROQUEL XR.

4. The label mentions metabolic changes associated with atypical antipsychotic drugs, including SEROQUEL XR, such as hyperglycemia, dyslipidemia, and weight gain. These metabolic changes can have cardiovascular implications, highlighting a potential cardiotoxicity risk with the use of SEROQUEL XR.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",63cf6e35-4d68-4316-8579-823419f386de,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=63cf6e35-4d68-4316-8579-823419f386de&type=display
909,QUINAPRIL,"1. The drug label warns of fetal toxicity associated with drugs that act directly on the renin-angiotensin system, which can cause injury and death to the developing fetus. The drug itself is associated with fetal toxicity risks.

2. The label mentions that patients receiving ACE inhibitors, including quinapril, may experience various adverse reactions, including angioedema, which has been reported in patients treated with ACE inhibitors. The drug itself is associated with the risk of angioedema reactions.

3. Anaphylactoid reactions, including head and neck angioedema, have been reported in patients receiving ACE inhibitors like quinapril. The drug itself is associated with the risk of anaphylactoid reactions.

4. Intestinal angioedema has been reported in patients treated with ACE inhibitors, and this condition should be considered in patients presenting with abdominal pain. The drug itself is associated with the risk of intestinal angioedema.

5. ACE inhibitors, including quinapril, have been associated with rare cases of hepatic failure, starting with cholestatic jaundice and progressing to fulminant hepatic necrosis. The drug itself is associated with the risk of hepatic failure.

6. Excessive hypotension is rare in patients with uncomplicated hypertension treated with quinapril alone, but caution should be observed when initiating therapy in patients with heart failure. The drug itself is associated with the risk of hypotension reactions.

7. ACE inhibitors, like quinapril, have been shown to cause agranulocytosis and bone marrow depression in rare cases, especially in patients with renal impairment or collagen vascular disease. The drug itself is associated with the risk of neutropenia and agranulocytosis.

8. Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy can lead to fetal renal function impairment and increased fetal morbidity and death. The drug itself is associated with the risk of fetal toxicity during pregnancy.",Less,No,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",8ded0773-3aec-4e89-9836-d22a5a84abf0,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8ded0773-3aec-4e89-9836-d22a5a84abf0&type=display
910,QUINIDINE GLUCONATE,"1. The drug quinidine is an antiarrhythmic agent with Class Ia activity, which can lead to an increase in ventricular automaticity and polymorphic ventricular tachycardias, including torsades de pointes (associated with the drug itself).
2. Quinidine prolongs the QT interval in a dose-related fashion, potentially causing ventricular arrhythmias and torsades de pointes (associated with the drug itself).
3. Quinidine has been associated with an increased risk of mortality in patients with non-life-threatening ventricular arrhythmias, with a statistically significant threefold relative risk of death compared to alternative antiarrhythmics (associated with the drug itself).
4. Quinidine can cause a paradoxical increase in ventricular rate in atrial flutter/fibrillation, leading to a very high ventricular rate that may be poorly tolerated (associated with the drug itself).
5. In patients with sick sinus syndrome, quinidine can cause marked sinus node depression and bradycardia, although in most patients, it is associated with an increase in the sinus rate (associated with the drug itself).
6. Quinidine has anticholinergic activity, negative inotropic activity, and acts as an -adrenergic antagonist, potentially leading to adverse cardiac effects (associated with the drug itself).
7. Quinidine has been reported to cause ventricular arrhythmias such as frequent extrasystoles, ventricular tachycardia, ventricular flutter, and ventricular fibrillation (associated with the drug itself).
8. Quinidine can lead to exacerbated bradycardia in patients with sick sinus syndrome (associated with the drug itself).
9. Quinidine has proarrhythmic effects, including prolongation of the QT interval, which can increase the risk of torsades de pointes, a life-threatening ventricular arrhythmia (associated with the drug itself).",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",ad2ad985-cca2-25b5-e053-2995a90a402f,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=ad2ad985-cca2-25b5-e053-2995a90a402f&type=display
911,QUINIDINE SULFATE TABLET,"1. The drug Quinidine Sulfate is associated with cardiotoxicity risks, including prolongation of the QT interval, which may lead to ventricular arrhythmias such as torsades de pointes. (The drug itself is associated with the cardiotoxicity risk.)

2. Quinidine has proarrhythmic effects, as it prolongs the QT interval, increasing the risk of torsades de pointes, a life-threatening ventricular arrhythmia. (The drug itself is associated with the cardiotoxicity risk.)

3. Quinidine may cause a paradoxical increase in ventricular rate in atrial flutter/fibrillation, leading to a very high ventricular rate that may be poorly tolerated. (The drug itself is associated with the cardiotoxicity reaction.)

4. In patients with the sick sinus syndrome, quinidine can cause marked sinus node depression and bradycardia. (The drug itself is associated with the cardiotoxicity reaction.)

5. Quinidine should be used with caution in patients at high risk of complete atrioventricular block, as it may exacerbate heart block. (The drug itself is associated with the cardiotoxicity risk.)

6. Quinidine has been associated with various adverse reactions, including ventricular arrhythmias, hypotension, syncope, and other cardiac effects. (The drug itself is associated with the cardiotoxicity reactions.)",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",b0d6341b-d880-4f0b-8844-bc788c03004a,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=b0d6341b-d880-4f0b-8844-bc788c03004a&type=display
912,QUININE SULFATE,"1. The drug label warns that quinine sulfate, the active ingredient in QUALAQUIN, has been associated with QT interval prolongation, potentially leading to serious cardiac arrhythmias such as torsades de pointes and ventricular fibrillation. This indicates that the drug itself is associated with cardiotoxicity risks.

2. The label also mentions that quinine sulfate has been rarely linked to potentially fatal cardiac arrhythmias, including torsades de pointes and ventricular fibrillation. This suggests that the drug itself can cause cardiotoxicity reactions.

3. Additionally, the drug label highlights that quinine sulfate may cause concentration-dependent prolongation of the PR and QRS interval, particularly posing a risk to patients with underlying structural heart disease or preexisting conduction system abnormalities. This indicates that the drug itself can lead to cardiotoxicity reactions.

4. The label warns against using QUALAQUIN with other drugs known to prolong the QT interval, such as certain antiarrhythmic agents, as this can further increase the risk of cardiac arrhythmias like torsades de pointes. This suggests that the drug itself can exacerbate cardiotoxicity risks when combined with certain medications.

5. Furthermore, the drug label mentions that QUALAQUIN has been associated with an increased risk of atrial fibrillation and flutter, potentially leading to a paradoxical increase in ventricular rate. This indicates that the drug itself can contribute to cardiotoxicity reactions, particularly in patients with atrial fibrillation or flutter.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",1c44c8b7-8b38-4487-a8ba-a94f708d1f50,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=1c44c8b7-8b38-4487-a8ba-a94f708d1f50&type=display
913,RABEPRAZOLE SODIUM,"1. **Warnings and Precautions - Interaction with Warfarin**: The drug label warns about the potential interaction between rabeprazole (ACIPHEX) and warfarin, which may lead to increased INR and prothrombin time, potentially causing abnormal bleeding and death. The drug itself is not associated with cardiotoxicity but can impact the anticoagulant effect of warfarin.

2. **Adverse Reactions - Postmarketing Experience**: The postmarketing experience section lists various adverse reactions reported after the approval of rabeprazole, including blood and lymphatic system disorders like hemolytic anemia and thrombocytopenia, which can be associated with cardiotoxicity risks. The drug itself is not directly causing these reactions but may be linked to potential cardiotoxic effects.

3. **Drug Interactions - Methotrexate**: The drug label mentions that concomitant use of rabeprazole with methotrexate may elevate and prolong serum levels of methotrexate, leading to methotrexate toxicities. The drug itself is not causing cardiotoxicity but can impact the toxicity of methotrexate, which may have cardiotoxic effects.

Please consult the full prescribing information for a comprehensive understanding of the cardiotoxicity risks and reactions associated with ACIPHEX (rabeprazole sodium) delayed-release tablets.",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",1eb38279-0237-4967-be7a-c53a826c1138,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=1eb38279-0237-4967-be7a-c53a826c1138&type=display
914,RADIUM RA 223 DICHLORIDE,"1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with Xofigo (radium Ra 223 dichloride) injection itself.

2. The drug label focuses primarily on bone marrow suppression as a significant risk associated with Xofigo, but does not mention any direct cardiotoxicity risks or reactions.

3. The label does not indicate any direct association between Xofigo and cardiotoxicity risks or reactions. The drug primarily targets bone metastases in patients with castration-resistant prostate cancer and does not have a known direct impact on cardiac function.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",a398400e-bd31-41a9-9696-4f7c06569ede,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a398400e-bd31-41a9-9696-4f7c06569ede&type=display
915,RALOXIFENE HYDROCHLORIDE,"1. The drug label for EVISTA highlights an increased risk of venous thromboembolism, including deep vein thrombosis and pulmonary embolism, associated with the use of EVISTA. Women with a history of venous thromboembolism should not take EVISTA.

2. The label also warns of an increased risk of death due to stroke in postmenopausal women with documented coronary heart disease or at increased risk for major coronary events who are treated with EVISTA. The drug itself was associated with an increased risk of death due to stroke in this specific population.

3. EVISTA should not be used for the primary or secondary prevention of cardiovascular disease, as no cardiovascular benefit was demonstrated in a clinical trial of postmenopausal women with coronary heart disease or at increased risk for coronary events. The drug itself was not shown to provide cardiovascular benefits in this trial.

4. The label advises caution in using EVISTA in patients with hepatic impairment and recommends monitoring serum triglycerides in women with a history of hypertriglyceridemia when treated with estrogens. EVISTA was associated with potential risks in patients with hepatic impairment and a history of hypertriglyceridemia when treated with estrogens.

5. Concomitant use of EVISTA with systemic estrogens is not recommended, and caution should be exercised when using EVISTA with other highly protein-bound drugs. EVISTA may affect the protein binding of other drugs, and caution is advised when using it with certain medications.",Less,No,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",fcaaa6dc-74e8-4fb8-800c-5574bf0f8de9,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fcaaa6dc-74e8-4fb8-800c-5574bf0f8de9&type=display
916,RAMELTEON,1. The drug label for ROZEREM does not mention any cardiotoxicity risks or cardiotoxicity reactions associated with the use of this medication. No information is provided regarding any direct impact on the cardiovascular system or any cardiotoxic effects related to ROZEREM.,No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",9de82310-70e8-47b9-b1fc-6c6848b99455,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=9de82310-70e8-47b9-b1fc-6c6848b99455&type=display
917,RAMIPRIL,"1. The drug ALTACE (ramipril) is associated with a warning of fetal toxicity, which can cause injury and death to the developing fetus when pregnancy is detected, leading to the recommendation to discontinue ALTACE as soon as possible. (Drug-associated cardiotoxicity risk)

2. ALTACE is indicated for the treatment of hypertension, reducing the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. (Drug-associated cardiotoxicity risk)

3. ALTACE is indicated for patients at high risk of developing a major cardiovascular event to reduce the risk of myocardial infarction, stroke, or death from cardiovascular causes. (Drug-associated cardiotoxicity risk)

4. ALTACE is indicated in stable patients with congestive heart failure post-myocardial infarction to decrease the risk of death and failure-related hospitalization. (Drug-associated cardiotoxicity risk)

5. The drug label mentions that ALTACE can cause symptomatic hypotension, especially in patients who are volume- and/or salt-depleted, and may lead to excessive hypotension in patients with heart failure post-myocardial infarction. (Drug-associated cardiotoxicity reaction)

6. ALTACE has been associated with angioedema, including potentially fatal angioedema of the face, extremities, lips, tongue, glottis, and larynx. (Drug-associated cardiotoxicity reaction)

7. ALTACE has been rarely associated with hepatic failure and impaired liver function, leading to cholestatic jaundice and fulminant hepatic necrosis. Discontinuation of ALTACE is recommended if jaundice or marked elevations of hepatic enzymes develop. (Drug-associated cardiotoxicity reaction)

8. ALTACE may cause changes in renal function, including oliguria, azotemia, acute renal failure, and death, particularly in patients with severe congestive heart failure or renal artery stenosis. (Drug-associated cardiotoxicity reaction)",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",0fc34cd8-86e6-4034-73bd-4263a68ba046,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=0fc34cd8-86e6-4034-73bd-4263a68ba046&type=display
918,RANITIDINE,"1. **Cardiotoxicity Risk**: Rare reports of arrhythmias such as tachycardia, bradycardia, atrioventricular block, and premature ventricular beats have been associated with the use of Ranitidine Tablets, indicating a potential risk of cardiotoxicity.

2. **Cardiotoxicity Reaction**: Central Nervous System reactions such as reversible mental confusion, agitation, depression, and hallucinations have been reported, predominantly in severely ill elderly patients, suggesting a potential risk of cardiotoxicity reactions.

3. **Cardiotoxicity Risk**: Cardiovascular effects, including rare reports of arrhythmias, have been observed with the use of Ranitidine Tablets, indicating a potential risk of cardiotoxicity.

4. **Cardiotoxicity Reaction**: In some cases, reversible blurred vision suggestive of a change in accommodation has been reported, which could indicate potential cardiotoxicity reactions associated with the use of Ranitidine Tablets.

5. **Cardiotoxicity Risk**: Rare cases of hepatic failure have been reported, which may indirectly impact cardiovascular function, suggesting a potential risk of cardiotoxicity with the use of Ranitidine Tablets.

6. **Cardiotoxicity Reaction**: Rare cases of arthralgias and myalgias have been reported, which could potentially impact cardiovascular health, indicating a potential risk of cardiotoxicity reactions associated with Ranitidine Tablets.

7. **Cardiotoxicity Risk**: Blood count changes, including leukopenia, granulocytopenia, and thrombocytopenia, have occurred in a few patients, which may have implications for cardiovascular health, suggesting a potential risk of cardiotoxicity with the use of Ranitidine Tablets.

8. **Cardiotoxicity Reaction**: Rare cases of agranulocytosis, pancytopenia, and aplastic anemia have been reported, which could impact overall health and potentially lead to cardiotoxicity reactions associated with the use of Ranitidine Tablets.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",9f416ce0-012f-4194-9382-74ac71e4b2a9,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=9f416ce0-012f-4194-9382-74ac71e4b2a9&type=display
919,RANOLAZINE,"1. The drug label mentions that ranolazine can cause QT interval prolongation, especially at high doses, with limited information available on its effects when used with other QT interval-prolonging drugs or in patients with certain conditions that may predispose them to prolonged QT intervals. (Ranolazine is associated with the risk of QT interval prolongation.)

2. It is noted that ranolazine can lead to renal failure, particularly in patients with moderate to severe renal impairment. Acute renal failure has been observed in patients with severe renal impairment while taking ranolazine. (Ranolazine is associated with the risk of renal failure.)

3. The drug label also lists various adverse reactions related to cardiotoxicity, including bradycardia, palpitations, and syncope, which were reported in patients treated with ranolazine. (Ranolazine is associated with cardiotoxicity reactions such as bradycardia, palpitations, and syncope.)

4. Additionally, the label mentions that ranolazine can cause hypotension and orthostatic hypotension, which are considered as potential cardiotoxic reactions associated with the drug. (Ranolazine is associated with the risk of hypotension and orthostatic hypotension.)

5. The drug label further states that ranolazine may lead to other potentially medically important adverse reactions, including angioedema, renal failure, and thrombocytopenia, which are considered cardiotoxic reactions. (Ranolazine is associated with the risk of angioedema, renal failure, and thrombocytopenia as potential cardiotoxic reactions.)

Overall, the drug label highlights the potential cardiotoxicity risks and reactions associated with ranolazine, emphasizing the importance of monitoring patients for these adverse effects during treatment.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",dd9f81e4-50da-4551-aed5-559d304df42e,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=dd9f81e4-50da-4551-aed5-559d304df42e&type=display
920,RASAGILINE,"1. **Hypertension Risk**: Rasagiline tablets may cause hypertension, including severe hypertensive syndromes, at recommended doses. The medication adjustment may be necessary if elevation of blood pressure is sustained. Patients should be monitored for new-onset hypertension or hypertension that is not adequately controlled after starting rasagiline. The drug itself is associated with the risk of hypertension.

2. **Orthostatic Hypotension Risk**: Rasagiline may cause hypotension, especially orthostatic hypotension. The incidence of orthostatic hypotension was reported in clinical trials, with a higher frequency in patients receiving rasagiline compared to placebo. The risk for post-treatment hypotension was also noted. The drug itself is associated with the risk of orthostatic hypotension.

3. **Dyskinesia Risk**: When used as an adjunct to levodopa, rasagiline may cause dyskinesia or potentiate dopaminergic side effects, exacerbating preexisting dyskinesia. Decreasing the levodopa dose may lessen or eliminate this side effect. The drug itself is associated with the risk of dyskinesia.

4. **Hallucinations and Psychotic-Like Behavior Risk**: Rasagiline may cause hallucinations and psychotic-like behavior. The incidence of hallucinations was reported in clinical trials, with a higher frequency in patients receiving rasagiline compared to placebo. Patients should be informed of the possibility of developing hallucinations and instructed to report them promptly. The drug itself is associated with the risk of hallucinations and psychotic-like behavior.

5. **Impulse Control/Compulsive Behaviors Risk**: Case reports suggest that patients taking rasagiline may experience intense urges to gamble, increased sexual urges, intense urges to spend money, binge eating, and other intense urges. The drug itself is associated with the risk of impulse control and compulsive behaviors.",Most,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",d9168d62-814a-444f-9d70-11674def339d,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=d9168d62-814a-444f-9d70-11674def339d&type=display
921,REGORAFENIB,"1. Cardiotoxicity risks associated with STIVARGA include an increased incidence of myocardial ischemia and infarction in patients treated with the drug, as observed in randomized placebo-controlled trials. (The drug itself was associated with an increased risk of myocardial ischemia and infarction.)

2. Patients who develop new or acute onset cardiac ischemia or infarction while on STIVARGA should have the drug withheld, and treatment should only be resumed after resolution of acute cardiac ischemic events if the potential benefits outweigh the risks of further cardiac ischemia. (The drug itself was associated with the need to withhold treatment in cases of cardiac ischemia or infarction.)

3. Cardiac ischemia and infarction were reported in a higher percentage of patients receiving STIVARGA compared to those receiving a placebo in randomized placebo-controlled trials. (The drug itself was associated with an increased incidence of cardiac ischemia and infarction.)

4. Patients experiencing severe or life-threatening hemorrhage while on STIVARGA should have the drug permanently discontinued. (The drug itself was associated with the risk of severe or life-threatening hemorrhage.)

5. STIVARGA caused an increased incidence of hemorrhage, with fatal hemorrhagic events reported in patients, including those involving the central nervous system or the respiratory, gastrointestinal, or genitourinary tracts. (The drug itself was associated with an increased risk of hemorrhage, including fatal events.)

6. Patients receiving STIVARGA should have their INR levels monitored more frequently if they are also receiving warfarin. (The drug itself was associated with the need for more frequent monitoring of INR levels in patients on warfarin.)

7. Patients who develop reversible posterior leukoencephalopathy syndrome (RPLS) while on STIVARGA should discontinue the drug. (The drug itself was associated with the development of RPLS.)

8. STIVARGA was not associated with any specific cardiotoxicity reactions in the provided drug label information.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",824f19c9-0546-4a8a-8d8f-c4055c04f7c7,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=824f19c9-0546-4a8a-8d8f-c4055c04f7c7&type=display
922,RELUGOLIX,"1. The drug ORGOVYX, a gonadotropin-releasing hormone (GnRH) receptor antagonist, may prolong the QT/QTc interval as a potential risk associated with androgen deprivation therapy, but it does not directly cause cardiotoxicity (5.1).

2. ORGOVYX can cause hypersensitivity reactions, including angioedema, which may lead to serious cases of angioedema, but it is not directly linked to cardiotoxicity (5.2).

3. The drug ORGOVYX is not associated with direct cardiotoxicity but can cause embryo-fetal toxicity, which may indirectly impact cardiovascular health due to potential fetal harm and loss of pregnancy when administered to a pregnant female (5.3).

4. In a clinical trial, serious adverse reactions occurred in patients receiving ORGOVYX, including myocardial infarction, arrhythmia, and acute kidney injury, which are cardiotoxicity risks associated with the drug (6.1).

5. Fatal adverse reactions, such as myocardial infarction and acute kidney injury, were reported in patients receiving ORGOVYX, indicating a potential cardiotoxicity risk with the drug (6.1).

6. Permanent discontinuation of ORGOVYX due to adverse reactions, including cardiac-related issues like atrioventricular block and cardiac failure, suggests a potential cardiotoxicity risk associated with the drug (6.1).",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",077a92f6-9f1b-479a-87c7-c92b5db6aa9c,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=077a92f6-9f1b-479a-87c7-c92b5db6aa9c&type=display
923,REMIFENTANIL HYDROCHLORIDE,"1. ULTIVA is contraindicated for epidural or intrathecal administration due to the presence of glycine in the formulation, which is not directly associated with cardiotoxicity risk.

2. ULTIVA is contraindicated in patients with hypersensitivity to remifentanil, which may lead to anaphylaxis but is not specifically linked to cardiotoxicity.

3. Bradycardia may occur with ULTIVA use, and patients should be monitored for changes in heart rate during dosage initiation and titration. Bradycardia is a potential cardiotoxicity reaction associated with ULTIVA.

4. Hypotension is a known risk with ULTIVA use, and blood pressure should be monitored during dosage initiation and titration. Hypotension is a cardiotoxicity risk linked to ULTIVA.

5. Intraoperative awareness has been reported in patients under 55 years of age when ULTIVA is administered with propofol infusion rates of  75 mcg/kg/min, which may lead to increased stress on the heart and potential cardiotoxicity.

6. ULTIVA should be used with caution in patients with biliary tract disease, including acute pancreatitis, as worsening symptoms may occur. While not directly cardiotoxic, these conditions can indirectly impact cardiac function.

7. Increased risk of seizures in patients with seizure disorders should be monitored during ULTIVA therapy, as seizures can have secondary effects on cardiovascular function. This is a cardiotoxicity risk associated with ULTIVA use.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",8b4c8696-e23e-4c51-a4d2-babab5bd945a,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8b4c8696-e23e-4c51-a4d2-babab5bd945a&type=display
924,REMIMAZOLAM BESYLATE,"1. The drug BYFAVO has been associated with hypoxia, bradycardia, and hypotension. Continuous monitoring of vital signs during sedation and recovery is recommended. (BYFAVO associated with cardiotoxicity risk)

2. Clinically notable hypoxia, bradycardia, and hypotension were observed in Phase 3 studies of BYFAVO. Continuous monitoring of vital signs during sedation and recovery is emphasized. (BYFAVO associated with cardiotoxicity risk)

3. BYFAVO has been shown to be compatible with intravenous fluids such as 0.9% Sodium Chloride Injection, USP, and Ringer's Solution. (No direct mention of cardiotoxicity risk)

4. The most common adverse reactions observed with BYFAVO administration include hypotension, hypertension, diastolic hypertension, systolic hypertension, and diastolic hypotension. (BYFAVO associated with cardiotoxicity reactions)

5. In clinical studies, BYFAVO administration led to adverse reactions such as hypotension, hypertension, bradycardia, tachycardia, and diastolic hypotension. (BYFAVO associated with cardiotoxicity reactions)

6. BYFAVO has been associated with adverse reactions like hypotension, hypertension, diastolic hypertension, systolic hypertension, hypoxia, and diastolic hypotension. (BYFAVO associated with cardiotoxicity reactions)",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",4e1838f2-b999-41a7-a761-d94f09aa531f,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=4e1838f2-b999-41a7-a761-d94f09aa531f&type=display
925,REPAGLINIDE,"1. **Serious Cardiovascular Adverse Reactions with Concomitant NPH-insulin**: PRANDIN is not indicated for use in combination with NPH-insulin. (The drug itself was not associated with cardiotoxicity but rather the combination with NPH-insulin was linked to serious cardiovascular adverse reactions.)

2. **Macrovascular Outcomes**: There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with PRANDIN. (The drug itself was not shown to reduce macrovascular risk.)

3. **Cardiovascular Events**: The incidence of total serious cardiovascular adverse events, including ischemia, was higher for PRANDIN than for sulfonylurea drugs in controlled comparator clinical trials. (The drug itself was associated with a higher incidence of serious cardiovascular events compared to other drugs in clinical trials.)

4. **Combination Therapy with Thiazolidinediones**: Peripheral edema and heart failure were reported in patients on PRANDIN-thiazolidinedione combination therapy, with episodes of edema and congestive heart failure observed in some cases. (The combination therapy involving PRANDIN was associated with peripheral edema and heart failure.)

5. **Summary of Serious Cardiovascular Events**: PRANDIN was associated with a higher incidence of serious cardiovascular events, including cardiac ischemic events, compared to sulfonylurea drugs in controlled clinical trials. (The drug itself was linked to a higher rate of serious cardiovascular events compared to other drugs in clinical trials.)

In summary, while PRANDIN itself was not directly associated with cardiotoxicity risks, it was linked to a higher incidence of serious cardiovascular events in clinical trials when used in combination with certain medications or compared to other drugs.",Most,No,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",813f781f-7db8-49ed-b4ed-a829c37eddb7,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=813f781f-7db8-49ed-b4ed-a829c37eddb7&type=display
926,REPOSITORY CORTICOTROPIN,"1. The drug label warns that chronic administration of corticotropin may lead to adverse effects that are not reversible, indicating that the drug itself is associated with cardiotoxicity risks.

2. Prolonged use of corticotropin may produce posterior subcapsular cataracts and glaucoma with possible damage to the optic nerves, suggesting potential cardiotoxicity reactions associated with the drug.

3. Corticotropin can cause elevation of blood pressure, salt and water retention, and increased excretion of potassium, indicating that the drug itself is associated with cardiotoxicity risks.

4. Corticotropin may mask some signs of infection, and new infections including those of the eye due to fungi or viruses may appear during its use, suggesting potential cardiotoxicity reactions associated with the drug.

5. Corticotropin may lead to hypertension and congestive heart failure, indicating that the drug itself is associated with cardiotoxicity risks.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",f27544ee-a0e2-4d84-b193-1c9efdf9e34c,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=f27544ee-a0e2-4d84-b193-1c9efdf9e34c&type=display
927,RIBAVIRIN,"1. Ribavirin for Inhalation Solution, USP has been associated with pulmonary and cardiovascular adverse reactions. Pulmonary function significantly deteriorated in adults with chronic obstructive lung disease and asthmatic adults during treatment with aerosolized Ribavirin for Inhalation Solution, USP.

2. Aerosolized Ribavirin for Inhalation Solution, USP has been linked to worsening of respiratory status, bronchospasm, pulmonary edema, hypoventilation, cyanosis, dyspnea, bacterial pneumonia, pneumothorax, apnea, atelectasis, and ventilator dependence in patients, indicating a potential risk of cardiotoxicity reactions.

3. Cardiovascular adverse events reported with the use of Ribavirin for Inhalation Solution, USP include cardiac arrest, hypotension, bradycardia, and digitalis toxicity. Additionally, bigeminy, bradycardia, and tachycardia have been observed in patients with underlying congenital heart disease, suggesting a potential association with cardiotoxicity risks.

4. Some patients requiring assisted ventilation experienced serious difficulties due to inadequate ventilation and gas exchange, potentially related to Ribavirin for Inhalation Solution, USP administration. Precipitation of the drug within the ventilatory apparatus led to increased positive end expiratory pressure and positive inspiratory pressure, indicating a possible cardiotoxicity risk.

5. Measures to avoid complications such as Ribavirin for Inhalation Solution, USP precipitation and ventilator malfunction should be followed carefully to minimize the risk of cardiotoxicity reactions. Accumulation of fluid in tubing and increased pulmonary pressures due to drug precipitation within the ventilator apparatus have been noted, emphasizing the importance of proper administration to prevent cardiotoxicity risks.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",7ea8dafa-d3d8-493e-a0db-e783d92fb13f,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7ea8dafa-d3d8-493e-a0db-e783d92fb13f&type=display
928,RIBOCICLIB,"1. The drug KISQALI has been shown to prolong the QT interval in a concentration-dependent manner, which may require dose interruption, reduction, or discontinuation as described in the label. (The drug itself is associated with QT interval prolongation.)

2. Across clinical trials, a small percentage of patients treated with KISQALI experienced QT prolongation, with reversible ECG changes and no reported cases of Torsades de Pointes. (The drug itself is associated with QT prolongation.)

3. In MONALEESA-2, one sudden death occurred in a patient with Grade 3 hypokalemia and Grade 2 QT prolongation while on the KISQALI plus letrozole treatment arm. (The drug itself is associated with QT prolongation and a potential risk of sudden death.)

4. The label advises assessing ECG prior to initiation of treatment with KISQALI and monitoring serum electrolytes regularly to manage potential QT prolongation risks. (The drug itself is associated with the need for ECG assessments and electrolyte monitoring to mitigate QT prolongation risks.)",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",aaeaef94-f3f5-4367-8ea2-b181d7be2da8,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=aaeaef94-f3f5-4367-8ea2-b181d7be2da8&type=display
929,RIFABUTIN,"1. **Cardiotoxicity Risk**: The drug label does not mention any direct association of Mycobutin (rifabutin) with cardiotoxicity risk.

2. **Cardiotoxicity Reactions**: The drug label does not list any cardiotoxicity reactions associated with the use of Mycobutin (rifabutin).",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",3e1a6613-bdd3-4261-93b3-d7f5cc09064b,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=3e1a6613-bdd3-4261-93b3-d7f5cc09064b&type=display
930,RIFAMPIN,"1. The drug label does not mention any specific cardiotoxicity risks or cardiotoxicity reactions associated with the use of Rifadin (rifampin capsules USP) or Rifadin IV (rifampin for injection USP).

2. There is no information provided in the drug label regarding cardiotoxicity risks or cardiotoxicity reactions related to the use of Rifadin or Rifadin IV.

3. The drug label does not contain any details about cardiotoxicity risks or cardiotoxicity reactions linked to the administration of Rifadin or Rifadin IV.

Overall, based on the information provided in the drug label, there are no mentions of cardiotoxicity risks or cardiotoxicity reactions associated with the use of Rifadin or Rifadin IV.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",87839f65-cb33-412e-929e-564136501a84,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=87839f65-cb33-412e-929e-564136501a84&type=display
931,RIFAMYCIN,"1. The drug label does not mention any cardiotoxicity risks or cardiotoxicity reactions associated with AEMCOLO itself. 

2. AEMCOLO is contraindicated in patients with a known hypersensitivity to rifamycin, but there is no specific mention of cardiotoxicity risks or reactions in relation to this contraindication.

3. The drug label does not include any information regarding cardiotoxicity risks or cardiotoxicity reactions in the Warnings and Precautions section.

4. The Adverse Reactions section lists the most common adverse reactions as headache and constipation, with no mention of cardiotoxicity risks or reactions.

Overall, based on the information provided in the drug label, AEMCOLO is not associated with cardiotoxicity risks or cardiotoxicity reactions.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",b31ff668-ee1f-4d89-8b69-68df2a0d2243,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=b31ff668-ee1f-4d89-8b69-68df2a0d2243&type=display
932,RIFAPENTINE,"1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with PRIFTIN (rifapentine) itself.

2. The drug label does not attribute any cardiotoxicity risks or reactions to PRIFTIN (rifapentine) in the sections discussing adverse reactions, warnings, precautions, or clinical trials for active pulmonary tuberculosis and latent tuberculosis infection.

3. There is no mention of cardiotoxicity risks or reactions related to PRIFTIN (rifapentine) in the sections discussing drug interactions, contraindications, or administration of the medication.

Overall, based on the information provided in the drug label, PRIFTIN (rifapentine) does not appear to be associated with cardiotoxicity risks or reactions.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",3a64fb70-b85e-43d9-8bcd-7e893f568ae1,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=3a64fb70-b85e-43d9-8bcd-7e893f568ae1&type=display
933,RIFAXIMIN,"1. **Warnings and Precautions - Hepatic Impairment:** The drug label mentions that caution should be exercised when using XIFAXAN in patients with severe (Child-Pugh Class C) hepatic impairment. This is due to the increased systemic exposure in these patients, but it does not directly associate the drug with cardiotoxicity risk.

2. **Warnings and Precautions - Postmarketing Experience:** The drug label states that cases of rhabdomyolysis have been reported in patients with cirrhosis, with and without concomitant statin use. This suggests a potential cardiotoxicity risk associated with the drug, particularly in patients with cirrhosis.

3. **Warnings and Precautions - Postmarketing Experience:** Severe cutaneous adverse reactions, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), have been reported in association with the use of rifaximin in patients with cirrhosis. While these reactions are not directly related to cardiotoxicity, they indicate severe adverse effects that may impact overall health, including cardiac function.

Please note that while the drug label does not explicitly state cardiotoxicity as a common or specific adverse reaction of XIFAXAN, the mentioned risks and reactions suggest potential implications for cardiac health, especially in patients with hepatic impairment or cirrhosis.",Less,Yes.,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",c5e8e2fd-7087-4b78-9181-cc259c0be2f1,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=c5e8e2fd-7087-4b78-9181-cc259c0be2f1&type=display
934,RILPIVIRINE HYDROCHLORIDE,"1. The drug label mentions that in healthy subjects, higher doses of the drug have been shown to prolong the QTc interval of the electrocardiogram, indicating a potential risk of torsade de pointes. The drug itself was associated with the risk of QTc prolongation, which can lead to cardiotoxicity.

2. The label advises considering alternatives to the drug when coadministered with medications known to have a risk of torsade de pointes, emphasizing the importance of monitoring for potential cardiotoxic effects. The drug itself was not directly linked to cardiotoxicity in this statement but highlighted the need to avoid drugs that could increase the risk.

3. The drug label also mentions that the concomitant use of the drug with other medications may result in significant drug interactions, potentially leading to the loss of therapeutic effect and resistance, including possible cardiotoxic reactions. The drug itself was not directly associated with cardiotoxicity in this statement but warned about the risks of interactions that could impact cardiac health.",Less,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",03880372-2c68-45c6-a53a-f420c49541d6,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=03880372-2c68-45c6-a53a-f420c49541d6&type=display
935,RILUZOLE,1. The drug label for RILUTEK (riluzole) does not mention any specific cardiotoxicity risks or cardiotoxicity reactions associated with the use of this medication.,No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",6ddc26d7-a6fe-46dd-8b49-c55aa111f83e,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=6ddc26d7-a6fe-46dd-8b49-c55aa111f83e&type=display
936,RIMANTADINE HYDROCHLORIDE,"1. The drug label mentions that overdoses of a related drug, amantadine, have been reported with adverse reactions such as cardiac arrhythmia, which suggests that amantadine, not rimantadine, is associated with cardiotoxicity risks.

2. In controlled clinical trials of rimantadine hydrochloride, central nervous system and gastrointestinal adverse events were reported in geriatric subjects, with symptoms such as dizziness, headache, anxiety, asthenia, and fatigue occurring more frequently in those treated with rimantadine than in those receiving placebo. This indicates that rimantadine may be associated with central nervous system adverse events in geriatric patients, but it is not explicitly stated that these events are cardiotoxic in nature.

3. The drug label also mentions that higher than recommended doses of rimantadine hydrochloride led to increased rates of adverse events, including gastrointestinal and nervous system symptoms. Symptoms such as hypertension, cerebrovascular disorder, and cardiac failure were reported at higher doses, suggesting a potential association between rimantadine and cardiotoxicity risks.",Less,No,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",49f7d69a-820b-4c75-a31d-b2104c019c12,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=49f7d69a-820b-4c75-a31d-b2104c019c12&type=display
937,RIMEGEPANT SULFATE,"1. The drug label does not mention any cardiotoxicity risks or cardiotoxicity reactions associated with NURTEC ODT itself.

2. In clinical studies, no clinically relevant differences in resting blood pressure were observed when rimegepant was concomitantly administered with sumatriptan, indicating that rimegepant did not cause any cardiotoxicity risks.

3. At a single dose 4 times the recommended dose, rimegepant did not prolong the QT interval to any clinically relevant extent, suggesting that rimegepant did not pose any cardiotoxicity risks in this aspect.

4. Overall, the drug label does not indicate any direct association between NURTEC ODT and cardiotoxicity risks or cardiotoxicity reactions based on the information provided.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",9ef08e09-1098-35cc-e053-2a95a90a3e1d,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=9ef08e09-1098-35cc-e053-2a95a90a3e1d&type=display
938,RIOCIGUAT,"1. **Cardiotoxicity Risk:**
   - The drug label does not explicitly mention any direct cardiotoxicity risk associated with the drug itself.

2. **Cardiotoxicity Reactions:**
   - The drug label does not list cardiotoxicity reactions as adverse events associated with the drug.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",7b57509a-3d5d-41d4-8fed-1471e26372a3,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7b57509a-3d5d-41d4-8fed-1471e26372a3&type=display
939,RIPRETINIB,"1. Cardiac Dysfunction: Assess ejection fraction by echocardiogram or MUGA scan prior to initiating QINLOCK and during treatment, as clinically indicated. Permanently discontinue QINLOCK for Grade 3 or 4 left ventricular systolic dysfunction. (The drug QINLOCK is associated with the risk of cardiac dysfunction and may lead to Grade 3 or 4 left ventricular systolic dysfunction.)

2. Risk of Impaired Wound Healing: Withhold QINLOCK for at least 1 week prior to elective surgery. Do not administer for at least 2 weeks following major surgery and until adequate wound healing. The safety of resumption of QINLOCK after resolution of wound healing complications has not been established. (QINLOCK is associated with the risk of impaired wound healing, which may affect patients undergoing surgery.)

3. Hypertension: Do not initiate QINLOCK in patients with uncontrolled hypertension. Monitor blood pressure as clinically indicated during treatment with QINLOCK, and initiate or adjust antihypertensive therapy as appropriate. Based on severity, withhold QINLOCK and then resume at the same or reduced dose or permanently discontinue. (QINLOCK is associated with the risk of hypertension, and patients with uncontrolled hypertension should not start the medication. Monitoring and management of blood pressure are necessary during treatment.)

4. Cardiac Dysfunction: In INVICTUS, cardiac failure occurred in 1.2% of the 85 patients who received QINLOCK. In the pooled safety population, cardiac dysfunction occurred in 1.7% of patients, including Grade 3 adverse reactions in 1.1%. (QINLOCK has been associated with cardiac dysfunction, including cardiac failure and Grade 3 adverse reactions in clinical trials.)

5. Cardiac Dysfunction: In INVICTUS, Grade 3 decreased ejection fraction occurred in 2.6% of the 77 patients who received QINLOCK and who had a baseline and at least one post-baseline echocardiogram. In the pooled safety population, Grade 3 decreased ejection fraction occurred in 3.4% of the 263 patients who received QINLOCK and who had a baseline and at least one post-baseline echocardiogram. (QINLOCK has been associated with Grade 3 decreased ejection fraction in clinical trials, indicating a potential cardiotoxic effect.)

Please note that the drug label provides information on the association of QINLOCK with cardiotoxicity risks and reactions based on clinical trials and safety data. It is essential for healthcare providers to monitor patients for these potential adverse effects during treatment with QINLOCK.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",9f18e462-03dd-4296-a02a-a0577e3ee78d,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=9f18e462-03dd-4296-a02a-a0577e3ee78d&type=display
940,RISDIPLAM,"1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with EVRYSDI (risdiplam).
2. Clinical studies did not observe any clinically significant QTc interval prolongation with EVRYSDI at the maximum recommended dose.
3. The drug label states that at the maximum recommended dose, EVRYSDI did not cause any clinically significant QTc interval prolongation.
4. No cardiotoxicity risks or reactions were directly attributed to EVRYSDI in the drug label information provided.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",eceb9a99-7191-4be5-87c3-0102707cf98e,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=eceb9a99-7191-4be5-87c3-0102707cf98e&type=display
941,RISEDRONATE SODIUM,"1. The drug label for ACTONEL does not mention any specific cardiotoxicity risks or reactions associated with the drug itself. 

2. The adverse reactions reported in clinical trials for ACTONEL primarily focus on musculoskeletal pain, gastrointestinal issues, and laboratory test findings related to calcium and phosphate levels. 

3. There is no mention of cardiotoxicity as a known risk or adverse reaction directly linked to the use of ACTONEL in the provided drug label information. 

Overall, based on the information provided in the drug label, ACTONEL does not appear to be associated with cardiotoxicity risks or reactions. It is important to consult with a healthcare provider for a comprehensive understanding of the drug's potential effects on cardiovascular health.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",24ed00e0-25e2-49a8-97fc-66c1b417dc0b,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=24ed00e0-25e2-49a8-97fc-66c1b417dc0b&type=display
942,RISPERIDONE,"1. **Increased Mortality in Elderly Patients with Dementia-Related Psychosis**: Elderly patients with dementia-related psychosis treated with antipsychotic drugs, including UZEDY, are at an increased risk of death. The drug itself is associated with an increased risk of mortality in this patient population.

2. **Cerebrovascular Adverse Reactions, Including Stroke, in Elderly Patients with Dementia-Related Psychosis**: Cerebrovascular adverse reactions, such as stroke and transient ischemic attack, were reported in elderly patients with dementia-related psychosis treated with oral risperidone. UZEDY is not approved for use in patients with dementia-related psychosis, and the drug itself is associated with an increased risk of cerebrovascular adverse reactions.

3. **Orthostatic Hypotension and Syncope**: UZEDY may induce orthostatic hypotension, leading to dizziness, tachycardia, and syncope, likely due to its alpha-adrenergic antagonistic properties. The drug itself is associated with orthostatic hypotension and syncope, particularly in patients with known cardiovascular disease, cerebrovascular disease, or conditions predisposing to hypotension.

4. **Falls**: Antipsychotics, including UZEDY, may cause somnolence, postural hypotension, and motor instability, increasing the risk of falls and related injuries. The drug itself is associated with an increased risk of falls, especially in elderly patients or those on long-term antipsychotic therapy.",Less,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",734eb776-4be0-4808-834b-0d8b0f9e021e,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=734eb776-4be0-4808-834b-0d8b0f9e021e&type=display
943,RITONAVIR,"1. **Cardiotoxicity Risk**: Ritonavir (NORVIR) has been associated with PR interval prolongation in some patients, potentially leading to second or third-degree atrioventricular block. The drug itself is linked to PR interval prolongation, which may pose a risk of cardiac conduction abnormalities.

2. **Cardiotoxicity Reaction**: Cases of second or third-degree heart block have been reported in patients receiving ritonavir (NORVIR). The drug itself has been associated with these cardiac conduction abnormalities, indicating a potential risk of serious cardiotoxic reactions.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",2849298e-de6e-47bb-8194-56e075b33fc3,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=2849298e-de6e-47bb-8194-56e075b33fc3&type=display
944,RIVAROXABAN,"1. The drug XARELTO is associated with a warning regarding premature discontinuation increasing the risk of thrombotic events, including cardiotoxicity risks. Premature discontinuation of XARELTO, an oral anticoagulant, can lead to an increased risk of thrombotic events, which may include cardiotoxicity risks.

2. XARELTO carries a boxed warning about spinal/epidural hematoma, which can result in long-term or permanent paralysis, but this is not directly related to cardiotoxicity risks. Epidural or spinal hematomas have occurred in patients treated with XARELTO who are receiving neuraxial anesthesia or undergoing spinal puncture, which can lead to neurological impairment but not specifically cardiotoxicity reactions.

3. The drug label mentions the risk of major cardiovascular events in patients with coronary artery disease (CAD) and peripheral artery disease (PAD) when using XARELTO in combination with aspirin, but this is not a direct cardiotoxicity risk associated with XARELTO alone. XARELTO, in combination with aspirin, is indicated to reduce the risk of major cardiovascular events in patients with CAD and major thrombotic vascular events in patients with PAD, but the cardiotoxicity risks are not solely attributed to XARELTO.

In summary, while XARELTO is associated with warnings and risks related to thrombotic events and neurological impairment, direct cardiotoxicity risks or reactions specifically caused by XARELTO alone are not explicitly mentioned in the drug label.",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",10db92f9-2300-4a80-836b-673e1ae91610,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=10db92f9-2300-4a80-836b-673e1ae91610&type=display
945,RIVASTIGMINE TARTRATE,"1. The drug Exelon (rivastigmine tartrate) is not associated with an increased incidence of cardiovascular adverse events, heart rate or blood pressure changes, or ECG abnormalities. Syncopal episodes have been reported in 3% of patients receiving 6-12 mg/day of Exelon, compared to 2% of placebo patients. (The drug itself is not associated with cardiotoxicity risks.)

2. Drugs that increase cholinergic activity may have vagotonic effects on heart rate (e.g., bradycardia). The potential for this action may be particularly important to patients with ""sick sinus syndrome"" or other supraventricular cardiac conduction conditions. In clinical trials, Exelon was not associated with any increased incidence of cardiovascular adverse events, heart rate or blood pressure changes, or ECG abnormalities. (The drug itself is not associated with cardiotoxicity risks.)

3. Like other drugs that increase cholinergic activity, Exelon should be used with care in patients with a history of asthma or obstructive pulmonary disease. (The drug itself is not associated with cardiotoxicity risks.)

4. Drugs that increase cholinergic activity are believed to have some potential for causing seizures. However, seizure activity also may be a manifestation of Alzheimer's disease. (The drug itself is not directly associated with cardiotoxicity risks.)

5. Exelon as a cholinesterase inhibitor is likely to exaggerate succinylcholine-type muscle relaxation during anesthesia. (The drug itself may have an indirect effect on muscle relaxation during anesthesia but is not directly associated with cardiotoxicity risks.)",Less,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",fead084a-a376-4d57-bdf0-aa7ed3655505,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fead084a-a376-4d57-bdf0-aa7ed3655505&type=display
946,RIZATRIPTAN BENZOATE,"1. RizaFilm is contraindicated in patients with a history of ischemic heart disease, coronary artery vasospasm, stroke, transient ischemic attack, Wolff-Parkinson-White syndrome, peripheral vascular disease, ischemic bowel disease, uncontrolled hypertension, recent use of another 5-HT1 agonist or ergotamine-containing medication, hemiplegic or basilar migraine, recent use of MAO-A inhibitors, co-administration with propranolol, or hypersensitivity to rizatriptan or any of the ingredients of RizaFilm. (The drug itself is associated with these cardiotoxicity risks.)

2. RizaFilm may cause serious cardiac adverse reactions, including acute myocardial infarction, in patients with multiple cardiovascular risk factors. Patients with coronary artery disease or coronary artery vasospasm should not receive RizaFilm. (The drug itself is associated with the risk of myocardial ischemia and myocardial infarction.)

3. Life-threatening disturbances of cardiac rhythm, such as ventricular tachycardia and ventricular fibrillation leading to death, have been reported following the administration of 5-HT1 agonists like RizaFilm. Discontinue RizaFilm if these disturbances occur. (The drug itself is associated with the risk of arrhythmias.)

4. Sensations of tightness, pain, pressure, and heaviness in the chest, throat, neck, and jaw may occur after treatment with rizatriptan, the active ingredient in RizaFilm. While these symptoms are usually noncardiac in origin, a cardiac evaluation is recommended for patients at high cardiac risk. (The drug itself is not directly associated with these symptoms but warrants cardiac evaluation in high-risk patients.)

5. Cerebral hemorrhage, subarachnoid hemorrhage, and stroke have occurred in patients treated with 5-HT1 agonists like RizaFilm, leading to fatalities. Discontinue RizaFilm if a cerebrovascular event occurs. (The drug itself is associated with the risk of cerebrovascular events.)

6. RizaFilm may cause non-coronary vasospastic reactions, such as peripheral vascular ischemia and gastrointestinal vascular ischemia. Transient and permanent blindness have been reported with the use of 5-HT1 agonists. (The drug itself is associated with the risk of vasospasm reactions and visual disturbances.)

7. Significant elevation in blood pressure, including hypertensive crisis, has been reported in patients receiving 5-HT1 agonists like rizatriptan. RizaFilm is contraindicated in patients with uncontrolled hypertension. (The drug itself is associated with the risk of increased blood pressure.)

In summary, RizaFilm is associated with various cardiotoxicity risks, including myocardial ischemia, arrhythmias, vasospastic reactions, and increased blood pressure, which may lead to serious adverse events in susceptible patients. Close monitoring and prompt discontinuation of the drug are recommended if cardiotoxicity reactions occur.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",fa32794e-d26d-e0bf-e053-6294a90abb0e,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fa32794e-d26d-e0bf-e053-6294a90abb0e&type=display
947,ROCURONIUM,"1. **Cardiotoxicity Risk**: The drug label mentions that rocuronium bromide may be associated with increased pulmonary vascular resistance, indicating a potential risk for cardiotoxicity in patients with pulmonary hypertension or valvular heart disease. The drug itself is associated with the risk of increased pulmonary vascular resistance, suggesting a potential cardiotoxic effect in specific patient populations.

2. **Cardiotoxicity Reaction**: The label does not specifically mention any direct cardiotoxic reactions associated with rocuronium bromide. However, it does caution about the potential for increased pulmonary vascular resistance, which could impact cardiac function in patients with certain cardiovascular conditions. No direct cardiotoxic reactions are explicitly stated in the provided drug label information.",Less,No,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",6045ed5a-5d2c-4f17-aaba-458fbf87e85c,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=6045ed5a-5d2c-4f17-aaba-458fbf87e85c&type=display
948,ROFLUMILAST,1. The drug label for ZORYVE cream does not mention any cardiotoxicity risks or cardiotoxicity reactions associated with the use of the drug.,No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",ec1bb0d1-f38a-4080-831a-68791d1d1fdb,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=ec1bb0d1-f38a-4080-831a-68791d1d1fdb&type=display
949,ROLAPITANT,"1. The drug VARUBI (rolapitant) is not associated with clinically relevant cardiotoxicity risks. At an oral dose of 720 mg (4 times the recommended oral dose), VARUBI does not prolong the QT interval to any clinically relevant extent. (Source: Clinical Pharmacology, Section 12.2)

2. VARUBI (rolapitant) has not been reported to cause any cardiotoxicity reactions in patients. The drug does not have a significant impact on cardiac electrophysiology, specifically the QT interval, even at a dose four times higher than the recommended oral dose. (Source: Clinical Pharmacology, Section 12.2)",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",a52896cd-4a98-49b8-82db-bf1985a64d97,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a52896cd-4a98-49b8-82db-bf1985a64d97&type=display
950,ROMIDEPSIN,"1. The drug ISTODAX (romidepsin) is associated with potential cardiotoxicity risks, as it can cause electrocardiographic changes, including T-wave and ST-segment changes, in patients with congenital long QT syndrome, a history of significant cardiovascular disease, and those taking medications leading to significant QT prolongation.

2. Romidepsin, the active ingredient in ISTODAX, may lead to delayed concentration-dependent increases in heart rate in patients with advanced cancer, with a maximum mean increase of 20 beats per minute occurring at the 6-hour time point after the start of romidepsin infusion.

3. The drug label advises considering cardiovascular monitoring of ECGs at baseline and periodically during treatment with ISTODAX, especially in patients with congenital long QT syndrome, significant cardiovascular disease history, and those taking medications that prolong QT interval, to assess for potential electrocardiographic changes.

4. Prior to administration of ISTODAX, it is recommended to confirm that potassium and magnesium levels are within the normal range, as part of the precautions to manage potential electrocardiographic changes and cardiotoxicity risks associated with the drug.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",03b39d40-90fe-11df-9de6-0002a5d5c51b,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=03b39d40-90fe-11df-9de6-0002a5d5c51b&type=display
951,ROPINIROLE HYDROCHLORIDE,"1. **Cardiotoxicity Risk**: The drug REQUIP XL (ropinirole extended-release tablets) was not associated with clear effects on average changes in blood pressure or heart rate compared with placebo. However, there was an increased incidence of patients treated with REQUIP XL who met various outlier criteria for severe systolic blood pressure increase and moderate pulse changes compared to placebo.

2. **Cardiotoxicity Reactions**: In the placebo-controlled study for advanced Parkinson's disease, syncope (fainting) was observed in 1% of patients who received REQUIP XL, and hypotension was reported as an adverse event in 2% of patients. Orthostatic hypotension was reported in 5% of patients receiving REQUIP XL. Additionally, there were reports of significant decrements in blood pressure unrelated to standing and severe systolic and diastolic blood pressure decreases in patients taking REQUIP XL. These effects were observed during both the titration and maintenance phases of treatment.",Less,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",2deb758c-659e-4e5a-a087-0e9c422f2fe1,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=2deb758c-659e-4e5a-a087-0e9c422f2fe1&type=display
952,ROSIGLITAZONE MALEATE,"1. **Cardiotoxicity Risk**: Thiazolidinediones, including rosiglitazone (AVANDIA), can cause or exacerbate congestive heart failure in some patients. This risk is associated with the drug itself.

2. **Cardiotoxicity Reaction**: Signs and symptoms of heart failure, such as excessive weight gain, dyspnea, and edema, should be monitored in patients taking AVANDIA. If these symptoms develop, heart failure should be managed according to current standards of care, and discontinuation or dose reduction of AVANDIA should be considered. This reaction is associated with the drug itself.

3. **Cardiotoxicity Risk**: AVANDIA has been associated with an increased risk of myocardial ischemic events, such as angina or myocardial infarction, based on a meta-analysis of clinical studies. The available data on this risk are inconclusive. This risk is associated with the drug itself.

4. **Cardiotoxicity Reaction**: Patients with congestive heart failure (CHF) NYHA Class I and II treated with AVANDIA have an increased risk of cardiovascular events, as shown in a clinical study. This reaction is associated with the drug itself.

5. **Cardiotoxicity Reaction**: AVANDIA is not recommended in patients with symptomatic heart failure and is contraindicated in patients with established NYHA Class III or IV heart failure. This reaction is associated with the drug itself.

6. **Cardiotoxicity Risk**: In studies where AVANDIA was added to insulin, there was an increased risk of congestive heart failure and myocardial ischemia. This risk is associated with the drug itself.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",ef14122b-7fff-45fa-b13b-0ea9e48bd57d,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=ef14122b-7fff-45fa-b13b-0ea9e48bd57d&type=display
953,ROSUVASTATIN,"1. The drug EZALLOR SPRINKLE is indicated to reduce the risk of stroke, myocardial infarction, and arterial revascularization procedures in adults at increased risk of cardiovascular disease based on specific criteria. The drug itself is associated with reducing the risk of these cardiovascular events.

2. The drug may cause myopathy and rhabdomyolysis, with risk factors including age, renal impairment, and certain drug interactions. Discontinuation of EZALLOR SPRINKLE is recommended if markedly elevated CK levels occur or myopathy is suspected. The drug EZALLOR SPRINKLE is associated with the risk of myopathy and rhabdomyolysis.

3. Rare reports of immune-mediated necrotizing myopathy (IMNM) have been associated with statin use, including EZALLOR SPRINKLE. Discontinuation of the drug is advised if IMNM is suspected. The drug EZALLOR SPRINKLE is associated with the risk of immune-mediated necrotizing myopathy.

4. Increases in serum transaminases have been reported with EZALLOR SPRINKLE use, with rare cases of fatal and non-fatal hepatic failure. Liver enzyme testing is recommended before initiating therapy and as clinically indicated thereafter. Prompt discontinuation of EZALLOR SPRINKLE is advised if serious hepatic injury occurs. The drug EZALLOR SPRINKLE is associated with the risk of hepatic dysfunction.",Less,No,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",619add8c-3e39-4bb7-8828-450bd82c0404,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=619add8c-3e39-4bb7-8828-450bd82c0404&type=display
954,ROSUVASTATIN CALCIUM,"1. The drug label mentions that CRESTOR (rosuvastatin calcium) is associated with skeletal muscle effects, such as myopathy and rhabdomyolysis, with risks increasing at the highest dose of 40 mg. The drug itself is linked to the increased risk of myopathy and rhabdomyolysis.

2. Additionally, the label warns about liver enzyme abnormalities, including persistent elevations in hepatic transaminases, which can occur with the use of CRESTOR. The drug itself is associated with liver enzyme abnormalities.

3. The label also cautions about the potential for proteinuria and hematuria in patients taking CRESTOR, particularly at the higher dose of 40 mg. The drug itself is linked to the occurrence of proteinuria and hematuria.

4. Furthermore, the label mentions that increases in HbA1c and fasting serum glucose levels have been reported with HMG-CoA reductase inhibitors, including CRESTOR, with instances where these increases may exceed the threshold for the diagnosis of diabetes mellitus. The drug itself is associated with increases in HbA1c and fasting serum glucose levels.

5. Lastly, the label discusses the postmarketing experience of cognitive impairment associated with statin use, including memory loss, forgetfulness, amnesia, memory impairment, and confusion. The drug itself is associated with cognitive impairment, although the reports are generally nonserious and reversible upon discontinuation.",Less,No,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",303f6c6c-c9ec-4a29-b2c9-2e81cc0e50f0,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=303f6c6c-c9ec-4a29-b2c9-2e81cc0e50f0&type=display
955,RUBIDIUM CHLORIDE RB-82,"1. **Warnings and Precautions**: The drug label warns of serious adverse reactions such as myocardial infarction, arrhythmia, hypotension, broncho-constriction, and cerebrovascular events associated with pharmacologic induction of cardiovascular stress. The drug itself is associated with the risk of these cardiotoxic reactions.

2. **Dosage and Administration**: The label advises using the lowest dose necessary to obtain adequate cardiac visualization and individualizing the dose based on multiple factors. While not directly stating cardiotoxicity risks, the emphasis on minimizing the dose suggests a concern for potential cardiotoxic effects.

3. **Dosage and Administration**: The label instructs to start imaging acquisition 60 to 90 seconds after completion of the infusion, with longer circulation times anticipated in certain cases. This guidance aims to minimize the duration of potential cardiotoxic exposure during imaging procedures.

4. **Dosage and Administration**: The label recommends waiting 10 minutes after completion of rest image acquisition before administering a pharmacologic stress agent, emphasizing the importance of timing to manage potential cardiotoxic effects.

5. **Warnings and Precautions**: The label highlights the risk of high-level radiation exposure with the use of incorrect eluent, which can lead to high strontium breakthrough levels. The drug itself is not directly cardiotoxic, but the incorrect use of the eluent can result in radiation exposure to critical organs, including the heart.

6. **Warnings and Precautions**: Excess radiation exposure can occur if the levels of strontium in the rubidium Rb 82 chloride injection exceed specified limits. While not a direct cardiotoxic effect, excess radiation exposure can have cardiotoxic implications due to the impact on critical organs.

7. **Warnings and Precautions**: The label advises strictly adhering to the generator eluate testing protocol to minimize the risk of excess radiation exposure, including daily testing and additional testing at Alert Limits. This protocol aims to prevent potential cardiotoxic effects associated with radiation exposure.

8. **Warnings and Precautions**: The label instructs to stop using the generator if it reaches any of its Expiration Limits, which include specific levels of strontium in the eluate. This precaution is essential to prevent potential cardiotoxic effects from excessive radiation exposure due to expired or compromised generators.",Less,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",ee95aa18-9f2f-40eb-9b4c-583bea6f36bf,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=ee95aa18-9f2f-40eb-9b4c-583bea6f36bf&type=display
956,RUCAPARIB,"1. The drug Rubraca (rucaparib) is associated with a positive concentration-QTc relationship, where a mean QTcF increase of 14.9 msec was observed at the approved recommended dosage of 600 mg twice daily. This indicates a potential risk of QTc prolongation with Rubraca use. (Rubraca was associated with a positive concentration-QTc relationship.)

2. The drug label mentions that Rubraca has not been studied in patients with severe hepatic impairment, which suggests caution should be exercised in patients with hepatic impairment due to potential effects on drug metabolism and clearance that could impact cardiotoxicity risks. (Rubraca has not been studied in patients with severe hepatic impairment, indicating a lack of specific data on cardiotoxicity risks in this population.)

3. Rubraca was shown to decrease tumor growth in mouse xenograft models of human cancer with or without deficiencies in BRCA, suggesting potential cardiotoxicity risks associated with its mechanism of action involving DNA repair and apoptosis. (Rubraca has been shown to decrease tumor growth in mouse xenograft models, indicating a potential link to cardiotoxicity risks through its mechanism of action.)

Please note that while the drug label does not explicitly state cardiotoxicity as a common adverse reaction, the information provided suggests potential risks related to cardiac electrophysiology and the drug's mechanism of action. It is important to consult with healthcare providers for a comprehensive understanding of the cardiotoxicity risks associated with Rubraca use.",Less,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",a6d46c03-bb1d-417b-b8e5-3bffe352fe29,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a6d46c03-bb1d-417b-b8e5-3bffe352fe29&type=display
957,RUFINAMIDE,"1. The drug label mentions that BANZEL is contraindicated in patients with Familial Short QT syndrome, indicating that the drug itself is associated with a cardiotoxicity risk related to this syndrome.

2. The label also warns about central nervous system reactions associated with BANZEL use, including somnolence, fatigue, coordination abnormalities, dizziness, gait disturbances, and ataxia. While these reactions are not directly related to cardiotoxicity, they can impact a patient's ability to drive or operate machinery, which could indirectly lead to safety concerns related to cardiac health.

3. Formal cardiac ECG studies demonstrated that BANZEL can shorten the QT interval, with a mean shortening of 20 msec observed at higher doses. This QT shortening is a direct cardiotoxicity risk associated with the drug. The label specifies that reductions of the QT interval below 300 msec were not observed in formal studies, and there was no signal for drug-induced sudden death or ventricular arrhythmias.

4. The label further highlights that patients with Familial Short QT syndrome should not be treated with BANZEL due to the potential risk of sudden death and ventricular arrhythmias associated with QT shortening. This indicates a direct cardiotoxicity risk related to the drug's effect on the QT interval.",Less,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",0a3fa925-1abd-458a-bd57-4ae780a1ef2d,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=0a3fa925-1abd-458a-bd57-4ae780a1ef2d&type=display
958,RUXOLITINIB,"1. The drug label for OPZELURA cream includes warnings about serious adverse cardiovascular events (MACE) associated with the use of Janus kinase inhibitors, including a higher rate of MACE observed in patients treated with OPZELURA compared to TNF blockers. The drug itself is associated with an increased risk of MACE.

2. Additionally, the label mentions thromboembolic events observed in trials with OPZELURA, including thrombosis such as deep vein thrombosis (DVT), pulmonary embolism (PE), and arterial thrombosis. The drug itself is associated with an increased risk of thromboembolic events.

3. The label also highlights the higher rate of all-cause mortality, including sudden cardiovascular death, observed in patients treated with Janus kinase inhibitors, including OPZELURA, compared to TNF blockers. The drug itself is associated with an increased risk of mortality, including cardiovascular-related deaths.

4. Furthermore, the label discusses the risk of major adverse cardiovascular events (MACE) defined as cardiovascular death, myocardial infarction, and stroke, which were observed at a higher rate in patients treated with OPZELURA compared to TNF blockers. The drug itself is associated with an increased risk of major adverse cardiovascular events.

5. The label also mentions lipid elevations associated with treatment with oral ruxolitinib, including increases in total cholesterol, low-density lipoprotein (LDL) cholesterol, and triglycerides. The drug itself is associated with lipid elevations, which can contribute to cardiovascular risk factors.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",24da5509-6631-4795-9d42-273faecd08e7,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=24da5509-6631-4795-9d42-273faecd08e7&type=display
959,RYDAPT,"1. The drug label mentions that RYDAPT may cause QT prolongation on electrocardiogram (ECG) as an adverse reaction. This indicates that the drug itself is associated with the risk of QT prolongation, which is a form of cardiotoxicity.

2. Additionally, the label states that there were cases of interstitial lung disease and pneumonitis, some of which were fatal, in patients treated with RYDAPT either as monotherapy or with chemotherapy. While these are primarily respiratory issues, they can also have cardiotoxic effects due to the impact on lung function and oxygenation, potentially affecting the heart.

3. The label also mentions that there were reports of pulmonary edema as an adverse reaction in patients with advanced systemic mastocytosis treated with RYDAPT. Pulmonary edema can lead to cardiac strain and compromise heart function, indicating a potential cardiotoxic effect.

Overall, the drug label for RYDAPT highlights the risks of cardiotoxicity through potential adverse reactions such as QT prolongation, interstitial lung disease, pneumonitis, and pulmonary edema associated with the use of the drug.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",11fa3fc9-6776-49a6-b1c1-653f627c3e58,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=11fa3fc9-6776-49a6-b1c1-653f627c3e58&type=display
960,SAFINAMIDE MESYLATE,"1. XADAGO is a monoamine oxidase type B (MAO-B) inhibitor indicated as adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease (PD) experiencing ""off"" episodes. The drug XADAGO itself is not associated with cardiotoxicity risks in this sentence.

2. XADAGO may cause or exacerbate hypertension. The drug XADAGO itself is associated with the risk of hypertension.

3. XADAGO is a selective inhibitor of MAO-B at the recommended dosages of 50 mg or 100 mg daily. Selectivity for inhibiting MAO-B decreases above the recommended daily dosages. Therefore, XADAGO should not be used at daily dosages exceeding those recommended because of the risks of hypertension, exacerbation of existing hypertension, or hypertensive crisis. The drug XADAGO itself is associated with the risk of hypertension.

4. XADAGO may cause serotonin syndrome when used with MAO inhibitors, antidepressants, or opioid drugs. The drug XADAGO itself is associated with the risk of serotonin syndrome.

5. XADAGO tablets contain safinamide, which is a MAO-B inhibitor. Inhibition of MAO-B activity, by blocking the catabolism of dopamine, is thought to result in an increase in dopamine levels and a subsequent increase in dopaminergic activity in the brain. The drug XADAGO itself is not directly associated with cardiotoxicity risks in this sentence.

6. XADAGO inhibits monoamine oxidase B (MAO-B), with more than 1000-fold selectivity over MAO-A. In clinical studies, complete inhibition (>90%) of MAO-B was measured at doses > 20 mg. The drug XADAGO itself is not directly associated with cardiotoxicity risks in this sentence.

7. The effect of XADAGO on the QTc interval was evaluated in a randomized placebo and positive controlled double-blind, multiple-dose parallel thorough QTc study in 240 healthy subjects. At a dose of 350 mg (3.5 times the maximum recommended dosage), XADAGO did not prolong the QTc interval. The drug XADAGO itself is not associated with QTc prolongation or cardiotoxicity risks in this sentence.",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",c4d65f28-983f-42b4-bb23-023ae0fe81b2,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=c4d65f28-983f-42b4-bb23-023ae0fe81b2&type=display
961,SAPROPTERIN DIHYDROCHLORIDE,"1. The drug label does not mention any specific cardiotoxicity risks or cardiotoxicity reactions associated with sapropterin dihydrochloride tablets or powder for oral solution. 

2. There is no information provided in the drug label regarding any cardiotoxicity risks or reactions linked to the use of sapropterin dihydrochloride in patients with hyperphenylalaninemia due to tetrahydrobiopterin-responsive Phenylketonuria (PKU).

3. The drug label does not contain any details about cardiotoxicity risks or cardiotoxicity reactions related to the administration of sapropterin dihydrochloride tablets or powder for oral solution in pediatric patients or adults with PKU.

Overall, based on the information provided in the drug label, there are no mentions of cardiotoxicity risks or cardiotoxicity reactions associated with the use of sapropterin dihydrochloride tablets or powder for oral solution in patients with hyperphenylalaninemia due to tetrahydrobiopterin-responsive Phenylketonuria (PKU).",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",83bf50fd-f70c-037a-5c8f-b32f69208d20,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=83bf50fd-f70c-037a-5c8f-b32f69208d20&type=display
962,SAQUINAVIR MESYLATE,"1. The drug label states that INVIRASE should not be administered concurrently with certain drugs like rifampin, terfenadine, cisapride, astemizole, pimozide, triazolam, midazolam, or ergot derivatives due to the risk of serious or life-threatening reactions, such as cardiac arrhythmias or prolonged sedation. (The drug itself is associated with the cardiotoxicity risk.)

2. The label also mentions that HIV-1 mutants with reduced susceptibility to saquinavir have been selected during in vitro passage, with specific substitutions in the HIV protease gene associated with reduced susceptibility to saquinavir. (The drug itself is associated with the development of resistance, not direct cardiotoxicity.)

3. It further states that HIV-1 isolates with reduced susceptibility to saquinavir emerged in some patients treated with INVIRASE, with specific mutations identified that contributed to resistance to saquinavir. (The drug itself is associated with the development of resistance, not direct cardiotoxicity.)

4. The label indicates that among protease inhibitors, variable cross-resistance has been observed, with some HIV-1 isolates displaying broad cross-resistance to all protease inhibitors, including saquinavir. (The drug itself is associated with the development of resistance, not direct cardiotoxicity.)

5. Additionally, the label warns that INVIRASE/ritonavir should not be administered concurrently with certain drugs like amiodarone, bepridil, flecainide, propafenone, quinidine, or ergot derivatives due to the potential for serious and/or life-threatening reactions. (The drug itself is associated with the cardiotoxicity risk.)

6. The label also mentions that coadministration of INVIRASE with ritonavir and fluticasone propionate is not recommended due to the potential for systemic corticosteroid side effects, including Cushing's syndrome and adrenal suppression. (The drug itself is associated with the cardiotoxicity risk.)

7. Furthermore, the label advises caution when INVIRASE and digoxin are coadministered, with monitoring of digoxin serum concentrations and potential dose adjustments due to the interaction between the two drugs. (The drug itself is associated with the cardiotoxicity risk.)

8. Lastly, the label highlights that elevated cholesterol and/or triglyceride levels have been observed in some patients taking saquinavir in combination with ritonavir, with marked elevation in triglyceride levels posing a risk factor for pancreatitis. Lipid disorders should be monitored and managed appropriately in patients on this therapy. (The drug itself is associated with the risk of hyperlipidemia, which can lead to pancreatitis but is not a direct cardiotoxicity risk.)",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",b8b53129-06ab-4143-b9b7-7675e49a52ef,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=b8b53129-06ab-4143-b9b7-7675e49a52ef&type=display
963,SARECYCLINE HYDROCHLORIDE,"1. SEYSARA is a tetracycline-class drug that has not been associated with prolonging the QT interval to a clinically relevant extent, indicating no direct cardiotoxicity risk.
   
2. The drug label does not mention any specific cardiotoxicity reactions or risks associated with SEYSARA itself. 

Please note that while the drug label does not highlight any direct cardiotoxicity risks or reactions associated with SEYSARA, it is important to consult with a healthcare provider for a comprehensive understanding of potential side effects and risks related to this medication.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",b200957c-3004-4988-be97-9fd619a83649,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=b200957c-3004-4988-be97-9fd619a83649&type=display
964,SAXAGLIPTIN,"1. Cardiotoxicity Risk: The drug ONGLYZA is associated with an increased risk of heart failure, as evidenced by a higher rate of hospitalization for heart failure in patients treated with ONGLYZA compared to those on placebo in a cardiovascular outcomes trial. The risk of hospitalization for heart failure was estimated to be higher in the ONGLYZA group, indicating an association between the drug and heart failure risk.

2. Cardiotoxicity Reaction: Patients with known risk factors for heart failure should consider the risks and benefits of ONGLYZA before initiating treatment. Monitoring for signs and symptoms of heart failure during therapy is recommended, and patients should be advised to report any characteristic symptoms of heart failure promptly. If heart failure develops, evaluation and management according to current standards of care should be undertaken, including consideration of discontinuing ONGLYZA. The drug itself is associated with an increased risk of hospitalization for heart failure, indicating a potential cardiotoxicity reaction.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",c5116390-e0fe-4969-94cb-e9de5165fbab,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=c5116390-e0fe-4969-94cb-e9de5165fbab&type=display
965,SECNIDAZOLE,"1. The drug SOLOSEC (secnidazole) is associated with a potential risk for carcinogenicity based on findings in mice and rats treated with nitroimidazole derivatives, structurally related to secnidazole. It is unclear if the positive tumor findings in rodent studies indicate a risk to patients taking a single dose of SOLOSEC for bacterial vaginosis. Avoid chronic use to mitigate this risk. (Drug-associated potential risk for carcinogenicity)

2. In a Phase 1 study evaluating the effect of secnidazole on the QTc interval in healthy adult subjects, there was a positive relationship between secnidazole concentrations and the QTc interval. However, there was no clinically relevant increase in the QTc interval following the administration of SOLOSEC. (No direct association of drug with cardiotoxicity)

3. Postmarketing reports have indicated that nausea, vomiting, diarrhea, abdominal pain, dizziness, and headache may occur when SOLOSEC is taken concomitantly with alcohol. (Drug-associated adverse reactions with alcohol)

4. Metronidazole, another nitroimidazole agent structurally related to secnidazole, has been associated with severe irreversible hepatotoxicity and acute liver failure, including fatal outcomes, in patients with Cockayne syndrome. (Association of metronidazole with severe hepatotoxicity in specific patient population)

5. In vitro studies showed that secnidazole had no effect on aldehyde dehydrogenase activity, but postmarketing observations have reported adverse reactions when SOLOSEC was taken with alcohol, suggesting a potential interaction leading to cardiotoxicity symptoms. (Potential drug-alcohol interaction leading to cardiotoxicity symptoms)",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",551e43d5-f700-4d6e-8029-026f8a8932ff,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=551e43d5-f700-4d6e-8029-026f8a8932ff&type=display
966,SELEGILINE HYDROCHLORIDE,"1. ZELAPAR should not be used at daily doses exceeding those recommended (2.5 mg/day) due to the risks associated with non-selective inhibition of MAO, which may lead to hypertensive reactions, including hypertension. The selectivity of ZELAPAR for MAO-B may not be absolute even at the recommended daily dose, and the selectivity decreases with increasing doses, potentially causing hypertensive reactions. (The drug itself is associated with the cardiotoxicity risk of hypertension.)

2. Uncontrolled hypertension, including hypertensive crisis, has been reported when taking the recommended dose of swallowed selegiline and a sympathomimetic medication (ephedrine). This indicates a potential risk of uncontrolled hypertension when ZELAPAR is used in combination with sympathomimetic medications. (The drug itself is associated with the cardiotoxicity risk of uncontrolled hypertension.)

3. Reports of hypertensive reactions have occurred in patients who ingested tyramine-containing consumables while receiving swallowed selegiline at the recommended dose, indicating a potential risk of hypertensive reactions with dietary tyramine intake. (The drug itself is associated with the cardiotoxicity risk of hypertensive reactions.)

4. A pharmacodynamic study showed increased tyramine sensitivity for increasing blood pressure and decreased selectivity for MAO-B with dosing above the recommended level, suggesting a potential risk of increased blood pressure and loss of selectivity for MAO-B with higher doses of ZELAPAR. (The drug itself is associated with the cardiotoxicity risk of increased blood pressure and loss of selectivity for MAO-B at higher doses.)

5. The safe use of ZELAPAR at doses above 2.5 mg daily without dietary tyramine restrictions has not been established, indicating a potential risk of uncontrolled hypertension with higher doses of ZELAPAR. (The drug itself is associated with the cardiotoxicity risk of uncontrolled hypertension at higher doses.)

6. In controlled trials, assessments showed an increased risk for orthostatic hypotension in patients taking ZELAPAR compared to placebo, particularly after increasing the daily dose from 1.25 to 2.5 mg, suggesting a potential risk of orthostatic hypotension with dose escalation of ZELAPAR. (The drug itself is associated with the cardiotoxicity risk of orthostatic hypotension with dose escalation.)

7. The incidence of orthostatic hypotension was higher in geriatric patients (65 years) than in non-geriatric patients, indicating an increased risk of orthostatic hypotension in elderly patients receiving ZELAPAR. (The drug itself is associated with the cardiotoxicity risk of orthostatic hypotension in elderly patients.)",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",380d7717-2a79-42f3-a712-efe5e7696ba0,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=380d7717-2a79-42f3-a712-efe5e7696ba0&type=display
967,SELENIOUS ACID,"1. The drug label does not mention any specific cardiotoxicity risks or cardiotoxicity reactions associated with Selenious Acid Injection itself. 

2. However, it does warn about the potential risk of pulmonary embolism due to pulmonary vascular precipitates in patients receiving parenteral nutrition solutions. This risk is not directly attributed to Selenious Acid Injection but is a general warning for patients receiving parenteral nutrition. If signs of pulmonary distress occur, the infusion should be stopped, and a medical evaluation initiated.

3. Additionally, the label mentions the importance of considering vein damage and thrombosis risks when administering solutions with osmolarity of 900 mOsmol/L or more. This risk is not specific to Selenious Acid Injection but is a general precaution for parenteral nutrition solutions with high osmolarity. It emphasizes the need to infuse such solutions through a central venous catheter to prevent vein irritation, damage, or thrombosis.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",49324999-50e3-43ed-a8dd-156d6dbedd9f,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=49324999-50e3-43ed-a8dd-156d6dbedd9f&type=display
968,SELEXIPAG,"1. **Warnings and Precautions**: The drug label mentions the risk of pulmonary edema in patients with pulmonary veno-occlusive disease. If signs of pulmonary edema occur, the possibility of associated pulmonary veno-occlusive disease should be considered. The drug itself is not directly associated with causing pulmonary edema but advises discontinuing treatment if confirmed.

2. **Adverse Reactions**: The label lists adverse reactions occurring more frequently on UPTRAVI compared to placebo, including headache, diarrhea, jaw pain, nausea, myalgia, vomiting, pain in extremity, and flushing. While these reactions are not directly related to cardiotoxicity, they are common side effects of the drug.

3. **Clinical Pharmacology**: The label states that at the maximum tolerated dose of UPTRAVI tablets, the drug does not prolong the QT interval to any clinically relevant extent. This indicates that the drug itself is not associated with significant cardiac electrophysiological effects.

4. **Drug Interaction Studies**: In vitro studies show that selexipag and its active metabolite do not inhibit or induce cytochrome P450 enzymes and transport proteins at clinically relevant concentrations. This suggests that the drug is not likely to cause cardiotoxicity through interactions with these pathways.

Overall, while the drug label does not directly link UPTRAVI to cardiotoxicity risks or reactions, it provides information on potential adverse effects and interactions that may impact cardiac health.",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",a7a23b87-f892-4e2c-8e2e-ebf841220f90,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a7a23b87-f892-4e2c-8e2e-ebf841220f90&type=display
969,SELINEXOR,"1. **Cardiotoxicity Risks:**
   - The drug label does not mention any specific cardiotoxicity risks associated with XPOVIO (selinexor) tablets.

2. **Cardiotoxicity Reactions:**
   - The drug label does not attribute any cardiotoxicity reactions directly to XPOVIO (selinexor) tablets.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",f6dd2682-75a6-4863-90a8-a3197f6f78a8,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=f6dd2682-75a6-4863-90a8-a3197f6f78a8&type=display
970,SELPERCATINIB,"1. **QT Interval Prolongation**: RETEVMO can cause concentration-dependent QT interval prolongation. An increase in QTcF interval to >500 ms was measured in 7% of patients and an increase in the QTcF interval of at least 60 ms over baseline was measured in 20% of patients. The drug itself was associated with QT interval prolongation.

2. **Hypertension**: Hypertension occurred in 41% of patients, including Grade 3 hypertension in 20% and Grade 4 in one patient. Treatment-emergent hypertension was most commonly managed with anti-hypertension medications. The drug itself was associated with causing hypertension.

3. **Hemorrhagic Events**: Serious, including fatal hemorrhagic events, can occur with RETEVMO. Grade 3 hemorrhagic events occurred in 3.1% of patients treated with RETEVMO. The drug itself was associated with causing hemorrhagic events.

4. **Hypersensitivity**: Hypersensitivity occurred in 6% of patients receiving RETEVMO, including Grade 3 hypersensitivity in 1.9%. Signs and symptoms of hypersensitivity included fever, rash, and arthralgias or myalgias with concurrent decreased platelets or transaminitis. The drug itself was associated with causing hypersensitivity reactions.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",7fa848ba-a59c-4144-9f52-64d090f4d828,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7fa848ba-a59c-4144-9f52-64d090f4d828&type=display
971,SELUMETINIB,"1. Cardiotoxicity risk associated with KOSELUGO: The drug label mentions that cardiomyopathy, defined as a decrease in left ventricular ejection fraction (LVEF)  10% below baseline, occurred in pediatric patients who received KOSELUGO in clinical trials.
   
2. Cardiotoxicity reaction caused by KOSELUGO: The label states that decreased LVEF occurred in a percentage of pediatric patients who received KOSELUGO, leading to dose reductions or permanent discontinuation of the drug.

3. Cardiotoxicity risk associated with KOSELUGO: The safety of KOSELUGO has not been established in patients with a history of impaired LVEF or a baseline ejection fraction below the institutional lower limit of normal, indicating a potential risk of cardiomyopathy with this drug.

4. Cardiotoxicity reaction caused by KOSELUGO: The label advises assessing ejection fraction by echocardiogram before initiating treatment and at regular intervals during treatment to monitor for cardiomyopathy. It also recommends withholding, reducing the dose, or permanently discontinuing KOSELUGO based on the severity of adverse reactions related to cardiomyopathy.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",7d042c61-f28f-4ab5-ab10-d7558c0d49ff,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7d042c61-f28f-4ab5-ab10-d7558c0d49ff&type=display
972,SEMAGLUTIDE,"1. The drug label for WEGOVY (semaglutide) injection mentions a warning about the risk of thyroid C-cell tumors in rodents due to semaglutide exposure, but it is unknown if WEGOVY causes thyroid C-cell tumors in humans. The label states that WEGOVY is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), and patients should be counseled about the potential risk of MTC and symptoms of thyroid tumors. (The drug itself is associated with the risk of thyroid C-cell tumors in rodents, but it is unknown if it causes these tumors in humans.)

2. The label also includes warnings about acute pancreatitis, acute gallbladder disease, hypoglycemia, acute kidney injury, hypersensitivity reactions, diabetic retinopathy complications in patients with type 2 diabetes, heart rate increase, and suicidal behavior and ideation. These warnings highlight potential adverse reactions associated with WEGOVY use, but do not specifically mention cardiotoxicity risks or reactions. (The drug label does not directly associate WEGOVY with cardiotoxicity risks or reactions.)",Less,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",ee06186f-2aa3-4990-a760-757579d8f77b,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b&type=display
973,SERTRALINE,"1. **QTc Prolongation**: The drug label mentions that during post-marketing use of sertraline, cases of QTc prolongation and Torsade de Pointes (TdP) have been reported. The drug itself was associated with QTc prolongation, indicating a risk of cardiotoxicity.

2. **Cardiac Disorders**: The label lists various cardiac disorders reported post-marketing, including AV block, bradycardia, atrial arrhythmias, and ventricular tachycardia (including Torsade de Pointes). These cardiac disorders were associated with the use of sertraline, indicating potential cardiotoxicity reactions.

3. **Cardiac Disorders**: Additionally, the label mentions that there have been reports of severe liver events, including hepatitis, jaundice, and liver failure, some with fatal outcomes. While these events primarily affect the liver, severe liver events can have secondary effects on the cardiovascular system, potentially leading to cardiotoxicity.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",1548faf9-8625-f871-e063-6394a90a931f,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=1548faf9-8625-f871-e063-6394a90a931f&type=display
974,SETMELANOTIDE,"1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with IMCIVREE (setmelanotide) injection for subcutaneous use. No cardiotoxicity risks or reactions were attributed to the drug itself in the provided drug label information. 

2. The drug label primarily focuses on indications, dosage and administration, contraindications, warnings, precautions, adverse reactions, and use in specific populations related to weight management in patients with monogenic or syndromic obesity. 

3. While the label does not mention cardiotoxicity risks, it does highlight other important warnings and precautions such as disturbance in sexual arousal, depression and suicidal ideation, hypersensitivity reactions, skin pigmentation changes, and risks associated with benzyl alcohol preservative in neonates and low birth weight infants. 

4. It is important to note that the absence of specific cardiotoxicity risks in the drug label does not imply that the drug is entirely without any potential cardiovascular side effects. Monitoring for any unexpected adverse reactions, including those related to the cardiovascular system, should be part of the overall patient management plan when using IMCIVREE. 

5. Patients and healthcare providers should remain vigilant for any signs or symptoms of cardiotoxicity or other adverse events while using IMCIVREE and report any concerns promptly to the healthcare provider or the appropriate regulatory authorities.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",70c3ccf7-4df0-4c75-ba07-fede9970c8d9,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=70c3ccf7-4df0-4c75-ba07-fede9970c8d9&type=display
975,SEVELAMER CARBONATE,"1. The drug label does not mention any specific cardiotoxicity risks or cardiotoxicity reactions associated with Renvela (sevelamer carbonate) itself.

2. The label primarily focuses on gastrointestinal adverse events, reductions in vitamins D, E, K, and folic acid levels, and drug interactions, but does not highlight any direct cardiotoxic effects or risks related to the use of Renvela. 

3. Therefore, based on the information provided in the drug label, Renvela is not associated with cardiotoxicity risks or cardiotoxicity reactions.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",e6328460-a57b-450b-a48c-6dcd4b476360,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=e6328460-a57b-450b-a48c-6dcd4b476360&type=display
976,SEVELAMER HYDROCHLORIDE,1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with sevelamer hydrochloride tablets.,No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",d8729e42-dbbd-4954-9ce0-298743a15a06,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=d8729e42-dbbd-4954-9ce0-298743a15a06&type=display
977,SILDENAFIL,"1. The drug LIQREV, a phosphodiesterase-5 (PDE-5) inhibitor, is associated with vasodilatory effects that may lead to mild and transient decreases in blood pressure, potentially posing a risk for patients with certain underlying conditions (hypotension or on antihypertensive therapy). LIQREV itself is linked to this vasodilatory effect, which could result in hypotension (5.1).

2. LIQREV is contraindicated in patients with pulmonary veno-occlusive disease (PVOD) due to the potential for pulmonary vasodilators like LIQREV to worsen the cardiovascular status of such patients. The drug itself is associated with the risk of worsening pulmonary vascular occlusive disease, particularly in patients with PVOD (5.2).

3. The drug label mentions that LIQREV may cause vaso-occlusive crises in patients with pulmonary hypertension secondary to sickle cell disease. LIQREV is linked to an increased risk of vaso-occlusive crises in this specific patient population. The effectiveness and safety of LIQREV in treating pulmonary hypertension secondary to sickle cell disease have not been established (5.8).

4. Postmarketing experience with sildenafil, the active ingredient in LIQREV, indicated serious cardiovascular, cerebrovascular, and vascular events, including myocardial infarction, sudden cardiac death, and ventricular arrhythmia. These events were reported in temporal association with the use of sildenafil, suggesting a potential cardiotoxicity risk associated with the drug (12.3).

5. In patients with systemic hypertension, chronic dosing of sildenafil 80 mg three times a day resulted in reductions in systolic and diastolic blood pressures. LIQREV, containing sildenafil, is associated with these reductions in blood pressure, indicating a potential cardiotoxicity risk related to changes in blood pressure (12.2).",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",13fb930a-fc46-4e0d-8d05-39162c156714,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=13fb930a-fc46-4e0d-8d05-39162c156714&type=display
978,SILODOSIN,"1. The drug RAPAFLO, a selective alpha-1 adrenergic receptor antagonist, is indicated for the treatment of benign prostatic hyperplasia (BPH) and is not associated with the treatment of hypertension. (No cardiotoxicity risk mentioned)

2. Postural hypotension, including dizziness, may occur when starting RAPAFLO treatment, potentially leading to syncope, cautioning patients about activities requiring alertness. (RAPAFLO may cause postural hypotension but not directly cardiotoxicity)

3. No specific cardiotoxicity risks or reactions were mentioned in the drug label for RAPAFLO. (No cardiotoxicity risk mentioned)

Overall, the drug label for RAPAFLO does not highlight any direct cardiotoxicity risks or reactions associated with the use of the medication.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",da0314f6-b1d6-44ee-8b1e-f763dbb8613f,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=da0314f6-b1d6-44ee-8b1e-f763dbb8613f&type=display
979,SIMVASTATIN,"1. ZOCOR is indicated to reduce the risk of total mortality by reducing the risk of coronary heart disease death, non-fatal myocardial infarction, and stroke in adults with established coronary heart disease, cerebrovascular disease, peripheral vascular disease, and/or diabetes, who are at high risk of coronary heart disease events. (The drug itself is associated with reducing the risk of cardiotoxic events.)

2. ZOCOR may cause myopathy and rhabdomyolysis, with risk factors including age 65 years or greater, uncontrolled hypothyroidism, renal impairment, concomitant use with certain other drugs, and higher ZOCOR dosage. Chinese patients may be at higher risk for myopathy. (The drug itself is associated with the risk of myopathy and rhabdomyolysis.)

3. In clinical studies, ZOCOR-treated patients had incidences of myopathy and rhabdomyolysis, with higher incidences observed with higher ZOCOR dosages. (The drug itself is associated with the risk of myopathy and rhabdomyolysis.)

4. ZOCOR has been associated with elevations in liver enzyme tests, with moderate elevations reported and persistent increases in some cases. Rare postmarketing reports of fatal and non-fatal hepatic failure have occurred in patients taking statins, including ZOCOR. (The drug itself is associated with hepatic dysfunction.)

5. ZOCOR has been linked to increases in HbA1c and fasting serum glucose levels, which have been reported with statins, including ZOCOR. Lifestyle measures are recommended to optimize these levels. (The drug itself is associated with increases in HbA1c and fasting serum glucose levels.)

6. ZOCOR is a substrate of CYP3A4 and OATP1B1, and its exposure can be significantly increased with concomitant administration of inhibitors of CYP3A4 and OATP1B1, leading to an increased risk of myopathy and rhabdomyolysis. (The drug itself is associated with an increased risk of myopathy and rhabdomyolysis when used with certain drugs.)

7. ZOCOR may potentiate the effect of coumarin anticoagulants and increase the INR, which can lead to clinically evident bleeding. (The drug itself is associated with an increased risk of bleeding when used with coumarin anticoagulants.)",Less,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",8f55d5de-5a4f-4a39-8c84-c53976dd6af9,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8f55d5de-5a4f-4a39-8c84-c53976dd6af9&type=display
980,SINCALIDE,1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with Sincalide for Injection.,No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",efbc189e-f5f8-0ac7-e053-2995a90a68a9,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=efbc189e-f5f8-0ac7-e053-2995a90a68a9&type=display
981,SIPONIMOD,"1. The drug MAYZENT is associated with cardiotoxicity risks, including bradyarrhythmia and atrioventricular conduction delays, due to its transient decrease in heart rate upon initiation of treatment. First-dose monitoring is recommended for patients with specific preexisting cardiac conditions, such as sinus bradycardia, first- or second-degree AV block, or a history of myocardial infarction or heart failure.

2. MAYZENT may result in transient atrioventricular conduction delays, such as first-degree AV block, which occurred in a small percentage of patients in clinical trials. These conduction abnormalities were typically asymptomatic, transient, and did not require discontinuation of MAYZENT treatment.

3. Patients with certain preexisting cardiac conditions, such as significant QT prolongation, arrhythmias requiring specific anti-arrhythmic drugs, or history of heart conditions, should seek advice from a cardiologist before initiating MAYZENT treatment to determine the most appropriate monitoring strategy.

4. The drug MAYZENT was not studied in patients with recent myocardial infarction, unstable angina, stroke, TIA, decompensated heart failure, or certain cardiac conduction disorders, and is contraindicated in these patients due to potential cardiotoxicity risks.

5. Significant bradycardia may be poorly tolerated in patients with specific medical conditions, and MAYZENT is not recommended in these cases. If treatment is considered, consultation with a cardiologist is advised to assess the benefit-risk profile and determine appropriate monitoring strategies.

6. Concomitant use of MAYZENT with drugs that decrease heart rate, such as beta-blockers, calcium channel blockers, or other heart rate-lowering medications, may lead to severe bradycardia and heart block, emphasizing the importance of careful monitoring and consultation with healthcare providers.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",44492772-5aed-4627-bd85-e8e89f308bb3,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=44492772-5aed-4627-bd85-e8e89f308bb3&type=display
982,SIROLIMUS,"1. The drug label warns that the use of Rapamune in liver transplant patients is not recommended due to potential adverse outcomes, including excess mortality, graft loss, and hepatic artery thrombosis (HAT), which were associated with the use of Rapamune in combination with tacrolimus in liver transplant patients. (The drug itself was associated with the cardiotoxicity risk in liver transplant patients.)

2. In lung transplant patients, cases of bronchial anastomotic dehiscence, most of which were fatal, have been reported when Rapamune was used as part of an immunosuppressive regimen. The safety and efficacy of Rapamune in lung transplant patients have not been established, and its use is not recommended. (The drug itself was associated with the cardiotoxicity risk in lung transplant patients.)

3. Rapamune has been associated with the development of angioedema, and the concomitant use of Rapamune with other drugs known to cause angioedema, such as angiotensin-converting enzyme (ACE) inhibitors, may increase the risk of developing angioedema. Elevated sirolimus levels may also potentiate angioedema. (The drug itself was associated with the risk of angioedema, which can be considered a cardiotoxicity reaction.)

4. Reports of impaired or delayed wound healing, including lymphocele and wound dehiscence, have been observed in patients receiving Rapamune. This may be due to the inhibition of certain growth factors affecting angiogenesis, fibroblast proliferation, and vascular permeability. (The drug itself was associated with impaired wound healing, which can indirectly impact cardiovascular health.)

5. There have been reports of fluid accumulation, including peripheral edema, lymphedema, pleural effusion, ascites, and pericardial effusions in patients receiving Rapamune. Some cases required intervention due to hemodynamically significant effusions and tamponade. (The drug itself was associated with fluid accumulation, which can lead to cardiovascular complications.)",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",3275b824-3f82-4151-2ab2-0036a9ba0acc,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=3275b824-3f82-4151-2ab2-0036a9ba0acc&type=display
983,SITAGLIPTIN,"1. ZITUVIO, a dipeptidyl peptidase-4 (DPP-4) inhibitor, is associated with heart failure risks observed with other DPP-4 inhibitors. Consider risks and benefits in patients with known risk factors for heart failure and monitor for signs and symptoms during therapy. Evaluate and manage heart failure symptoms according to standard care and consider discontinuation of ZITUVIO if needed.

2. ZITUVIO has been linked to acute renal failure, including cases requiring dialysis, as reported postmarketing. Assessment of renal function is recommended before initiating ZITUVIO and periodically thereafter. Dosage adjustment is advised for patients with moderate or severe renal impairment and those with end-stage renal disease (ESRD) on dialysis.

3. ZITUVIO, when used in combination with insulin or insulin secretagogues, may increase the risk of hypoglycemia. Lower doses of insulin or insulin secretagogue may be necessary to reduce the risk of hypoglycemia when used with ZITUVIO.

4. ZITUVIO has been associated with severe and disabling arthralgia in patients taking DPP-4 inhibitors. Consider discontinuing the drug if severe joint pain is observed.

5. Postmarketing reports have linked DPP-4 inhibitors, including ZITUVIO, to bullous pemphigoid cases requiring hospitalization. Patients should be advised to report any development of blisters or erosions, and ZITUVIO should be discontinued if bullous pemphigoid is suspected. Referral to a dermatologist for diagnosis and treatment may be necessary.",Less,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",abfdea45-c0ca-41e3-a510-e89810bc9cfe,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=abfdea45-c0ca-41e3-a510-e89810bc9cfe&type=display
984,SODIUM ACETATE,"1. **Warnings**: The drug label warns that solutions containing sodium ions should be used with great care in patients with congestive heart failure, severe renal insufficiency, and edema with sodium retention, suggesting that the drug itself may exacerbate these conditions and pose a cardiotoxicity risk.

2. **Precautions**: Caution is advised in administering sodium-containing solutions to patients with severe renal function impairment, cirrhosis, cardiac failure, or other edematous or sodium-retaining states, indicating that the drug may contribute to cardiotoxicity in these patient populations.

3. **Adverse Reactions**: The label mentions that sodium overload can occur with intravenous infusion of excessive amounts of sodium-containing solutions, implying that the drug can lead to cardiotoxicity reactions such as sodium overload and associated complications.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",c3be2468-45e8-4ecc-a30b-e966743a563f,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=c3be2468-45e8-4ecc-a30b-e966743a563f&type=display
985,SODIUM CHLORIDE,"1. **Contraindications**: The drug label mentions that the solutions are contraindicated where the administration of sodium or chloride could be clinically detrimental. This indicates that the drug itself is associated with a cardiotoxicity risk due to the potential detrimental effects of sodium or chloride administration on the cardiovascular system.

2. **Warnings**: The label warns that the administration of intravenous solutions can lead to fluid and/or solute overload, resulting in dilution of serum electrolyte concentrations, overhydration, congested states, or pulmonary edema. It further states that solutions containing sodium ions should be used with great care in patients with congestive heart failure, severe renal insufficiency, and sodium retention with edema. This suggests that the drug itself is associated with cardiotoxicity risks, especially in patients with specific conditions like congestive heart failure and renal insufficiency.

3. **Precautions**: The label advises caution in administering solutions containing sodium to patients with renal or cardiovascular insufficiency, particularly in postoperative or elderly patients. It also mentions that infusion of more than one liter of isotonic sodium chloride per day may result in hypernatremia and an acidifying effect. This indicates that the drug itself poses cardiotoxicity risks, especially in patients with impaired renal function or those receiving corticosteroids.

4. **Adverse Reactions**: The label mentions that reactions due to the solution or administration technique may include hypervolemia, which can lead to congested states. It also warns about the possibility of adverse reactions to drug additives. This suggests that the drug itself may contribute to cardiotoxicity reactions such as hypervolemia and congested states.

In summary, the drug label indicates that the administration of sodium chloride injections can pose cardiotoxicity risks, especially in patients with specific conditions like congestive heart failure, renal insufficiency, and sodium retention. The drug itself is associated with potential adverse effects on the cardiovascular system, including fluid overload, electrolyte imbalances, and congested states.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",7f22c06b-6b4d-4b49-a4b2-d2169f2bd653,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7f22c06b-6b4d-4b49-a4b2-d2169f2bd653&type=display
986,SODIUM FERRIC GLUCONATE COMPLEX,"1. Cardiotoxicity Risks:
- Ferrlecit is associated with potential cardiotoxicity risks, as indicated by reported adverse reactions such as chest pain, hypertension, syncope, tachycardia, bradycardia, vasodilatation, angina pectoris, and myocardial infarction in adult patients during clinical trials. These reactions suggest a possible cardiotoxicity risk associated with Ferrlecit use.

2. Cardiotoxicity Reactions:
- Ferrlecit has been linked to cardiotoxicity reactions, including hypotension, hypertension, syncope, tachycardia, and bradycardia, as reported in clinical trials involving adult patients. These reactions indicate a direct association between Ferrlecit administration and potential cardiotoxic effects.

3. Cardiotoxicity Risks in Pediatrics:
- In pediatric patients aged 6 to 15 years receiving Ferrlecit, adverse reactions such as hypotension, headache, hypertension, tachycardia, and vomiting were reported, suggesting potential cardiotoxicity risks associated with Ferrlecit use in this population.

4. Cardiotoxicity Reactions in Pediatrics:
- Pediatric patients receiving Ferrlecit may experience cardiotoxicity reactions, including hypotension, tachycardia, fever, headache, abdominal pain, nausea, vomiting, pharyngitis, diarrhea, infection, rhinitis, and thrombosis, as observed in clinical trials. These reactions highlight the potential cardiotoxic effects of Ferrlecit in pediatric populations.

Overall, the drug label for Ferrlecit indicates that both adult and pediatric patients may be at risk of experiencing cardiotoxicity reactions, including various cardiovascular symptoms, during treatment with Ferrlecit. It is essential for healthcare providers to monitor patients for signs of cardiotoxicity and manage these potential risks appropriately.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",1fe028ff-42ac-4329-b1a5-a9dadfcb79f6,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=1fe028ff-42ac-4329-b1a5-a9dadfcb79f6&type=display
987,SODIUM FLUORIDE F 18,"1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with Sodium Fluoride F 18 Injection USP.
2. No information is provided regarding any cardiotoxicity risks or reactions linked to the use of Sodium Fluoride F 18 Injection USP in the drug label.
3. There are no references to cardiotoxicity risks or reactions related to Sodium Fluoride F 18 Injection USP in the drug label.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",e435568c-f8d2-4cee-aceb-c68b277ad8f5,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=e435568c-f8d2-4cee-aceb-c68b277ad8f5&type=display
988,SODIUM IODIDE I 123,1. The drug label does not mention any cardiotoxicity risks or cardiotoxicity reactions associated with Sodium Iodide I 123.,No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",50415c27-1928-4307-b1dc-648f47edf65d,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=50415c27-1928-4307-b1dc-648f47edf65d&type=display
989,SODIUM IODIDE I-131,"1. The drug Sodium Iodide I-131 is associated with cardiotoxicity risks, as it may cause or worsen hyperthyroidism and thyrotoxic cardiac disease, leading to radiation-induced thyroiditis. The drug itself is linked to the risk of radiation-induced thyroiditis, which can result in the release of thyroid hormone and subsequent cardiac issues.

2. Sodium Iodide I-131 may also cause radiation-induced toxicities, including dose-dependent fatalities such as bone marrow suppression and malignancy, which can lead to hematopoietic suppression manifesting as thrombocytopenia or neutropenia. The drug is directly associated with the risk of radiation-induced toxicities, which can impact the cardiovascular system and overall health.

3. Additionally, sodium Iodide I-131 has been reported to cause hypersensitivity reactions, including anaphylaxis, which may affect the cardiovascular system. While iodide itself is not considered an allergen, the drug may trigger hypersensitivity reactions related to its components, potentially impacting cardiac function.

4. Postmarketing experience has shown that sodium Iodide I-131 can lead to cardiac disorders such as chest pain and tachycardia, indicating potential cardiotoxicity reactions associated with the drug. These adverse reactions, reported voluntarily, suggest a possible link between the drug and cardiac issues in patients who have received Sodium Iodide I-131 therapy.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",380e8e26-0625-4233-b36e-afb9f66e8a77,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=380e8e26-0625-4233-b36e-afb9f66e8a77&type=display
990,SODIUM IOTHALAMATE I-125 INJECTION,"1. The drug label does not mention any specific cardiotoxicity risks associated with Glofil-125.
2. The drug label does not report any cardiotoxicity reactions linked to the use of Glofil-125.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",7f250086-2837-484b-9674-e09856b34cb0,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7f250086-2837-484b-9674-e09856b34cb0&type=display
991,SODIUM NITRITE,"1. Sodium nitrite can cause serious adverse reactions and death in humans, including hypotension and methemoglobin formation, which diminishes oxygen carrying capacity. The drug itself is associated with the risk of hypotension and methemoglobin formation.

2. Sodium nitrite has been associated with severe hypotension, methemoglobinemia, and death at doses less than twice the recommended therapeutic doses. The drug itself is associated with the risk of severe hypotension and methemoglobinemia.

3. Severe hypotension, methemoglobinemia, cardiac dysrhythmias, coma, and death have been reported in patients without life-threatening cyanide poisoning but who were treated with sodium nitrite at doses less than twice those recommended for the treatment of cyanide poisoning. The drug itself is associated with the risk of severe hypotension, methemoglobinemia, cardiac dysrhythmias, coma, and death.

4. Sodium nitrite administration has been reported to cause or significantly contribute to mortality in adults at oral doses as low as 1 g and intravenous doses as low as 600 mg. The drug itself is associated with the risk of mortality at certain doses.

5. Cyanosis may become apparent at a methemoglobin level of 10-20%, and other clinical signs and symptoms of sodium nitrite toxicity can be apparent at methemoglobin levels as low as 15%. The drug itself is associated with the risk of cyanosis and other signs of toxicity at specific methemoglobin levels.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",52f01c6e-172a-47a9-98a6-9eab7651a032,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=52f01c6e-172a-47a9-98a6-9eab7651a032&type=display
992,SODIUM NITROPRUSSIDE,"1. **Cardiotoxicity Risk**: The drug label warns of excessive hypotension caused by Sodium Nitroprusside, which can lead to irreversible ischemic injuries or death. The drug itself is associated with the risk of excessive hypotension leading to cardiotoxicity.

2. **Cardiotoxicity Risk**: Sodium nitroprusside metabolism produces dose-related cyanide, which can be lethal. The drug itself is associated with the risk of cyanide toxicity, which can lead to cardiotoxicity.

3. **Cardiotoxicity Reaction**: The most common adverse reactions include hypotension and cyanide toxicity. The drug itself is associated with causing hypotension and cyanide toxicity, both of which can have cardiotoxic effects.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",5acf0836-93ff-4064-b888-3f560e8a558d,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=5acf0836-93ff-4064-b888-3f560e8a558d&type=display
993,SODIUM OXYBATE,"1. The drug label mentions that LUMRYZ has a high sodium content, and patients sensitive to sodium intake, such as those with heart failure, hypertension, or impaired renal function, should consider the amount of daily sodium intake in each dose of LUMRYZ. This indicates that the drug itself is associated with a cardiotoxicity risk due to its high sodium content.

2. The label also states that in a study where sodium oxybate was orally administered to pregnant rats throughout pregnancy and lactation, it resulted in increased stillbirths and decreased offspring postnatal viability and growth at a clinically relevant dose. This suggests that the drug itself may have cardiotoxic effects on offspring viability and growth when exposed during pregnancy and lactation.

3. Additionally, the label mentions that in a juvenile animal toxicity study where sodium oxybate was orally administered to rats during the juvenile period of development, mortality was observed at higher doses, along with reduced body weight gain and delayed sexual maturation. This indicates that the drug itself may have cardiotoxic effects on juvenile rats, leading to mortality and developmental issues.

Overall, the drug label suggests that LUMRYZ, specifically sodium oxybate, is associated with cardiotoxicity risks and reactions, particularly in relation to sodium intake, pregnancy, lactation, and juvenile development.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",10e5e40c-52f3-4c73-8a34-2c29c690a934,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=10e5e40c-52f3-4c73-8a34-2c29c690a934&type=display
994,SODIUM PHENYLBUTYRATE,1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with PHEBURANE.,No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",d15f2cbf-4d22-40b5-8ef9-16b9d323a7f9,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=d15f2cbf-4d22-40b5-8ef9-16b9d323a7f9&type=display
995,SODIUM POLYSTYRENE SULFONATE,"1. **Cardiotoxicity Risk**: The drug label warns that serious potassium deficiency can occur from sodium polystyrene sulfonate therapy, which may lead to severe hypokalemia. The drug itself is associated with the risk of causing serious potassium deficiency, leading to cardiotoxicity.

2. **Cardiotoxicity Risk**: The label mentions that hypokalemia can result in various cardiac arrhythmias, such as premature atrial, nodal, and ventricular contractions, as well as tachycardias. The drug itself is associated with the risk of causing hypokalemia, which can lead to cardiotoxic effects.

3. **Cardiotoxicity Risk**: It is stated that marked hypokalemia can manifest as severe muscle weakness, paralysis, and cardiac arrhythmias, with potential exaggeration of the toxic effects of digitalis. The drug itself is associated with the risk of causing marked hypokalemia, leading to cardiotoxic manifestations.

4. **Cardiotoxicity Reaction**: The label warns that electrocardiographic changes consistent with hypokalemia or hypocalcemia, as well as cardiac arrhythmias, may occur in cases of overdosage with sodium polystyrene sulfonate. The drug itself is associated with the potential to cause cardiotoxic reactions in cases of overdosage.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",676c3d81-d575-43f6-8748-e04b7c0cafeb,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=676c3d81-d575-43f6-8748-e04b7c0cafeb&type=display
996,SODIUM TETRADECYL SULFATE,"1. The drug label mentions that severe adverse local effects, including tissue necrosis, may occur following extravasation of Sotradecol, indicating that the drug itself is associated with the risk of local tissue damage.
   
2. The label warns about the potential for allergic reactions, including fatal anaphylaxis, which have been reported with the use of Sotradecol. This indicates that the drug itself can lead to cardiotoxic reactions such as anaphylactic shock.

3. It is noted that cerebrovascular accidents, myocardial infarctions, and other cardiac events have been reported in close temporal relationship with the administration of Sotradecol, suggesting that the drug itself may be associated with cardiotoxicity reactions.

4. The label also mentions that arterial embolism, including stroke, transient ischemic attack, and impaired cardiac function, have been reported with the use of Sotradecol, especially when the product is foamed with room air. This indicates that the drug itself can lead to arterial embolism and cardiotoxic events.

5. Additionally, the development of deep vein thrombosis and pulmonary embolism has been reported following sclerotherapy treatment with Sotradecol, suggesting that the drug itself may contribute to cardiotoxic complications such as embolism.

Overall, the drug label highlights several instances where Sotradecol is associated with cardiotoxicity risks and reactions, including local tissue damage, allergic reactions, arterial embolism, and cardiac events like myocardial infarction and stroke.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",c76f4b3b-9f93-349f-e053-2995a90a2d57,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=c76f4b3b-9f93-349f-e053-2995a90a2d57&type=display
997,SODIUM THIOSULFATE,"1. The drug label mentions that the most common adverse reactions associated with the drug include hypotension, headache, and disorientation. This suggests that the drug itself may be associated with cardiotoxicity risks.

2. The label also states that sodium thiosulfate may contain trace impurities of sodium sulfite. While this does not directly indicate cardiotoxicity risks, sulfites can sometimes trigger adverse reactions in individuals with sensitivities, potentially affecting cardiovascular health.

3. Additionally, the label advises monitoring blood pressure during treatment, which implies a potential risk of hypotension or other cardiovascular effects associated with the drug.

Overall, the drug label suggests that sodium thiosulfate may pose cardiotoxicity risks, as indicated by the reported adverse reactions and the need for monitoring blood pressure during treatment.",Less,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",82f55408-2de9-463d-85e8-b39c3b259f0b,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=82f55408-2de9-463d-85e8-b39c3b259f0b&type=display
998,SODIUM ZIRCONIUM CYCLOSILICATE,1. The drug label for LOKELMA does not mention any cardiotoxicity risks or cardiotoxicity reactions associated with the use of the drug.,No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",90bf8e28-748d-4e4b-a19f-9cf483370eff,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=90bf8e28-748d-4e4b-a19f-9cf483370eff&type=display
999,SOFOSBUVIR,"1. The drug label warns of a serious risk of symptomatic bradycardia when SOVALDI is coadministered with amiodarone, particularly in patients also taking beta blockers or with underlying cardiac comorbidities and/or advanced liver disease. Coadministration of amiodarone with SOVALDI is not recommended, and cardiac monitoring is advised due to the potential for serious symptomatic bradycardia. (The drug itself is not associated with cardiotoxicity but rather the coadministration with amiodarone poses the risk.)

2. The drug label mentions that postmarketing cases of symptomatic bradycardia, including cases requiring pacemaker intervention, have been reported when amiodarone is coadministered with a sofosbuvir-containing regimen. A fatal cardiac arrest was reported in a patient taking amiodarone coadministered with a sofosbuvir-containing regimen. Bradycardia generally occurred within hours to days, but cases have been observed up to 2 weeks after initiating HCV treatment. (The drug itself is not directly associated with cardiotoxicity, but the coadministration with amiodarone is linked to the risk.)

3. The drug label advises that patients taking amiodarone who have no alternative treatment options and need to be coadministered with SOVALDI should undergo cardiac monitoring in an in-patient setting for the first 48 hours of coadministration, followed by outpatient or self-monitoring of the heart rate for at least the first 2 weeks of treatment. Patients who develop signs or symptoms of bradycardia should seek immediate medical evaluation. (The drug itself is not the cause of cardiotoxicity, but the coadministration with amiodarone requires careful monitoring.)

In summary, SOVALDI itself is not directly associated with cardiotoxicity risks, but the coadministration of amiodarone with SOVALDI poses a serious risk of symptomatic bradycardia, which can lead to severe cardiac events. Monitoring and caution are advised when these medications are used together.",Less,No,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",80beab2c-396e-4a37-a4dc-40fdb62859cf,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=80beab2c-396e-4a37-a4dc-40fdb62859cf&type=display
1000,SOLIFENACIN SUCCIATE; SOLIFENACIN SUCCINATE,"1. The drug Solifenacin Succinate Tablets, a muscarinic antagonist, was evaluated for its effect on the QT interval in a study involving healthy women. The study found that the highest dose of solifenacin succinate was associated with a mean increase in the Fridericia-corrected QT interval, indicating a potential risk of QT prolongation. (Drug-associated cardiotoxicity risk)

2. The label mentions that solifenacin succinate is a competitive muscarinic receptor antagonist, which plays a role in cholinergically mediated functions, including contractions of urinary bladder smooth muscle. This mechanism of action does not directly indicate a cardiotoxicity risk. (No direct cardiotoxicity risk mentioned)

3. In a study evaluating the effect of solifenacin succinate on the QT interval, it was found that the drug at a higher dose was associated with QT prolongation, although the effect was less than that of the positive control moxifloxacin. The study was not designed to draw direct statistical conclusions between the drugs or the dose levels. (Drug-associated cardiotoxicity risk)

4. The label also mentions that solifenacin succinate is extensively metabolized in the liver, primarily through CYP3A4, with alternate metabolic pathways. The label does not directly link this metabolic process to cardiotoxicity risks. (No direct cardiotoxicity risk mentioned)

5. The label includes information on the pharmacokinetics of solifenacin succinate, such as its absorption, distribution, metabolism, and elimination. While these details provide insights into how the drug is processed in the body, they do not specifically address cardiotoxicity risks. (No direct cardiotoxicity risk mentioned)",Less,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",d155c739-6870-4938-ba91-8c1b4b90afe4,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=d155c739-6870-4938-ba91-8c1b4b90afe4&type=display
1001,SOLRIAMFETOL,"1. **Blood Pressure and Heart Rate Increases**: SUNOSI is associated with increases in systolic blood pressure, diastolic blood pressure, and heart rate in a dose-dependent manner. The drug itself is linked to these cardiovascular effects, which can pose risks, especially in patients with underlying cardiovascular conditions or hypertension.

2. **Psychiatric Symptoms**: SUNOSI has been associated with psychiatric adverse reactions, including anxiety, insomnia, and irritability. The drug itself is linked to the emergence or exacerbation of psychiatric symptoms, particularly in patients with a history of psychosis or bipolar disorders.

3. **Adverse Reactions**: The most common adverse reactions reported with SUNOSI include headache, nausea, decreased appetite, anxiety, and insomnia. While not directly labeled as cardiotoxicity reactions, the drug's impact on blood pressure and heart rate can indirectly affect cardiovascular health and warrant monitoring for potential cardiotoxic effects.

4. **Warnings and Precautions**: SUNOSI increases blood pressure and heart rate, which can elevate the risk of major adverse cardiovascular events (MACE) such as stroke, heart attack, and cardiovascular death. The drug itself is associated with these cardiovascular risks, particularly in patients with multiple risk factors for MACE, pre-existing hypertension, or cardiovascular disease.

5. **Drug Interactions**: Caution is advised when co-administering SUNOSI with other drugs that increase blood pressure and/or heart rate. While not directly stating cardiotoxicity risks, the potential interactions with drugs affecting blood pressure and heart rate highlight the importance of monitoring for cardiotoxic effects when combining medications with SUNOSI.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",362f206b-73e7-4009-8c34-5a9df55679ab,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=362f206b-73e7-4009-8c34-5a9df55679ab&type=display
1002,SONIDEGIB,"1. The drug ODOMZO, a hedgehog pathway inhibitor, does not prolong the QTc interval at a dose of 800 mg once daily, indicating no direct association with cardiotoxicity.
   
2. Sonidegib, the active ingredient in ODOMZO, exhibited dose-proportional increases in AUC and Cmax over a certain dose range, but less than dose-proportional increases at higher doses, suggesting no direct cardiotoxicity risk.

3. In clinical studies, ODOMZO did not show any significant cardiac electrophysiological effects at the recommended dose of 200 mg once daily, indicating no direct cardiotoxicity concerns.

4. The drug ODOMZO was not associated with any clinically meaningful effects on sonidegib exposure when coadministered with acid-reducing agents, further supporting its minimal cardiotoxicity risk.

Overall, the drug label does not indicate any direct association between ODOMZO and cardiotoxicity risks or reactions based on the provided information.",Less,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",028312dc-d155-4fd5-8abd-6bb9f011d3cc,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=028312dc-d155-4fd5-8abd-6bb9f011d3cc&type=display
1003,SORAFENIB,"1. **Cardiovascular Events**: The drug NEXAVAR is associated with cardiovascular events, including cardiac ischemia/infarction, with an incidence higher in NEXAVAR-treated patients compared to those on placebo in studies for hepatocellular carcinoma (HCC), renal cell carcinoma (RCC), and differentiated thyroid carcinoma (DTC).

2. **Hemorrhage**: While NEXAVAR administration may increase the risk of bleeding, the incidence of bleeding events was similar in NEXAVAR-treated patients and those on placebo in studies for HCC, RCC, and DTC.

3. **Hypertension**: NEXAVAR is linked to hypertension, with higher rates in NEXAVAR-treated patients compared to placebo in HCC, RCC, and DTC studies. The hypertension was usually mild to moderate and manageable with antihypertensive therapy.

4. **QT Interval Prolongation**: NEXAVAR can prolong the QT/QTc interval, increasing the risk of ventricular arrhythmias. Patients with certain conditions or on specific medications known to prolong QT interval should avoid NEXAVAR, and monitoring of electrolytes and ECGs is recommended.

5. **Impaired Wound Healing**: NEXAVAR has the potential to impair wound healing due to its inhibition of the VEGF signaling pathway. Patients should withhold NEXAVAR before elective surgery and until adequate wound healing post-surgery, as the safety of resuming NEXAVAR after wound healing complications is not established.

6. **Increased Mortality in Squamous Cell Lung Cancer**: In patients with squamous cell lung cancer, NEXAVAR administered in combination with carboplatin/paclitaxel was associated with increased mortality compared to carboplatin/paclitaxel alone. Therefore, this combination is contraindicated in squamous cell lung cancer patients.

7. **Drug-Induced Liver Injury**: NEXAVAR may cause drug-induced liver injury, characterized by hepatocellular liver damage. Regular monitoring of liver function tests is recommended, and NEXAVAR should be discontinued in cases of unexplained transaminase elevations.

8. **Embryo-Fetal Toxicity**: NEXAVAR may cause fetal harm when administered to pregnant women based on animal studies. Effective contraception is advised for females of reproductive potential during NEXAVAR treatment and for a specified period after the last dose.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",b50667e4-5ebc-4968-a646-d605058dbef0,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=b50667e4-5ebc-4968-a646-d605058dbef0&type=display
1004,SOTALOL HYDROCHLORIDE,"1. **Cardiotoxicity Risk**: Sotalol can cause life-threatening ventricular tachycardia associated with QT interval prolongation. This risk is directly associated with the drug itself.

2. **Cardiotoxicity Risk**: Sotalol can cause serious and potentially fatal ventricular arrhythmias such as sustained VT/VF, primarily Torsade de Pointes (TdP). Factors such as reduced creatinine clearance, female sex, higher doses, reduced heart rate, and history of sustained VT/VF or heart failure increase the risk of TdP. The risk of TdP can be reduced by adjusting the sotalol dose according to creatinine clearance and monitoring the ECG for excessive increases in the QT interval. This risk is directly associated with the drug itself.

3. **Cardiotoxicity Reaction**: The most common adverse reactions leading to discontinuation of oral sotalol were fatigue, bradycardia, proarrhythmia, dyspnea, and QT interval prolongation. These reactions are associated with the use of sotalol and its cardiotoxic effects.

4. **Cardiotoxicity Reaction**: In cases of massive intentional overdosage of sotalol, clinical findings included hypotension, bradycardia, cardiac asystole, prolongation of QT interval, Torsade de Pointes, ventricular tachycardia, and premature ventricular complexes. These reactions are associated with the use of sotalol and its cardiotoxic effects.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",1f33f900-0777-4a92-a7f7-00cf3d57d95c,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=1f33f900-0777-4a92-a7f7-00cf3d57d95c&type=display
1005,SOTORASIB,"1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with LUMAKRAS (sotorasib). 

2. The drug label states that at the approved recommended dosage, LUMAKRAS does not cause large mean increases in the QTc interval (> 20 msec), indicating that the drug itself is not associated with significant cardiotoxicity risks related to QT prolongation. 

Therefore, based on the information provided in the drug label, LUMAKRAS (sotorasib) does not appear to be associated with cardiotoxicity risks or cardiotoxic reactions.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",c80a362c-7ac3-4894-a076-0691e68ef8c1,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=c80a362c-7ac3-4894-a076-0691e68ef8c1&type=display
1006,SOYBEAN OIL,"1. **Warnings and Precautions (5.1):** The drug label mentions that rapid infusion of intravenous lipid emulsions, including Nutrilipid 20%, in neonates and infants has been associated with acute respiratory distress, metabolic acidosis, and death. This indicates that the rapid infusion of the drug itself has been linked to cardiotoxicity risks in this specific patient population.

2. **Warnings and Precautions (5.2):** The label states that patients receiving parenteral nutrition, especially preterm neonates, are at an increased risk of parenteral nutrition-associated liver disease (PNALD), which can progress to liver complications. While this does not directly mention cardiotoxicity, liver complications can impact overall health, including cardiac function, indirectly suggesting a potential cardiotoxicity risk associated with the drug in patients developing PNALD.

3. **Warnings and Precautions (5.5):** The label discusses fat overload syndrome, a rare condition associated with intravenous lipid formulations, characterized by a sudden deterioration in the patient's condition, including coagulation disorders and hepatomegaly. This suggests that the drug may contribute to cardiotoxicity risks through the development of coagulation disorders and potential liver involvement, which can impact cardiac function.

4. **Warnings and Precautions (5.7):** The drug label indicates that patients with hypertriglyceridemia, a condition where serum triglyceride levels exceed 1,000 mg/dL, are contraindicated for Nutrilipid 20%. It highlights the risk of pancreatitis and other complications associated with hypertriglyceridemia, indirectly suggesting a potential cardiotoxicity risk due to the impact of elevated triglyceride levels on cardiovascular health.

5. **Warnings and Precautions (5.9):** The label mentions the need to monitor fluid status closely in patients with pulmonary edema or heart failure, indicating a potential risk of fluid overload-related cardiotoxicity with the drug. Additionally, it advises monitoring serum triglycerides, which, if elevated, can lead to complications like pancreatitis, impacting cardiovascular health.",Less,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",193290b1-a0a1-4054-a22a-de5c9e7a8b73,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=193290b1-a0a1-4054-a22a-de5c9e7a8b73&type=display
1007,SPIRONOLACTONE,"1. **Cardiotoxicity Risk**: The drug ALDACTONE is indicated for the treatment of heart failure, which includes NYHA Class IIIIV heart failure and reduced ejection fraction to increase survival, manage edema, and reduce the need for hospitalization for heart failure. (The drug itself is not associated with cardiotoxicity risk in this context.)

2. **Cardiotoxicity Risk**: ALDACTONE is also indicated as an add-on therapy for the treatment of hypertension to lower blood pressure, reducing the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. (The drug itself is not associated with cardiotoxicity risk in this context.)

3. **Cardiotoxicity Reaction**: The most common adverse reaction with ALDACTONE treatment is gynecomastia. In the RALES study, about 9% of male subjects developed gynecomastia when treated with spironolactone. The risk of gynecomastia increases in a dose-dependent manner. (The drug itself is associated with the adverse reaction of gynecomastia, not cardiotoxicity.)

4. **Cardiotoxicity Risk**: ALDACTONE can cause hyperkalemia, which is a risk factor for cardiotoxicity. Patients with impaired renal function or those taking concomitant medications that increase potassium levels are at an increased risk of hyperkalemia. Monitoring of serum potassium levels is recommended to manage this risk. (The drug itself is associated with the risk of hyperkalemia, which can lead to cardiotoxicity.)

5. **Cardiotoxicity Reaction**: Excessive diuresis with ALDACTONE may lead to symptomatic dehydration, hypotension, and worsening renal function, particularly in salt-depleted patients or those taking certain medications. Worsening of renal function can also occur with concomitant use of nephrotoxic drugs. Monitoring of volume status and renal function is advised to prevent these adverse effects. (The drug itself is associated with the risk of worsening renal function, which can lead to cardiotoxicity.)

6. **Cardiotoxicity Reaction**: ALDACTONE can cause electrolyte and metabolic abnormalities, including hyponatremia, hypomagnesemia, hypocalcemia, hypochloremic alkalosis, and hyperglycemia. These abnormalities can impact cardiac function and lead to cardiotoxicity. Monitoring of serum electrolytes and blood glucose is recommended to manage these risks. (The drug itself is associated with the risk of electrolyte and metabolic abnormalities, which can contribute to cardiotoxicity.)",Less,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",0fed2822-3a03-4b64-9857-c682fcd462bc,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=0fed2822-3a03-4b64-9857-c682fcd462bc&type=display
1008,STAVUDINE,"1. **Cardiotoxicity Risk**: The drug label warns about lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, associated with the use of nucleoside analogues alone or in combination, including stavudine and other antiretrovirals. This risk is not directly attributed to stavudine alone but to nucleoside analogues in general.

2. **Cardiotoxicity Risk**: Fatal lactic acidosis has been reported in pregnant women who received the combination of stavudine and didanosine with other antiretroviral agents. The combination of stavudine and didanosine should be used with caution during pregnancy, and the potential benefit should outweigh the potential risk. This risk is associated with the combination of stavudine and didanosine, not stavudine alone.

3. **Cardiotoxicity Reaction**: The label mentions that cases of fatal and nonfatal pancreatitis have occurred during therapy when ZERIT was part of a combination regimen that included didanosine in both treatment-naive and treatment-experienced patients, regardless of the degree of immunosuppression. This reaction is associated with the combination of stavudine and didanosine, not stavudine alone.",Less,No,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",8bb73c56-74cb-4602-b9a3-57bd1082b434,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8bb73c56-74cb-4602-b9a3-57bd1082b434&type=display
1009,STERILE WATER FOR INJECTION,"1. The drug label does not specifically mention cardiotoxicity risks associated with Sterile Water for Injection, USP itself.

2. The label does not indicate that Sterile Water for Injection, USP is associated with cardiotoxicity reactions.

3. There is no mention in the drug label that Sterile Water for Injection, USP causes or is linked to cardiotoxicity risks.

4. The drug label does not attribute any cardiotoxicity reactions to Sterile Water for Injection, USP.

Overall, based on the information provided in the drug label, there are no references to cardiotoxicity risks or cardiotoxicity reactions associated with Sterile Water for Injection, USP.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",99e99a50-82d5-aff6-e053-2a95a90a8c56,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=99e99a50-82d5-aff6-e053-2a95a90a8c56&type=display
1010,STIRIPENTOL,"1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with DIACOMIT (stiripentol) itself. 

2. The drug label focuses on the treatment of seizures associated with Dravet syndrome and provides information on dosing, administration, adverse reactions, drug interactions, and use in specific populations. 

3. While the label includes warnings and precautions related to somnolence, decreased appetite and weight, neutropenia, thrombocytopenia, withdrawal symptoms, risks in patients with phenylketonuria, and suicidal behavior, there is no mention of cardiotoxicity risks or reactions specifically linked to DIACOMIT. 

4. The label emphasizes monitoring for various adverse reactions, including somnolence, agitation, weight changes, and hematologic abnormalities, but does not highlight any direct cardiotoxic effects associated with the use of DIACOMIT. 

5. Overall, the drug label does not attribute any cardiotoxicity risks or reactions to DIACOMIT (stiripentol) based on the information provided.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",58304ba8-9779-4658-811e-94ffe08c3f16,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=58304ba8-9779-4658-811e-94ffe08c3f16&type=display
1011,STREPTOMYCIN,"1. The drug label warns that the risk of severe neurotoxic reactions, including disturbances of vestibular and cochlear function, optic nerve dysfunction, peripheral neuritis, arachnoiditis, and encephalopathy, is sharply increased in patients with impaired renal function or pre-renal azotemia. The incidence of clinically detectable, irreversible vestibular damage is particularly high in patients treated with streptomycin. (The drug itself is associated with the risk of neurotoxic reactions, not specifically cardiotoxicity.)

2. The label advises that renal function should be monitored carefully, and patients with renal impairment and/or nitrogen retention should receive reduced doses. The peak serum concentration in individuals with kidney damage should not exceed 20 to 25 mcg/mL. (The drug itself is associated with the risk of neurotoxic reactions, not specifically cardiotoxicity.)

3. The label states that streptomycin can result in respiratory paralysis from neuromuscular blockage, especially when the drug is given soon after the use of anesthesia or muscle relaxants. The administration of streptomycin in parenteral form should be reserved for patients where adequate laboratory and audiometric testing facilities are available during therapy. (The drug itself is associated with the risk of respiratory paralysis, not specifically cardiotoxicity.)

4. The label mentions that streptomycin is the least nephrotoxic of the aminoglycosides, but nephrotoxicity can occur rarely. Clinical judgment as to termination of therapy must be exercised when side effects occur. (The drug itself is associated with the risk of nephrotoxicity, not specifically cardiotoxicity.)

5. The label further notes that streptomycin may cause vestibular ototoxicity, cochlear ototoxicity, and other adverse reactions such as paresthesia, rash, fever, urticaria, angioneurotic edema, and eosinophilia. Cochlear ototoxicity, deafness, and other reactions are less frequent but possible. (The drug itself is associated with the risk of ototoxicity, not specifically cardiotoxicity.)

6. The label advises that vestibular symptoms generally appear early and are usually reversible with early detection and cessation of streptomycin administration. Vestibular dysfunction resulting from streptomycin administration is cumulatively related to the total daily dose. (The drug itself is associated with the risk of vestibular dysfunction, not specifically cardiotoxicity.)

7. The label recommends that caloric and audiometric tests be done prior to, during, and following intensive therapy with streptomycin to facilitate the detection of any vestibular dysfunction and/or impairment of hearing that may occur. (The drug itself is associated with the risk of vestibular dysfunction and hearing impairment, not specifically cardiotoxicity.)

In summary, the drug label for streptomycin warns of various neurotoxic reactions, nephrotoxicity, and ototoxicity risks associated with the drug, but does not specifically mention cardiotoxicity as a known risk or reaction.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",abd1f64e-4283-4370-aae8-3666316aa36e,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=abd1f64e-4283-4370-aae8-3666316aa36e&type=display
1012,STREPTOZOCIN,"1. The drug label for ZANOSAR does not specifically mention cardiotoxicity risks or cardiotoxicity reactions associated with the use of this drug. The label primarily focuses on renal toxicity, gastrointestinal effects, hematological toxicity, metabolic abnormalities, and genitourinary issues as potential adverse reactions.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",15d161ed-9e7b-4c92-ba45-0556d2423e67,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=15d161ed-9e7b-4c92-ba45-0556d2423e67&type=display
1013,STRONTIUM CHLORIDE SR-89,"1. The drug label does not mention any specific cardiotoxicity risks associated with Strontium Chloride Sr-89 Injection.
2. No cardiotoxicity reactions related to the drug itself are mentioned in the drug label.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",c89bcf16-399d-48e0-a4e3-849261aaa310,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=c89bcf16-399d-48e0-a4e3-849261aaa310&type=display
1014,SUCCIMER,"1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with NEPHROSCAN (technetium Tc 99m succimer injection) itself.

2. The label does not indicate any direct association between NEPHROSCAN and cardiotoxicity risks or reactions.

3. NEPHROSCAN, after radiolabeling with technetium Tc 99m succimer, is primarily indicated for renal scintigraphic evaluation and does not mention any cardiotoxicity risks or reactions.

4. The drug label does not list any cardiotoxicity risks or reactions related to the use of NEPHROSCAN.

5. There is no mention of cardiotoxicity risks or reactions linked to NEPHROSCAN in the drug label.

Overall, based on the information provided in the drug label, NEPHROSCAN does not appear to be associated with cardiotoxicity risks or reactions.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",ddd90c4a-5792-49c9-837f-710d1a604742,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=ddd90c4a-5792-49c9-837f-710d1a604742&type=display
1015,SUCCINYLCHOLINE CHLORIDE,"1. The drug label warns of ventricular dysrhythmias, cardiac arrest, and death from hyperkalemic rhabdomyolysis in pediatric patients associated with the use of Succinylcholine Chloride Injection. The drug itself is linked to these cardiotoxicity risks.

2. The label advises immediate treatment for hyperkalemia in pediatric patients who experience cardiac arrest soon after administration of Succinylcholine Chloride Injection, not due to other causes. The drug is associated with the risk of cardiotoxicity in pediatric patients.

3. Succinylcholine Chloride Injection is contraindicated in patients with known hypersensitivity to succinylcholine, as severe anaphylactic reactions have been reported. The drug itself can lead to severe anaphylactic reactions, which may include cardiotoxicity.

4. The drug label mentions that succinylcholine may induce serious cardiac arrhythmias or cardiac arrest due to hyperkalemia in patients with electrolyte abnormalities or digitalis toxicity. Succinylcholine Chloride Injection is associated with the risk of hyperkalemia-induced cardiotoxicity.

5. Malignant hyperthermia, a potentially fatal condition, may be triggered by succinylcholine in susceptible individuals. The drug itself can lead to malignant hyperthermia, which may present with cardiotoxic effects such as arrhythmias and hemodynamic instability.

6. Intravenous bolus administration of Succinylcholine Chloride Injection in pediatric patients may result in profound bradycardia or asystole. The drug itself is associated with the risk of bradycardia, which can progress to asystole, particularly in pediatric patients.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",cb5b3361-9099-4a12-b545-f1e50b0781dd,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=cb5b3361-9099-4a12-b545-f1e50b0781dd&type=display
1016,SUCRALFATE,"1. The drug label does not mention any specific cardiotoxicity risks associated with Carafate (sucralfate) itself.

2. The drug label does not indicate that Carafate (sucralfate) is associated with cardiotoxicity reactions.

Overall, based on the information provided in the drug label, there are no mentions of cardiotoxicity risks or reactions related to the use of Carafate (sucralfate).",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",c87c6b50-6977-4fa7-ae98-40c0753f7aee,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=c87c6b50-6977-4fa7-ae98-40c0753f7aee&type=display
1017,SUCROFERRIC OXYHYDROXIDE,1. The drug label for Velphoro does not mention any cardiotoxicity risks or cardiotoxicity reactions associated with the use of the drug.,No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",237da26c-f38c-4faa-93ad-735e71c9d0c1,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=237da26c-f38c-4faa-93ad-735e71c9d0c1&type=display
1018,SUFENTANIL,"1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with DSUVIA (sufentanil) itself. 

2. However, the label does highlight the potential for severe hypotension, including orthostatic hypotension and syncope, in ambulatory patients using DSUVIA. This risk is attributed to the drug's potential to cause vasodilation, which can reduce cardiac output and blood pressure, especially in patients with compromised blood volume or those taking certain CNS depressant drugs. The label advises monitoring patients for signs of hypotension after initiating DSUVIA. The drug itself is not directly associated with cardiotoxicity but may lead to severe hypotension, which can have cardiovascular implications.",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",8b580f3d-e3b5-4086-b093-87a980631147,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8b580f3d-e3b5-4086-b093-87a980631147&type=display
1019,SUGAMMADEX,"1. **Cardiotoxicity Risk**: Cases of marked bradycardia, some leading to cardiac arrest, have been observed within minutes after administration of BRIDION, indicating a direct association of the drug with cardiotoxicity risk.

2. **Cardiotoxicity Reaction**: Other cardiac rhythm abnormalities reported post-marketing include atrial fibrillation, atrioventricular block, cardiac/cardiorespiratory arrest, ECG ST segment changes, and supraventricular tachycardia, suggesting a potential association of BRIDION with cardiotoxicity reactions.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",5171d883-fe8f-482c-97ab-40b00975b64a,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=5171d883-fe8f-482c-97ab-40b00975b64a&type=display
1020,SULFADIAZINE,"1. The drug label does not mention any specific cardiotoxicity risks associated with sulfadiazine itself.

2. The label does not indicate that sulfadiazine is associated with cardiotoxicity reactions.

3. There is no mention in the drug label of sulfadiazine causing any cardiotoxicity risks.

4. The drug label does not list any cardiotoxicity reactions linked to sulfadiazine use.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",8993651b-fff6-4e3f-9b60-78587bc9bcee,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8993651b-fff6-4e3f-9b60-78587bc9bcee&type=display
1021,SULFASALAZINE,"1. The drug label mentions that there have been reports of hepatotoxicity, including elevated liver function tests, jaundice, cholestatic jaundice, cirrhosis, hepatitis cholestatic, cholestasis, and possible hepatocellular damage, including liver necrosis and liver failure, associated with the use of sulfasalazine. These reactions suggest a potential risk of liver toxicity associated with the drug itself.

2. Additionally, the label reports a case of Kawasaki-like syndrome, which included hepatic function changes, associated with the use of sulfasalazine. This indicates a potential risk of systemic inflammatory reactions affecting multiple organs, including the liver, linked to the drug.

3. The drug label also mentions that there have been postmarketing reports of myocarditis, a cardiac disorder, associated with products containing or metabolized to mesalamine, which is a component of sulfasalazine. This suggests a potential risk of myocarditis linked to the drug or its metabolites.

4. Furthermore, the label includes information about anaphylaxis, an immune system disorder, as a potential adverse reaction associated with the use of sulfasalazine. Anaphylaxis can lead to cardiovascular complications, indicating a potential risk of cardiotoxicity related to severe allergic reactions to the drug.

5. Lastly, the drug label lists pallor, a vascular disorder, as a rare adverse reaction reported in postmarketing use of products containing or metabolized to mesalamine. This suggests a potential risk of vascular-related symptoms, including cardiovascular effects, associated with the drug or its metabolites.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",b9ef541a-93c8-4428-ba45-398aa0b327d1,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=b9ef541a-93c8-4428-ba45-398aa0b327d1&type=display
1022,SULINDAC,"1. The drug label states that nonsteroidal anti-inflammatory drugs (NSAIDs), including sulindac, are associated with an increased risk of serious cardiovascular thrombotic events, such as myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with the duration of use.

2. Sulindac tablets are contraindicated in patients who have undergone coronary artery bypass graft (CABG) surgery, indicating that the drug itself is linked to an increased risk of cardiovascular events in this specific population.

3. The label warns that NSAIDs, including sulindac, can lead to the onset of new hypertension or worsening of pre-existing hypertension, potentially contributing to an increased incidence of cardiovascular events. It also mentions that patients taking thiazides or loop diuretics may have impaired responses to these therapies when taking NSAIDs.

4. The label highlights that NSAIDs, including sulindac, should be used with caution in patients with heart failure, as they may experience fluid retention and edema. It mentions that the drug may blunt the cardiovascular effects of certain therapeutic agents used to treat these conditions, such as diuretics, ACE inhibitors, or angiotensin receptor blockers.

5. The label further warns about the increased risk of hospitalizations for heart failure in patients treated with NSAIDs, including sulindac, based on a meta-analysis of randomized controlled trials. It emphasizes the importance of avoiding the use of sulindac in patients with severe heart failure unless the benefits outweigh the risks.

6. Additionally, the label mentions that NSAIDs, including sulindac, can lead to gastrointestinal adverse events, such as bleeding, ulceration, and perforation, which can be fatal. It advises extreme caution in prescribing NSAIDs to patients with a prior history of ulcer disease or gastrointestinal bleeding, as these individuals have a significantly increased risk of developing a GI bleed while on NSAID therapy.

7. The label also discusses the potential hepatic effects of sulindac, noting that rare cases of severe hepatic reactions, including jaundice and fatal fulminant hepatitis, have been reported. It suggests monitoring patients for signs of liver dysfunction and discontinuing sulindac if abnormal liver tests persist or worsen.

8. Furthermore, the label mentions that long-term administration of NSAIDs, including sulindac, has resulted in renal papillary necrosis and other renal injuries. It highlights that patients at greatest risk of renal toxicity are those with impaired renal function, heart failure, liver dysfunction, or those taking diuretics and ACE inhibitors. It advises close monitoring of renal function in patients with significantly impaired renal function who are prescribed sulindac.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",68d4eeed-2501-494b-b979-502720de86c0,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=68d4eeed-2501-494b-b979-502720de86c0&type=display
1023,SUMATRIPTAN SUCCINATE,"1. The drug ONZETRA Xsail is contraindicated in patients with a history of coronary artery disease (CAD) or coronary vasospasm, indicating that the drug itself is associated with a cardiotoxicity risk.

2. The drug ONZETRA Xsail may cause myocardial ischemia, myocardial infarction, and Prinzmetal's angina, with rare reports of serious cardiac adverse reactions, including acute myocardial infarction, occurring within a few hours following administration of sumatriptan. This suggests that the drug itself is associated with a cardiotoxicity risk.

3. Life-threatening disturbances of cardiac rhythm, including ventricular tachycardia and ventricular fibrillation leading to death, have been reported within a few hours following the administration of 5-HT1 agonists, including ONZETRA Xsail. Discontinue ONZETRA Xsail if these disturbances occur, indicating that the drug itself is associated with a cardiotoxicity risk.

4. Sensations of tightness, pain, pressure, and heaviness in the chest, throat, neck, and jaw may occur after treatment with 5-HT1 agonists, including ONZETRA Xsail. While these symptoms are usually non-cardiac in origin, a cardiac evaluation is recommended for high-risk patients, suggesting that the drug itself may be associated with a cardiotoxicity risk.

5. Cerebral hemorrhage, subarachnoid hemorrhage, stroke, and other cerebrovascular events have occurred in patients treated with 5-HT1 agonists, including sumatriptan. Some of these events have resulted in fatalities, indicating that the drug itself is associated with a cardiotoxicity risk.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",a8a9889e-69b9-4a57-b8c0-d40b1025c559,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a8a9889e-69b9-4a57-b8c0-d40b1025c559&type=display
1024,SUNITINIB MALATE,"1. **Cardiotoxicity Risk**: SUTENT has been associated with severe cardiotoxicity risks, including myocardial ischemia, myocardial infarction, heart failure, cardiomyopathy, and decreased left ventricular ejection fraction (LVEF) to below the lower limit of normal, some of which have led to death.

2. **Cardiotoxicity Reaction**: In clinical trials, 3% of patients treated with SUTENT experienced heart failure, with 71% of these patients reported as having recovered. Fatal cardiac failure was reported in less than 1% of patients, indicating a direct association between SUTENT and cardiotoxicity reactions.

3. **Cardiotoxicity Risk**: Patients with a history of cardiac events within 12 months prior to SUTENT administration were excluded from clinical studies, suggesting a known risk of cardiotoxicity associated with SUTENT use in patients with pre-existing cardiac conditions.

4. **Cardiotoxicity Reaction**: Patients who developed clinical manifestations of congestive heart failure (CHF) while on SUTENT were advised to discontinue the drug, indicating a direct link between SUTENT use and the development of CHF.

5. **Cardiotoxicity Risk**: Monitoring of left ventricular ejection fraction (LVEF) at baseline and periodically during treatment was recommended to detect any potential cardiotoxic effects of SUTENT, highlighting the drug's association with cardiac function changes.

6. **Cardiotoxicity Reaction**: Patients without clinical evidence of CHF but with a decrease in LVEF to below baseline or the lower limit of normal were advised to interrupt SUTENT and consider dose reduction, indicating a direct impact of SUTENT on cardiac function.

7. **Cardiotoxicity Risk**: SUTENT was associated with QT interval prolongation in a dose-dependent manner, increasing the risk of ventricular arrhythmias, including Torsade de Pointes, suggesting a potential cardiotoxic effect of the drug.

8. **Cardiotoxicity Reaction**: Patients at higher risk of developing QT interval prolongation were advised to be monitored closely for electrocardiogram changes and electrolyte disturbances during SUTENT treatment, indicating a direct association between SUTENT and QT interval prolongation-related cardiotoxicity.

Overall, the drug label for SUTENT clearly outlines the risks of cardiotoxicity associated with the medication, including specific recommendations for monitoring and managing potential cardiac adverse reactions during treatment.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",a5d555f5-d66a-4f94-abcf-96fa6d71a32f,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a5d555f5-d66a-4f94-abcf-96fa6d71a32f&type=display
1025,SUVOREXANT,"1. In the section on Drug Interactions, it is mentioned that BELSOMRA was co-administered with alcohol, showing additive psychomotor impairment, but there was no alteration in the pharmacokinetics of BELSOMRA. This indicates that BELSOMRA itself was not associated with cardiotoxicity risk but may have additive effects when combined with alcohol.

2. In the section on Post-Marketing Experience, it is noted that cardiac disorders such as palpitations and tachycardia have been identified during post-approval use of BELSOMRA. This suggests that BELSOMRA may be associated with cardiotoxicity reactions based on post-marketing reports.

3. The section on Use in Specific Populations mentions that in animal reproduction studies, oral administration of suvorexant to pregnant rats and rabbits during the period of organogenesis decreased maternal body weight and/or weight gain. This indicates potential maternal effects that could indirectly impact cardiotoxicity risks.

Overall, while BELSOMRA itself may not be directly linked to cardiotoxicity risks, post-marketing reports have identified cardiac disorders as adverse reactions. Additionally, the drug's effects on maternal health in animal studies could indirectly impact cardiotoxicity risks.",Less,Yes,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",e5b72731-1acb-45b7-9c13-290ad12d3951,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=e5b72731-1acb-45b7-9c13-290ad12d3951&type=display
1026,"SYNTHETIC CONJUGATED ESTROGENS, A","1. Estrogens, including synthetic conjugated estrogens in Cenestin, should not be used for the prevention of cardiovascular disease. The Womens Health Initiative (WHI) study reported increased risks of myocardial infarction, stroke, invasive breast cancer, pulmonary emboli, and deep vein thrombosis in postmenopausal women during treatment with oral conjugated equine estrogens combined with medroxyprogesterone acetate relative to placebo. (The drug itself was associated with an increased risk of cardiovascular events.)

2. Estrogens have been associated with an increased risk of cardiovascular events such as myocardial infarction and stroke, as well as venous thrombosis and pulmonary embolism. If any of these occur or are suspected, estrogens should be discontinued immediately. Risk factors for arterial vascular disease and venous thromboembolism should be managed appropriately. (The drug itself was associated with an increased risk of cardiovascular events.)

3. In the Womens Health Initiative (WHI) study, an increase in the number of strokes was observed in women receiving conjugated equine estrogens compared to placebo. The study also reported an increased risk of coronary heart disease events and stroke in women receiving conjugated equine estrogens combined with medroxyprogesterone acetate compared to placebo. (The drug itself was associated with an increased risk of strokes and coronary heart disease events.)

4. In the WHI study, an increase in venous thromboembolism (VTE), including deep venous thrombosis and pulmonary embolism, was observed in women receiving conjugated equine estrogens combined with medroxyprogesterone acetate compared to placebo. The rate of VTE was higher in the estrogen-progestin group than in the placebo group. (The drug itself was associated with an increased risk of venous thromboembolism.)

5. Estrogens should be discontinued at least 4 to 6 weeks before surgery associated with an increased risk of thromboembolism or during periods of prolonged immobilization. This precaution is due to the potential risk of thromboembolism associated with estrogen use. (The drug itself was associated with an increased risk of thromboembolism.)

6. Large doses of estrogen have been shown to increase the risks of nonfatal myocardial infarction, pulmonary embolism, and thrombophlebitis in men. This finding suggests a potential cardiotoxic effect of estrogen therapy. (The drug itself was associated with an increased risk of cardiovascular events in men.)

7. Estrogens have been associated with an increased risk of gallbladder disease requiring surgery in postmenopausal women. This indicates a potential cardiotoxic effect of estrogen therapy. (The drug itself was associated with an increased risk of gallbladder disease.)

8. Estrogens may lead to severe hypercalcemia in patients with breast cancer and bone metastases. If hypercalcemia occurs, estrogen therapy should be stopped, indicating a potential cardiotoxic effect of estrogen therapy. (The drug itself was associated with an increased risk of hypercalcemia.)

In summary, the drug label for Cenestin highlights several cardiotoxicity risks associated with estrogen therapy, including an increased risk of cardiovascular events, strokes, venous thromboembolism, and gallbladder disease. These risks emphasize the importance of careful monitoring and consideration of individual patient factors when prescribing this medication.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",1cd07b54-f66f-4040-9058-462324267196,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=1cd07b54-f66f-4040-9058-462324267196&type=display
1027,"SYNTHETIC CONJUGATED ESTROGENS, B","1. The drug label states that estrogen and estrogen/progestin therapies have been associated with an increased risk of cardiovascular events such as myocardial infarction and stroke, as well as venous thrombosis and pulmonary embolism (venous thromboembolism (VTE)). The drug itself was associated with the increased risk of cardiovascular events.

2. The label mentions that in the estrogen-alone substudy of the Womens Health Initiative (WHI) study, a statistically significant increased risk of stroke was reported in women receiving conjugated estrogens (CE 0.625 mg) daily compared to women receiving placebo. The drug itself was associated with the increased risk of stroke.

3. In the estrogen-plus-progestin substudy of the WHI study, a statistically significant increased risk of stroke was reported in women receiving conjugated estrogens (CE 0.625 mg) combined with medroxyprogesterone acetate (MPA 2.5 mg) daily compared to placebo. The drug itself was associated with the increased risk of stroke.

4. The label also mentions that in the estrogen-alone substudy of WHI, the risk of venous thromboembolism (DVT and PE) was reported to be increased for women taking conjugated equine estrogens. The drug itself was associated with the increased risk of venous thromboembolism.

5. In the estrogen-plus-progestin substudy of WHI, a statistically significant 2-fold greater rate of VTE was reported in women receiving conjugated estrogens (CE/MPA) compared to women receiving placebo. The drug itself was associated with the increased risk of venous thromboembolism.

6. The label advises that if feasible, estrogens should be discontinued at least 4 to 6 weeks before surgery associated with an increased risk of thromboembolism or during periods of prolonged immobilization. The drug itself was associated with the increased risk of thromboembolism.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",c0625060-29c7-4cda-b6f9-cfa15e59775e,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=c0625060-29c7-4cda-b6f9-cfa15e59775e&type=display
1028,TACROLIMUS,"1. **QT Prolongation Risk**: ENVARSUS XR may prolong the QT/QTc interval and cause Torsades de pointes. This risk is associated with the drug itself. Patients with congenital long QT syndrome should avoid ENVARSUS XR. Monitoring of electrolytes and periodic electrocardiograms is recommended for patients with certain conditions or taking specific medications that may lead to QT prolongation. Co-administration with other drugs that prolong the QT interval may necessitate a reduction in ENVARSUS XR dosage to mitigate the risk of cardiotoxicity.

2. **Hypertension**: Hypertension is a common adverse reaction to ENVARSUS XR therapy. This risk is associated with the drug itself. Antihypertensive therapy may be required, but caution is advised as some antihypertensive drugs can increase the risk of hyperkalemia. Calcium-channel blocking agents may increase tacrolimus blood concentrations, necessitating a dosage adjustment of ENVARSUS XR. Monitoring of blood pressure and potassium levels is recommended during treatment to manage potential cardiotoxic effects.

3. **Hyperkalemia**: Mild to severe hyperkalemia has been reported with tacrolimus, including ENVARSUS XR. This risk is associated with the drug itself. Concomitant use of agents associated with hyperkalemia may further increase the risk. Regular monitoring of serum potassium levels is advised during treatment to detect and manage hyperkalemia promptly. Adjustments in medication or dosage may be necessary to address cardiotoxicity related to hyperkalemia.

4. **Neurotoxicity**: ENVARSUS XR may cause neurotoxicities, including posterior reversible encephalopathy syndrome (PRES) and other neurological symptoms. This risk is associated with the drug itself. Symptoms such as tremors, headache, and changes in mental status should be monitored, and dosage reduction or discontinuation of ENVARSUS XR may be required if neurotoxicity occurs. Regular assessment for neurologic abnormalities is essential to prevent potential cardiotoxic effects of neurotoxicity.",Less,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",de2315b0-6344-43ac-9aea-3e3b68d828e7,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=de2315b0-6344-43ac-9aea-3e3b68d828e7&type=display
1029,TACROLIMUS; TACROLIMUS CAPSULES,"1. The drug label warns about the risk of myocardial hypertrophy, advising consideration of dosage reduction or discontinuation due to this potential cardiotoxicity. The drug itself is associated with the risk of myocardial hypertrophy.

2. Additionally, the label mentions the potential for hypertension as an adverse reaction to the drug, indicating that patients may require antihypertensive therapy. The drug itself is associated with the risk of hypertension.

3. The label also highlights the risk of QT prolongation, which can be a sign of cardiotoxicity. However, it does not explicitly state that the drug itself causes this QT prolongation.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",bf191c03-3e4b-4b45-a0d2-47809a847af6,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=bf191c03-3e4b-4b45-a0d2-47809a847af6&type=display
1030,TADALAFIL,"1. The drug ADCIRCA (tadalafil) is a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of pulmonary arterial hypertension (PAH) to improve exercise ability. It is not recommended in patients with pulmonary veno-occlusive disease due to potential adverse effects on cardiovascular disease. (ADCIRCA itself is associated with cardiotoxicity risk)

2. ADCIRCA has vasodilatory properties that may result in transient decreases in blood pressure. Patients with underlying cardiovascular disease could be adversely affected by these vasodilatory effects. (ADCIRCA itself is associated with cardiotoxicity risk)

3. Pulmonary vasodilators like ADCIRCA may worsen the cardiovascular status of patients with pulmonary veno-occlusive disease. Administration of ADCIRCA to such patients is not recommended. (ADCIRCA itself is associated with cardiotoxicity risk)

4. ADCIRCA may potentiate the hypotensive effects of GC stimulators. (ADCIRCA itself is associated with cardiotoxicity risk)

5. Sudden loss of vision, including non-arteritic ischemic optic neuropathy (NAION), has been reported with the use of phosphodiesterase type 5 (PDE-5) inhibitors like tadalafil. (ADCIRCA itself is associated with cardiotoxicity risk)

6. Cases of sudden decrease or loss of hearing have been reported in patients taking tadalafil. It is unclear whether these events are directly related to the use of PDE5 inhibitors. (ADCIRCA itself is associated with cardiotoxicity risk)

7. Prolonged erections greater than 4 hours and priapism have been reported with the use of ADCIRCA. Patients with conditions predisposing them to priapism are at increased risk. (ADCIRCA itself is associated with cardiotoxicity risk)

8. Serious cardiovascular events, including myocardial infarction, sudden cardiac death, stroke, chest pain, palpitations, and tachycardia, have been reported postmarketing in temporal association with the use of tadalafil. (ADCIRCA is associated with cardiotoxicity reactions)

9. Hypersensitivity reactions including urticaria, StevensJohnson syndrome, and exfoliative dermatitis have been reported post-approval with tadalafil use. (ADCIRCA is associated with cardiotoxicity reactions)

10. Cases of sudden decrease or loss of hearing have been reported postmarketing in temporal association with the use of PDE5 inhibitors, including tadalafil. (ADCIRCA is associated with cardiotoxicity reactions)

11. Priapism has been reported as an adverse reaction post-approval with tadalafil use. (ADCIRCA is associated with cardiotoxicity reactions)",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",ff61b237-be8e-461b-8114-78c52a8ad0ae,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=ff61b237-be8e-461b-8114-78c52a8ad0ae&type=display
1031,TAFENOQUINE,"1. The drug ARAKODA contains tafenoquine, an antimalarial agent for oral administration. The effect of tafenoquine on the QT interval was evaluated in a study of healthy adult subjects, where a mean increase in the QTcF interval for tafenoquine was less than 20 msec. (The drug tafenoquine was associated with QT interval evaluation, showing a minimal increase within safe limits.)

2. In clinical trials, ARAKODA was administered with a high-calorie, high-fat meal, and the pharmacokinetics of tafenoquine were studied following single dose administration. Plasma tafenoquine AUC inf increased by 41% when administered with a high-calorie, high-fat meal compared to the fasted state. (The drug tafenoquine was associated with changes in pharmacokinetics when administered with a high-calorie, high-fat meal.)

Please note that while the drug tafenoquine was associated with these cardiotoxicity risks and evaluations, the information provided does not indicate any significant cardiotoxicity concerns associated with the use of ARAKODA.",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",299e49d8-470f-4779-a010-4a1ee0e0c6cd,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=299e49d8-470f-4779-a010-4a1ee0e0c6cd&type=display
1032,TAFENOQUINE SUCCINATE,"1. The drug label mentions that tafenoquine, the active ingredient in KRINTAFEL, was evaluated in a Phase 1 study for its effect on the QTc interval in healthy adult subjects. At a cumulative dose of 1,200 mg, tafenoquine did not prolong the QTc interval to any clinically relevant extent. This suggests that tafenoquine itself was not associated with significant QTc prolongation.

2. The label also states that a saturable relationship was identified between tafenoquine exposure and clinical response, indicating that tafenoquine exposures achieved with doses of 300 mg and higher are on the plateau of the exposure-response curve. This suggests that tafenoquine itself did not cause significant cardiotoxicity risks based on exposure-response relationships.

3. Additionally, the label mentions that no clinically significant effects on tafenoquine pharmacokinetics were observed when coadministered with other antimalarials or substrates of various cytochrome P450 enzymes in healthy subjects. This suggests that tafenoquine itself did not have significant interactions that would lead to cardiotoxicity risks.

Overall, based on the information provided in the drug label, tafenoquine (KRINTAFEL) does not appear to be associated with significant cardiotoxicity risks or reactions.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",5cf989d5-36f5-4561-a30b-9fcb9deb6b6a,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=5cf989d5-36f5-4561-a30b-9fcb9deb6b6a&type=display
1033,TALAZOPARIB,"1. **Warnings and Precautions - Myelodysplastic Syndrome/Acute Myeloid Leukemia (MDS/AML):** The drug label mentions that MDS/AML has been reported in patients exposed to TALZENNA, and some cases were fatal. Patients should be monitored for hematological toxicity, and TALZENNA should be discontinued if MDS/AML is confirmed. **(The drug itself was associated with the risk of MDS/AML.)**

2. **Warnings and Precautions - Myelosuppression:** TALZENNA may affect hematopoiesis and can cause anemia, neutropenia, and/or thrombocytopenia. Grade 3 anemia, neutropenia, and thrombocytopenia were reported in patients receiving TALZENNA. **(The drug itself was associated with the risk of myelosuppression.)**

3. **Warnings and Precautions - Embryo-Fetal Toxicity:** TALZENNA can cause fetal harm when administered to a pregnant woman. Animal studies showed fetal malformations and embryo-fetal death at exposures equivalent to those in patients receiving the recommended dose. Pregnant women and females of reproductive potential should be advised of the potential risk to the fetus and to use effective contraception. **(The drug itself was associated with the risk of embryo-fetal toxicity.)**

4. **Adverse Reactions - Clinical Trials Experience:** The most common adverse reactions included fatigue, anemia, fractures, and dizziness in patients receiving TALZENNA in combination with enzalutamide. **(The drug itself was associated with these adverse reactions, including fractures.)**

5. **Warnings and Precautions - Effect of Other Drugs on TALZENNA:** Coadministration of TALZENNA with certain P-glycoprotein (P-gp) inhibitors may increase talazoparib concentrations, potentially increasing the risk of adverse reactions. Patients should be monitored for increased adverse reactions when TALZENNA is coadministered with P-gp inhibitors. **(The drug itself was not directly associated with cardiotoxicity risks in this section, but the interaction with P-gp inhibitors could potentially impact cardiotoxicity.)**",Less,No,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",c6fd147f-a77e-4a0b-9280-e82ecc41b4be,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=c6fd147f-a77e-4a0b-9280-e82ecc41b4be&type=display
1034,TALC,1. The drug label does not mention any specific cardiotoxicity risks or cardiotoxicity reactions associated with Steritalc (talc) powder for intrapleural use.,No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",c94e51d9-beef-4b06-e053-2a95a90a754a,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=c94e51d9-beef-4b06-e053-2a95a90a754a&type=display
1035,TAMOXIFEN CITRATE,"1. The drug label warns of thromboembolic events, including deep vein thrombosis and pulmonary embolism, associated with tamoxifen therapy. The risk of thromboembolic events increases when tamoxifen is coadministered with chemotherapy. (The drug itself is associated with the risk of thromboembolic events.)

2. The label advises careful consideration of the risks and benefits of tamoxifen in women with a history of thromboembolic events. Tamoxifen is contraindicated in women with a history of deep vein thrombosis or pulmonary embolus if used for certain indications. (The drug itself is associated with the risk of thromboembolic events.)

3. Data from clinical trials show an increased incidence of stroke among women randomized to tamoxifen compared to those on placebo. The incidence of stroke was higher in the tamoxifen group, with some cases being fatal. (The drug itself is associated with the risk of stroke.)

4. The drug label mentions an increased risk of developing cataracts and the need for cataract surgery in patients receiving tamoxifen. Tamoxifen was associated with an increased risk of having cataract surgery compared to placebo. (The drug itself is associated with the risk of cataracts and the need for cataract surgery.)

5. The label discusses the occurrence of venous thromboembolic events, including deep vein thrombosis, in patients receiving tamoxifen. The incidence of deep venous thromboembolic events was higher in the tamoxifen group compared to placebo. (The drug itself is associated with the risk of venous thromboembolic events.)

6. The drug label mentions ischemic cerebrovascular events and ischemic cardiovascular disease as potential adverse reactions associated with tamoxifen therapy. The incidence of these events was higher in patients receiving tamoxifen compared to placebo. (The drug itself is associated with the risk of ischemic cerebrovascular events and ischemic cardiovascular disease.)",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",1e6ff055-590c-41e6-9530-1fdf04cdbd02,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=1e6ff055-590c-41e6-9530-1fdf04cdbd02&type=display
1036,TAMSULOSIN HYDROCHLORIDE,"1. **Warnings and Precautions**: Patients starting treatment with FLOMAX capsules should be cautioned about the potential risk of orthostasis, including postural hypotension, dizziness, and vertigo, which were detected more frequently in FLOMAX-treated patients than in placebo recipients. The drug itself was associated with the risk of orthostasis.

2. **Warnings and Precautions**: FLOMAX capsules should not be used in combination with strong inhibitors of CYP3A4, as this can lead to potential drug interactions that may impact cardiotoxicity risks. The drug itself was not directly associated with cardiotoxicity but could increase the risk when combined with certain medications.

3. **Warnings and Precautions**: Caution should be exercised with concomitant administration of warfarin and FLOMAX capsules due to potential drug interactions that could affect cardiotoxicity. The drug itself was not directly associated with cardiotoxicity but could impact the effects of warfarin.

4. **Adverse Reactions**: In postmarketing experience, adverse reactions such as dyspnea, palpitations, hypotension, atrial fibrillation, arrhythmia, and tachycardia have been reported, which may indicate potential cardiotoxicity risks associated with FLOMAX capsules. The drug itself was associated with reported adverse reactions that suggest cardiotoxicity risks.

5. **Adverse Reactions**: Reports of skin desquamation, Stevens-Johnson syndrome, erythema multiforme, and liver injury have been received during the postmarketing period, indicating potential serious adverse effects, including cardiotoxicity reactions. The drug itself was associated with reported adverse reactions that suggest potential cardiotoxicity risks.

6. **Drug Interactions**: FLOMAX capsules should be used with caution in combination with other alpha adrenergic blocking agents, as interactions may impact cardiotoxicity risks. The drug itself was not directly associated with cardiotoxicity but could increase the risk when combined with other alpha adrenergic blocking agents.

7. **Drug Interactions**: Caution is advised when FLOMAX capsules are coadministered with PDE5 inhibitors, as this combination can potentially cause symptomatic hypotension, indicating a possible cardiotoxicity risk. The drug itself was not directly associated with cardiotoxicity but could increase the risk when combined with PDE5 inhibitors.",Less,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",6771ad8e-ac92-4aec-b484-5d8350a353f8,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=6771ad8e-ac92-4aec-b484-5d8350a353f8&type=display
1037,TAPENTADOL HYDROCHLORIDE,"1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with NUCYNTA tablets themselves.

2. However, the label does warn about the risks of concomitant use of opioids with benzodiazepines or other central nervous system depressants, including alcohol, which may result in profound sedation, respiratory depression, coma, and death. This combination can lead to serious, life-threatening respiratory depression, but it does not directly attribute cardiotoxicity risks to NUCYNTA tablets.

3. The label also cautions about the potential for severe hypotension, particularly during dosage initiation and titration, and advises against the use of NUCYNTA tablets in patients with circulatory shock. While severe hypotension can have cardiovascular implications, it does not specify direct cardiotoxicity risks associated with NUCYNTA tablets.

Overall, while NUCYNTA tablets are not directly linked to cardiotoxicity risks in the drug label, caution is advised regarding potential respiratory depression and hypotension when used in combination with other medications or in specific patient populations.",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",80938c30-9fe3-4c7d-9d9c-5476638cfb2d,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=80938c30-9fe3-4c7d-9d9c-5476638cfb2d&type=display
1038,TASIMELTEON,1. The drug label does not mention any cardiotoxicity risks or cardiotoxicity reactions associated with HETLIOZ (tasimelteon).,No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",ca4a9b63-708e-49e9-8f9b-010625443b90,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=ca4a9b63-708e-49e9-8f9b-010625443b90&type=display
1039,TAZEMETOSTAT,"1. The drug label for TAZVERIK (tazemetostat) does not mention any specific cardiotoxicity risks or reactions associated with the drug itself. 

2. The label primarily focuses on secondary malignancies and embryo-fetal toxicity as significant warnings and precautions, but does not highlight any direct cardiotoxic effects or risks related to TAZVERIK. 

3. The clinical pharmacology section of the label mentions that tazemetostat did not cause a large mean increase in the heart-rate corrected QT (QTc) interval at the approved recommended dosage, indicating no significant cardiotoxic effects observed in the study. 

Overall, based on the information provided in the drug label, there is no direct association between TAZVERIK (tazemetostat) and cardiotoxicity risks or reactions mentioned in the label.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",7db07b5f-4e22-467c-9c0a-f830b08dbb1d,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7db07b5f-4e22-467c-9c0a-f830b08dbb1d&type=display
1040,TECHNETIUM TC 99M MEDRONATE,"1. The drug label mentions that several reactions have been reported in association with other radiopharmaceuticals of the diphosphonate class, particularly Technetium Tc 99m Medronate. These reactions are usually hypersensitivity reactions characterized by itching, various skin rashes, hypotension, chills, nausea, fever, and vomiting. One death secondary to cardiac arrhythmia following the administration of Technetium Tc 99m Medronate has been reported. (The drug itself was associated with cardiotoxicity reactions.)

2. Additionally, one case of cardiac arrest in a patient undergoing pulmonary function testing one and one-half hours after the performance of a bone scan using Technetium Tc 99m Medronate has been reported. (The drug itself was associated with cardiotoxicity reactions.)",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",3c91d0d8-6cc5-834c-bda0-aa83a873b9fb,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=3c91d0d8-6cc5-834c-bda0-aa83a873b9fb&type=display
1041,TECHNETIUM TC 99M OXIDRONATE,"1. The drug label warns that Technetium Tc 99m Oxidronate may cause life-threatening hypersensitivity reactions, including cardiotoxicity. The drug itself is associated with the risk of cardiotoxicity reactions.

2. The label advises to have cardiopulmonary resuscitation equipment and personnel available and to monitor all patients for hypersensitivity reactions, which may include cardiotoxicity. The drug itself is associated with the risk of cardiotoxicity reactions.

3. The label mentions that this class of compounds is known to complex cations such as calcium, and particular caution should be used with patients who have or may be predisposed to hypocalcemia, which can lead to cardiotoxicity. The drug itself is associated with the risk of cardiotoxicity reactions.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",6fc2e41e-a1bf-4e0f-924a-88be0372d4af,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=6fc2e41e-a1bf-4e0f-924a-88be0372d4af&type=display
1042,TECHNETIUM TC 99M SESTAMIBI,"1. **Cardiotoxicity Risk**: Pharmacologic induction of cardiovascular stress may be associated with serious adverse events such as myocardial infarction, arrhythmia, hypotension, bronchoconstriction, and cerebrovascular events. (The drug itself is associated with the risk of cardiotoxicity during cardiovascular stress.)

2. **Cardiotoxicity Reaction**: Technetium Tc99m Sestamibi has been rarely associated with acute severe allergic and anaphylactic events of angioedema and generalized urticaria. In some patients, allergic symptoms developed on the second injection during Technetium Tc99m Sestamibi imaging. (The drug itself is associated with the occurrence of acute severe allergic and anaphylactic reactions, which can include cardiotoxic manifestations like angioedema and generalized urticaria.)

3. **Cardiotoxicity Risk**: In studying patients in whom cardiac disease is known or suspected, care should be taken to assure continuous monitoring and treatment in accordance with safe, accepted clinical procedure. Infrequently, death has occurred 4 to 24 hours after Tc99m Sestamibi use and is usually associated with exercise stress testing. (The drug itself is associated with the risk of adverse cardiac events, including death, particularly in the context of exercise stress testing.)

4. **Cardiotoxicity Risk**: Pharmacologic induction of cardiovascular stress may be associated with serious adverse events such as myocardial infarction, arrhythmia, hypotension, bronchoconstriction, and cerebrovascular events. Caution should be used when pharmacologic stress is selected as an alternative to exercise; it should be used when indicated and in accordance with the pharmacologic stress agent's labeling. (The drug itself is associated with the risk of serious cardiovascular events during pharmacologic stress, and caution is advised in such scenarios.)

5. **Cardiotoxicity Reaction**: Technetium Tc99m Sestamibi has been rarely associated with acute severe allergic and anaphylactic events of angioedema and generalized urticaria. In some patients, the allergic symptoms developed on the second injection during Tc99m Sestamibi imaging. Patients who receive Technetium Tc99m Sestamibi for either myocardial or breast imaging are receiving the same drug. Caution should be exercised, and emergency equipment should be available when administering Technetium Tc99m Sestamibi. Also, before administering Technetium Tc99m Sestamibi Injection, patients should be asked about the possibility of allergic reactions to the drug. (The drug itself is associated with the risk of acute severe allergic and anaphylactic reactions, including angioedema and generalized urticaria, which can have cardiotoxic manifestations.)",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",4110d0f4-3bcf-4688-a39f-42a81064c796,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=4110d0f4-3bcf-4688-a39f-42a81064c796&type=display
1043,TECHNETIUM TC 99M SULFUR COLLOID,"1. Anaphylactic reactions, including rare fatalities, have occurred following intravenously administered Technetium Tc 99m Sulfur Colloid. The drug itself was not directly associated with cardiotoxicity but was linked to anaphylactic reactions, which can include cardiotoxic effects such as hypotension and bronchospasm.

2. The most frequently reported adverse reactions include hypotension, which is a cardiotoxic effect. The drug itself was not directly associated with causing hypotension but was reported as an adverse reaction that can include cardiotoxicity.

3. The drug label does not specifically mention cardiotoxicity risks or reactions associated with cardiotoxicity caused by Technetium Tc 99m Sulfur Colloid Injection. However, it is important to note that anaphylactic reactions, hypotension, and other adverse effects can have cardiotoxic manifestations and should be monitored closely during administration.",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",eeaf70fd-46bd-4fec-ba9d-2366fdf07888,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=eeaf70fd-46bd-4fec-ba9d-2366fdf07888&type=display
1044,TECHNETIUM TC 99M-LABELED RED BLOOD CELLS,"1. The drug label does not mention any cardiotoxicity risks or cardiotoxicity reactions associated with UltraTag RBC, the technetium Tc 99m-labeled red blood cells kit.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",9f999b75-8a66-40bf-9352-478850b41225,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=9f999b75-8a66-40bf-9352-478850b41225&type=display
1045,TECHNETIUM TC99M PYROPHOSPHATE,"1. The drug label mentions that Technetium Tc 99m Pyrophosphate Injection has a specific affinity for areas of osteogenesis and is concentrated in the injured myocardium, primarily in areas of irreversibly damaged myocardial cells. This indicates that the drug itself is not associated with cardiotoxicity risk but rather has an affinity for damaged myocardial cells.

2. The label also states that false negative images can occur in the diagnosis of confirmed myocardial infarction when using this drug as an adjunct, with an incidence of 6 percent. Additionally, false positive images have been reported in various cardiac conditions. These risks suggest that the drug itself may not directly cause cardiotoxicity but can lead to inaccurate imaging results in cardiac evaluations.

3. Preliminary reports mentioned in the label indicate that brain scans using Sodium Pertechnetate Tc99m Injection, which is used in conjunction with this drug, may be impaired if preceded by a bone scan using an agent containing stannous ions. This impairment could result in false positive or false negative brain scans. This suggests that the combination of the two agents may lead to cardiotoxicity risks related to brain imaging accuracy.

In summary, while the drug Technetium Tc 99m Pyrophosphate Injection itself is not directly associated with cardiotoxicity risks, it can lead to false imaging results in cardiac evaluations and may impact brain scans when used in combination with other agents, potentially affecting patient care and outcomes.",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",1f0cbd23-2fb3-43b7-b8af-7de246151149,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=1f0cbd23-2fb3-43b7-b8af-7de246151149&type=display
1046,TEDIZOLID PHOSPHATE,"1. In the Clinical Pharmacology section, it is mentioned that SIVEXTRO does not affect cardiac repolarization based on a thorough QTc study, indicating that the drug itself is not associated with cardiotoxicity risks.

2. No other sections of the drug label mention any cardiotoxicity risks or reactions associated with SIVEXTRO, suggesting that cardiotoxicity is not a known concern with the use of this medication.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",75672079-589f-451a-bdbf-eaebcfcc80a9,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=75672079-589f-451a-bdbf-eaebcfcc80a9&type=display
1047,TEGASEROD,"1. ZELNORM is contraindicated in patients with a history of myocardial infarction, stroke, transient ischemic attack, or angina, indicating that the drug itself is associated with cardiotoxicity risks.

2. The drug label warns about cardiovascular ischemic events, including major adverse cardiovascular events (MACE), in patients taking ZELNORM. It states that patients with an increased risk of developing adverse cardiovascular events based on their medical history should be assessed before treatment with ZELNORM, suggesting an association between the drug and cardiotoxicity risks.

3. The label advises discontinuing ZELNORM in patients who experience a myocardial infarction, stroke, transient ischemic attack, or angina, indicating that the drug may contribute to these cardiovascular events.

4. A retrospective analysis of clinical trial data identified an imbalance in major adverse cardiovascular events (MACE) in patients taking ZELNORM compared to placebo, particularly in patients with a history of cardiovascular ischemic disease and/or multiple cardiovascular risk factors, suggesting a potential association between the drug and cardiotoxicity risks.

5. The drug label mentions that ZELNORM was associated with an increase in abdominal surgeries, primarily due to a numerical imbalance in cholecystectomies reported in patients treated with ZELNORM, indicating a potential link between the drug and abdominal surgical procedures.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",6a44eefe-fbe8-431c-a418-2571b26aa42e,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=6a44eefe-fbe8-431c-a418-2571b26aa42e&type=display
1048,TELAVANCIN HYDROCHLORIDE,"1. The drug label warns about QTc prolongation risks associated with VIBATIV, stating that doses of the drug prolonged the QTc interval in healthy volunteers. The drug label advises caution when prescribing VIBATIV to patients taking drugs known to prolong the QT interval, and it should be avoided in patients with certain cardiac conditions.

2. Telavancin, the active ingredient in VIBATIV, is mentioned to interfere with certain coagulation tests used to monitor blood clotting. The drug label specifies that telavancin interferes with laboratory coagulation tests, including prothrombin time, international normalized ratio, and activated partial thromboplastin time, when samples are drawn within 0 to 18 hours after VIBATIV administration.

3. The drug label does not directly associate VIBATIV with cardiotoxicity reactions but mentions that telavancin, the drug's active ingredient, does not interfere with coagulation itself. However, telavancin interferes with specific coagulation tests, and alternative tests or anticoagulants may be considered for patients requiring monitoring while on VIBATIV treatment.",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",5359b759-db7c-4672-9e8a-59c93869bd91,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=5359b759-db7c-4672-9e8a-59c93869bd91&type=display
1049,TELITHROMYCIN,"1. Telithromycin, the active ingredient in Ketek tablets, has the potential to prolong the QTc interval of the electrocardiogram in some patients, which may lead to an increased risk for ventricular arrhythmias, including torsades de pointes. Telithromycin itself is associated with the risk of QTc prolongation and subsequent ventricular arrhythmias.

2. Cases of torsades de pointes have been reported post-marketing with Ketek, although no cardiovascular morbidity or mortality attributable to QTc prolongation occurred in clinical trials involving 4780 patients. Ketek has been associated with cases of torsades de pointes, a serious ventricular arrhythmia.

3. Telithromycin should be avoided in patients with congenital prolongation of the QTc interval, ongoing proarrhythmic conditions, or those receiving certain antiarrhythmic agents. The drug itself is linked to the risk of QTc prolongation and should be avoided in specific patient populations.

4. Ketek has been associated with visual disturbances, including blurred vision, difficulty focusing, and diplopia, which may affect activities such as driving or operating machinery. The drug itself is linked to visual disturbances that can impact daily activities.

5. Ketek has been reported to cause transient loss of consciousness, including cases associated with vagal syndrome. The drug itself is associated with the risk of transient loss of consciousness, which may pose a safety concern for patients.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",ba1cca98-f350-4655-88e3-6ef990779fb9,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=ba1cca98-f350-4655-88e3-6ef990779fb9&type=display
1050,TELMISARTAN,"1. The drug label warns about fetal toxicity associated with the use of MICARDIS during pregnancy, stating that drugs acting on the renin-angiotensin system can cause injury and death to the developing fetus. MICARDIS should be discontinued as soon as pregnancy is detected to avoid fetal harm.

2. The label mentions that in patients with an activated renin-angiotensin system, such as volume- or salt-depleted patients, symptomatic hypotension may occur after initiating therapy with MICARDIS. It advises correcting this condition before administration or starting treatment under close medical supervision with a reduced dose.

3. Hyperkalemia may occur in patients on angiotensin II receptor blockers like MICARDIS, particularly in those with advanced renal impairment, heart failure, or on certain medications. Periodic monitoring of serum electrolytes is recommended to detect possible imbalances, especially in high-risk patients.

4. The label cautions about the potential changes in renal function in susceptible individuals due to inhibiting the renin-angiotensin-aldosterone system with MICARDIS. It mentions that treatment with angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor antagonists, including MICARDIS, has been associated with renal function changes, oliguria, and acute renal failure in certain patients.

5. Dual blockade of the renin-angiotensin-aldosterone system with angiotensin-receptor blockers, ACE inhibitors, or aliskiren is linked to increased risks of hypotension, hyperkalemia, and changes in renal function compared to monotherapy. The label advises against combining RAS inhibitors and recommends close monitoring of blood pressure, renal function, and electrolytes in patients on MICARDIS and other RAS-affecting agents.",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",cfb9309f-e0df-4a55-9542-0e869fce05fb,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=cfb9309f-e0df-4a55-9542-0e869fce05fb&type=display
1051,TELOTRISTAT ETHYL,"1. The drug Xermelo (telotristat ethyl) was studied in healthy subjects and did not prolong the QT interval to any clinically relevant extent, indicating no direct association with cardiotoxicity risk.

2. Telotristat ethyl, the active metabolite of Xermelo, was not found to induce or inhibit CYP enzymes in
in vitro
studies, suggesting a low potential for drug interactions that could lead to cardiotoxicity.

3. In a clinical trial, Xermelo did not show improvement in symptoms of carcinoid syndrome such as abdominal pain or flushing, indicating no direct cardiotoxic effects associated with the drug itself.

4. The drug Xermelo was not associated with any adverse cardiac events or cardiotoxicity reactions in the clinical trial data provided in the drug label.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",f9108ac3-ca6e-4faf-9d04-953abb64d072,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=f9108ac3-ca6e-4faf-9d04-953abb64d072&type=display
1052,TEMAZEPAM,"1. The drug label warns about the risks associated with concomitant use of benzodiazepines like temazepam capsules and opioids, which may lead to profound sedation, respiratory depression, coma, and death. The drug itself is not directly associated with cardiotoxicity but warns about the risks when used in combination with opioids.

2. The label mentions that benzodiazepines, including temazepam capsules, can lead to risks of abuse, misuse, and addiction, potentially resulting in overdose or death. While not directly linked to cardiotoxicity, the abuse and misuse of benzodiazepines can lead to serious adverse outcomes, including respiratory depression, which can impact cardiovascular function.

3. It is highlighted that continued use of benzodiazepines, such as temazepam capsules, may result in physical dependence, with risks increasing with longer treatment duration and higher doses. Abrupt discontinuation or rapid dosage reduction of temazepam capsules can lead to acute withdrawal reactions, which can be life-threatening. While not explicitly stating cardiotoxicity, abrupt withdrawal can lead to severe physiological responses that may impact cardiovascular health.",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",c9bc61b4-a579-4003-98da-b6f6e381c150,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=c9bc61b4-a579-4003-98da-b6f6e381c150&type=display
1053,TEMOZOLOMIDE,1. The drug TEMODAR does not appear to be associated with cardiotoxicity risks or cardiotoxicity reactions based on the provided drug label information. No specific mention of cardiotoxicity risks or reactions related to the heart or cardiovascular system was found in the drug label.,No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",046a9011-3911-4d3f-a15f-fbb56d5aad56,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=046a9011-3911-4d3f-a15f-fbb56d5aad56&type=display
1054,TEMSIROLIMUS,"1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with TORISEL (temsirolimus) itself.

2. The drug label primarily focuses on adverse reactions related to hypersensitivity/infusion reactions, hepatic impairment, hyperglycemia, infections, interstitial lung disease, hyperlipidemia, bowel perforation, renal failure, wound healing complications, intracerebral hemorrhage, proteinuria, and nephrotic syndrome. 

3. While TORISEL is not directly linked to cardiotoxicity risks or reactions in the provided drug label, it is essential to consult healthcare professionals for a comprehensive understanding of potential cardiotoxic effects or interactions with other medications that may impact cardiovascular health.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",95b7dc92-2180-42f1-8699-3c28f609e674,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=95b7dc92-2180-42f1-8699-3c28f609e674&type=display
1055,TENAPANOR HYDROCHLORIDE,"1. The drug label does not mention any cardiotoxicity risks or reactions associated with IBSRELA (tenapanor) tablets. 

Therefore, based on the information provided in the drug label, there are no indications that IBSRELA is associated with cardiotoxicity risks or reactions.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",2102da5f-a1a0-4ac7-a1f6-38698cf7273a,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=2102da5f-a1a0-4ac7-a1f6-38698cf7273a&type=display
1056,TENOFOVIR ALAFENAMIDE,"1. The drug label for VEMLIDY does not mention any specific cardiotoxicity risks or reactions associated with the drug itself. 

2. The label primarily focuses on warnings and precautions related to severe acute exacerbation of hepatitis B upon discontinuation of treatment, risk of HIV-1 resistance in coinfected patients, renal impairment, and lactic acidosis/hepatomegaly with steatosis. 

3. While the label does not directly link VEMLIDY to cardiotoxicity risks or reactions, it is essential for healthcare providers to monitor patients for any signs or symptoms of cardiotoxicity during treatment with VEMLIDY, as with any medication. 

4. Patients should report any new or worsening symptoms that could potentially be related to cardiotoxicity to their healthcare provider promptly for further evaluation and management. 

5. Overall, the drug label does not highlight cardiotoxicity as a specific risk associated with VEMLIDY but emphasizes the importance of monitoring and reporting any adverse reactions during treatment.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",72e6b33c-0351-4070-9172-eeaa186c01d2,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=72e6b33c-0351-4070-9172-eeaa186c01d2&type=display
1057,TENOFOVIR DISOPROXIL FUMARATE,"1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with VIREAD itself. 

2. VIREAD is primarily associated with renal impairment, bone mineral density changes, and lactic acidosis/severe hepatomegaly with steatosis, but no direct cardiotoxicity risks or reactions are mentioned in the label. 

3. The adverse reactions listed in the label focus on renal impairment, bone loss, and liver-related issues, with no explicit mention of cardiotoxicity risks or reactions attributed to VIREAD. 

In summary, the drug label for VIREAD does not highlight any cardiotoxicity risks or reactions directly linked to the use of the medication.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",33fd6418-fbdc-42ca-a50d-ce2a476a5418,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=33fd6418-fbdc-42ca-a50d-ce2a476a5418&type=display
1058,TEPOTINIB HYDROCHLORIDE,"1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with TEPMETKO (tepotinib) tablets for the treatment of metastatic non-small cell lung cancer harboring MET exon 14 skipping alterations.

2. The drug label does not indicate any cardiotoxicity risks or reactions directly caused by TEPMETKO. 

3. No information is provided in the drug label regarding cardiotoxicity risks or reactions related to the use of TEPMETKO. 

Overall, based on the information provided in the drug label, there are no mentions of cardiotoxicity risks or reactions associated with TEPMETKO.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",80a0f1b9-071a-47f5-9e67-32d638a669dc,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=80a0f1b9-071a-47f5-9e67-32d638a669dc&type=display
1059,TERAZOSIN,"1. The drug terazosin, an alpha-1-selective adrenoceptor blocking agent, has been associated with lowering blood pressure in hypertensive patients due to its vasodilatory hypotensive action by blocking alpha-1-adrenoceptors. This effect is mainly responsible for decreasing total peripheral vascular resistance, leading to a gradual decrease in blood pressure within 15 minutes following oral administration.

2. In clinical trials, patients with mild or moderate hypertension who were administered terazosin experienced a decrease in blood pressure, with effects persisting throughout the dosing interval. The drug showed a greater blood pressure effect associated with peak plasma concentrations shortly after dosing, with a position-dependent increase in the erect position and a slight increase in heart rate in the first few hours after dosing.

3. Patients treated with terazosin may experience orthostatic hypotension, with symptoms such as dizziness, lightheadedness, and palpitations being common. The risk of orthostatic effects is greatest during the initial seven days of treatment but continues at all time intervals. Patients with occupations where such events could pose risks should be treated with caution.

4. In clinical trials, syncope (fainting) was reported in about 1% of hypertensive patients treated with terazosin, and syncope was not necessarily associated only with the first dose. If syncope occurs, patients should be placed in a recumbent position and treated supportively as necessary. The orthostatic effect of terazosin is greater shortly after dosing, and the risk of events is highest during the initial seven days of treatment but persists at all time intervals.

5. Rarely, terazosin and other alpha-1 antagonists have been associated with priapism (painful penile erection) in patients. Priapism is a serious condition that can lead to permanent impotence if not promptly treated. Patients must be advised about the seriousness of this condition and seek immediate medical attention if priapism occurs.",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",64251bda-afa8-4d0e-93dd-36753dd5f112,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=64251bda-afa8-4d0e-93dd-36753dd5f112&type=display
1060,TERBINAFINE HYDROCHLORIDE,"1. The drug label for Terbinafine tablets does not mention any specific cardiotoxicity risks or reactions associated with the drug itself. 

2. The label primarily focuses on hepatotoxicity risks, taste disturbance, smell disturbance, depressive symptoms, hematologic effects, and serious skin/hypersensitivity reactions. 

3. While the label does not highlight any direct cardiotoxicity risks or reactions linked to Terbinafine tablets, it is important to consult with a healthcare provider for a comprehensive understanding of potential side effects and risks associated with this medication.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",2886b2ff-815f-4621-bc28-1fea082c1920,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=2886b2ff-815f-4621-bc28-1fea082c1920&type=display
1061,TERBUTALINE SULFATE,"1. The drug label warns against prolonged tocolysis with terbutaline sulfate, stating that it should not be used for maintenance tocolysis due to serious adverse reactions, including death, reported in pregnant women. The drug itself is associated with the risk of cardiotoxicity reactions such as increased heart rate, cardiac arrhythmias, pulmonary edema, and myocardial ischemia in pregnant women.

2. The label mentions that terbutaline sulfate, as a beta-adrenergic agonist, can produce clinically significant cardiovascular effects in some patients, including changes in pulse rate, blood pressure, and ECG findings. While these effects are uncommon at recommended doses, the drug itself is associated with the risk of cardiotoxicity reactions.

3. Additionally, the label highlights that terbutaline sulfate may cause seizures in rare cases, with no recurrence upon discontinuation of the drug. The drug itself is associated with the risk of seizures as a potential cardiotoxicity reaction.

4. The label advises caution in using terbutaline sulfate in patients with cardiovascular disorders, as beta-adrenergic agonists like terbutaline can lead to significant cardiovascular effects. The drug itself is associated with the risk of cardiotoxicity reactions, especially in patients with underlying cardiovascular conditions.

5. Furthermore, the label mentions that terbutaline sulfate should be used with caution in patients with hypertension, coronary insufficiency, and cardiac arrhythmias due to potential cardiovascular effects. The drug itself is associated with the risk of cardiotoxicity reactions, particularly in patients with pre-existing cardiovascular disorders.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",613df3cb-4d55-4d12-ab08-a932481aaa0b,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=613df3cb-4d55-4d12-ab08-a932481aaa0b&type=display
1062,TERIFLUNOMIDE,"1. A total of four cardiovascular deaths, including sudden deaths and one myocardial infarction, were reported among approximately 2600 patients exposed to AUBAGIO in the premarketing database. These events occurred during uncontrolled extension studies, one to nine years after initiation of treatment. (The drug, AUBAGIO, was associated with cardiovascular deaths in the premarketing database.)

Please note that this summary is based on the information provided in the drug label you shared. It is important to consult the full prescribing information and healthcare professionals for comprehensive information on cardiotoxicity risks associated with AUBAGIO.",Less,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",4650d12c-b9c8-4525-b07f-a2d773eca155,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=4650d12c-b9c8-4525-b07f-a2d773eca155&type=display
1063,TERIPARATIDE,"1. **Warnings and Precautions, Osteosarcoma**: The drug FORTEO is associated with an increased risk of osteosarcoma, a malignant bone tumor, in both animal studies and post-marketing reports. However, an increased risk of osteosarcoma has not been observed in observational studies in humans.

2. **Warnings and Precautions, Hypercalcemia and Cutaneous Calcification**: FORTEO may cause hypercalcemia, which can lead to cardiotoxicity, especially in patients with pre-existing hypercalcemia. Additionally, serious reports of cutaneous calcification, including calciphylaxis, have been reported in patients taking FORTEO, which can have systemic effects, including potential cardiotoxicity.

3. **Drug Interactions, Digoxin**: FORTEO may transiently increase serum calcium levels, which can predispose patients to digitalis toxicity when used concomitantly with digoxin. This interaction poses a risk of cardiotoxicity due to the potential for increased serum calcium levels.

4. **Adverse Reactions, Postmarketing Experience**: Cases of hypercalcemia greater than 13 mg/dL have been reported with FORTEO use, which can lead to cardiotoxic effects. Additionally, sporadic reports of chest pain and acute dyspnea have been associated with FORTEO use, indicating potential cardiotoxic reactions.

In summary, FORTEO is associated with cardiotoxicity risks, primarily through the potential development of hypercalcemia, which can lead to cardiac complications. Patients taking FORTEO should be monitored for signs of cardiotoxicity, especially those with pre-existing cardiac conditions or those taking medications that may interact with FORTEO to increase the risk of cardiotoxic effects.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",aae667c5-381f-4f92-93df-2ed6158d07b0,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=aae667c5-381f-4f92-93df-2ed6158d07b0&type=display
1064,TESTOSTERONE CYPIONATE,"1. **Cardiovascular Risk**: Testosterone Cypionate Injection may increase the risk of major adverse cardiovascular events (MACE). This risk is associated with the use of the drug, as stated in the drug label.

2. **Worsening of Benign Prostatic Hyperplasia (BPH) and Potential Risk of Prostate Cancer**: Patients with BPH treated with androgens, including Testosterone Cypionate Injection, are at an increased risk for worsening signs and symptoms of BPH. This risk is associated with the use of the drug, as mentioned in the drug label.

3. **Venous Thromboembolism (VTE)**: VTE, including deep vein thrombosis (DVT) and pulmonary embolism (PE), have been reported in patients using testosterone products like Testosterone Cypionate Injection. This risk is associated with the use of the drug, as highlighted in the drug label.

4. **Edema**: Edema, with or without congestive heart failure (CHF), may occur in patients with pre-existing cardiac, renal, or hepatic disease who are using Testosterone Cypionate Injection. This risk is associated with the use of the drug, as indicated in the drug label.

5. **Sleep Apnea**: Testosterone Cypionate Injection may potentiate sleep apnea in patients with risk factors such as obesity or chronic lung diseases. This risk is associated with the use of the drug, as outlined in the drug label.

6. **Lipid Changes**: Testosterone may affect serum lipid profile, potentially requiring adjustments in lipid-lowering drugs or discontinuation of Testosterone Cypionate Injection. This risk is associated with the use of the drug, as specified in the drug label.

7. **Adverse Effects on Bone Maturation**: Testosterone use may result in acceleration of bone age and premature closure of epiphyses in pediatric patients, potentially compromising adult stature. This risk is associated with the use of the drug, as detailed in the drug label.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",cb411b78-0072-42b0-b75d-85ee96cfbf3c,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=cb411b78-0072-42b0-b75d-85ee96cfbf3c&type=display
1065,TESTOSTERONE ENANTHATE,"1. The drug XYOSTED can cause blood pressure increases that may lead to major adverse cardiovascular events (MACE), including non-fatal myocardial infarction, non-fatal stroke, and cardiovascular death. This risk is associated with the use of XYOSTED itself.

2. Before initiating XYOSTED, it is important to consider the patient's baseline cardiovascular risk and ensure that blood pressure is adequately controlled. This is a precautionary measure to manage the cardiotoxicity risk associated with XYOSTED.

3. Periodic monitoring for new-onset hypertension or exacerbations of pre-existing hypertension is recommended while using XYOSTED. Re-evaluation of the benefits versus risks of XYOSTED is necessary for patients who develop cardiovascular risk factors or disease during treatment. These actions are taken to address the cardiotoxicity risks linked to XYOSTED.

4. The drug label specifies that XYOSTED should only be used for the treatment of men with hypogonadal conditions associated with structural or genetic etiologies due to the cardiotoxicity risks involved with its use.

5. Long-term clinical safety trials have not been completed to fully assess the cardiovascular outcomes of testosterone replacement therapy, including XYOSTED, in adult males. This indicates a general concern about cardiotoxicity risks associated with testosterone replacement therapy, including XYOSTED.

6. Patients should be informed of the potential risk of major adverse cardiovascular events (MACE) when deciding to use or continue using XYOSTED. This is to ensure that patients are aware of the cardiotoxicity risks associated with XYOSTED.

7. The drug label also mentions that XYOSTED can cause increases in systolic blood pressure, which can contribute to the risk of MACE. This highlights the direct association of XYOSTED with cardiotoxicity risks.

Overall, the drug label emphasizes the importance of monitoring blood pressure, considering cardiovascular risk factors, and evaluating the benefits versus risks of XYOSTED to manage the cardiotoxicity risks associated with the drug.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",8a3d204c-be26-49e0-8599-0ac12a272e81,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8a3d204c-be26-49e0-8599-0ac12a272e81&type=display
1066,TESTOSTERONE UNDECANOATE,"1. TLANDO can cause blood pressure increases that may elevate the risk of major adverse cardiovascular events (MACE), such as non-fatal myocardial infarction, non-fatal stroke, and cardiovascular death. The drug itself is associated with the risk of blood pressure increases and subsequent cardiovascular events.

2. Before initiating TLANDO, it is important to consider the patient's baseline cardiovascular risk and ensure that blood pressure is adequately controlled. This precaution is necessary due to the cardiotoxicity risk associated with TLANDO.

3. Periodic monitoring for new-onset hypertension or exacerbations of pre-existing hypertension is recommended after starting TLANDO. This monitoring is essential to detect and manage potential cardiotoxicity reactions associated with the drug.

4. Re-evaluation of the benefits versus risks of TLANDO is advised for patients who develop cardiovascular risk factors or cardiovascular disease during treatment. This re-evaluation is necessary to assess the ongoing cardiotoxicity risks of using TLANDO.

5. TLANDO should only be used for the treatment of men with hypogonadal conditions associated with structural or genetic etiologies. This limitation is imposed to minimize the cardiotoxicity risks associated with the drug and ensure appropriate use in the indicated patient population.

6. Long-term clinical safety trials have not been conducted to assess the cardiovascular outcomes of testosterone replacement therapy in men. This lack of data highlights the importance of monitoring for cardiotoxicity risks and reactions during TLANDO treatment.

7. Patients should be informed of the potential risk of blood pressure increases and major adverse cardiovascular events when deciding to use or continue using TLANDO. This information is crucial for patients to understand the cardiotoxicity risks associated with the drug.

8. TLANDO can cause increases in blood pressure that may lead to major adverse cardiovascular events. The drug itself is directly linked to the risk of blood pressure elevation and subsequent cardiovascular complications.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",4b0b92e9-6d3c-a0e5-e1c7-342999f72580,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=4b0b92e9-6d3c-a0e5-e1c7-342999f72580&type=display
1067,TETRABENAZINE,"1. XENAZINE can cause a small increase in the corrected QT (QTc) interval, which may lead to the development of torsade de pointes-type ventricular tachycardia. The risk of torsade de pointes increases with the degree of QT prolongation caused by XENAZINE. (The drug itself is associated with QT prolongation and the risk of torsade de pointes.)

2. XENAZINE should be avoided in combination with other drugs known to prolong the QTc interval, such as antipsychotic medications, antibiotics, and certain antiarrhythmic medications. (The drug itself is not causing cardiotoxicity but is associated with an increased risk when combined with other QT-prolonging drugs.)

3. XENAZINE should also be avoided in patients with congenital long QT syndrome and those with a history of cardiac arrhythmias, as certain circumstances can further increase the risk of torsade de pointes and sudden death when using drugs that prolong the QTc interval. (The drug itself is not causing cardiotoxicity but is associated with an increased risk in specific patient populations.)

4. XENAZINE has been associated with postural dizziness in healthy volunteers, with one subject experiencing syncope and another subject having documented orthostasis. Monitoring of vital signs on standing should be considered in patients vulnerable to hypotension. (The drug itself is associated with postural dizziness and orthostatic hypotension.)

5. XENAZINE elevates serum prolactin concentrations, which can have implications for patients with prolactin-dependent conditions such as breast cancer. Chronic increase in serum prolactin levels has been associated with low estrogen levels and an increased risk of osteoporosis. If symptomatic hyperprolactinemia is suspected, appropriate laboratory testing should be done, and consideration should be given to discontinuing XENAZINE. (The drug itself is associated with hyperprolactinemia, which can have clinical implications for certain patients.)

6. XENAZINE binds to melanin-containing tissues, raising the possibility of accumulation and potential toxicity in these tissues over time. The clinical relevance of this binding is unknown, but prescribers should be aware of the possibility of long-term ophthalmologic effects. (The drug itself is associated with binding to melanin-containing tissues, which may lead to potential toxicity over extended use.)

In summary, XENAZINE is associated with cardiotoxicity risks such as QT prolongation and potential torsade de pointes, as well as other cardiovascular effects like postural dizziness and hyperprolactinemia. Prescribers should be cautious when using XENAZINE in patients with underlying cardiac conditions or those at risk for QT prolongation.",Less,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",ac768bab-8afa-4446-bc7f-caeeffec0cda,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=ac768bab-8afa-4446-bc7f-caeeffec0cda&type=display
1068,TETRACYCLINE HYDROCHLORIDE,"1. The drug label does not mention any specific cardiotoxicity risks associated with tetracycline hydrochloride capsules.
2. The drug label does not mention any cardiotoxicity reactions associated with tetracycline hydrochloride capsules.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",2c9208db-5f4f-4382-854f-6786b1e458db,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=2c9208db-5f4f-4382-854f-6786b1e458db&type=display
1069,TETRADECYL HYDROGEN SULFATE (ESTER),"1. The drug label mentions that stroke, transient ischemic attack, myocardial infarction, and impaired cardiac function have been reported in close temporal relationship with the administration of Sotradecol (sodium tetradecyl sulfate injection). This suggests that the drug itself is associated with cardiotoxicity risks.

2. It is also noted that these events may be caused by air embolism when using the product foamed with room air or thromboembolism. The safety and efficacy of Sotradecol foamed with room air have not been established, and its use should be avoided. This indicates that the drug itself can lead to cardiotoxicity reactions, particularly when used in specific formulations.

3. The label further warns about the development of deep vein thrombosis and pulmonary embolism following sclerotherapy treatment with sodium tetradecyl sulfate. Patients are advised to have post-treatment follow-up to assess for the development of deep vein thrombosis. This suggests that the drug can contribute to cardiotoxicity reactions such as thromboembolic events.

4. Additionally, the label mentions that arterial embolism, including stroke, transient ischemic attack, myocardial infarction, and impaired cardiac function, have been reported in association with the administration of Sotradecol. This indicates that the drug itself is linked to cardiotoxicity risks and reactions.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",f1756c28-dcd2-4b49-be62-07ca20682018,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=f1756c28-dcd2-4b49-be62-07ca20682018&type=display
1070,TETROFOSMIN,"1. **Warnings and Precautions (5.1):**
   - **Risk with exercise or pharmacologic stress:** The drug label mentions that patients evaluated with exercise or pharmacologic stress may experience serious adverse reactions such as myocardial infarction, arrhythmia, hypotension, bronchoconstriction, and cerebrovascular reactions. The drug itself is not directly associated with causing these risks but highlights the potential risks associated with stress testing procedures.

2. **Warnings and Precautions (5.2):**
   - **Radiation Risks:** The drug label states that technetium Tc99m contributes to a patient's overall long-term cumulative radiation exposure, which is associated with an increased risk of cancer. It emphasizes the importance of safe handling and preparation procedures to protect patients and healthcare workers from unintentional radiation exposure. The drug itself is not directly causing cardiotoxicity but is associated with radiation risks that can have long-term effects on the heart.

3. **Warnings and Precautions (5.3):**
   - **Hypersensitivity Reactions:** The drug label mentions hypersensitivity reactions, including anaphylaxis, dyspnea, bronchospasm, throat tightness, and other reactions, that have been observed after the administration of MYOVIEW. While not directly related to cardiotoxicity, these reactions can impact cardiovascular function and require monitoring and appropriate management.",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",98c85037-a907-4a3a-8864-c3a5298b4759,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=98c85037-a907-4a3a-8864-c3a5298b4759&type=display
1071,THALIDOMIDE,"1. The drug label warns of ischemic heart disease, including myocardial infarction, and stroke observed in patients treated with THALOMID in combination with dexamethasone. This suggests that THALOMID, when used in combination with dexamethasone, has been associated with cardiotoxicity risks.

2. The label also mentions cases of bradycardia reported in patients treated with THALOMID, some of which required medical interventions. This indicates that THALOMID itself has been associated with the risk of bradycardia, a form of cardiotoxicity.

3. Additionally, the label advises monitoring patients for bradycardia and possible syncope, with dose reduction or discontinuation of THALOMID potentially required. This suggests that THALOMID can lead to bradycardia, a cardiotoxic reaction that may necessitate changes in treatment.

4. The drug label highlights the occurrence of ischemic heart disease, including myocardial infarction, and stroke in patients with previously untreated multiple myeloma treated with THALOMID and dexamethasone. This indicates that THALOMID, in combination with dexamethasone, has been associated with cardiotoxicity reactions such as ischemic heart disease and stroke.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",2eda833b-1357-4ed4-a093-194524fcb061,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=2eda833b-1357-4ed4-a093-194524fcb061&type=display
1072,THEOPHYLLINE,"1. Theophylline should be used with extreme caution in patients with cardiac arrhythmias due to the increased risk of exacerbation of the concurrent condition. (The drug itself was not associated with causing cardiotoxicity but may exacerbate existing cardiac arrhythmias.)

2. Theophylline clearance is decreased by 50% or more in patients with congestive heart failure (CHF), and the extent of reduction in clearance appears to be directly correlated to the severity of the cardiac disease. (The drug itself was not associated with causing cardiotoxicity but may lead to decreased clearance in patients with CHF.)

3. Careful attention to dose reduction and frequent monitoring of serum theophylline concentrations are required in patients with CHF due to the decreased clearance of theophylline in these patients. (The drug itself was not associated with causing cardiotoxicity but may require dose adjustments in patients with CHF.)

4. Theophylline clearance is decreased by 50% or more in patients with hepatic insufficiency, such as cirrhosis, acute hepatitis, or cholestasis. (The drug itself was not associated with causing cardiotoxicity but may lead to decreased clearance in patients with hepatic insufficiency.)

5. Careful attention to dose reduction and frequent monitoring of serum theophylline concentrations are required in patients with reduced hepatic function due to the decreased clearance of theophylline in these patients. (The drug itself was not associated with causing cardiotoxicity but may require dose adjustments in patients with reduced hepatic function.)

6. Theophylline should be used with caution in patients with conditions that reduce theophylline clearance, such as acute pulmonary edema, congestive heart failure, cor pulmonale, fever, reduced renal function in infants, sepsis with multi-organ failure, and shock. (The drug itself was not directly associated with causing cardiotoxicity but may require caution and monitoring in patients with conditions affecting theophylline clearance.)",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",417c9df3-ed15-40ea-a653-b0442f367a54,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=417c9df3-ed15-40ea-a653-b0442f367a54&type=display
1073,THIAMINE HYDROCHLORIDE,"1. The drug label warns that thiamine hydrochloride injection contains aluminum, which may be toxic, especially with prolonged parenteral administration in patients with impaired kidney function, potentially leading to cardiotoxicity. The drug itself is not directly associated with cardiotoxicity but may contribute to aluminum toxicity, which can affect the heart.

2. The label mentions that patients with marginal thiamine status receiving dextrose intravenously should be given thiamine hydrochloride to prevent heart failure, indicating a potential risk of cardiotoxicity if thiamine deficiency is not addressed promptly. The drug itself is not causing cardiotoxicity but is necessary to prevent potential heart failure in this specific scenario.",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",63f3631b-ba1e-430c-a30b-dd05b2c00c13,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=63f3631b-ba1e-430c-a30b-dd05b2c00c13&type=display
1074,THIOGUANINE,1. The drug label does not specifically mention cardiotoxicity risks or cardiotoxicity reactions associated with thioguanine.,No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",44b0c461-47fb-4106-ba11-6ed85530235c,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=44b0c461-47fb-4106-ba11-6ed85530235c&type=display
1075,THIORIDAZINE HYDROCHLORIDE,"1. Thioridazine has been shown to prolong the QTc interval in a dose-related manner, and drugs with this potential, including thioridazine, have been associated with Torsades de pointes type arrhythmias and sudden death. (The drug itself is associated with cardiotoxicity risks.)

2. Thioridazine produces a dose-related prolongation of the QTc interval, which is associated with the ability to cause Torsades de pointes type arrhythmias, a potentially fatal polymorphic ventricular tachycardia, and sudden death. (The drug itself is associated with cardiotoxicity risks.)

3. Both Torsades de pointes type arrhythmias and sudden death have been reported in association with thioridazine. A causal relationship between these events and thioridazine therapy has not been established but, given the ability of thioridazine to prolong the QTc interval, such a relationship is possible. (The drug itself is associated with cardiotoxicity reactions.)

4. A crossover study in nine healthy males comparing single doses of thioridazine 10 mg and 50 mg with placebo demonstrated a dose-related prolongation of the QTc interval. (The drug itself is associated with cardiotoxicity risks.)

5. Prolongation of the QTc interval has been associated with the ability to cause Torsades de pointes type arrhythmias, a potentially fatal polymorphic ventricular tachycardia, and sudden death. (The drug itself is associated with cardiotoxicity risks.)

6. There are several published case reports of Torsades de pointes and sudden death associated with thioridazine treatment. A causal relationship between these events and thioridazine therapy has not been established but, given the ability of thioridazine to prolong the QTc interval, such a relationship is possible. (The drug itself is associated with cardiotoxicity reactions.)

7. Thioridazine can be toxic in overdose, with cardiac toxicity being of particular concern. (The drug itself is associated with cardiotoxicity risks.)",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",52fea941-0b47-41c1-b00d-f88150e8ab93,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=52fea941-0b47-41c1-b00d-f88150e8ab93&type=display
1076,THIOTHIXENE,"1. The drug label warns about the risk of increased mortality in elderly patients with dementia-related psychosis when treated with antipsychotic drugs, including thiothixene. The label states that the risk of death in drug-treated patients was higher compared to placebo-treated patients, with most deaths attributed to cardiovascular or infectious causes. Thiothixene is not approved for treating patients with dementia-related psychosis.

2. The label mentions that thiothixene may cause cardiovascular effects such as tachycardia, hypotension, lightheadedness, and syncope. It notes that nonspecific EKG changes have been observed in some patients receiving thiothixene, although the clinical significance of these changes is not known.

3. Thiothixene may lead to CNS effects like drowsiness, sedation, restlessness, agitation, and insomnia. Seizures and exacerbation of psychotic symptoms have been reported infrequently. Hyperreflexia has been observed in infants born to mothers who received structurally related drugs.

4. The drug label mentions that thiothixene can cause extrapyramidal symptoms, including pseudoparkinsonism, akathisia, and dystonia. Management of these symptoms depends on the type and severity, with rapid relief requiring the use of antiparkinson agents.

5. Thiothixene may result in dystonia, characterized by prolonged abnormal muscle contractions, especially in susceptible individuals during the initial days of treatment. Symptoms include spasm of neck muscles, swallowing difficulty, and tongue protrusion. The risk of acute dystonia is higher in males and younger age groups.

6. The label warns about persistent tardive dyskinesia that may occur in some patients on long-term thiothixene therapy or after discontinuation. Tardive dyskinesia is characterized by involuntary movements of the tongue, face, mouth, or jaw. Early detection is crucial, and patients should be monitored regularly.

7. Thiothixene may cause hepatic effects, including elevations in serum transaminase and alkaline phosphatase levels. Although transient, these effects have been infrequently observed. No clinically confirmed cases of jaundice due to thiothixene have been reported.

8. Hematologic effects such as leukopenia, leukocytosis, and occasionally agranulocytosis can occur with thiothixene. Other antipsychotic drugs have been associated with various blood disorders like agranulocytosis, eosinophilia, and anemia.

9. Thiothixene may lead to allergic reactions like rash, pruritus, urticaria, and photosensitivity. Although rare, cases of anaphylaxis have been reported. Exposure to sunlight should be minimized to avoid adverse skin reactions.

10. Autonomic effects such as dry mouth, blurred vision, constipation, increased sweating, and impotence may occur with thiothixene therapy. While infrequent, these effects should be monitored. Other antipsychotic drugs have been associated with additional autonomic effects like miosis and adynamic ileus.",Less,Yes,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",81c40311-7dc4-4332-8920-a39a8466aea6,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=81c40311-7dc4-4332-8920-a39a8466aea6&type=display
1077,TIAGABINE,1. The drug label does not mention any cardiotoxicity risks or reactions associated with tiagabine hydrochloride tablets.,No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",7036c6df-6527-4701-b484-6b962914b52a,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7036c6df-6527-4701-b484-6b962914b52a&type=display
1078,TICAGRELOR,"1. **Cardiotoxicity Risk Associated with Drug:**
   - BRILINTA is a P2Y12 platelet inhibitor that can cause significant, sometimes fatal bleeding, similar to other antiplatelet agents. This bleeding risk is highlighted as a warning in the drug label. The drug itself is associated with the risk of bleeding, which can lead to cardiotoxicity.

2. **Cardiotoxicity Risk Associated with Drug:**
   - Dyspnea was reported more frequently with BRILINTA than with control agents in clinical trials. Dyspnea from BRILINTA is self-limiting. The drug itself is associated with the risk of dyspnea, which can be a symptom of cardiotoxicity.

3. **Cardiotoxicity Risk Associated with Drug:**
   - BRILINTA can cause ventricular pauses, including bradyarrhythmias such as AV block, as reported in the postmarketing setting. Patients with a history of certain cardiac conditions were excluded from clinical studies due to the increased risk of developing bradyarrhythmias with ticagrelor. The drug itself is associated with the risk of bradyarrhythmias, which can lead to cardiotoxicity.

4. **Cardiotoxicity Risk Associated with Drug:**
   - Central sleep apnea, including Cheyne-Stokes respiration, has been reported in the post-marketing setting in patients taking ticagrelor, including recurrence or worsening of central sleep apnea following rechallenge. If central sleep apnea is suspected, further clinical assessment is recommended. The drug itself is associated with the risk of central sleep apnea, which can impact cardiovascular function and lead to cardiotoxicity.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",f7b3f443-e83d-4bf2-0e96-023448fed9a8,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=f7b3f443-e83d-4bf2-0e96-023448fed9a8&type=display
1079,TICLOPIDINE HYDROCHLORIDE,"1. Ticlopidine hydrochloride tablets are associated with life-threatening hematological adverse reactions, including neutropenia/agranulocytosis, thrombotic thrombocytopenic purpura (TTP), and aplastic anemia. (The drug itself is associated with these risks.)

2. Ticlopidine has been reported to cause neutropenia, with cases observed in clinical trials and postmarketing data. (The drug itself is associated with neutropenia.)

3. Thrombotic thrombocytopenic purpura (TTP) has been reported in patients taking ticlopidine, with an estimated incidence rate based on postmarketing data. (The drug itself is associated with TTP.)

4. Aplastic anemia has been reported in patients taking ticlopidine, with an estimated incidence rate based on postmarketing data. (The drug itself is associated with aplastic anemia.)

5. Ticlopidine can cause severe hematological adverse reactions, which may occur within a few days to weeks of therapy initiation. (The drug itself is associated with severe hematological adverse reactions.)

6. Ticlopidine should be monitored for evidence of neutropenia or TTP during the first 3 months of treatment, and therapy should be discontinued if any such evidence is observed. (The drug itself is associated with the need for monitoring and potential discontinuation in case of adverse reactions.)

7. Ticlopidine is a platelet aggregation inhibitor that interferes with platelet membrane function, leading to inhibition of platelet aggregation and prolongation of bleeding time. (The drug itself affects platelet function.)

8. Ticlopidine binds reversibly to plasma proteins and is extensively metabolized by the liver. (The drug itself is metabolized by the liver.)

9. Ticlopidine has nonlinear pharmacokinetics, with clearance decreasing on repeated dosing, especially in older patients. (The drug itself has nonlinear pharmacokinetics.)

10. Ticlopidine is contraindicated in patients with hematopoietic disorders, active pathological bleeding, severe liver impairment, and hypersensitivity to the drug. (The drug itself is contraindicated in these conditions.)

11. Ticlopidine has been associated with increased serum cholesterol and triglycerides levels. (The drug itself is associated with cholesterol elevation.)

12. Ticlopidine has been studied in patients undergoing coronary stent placement to reduce the risk of thrombotic events. (The drug itself is studied in this context.)

13. Ticlopidine has been shown to reduce the incidence of stent thrombosis when used as adjunctive therapy with aspirin in patients undergoing coronary stent implantation. (The drug itself is associated with reduced stent thrombosis.)

14. Ticlopidine has been associated with serious bleeding complications and neutropenia in patients undergoing coronary stent placement. (The drug itself is associated with these complications.)

15. Ticlopidine should be used with caution in patients at risk of increased bleeding and should be discontinued prior to elective surgery to minimize bleeding risks. (The drug itself is associated with increased bleeding risks.)

16. Ticlopidine has been associated with prolonged bleeding time, which can be normalized with methylprednisolone or platelet transfusions. (The drug itself is associated with prolonged bleeding time.)

17. Ticlopidine should be used with caution in patients with lesions prone to bleeding, and caution should be exercised when coadministering with drugs that may induce bleeding. (The drug itself is associated with increased bleeding risks.)

18. Ticlopidine has been associated with elevations in liver function tests, and liver function should be monitored during therapy. (The drug itself is associated with liver function abnormalities.)

19. Ticlopidine may interact with other drugs, affecting their plasma levels and clearance. (The drug itself may interact with other drugs.)

20. Ticlopidine's oral bioavailability is increased when taken with food, and it should be administered with food to maximize gastrointestinal tolerance. (The drug itself is affected by food interactions.)

21. Ticlopidine has not shown evidence of carcinogenic or mutagenic potential in animal studies. (The drug itself has not shown carcinogenic or mutagenic effects in animals.)

22. Ticlopidine is classified as Pregnancy Category B, and its use during pregnancy should be considered only if clearly needed. (The drug itself is classified as Pregnancy Category B.)

23. Ticlopidine is excreted in rat milk, and its excretion in human milk is unknown. Caution should be exercised when considering its use in nursing mothers. (The drug itself is excreted in rat milk.)

24. Safety and effectiveness of ticlopidine in pediatric patients have not been established. (The drug itself has not been established as safe and effective in pediatric patients.)

25. Clearance of ticlopidine is lower in elderly patients, and trough levels are increased in this population. (The drug itself is associated with altered clearance in elderly patients.)",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",77d619f8-05a3-408a-a6f8-1511694b6a24,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=77d619f8-05a3-408a-a6f8-1511694b6a24&type=display
1080,TIGECYCLINE,"1. **Warnings and Precautions:** Anaphylactic reactions have been reported with tigecycline, and may be life-threatening. Tigecycline is structurally similar to tetracycline-class antibiotics and should be avoided in patients with known hypersensitivity to tetracycline-class antibiotics. (The drug itself is not associated with cardiotoxicity risk but may cause anaphylactic reactions.)

2. **Warnings and Precautions:** Hepatic Adverse Effects: Increases in total bilirubin concentration, prothrombin time, and transaminases have been seen in patients treated with tigecycline. Isolated cases of significant hepatic dysfunction and hepatic failure have been reported in patients being treated with tigecycline. Some of these patients were receiving multiple concomitant medications. Patients who develop abnormal liver function tests during tigecycline therapy should be monitored for evidence of worsening hepatic function and evaluated for risk/benefit of continuing tigecycline therapy. Hepatic dysfunction may occur after the drug has been discontinued. (The drug itself is not directly associated with cardiotoxicity risk but may lead to hepatic adverse effects.)

3. **Warnings and Precautions:** Pancreatitis: Acute pancreatitis, including fatal cases, has occurred in association with tigecycline treatment. The diagnosis of acute pancreatitis should be considered in patients taking tigecycline who develop clinical symptoms, signs, or laboratory abnormalities suggestive of acute pancreatitis. Cases have been reported in patients without known risk factors for pancreatitis. Patients usually improve after tigecycline discontinuation. Consideration should be given to the cessation of the treatment with tigecycline in cases suspected of having developed pancreatitis. (The drug itself is not directly associated with cardiotoxicity risk but may lead to pancreatitis.)

4. **Warnings and Precautions:** Fetal Harm: Tigecycline may cause fetal harm when administered to a pregnant woman. If the patient becomes pregnant while taking tigecycline, the patient should be apprised of the potential hazard to the fetus. Results of animal studies indicate that tigecycline crosses the placenta and is found in fetal tissues. Decreased fetal weights in rats and rabbits (with associated delays in ossification) and fetal loss in rabbits have been observed with tigecycline. (The drug itself is not associated with cardiotoxicity risk but may cause fetal harm.)

5. **Warnings and Precautions:** Tooth Discoloration: The use of tigecycline during tooth development (last half of pregnancy, infancy, and childhood to the age of 8 years) may cause permanent discoloration of the teeth (yellow-gray-brown). Results of studies in rats with tigecycline have shown bone discoloration. Tigecycline should not be used during tooth development unless other drugs are not likely to be effective or are contraindicated. (The drug itself is not associated with cardiotoxicity risk but may cause tooth discoloration.)

6. **Warnings and Precautions:** Clostridium difficile-Associated Diarrhea (CDAD): Clostridium difficile-associated diarrhea (CDAD) has been reported with the use of nearly all antibacterial agents, including tigecycline, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile. C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin-producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated. (The drug itself is not directly associated with cardiotoxicity risk but may lead to CDAD.)",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",acf5dbe5-ca75-4300-816f-b3f4625f6e7d,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=acf5dbe5-ca75-4300-816f-b3f4625f6e7d&type=display
1081,TINIDAZOLE,"1. The drug label for Tindamax (tinidazole) does not specifically mention cardiotoxicity risks associated with the drug itself.

2. The label does not report any cardiotoxicity reactions or risks related to the use of Tindamax. 

Overall, based on the information provided in the drug label, there are no mentions of cardiotoxicity risks or reactions associated with Tindamax.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",a0d01539-8413-4703-94cc-d221918630a1,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a0d01539-8413-4703-94cc-d221918630a1&type=display
1082,TIOPRONIN,"1. The drug label mentions that THIOLA may potentially cause serious adverse reactions reported for d-penicillamine, including complications such as aplastic anemia, agranulocytosis, thrombocytopenia, Goodpastures syndrome, or myasthenia gravis. It is noted that no deaths have been directly reported from THIOLA treatment, but a fatal outcome is possible, similar to what has been reported with d-penicillamine therapy. (The drug itself is associated with the potential cardiotoxicity risk.)

2. The label also warns that leukopenia of the granulocytic series may develop without eosinophilia, and thrombocytopenia may be immunologic in origin or occur on an idiosyncratic basis. It is emphasized that a reduction in peripheral blood white count to less than 3500/cubic mm or in platelet count to below 100,000 cubic mm mandates cessation of therapy. Patients are advised to report promptly any symptoms or signs of these hematological abnormalities. (The drug itself is associated with the potential cardiotoxicity risk.)

3. Proteinuria, sometimes severe enough to cause nephrotic syndrome, may develop from membranous glomerulopathy. Close observation of affected patients is deemed mandatory. The label mentions that the following complications, though rare, have been reported during d-penicillamine therapy and could occur during THIOLA treatment. It is advised that when abnormal urinary findings are associated with hemoptysis and pulmonary infiltrates suggestive of Goodpastures syndrome, THIOLA treatment should be stopped. (The drug itself is associated with the potential cardiotoxicity risk.)

4. The label further states that jaundice and abnormal liver function tests have been reported during THIOLA therapy for non-cystinuric conditions. While a direct cause-and-effect relationship has not been established based on these reports, patients should be carefully monitored, and if any abnormalities are noted, the drug should be discontinued and the patient treated with appropriate measures. (The drug itself is associated with the potential cardiotoxicity risk.)

5. The label highlights that THIOLA treatment may potentially be associated with all the adverse reactions reported with d-penicillamine, including gastrointestinal side effects, impairment in taste and smell, dermatologic complications, hypersensitivity reactions, hematologic abnormalities, renal complications, pulmonary manifestations, and neurologic complications. It is noted that these reactions are more likely to develop during THIOLA therapy among patients who had previously shown toxicity to d-penicillamine. (The drug itself is associated with the potential cardiotoxicity risk.)",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",494a714e-923c-cd57-df6c-12886afb265a,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=494a714e-923c-cd57-df6c-12886afb265a&type=display
1083,TIPRANAVIR,"1. The drug label for APTIVUS (tipranavir) does not specifically mention cardiotoxicity risks or cardiotoxicity reactions associated with the drug itself. 

2. The label primarily focuses on hepatotoxicity, intracranial hemorrhage, and other adverse reactions related to hepatic impairment, coagulation, and metabolic effects. 

3. While the label does not directly link APTIVUS to cardiotoxicity, it does caution about potential drug interactions and adverse reactions that could impact cardiovascular health, such as lipid abnormalities and metabolic disorders. 

4. It is important to consult the full prescribing information for APTIVUS for a comprehensive understanding of all potential risks and adverse reactions associated with the drug.",Less,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",08982e49-d2eb-4b25-b01a-1be52fd669ef,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=08982e49-d2eb-4b25-b01a-1be52fd669ef&type=display
1084,TIROFIBAN,"1. **Warnings and Precautions**: AGGRASTAT can cause serious bleeding. If bleeding cannot be controlled, discontinue AGGRASTAT. (The drug itself is not directly associated with cardiotoxicity but can lead to serious bleeding, which can indirectly impact cardiac health.)

2. **Adverse Reactions**: Bleeding is the most commonly reported adverse reaction. (Bleeding can lead to cardiotoxicity as a potential adverse effect of the drug.)

3. **Post-Marketing Experience**: Severe allergic reactions, including anaphylactic reactions, have occurred during the first day of AGGRASTAT infusion. Some cases have been associated with severe thrombocytopenia. (Severe allergic reactions and thrombocytopenia can have cardiotoxic effects as part of the body's response to these reactions.)

4. **Drug Interactions**: Coadministration of fibrinolytics, anticoagulants, and antiplatelet agents increases the risk of bleeding. (Increased bleeding risk due to drug interactions can indirectly lead to cardiotoxicity.)

5. **Overdosage**: In clinical trials, inadvertent overdosage with AGGRASTAT occurred, leading to bleeding events, primarily minor mucocutaneous bleeding events and minor bleeding at the sites of cardiac catheterization. (Overdosage can result in bleeding events that may have cardiotoxic consequences.)

Overall, while AGGRASTAT itself is not directly associated with cardiotoxicity, the drug's potential to cause serious bleeding, allergic reactions, and thrombocytopenia can indirectly lead to cardiotoxic effects in patients.",Less,No,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",fe0ced75-ccbf-4d2e-bd0d-b57e60ab913f,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fe0ced75-ccbf-4d2e-bd0d-b57e60ab913f&type=display
1085,TIVOZANIB,"1. FOTIVDA can cause serious, sometimes fatal, cardiac failure. Cardiac failure in FOTIVDA-treated patients occurred in 1.6%, with 1% of events  Grade 3, and 0.6% events were fatal. (The drug itself is associated with the risk of cardiac failure.)

2. FOTIVDA can cause serious, sometimes fatal, cardiac ischemia and arterial thromboembolic events. Cardiac ischemia in FOTIVDA-treated patients occurred in 3.2%, with 1.5% of events  Grade 3, and 0.4% events were fatal. Arterial thromboembolic events were reported in 2% of FOTIVDA-treated patients, including death due to ischemic stroke (0.1%). (The drug itself is associated with the risk of cardiac ischemia and arterial thromboembolic events.)

3. FOTIVDA can cause serious, sometimes fatal, venous thromboembolic events. Venous thromboembolic events occurred in 2.4% of patients treated with FOTIVDA, including death (0.3%). (The drug itself is associated with the risk of venous thromboembolic events.)

4. FOTIVDA can cause serious, sometimes fatal, hemorrhagic events. Hemorrhagic events occurred in 11% of patients treated with FOTIVDA, including death (0.2%). (The drug itself is associated with the risk of hemorrhagic events.)

5. FOTIVDA has the potential to adversely affect wound healing. Withhold FOTIVDA for at least 24 days before elective surgery. Do not administer for at least 2 weeks following major surgery and until adequate wound healing. The safety of resumption of FOTIVDA after resolution of wound healing complications has not been established. (The drug itself is associated with the risk of impaired wound healing.)

6. Reversible posterior leukoencephalopathy syndrome (RPLS), a syndrome of subcortical vasogenic edema diagnosed by MRI, can occur with FOTIVDA. Perform an evaluation for RPLS in any patient presenting with seizures, headaches, visual disturbances, confusion, or altered mental function. Discontinue FOTIVDA in patients who develop RPLS. (The drug itself is associated with the risk of reversible posterior leukoencephalopathy syndrome.)",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",de77155c-ecf2-4f15-9758-21d271449d83,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=de77155c-ecf2-4f15-9758-21d271449d83&type=display
1086,TIZANIDINE,"1. **Cardiotoxicity Risk**: Tizanidine is a central alpha-2-adrenergic agonist that can produce hypotension, with syncope reported in the post-marketing setting. The drug itself is associated with the risk of significant hypotension, which may be minimized by dose titration and monitoring for signs and symptoms of hypotension before advancing the dose.

2. **Cardiotoxicity Risk**: Tizanidine may cause hepatocellular liver injury, which can lead to liver function abnormalities. The drug itself is associated with the risk of liver injury, and monitoring of aminotransferase levels is recommended to detect and manage this potential adverse reaction.

3. **Cardiotoxicity Reaction**: Tizanidine can cause sedation, which may interfere with everyday activities. The sedative effects of tizanidine, when combined with alcohol and other CNS depressants, can lead to additive effects on the central nervous system. The drug itself is associated with sedation, which can impact daily functioning and may lead to adverse events when combined with other depressants.

4. **Cardiotoxicity Reaction**: Tizanidine use has been associated with hallucinations, including visual hallucinations or delusions. The drug itself is associated with the risk of hallucinosis, and discontinuation should be considered if patients develop hallucinations or psychotic-like symptoms.

5. **Cardiotoxicity Risk**: Tizanidine is contraindicated in patients taking potent inhibitors of CYP1A2, such as fluvoxamine or ciprofloxacin, due to the potential for adverse reactions like hypotension, bradycardia, or excessive drowsiness. The drug itself is associated with the risk of adverse reactions when used concomitantly with these inhibitors, highlighting the importance of avoiding such combinations.

6. **Cardiotoxicity Reaction**: Tizanidine should be used with caution in patients with renal insufficiency, as clearance is reduced by more than 50%. Patients with renal impairment should be closely monitored for common adverse events like dry mouth, somnolence, asthenia, and dizziness, which can serve as indicators of potential overdose. The drug itself is associated with an increased risk of adverse reactions in patients with renal impairment, necessitating careful monitoring and dose adjustments.",Most,Yes,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",ef7673f4-e0c1-4d79-af36-2f2ed2cc28f7,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=ef7673f4-e0c1-4d79-af36-2f2ed2cc28f7&type=display
1087,TIZANIDINE HYDROCHLORIDE,"1. **Cardiotoxicity Risk**: Zanaflex (tizanidine hydrochloride) is a central alpha-2-adrenergic agonist indicated for the management of spasticity. The drug itself is not directly associated with cardiotoxicity risk.

2. **Hypotension**: Zanaflex can produce hypotension due to its alpha-2-adrenergic agonist properties. Syncope and significant hypotension have been reported, especially when used with other antihypertensive medications. Concomitant use with other alpha-2-adrenergic agonists is not recommended. The drug itself is associated with the risk of hypotension.

3. **Risk of Liver Injury**: Zanaflex may cause hepatocellular liver injury. Monitoring of liver function tests is recommended, and the drug should be used with caution in patients with hepatic impairment. The drug itself is associated with the risk of liver injury.

4. **Sedation**: Zanaflex can cause sedation, which may interfere with daily activities. The sedative effects of Zanaflex can be additive with alcohol and other CNS depressants. Monitoring for excess sedation is advised when using Zanaflex with other CNS depressants. The drug itself is associated with the risk of sedation.

5. **Hallucinosis/Psychotic-Like Symptoms**: Zanaflex use has been associated with hallucinations. Patients may experience visual hallucinations or delusions, and discontinuation of Zanaflex should be considered if hallucinations develop. The drug itself is associated with the risk of hallucinosis.

6. **Withdrawal Adverse Reactions**: Withdrawal from Zanaflex can lead to rebound hypertension, tachycardia, and hypertonia. Slow dose reduction is recommended, especially in patients on high doses or concomitant narcotics. The drug itself is associated with the risk of withdrawal adverse reactions.",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",043d9e51-bfa2-4add-9058-5ece332f7e99,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=043d9e51-bfa2-4add-9058-5ece332f7e99&type=display
1088,TOBRAMYCIN SULFATE,"1. The drug label for TOBRAMYCIN for injection does not mention any specific cardiotoxicity risks or cardiotoxicity reactions associated with the use of this drug. The highlighted risks primarily focus on nephrotoxicity, ototoxicity, neuromuscular blockade, and embryo-fetal toxicity. No cardiotoxicity risks or reactions are mentioned in the provided drug label information.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",9a5cecd6-aa65-42d2-b15a-06b4fcebcc0f,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=9a5cecd6-aa65-42d2-b15a-06b4fcebcc0f&type=display
1089,TOFACITINIB,"1. The drug XELJANZ/XELJANZ XR/XELJANZ Oral Solution is associated with a higher rate of all-cause mortality, including sudden cardiovascular death, compared to TNF blockers in rheumatoid arthritis patients. (The drug is associated with an increased risk of mortality, including cardiovascular death.)

2. XELJANZ has been linked to malignancies, including lymphomas and lung cancers, at a higher rate compared to TNF blockers in rheumatoid arthritis patients. (The drug is associated with an increased risk of malignancies, including lymphomas and lung cancers.)

3. Patients treated with XELJANZ have a higher rate of major adverse cardiovascular events (MACE), such as cardiovascular death, myocardial infarction, and stroke, compared to TNF blockers in rheumatoid arthritis patients. (The drug is associated with an increased risk of major adverse cardiovascular events.)

4. Thrombosis, including pulmonary embolism, deep venous thrombosis, and arterial thrombosis, has occurred in patients treated with XELJANZ, leading to serious events and some deaths, especially in rheumatoid arthritis patients. (The drug is associated with an increased risk of thrombosis, including serious events and deaths.)",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",cf74ba2f-afc5-4baa-8594-979c889a5831,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=cf74ba2f-afc5-4baa-8594-979c889a5831&type=display
1090,TOLCAPONE,"1. The drug label for TASMAR (tolcapone) warns of potentially fatal acute fulminant liver failure as a significant risk associated with the medication. The drug itself is not directly associated with cardiotoxicity risks in this context.

2. The label advises that TASMAR should not be initiated if the patient exhibits clinical evidence of liver disease or if liver enzyme levels exceed two times the upper limit of normal. This precaution is related to liver injury risks and not cardiotoxicity.

3. Patients who develop evidence of hepatocellular injury while on TASMAR may be at increased risk for liver injury if the drug is reintroduced. This statement pertains to liver injury risks and not cardiotoxicity.

4. The label mentions that increases in liver enzymes, such as ALT or AST, occurred in a small percentage of patients treated with TASMAR, leading to discontinuation in some cases. These enzyme elevations are associated with liver injury and not cardiotoxicity.

5. The drug label does not specifically mention any direct association between TASMAR and cardiotoxicity risks or reactions. The focus is primarily on liver-related adverse events and monitoring for liver function during treatment with the medication.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",a0e47a9d-78e7-4523-983a-aa259f221736,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a0e47a9d-78e7-4523-983a-aa259f221736&type=display
1091,TOLMETIN SODIUM,"1. The drug label states that nonsteroidal anti-inflammatory drugs (NSAIDs), including tolmetin sodium capsules, are associated with an increased risk of serious cardiovascular thrombotic events, such as myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use. (The drug itself is associated with the cardiotoxicity risk.)

2. Tolmetin sodium capsules are contraindicated in the setting of coronary artery bypass graft (CABG) surgery due to the cardiovascular thrombotic risk. (The drug itself is associated with the cardiotoxicity risk.)

3. The label warns about the potential risk of cardiovascular thrombotic events with NSAID use, advising to use the lowest effective dose for the shortest duration possible to minimize the risk. (The drug itself is associated with the cardiotoxicity risk.)

4. It is mentioned that patients with known cardiovascular disease or risk factors have a higher absolute incidence of excess serious cardiovascular thrombotic events due to NSAID use. (The drug itself is associated with the cardiotoxicity risk.)

5. The label highlights that observational studies have shown an increased risk of reinfarction, cardiovascular-related death, and all-cause mortality in post-myocardial infarction patients treated with NSAIDs. (The drug itself is associated with the cardiotoxicity risk.)

6. Tolmetin should be avoided in patients with severe heart failure, as NSAIDs can worsen heart failure, leading to hospitalization and death. (The drug itself is associated with the cardiotoxicity risk.)

7. The label mentions that NSAIDs, including tolmetin, can lead to the onset of new hypertension or worsening of preexisting hypertension, contributing to an increased incidence of cardiovascular events. (The drug itself is associated with the cardiotoxicity risk.)

8. It is advised to monitor blood pressure closely during NSAID treatment, especially in patients with hypertension, as NSAIDs, including tolmetin, can affect the response to antihypertensive medications. (The drug itself is associated with the cardiotoxicity risk.)

9. The label warns about the increased risk of hospitalizations for heart failure in patients treated with NSAIDs, including tolmetin, based on meta-analyses of randomized controlled trials. (The drug itself is associated with the cardiotoxicity risk.)

10. It is mentioned that fluid retention and edema have been observed in some patients treated with NSAIDs, which can impact cardiovascular conditions. (The drug itself is associated with the cardiotoxicity risk.)",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",41b7704e-25a1-45e8-93c0-9ac2f0effef9,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=41b7704e-25a1-45e8-93c0-9ac2f0effef9&type=display
1092,TOLTERODINE TARTRATE,"1. The drug label mentions that tolterodine, the active ingredient in Detrol LA, was evaluated for its effect on the QT interval in a study involving healthy volunteers. The study showed that tolterodine at doses of 2 mg and 4 mg had an effect on the QT interval, with a mean increase in heart rate associated with the drug. This indicates that tolterodine itself was associated with QT interval changes, which can be a risk factor for cardiotoxicity.

2. The label also states that the effect of tolterodine on the QT interval was found to correlate with plasma concentration of the drug. Additionally, the study suggested that there was a greater QT interval increase in CYP2D6 poor metabolizers compared to extensive metabolizers after tolterodine treatment. This information implies that tolterodine itself can impact the QT interval, potentially leading to cardiotoxicity in certain individuals based on their metabolic profile.

3. Furthermore, the label mentions that the QT effect of tolterodine immediate release tablets appeared greater at higher doses, such as 8 mg/day, compared to lower doses like 4 mg/day. The study also noted that the effect of tolterodine at 8 mg/day was not as large as that observed with the active control moxifloxacin. This suggests that tolterodine itself may have a dose-dependent effect on the QT interval, which is a known risk factor for cardiotoxicity.

4. It is important to note that the drug label specifies that there has been no association of Torsade de Pointes in the international post-marketing experience with Detrol or Detrol LA. This statement indicates that while there are risks associated with tolterodine and its effect on the QT interval, there have been no reported cases of this specific type of life-threatening arrhythmia in relation to the use of Detrol or Detrol LA.",Less,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",d7274947-4f88-47ee-a39f-bd5ac46fcf8d,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=d7274947-4f88-47ee-a39f-bd5ac46fcf8d&type=display
1093,TOLVAPTAN,"1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with SAMSCA itself. 

2. However, the label does caution against using SAMSCA in patients with autosomal dominant polycystic kidney disease (ADPKD) due to the risk of hepatotoxicity, which is related to liver injury and not directly cardiotoxicity.

3. Additionally, the label advises monitoring patients for signs of dehydration and hypovolemia, which can occur due to the aquaresis induced by SAMSCA therapy. While dehydration can indirectly impact cardiovascular function, it is not a direct cardiotoxic effect of the drug.

4. The label also mentions that SAMSCA should not be co-administered with hypertonic saline, which is a precaution related to electrolyte balance and not a direct cardiotoxic effect.

Overall, the drug label for SAMSCA does not directly associate the drug with cardiotoxicity risks or reactions. The focus is primarily on liver injury, dehydration, and electrolyte imbalances as potential adverse effects of the medication.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",5526617c-c7b9-4556-886d-729bbabbc566,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=5526617c-c7b9-4556-886d-729bbabbc566&type=display
1094,TOPIRAMATE,"1. Acute Myopia and Secondary Angle Closure Glaucoma Syndrome: The drug QUDEXY XR (topiramate) was associated with a risk of acute myopia and secondary angle closure glaucoma, which could lead to permanent visual loss. Discontinuation of QUDEXY XR was recommended as soon as possible to address this cardiotoxicity risk.

2. Visual Field Defects: QUDEXY XR was associated with the risk of visual field defects, independent of elevated intraocular pressure. If visual problems occurred during treatment with QUDEXY XR, consideration should be given to discontinuing the drug to address this cardiotoxicity risk.

3. Metabolic Acidosis: QUDEXY XR was associated with the risk of causing metabolic acidosis, characterized by decreased serum bicarbonate levels. This metabolic acidosis was caused by renal bicarbonate loss due to carbonic anhydrase inhibition by QUDEXY XR. Monitoring of serum bicarbonate levels and consideration of dose reduction or discontinuation of QUDEXY XR were recommended to address this cardiotoxicity risk.

4. Decrease in Bone Mineral Density: Immediate-release topiramate, the active ingredient in QUDEXY XR, was associated with negative effects on bone mineral density in pediatric patients. Statistically significant decreases in bone mineral density were observed, indicating a potential cardiotoxicity risk related to bone health. Monitoring and consideration of these effects were recommended to address this cardiotoxicity risk.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",46f54677-3a22-4c38-9b92-923020164e15,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=46f54677-3a22-4c38-9b92-923020164e15&type=display
1095,TOPOTECAN,"1. The drug label for HYCAMTIN capsules does not mention any specific cardiotoxicity risks or reactions associated with the drug itself. 

2. The label primarily focuses on myelosuppression, diarrhea, interstitial lung disease, and embryo-fetal toxicity as the main warnings and precautions for HYCAMTIN capsules. 

3. While the label does not directly mention cardiotoxicity risks or reactions related to the drug, it is important to consult with a healthcare provider for a comprehensive understanding of potential side effects, including any potential cardiotoxicity concerns.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",aa0815bb-8916-4c2c-9201-b04eb78e91fa,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=aa0815bb-8916-4c2c-9201-b04eb78e91fa&type=display
1096,TOREMIFENE CITRATE,"1. The drug FARESTON has been shown to prolong the QTc interval in a dose- and concentration-related manner, which can lead to ventricular tachycardia called Torsade de pointes, potentially resulting in syncope, seizure, and death. Toremifene itself is associated with the risk of QT prolongation and subsequent cardiotoxicity.

2. Patients with congenital/acquired QT prolongation, uncorrected hypokalemia, or uncorrected hypomagnesemia should not be prescribed toremifene due to the risk of QT prolongation. Additionally, drugs known to prolong the QT interval and strong CYP3A4 inhibitors should be avoided when using toremifene. Toremifene itself is associated with the risk of QT prolongation and subsequent cardiotoxicity.

3. Toremifene should be avoided in patients with long QT syndrome, and caution should be exercised in patients with congestive heart failure, hepatic impairment, and electrolyte abnormalities. Hypokalemia or hypomagnesemia must be corrected before initiating toremifene, and these electrolytes should be monitored periodically during therapy. Drugs that prolong the QT interval should be avoided. Toremifene itself is associated with the risk of QT prolongation and subsequent cardiotoxicity.

4. The drug label also mentions that dose and concentration-related increases in the QTc interval and T wave changes were observed in healthy male volunteers taking toremifene. Toremifene had no effects on heart rate, PR, and QRS interval duration. Toremifene itself is associated with the risk of QT prolongation and subsequent cardiotoxicity.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",2cab8dd1-3a10-48e6-86ce-0e5275ed49e5,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=2cab8dd1-3a10-48e6-86ce-0e5275ed49e5&type=display
1097,TORSEMIDE,"1. The drug label mentions that SOAANZ (torsemide) tablets are indicated for the treatment of edema associated with heart failure or renal disease, indicating that the drug is used in patients with heart failure, which is a condition associated with cardiotoxicity risk.

2. The label warns about the potential risk of hypotension and worsening renal function with SOAANZ use, particularly in salt-depleted patients or those taking renin-angiotensin aldosterone inhibitors, which can lead to acute renal failure, a condition that can impact the cardiovascular system. The drug itself is not directly associated with cardiotoxicity but can lead to complications that affect the heart.

3. Additionally, electrolyte and metabolic abnormalities, such as hypokalemia, hyponatremia, and hyperglycemia, are mentioned as potential adverse effects of SOAANZ, which can have indirect effects on the cardiovascular system. The drug itself is not causing direct cardiotoxicity but can lead to electrolyte imbalances that may impact the heart.

4. Ototoxicity, including tinnitus and hearing loss, has been observed with loop diuretics like torsemide, especially at higher doses or in patients with severe renal impairment, which can indirectly affect cardiovascular health. The drug itself is not directly causing cardiotoxicity but can lead to ototoxic effects that may impact overall health, including the cardiovascular system.",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",05eaa163-b6e9-438a-85f8-6a60e743d460,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=05eaa163-b6e9-438a-85f8-6a60e743d460&type=display
1098,TRABECTEDIN,"1. Cardiotoxicity risks associated with YONDELIS include severe and fatal cardiomyopathy, which can occur. Patients with specific risk factors such as left ventricular ejection fraction (LVEF) < lower limit of normal, prior cumulative anthracycline dose of 300 mg/m2, age 65 years, or a history of cardiovascular disease may be at increased risk of developing new or worsening cardiac dysfunction. The drug itself is associated with the risk of cardiomyopathy.

2. In clinical trials, cardiomyopathy, including cardiac failure, ejection fraction decreased, and other cardiac issues, occurred in patients receiving YONDELIS. The incidence of cardiomyopathy was higher in patients treated with YONDELIS compared to those receiving dacarbazine. The drug itself was associated with the occurrence of cardiomyopathy in patients.

3. Patients are advised to undergo assessment of left ventricular ejection fraction (LVEF) by echocardiogram or multigated acquisition (MUGA) scan before initiation of YONDELIS and at regular intervals during treatment. Discontinuation of YONDELIS is recommended for patients who develop decreased LVEF or cardiomyopathy. The drug itself is linked to the need for monitoring and potential discontinuation in cases of cardiotoxicity.

4. The labeling highlights that severe and fatal cardiomyopathy can occur with YONDELIS, emphasizing the importance of monitoring for signs of cardiac dysfunction during treatment. Patients experiencing Grade 3 or 4 cardiac adverse events indicative of cardiomyopathy should discontinue YONDELIS. The drug itself is directly associated with the risk of severe cardiomyopathy and cardiac dysfunction in patients.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",472bd78e-be17-4b9d-90f4-9482c3aec9ff,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=472bd78e-be17-4b9d-90f4-9482c3aec9ff&type=display
1099,TRAMADOL HYDROCHLORIDE,"1. The drug CONZIP, which contains tramadol hydrochloride, has been associated with serious and life-threatening risks, including addiction, abuse, and misuse, which can lead to overdose and death. Patients should be assessed for these behaviors and conditions regularly. (The drug itself is associated with addiction, abuse, and misuse risks.)

2. Serious, life-threatening, or fatal respiratory depression may occur with the use of CONZIP, especially during initiation or following a dosage increase. Proper dosing and titration are essential to reduce the risk of respiratory depression. (The drug itself is associated with respiratory depression risks.)

3. Accidental ingestion of CONZIP, especially by children, can result in a fatal overdose of tramadol. (The drug itself is associated with the risk of fatal overdose in case of accidental ingestion.)

4. Concomitant use of opioids with benzodiazepines or other central nervous system depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (The drug itself is associated with the risk of respiratory depression and other serious outcomes when used concomitantly with certain substances.)

5. Healthcare providers are encouraged to complete a REMS-compliant education program and counsel patients on serious risks, safe use, and the importance of reading the Medication Guide with each prescription. (The drug itself is associated with serious risks that require education and counseling.)

6. Life-threatening respiratory depression and death have occurred in children who received tramadol, the active ingredient in CONZIP. Some cases occurred following tonsillectomy and/or adenoidectomy, with evidence of ultra-rapid metabolism of tramadol due to a CYP2D6 polymorphism. (The drug itself is associated with life-threatening respiratory depression risks in children.)

7. CONZIP is contraindicated in children younger than 12 years of age and in children younger than 18 years of age following tonsillectomy and/or adenoidectomy. Avoid use in adolescents 12 to 18 years of age with other risk factors that may increase sensitivity to tramadol's respiratory depressant effects. (The drug itself is contraindicated in certain pediatric populations due to the risk of respiratory depression.)

8. The drug label does not specifically mention cardiotoxicity risks or reactions associated with CONZIP.",Less,No,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",a65b4d05-3a1c-4aa1-848a-d20ac9aaf62f,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a65b4d05-3a1c-4aa1-848a-d20ac9aaf62f&type=display
1100,TRAMETINIB,"1. MEKINIST, when administered with dabrafenib, has been associated with cardiomyopathy, including cardiac failure, with a decrease in left ventricular ejection fraction (LVEF)  10% from baseline and below the institutional lower limit of normal (LLN) in 6% of adult patients. This cardiomyopathy led to dose interruption or discontinuation of MEKINIST in 3% and < 1% of patients, respectively. Cardiomyopathy resolved in 45 of 50 patients who received MEKINIST with dabrafenib.

2. MEKINIST, when administered with dabrafenib in pediatric patients, has been associated with cardiomyopathy, defined as a decrease in LVEF  10% from baseline and below the institutional LLN, in 9% of patients. 

3. Patients receiving MEKINIST are advised to undergo assessment of LVEF by echocardiogram or multigated acquisition (MUGA) scan before initiation of MEKINIST as a single agent or with dabrafenib, one month after initiation, and then at 2- to 3-month intervals while on treatment. For an asymptomatic absolute decrease in LVEF of 10% or greater from baseline that is below the LLN, MEKINIST should be withheld for up to 4 weeks. If LVEF improves to normal value, MEKINIST can be resumed at a lower dose. If no improvement occurs within 4 weeks, MEKINIST should be permanently discontinued. For symptomatic cardiomyopathy or an absolute decrease in LVEF of greater than 20% from baseline that is below LLN, MEKINIST should be permanently discontinued.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",0002ad27-779d-42ab-83b5-bc65453412a1,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1&type=display
1101,TRANEXAMIC ACID,"1. The drug label mentions a risk of thrombosis with concomitant use of Factor IX, advising to avoid concomitant use as it may increase the risk of thromboembolic adverse reactions associated with tranexamic acid. The drug itself is associated with the risk of thrombosis due to its antifibrinolytic properties. 

2. It warns about the risk of medication errors due to incorrect route of administration, stating that serious adverse reactions, including seizures and cardiac arrhythmias, have occurred when the drug was inadvertently administered intrathecally instead of intravenously. The drug itself is not directly causing cardiotoxicity but can lead to serious adverse reactions if administered incorrectly.

3. The label mentions that tranexamic acid may cause seizures, including focal and generalized seizures, particularly during cardiovascular surgery or if inadvertently given into the neuraxial system. The drug itself is associated with the risk of seizures, especially in high doses or if administered incorrectly.

4. It also highlights the potential for hypersensitivity reactions, including anaphylactic reactions, with the use of intravenous tranexamic acid. The drug itself can lead to hypersensitivity reactions, which may include cardiotoxic manifestations in severe cases.

5. The label advises that visual disturbances, although not seen in humans, have been observed in animals following tranexamic acid administration. It recommends discontinuing the drug if changes in ophthalmological examination occur. While the drug itself is not directly linked to visual disturbances in humans, it is important to monitor for any ocular symptoms that may indicate cardiotoxicity.

6. Lastly, it mentions that CYKLOKAPRON may cause dizziness and advises patients to avoid driving or using machinery if dizziness occurs. The drug itself can lead to dizziness, which may impact a patient's ability to safely operate machinery or drive, posing a potential cardiotoxic risk.",Less,No,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",6e89a7d9-4da4-42aa-b7f8-c602c24eefe5,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=6e89a7d9-4da4-42aa-b7f8-c602c24eefe5&type=display
1102,TRANYLCYPROMINE SULFATE,"1. **Hypertensive Crisis and Hypertension**: The drug PARNATE, a monoamine oxidase inhibitor (MAOI), has been associated with hypertensive crises caused by the ingestion of foods or beverages with high tyramine content. It may also lead to hypertensive reactions and crises with concomitant use of other drugs. Patients with hyperthyroidism may be at greater risk of hypertensive crisis.

2. **Hypertensive Crisis and Hypertension**: Clinically significant increases in blood pressure have been reported after the administration of MAOIs, including PARNATE, in patients not ingesting tyramine-rich foods or beverages. Blood pressure should be assessed before prescribing PARNATE, and close monitoring is necessary for all patients taking the drug.

3. **Hypertensive Crisis and Hypertension**: Patients should be instructed to avoid foods and beverages with high tyramine content while being treated with PARNATE and for 2 weeks after stopping the medication. Careful evaluation of the benefits and risks of PARNATE therapy is essential in patients with hypertension or confirmed/suspected cerebrovascular or cardiovascular disorders that increase the risk for complications from severe hypertension.

4. **Hypertensive Crisis and Hypertension**: In patients taking PARNATE, blood pressure should be closely monitored to detect evidence of increased blood pressure. Full reliance should not be placed solely on blood pressure readings, and patients should be observed for other signs and symptoms of hypertensive crisis.

5. **Hypertensive Crisis and Hypertension**: Therapy should be interrupted with symptoms that may be prodromal or a manifestation of a hypertensive crisis, and patients should be evaluated immediately. Discontinuation of PARNATE, other drugs, foods, or beverages suspected to contribute to the hypertensive crisis should be done promptly.

6. **Hypertensive Crisis and Hypertension**: Patients with severe elevations in blood pressure require immediate blood pressure reduction. Fever should be managed by external cooling, and additional measures to control the causes of hyperthermia may be necessary.

7. **Hypertensive Crisis and Hypertension**: Postural hypotension, a major adverse reaction at doses above 30 mg daily, may result in syncope. Symptoms of postural hypotension are commonly seen in patients with pre-existing hypertension. Blood pressure usually returns to pretreatment levels upon discontinuation of PARNATE.

8. **Hypertensive Crisis and Hypertension**: Dosage increases should be made more gradually in patients with a tendency toward hypotension and/or postural hypotension, especially in elderly patients. Patients should be closely observed for postural changes in blood pressure throughout treatment.

9. **Hypertensive Crisis and Hypertension**: Postural hypotension may be relieved by having patients lie down until blood pressure returns to normal. When PARNATE is used concomitantly with other agents known to cause hypotension, the possibility of additive hypotensive effects should be considered.

10. **Hypertensive Crisis and Hypertension**: Careful consideration of the risk of agents and techniques that increase the risk for hypotension or other adverse reactions to PARNATE is necessary during anesthesia and perioperative care. Avoid the use of agents contraindicated for concomitant use with PARNATE in these situations.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",b72d8187-dfcc-4ea0-b5e9-c0be95b69a27,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=b72d8187-dfcc-4ea0-b5e9-c0be95b69a27&type=display
1103,TRAZODONE HYDROCHLORIDE,"1. Trazodone hydrochloride may be arrhythmogenic in patients with preexisting cardiac disease, as indicated by clinical studies. Arrhythmias identified include isolated PVCs, ventricular couplets, tachycardia with syncope, and torsade de pointes. Postmarketing events, including torsade de pointes, have been reported at doses of 100 mg or less with the immediate-release form of trazodone hydrochloride tablets. The drug itself is associated with the risk of cardiac arrhythmias.

2. Trazodone hydrochloride prolongs the QT/QTc interval, and its use should be avoided in patients with known QT prolongation or in combination with other drugs that are inhibitors of CYP3A4. This includes certain antiarrhythmics, antipsychotic medications, and antibiotics that are known to prolong the QT interval. Concomitant administration of drugs may increase the risk of cardiac arrhythmia. The drug itself is associated with the risk of QT prolongation and subsequent arrhythmias.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",78c3188c-d42f-4d3d-aa42-3c146dfe08ee,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=78c3188c-d42f-4d3d-aa42-3c146dfe08ee&type=display
1104,TREPROSTINIL,"1. **Warnings and Precautions (5.1):** Tyvaso DPI may cause symptomatic hypotension. (The drug itself is associated with the risk of symptomatic hypotension.)
   
2. **Warnings and Precautions (5.2):** Tyvaso DPI inhibits platelet aggregation and increases the risk of bleeding. (The drug itself is associated with the risk of increased bleeding due to platelet aggregation inhibition.)

3. **Warnings and Precautions (5.4):** Tyvaso DPI may cause bronchospasm, especially in patients with a history of hyperreactive airway disease. (The drug itself is associated with the risk of bronchospasm, particularly in patients with a history of hyperreactive airway disease.)

4. **Adverse Reactions (6.1):** The most common adverse reactions include cough, headache, throat irritation/pharyngolaryngeal pain, nausea, flushing, dyspnea, and syncope. (These adverse reactions may be indicative of cardiotoxicity reactions, such as syncope, which can be related to cardiovascular effects.)

5. **Clinical Studies (14.1):** In the TRIUMPH I study, patients receiving Tyvaso Inhalation Solution had a placebo-corrected median change from baseline in peak 6-minute walk distance (6MWD) of 20 meters at Week 12. (The improvement in exercise ability, as measured by 6MWD, may indirectly reflect cardiovascular effects, which could be related to cardiotoxicity.)

6. **Clinical Studies (14.3):** In the INCREASE study, patients treated with Tyvaso Inhalation Solution had a placebo-corrected median change from baseline in peak 6MWD of 21 meters at Week 16. Treatment with Tyvaso Inhalation Solution also resulted in a statistically significant increase in the time to first clinical worsening event and a reduction in the risk of clinical worsening. (The improvement in exercise ability and clinical outcomes may suggest cardiovascular benefits or risks associated with the drug's cardiotoxicity profile.)",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",ddc3d400-bcb3-4b09-aae2-0768b10a5b0f,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=ddc3d400-bcb3-4b09-aae2-0768b10a5b0f&type=display
1105,TRIAMTERENE CAPSULES,"1. The drug Triamterene, a potassium-sparing diuretic, may occasionally cause increases in serum potassium levels, which can result in hyperkalemia. This risk is associated with the drug itself.
   
2. Unchecked hyperkalemia can be fatal, especially in patients with renal impairment, diabetes, the elderly, or those who are severely ill. Serum potassium levels must be monitored frequently, particularly when patients are on Triamterene, when dosages are changed, or during any illness that may affect renal function. This cardiotoxicity risk is associated with the drug itself.

3. There have been isolated reports of hypersensitivity reactions to Triamterene, necessitating regular observation for blood dyscrasias, liver damage, or other idiosyncratic reactions. This risk is associated with the drug itself.

4. If hyperkalemia is present or suspected, an electrocardiogram should be obtained to assess for cardiac irregularities. In the presence of hyperkalemia, discontinuing Triamterene and any potassium supplementation, and substituting with a thiazide alone may be sufficient. Additional therapies may be required for a widened QRS complex or arrhythmia. This cardiotoxicity risk is associated with the drug itself.

5. Triamterene tends to conserve potassium, potentially leading to increases in serum potassium levels and, in rare instances, hyperkalemia. Hyperkalemia has been associated with cardiac irregularities. This risk is associated with the drug itself.

6. Electrolyte imbalance, often seen in conditions like congestive heart failure, renal disease, or cirrhosis, may be exacerbated or independently caused by effective diuretics like Triamterene. The use of full diuretic doses with restricted salt intake can result in a low-salt syndrome. This cardiotoxicity risk is associated with the drug itself.

7. Triamterene can cause mild nitrogen retention, which is reversible upon drug withdrawal, and may rarely lead to metabolic acidosis. This cardiotoxicity risk is associated with the drug itself.

8. Triamterene may elevate uric acid levels, especially in individuals predisposed to gouty arthritis. This risk is associated with the drug itself.

9. Triamterene has been reported in renal stones in association with other calculus components, cautioning its use in patients with a history of renal stones. This risk is associated with the drug itself.

10. In the event of overdosage of Triamterene, electrolyte imbalance, particularly hyperkalemia, is a major concern. Symptoms may include nausea, vomiting, gastrointestinal disturbances, and weakness. Immediate evacuation of the stomach should be induced, and careful evaluation of electrolyte balance should be conducted. This cardiotoxicity risk is associated with the drug itself.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",93c2a15e-c8c0-429f-8085-f8b647c39dcf,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=93c2a15e-c8c0-429f-8085-f8b647c39dcf&type=display
1106,TRIAZOLAM,"1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with Halcion itself. 

2. The label primarily focuses on warnings related to the risks of concomitant use with opioids, abuse, misuse, addiction, dependence, and withdrawal reactions. 

3. While the label does not directly link Halcion to cardiotoxicity, it does highlight the importance of monitoring patients for various adverse reactions, including those related to the central nervous system and respiratory function. 

4. It is essential to consult the full prescribing information for a comprehensive understanding of all potential risks and adverse reactions associated with Halcion.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",a0da0dba-a56d-486b-a45b-e8a7cdfbeac6,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a0da0dba-a56d-486b-a45b-e8a7cdfbeac6&type=display
1107,TRICLABENDAZOLE,"1. The drug EGATEN (triclabendazole) is associated with QT prolongation, which can lead to prolongation of the QTc interval. The magnitude of QTc prolongation can increase with increasing treatment duration of EGATEN. Administration of EGATEN concurrently with certain medications or in patients with hepatic impairment may increase the risk for QT prolongation. (Drug-associated cardiotoxicity risk)

2. Patients with a history of prolongation of the QTc interval, symptoms compatible with a long QT interval, electrolyte imbalance like hypokalemia, or those taking medications known to prolong the QTc interval should have their electrocardiogram (ECG) monitored while using EGATEN. If signs of cardiac arrhythmia occur during treatment with EGATEN, the treatment should be stopped, and ECG monitoring should continue. (Drug-associated cardiotoxicity risk)

3. In clinical trials, the most common adverse reactions associated with triclabendazole at a dose of 20 mg/kg include abdominal pain, musculoskeletal chest pain, and chest discomfort. These reactions may be indicative of cardiotoxicity and should be monitored closely during treatment with EGATEN. (Cardiotoxicity reactions)

4. Liver enzyme elevations were observed in up to one third of patients in clinical studies, with some patients experiencing post-treatment elevations in bilirubin, aspartate aminotransferase (AST), alkaline phosphatase (ALP), and alanine aminotransferase (ALT). Transient increases in liver enzymes and total bilirubin in patients receiving triclabendazole are reported, which may indicate potential liver toxicity that could impact cardiac function. (Possible cardiotoxicity risk)

5. The drug EGATEN has been associated with resistance, which may impact its effectiveness in treating fascioliasis. Resistance to triclabendazole has been reported, suggesting potential treatment failure and the need for close monitoring of patients for adverse reactions, including cardiotoxicity. (Drug-associated cardiotoxicity risk)",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",5552884e-10ea-450c-9658-d3d4f33c946e,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=5552884e-10ea-450c-9658-d3d4f33c946e&type=display
1108,TRIENTINE HYDROCHLORIDE,1. The drug label does not mention any cardiotoxicity risks or cardiotoxicity reactions associated with Syprine (trientine hydrochloride).,No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",c34f77a7-996b-4470-b5df-d946a7fe5dbe,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=c34f77a7-996b-4470-b5df-d946a7fe5dbe&type=display
1109,TRIFLUOPERAZINE HYDROCHLORIDE,"1. The drug label warns of an increased risk of mortality in elderly patients with dementia-related psychosis who are treated with antipsychotic drugs, including trifluoperazine hydrochloride. The risk of death in drug-treated patients was found to be higher compared to placebo-treated patients, with most deaths attributed to cardiovascular causes such as heart failure and sudden death.

2. Trifluoperazine hydrochloride may cause tardive dyskinesia, a potentially irreversible syndrome of involuntary movements. The label advises that the drug itself may increase the risk of developing tardive dyskinesia, especially with prolonged use or higher doses.

3. Neuroleptic Malignant Syndrome (NMS), a potentially fatal symptom complex, has been reported in association with antipsychotic drugs like trifluoperazine hydrochloride. The label states that the drug can lead to NMS, which manifests as hyperpyrexia, muscle rigidity, altered mental status, and autonomic instability.

4. Trifluoperazine hydrochloride may cause an encephalopathic syndrome, characterized by weakness, lethargy, fever, tremulousness, and confusion, which can lead to irreversible brain damage. The label suggests that the drug itself may contribute to this syndrome, especially when used in combination with lithium.

5. The drug label cautions that trifluoperazine hydrochloride may impair mental and physical abilities, particularly during the initial days of therapy. Patients are advised to be cautious with activities requiring alertness, as the drug itself may lead to impairment.

6. Trifluoperazine hydrochloride may cause hypotension, especially with large doses or parenteral administration, which should be avoided in patients with impaired cardiovascular systems. The label indicates that the drug itself can result in hypotension and advises appropriate management strategies if hypotension occurs.

7. Phenothiazines, including trifluoperazine hydrochloride, may interfere with thermoregulatory mechanisms, posing a risk in individuals exposed to extreme heat. The label suggests that the drug itself may contribute to thermoregulatory disturbances, warranting caution in such situations.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",e63617bb-8186-43d3-9d01-aa53217343e4,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=e63617bb-8186-43d3-9d01-aa53217343e4&type=display
1110,TRIHEPTANOIN,"1. Feeding tube dysfunction may occur with the use of DOJOLVI, and it was reported in patients receiving triheptanoin. The contribution of DOJOLVI to feeding tube dysfunction cannot be ruled out. Regular monitoring of the feeding tube is advised to ensure proper functioning and integrity.

2. Baseline cardiovascular function in patients treated with triheptanoin was normal, and after 4 months, patients in the study had similar changes in cardiovascular parameters compared to another treatment group. There were no significant differences observed in cardiovascular function between the groups treated with triheptanoin and another fatty acid.

3. No specific mention of direct cardiotoxicity risks or reactions associated with DOJOLVI or triheptanoin was provided in the drug label. The focus was primarily on gastrointestinal adverse reactions and feeding tube dysfunction as potential adverse effects of the medication.",Less,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",4cfeb8bd-143e-4dd7-bc34-b0bcda02460d,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=4cfeb8bd-143e-4dd7-bc34-b0bcda02460d&type=display
1111,TRIHEXYPHENIDYL HYDROCHLORIDE,"1. The drug label mentions that patients with cardiac disorders should be closely monitored while using trihexyphenidyl due to its atropine-like properties, which can have untoward reactions. (The drug itself is associated with cardiotoxicity risk.)

2. Elderly patients over the age of 60 may experience cognitive dysfunctions, including confusion and memory impairment, when using trihexyphenidyl. (The drug itself is associated with cardiotoxicity risk.)

3. The label also warns that abrupt withdrawal of treatment for parkinsonism may result in acute exacerbation of symptoms, including neuroleptic malignant syndrome (NMS). (The drug itself is associated with cardiotoxicity risk.)

4. Trihexyphenidyl may cause side effects such as tachycardia, which is a potential cardiotoxic reaction. (The drug itself is associated with cardiotoxicity risk.)

5. Patients with hypertension should be closely monitored while using trihexyphenidyl due to its potential cardiotoxic effects. (The drug itself is associated with cardiotoxicity risk.)

6. The label mentions that trihexyphenidyl has been shown to cause cognitive dysfunctions in the elderly, including confusion and memory impairment, which are potential cardiotoxic reactions. (The drug itself is associated with cardiotoxicity risk.)

7. Trihexyphenidyl may cause neuropsychiatric signs such as anxiety, hallucinations, and seizures, which are potential cardiotoxic reactions. (The drug itself is associated with cardiotoxicity risk.)

8. The label advises that patients with cardiac disorders should be monitored closely while using trihexyphenidyl due to its potential cardiotoxic effects. (The drug itself is associated with cardiotoxicity risk.)

9. Trihexyphenidyl may cause tachycardia, which is a potential cardiotoxic reaction. (The drug itself is associated with cardiotoxicity risk.)

10. The label mentions that patients with hypertension should be closely monitored while using trihexyphenidyl due to its potential cardiotoxic effects. (The drug itself is associated with cardiotoxicity risk.)",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",1e98bd29-c339-4ede-841a-1b2834aaf48b,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=1e98bd29-c339-4ede-841a-1b2834aaf48b&type=display
1112,TRILACICLIB,"1. COSELA is a kinase inhibitor indicated to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive-stage small cell lung cancer. (No mention of cardiotoxicity risk associated with the drug itself)
   
2. COSELA administration can cause injection-site reactions including phlebitis and thrombophlebitis. Injection-site reactions including phlebitis and thrombophlebitis occurred in 56 (21%) of 272 patients receiving COSELA in clinical trials. (No mention of cardiotoxicity risk associated with the drug itself)

3. COSELA administration can cause acute drug hypersensitivity reactions, including facial edema and urticaria. Acute drug hypersensitivity reactions occurred in 16 (6%) of 272 patients receiving COSELA in clinical trials. (No mention of cardiotoxicity risk associated with the drug itself)

4. Severe, life-threatening, or fatal interstitial lung disease (ILD) and/or pneumonitis can occur in patients treated with cyclin-dependent kinases (CDK)4/6 inhibitors, the same drug class as COSELA. ILD/pneumonitis occurred in 1 (0.4%) of 272 patients receiving COSELA in clinical trials. (No mention of cardiotoxicity risk associated with the drug itself)

5. Based on its mechanism of action, COSELA can cause fetal harm when administered to a pregnant woman. Females of reproductive potential should use effective contraception during treatment with COSELA. (No mention of cardiotoxicity risk associated with the drug itself)

6. Serious adverse reactions occurred in 30% of patients receiving COSELA. Serious adverse reactions reported in >3% of patients who received COSELA included respiratory failure, hemorrhage, and thrombosis. (No direct mention of cardiotoxicity risk associated with the drug itself, but serious adverse reactions may include cardiotoxicity)

7. COSELA is an inhibitor of OCT2, MATE1, and MATE-2K. Co-administration of COSELA may increase the concentration or net accumulation of certain drugs in the kidney, such as dofetilide, which can cause serious ventricular arrhythmias associated with QT interval prolongation. (Indirect mention of potential cardiotoxicity risk associated with co-administration of certain drugs with COSELA)

In summary, while COSELA itself is not directly associated with cardiotoxicity risks, there is a mention of potential serious adverse reactions, including respiratory failure and thrombosis, which may indirectly involve cardiotoxicity. Additionally, co-administration of COSELA with certain drugs may increase the risk of cardiotoxicity, such as QT interval prolongation with dofetilide.",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",4b06922c-498d-4871-a037-84a44e6a6b6c,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=4b06922c-498d-4871-a037-84a44e6a6b6c&type=display
1113,TRIMETHOBENZAMIDE HYDROCHLORIDE,"1. The drug label does not mention any specific cardiotoxicity risks associated with Tigan (trimethobenzamide hydrochloride).
2. The label does not indicate that Tigan itself is associated with cardiotoxicity reactions.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",7da90678-b229-4ad6-9193-2b8a3e9ba695,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7da90678-b229-4ad6-9193-2b8a3e9ba695&type=display
1114,TRIMETHOPRIM,"1. The drug label does not mention any specific cardiotoxicity risks associated with trimethoprim itself.
2. The label does not indicate that trimethoprim is associated with cardiotoxicity reactions.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",73ccebc1-7412-2424-d62c-a5180ec52d81,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=73ccebc1-7412-2424-d62c-a5180ec52d81&type=display
1115,TRIMIPRAMINE MALEATE,"1. The drug label mentions that trimipramine maleate capsules have been associated with cardiovascular adverse reactions such as hypotension, hypertension, tachycardia, palpitation, myocardial infarction, arrhythmias, heart block, and stroke. (The drug itself is associated with cardiotoxicity risks.)

2. The label also notes that trimipramine maleate capsules may cause confusional states, anxiety, restlessness, agitation, insomnia, nightmares, hypomania, and exacerbation of psychosis, which can be psychiatric symptoms related to cardiotoxicity. (The drug itself is associated with psychiatric symptoms that may be related to cardiotoxicity.)

3. Additionally, trimipramine maleate capsules may lead to neurological symptoms like numbness, tingling, paresthesias, incoordination, ataxia, tremors, peripheral neuropathy, extrapyramidal symptoms, seizures, alterations in EEG patterns, tinnitus, and syndrome of inappropriate ADH secretion. (The drug itself is associated with neurological symptoms that may be related to cardiotoxicity.)

4. The drug label mentions anticholinergic effects such as dry mouth, blurred vision, constipation, urinary retention, and dilation of the urinary tract, which can be related to cardiotoxicity risks. (The drug itself is associated with anticholinergic effects that may be related to cardiotoxicity.)

5. Trimipramine maleate capsules may cause allergic reactions like skin rash, urticaria, itching, and edema of the face and tongue, which can be indicative of cardiotoxicity risks. (The drug itself is associated with allergic reactions that may be related to cardiotoxicity.)

6. The label also mentions hematologic adverse reactions including bone marrow depression, agranulocytosis, eosinophilia, purpura, and thrombocytopenia, which can be associated with cardiotoxicity risks. (The drug itself is associated with hematologic adverse reactions that may be related to cardiotoxicity.)

7. Trimipramine maleate capsules may lead to gastrointestinal symptoms like nausea, vomiting, diarrhea, abdominal cramps, and black tongue, which can be related to cardiotoxicity risks. (The drug itself is associated with gastrointestinal symptoms that may be related to cardiotoxicity.)

8. Endocrine effects such as gynecomastia, breast enlargement, galactorrhea, changes in libido, impotence, testicular swelling, and alterations in blood sugar levels are mentioned in the label, which can be associated with cardiotoxicity risks. (The drug itself is associated with endocrine effects that may be related to cardiotoxicity.)

9. Other adverse reactions like jaundice, altered liver function, weight changes, perspiration, flushing, urinary frequency, drowsiness, dizziness, weakness, fatigue, headache, parotid swelling, and alopecia are listed, which can be indicative of cardiotoxicity risks. (The drug itself is associated with various other adverse reactions that may be related to cardiotoxicity.)",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",4f31df66-7dc2-1f04-e054-00144ff88e88,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=4f31df66-7dc2-1f04-e054-00144ff88e88&type=display
1116,TRIPTORELIN,"1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with TRIPTODUR (triptorelin) itself.

2. The drug label does not attribute any cardiotoxicity risks or reactions to TRIPTODUR (triptorelin) use.

3. There is no mention in the drug label of TRIPTODUR (triptorelin) being linked to cardiotoxicity risks or reactions.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",f41380e7-b830-432d-a5f5-a872932f107e,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=f41380e7-b830-432d-a5f5-a872932f107e&type=display
1117,TRIPTORELIN PAMOATE,"1. The drug TRELSTAR, a gonadotropin releasing hormone (GnRH) agonist, has been associated with an increased risk of myocardial infarction, sudden cardiac death, and stroke in men. Providers are advised to monitor patients for symptoms and signs suggestive of cardiovascular disease and manage accordingly based on institutional guidelines. (Associated risk with TRELSTAR)

2. TRELSTAR may prolong the QT/QTc interval, potentially leading to cardiotoxicity. Providers should consider the risks and benefits of androgen deprivation therapy in patients with congenital long QT syndrome, congestive heart failure, electrolyte abnormalities, or those taking drugs known to prolong the QT interval. Electrolyte abnormalities should be corrected, and periodic monitoring of electrocardiograms and electrolytes may be necessary. (Potential cardiotoxicity risk with TRELSTAR)

3. Convulsions have been reported in patients treated with GnRH analogs, including TRELSTAR, with or without a history of predisposing factors. Patients who experience convulsions should be managed according to institutional guidelines. (Associated risk with TRELSTAR)",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",b1b84d62-a369-a4b7-5c41-dd1f553a18f3,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=b1b84d62-a369-a4b7-5c41-dd1f553a18f3&type=display
1118,TROMETHAMINE,"1. The drug label mentions that Tham Solution (tromethamine injection) is indicated for the prevention and correction of metabolic acidosis associated with cardiac bypass surgery, cardiac arrest, and ACD blood acidity correction during cardiac bypass surgery. The label states that Tham Solution has been found to be beneficial in correcting metabolic acidosis during or after cardiac bypass surgery, which may involve cardiotoxicity risks due to the underlying cardiac conditions. (Associated with cardiotoxicity risk)

2. The label also notes that Tham Solution may be added directly to ACD blood used for priming the pump-oxygenator during cardiac bypass surgery to correct the acidity of the blood. This suggests that the drug itself is not associated with cardiotoxicity risks but is used to address acid-base imbalances in the context of cardiac procedures. (Not associated with cardiotoxicity risk)

3. In cases of cardiac arrest, Tham Solution may be administered intraventricularly to correct acidosis and help in resuscitative efforts. The label mentions that Tham Solution has been effective in correcting acidosis and aiding in the response to resuscitative efforts in some cases of cardiac arrest. While the drug is not directly linked to causing cardiac arrest, its use in this context may involve cardiotoxicity risks due to the critical condition of the patients. (Associated with cardiotoxicity risk)

4. The label advises that Tham Solution should be administered slowly and in amounts sufficient to correct existing acidosis, to avoid overdosage and alkalosis, which can lead to hypoglycemia. It also mentions that overdosage in terms of total drug and/or too rapid administration may cause prolonged hypoglycemia. These warnings highlight the importance of careful dosing and monitoring to prevent adverse effects, including potential cardiotoxicity reactions. (Associated with cardiotoxicity risk)

5. The label cautions that large doses of Tham Solution may depress ventilation, leading to increased blood pH and reduced CO2 concentration, which can impact respiratory function. It advises adjusting the dosage to prevent blood pH from increasing above normal levels. This respiratory depression risk may indirectly affect cardiac function due to the interplay between respiratory and cardiovascular systems. (Associated with cardiotoxicity risk)",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",4af52118-c12b-4ad5-30bb-959848357e8a,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=4af52118-c12b-4ad5-30bb-959848357e8a&type=display
1119,TROSPIUM CHLORIDE,"1. Trospium Chloride Extended-Release Capsules, a muscarinic antagonist, were not associated with an increase in individual corrected QT interval (QTcI) or Fridericia corrected QT interval (QTcF) at any time during steady-state measurement in healthy volunteers. Trospium chloride was not linked to QT interval prolongation in clinical trials.

2. In a study with an immediate-release formulation of trospium chloride, asymptomatic, non-specific T-wave inversions were observed more often in subjects receiving trospium chloride than in those receiving placebo or moxifloxacin. Trospium chloride was associated with T-wave inversions, but the clinical significance of this finding is unknown.

3. Trospium chloride was not associated with an increase in heart rate in overactive bladder patients in two Phase 3 trials. However, in a study with an immediate-release formulation, trospium chloride was linked to an increase in heart rate that correlated with increasing plasma concentration. Trospium chloride was associated with an elevation in heart rate in the immediate-release formulation study.

4. Trospium chloride was not associated with any treatment-emergent serious adverse events related to the cardiovascular system in clinical trials. Trospium chloride did not lead to any serious adverse events related to the cardiovascular system in the clinical trials conducted.

5. Trospium chloride was not associated with any significant cardiovascular adverse reactions in post-marketing experience. Trospium chloride did not cause any significant cardiovascular adverse reactions in post-marketing reports.

Overall, trospium chloride, as described in the drug label, was not directly linked to cardiotoxicity risks or cardiotoxic reactions in the clinical trials and post-marketing experience mentioned.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",c1c8bd8b-7ff8-5940-e053-2995a90ae656,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=c1c8bd8b-7ff8-5940-e053-2995a90ae656&type=display
1120,TRYPAN BLUE,1. The drug label for VisionBlue 0.06% does not mention any cardiotoxicity risks or cardiotoxicity reactions associated with the use of this ophthalmic solution. No information is provided regarding any potential cardiotoxic effects of VisionBlue 0.06%.,No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",a44bc2ef-3d7f-4125-a7f7-c5969b1b4142,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a44bc2ef-3d7f-4125-a7f7-c5969b1b4142&type=display
1121,TUCATINIB,"1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with TUKYSA itself. 

2. The drug label does not indicate any direct association between TUKYSA and cardiotoxicity risks or reactions. 

3. There is no mention in the drug label of TUKYSA being linked to cardiotoxicity risks or reactions. 

Overall, the drug label for TUKYSA does not highlight any cardiotoxicity risks or reactions directly attributed to the drug itself.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",f27eb1b9-b7fc-424e-988f-84dd7bb195a3,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=f27eb1b9-b7fc-424e-988f-84dd7bb195a3&type=display
1122,UBROGEPANT,"1. The drug UBRELVY, containing the active ingredient ubrogepant, is a calcitonin gene-related peptide receptor antagonist used for the acute treatment of migraine in adults. (No mention of cardiotoxicity risk associated with the drug itself)

2. The drug does not prolong the QT interval to any clinically relevant extent at a dose 2 times the maximum recommended daily dose. (No cardiotoxicity risk associated with the drug itself)

3. Ubrogepant is eliminated mainly through metabolism, primarily by CYP3A4. (No mention of cardiotoxicity risk associated with the drug itself)

4. No significant pharmacokinetic interactions were observed for either ubrogepant or co-administered drugs when UBRELVY was administered with various medications. (No mention of cardiotoxicity risk associated with the drug itself)

5. In vitro studies showed that ubrogepant is not an inhibitor of CYP1A2, 2B6, or 3A4, and it is not an inducer of CYP1A2, 2B6, or 3A4 at clinically relevant concentrations. (No mention of cardiotoxicity risk associated with the drug itself)

6. Ubrogepant is a weak inhibitor of CYP2C8, 2C9, 2D6, 2C19, MAO-A, and UGT1A1, but the in vitro inhibition potential is not expected to be clinically significant. (No mention of cardiotoxicity risk associated with the drug itself)

7. Ubrogepant is a substrate of BCRP and P-gp efflux transporters, and the use of inhibitors of these transporters may increase the exposure of ubrogepant. (No mention of cardiotoxicity risk associated with the drug itself)

8. Ubrogepant is a weak substrate of OATP1B1, OATP1B3, and OAT1, but not a substrate of OAT3. It is not an inhibitor of P-gp, BCRP, BSEP, MRP3, MRP4, OAT1, OAT3, or NTCP transporters. (No mention of cardiotoxicity risk associated with the drug itself)

9. Co-administration of UBRELVY with ketoconazole, a strong CYP3A4 inhibitor, resulted in a significant increase in exposure of ubrogepant. (No direct mention of cardiotoxicity risk associated with the drug itself, but potential for increased exposure)

10. Co-administration of UBRELVY with rifampin, a strong CYP3A4 inducer, resulted in a significant reduction in ubrogepant exposure. (No direct mention of cardiotoxicity risk associated with the drug itself, but potential for reduced exposure)

In summary, the drug label for UBRELVY does not directly associate the drug itself with cardiotoxicity risks or cardiotoxicity reactions. The focus is primarily on the drug's metabolism, drug interactions, and pharmacokinetics without specific mention of cardiotoxic effects.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",fd9f9458-fd96-4688-be3f-f77b3d1af6ab,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fd9f9458-fd96-4688-be3f-f77b3d1af6ab&type=display
1123,ULTRAMICROSIZE GRISEOFULVIN,"1. The drug label does not mention any specific cardiotoxicity risks associated with Ultramicrosize Griseofulvin tablets, USP 125 mg and 250 mg.
2. The label does not indicate that the drug itself is associated with cardiotoxicity reactions.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",37b4d132-84f1-4394-b468-7e74eeec61eb,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=37b4d132-84f1-4394-b468-7e74eeec61eb&type=display
1124,UMECLIDINIUM,"1. **Cardiotoxicity Risk**: The drug INCRUSE ELLIPTA, containing umeclidinium, was evaluated for its potential to prolong the QTc interval in a study with healthy subjects. Following repeat doses of umeclidinium at 500 mcg once daily for 10 days, it was determined that umeclidinium did not prolong the QTc interval to any clinically relevant extent.

2. **Cardiotoxicity Reactions**: The drug INCRUSE ELLIPTA, containing umeclidinium, was not associated with any specific cardiotoxicity reactions in the clinical trials or postmarketing experience mentioned in the drug label. No adverse events related to cardiotoxicity were reported as common or serious adverse reactions.",Less,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",dbb64747-1505-49d7-9a33-99dd402e96d3,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=dbb64747-1505-49d7-9a33-99dd402e96d3&type=display
1125,UREA C-13,"1. The drug label does not mention any cardiotoxicity risks or cardiotoxicity reactions associated with the drug Pranactin-Citric (urea c-13 powder, for solution).",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",571577b1-2160-4c2f-b953-062c15373fcb,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=571577b1-2160-4c2f-b953-062c15373fcb&type=display
1126,"UREA, C-14",1. The drug label does not mention any cardiotoxicity risks or cardiotoxicity reactions associated with PYtest (14C-Urea Capsules).,No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",13148b04-9295-41bb-bd8b-76dbd4ce7c00,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=13148b04-9295-41bb-bd8b-76dbd4ce7c00&type=display
1127,URIDINE TRIACETATE,"1. The drug label does not mention any cardiotoxicity risks or cardiotoxicity reactions associated with XURIDEN.
2. No adverse reactions related to cardiotoxicity were reported in clinical trials with XURIDEN in patients with hereditary orotic aciduria.
3. The drug label does not contain any warnings or precautions regarding cardiotoxicity for XURIDEN.
4. There is no mention of any cardiotoxicity concerns in the clinical pharmacology section related to XURIDEN.
5. Overall, the drug label for XURIDEN does not indicate any association with cardiotoxicity risks or cardiotoxicity reactions.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",40606ca9-4f14-45b7-8632-fc2d17d11a2e,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=40606ca9-4f14-45b7-8632-fc2d17d11a2e&type=display
1128,URSODIOL,1. The drug label does not mention any cardiotoxicity risks or cardiotoxicity reactions associated with the use of URSO 250 and URSO FORTE.,No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",e8fc4fc2-fe5c-4cba-b6e0-5ceaf2157a61,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=e8fc4fc2-fe5c-4cba-b6e0-5ceaf2157a61&type=display
1129,URSOSIOL,"1. The drug label does not mention any cardiotoxicity risks or cardiotoxicity reactions associated with Ursodiol Capsules, USP itself. 

2. The label states that Ursodiol therapy has not been associated with liver damage, and that abnormalities in liver enzymes have not been linked to Ursodiol capsules therapy. It also mentions that ursodiol capsules have been shown to decrease liver enzyme levels in liver disease. No direct association with cardiotoxicity is mentioned.

3. The label does not indicate any specific cardiotoxicity risks or reactions related to the use of Ursodiol Capsules, USP. 

Overall, the drug label does not highlight any cardiotoxicity risks or reactions associated with Ursodiol Capsules, USP.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",fff2640b-b704-4303-acae-8647fce58a08,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fff2640b-b704-4303-acae-8647fce58a08&type=display
1130,VALACYCLOVIR,"1. **Warnings and Precautions - Thrombotic Thrombocytopenic Purpura/Hemolytic Uremic Syndrome (TTP/HUS):** Valacyclovir has been associated with thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS) in patients with advanced HIV-1 disease and transplant recipients receiving high doses of valacyclovir. Treatment with valacyclovir should be stopped immediately if clinical symptoms and laboratory findings consistent with TTP/HUS occur.

2. **Warnings and Precautions - Acute Renal Failure:** Valacyclovir has been associated with cases of acute renal failure, particularly in elderly patients, patients with underlying renal disease, patients receiving higher-than-recommended doses, patients on nephrotoxic drugs, and inadequately hydrated patients. Caution should be exercised when administering valacyclovir to these patient populations, and dosage reduction is recommended for those with impaired renal function.

3. **Warnings and Precautions - Central Nervous System Effects:** Valacyclovir has been associated with central nervous system adverse reactions, such as agitation, hallucinations, confusion, and encephalopathy, in both adult and pediatric patients with or without reduced renal function. Elderly patients are more likely to experience these adverse reactions. Valacyclovir should be discontinued if central nervous system adverse reactions occur.",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",7c332401-afb6-455b-b61a-ea108a377ef6,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7c332401-afb6-455b-b61a-ea108a377ef6&type=display
1131,VALBENAZINE,"1. The drug label warns about QT prolongation, which may cause an increase in the QT interval. It states that INGREZZA and INGREZZA SPRINKLE may prolong the QT interval, but the degree of QT prolongation is not clinically significant at expected concentrations with recommended dosing. The drug itself is associated with QT prolongation but not considered clinically significant at expected concentrations.

2. The label advises avoiding the use of INGREZZA and INGREZZA SPRINKLE in patients with congenital long QT syndrome or with arrhythmias associated with a prolonged QT interval. It suggests assessing the QT interval before increasing the dosage in patients at increased risk of a prolonged QT interval. The drug itself is associated with an increased risk of QT prolongation in patients with these conditions.

3. Additionally, the label mentions that for patients who are CYP2D6 poor metabolizers or are taking strong CYP2D6 inhibitors, dose reduction may be necessary due to the potential for clinically significant QT prolongation. It recommends reducing the dose of INGREZZA or INGREZZA SPRINKLE to 40 mg once daily in these cases. The drug itself is associated with an increased risk of QT prolongation in patients who are CYP2D6 poor metabolizers or are taking strong CYP2D6 inhibitors.",Less,Yes,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",4c970164-cafb-421f-9eb5-c226ef0a3417,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=4c970164-cafb-421f-9eb5-c226ef0a3417&type=display
1132,VALGANCICLOVIR,1. The drug label does not mention any specific cardiotoxicity risks or cardiotoxicity reactions associated with valganciclovir hydrochloride.,No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",39452b74-161d-4525-a0f7-fe486f001513,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=39452b74-161d-4525-a0f7-fe486f001513&type=display
1133,VALPROATE SODIUM,"1. **Cardiotoxicity Risks:**
   - The drug label does not mention any specific cardiotoxicity risks associated with Valproate Sodium Injection.

2. **Cardiotoxicity Reactions:**
   - The drug label does not list any cardiotoxicity reactions associated with the use of Valproate Sodium Injection.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",856ecdad-a8e0-4bda-a217-cd7948ddfa59,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=856ecdad-a8e0-4bda-a217-cd7948ddfa59&type=display
1134,VALPROIC ACID,"1. The drug label does not specifically mention cardiotoxicity risks or cardiotoxicity reactions associated with valproic acid oral solution.

2. Therefore, based on the information provided in the drug label, there are no direct references to cardiotoxicity risks or cardiotoxicity reactions linked to the use of valproic acid oral solution.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",531c0fc7-5e80-49a5-a9d1-0916ec45d52c,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=531c0fc7-5e80-49a5-a9d1-0916ec45d52c&type=display
1135,VALRUBICIN,"1. The drug VALSTAR, containing valrubicin, is an anthracycline topoisomerase inhibitor indicated for intravesical therapy of BCG-refractory carcinoma in situ (CIS) of the urinary bladder. The label does not mention any direct association of the drug with cardiotoxicity risks.

2. The label does not list any specific cardiotoxicity risks or reactions associated with the use of VALSTAR. 

3. The drug label primarily focuses on the intravesical use of VALSTAR for the treatment of bladder cancer and does not highlight any cardiotoxic effects or risks related to the drug. 

Overall, based on the information provided in the drug label, VALSTAR does not appear to be directly associated with cardiotoxicity risks or reactions.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",e96f30a0-6662-11de-8f80-0002a5d5c51b,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=e96f30a0-6662-11de-8f80-0002a5d5c51b&type=display
1136,VALSARTAN,"1. **Cardiotoxicity Risk**: The drug label for Diovan (valsartan) includes a warning about fetal toxicity, stating that drugs acting on the renin-angiotensin system can cause injury and death to the developing fetus. This risk is associated with the drug itself.

2. **Cardiotoxicity Reactions**: The label mentions that in patients with heart failure or post-myocardial infarction, Diovan may lead to hypotension, which is a common adverse reaction. However, discontinuation of therapy due to symptomatic hypotension is usually not necessary when dosing instructions are followed. This reaction is associated with the drug itself.

3. **Cardiotoxicity Reactions**: In heart failure trials, Diovan-treated patients had a higher incidence of dizziness, hypotension, diarrhea, arthralgia, back pain, fatigue, and hyperkalemia compared to placebo-treated patients. These reactions are associated with the drug itself.

4. **Cardiotoxicity Reactions**: Post-myocardial infarction patients treated with Diovan experienced hypotension, cough, and increased blood creatinine, which led to discontinuation of therapy in some cases. These reactions are associated with the drug itself.

5. **Cardiotoxicity Risk**: The label also warns about the potential for impaired renal function, including acute renal failure, in patients whose renal function may depend on the activity of the renin-angiotensin system. This risk is associated with the drug itself.

6. **Cardiotoxicity Reactions**: Diovan may lead to hyperkalemia in some patients with heart failure, particularly those with pre-existing renal impairment. Dosage reduction or discontinuation of Diovan may be necessary in such cases. This reaction is associated with the drug itself.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",5ddba454-f3e6-43c2-a7a6-58365d297213,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=5ddba454-f3e6-43c2-a7a6-58365d297213&type=display
1137,VANCOMYCIN,"1. The drug label warns of potential infusion reactions, including hypotension, shock, and cardiac arrest, associated with rapid administration of Vancomycin Injection. The drug itself is associated with these infusion-related cardiotoxicity risks.

2. Vancomycin Injection may cause ""red man syndrome,"" characterized by pruritus and erythema involving the face, neck, and upper torso, which can be a manifestation of infusion reactions. The drug itself is associated with this cardiotoxicity reaction.

3. The label mentions that vancomycin can result in acute kidney injury, including acute renal failure, due to interstitial nephritis or acute tubular necrosis, which may lead to cardiotoxicity. The drug itself is associated with nephrotoxicity, which can indirectly impact cardiac function.

4. Ototoxicity, such as hearing loss, tinnitus, dizziness, or vertigo, has been reported in patients receiving vancomycin, which can also affect cardiac function. The drug itself is associated with ototoxicity, which can have implications for cardiotoxicity.

5. Severe dermatologic reactions, like toxic epidermal necrolysis and Stevens-Johnson syndrome, have been reported with vancomycin use, which can potentially lead to systemic effects, including cardiotoxicity. The drug itself is associated with severe dermatologic reactions that may have cardiotoxic implications.

6. The drug label does not specifically mention direct cardiotoxicity risks or reactions associated with vancomycin use beyond the general adverse reactions listed. It is important to monitor patients for any signs or symptoms of cardiotoxicity during vancomycin therapy.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",60bee69b-be70-412c-9e83-a24a0a8a5e7b,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=60bee69b-be70-412c-9e83-a24a0a8a5e7b&type=display
1138,VANCOMYCIN HYDROCHLORIDE,"1. **Warnings**: Rapid bolus administration of vancomycin may be associated with exaggerated hypotension, including shock, and rarely, cardiac arrest. The drug itself was associated with the risk of cardiotoxicity reactions.

2. **Warnings**: Vancomycin should be administered over a period of not less than 60 minutes to avoid rapid-infusion-related reactions. Stopping the infusion usually results in prompt cessation of these reactions. The drug itself was associated with the risk of cardiotoxicity reactions.

3. **Warnings**: Vancomycin exposure may result in acute kidney injury (AKI), with the risk increasing as systemic exposure/serum levels increase. Monitor renal function in all patients receiving vancomycin, especially those with underlying renal impairment. The drug itself was associated with the risk of cardiotoxicity reactions.

4. **Warnings**: Ototoxicity has occurred in patients receiving vancomycin, which may be transient or permanent. It has been reported mostly in patients who have been given excessive doses, have underlying hearing loss, or are receiving concomitant therapy with another ototoxic agent. The drug itself was associated with the risk of cardiotoxicity reactions.

5. **Warnings**: Severe dermatologic reactions such as toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome (SJS), and other reactions have been reported in association with the use of vancomycin. Cutaneous signs or symptoms reported include skin rashes, mucosal lesions, and blisters. The drug itself was associated with the risk of cardiotoxicity reactions.

6. **Warnings**: Hemorrhagic occlusive retinal vasculitis, including permanent loss of vision, occurred in patients receiving intracameral or intravitreal administration of vancomycin during or after cataract surgery. The safety and efficacy of vancomycin administered by these routes have not been established. The drug itself was associated with the risk of cardiotoxicity reactions.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",99e523d8-9bde-43cb-8434-497015e5dcbd,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=99e523d8-9bde-43cb-8434-497015e5dcbd&type=display
1139,VARDENAFIL HYDROCHLORIDE,"1. The drug STAXYN, a phosphodiesterase 5 (PDE5) inhibitor, is indicated for the treatment of erectile dysfunction. (The drug itself is not associated with cardiotoxicity risk.)

2. Physicians should consider the cardiovascular status of patients before prescribing STAXYN, as there is a degree of cardiac risk associated with sexual activity. The drug should not be used in men for whom sexual activity is not recommended due to underlying cardiovascular status. (The drug itself is not associated with cardiotoxicity risk.)

3. Patients with left ventricular outflow obstruction may be sensitive to vasodilators like PDE5 inhibitors, including STAXYN. (The drug itself is not associated with cardiotoxicity risk.)

4. Vardenafil, the active ingredient in STAXYN, has systemic vasodilatory properties that can result in transient decreases in blood pressure. Physicians should consider the potential adverse effects on patients with underlying cardiovascular disease. (The drug itself is not associated with cardiotoxicity risk.)

5. STAXYN should not be used in patients with unstable angina, hypotension, uncontrolled hypertension, recent history of stroke, life-threatening arrhythmia, or severe cardiac failure until further information is available. (The drug itself is not associated with cardiotoxicity risk.)

6. Patients with anatomical deformation of the penis or conditions predisposing them to priapism should use STAXYN with caution. Priapism lasting longer than 4 hours requires immediate medical attention to prevent tissue damage and loss of potency. (The drug itself is not associated with cardiotoxicity risk.)

7. Patients should stop using STAXYN and seek medical attention in case of sudden loss of vision in one or both eyes, which may indicate non-arteritic anterior ischemic optic neuropathy (NAION). The drug has not been evaluated in patients with hereditary degenerative retinal disorders. (The drug itself is not associated with cardiotoxicity risk.)

8. Patients should discontinue STAXYN and seek medical attention in the event of sudden decrease or loss of hearing, which has been reported in temporal association with PDE5 inhibitors like vardenafil. (The drug itself is not associated with cardiotoxicity risk.)

9. Caution is advised when co-administering PDE5 inhibitors like STAXYN with alpha-blockers, as the combination can lead to significant blood pressure lowering and symptomatic hypotension in some patients. (The drug itself is not associated with cardiotoxicity risk.)

10. Patients with congenital or acquired QT prolongation, or those taking certain antiarrhythmic medications, should avoid using STAXYN. (The drug itself is not associated with cardiotoxicity risk.)

In summary, while STAXYN is not directly associated with cardiotoxicity risks, caution is advised in patients with underlying cardiovascular conditions, and certain precautions should be taken to minimize potential cardiovascular effects when using this medication.",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",1f71920c-0e54-46e8-82c8-3ea5d212d469,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=1f71920c-0e54-46e8-82c8-3ea5d212d469&type=display
1140,VARENICLINE TARTRATE,"1. Cardiovascular Events: Patients with underlying cardiovascular (CV) disease may be at increased risk of CV events when using CHANTIX. The drug was associated with an increased incidence of nonfatal myocardial infarction (MI) and nonfatal stroke compared to placebo in a smoking cessation trial. However, all-cause and CV mortality was lower in patients treated with CHANTIX. Patients should be instructed to notify their healthcare providers of new or worsening CV symptoms and seek immediate medical attention if they experience signs and symptoms of MI or stroke. (CHANTIX was associated with an increased risk of CV events in patients with underlying CV disease.)

2. A meta-analysis of 15 CHANTIX efficacy trials showed an increased hazard ratio for Major Adverse Cardiovascular Events (MACE) of 1.95, although the finding was not statistically significant. Few MACE events occurred during the trial, and the findings did not contribute substantively to the understanding of CV risk with CHANTIX. (CHANTIX was not statistically significantly associated with an increased risk of MACE in the meta-analysis.)

3. The comprehensive evaluation of CV risk with CHANTIX suggests that patients with underlying CV disease may be at increased risk of CV events. Instruct patients to notify their healthcare providers of new or worsening CV symptoms and seek immediate medical attention if they experience signs and symptoms of MI or stroke. (CHANTIX was associated with an increased risk of CV events in patients with underlying CV disease.)

4. In a large postmarketing neuropsychiatric safety outcome trial, an analysis of adjudicated MACE events was conducted for patients while in the trial and during a 28-week non-treatment extension period. Few MACE events occurred during the trial, and the findings did not contribute substantively to the understanding of CV risk with CHANTIX. (CHANTIX was not associated with a significant increase in MACE events in the postmarketing trial.)

In summary, CHANTIX has been associated with an increased risk of cardiovascular events, particularly in patients with underlying cardiovascular disease. Patients should be closely monitored for new or worsening CV symptoms, and immediate medical attention should be sought if signs of myocardial infarction or stroke are experienced while using CHANTIX.",Less,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",f0ff4f27-5185-4881-a749-c6b7a0ca5696,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=f0ff4f27-5185-4881-a749-c6b7a0ca5696&type=display
1141,VASOPRESSIN,"1. The drug label mentions that vasopressin injection can worsen cardiac function, indicating that the drug itself is associated with the risk of worsening cardiac function.
   
2. The label also states that reversible diabetes insipidus can occur as an adverse reaction to vasopressin injection, which may manifest as polyuria, dilute urine, and hypernatremia. This adverse reaction is not directly related to cardiotoxicity but can impact fluid and electrolyte balance, which can indirectly affect cardiac function.

3. Adverse reactions associated with vasopressin injection include decreased cardiac output, bradycardia, tachyarrhythmias, and ischemia in various parts of the body, including the heart (myocardial ischemia). These adverse reactions suggest that the drug itself can lead to cardiotoxicity reactions.

4. The label also mentions that the pressor effects of catecholamines and vasopressin injection are expected to be additive, indicating a potential interaction that could impact cardiovascular function.

In summary, vasopressin injection is associated with the risk of worsening cardiac function and can lead to adverse reactions such as bradycardia, tachyarrhythmias, and myocardial ischemia, indicating potential cardiotoxicity effects.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",0ab267f4-9ec9-44fd-8521-f975074667d9,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=0ab267f4-9ec9-44fd-8521-f975074667d9&type=display
1142,VECURONIUM BROMIDE,"1. The drug label mentions that vecuronium bromide itself is not associated with clinically significant effects on hemodynamic parameters, such as systolic, diastolic, or mean arterial pressure, and does not counteract hemodynamic changes caused by anesthetic agents or other factors known to alter hemodynamics.

2. It is noted that the drug vecuronium bromide has not been studied in patients with hemodynamic dysfunction secondary to cardiac valvular disease, indicating a lack of specific data on its effects in this population.

3. The label states that there are reports in the literature of increased effect and longer duration of action of vecuronium in the elderly compared to younger patients, but other reports have found no significant differences between healthy elderly and younger adults, suggesting variability in response based on age.

4. The drug label mentions that vecuronium bromide itself has no known effect on consciousness, pain threshold, or cerebration, indicating that it does not impact central nervous system functions.

5. It is highlighted that the drug vecuronium bromide has not been studied sufficiently to determine if it is capable of triggering malignant hyperthermia, a potentially fatal hypermetabolic condition of skeletal muscle, indicating a lack of conclusive data on this specific adverse effect.",Less,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",b012b1b1-9e59-4525-8f4d-dae98344d15f,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=b012b1b1-9e59-4525-8f4d-dae98344d15f&type=display
1143,VEMURAFENIB,"1. **QT Prolongation**: ZELBORAF has been associated with concentration-dependent QT prolongation, which may increase the risk of ventricular arrhythmias, including Torsade de Pointes. Patients with uncorrectable electrolyte abnormalities, QTc > 500 ms, or long QT syndrome should not start treatment with ZELBORAF. Monitoring of ECG and electrolytes is recommended before and during treatment to manage this cardiotoxicity risk.

2. **Hepatotoxicity**: ZELBORAF has been linked to liver injury leading to functional hepatic impairment, including coagulopathy or other organ dysfunction. Monitoring of liver enzymes, alkaline phosphatase, and bilirubin is advised before initiating ZELBORAF and monthly during treatment to manage this potential cardiotoxicity reaction.

3. **Concurrent Administration with Ipilimumab**: The safety and effectiveness of ZELBORAF in combination with ipilimumab have not been established. In a dose-finding trial, Grade 3 increases in transaminases and bilirubin occurred in a majority of patients who received concurrent ipilimumab and vemurafenib. This combination may pose an increased risk of hepatotoxicity, a form of cardiotoxicity.

4. **QT Prolongation**: ZELBORAF has been associated with QT prolongation, leading to an increased risk of ventricular arrhythmias, including Torsade de Pointes. Monitoring of ECG and electrolytes is recommended before and during treatment to manage this cardiotoxicity risk. Withholding ZELBORAF in patients with QTc > 500 ms and restarting at a reduced dose upon recovery is advised to prevent further cardiotoxic effects.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",38eea320-7e0c-485a-bc30-98c3c45e2763,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=38eea320-7e0c-485a-bc30-98c3c45e2763&type=display
1144,VENETOCLAX,"1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with VENCLEXTA itself. 

2. However, it is important to note that the label does not include all possible information, so it is recommended to consult the full prescribing information for a comprehensive understanding of any potential cardiotoxicity risks or reactions related to VENCLEXTA.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",b118a40d-6b56-cee3-10f6-ded821a97018,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=b118a40d-6b56-cee3-10f6-ded821a97018&type=display
1145,VENLAFAXINE HYDROCHLORIDE,"1. The drug label for Effexor XR does not specifically mention cardiotoxicity risks or cardiotoxicity reactions associated with the use of this medication. 

2. The label primarily focuses on warnings and precautions related to suicidal thoughts and behaviors, serotonin syndrome, elevated blood pressure, increased risk of bleeding, angle-closure glaucoma, activation of mania or hypomania, discontinuation syndrome, seizures, hyponatremia, interstitial lung disease, eosinophilic pneumonia, and sexual dysfunction. 

3. While Effexor XR is associated with various adverse reactions and risks, cardiotoxicity is not highlighted as a significant concern in the provided drug label information. 

4. It is important for healthcare providers and patients to be aware of all potential risks and side effects associated with Effexor XR and to consult with a healthcare professional for personalized medical advice and monitoring during treatment.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",c848a5d8-ba94-4c84-80e3-0bf35fb8e32e,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=c848a5d8-ba94-4c84-80e3-0bf35fb8e32e&type=display
1146,VENOFER (IRON SUCROSE),"1. The drug label mentions that Venofer may cause hypotension, which is a cardiotoxicity risk. Venofer itself is associated with the risk of hypotension.
   
2. The label also states that hypotension following administration of Venofer may be related to the rate of administration and/or total dose administered, indicating a potential cardiotoxicity risk associated with the drug.

3. In the section on adverse reactions, it is noted that hypotension is one of the most common adverse reactions in adult patients receiving Venofer, further highlighting the cardiotoxicity risk associated with the drug.

4. Post-marketing experience reports adverse reactions such as cardiac failure congestive, which is a cardiotoxicity reaction associated with Venofer.

5. The label mentions that severe adverse reactions, including circulatory failure (severe hypotension, shock including in the context of anaphylactic reaction), may occur in pregnant women with parenteral iron products like Venofer, potentially leading to fetal bradycardia, indicating a cardiotoxicity risk associated with the drug in pregnant patients.

6. Post-marketing experience also lists bradycardia as a cardiac disorder associated with Venofer, indicating a cardiotoxicity reaction linked to the drug.

7. The label further mentions that symptoms associated with Venofer total dosage or infusing too rapidly include cardiovascular collapse, highlighting a potential cardiotoxicity reaction associated with the drug.

8. In summary, Venofer is associated with cardiotoxicity risks such as hypotension and circulatory failure, with potential cardiotoxicity reactions including bradycardia and cardiovascular collapse reported in post-marketing experience and clinical studies.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",c59cb54c-bee5-96d6-e053-2995a90a767c,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=c59cb54c-bee5-96d6-e053-2995a90a767c&type=display
1147,VERAPAMIL HYDROCHLORIDE,"1. Verapamil Hydrochloride Extended-Release Capsules (PM) is contraindicated in patients with severe left ventricular dysfunction, indicating that the drug itself is associated with a cardiotoxicity risk.

2. The drug may cause congestive heart failure or pulmonary edema to develop, particularly in patients with severe left ventricular dysfunction or ventricular dysfunction receiving beta-adrenergic blockers.

3. Verapamil may occasionally lead to hypotension, which can result in dizziness or symptomatic hypotension, with a low incidence observed in clinical studies.

4. Elevated liver enzymes have been reported with verapamil use, and periodic monitoring of liver function is recommended due to potential hepatocellular injury.

5. In patients with atrial flutter or atrial fibrillation and an accessory bypass tract, verapamil may lead to ventricular fibrillation, indicating a potential cardiotoxicity risk in this specific patient population.

6. Verapamil's effect on AV conduction and the SA node may result in asymptomatic first-degree AV block and transient bradycardia, with higher degrees of AV block observed infrequently in previous clinical trials.

7. Patients with hypertrophic cardiomyopathy receiving verapamil therapy may experience serious adverse effects, such as pulmonary edema, severe hypotension, sinus bradycardia, second-degree AV block, and sinus arrest, indicating a potential cardiotoxicity risk in this patient population.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",18f6d349-8c5c-4443-ac65-16bf6619ecdc,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=18f6d349-8c5c-4443-ac65-16bf6619ecdc&type=display
1148,VERICIGUAT,"1. The drug label for VERQUVO includes a warning about embryo-fetal toxicity, advising against administering the drug to pregnant females due to the potential for fetal harm. The drug itself is associated with the risk of embryo-fetal toxicity.

2. The label mentions that VERQUVO was evaluated in a clinical trial where hypotension and anemia were reported as the most common adverse reactions. These adverse reactions were associated with the use of VERQUVO.

3. In the clinical trial, VERQUVO demonstrated a dose-dependent reduction in NT-proBNP, a biomarker in heart failure, compared to placebo when added to standard care. This reduction in NT-proBNP was associated with the use of VERQUVO.

4. The label also discusses the potential for hypotension as a result of drug interactions, specifically with PDE-5 inhibitors. Concomitant use of VERQUVO with PDE-5 inhibitors is not recommended due to the potential for hypotension.",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",17056d73-1b1b-4bf2-9c07-b7a9367f0d6d,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=17056d73-1b1b-4bf2-9c07-b7a9367f0d6d&type=display
1149,VERTEPORFIN FOR INJECTION,"1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with VISUDYNE (verteporfin for injection) itself.

2. The drug label does not indicate any direct association between VISUDYNE and cardiotoxicity risks or reactions in the sections provided. 

3. No information regarding cardiotoxicity risks or reactions related to VISUDYNE is mentioned in the drug label sections reviewed. 

Overall, based on the information provided in the drug label, there are no references to cardiotoxicity risks or reactions attributed to VISUDYNE (verteporfin for injection).",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",2f0a34ce-3c57-4ac8-b28e-512be807272f,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=2f0a34ce-3c57-4ac8-b28e-512be807272f&type=display
1150,VIBEGRON,"1. The drug GEMTESA (vibegron) is a beta-3 adrenergic agonist indicated for the treatment of overactive bladder (OAB) in adults, but there is no mention of the drug being associated with cardiotoxicity risks in this section.

2. The drug label does not mention any cardiotoxicity risks or reactions associated with GEMTESA in the Dosage and Administration section.

3. The Contraindications section states that GEMTESA should not be used in patients with known hypersensitivity to vibegron or any components of the product, but it does not mention any cardiotoxicity risks.

4. The Warnings and Precautions section highlights urinary retention as a potential risk associated with GEMTESA, especially in patients with bladder outlet obstruction or taking muscarinic antagonist medications for OAB. There is no direct mention of cardiotoxicity risks in this section.

5. The Adverse Reactions section lists common adverse reactions reported with GEMTESA, including headache, urinary tract infection, and upper respiratory tract infection. There is no specific mention of cardiotoxicity reactions in this section.

6. The Drug Interactions section discusses the interaction of GEMTESA with digoxin, stating that concomitant use can increase digoxin concentrations. However, there is no direct mention of cardiotoxicity risks associated with this interaction.

7. The Clinical Pharmacology section details the mechanism of action, pharmacodynamics, and pharmacokinetics of vibegron, the active ingredient in GEMTESA. There is no specific mention of cardiotoxicity risks or reactions in this section.

Overall, based on the information provided in the drug label, there is no direct mention of GEMTESA being associated with cardiotoxicity risks or cardiotoxic reactions. The focus of the label is primarily on the treatment of overactive bladder and associated adverse effects.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",25f21d25-14f8-4fda-91f6-7aa8b68aa1c8,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=25f21d25-14f8-4fda-91f6-7aa8b68aa1c8&type=display
1151,VIGABATRIN,"1. The drug label does not mention any cardiotoxicity risks or cardiotoxicity reactions associated with SABRIL (vigabatrin). 

Therefore, based on the information provided in the drug label, SABRIL is not associated with cardiotoxicity risks or cardiotoxicity reactions.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",a88ac1b4-e2c9-45c0-b321-4785902172e3,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a88ac1b4-e2c9-45c0-b321-4785902172e3&type=display
1152,VILAZODONE HYDROCHLORIDE,"1. VIIBRYD is contraindicated in patients taking, or within 14 days of stopping, monoamine oxidase inhibitors (MAOIs), including MAOIs such as linezolid or intravenous methylene blue, due to an increased risk of serotonin syndrome, which can include cardiotoxicity reactions such as tachycardia and labile blood pressure. The drug itself is not directly associated with cardiotoxicity but can increase the risk when used with MAOIs.

2. VIIBRYD may increase the risk of bleeding events when used concomitantly with drugs that interfere with serotonin reuptake, such as aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), and anticoagulants. This increased risk of bleeding includes potential cardiotoxicity reactions like hemorrhages. The drug itself is not directly associated with cardiotoxicity but can contribute to the risk of bleeding events.

3. VIIBRYD should be used with caution in patients with a seizure disorder, as seizures can occur with treatment. Seizures can have cardiotoxic effects, and the drug itself is associated with an increased risk of seizures, which can lead to potential cardiotoxicity reactions.",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",4c55ccfb-c4cf-11df-851a-0800200c9a66,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=4c55ccfb-c4cf-11df-851a-0800200c9a66&type=display
1153,VILOXAZINE HYDROCHLORIDE,"1. **Blood Pressure and Heart Rate Increases**: Qelbree can cause an increase in heart rate and diastolic blood pressure. The drug itself is associated with the risk of increased heart rate and blood pressure in both pediatric and adult patients, as observed in clinical studies.

2. **Activation of Mania or Hypomania**: Noradrenergic drugs, such as Qelbree, may induce a manic or mixed episode in patients with bipolar disorder. The drug itself is associated with the risk of activating mania or hypomania in patients with bipolar disorder, as stated in the warnings and precautions section.

3. **Somnolence and Fatigue**: Qelbree can cause somnolence and fatigue. The drug itself is associated with the risk of somnolence and fatigue in both pediatric and adult patients, as reported in clinical trials. Patients are advised to use caution when driving or operating machinery due to potential somnolence and fatigue caused by the drug.",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",aedf408d-0f84-418d-9416-7c39ddb0d29a,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=aedf408d-0f84-418d-9416-7c39ddb0d29a&type=display
1154,VILTOLARSEN,1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with VILTEPSO (viltolarsen) injection for the treatment of Duchenne muscular dystrophy (DMD).,No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",1ffff9a8-6d6a-4dcb-8493-1b6cc3a5d123,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=1ffff9a8-6d6a-4dcb-8493-1b6cc3a5d123&type=display
1155,VINBLASTINE SULFATE,"1. The drug label mentions that vinblastine sulfate has been associated with cardiac effects such as myocardial infarction, angina pectoris, and transient abnormalities of ECG related to coronary ischemia, although these occurrences are very rare. (The drug itself is associated with cardiotoxicity risks.)

2. In combination therapy with vinblastine sulfate, bleomycin, and cisplatin for testicular cancer, cases of unexpected myocardial infarction and cerebrovascular accidents have been reported. Raynauds phenomenon has also been observed with this combination. (The drug itself is associated with cardiotoxicity reactions in combination therapy.)

3. The label also mentions that vinblastine sulfate may cause hypertension, and that cases of Raynauds phenomenon have been reported when patients are treated with vinblastine sulfate in combination with bleomycin and cisplatin for testicular cancer. (The drug itself is associated with cardiotoxicity risks.)

4. Additionally, the label states that acute shortness of breath and severe bronchospasm have been reported following the administration of vinca alkaloids, particularly when used in combination with mitomycin-C, and may require aggressive treatment, especially in patients with pre-existing pulmonary dysfunction. (The drug itself is associated with cardiotoxicity risks in combination therapy.)

5. The label warns that vinblastine sulfate should be used with caution in patients with ischemic cardiac disease. (The drug itself is associated with cardiotoxicity risks.)",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",f073b58e-56d6-4c8d-a2ce-b37719402d77,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=f073b58e-56d6-4c8d-a2ce-b37719402d77&type=display
1156,VINCRISTINE SULFATE,"1. The drug label mentions that chemotherapy combinations including vincristine sulfate, when given to patients previously treated with mediastinal radiation, have been associated with coronary artery disease and myocardial infarction. Causality has not been established. (The drug itself was not directly associated with cardiotoxicity but was mentioned in combination with other treatments.)

2. The label also states that acute respiratory distress syndrome has been reported as a pulmonary adverse reaction following the administration of vincristine sulfate. (The drug itself was associated with the risk of acute respiratory distress syndrome.)

3. Additionally, the label mentions that hypertension and hypotension have occurred as cardiovascular adverse reactions following the administration of vincristine sulfate. (The drug itself was associated with the risk of causing hypertension and hypotension as cardiovascular adverse reactions.)",Less,No,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",49596de6-ab18-49d1-9e5b-30968fc21c36,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=49596de6-ab18-49d1-9e5b-30968fc21c36&type=display
1157,VINORELBINE,"1. **Cardiotoxicity Risk Associated with Vinorelbine**: The drug label does not specifically mention cardiotoxicity risks associated with vinorelbine.

2. **Cardiotoxicity Reactions**: The drug label does not list cardiotoxicity reactions as a common adverse reaction or a specific warning associated with vinorelbine use.",Less,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",dd3dcc9a-e40c-4677-9ee6-f318e7c7d835,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=dd3dcc9a-e40c-4677-9ee6-f318e7c7d835&type=display
1158,VISMODEGIB,"1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with ERIVEDGE (vismodegib) itself. 

2. The drug label states that ERIVEDGE did not prolong the QT interval to any clinically relevant extent following 7 days of 150 mg once-daily dosing, indicating no direct association with cardiotoxicity in terms of QT prolongation. 

3. Overall, there is no explicit mention of cardiotoxicity risks or reactions directly attributed to ERIVEDGE in the provided drug label information.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",eb368bb6-80e3-4df9-8a85-91df0a2ada6a,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=eb368bb6-80e3-4df9-8a85-91df0a2ada6a&type=display
1159,VITAMIN A PALMITATE,"1. The drug label does not mention any specific cardiotoxicity risks associated with AQUASOL A (vitamin A palmitate injection). 

2. The label does not indicate that the drug itself is associated with cardiotoxicity reactions. 

3. There is no mention of cardiotoxicity risks or reactions related to the use of AQUASOL A in the drug label. 

Overall, based on the information provided in the drug label, there are no references to cardiotoxicity risks or reactions associated with the use of AQUASOL A.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",ec825f1c-c15f-44de-ad46-8ab9c49ec21c,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=ec825f1c-c15f-44de-ad46-8ab9c49ec21c&type=display
1160,VOCLOSPORIN,"1. The drug label warns about QT prolongation, stating that LUPKYNIS prolongs the QTc interval in a dose-dependent manner after single-dose administration at a dose higher than the recommended lupus nephritis therapeutic dose. The use of LUPKYNIS in combination with other drugs known to prolong QTc may result in clinically significant QT prolongation. (The drug itself is associated with QT prolongation.)

2. The label mentions that certain circumstances may increase the risk of torsade de pointes and/or sudden death in association with the use of drugs that prolong the QTc interval, including bradycardia, hypokalemia or hypomagnesemia, concomitant use of other drugs that prolong the QTc interval, and congenital prolongation of the QT interval. (The drug itself is associated with the risk of torsade de pointes and sudden death.)

3. Additionally, the label discusses neurotoxicity risks, including the risk of posterior reversible encephalopathy syndrome (PRES) and other neurologic abnormalities. It advises monitoring for neurologic symptoms and considering dosage reduction or discontinuation of LUPKYNIS if neurotoxicity occurs. (The drug itself is associated with neurotoxicity risks.)

4. The label does not specifically mention cardiotoxicity reactions related to LUPKYNIS. However, it does highlight the importance of monitoring for hypertension, which is a common adverse reaction of LUPKYNIS therapy and may require antihypertensive therapy. (The drug itself is associated with hypertension as an adverse reaction.)",Less,No,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",9f489295-1156-52c7-5fd0-5c4c52f9b813,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=9f489295-1156-52c7-5fd0-5c4c52f9b813&type=display
1161,VORAPAXAR,"1. The drug ZONTIVITY is associated with a warning of bleeding risk, including intracranial hemorrhage and fatal bleeding, due to its classification as an antiplatelet agent. This risk is highlighted in the boxed warning section of the drug label.

2. ZONTIVITY is contraindicated in patients with a history of stroke, transient ischemic attack (TIA), or intracranial hemorrhage (ICH) due to an increased risk of ICH associated with the drug. Discontinuation of ZONTIVITY is recommended for patients who experience a stroke, TIA, or ICH.

3. The drug label warns that ZONTIVITY increases the risk of bleeding, including intracranial hemorrhage and fatal bleeding, in proportion to the patient's underlying bleeding risk. Factors such as older age, low body weight, reduced renal or hepatic function, history of bleeding disorders, and concomitant use of certain medications can further elevate the risk of bleeding.

4. ZONTIVITY should be avoided in patients with active pathological bleeding, such as intracranial hemorrhage or peptic ulcer, as it can exacerbate bleeding risks. The drug label emphasizes the importance of considering the underlying risk of bleeding before initiating ZONTIVITY.

5. In clinical trials, ZONTIVITY was shown to increase the risk of bleeding, including severe, moderate, and fatal bleeding events, in patients with a history of myocardial infarction (MI) or peripheral arterial disease (PAD) who did not have a history of stroke or TIA. The drug was associated with a higher incidence of bleeding events compared to placebo in these patient populations.

6. The drug label also mentions that ZONTIVITY was evaluated for safety in over 13,000 patients, with bleeding being the most commonly reported adverse reaction. The study population included patients with evidence or a history of atherosclerosis, and ZONTIVITY was associated with an increased risk of bleeding events, including intracranial hemorrhage, in these patients.

7. ZONTIVITY is not recommended for use in patients with severe hepatic impairment due to the increased inherent risk of bleeding associated with the drug. The drug label advises against ZONTIVITY use in this patient population based on the potential cardiotoxicity risks.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",f2abe3ed-ed3d-4215-a489-b18341ce85bc,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=f2abe3ed-ed3d-4215-a489-b18341ce85bc&type=display
1162,VORICONAZOLE,"1. **Warnings and Precautions**: The drug label mentions the risk of **Arrhythmias and QT Prolongation** associated with VFEND. It advises correcting potassium, magnesium, and calcium levels before use and being cautious with patients having proarrhythmic conditions. The drug itself is associated with the risk of arrhythmias and QT prolongation.

2. **Contraindications**: The label states that coadministration of VFEND with certain medications like pimozide, quinidine, sirolimus, or ivabradine is contraindicated due to the risk of serious adverse reactions, including QT prolongation. The drug itself is associated with the risk of QT prolongation when used with these medications.

3. **Drug Interactions**: The label warns about the risk of increased plasma concentrations of drugs like pimozide, quinidine, and ivabradine when coadministered with VFEND, leading to QT prolongation and torsade de pointes. The drug itself is associated with the risk of QT prolongation when used with these medications.

4. **Contraindications**: Coadministration of VFEND with rifampin, carbamazepine, long-acting barbiturates, and St. John's Wort is contraindicated due to the likelihood of significantly decreased plasma voriconazole concentrations. The drug itself is associated with the risk of decreased efficacy when used with these medications.

5. **Contraindications**: The label mentions that coadministration of standard doses of voriconazole with efavirenz doses of 400 mg every 24 hours or higher is contraindicated due to significantly decreased plasma voriconazole concentrations. The drug itself is associated with the risk of decreased efficacy when used with high doses of efavirenz.

6. **Contraindications**: Coadministration of VFEND with high-dose ritonavir (400 mg every 12 hours) is contraindicated due to significantly decreased plasma voriconazole concentrations. The drug itself is associated with the risk of decreased efficacy when used with high doses of ritonavir.

7. **Warnings and Precautions**: The label advises monitoring patients for adrenal dysfunction when receiving VFEND and corticosteroids due to the risk of adrenal insufficiency. The drug itself is associated with the risk of adrenal dysfunction when used with corticosteroids.

In summary, VFEND is associated with cardiotoxicity risks such as arrhythmias, QT prolongation, and potential interactions with other medications that can lead to serious adverse reactions. It is important to monitor patients closely for these risks when using VFEND.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",dac26bcd-7a59-401f-9f66-a0649767cece,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=dac26bcd-7a59-401f-9f66-a0649767cece&type=display
1163,VORINOSTAT,"1. The drug ZOLINZA, containing vorinostat, was evaluated for its effects on the QTc interval in patients with advanced cancer. A single supratherapeutic 800-mg dose of vorinostat did not appear to prolong the QTc interval in these patients.
2. In clinical studies with CTCL patients, three out of 86 patients exposed to 400 mg of ZOLINZA once daily experienced Grade 1 or 2 clinical adverse reactions of QTc prolongation. Additionally, a retrospective analysis across multiple studies showed some patients with QTc prolongation.
3. The drug label mentions that vorinostat, the active ingredient in ZOLINZA, was not associated with QTc prolongation in a study with advanced cancer patients. However, some CTCL patients exposed to ZOLINZA experienced QTc prolongation, indicating a potential risk in this specific patient population.",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",cd86ee78-2781-468b-930c-3c4677bcc092,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=cd86ee78-2781-468b-930c-3c4677bcc092&type=display
1164,VORTIOXETINE,"1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with TRINTELLIX (vortioxetine) itself.
2. TRINTELLIX has not been associated with any clinically important changes in laboratory test parameters in serum chemistry (except sodium), hematology, and urinalysis as measured in the 6 to 8 week placebo-controlled studies. Hyponatremia has been reported with the treatment of TRINTELLIX.
3. TRINTELLIX has not been associated with any clinically significant effects on vital signs, including systolic and diastolic blood pressure and heart rate, as measured in placebo-controlled studies.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",1a5b68e2-14d0-419d-9ec6-1ca97145e838,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=1a5b68e2-14d0-419d-9ec6-1ca97145e838&type=display
1165,VOSORITIDE,"1. **Warnings and Precautions**: The drug label mentions a risk of low blood pressure associated with the drug VOXZOGO. Patients are instructed to be well-hydrated and have adequate food intake prior to administration to reduce the risk of a decrease in blood pressure and associated symptoms like dizziness, fatigue, and nausea. The drug itself is associated with the risk of transient decreases in blood pressure.

2. **Adverse Reactions**: The drug label lists decreased blood pressure as one of the most common adverse reactions (>10%) reported with VOXZOGO. Eight subjects treated with VOXZOGO experienced transient decreases in blood pressure compared to three subjects on placebo. The drug itself is associated with the adverse reaction of decreased blood pressure.

3. **Adverse Reactions**: Injection site reactions, including injection site erythema, swelling, urticaria, and pain, were reported in a high percentage of subjects receiving VOXZOGO. Injection site reactions occurred in 85% of subjects receiving VOXZOGO compared to 82% of subjects receiving placebo. The drug itself is associated with injection site reactions, which can be considered a form of localized cardiotoxicity.",Less,Yes,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",228e8560-04a4-4bb1-a81f-29531a9e4d27,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=228e8560-04a4-4bb1-a81f-29531a9e4d27&type=display
1166,VOXELOTOR,"1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with OXBRYTA (voxelotor) itself.

2. The drug label focuses on hypersensitivity reactions and laboratory test interference as potential risks associated with OXBRYTA use, but does not mention any cardiotoxicity risks or reactions caused by the drug.

3. The drug label emphasizes the importance of monitoring for hypersensitivity reactions, such as rash, shortness of breath, and facial swelling, but does not mention any cardiotoxicity risks or reactions linked to OXBRYTA.

4. The drug label does not indicate any cardiotoxicity risks or reactions related to OXBRYTA treatment, with the emphasis being on hypersensitivity reactions and laboratory test interference.

5. The drug label does not attribute any cardiotoxicity risks or reactions to OXBRYTA, with the focus on managing hypersensitivity reactions and potential laboratory test interference.

Overall, the drug label for OXBRYTA (voxelotor) does not mention any specific cardiotoxicity risks or reactions associated with the drug itself. The highlighted risks primarily focus on hypersensitivity reactions and laboratory test interference.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",3c557fac-29ec-483f-b691-8a935d4decc3,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=3c557fac-29ec-483f-b691-8a935d4decc3&type=display
1167,WARFARIN SODIUM,"1. The drug label for COUMADIN (warfarin sodium) mentions that the drug itself is not directly associated with cardiotoxicity risks. It is indicated for prophylaxis and treatment of venous thrombosis, pulmonary embolism, thromboembolic complications in atrial fibrillation, and reduction in the risk of death and thromboembolic events after myocardial infarction.

2. The label states that COUMADIN has no direct effect on an established thrombus or ischemic tissue damage, indicating that the drug does not cause cardiotoxicity reactions.

3. While COUMADIN is not linked to cardiotoxicity risks, the label does warn about the potential for systemic atheroemboli and cholesterol microemboli, which can lead to serious consequences such as necrosis or death. Discontinuation of COUMADIN is recommended if such emboli occur, suggesting that the drug may indirectly contribute to cardiotoxicity reactions in rare cases.

4. The label also mentions that COUMADIN should not be used as initial therapy in patients with heparin-induced thrombocytopenia (HIT) and heparin-induced thrombocytopenia with thrombosis syndrome (HITTS). Cases of limb ischemia, necrosis, and gangrene have occurred in patients when transitioning from heparin to COUMADIN, indicating a potential risk of cardiotoxicity reactions associated with the drug's use in these specific patient populations.",Less,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",91fa852c-b43d-4a55-983b-74aa6827125d,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=91fa852c-b43d-4a55-983b-74aa6827125d&type=display
1168,ZALEPLON,"1. The drug label does not mention any cardiotoxicity risks or reactions associated with the drug itself. 

2. The drug label focuses on the pharmacokinetics, clinical trials, drug interactions, and precautions related to the use of Sonata (zaleplon) for the treatment of insomnia. 

3. No specific information is provided regarding cardiotoxicity risks or reactions in relation to the use of Sonata (zaleplon). 

4. The drug label primarily discusses the efficacy, safety, and potential adverse effects of Sonata (zaleplon) in the context of its use as a hypnotic agent. 

5. It is important to note that the drug label does not highlight any cardiotoxicity concerns or reactions associated with Sonata (zaleplon) based on the information provided.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",43ac81cb-1e3f-4d44-86bd-13db2721d060,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=43ac81cb-1e3f-4d44-86bd-13db2721d060&type=display
1169,ZANUBRUTINIB,"1. **Cardiac Arrhythmias**: The drug label mentions that serious cardiac arrhythmias have occurred in patients treated with BRUKINSA. It states that atrial fibrillation and atrial flutter were reported in patients taking BRUKINSA, with Grade 3 or higher cases in some patients. The drug itself is associated with the risk of serious cardiac arrhythmias.

2. **Cardiac Arrhythmias Monitoring**: Patients with cardiac risk factors, hypertension, and acute infections may be at increased risk of cardiac arrhythmias. The label advises monitoring for signs and symptoms of cardiac arrhythmias and managing them appropriately. The drug itself is associated with the risk of cardiac arrhythmias.

3. **Cardiac Arrhythmias Management**: The label recommends considering the risks and benefits of continued BRUKINSA treatment in patients who experience cardiac arrhythmias. It emphasizes managing signs and symptoms appropriately. The drug itself is associated with the risk of cardiac arrhythmias.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",3e08fe23-d70e-424c-bc51-1222e320f902,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=3e08fe23-d70e-424c-bc51-1222e320f902&type=display
1170,ZICONOTIDE ACETATE,"1. The drug label does not mention any specific cardiotoxicity risks or reactions associated with PRIALT (ziconotide) itself. 

2. The label focuses on neuropsychiatric adverse reactions, cognitive impairment, and neurological impairment as potential risks of PRIALT use. 

3. It does not directly link PRIALT to cardiotoxicity, but it does mention the importance of monitoring serum creatine kinase levels due to elevations seen in some patients, which could be indicative of muscle-related issues but not necessarily cardiotoxicity. 

4. Overall, the drug label does not highlight cardiotoxicity as a primary concern or risk associated with PRIALT use.",No,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",b025d8ed-937d-4597-9ad1-0b2f6e0ee5b1,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=b025d8ed-937d-4597-9ad1-0b2f6e0ee5b1&type=display
1171,ZIDOVUDINE,"1. The drug label for RETROVIR (zidovudine) includes warnings and precautions about hematologic toxicity, myopathy, lactic acidosis, and severe hepatomegaly with steatosis, but does not specifically mention cardiotoxicity risks associated with the drug itself.

2. The label mentions that prolonged use of RETROVIR has been associated with symptomatic myopathy, which is a condition affecting muscle tissue, but does not directly link the drug to cardiotoxicity risks.

3. While the label discusses lactic acidosis and severe hepatomegaly with steatosis as potential adverse effects of nucleoside analogues like zidovudine, including RETROVIR, it does not indicate a direct association with cardiotoxicity risks.

4. Postmarketing experience reported cases of cardiomyopathy, a condition affecting the heart muscle, but the label does not specify a direct link between RETROVIR and this cardiotoxicity reaction.

Overall, the drug label for RETROVIR does not explicitly state that the drug itself is associated with cardiotoxicity risks or cardiotoxicity reactions.",Less,No,No,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",6df09f15-b102-431c-adde-d7aeef6f5d84,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=6df09f15-b102-431c-adde-d7aeef6f5d84&type=display
1172,ZILEUTON,"1. The drug label mentions that co-administration of ZYFLO and theophylline results in an approximate doubling of serum theophylline concentrations, which can lead to theophylline-related adverse events. This indicates that ZYFLO itself is associated with a cardiotoxicity risk due to its interaction with theophylline.

2. Additionally, co-administration of ZYFLO and warfarin results in a clinically significant increase in prothrombin time, which may require adjustment of anticoagulant dose. This suggests that ZYFLO itself is associated with a cardiotoxicity risk due to its interaction with warfarin.

3. The label also mentions that co-administration of ZYFLO and propranolol results in increased propranolol concentrations, leading to increased beta-blocker activity and potential heart rate changes. This indicates that ZYFLO itself is associated with a cardiotoxicity risk due to its interaction with propranolol.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",aee65202-fddb-497f-9f11-17cc727cb157,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=aee65202-fddb-497f-9f11-17cc727cb157&type=display
1173,ZINC CHLORIDE,"1. **Warnings**: Direct intramuscular or intravenous injection of Zinc 1 mg/mL (Zinc Chloride Injection, USP) is contraindicated as the acidic pH of the solution (2) may cause considerable tissue irritation. (The drug itself is associated with the risk of tissue irritation due to its acidic pH.)

2. **Overdosage**: Death resulted from an overdosage in which 1683 mg zinc was delivered intravenously over the course of 60 hours to a 72-year-old patient. Symptoms of zinc toxicity included hypotension (80/40 mm Hg), pulmonary edema, diarrhea, vomiting, jaundice, and oliguria, with a serum zinc level of 4184 mcg/dl. Calcium supplements may confer a protective effect against zinc toxicity. (The drug itself, when administered in an overdose, led to severe cardiotoxic reactions such as hypotension, pulmonary edema, and other symptoms of toxicity.)

Please note that while the drug label does not specifically mention cardiotoxicity as a common adverse reaction, the information provided highlights the potential risks associated with the drug's use in certain scenarios.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",9a1914a0-e195-4233-c1be-bc2075580eb8,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=9a1914a0-e195-4233-c1be-bc2075580eb8&type=display
1174,ZINC SULFATE,"1. **Warnings and Precautions - Pulmonary Embolism due to Pulmonary Vascular Precipitates:** The drug label mentions that pulmonary vascular precipitates causing pulmonary vascular emboli and pulmonary distress have been reported in patients receiving parenteral nutrition, but the cause of precipitate formation has not been determined in all cases. The drug itself was not directly associated with causing the cardiotoxicity risk, but the formation of precipitates during parenteral nutrition could lead to pulmonary embolism.

2. **Warnings and Precautions - Vein Damage and Thrombosis:** The label states that solutions with an osmolarity of 900 mOsmol/L or greater must be infused through a central catheter to prevent vein irritation, vein damage, and/or thrombosis. The drug itself was not directly associated with causing cardiotoxicity risk, but the high osmolarity of the solution could lead to vein damage and thrombosis if not administered correctly.

3. **Warnings and Precautions - Aluminum Toxicity:** The drug label mentions that Zinc Sulfate Injection contains aluminum, which may be toxic, especially in patients with impaired kidney function. The drug itself was not directly associated with causing cardiotoxicity risk, but the presence of aluminum in the solution could lead to toxicity, including cardiotoxic effects, in patients with renal impairment.

4. **Warnings and Precautions - Monitoring and Laboratory Tests:** The label advises monitoring fluid and electrolyte status, which includes monitoring for any electrolyte imbalances that could potentially lead to cardiotoxicity. The drug itself was not directly associated with causing cardiotoxicity risk, but the need for monitoring these parameters is crucial to prevent any adverse cardiac effects.

5. **Warnings and Precautions - Copper Deficiency:** The label mentions that high doses of supplemental zinc over extended periods may result in copper deficiency, leading to complications such as anemia, which can have cardiotoxic effects. The drug itself was indirectly associated with causing cardiotoxicity risk through the potential development of copper deficiency due to prolonged zinc supplementation.

6. **Warnings and Precautions - Hypersensitivity Reactions:** The label states that hypersensitivity reactions to zinc-containing products have been reported, including symptoms like facial swelling and dyspnea, which could indicate potential cardiotoxic reactions. The drug itself was indirectly associated with causing cardiotoxicity risk through hypersensitivity reactions that could manifest as cardiac symptoms.",Less,No,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",4b528c88-07a0-4dce-84c6-ccd32555bbff,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=4b528c88-07a0-4dce-84c6-ccd32555bbff&type=display
1175,ZIPRASIDONE HCL,"1. The drug Ziprasidone is associated with an increased risk of QT prolongation, which can lead to torsade de pointes-type arrhythmia and sudden death. The drug itself is linked to the risk of QT prolongation.
   
2. Ziprasidone should not be used in combination with other drugs known to prolong the QTc interval, as this can increase the risk of torsade de pointes and sudden death. The drug itself is associated with the risk of QT prolongation when used with certain other medications.

3. In clinical trials, oral Ziprasidone was found to increase the QTc interval compared to placebo, with some patients experiencing QTc intervals exceeding the clinically relevant threshold of 500 msec. The drug itself is linked to QT prolongation in some patients.

4. Although torsade de pointes has not been observed in premarketing studies, there have been rare post-marketing reports of this condition in the presence of multiple confounding factors. The drug itself is not definitively linked to torsade de pointes but has been reported in some cases.

5. Sudden unexplained deaths have been reported in patients taking Ziprasidone at recommended doses, although the premarketing experience did not reveal an excess risk of mortality compared to other antipsychotic drugs or placebo. The drug itself is associated with sudden unexplained deaths in some patients.

6. Ziprasidone should be avoided in patients with certain risk factors such as bradycardia, hypokalemia, hypomagnesemia, congenital long QT syndrome, or a history of cardiac arrhythmias. The drug itself is associated with an increased risk of cardiotoxicity in patients with these risk factors.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",022ff18b-88f4-4c60-b5cf-85b8491f0124,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=022ff18b-88f4-4c60-b5cf-85b8491f0124&type=display
1176,ZIPRASIDONE MESYLATE,"1. GEODON is contraindicated in patients with a known history of QT prolongation, recent acute myocardial infarction, or uncompensated heart failure due to its dose-related prolongation of the QT interval, which is associated with fatal arrhythmias. The drug itself is associated with the risk of QT prolongation and subsequent arrhythmias.

2. Ziprasidone should not be used in combination with other drugs known to prolong the QTc interval, and clinicians should be cautious about co-administering it with other medications that have demonstrated QT prolongation effects. The drug itself is associated with the risk of QT prolongation when used in combination with certain medications.

3. GEODON has been shown to increase the QTc interval compared to placebo, with a mean increase of approximately 10 msec at the highest recommended daily dose of 160 mg. While torsade de pointes has not been observed in premarketing studies, there have been rare post-marketing reports of sudden unexplained deaths in patients taking ziprasidone. The drug itself is associated with QTc prolongation and a potential risk of sudden death.

4. In a study comparing the QT/QTc prolonging effect of oral ziprasidone with other antipsychotic drugs, ziprasidone showed a greater increase in QTc interval compared to some comparators. While the study did not show an increased risk of mortality compared to other antipsychotic drugs, the larger prolongation of QTc length raises the possibility of a greater risk of sudden death with ziprasidone. The drug itself is associated with a greater QTc prolongation compared to certain antipsychotic drugs, potentially increasing the risk of sudden death.

5. Intramuscular ziprasidone administration has been associated with a mean increase in QTc interval from baseline, with no patients exceeding a QTc interval of 500 msec. The drug itself is associated with a moderate increase in QTc interval when administered intramuscularly.

6. GEODON should be avoided in patients with congenital long QT syndrome, a history of cardiac arrhythmias, or significant cardiovascular illness. The drug itself is associated with an increased risk of QT prolongation and arrhythmias in susceptible individuals.

7. GEODON's potential to prolong the QT/QTc interval compared to other antipsychotic drugs should be considered when choosing among alternative treatments. The drug itself is associated with a greater capacity to prolong the QT interval compared to several other antipsychotic drugs.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",5e19474a-6009-4c30-9e43-523dc9d3b267,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=5e19474a-6009-4c30-9e43-523dc9d3b267&type=display
1177,ZOLEDRONIC ACID,"1. Atrial fibrillation was reported as an adverse event in patients treated with zoledronic acid in a postmenopausal osteoporosis trial, with a higher incidence in the treatment group compared to placebo, suggesting an association with the drug.
   
2. In the same trial, serious adverse events of atrial fibrillation occurred in a subset of patients receiving zoledronic acid, indicating a potential risk of cardiotoxicity associated with the drug.

3. An ECG sub-study showed no difference in the incidence of atrial fibrillation between treatment groups, suggesting that these events were not related to the acute infusions of zoledronic acid.

4. The overall incidence of atrial fibrillation adverse events in the zoledronic acid treatment group was higher compared to the placebo group, indicating a potential association between zoledronic acid and atrial fibrillation.

5. No reports of osteonecrosis of the jaw (ONJ) were observed in the treatment groups in another trial, suggesting no direct association between zoledronic acid and ONJ in that specific study.

6. Cases of iritis/uveitis/episcleritis/conjunctivitis have been reported in patients treated with bisphosphonates, including zoledronic acid, indicating a potential risk of ocular adverse events associated with the drug.",Most,Yes,Less,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",3c79ff9c-a6f4-405d-b19c-7e473a61dedc,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=3c79ff9c-a6f4-405d-b19c-7e473a61dedc&type=display
1178,ZOLMITRIPTAN,"1. ZOMIG Nasal Spray is contraindicated in patients with ischemic heart disease or coronary artery vasospasm, as well as in those with symptomatic Wolff-Parkinson-White syndrome or other cardiac accessory conduction pathway disorders, indicating that the drug itself is associated with cardiotoxicity risks.

2. The drug label warns about the risk of myocardial ischemia, myocardial infarction, and Prinzmetals angina with ZOMIG use, advising healthcare providers to perform a cardiac evaluation in patients with multiple cardiovascular risk factors before administering the drug, suggesting a potential association between ZOMIG and cardiotoxicity risks.

3. ZOMIG may cause arrhythmias, with a recommendation to discontinue dosing if such disturbances occur, indicating a potential association between the drug and cardiotoxicity reactions.

4. The label mentions chest/throat/neck/jaw pain, tightness, pressure, or heaviness after ZOMIG use, stating that these symptoms are generally not associated with myocardial ischemia but advising evaluation for coronary artery disease in high-risk patients, suggesting a potential association between the drug and cardiotoxicity risks.

5. ZOMIG is contraindicated in patients with a history of stroke, transient ischemic attack, or hemiplegic or basilar migraine due to the higher risk of stroke, indicating a potential association between the drug and cerebrovascular events, which can have cardiotoxic implications.

6. The drug label warns about the potential for gastrointestinal ischemic events and peripheral vasospastic reactions with ZOMIG use, advising discontinuation of dosing if such events occur, suggesting a potential association between the drug and vasospasm reactions, which can have cardiotoxic effects.

7. ZOMIG is contraindicated in patients with uncontrolled hypertension, with a mention of significant elevations in blood pressure reported in some patients treated with 5-HT1 agonists, indicating a potential association between the drug and an increase in blood pressure, which can have cardiotoxic implications.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",84b51cb9-83f3-4a49-7fa3-1adc0f963658,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=84b51cb9-83f3-4a49-7fa3-1adc0f963658&type=display
1179,ZOLPIDEM TARTRATE,"1. Zolpidem Tartrate Capsules have been associated with infrequent adverse reactions related to the cardiovascular system, such as palpitations, cerebrovascular disorder, and tachycardia. The drug itself was associated with these cardiotoxicity risks.

2. Rare adverse reactions reported include angina pectoris, arrhythmia, myocardial infarction, and pulmonary embolism. These cardiotoxicity reactions were associated with the use of Zolpidem Tartrate Capsules.

3. The drug label also mentions rare cardiovascular adverse reactions like arteritis, circulatory failure, and ventricular tachycardia. These cardiotoxicity risks were linked to the use of Zolpidem Tartrate Capsules.

4. Additionally, the label lists palpitation as a frequent adverse reaction and hypertension as an infrequent reaction related to the cardiovascular system. These cardiotoxicity reactions were associated with the use of Zolpidem Tartrate Capsules.",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",2f1a3600-9bd6-3651-3ab5-1e4e0b0a3916,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=2f1a3600-9bd6-3651-3ab5-1e4e0b0a3916&type=display
1180,ZONISAMIDE,"1. Zonisamide, the active ingredient in ZONEGRAN, is associated with potential cardiotoxicity risks due to its mechanism of action on sodium and calcium channels, which may affect neuronal membranes and neurotransmission. (Drug-associated cardiotoxicity risk)

2. Zonisamide is a carbonic anhydrase inhibitor, and its contribution to metabolic acidosis may lead to cardiac arrhythmias as a potential cardiotoxic reaction. (Drug-associated cardiotoxicity risk)

3. Zonisamide-induced metabolic acidosis, a known adverse effect of the drug, can result in hyperventilation and cardiac arrhythmias, which are cardiotoxic reactions. (Drug-associated cardiotoxicity risk)

4. Chronic, untreated metabolic acidosis caused by zonisamide may increase the risk for cardiac arrhythmias, including those related to hyperammonemia, especially in the presence of other drugs that can cause hyperammonemia. (Drug-associated cardiotoxicity risk)

5. Zonisamide-induced metabolic acidosis can lead to severe sequelae such as cardiac arrhythmias, which are considered cardiotoxic reactions. (Drug-associated cardiotoxicity risk)

6. Zonisamide treatment has been associated with reductions in serum phosphorus and increases in serum alkaline phosphatase, changes that may be related to metabolic acidosis and osteomalacia, potentially impacting cardiac health. (Drug-associated cardiotoxicity risk)

7. Chronic, untreated metabolic acidosis in pediatric patients treated with zonisamide may reduce growth rates, potentially affecting cardiac development and function. (Drug-associated cardiotoxicity risk)

8. If metabolic acidosis persists with zonisamide treatment, consideration should be given to reducing the dose or discontinuing the drug, as persistent acidosis can lead to cardiac complications. (Drug-associated cardiotoxicity risk)

9. Zonisamide-induced metabolic acidosis can increase the risk for nephrolithiasis, which may indirectly impact cardiac health through potential renal complications. (Drug-associated cardiotoxicity risk)

10. Zonisamide treatment was associated with nephrolithiasis in a percentage of adult and pediatric patients, which can have implications for renal function and, consequently, cardiac health. (Drug-associated cardiotoxicity risk)",Most,Yes,Most,"Provide a summary of all the parts of the drug label that discuss cardiotoxicity risks and cardiotoxicity reactions for this drug.
    In your summary of each sentence, clearly state whether the drug itself was associated with or caused the cardiotoxicity risk.","Given the above information about a drug, answer 'was this drug associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        Now answer with just one word: No, Less, or Most","Given the above information about a drug, answer 'was this drug associated with Cardiotoxicity?'
        Now, answer with just one word: Yes or No","Given the above information about a drug, answer 'was this drug was associated with No Cardiotoxicity, Less Cardiotoxicity, or Most Cardiotoxicity?'
        In your definition of cardiotoxicity, consider (among other examples) the following to be Most Cardiotoxic:
        Heart damage that is fatal or life-threatening, death, need heart transplantation, (acute) myocardial infarction, heart attack, heart or cardiac failure, congestive heart failure (CHF), cardiomyopathy,
        myocarditis, coronary artery disease, myocardial ischemia, left ventricular dysfunction, cardiogenic shock, coronary, artery insufficiency, valvular heart disease, endocarditis, 
        Fatal or life-threatening arrhythmia, heart/cardiac arrest, cardiorespiratory arrest, torsade de pointes (TdP), AV block III, ventricular fibrillation, Brugada syndrome,
        Angina pectoris, increased angina, mitral valve regurgitation, heart valve thickening, cardio spasm, Ventricular tachycardia, long QT syndrome/QT interval
        prolongation, ventricular arrhythmias.  
         
        Consider the following (among other examples) to be less Cardiotoxic: Hypotension, hypertension, AV block I & II, atrial fibrillation, tachycardia, bradycardia, palptitations, and sinus node dysfunction 
        Now, answer with one word just: 'No', 'Less' or 'Most'",d12de43e-3ac3-4335-bc85-70d7366a91eb,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=d12de43e-3ac3-4335-bc85-70d7366a91eb&type=display
